fluorouracil has been researched along with Local Neoplasm Recurrence in 2675 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of lapatinib for the treatment of advanced or metastatic HER2-overexpressing breast cancer based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process." | 10.24 | Lapatinib for the treatment of HER2-overexpressing breast cancer. ( Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C, 2009) |
| "To determine whether induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improves survival vs cisplatin and fluorouracil (PF) prior to chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma." | 9.51 | Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. ( Cao, KJ; Chen, MY; Chen, QY; Chen, ZJ; Guo, L; Guo, X; Hu, D; Hua, YJ; Huang, PY; Ke, LR; Li, WZ; Liang, H; Liu, GY; Liu, T; Lu, N; Luo, DH; Lv, SH; Lv, X; Mai, HQ; Mo, HY; Qian, CN; Qiu, F; Sun, R; Tang, LQ; Tang, WB; Tong, LH; Wang, DS; Wang, L; Xia, WX; Xiang, YQ; Yang, W; Ye, YF; Yuan, TZ; Zhang, HX; Zhao, C, 2022) |
| "A current recommendation for the treatment of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) is conventional fractionated radiotherapy (RT) with concurrent cisplatin followed by adjuvant cisplatin and 5-fluorouracil (PF)." | 9.34 | NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. ( Chan, ATC; Chappell, R; Cheng, AAC; Choi, HCW; Kwong, DLW; Lee, AWM; Lu, TX; Ng, WT; Ngan, RKC; Sze, HCK; Tung, SY; Wong, FCS; Yiu, HHY; Yuen, KT, 2020) |
| "Induction cisplatin and gemcitabine chemotherapy is a standard treatment for locally advanced nasopharyngeal carcinoma (NPC)." | 9.34 | Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. ( Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K, 2020) |
| "We conducted a single-arm phase II trial to evaluate the efficacy and adverse effects (AEs) of an anti-epidermal growth factor receptor monoclonal antibody, nimotuzumab, combined with cisplatin and 5-fluorouracil (PF) as first-line treatment in recurrent metastatic nasopharyngeal carcinoma after radical radiotherapy." | 9.30 | Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. ( Chen, J; Chen, X; Chua, MLK; Han, F; Hu, G; Hu, X; Li, J; Mai, H; Miao, J; Shao, X; Shen, G; Shi, M; Wang, L; Wu, S; Xie, C; Zhang, N; Zhao, C, 2019) |
| "CEREBEL compared the incidence of CNS metastases as first site of relapse in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer receiving lapatinib-capecitabine or trastuzumab-capecitabine." | 9.20 | CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. ( Allerton, R; Bidoli, P; Chan, S; Chmielowska, E; Ciruelos, E; Dank, M; DeSilvio, M; Fabi, A; Gori, S; Hornyak, L; Karaszewska, B; Manikhas, A; Margolin, S; Nagi, F; Nusch, A; Parikh, R; Pivot, X; Santillana, S; Semiglazov, V; Swaby, RF; Żurawski, B, 2015) |
| "Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC)." | 9.20 | Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. ( Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D, 2015) |
| "Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients." | 9.20 | Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. ( Aftimos, P; Ameye, L; Beauduin, M; Bejarano Hernández, S; Cornez, N; de Azambuja, E; Delhaye, F; Diaz, M; Focan, C; Lemort, M; Paesmans, M; Piccart-Gebhart, M; Shih-Li, C; Suter, T; Vandenbossche, S; Vindevoghel, A, 2015) |
| "Although cisplatin combined with 5-fluorouracil is a common first-line regimen for advanced nasopharyngeal carcinoma (NPC), there are no standard regimens for refractory or relapsed patients." | 9.19 | Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy. ( Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Wang, XX, 2014) |
| "We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea." | 9.19 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. ( Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI, 2014) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 9.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| " This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer." | 9.17 | Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. ( Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 9.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| "To explore the impact of dose intensity (DI) in the adjuvant setting of breast cancer, a randomized phase III trial was conducted comparing postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide, methotrexate and fluorouracil (CMF)in high-risk breast cancer patients." | 9.16 | Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. ( Bafaloukos, D; Batistatou, A; Bobos, M; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Kosmidis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Stathopoulos, GP; Timotheadou, E, 2012) |
| "We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC)." | 9.16 | Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. ( Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S, 2012) |
| "005) evaluating first-line bevacizumab plus paclitaxel or capecitabine for locally recurrent or metastatic breast cancer." | 9.16 | Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. ( Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z, 2012) |
| "Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)." | 9.16 | Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial. ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012) |
| "The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial." | 9.15 | Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. ( Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA, 2011) |
| "We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection." | 9.15 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011) |
| "Capecitabine is frequently used in the treatment of recurrent/progressive metastatic breast cancer (MBC) after prior anthracycline and taxane therapy." | 9.14 | Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. ( Abdulnabi, R; Clemons, M; Gelmon, K; Iscoe, N; Jordaan, JP; Joy, AA; Kotliar, M; Lynch, J, 2010) |
| "To describe the considerations leading to marketing approval of ixabepilone in combination with capecitabine and as monotherapy for the treatment of advanced breast cancer that is refractory to other chemotherapies." | 9.13 | Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. ( Aziz, R; Booth, B; Bullock, J; Dagher, R; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kasliwal, R; Lechleider, RJ; Leighton, J; Pazdur, R; Pope, S; Sridhara, R, 2008) |
| "A dose-escalation study was conducted for patients with inoperable or recurrent breast cancer in order to determine the recommended dose (RD) of capecitabine combined with a fixed dose of weekly paclitaxel." | 9.13 | [A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer]. ( Horiguchi, J; Iino, Y; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, R; Odawara, H; Rokutanda, N; Sato, A; Takeyoshi, I; Tokiniwa, H, 2008) |
| "This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen." | 9.13 | Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008) |
| "We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)." | 9.12 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 9.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer." | 9.12 | Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006) |
| "Based on phase II data in advanced breast cancer (BC), the fluorouracil, epirubicin, and vinorelbine (FEN) combination was assessed as perioperative chemotherapy, integrated in a multidisciplinary treatment for locally advanced BC." | 9.12 | Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. ( Ardavanis, A; Arnogiannaki, N; Chrysochoou, M; Ioannidis, G; Karamouzis, M; Missitzis, I; Orphanos, G; Pissakas, G; Rigatos, G; Scorilas, A; Sotiropoulou, A; Tryfonopoulos, D, 2006) |
| "A phase-I clinical study of a combination therapy of vinorelbine and capecitabine was conducted in anthracycline- and taxane-pretreated patients with advanced/recurrent breast cancer." | 9.12 | [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ( Aogi, K; Fujii, H; Hatake, K; Noguchi, S; Saeki, T; Sano, M; Tabei, T; Tokuda, Y, 2006) |
| " Here, we investigate the prognostic and treatment predictive role of CCND1 and PAK1 gene amplification in postmenopausal breast cancer patients randomized to tamoxifen treatment or no adjuvant treatment." | 9.12 | Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. ( Ahnström Waltersson, M; Bostner, J; Fornander, T; Nordenskjöld, B; Skoog, L; Stål, O, 2007) |
| "This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive breast cancer." | 9.12 | Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. ( Bondar, G; Kossé, V; Lehmann, U; Maubach, L; Meurer, J; Possinger, K; Schmid, P; Tarutinov, V; Untch, M; Vassiljev, L; Wallwiener, D, 2007) |
| "The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma." | 9.12 | Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. ( Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H, 2007) |
| "To assess the efficacy and tolerability of combination therapy with capecitabine and cisplatin in patients with recurrent carcinoma of the uterine cervix." | 9.12 | A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. ( Benjapibal, M; Inthasorn, P; Leelaphatanadit, C; Therasakvichya, S; Thirapakawong, C, 2007) |
| "In an earlier study, we have demonstrated a high clinical and pathologic response rate of neoadjuvant paclitaxel (P) and cisplatin (C) for patients with locally advanced breast cancer (LABC)." | 9.11 | Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. ( Ajarim, DS; Al-Malik, OA; Al-Shabanah, M; Ezzat, AA; Ibrahim, EM; Rahal, MM; Raja, MA; Sorbris, R; Tulbah, AM, 2004) |
| "A phase I clinical trial was started in order to determine the recommended doses of capecitabine and epirubicin, when administered in combination with a fixed dose of cyclophosphamide (600 mg/m(2) day 1 q3 weeks) in patients with inoperable or recurrent breast cancer." | 9.11 | Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer. ( Hozumi, Y; Ito, Y; Iwata, H; Kobayashi, T; Morita, S; Ohno, S; Sakamoto, J; Toi, M, 2004) |
| "To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse." | 9.11 | Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. ( Bonadonna, G; Gianni, L; Moliterni, A; Valagussa, P; Zambetti, M, 2004) |
| "The goal of this multicenter, open-label phase II study was the clinical evaluation of combination therapy with the oral fluoropyrimidine capecitabine and the taxane paclitaxel in patients with metastatic breast cancer (MBC)." | 9.11 | Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. ( Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D, 2004) |
| "To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)." | 9.11 | A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004) |
| "To assess patterns of locoregional failure (LRF) in lymph node-positive (LN+) breast cancer patients treated with mastectomy and adjuvant chemotherapy (+/- tamoxifen) and without postmastectomy radiotherapy (PMRT) in five National Surgical Adjuvant Breast and Bowel Project trials." | 9.11 | Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized c ( Anderson, S; Bryant, J; Deutsch, M; Jeong, JH; Mamounas, E; Taghian, A; Wolmark, N, 2004) |
| "Since the need for nonanthracycline-containing chemotherapy regimens increases with the increased use of anthracyclines in earlier stages of breast cancer, we investigated the feasibility of the combination of docetaxel and 5-fluorouracil (5-FU) with folinic acid (FA)." | 9.11 | A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer. ( Nortier, JW; Rodenburg, CJ; Slee, PH; van Bochove, A, 2004) |
| "We randomized 1,475 premenopausal women with node-positive breast cancer to three, six, or nine courses of "classical" CMF (cyclophosphamide, methotrexate, and fluorouracil)." | 9.11 | Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca ( Bonetti, M; Carbone, A; Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Holmberg, SB; Lindtner, J; Nasi, ML; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B, 2005) |
| "Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)." | 9.11 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 9.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "The purpose of this study was to evaluate the efficacy and tolerance of the bimonthly administration of oxaliplatin in combination with high-dose leucovorin and infusional 5-fluorouracil (5-FU) (FOLFOX2 regimen) in patients with advanced colorectal cancer (ACC) who did not respond or whose disease progressed within 3 months after front-line treatment with CPT-11-containing regimens." | 9.10 | Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). ( Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N, 2002) |
| "Effective adjuvant treatment modalities in premenopausal breast cancer patients today include chemotherapy, ovariectomy, and tamoxifen administration." | 9.10 | Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breas ( Bauernhofer, T; Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Seifert, M; Steger, G; Steindorfer, P; Wette, V, 2002) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer." | 9.10 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003) |
| "Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine carbamate with high activity in metastatic breast cancer." | 9.10 | Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. ( Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G, 2003) |
| "Cimetidine has been shown to have beneficial effects in colorectal cancer patients." | 9.10 | Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002) |
| "Twenty-one patients with recurrent or metastatic breast cancer were treated with paclitaxel (Taxol) as a 1-hour infusion on day 1 only of a 14-day cycle." | 9.10 | Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer. ( Amamoo, MA; Collichio, FA; Fogleman, J; Graham, M; Griggs, J, 2002) |
| "Capecitabine, a tumor-selective, oral fluoropyrimidine, has demonstrated significant antitumor activity in patients with metastatic breast cancer." | 9.10 | Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study. ( Bokemeyer, C; Jakob, A; Kanz, L; Knop, S; Mayer, F; Schupp, M, 2002) |
| "Paclitaxel has significant antitumor activity in patients with metastaticbreast cancer who have been previously treated with or exposed to anthracycline-containing chemotherapy." | 9.10 | Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. ( Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R, 2002) |
| "This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 9.09 | Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. ( Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A, 1999) |
| "The aim of this study was to evaluate the toxicity and efficacy of the combination of 5-fluorouracil, bleomycin, epirubicin, and cisplatin (FBEC) in the treatment of patients with undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 9.09 | Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. ( Armand, JP; Azli, N; Chouaki, N; Couteau, C; Cvitkovic, E; Fandi, A; Hasbini, A; Taamma, A; Wibault, P, 1999) |
| "To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival." | 9.09 | Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Manfreda, D; Mittlböck, M; Mlineritsch, B; Samonigg, H; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 9.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer." | 9.09 | Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). ( Abeloff, MD; Hochster, H; Kucuk, O; Pandya, KJ; Skeel, RT, 1999) |
| "The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer." | 9.09 | Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000) |
| "QUASAR is a large trial of adjuvant chemotherapy for colorectal cancer in which clinicians could choose to deliver a standard adjuvant cytotoxic chemotherapy regimen, 5-fluorouracil (5-FU) and L-folinic acid (L-FA), in either a once-weekly or a four-weekly schedule." | 9.09 | Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. ( Barnwell, J; Gray, R; Kerr, DJ; McConkey, C, 2000) |
| "Irinotecan (CPT11) has established activity in the treatment of advanced colorectal cancer without cross-resistance with established 5-fluorouracil/folinic acid-based therapy." | 9.09 | Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. ( Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | 9.09 | Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| " 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas." | 9.09 | A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001) |
| "Sixty-one patients with primary node positive stage III breast cancers were randomized to receive postoperative radiotherapy and doxorubicin-based chemotherapy (eight cycles of CAFt: cyclophosphamide, adriamycin, oral ftorafur) with or without tamoxifen as adjuvant treatment." | 9.08 | The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. ( Blomqvist, C; Elomaa, I; Gröhn, P; Rissanen, P; Saarto, T; Tiusanen, K, 1995) |
| "A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks." | 9.08 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 9.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "The effects of medroxyprogesterone acetate (MPA) therapy on advanced or recurrent breast cancer and its influence on blood coagulation and the fibrinolytic system were compared among three different therapy regimens consisting of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) + MPA and CAF or MPA alone." | 9.08 | Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system. ( Abe, O; Aoki, N; Asaishi, K; Enomoto, K; Izuo, M; Koyama, H; Nomura, Y; Ohshima, A; Tominaga, T; Tsukada, T, 1995) |
| "In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2." | 9.08 | Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996) |
| "The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer." | 9.08 | Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. ( Abramson, N; Atkins, JN; Bryant, J; DeCillis, A; Deschenes, L; Dignam, J; Dimitrov, NV; Emir, B; Fisher, B; Margolese, RG; Shibata, H; Wickerham, DL; Wolmark, N, 1997) |
| "The objective of the study was to determine the response rate and associated toxicity of 5-fluorouracil and high-dose leucovorin in patients with recurrent adenocarcinoma of the cervix." | 9.08 | Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. ( Andersen, WA; Blessing, JA; Look, KY; Manetta, A; McGehee, R; Valea, FA; Webster, KD, 1997) |
| "To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of 5-fluorouracil (5-FU) in advanced or recurrent breast cancer patients who had been treated previously with at least one chemotherapeutic regimen, patients were treated with docetaxel as a 1-h infusion on day 1 followed by 5-FU as a continuous infusion on days 1 through 5 every 3-4 weeks." | 9.08 | A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. ( Adachi, I; Ando, M; Fujii, H; Igarashi, T; Itoh, K; Katsumata, N; Narabayashi, M; Ohtsu, T; Omuro, Y; Sasaki, Y; Taguchi, T; Tokue, Y; Wakita, H; Watanabe, T; Ying, DF, 1998) |
| "The usefulness of CAF [cyclophosphamide (CPA)/doxorubicin (ADR)/5-fluorouracil (5-FU)] + medroxyprogesterone acetate (MPA) therapy for advanced/recurrent breast cancer was studied in a randomised trial at 56 institutions." | 9.07 | Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. ( Abe, O; Abe, R; Enomoto, K; Hayasaka, H; Izuo, M; Ohshima, A; Takatani, O; Tominaga, T; Uchino, J; Watanabe, H, 1994) |
| "The clinical efficacy of "CMF" chemotherapy, (cyclophosphamide, methotrexate, 5-fluorouracil), was evaluated on advanced and recurrent breast cancer." | 9.07 | [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan]. ( Adachi, I; Fukami, A; Koyama, H; Nomura, Y; Tominaga, T, 1994) |
| "A randomized controlled trial was performed to study the efficiency of adjuvant chemotherapy with early intravesical instillation of Adriamycin and long-term oral administration of 5-fluorouracil in 275 patients with superficial bladder cancer." | 9.07 | Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1992) |
| "To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU." | 9.07 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992) |
| "Thirty patients with advanced breast cancer, previously treated with anthracycline and 5 fluorouracil in bolus administration, were evaluated with a chemotherapy regimen generally used in head and neck cancer." | 9.06 | [Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]. ( Bastit, P; Bugat, R; Cappelaere, P; Chauvergne, J; Fumoleau, P; Horner, D; Metz, R, 1990) |
| "A prospective controlled randomized trial testing adjuvant postoperative combination chemotherapy (5-fluorouracil, lomustine (CCNU) and vincristine) versus no adjuvant therapy in patients operated on for Dukes' C colorectal cancer is reported." | 9.06 | Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. ( Asklöf, G; Bergman, L; Domellöf, L; Hafström, L; Hansson, K; Kugelberg, C; Nilsson, T; Norryd, C; Rudenstam, CM; Wählby, L, 1990) |
| "On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix." | 9.06 | A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. ( Alberts, DS; Boutselis, JG; Green, S; Hannigan, EV; Surwit, EA; Wallace, DL; Weiss, GR, 1990) |
| "Forty-nine nonpregnant women with extensive condylomata acuminata of the vulva were studied to evaluate the effectiveness of topical 5-fluorouracil (5-FU) for treating vulvar condylomata and to compare the results of continuous use with periodic use of the medication." | 9.06 | Treatment of extensive vulvar condylomata acuminata with topical 5-fluorouracil. ( Krebs, HB, 1990) |
| "The relationship between hormone receptor status and the effect of adjuvant tamoxifen in early breast cancer remains controversial." | 9.06 | The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. ( Cedermark, B; Fornander, T; Glas, U; Johansson, H; Nordenskjöld, B; Rotstein, S; Rutqvist, LE; Skoog, L; Somell, A; Theve, T, 1989) |
| "Treatment with tamoxifen (TM), alone or in combination with cyclophosphamide, methotrexate, and fluorouracil (CMF), was used as an adjuvant to surgery in 433 patients with stage I, II, or III(T3a) breast cancer." | 9.06 | Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. ( Bianco, AR; D'Istria, M; De Placido, S; Delrio, G; Gallo, C; Marinelli, A; Pagliarulo, C; Petrella, G, 1988) |
| "Randomized clinical trials were conducted in patients with advanced/relapsed breast cancer, using CMitF (mitoxantrone, cyclophosphamide, and 5-fluorouracil) regimen in comparison with CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen." | 9.06 | [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer]. ( Sakai, K; Taguchi, T; Terasawa, T; Wada, H, 1986) |
| "Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy." | 9.06 | Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. ( Emrich, LJ; Lele, SB; Patsner, B; Piver, MS, 1986) |
| "A randomized controlled trial envelope method was conducted in 126 cases of recurrent breast cancer to compare the antitumor efficacy and toxicity of spansule (SF-SP) and gastro-soluble tegafur." | 9.05 | [Comparative study on two different types of tegafur for recurrent breast cancer]. ( Taguchi, T, 1984) |
| "In a controlled clinical trial, 52 patients with ER positive metastatic breast cancer were randomly assigned to receive initial treatment with either tamoxifen alone followed by sequential cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) after tumour progression of concurrent tamoxifen plus CMF, All 52 patients entered are eligible and 50 patients were currently assessable." | 9.05 | Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF. ( Bezwoda, WR; De Moor, NG; Derman, D; Lange, M; Levin, J, 1982) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 9.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 9.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| "To evaluate the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil (5-FU), in preventing postoperative recurrence of bladder cancer, a randomized controlled study with 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) as the reference standard was performed." | 9.05 | [A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer]. ( Hisazumi, H; Kanda, S; Katsumi, T; Kawaguchi, K; Mikawa, I; Misaki, T; Miyagi, T; Nakamura, T; Orito, M; Sakai, A, 1985) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 8.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "In Japan, standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) includes preoperative chemotherapy with fluorouracil plus cisplatin followed by esophagectomy." | 8.12 | Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ( Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T, 2022) |
| "To explore the efficacy and safety of gemcitabine (GEM) combined with cisplatin (DDP) in the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC)." | 8.12 | Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma. ( Cai, MB; Li, ZM; Nie, YH; Tan, YR; Yang, Q; Zhu, HB, 2022) |
| "To date, 5-fluorouracil-based chemotherapy is very important for locally advanced or metastatic colorectal cancer (CRC)." | 8.12 | Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness. ( Cheng, J; Jin, M; Lin, Z; Ren, J; Wang, L; Wu, G; Yang, K; Yu, D; Zhang, D; Zhang, T; Zhao, L; Zhou, P, 2022) |
| "Surgically resected colorectal cancer specimens from 89 patients were decellularized to produce patient-derived scaffold, which were seeded with HT29 cells, cultured for 3 weeks, and treated with 5-fluorouracil." | 8.12 | 5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information. ( Bexe Lindskog, E; Holdfeldt, A; Landberg, G; Salerno, S; Ståhlberg, A, 2022) |
| "Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response." | 8.12 | Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022) |
| "To investigate whether the addition of fluorouracil to docetaxel and cisplatin induction chemotherapy (IC) can truly improve the prognosis of patients with locoregionally advanced nasopharyngeal carcinoma (NPC)." | 8.12 | Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis. ( Liao, K; Qiu, WZ; Tao, HY; Yuan, YW; Zhan, ZJ; Zheng, RH, 2022) |
| "Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC)." | 7.96 | Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil. ( Mertens, LS; Noordzij, A; Pos, F; Schaake, EE; Schuring, N; van de Kamp, MW; van der Heijden, MS; van Rhijn, BWG; Voskuilen, CS, 2020) |
| "The high-budding group demonstrated resistance to 5-fluorouracil-based chemotherapy, whereas the low-budding group exhibited significant survival benefits from adjuvant chemotherapy in stage III colorectal cancer." | 7.91 | Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis. ( Hase, K; Kajiwara, Y; Mochizuki, S; Okamoto, K; Shinto, E; Ueno, H; Yamadera, M; Yamamoto, J, 2019) |
| "The current study suggests that the identification of predictive signatures of fluorouracil (5-FU) response for stage II and III colorectal cancer (CRC) could be confounded by chemotherapy-irrelevant low relapse risk." | 7.91 | Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. ( Ao, L; Cai, H; Guo, Y; Guo, Z; Li, N; Song, K; Song, X; Wang, X; Zhao, W; Zheng, W, 2019) |
| "Compared with conventional fluorouracil plus cisplatin (FP) regimen, gemcitabine plus cisplatin (GP) can prolong survival in patients with recurrent or metastatic nasopharyngeal carcinoma, but the economic impact of this practice remains unknown." | 7.91 | Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. ( Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T, 2019) |
| "This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel." | 7.88 | A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018) |
| "We wished to evaluate the efficacy and safety of liposomal paclitaxel and docetaxel for induction chemotherapy (IC) for nasopharyngeal carcinoma (NPC)." | 7.88 | Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma. ( Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC, 2018) |
| "The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 7.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
| "This retrospective study enrolled 131 patients with stage III colorectal cancer who underwent curative resection: 72 received 5-fluorouracil-based adjuvant chemotherapy (chemotherapy group) and 59 did not (surgery-alone group)." | 7.85 | Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer. ( Kameyama, H; Kobayashi, T; Kosugi, SI; Okamura, T; Shimada, Y; Tajima, Y; Wakai, T; Yagi, R, 2017) |
| "A total of 132 women with non-metastatic breast cancer receiving FEC (5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)) were prospectively enrolled." | 7.83 | A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. ( Au, HJ; Bies, RR; Carandang, D; Cass, CE; Clemons, M; Damaraju, S; Damaraju, VL; Hanson, J; Joy, AA; King, K; Koski, S; Kuzma, M; Mackey, JR; Pituskin, E; Prado, CM; Sawyer, MB; Scarfe, AG; Smylie, M; Tonkin, K; Vos, LJ, 2016) |
| "We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer." | 7.83 | In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016) |
| "The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma." | 7.81 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015) |
| "Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal." | 7.80 | Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. ( Chiu, J; Chu, KW; Epstein, RJ; Leung, R; Poon, J; Tang, V; Wong, H; Yau, T, 2014) |
| "We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer." | 7.80 | An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014) |
| "The effectiveness of 5-fluorouracil (5-FU)-based adjuvant chemotherapy is reported in patients with colorectal cancer (CRC), but the usefulness of 5-FU metabolic enzymes as predictive biomarkers of the efficacy of this chemotherapy remains unclear." | 7.80 | Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. ( Hasegawa, H; Ishii, Y; Kitagawa, Y; Okabayashi, K; Shigeta, K, 2014) |
| "Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer." | 7.80 | Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014) |
| "Our aim was to evaluate the efficacy and toxicity of cisplatin, fluorouracil, and docetaxel chemotherapy plus intensity-modulated radiotherapy (IMRT) for locoregionally advanced nasopharyngeal carcinoma (NPC)." | 7.79 | Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. ( Du, C; Hu, C; Ying, H; Zhang, Y; Zhou, J, 2013) |
| "The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy." | 7.78 | Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. ( Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY, 2012) |
| "A combination of 5-fluorouracil plus actinomycin D (5FU plus Act D) is the regimen that has been commonly administered to Chinese and Japanese gestational trophoblastic neoplasia patients as the first or second line of treatment with an excellent outcome." | 7.78 | Resistant gestational trophoblastic neoplasia patients treated with 5-fluorouracil plus actinomycin D. ( Manopunya, M; Suprasert, P, 2012) |
| "Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients with metastatic colorectal cancer (mCRC)." | 7.77 | A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. ( Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A, 2011) |
| "FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients." | 7.77 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma." | 7.76 | [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. ( Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK, 2010) |
| "A 77-year-old woman treated with capecitabine for late recurrence of breast cancer developed life-threatening toxicity shortly after receiving the second cycle of therapy." | 7.76 | Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer. ( Bozzarelli, S; Carnaghi, C; Colombo, P; De Vincenzo, F; Giorgetti, PL; Rimassa, L; Santoro, A; Sclafani, F, 2010) |
| "Data were collected from 1097 consecutive anthracycline-naive patients treated for metastatic breast cancer with epirubicin." | 7.74 | New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. ( Andersen, PK; Cortese, G; Nielsen, D; Nielsen, G; Ryberg, M; Skovsgaard, T, 2008) |
| "To give an update on the long-term outcome of an intensified protocol of combined radiochemotherapy (RCT) with 5-fluorouracil (5-FU) and cisplatin after initial transurethral resection of bladder tumor (TURBT) with selective organ preservation in bladder cancer." | 7.74 | Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. ( Dunst, J; Engehausen, DG; Krause, FS; Papadopoulos, T; Rödel, C; Sauer, R; Weiss, C, 2007) |
| "Taxanes (TX) were administered to 246 of 292 patients with recurrent/metastatic breast cancer (MBC) who were treated in Hiei Hospital between January 2001 and May 2006." | 7.74 | [Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer]. ( Iguchi, C; Kan, N; Kodama, H; Nio, Y; Yoshikawa, K, 2007) |
| "To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma." | 7.73 | Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. ( Adams, R; Jones, RS; Keene, KS; Penberthy, DR; Rich, TA; Shepard, RC, 2005) |
| "The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5'-TSER, 3'-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy." | 7.73 | Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. ( Adleff, V; Budai, B; Czeglédi, F; Gyergyay, F; Hitre, E; Horváth, Z; Kásler, M; Kovács, T; Kralovánszky, J; Láng, I; Lövey, J; Orosz, Z, 2005) |
| "Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer." | 7.73 | Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 7.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 7.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 7.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 7.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "Three dogs with advanced-stage adenocarcinoma of the gastrointestinal tract were treated by use of resection, adjuvant chemotherapy with cisplatin and 5-fluorouracil, and second-look laparotomy (SLL)." | 7.72 | Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. ( Gilson, SD; Stanclift, RM, 2004) |
| "We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously." | 7.71 | [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 7.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "Based on these results, we consider the addition of high-dose toremifene to the CAF therapy to be useful in the treatment of advanced and recurrent breast cancer." | 7.70 | Cyclophosphamide, adriamycin, 5-fluorouracil and high-dose toremifene for patients with advanced/recurrent breast cancer. The Japan Toremifene Cooperative Study Group. ( Aoyama, H; Hirata, K; Kimura, M; Kinoshita, H; Koyama, H; Monden, Y; Nomura, Y; Ogawa, M; Takashima, S; Tominaga, T; Uchino, J; Yoshida, M, 1998) |
| "We herein report the case of a patient with recurrent breast cancer who showed a remarkable improvement in her quality of life (QOL) as a result of a good response to medroxyprogesterone acetate (MPA)." | 7.70 | Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care. ( Higashi, Y; Iino, Y; Ishiguro, S; Kurihara, T; Morishita, Y; Suemasu, K; Tabei, T; Takeda, F, 1998) |
| "A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)." | 7.70 | [A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000) |
| "We have investigated the effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) on meningioma cells in two different culture systems, evaluated by the uptake of radiolabelled methionine." | 7.69 | Synergistic inhibitory effects of interferon-alpha and 5-fluorouracil in meningioma cells in vitro. ( Muhr, C; Smits, A; Wang, JL; Zhang, ZJ, 1996) |
| "Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen." | 7.67 | Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989) |
| "We report a case of recurrent adenocarcinoma of the bladder treated by intra-arterial infusion of 5-fluorouracil (5-FU)." | 7.67 | Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder. ( Fuchs, EF; Hatch, TR, 1989) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 7.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "This study was carried out to evaluate the effects of carmofur (Mifurol), a masked compound of 5-fluorouracil (5-FU), in preventing postoperative recurrence of urogenital carcinoma (especially in bladder cancer)." | 7.67 | [Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent]. ( Funai, K; Hayahara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Nishio, S; Yasumoto, R; Yuki, K, 1987) |
| "25 patients (2 females, 23 males, 20 to 40-year-old) suffering from condylomata acuminata (19 genital, 2 anal, and 4 genitoanal lesions) were locally treated with salicylic acid containing 5-fluorouracil (Verrumal) once a day." | 7.67 | [5-Fluorouracil treatment of condylomata acuminata]. ( Djawari, D, 1986) |
| "Twenty-five consecutive cases of inflammatory breast carcinoma were treated with high-dose cyclophosphamide and 5-fluorouracil in 5-day courses every 3 weeks for 2 years, with total mastectomy performed after the third course." | 7.67 | Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. ( Breau, JL; Israël, L; Morere, JF, 1986) |
| "The effects of combination chemotherapy including mitoxantrone (MXN) "M-VEMFH" for advanced breast cancer were studied." | 7.67 | [Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer]. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sugiura, I, 1985) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 7.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer." | 7.66 | [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer]. ( Abe, O; Enomoto, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1982) |
| "Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate." | 7.65 | Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. ( Bruckner, HW; Deppe, G, 1977) |
| "Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | 6.94 | Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
| "For stage II/Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic options." | 6.87 | Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. ( Gray, R; Handley, K; Hutchins, GGA; Kerr, D; Magill, L; Quirke, P; Seymour, M; Southward, K; Tinkler-Hundal, E; Treanor, D; Wright, A, 2018) |
| "Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression." | 6.82 | MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil. ( Gazouli, M; Lampropoulou, DI; Nemati, M; Pouya, FD; Rasmi, Y, 2022) |
| " Treatment consisted of paclitaxel at a dose of 135 mg/m(2) on day 1, cisplatin 25 mg/m(2)/day from day 1 to day 3 and 5-FU-continuous infusion for 120 h at a variable dosage from 600 to 1,000 mg/m(2)/day according to prior radiation." | 6.78 | Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. ( An, X; Chen, C; Li, YH; Liang, Y; Luo, HY; Wang, FH; Wang, ZQ; Zhang, L, 2013) |
| "Of these, 10 (22%) had inflammatory breast cancer (IBC), and 27 (60%) had estrogen receptor (ER)(+) disease." | 6.76 | Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. ( Buyse, ME; Dy, PA; Geyer, CE; Jacobs, SA; Liepman, MK; Mamounas, EP; Melnik, MK; Pajon, ER; Piette, F; Posada, JG; Rastogi, P; Robidoux, A; Swain, SM; Wolmark, N, 2011) |
| "Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection." | 6.75 | Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010) |
| "To evaluate the efficacy and safety of weekly or 3-week docetaxel in combination with capecitabine." | 6.75 | [A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer]. ( Bai, YX; Cheng, Y; Jiang, ZF; Jiao, SC; Li, X; Liu, DQ; Liu, JW; Liu, WC; Ren, J; Sun, Q; Tang, LL; Wang, HQ; Wang, Y; Wang, YS; Wei, Y; Xiao, JX; Xie, XD; Zhang, SH, 2010) |
| "Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks." | 6.74 | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009) |
| "For patients who have significant residual tumor after resection or relapse after radiation, the proper chemotherapy regimen has not yet been identified." | 6.72 | Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. ( Ahn, SD; Ghim, TT; Goo, HW; Khang, SK; Kim, YJ; Lee, MJ; Park, JB; Ra, YS; Song, JS, 2006) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 6.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "Thirty-six patients died because of disease progression, and 3 are alive with progressive disease." | 6.71 | Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A, 2005) |
| "Thirty-two patients (76%) had no oral mucositis." | 6.68 | Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 6.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| " Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions." | 6.67 | Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. ( Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992) |
| " Group A received (2"R)-4'-O-tetrahydropyranyladriamycin (THP) in combination with 5-fluorouracil (5-FU) and cyclophosphamide (CPA), while Group B was administered adriamycin (ADR) together with 5-FU and CPA." | 6.66 | A randomized controlled study of (2"R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tominaga, T, 1989) |
| "5-Fluorouracil was administered p." | 6.66 | Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1987) |
| " From the above results, THP in combination with cyclophosphamide and 5-Fluorouracil is comparable to ADR in efficacy and can be regarded as having better safety than ADR for the treatment of breast cancer." | 6.66 | [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer]. ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tanaka, T; Tominaga, T, 1986) |
| "172 patients who had had mastectomy for breast cancer were treated by repeated adjuvant chemotherapy, either with phenylalanine mustard (P." | 6.64 | Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Hahn, RG; Ingle, JN; O'Connell, MJ; O'Fallon, JR; Payne, WS; Rubin, J; Scanlon, PW, 1978) |
| "Capecitabine is an oral fluoropyrimidine that mimics continuous infusion 5-fluorouracil and generates 5-fluorouracil preferentially at the tumor site." | 6.41 | The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. ( Blum, JL, 2001) |
| "Capecitabine is an excellent treatment option for patients who require symptom palliation and who prefer oral medications." | 6.41 | Clinical status of capecitabine in the treatment of breast cancer. ( Gradishar, WJ, 2001) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of lapatinib for the treatment of advanced or metastatic HER2-overexpressing breast cancer based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process." | 6.24 | Lapatinib for the treatment of HER2-overexpressing breast cancer. ( Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C, 2009) |
| "This study was conducted before the approval of oxaliplatin, cetuximab, and bevacizumab and was designed to evaluate a novel microtubule targeting agent, T138067, in patients with metastatic colorectal cancer (CRC) previously treated with irinotecan and 5-fluorouracil." | 6.23 | Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. ( Bergsland, E; Berlin, JD; Lockhart, AC; Rosen, L; Rothenberg, M; Venook, A, 2008) |
| "On day 2 of re-treatment, serous retinal detachment recurred and treatment was discontinued." | 5.72 | [A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer]. ( Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K, 2022) |
| "Folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or modified FOLFIRINOX (mFFX) is the first-line standard of care for metastatic pancreatic adenocarcinoma; effective and safe treatment strategies are needed as survival remains poor." | 5.69 | Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. ( Bai, X; Chen, Y; Fu, Q; Gao, S; Guo, C; Huang, D; Li, X; Liang, T; Que, R; Shen, Y; Wu, J; Xiao, W; Xue, X; Zhang, M; Zhang, Q; Zhang, X, 2023) |
| "Trifluridine/tipiracil monotherapy is feasible and shows modest activity in patients with refractory esophageal squamous cell carcinoma." | 5.51 | Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. ( Hara, H; Hironaka, S; Horimatsu, T; Ishihara, R; Kasai, H; Kato, K; Kawaguchi, A; Kikuchi, O; Kojima, T; Mori, Y; Mukai, K; Muto, M; Tada, H; Tsushima, T; Uozumi, R, 2022) |
| "To determine whether induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improves survival vs cisplatin and fluorouracil (PF) prior to chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma." | 5.51 | Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. ( Cao, KJ; Chen, MY; Chen, QY; Chen, ZJ; Guo, L; Guo, X; Hu, D; Hua, YJ; Huang, PY; Ke, LR; Li, WZ; Liang, H; Liu, GY; Liu, T; Lu, N; Luo, DH; Lv, SH; Lv, X; Mai, HQ; Mo, HY; Qian, CN; Qiu, F; Sun, R; Tang, LQ; Tang, WB; Tong, LH; Wang, DS; Wang, L; Xia, WX; Xiang, YQ; Yang, W; Ye, YF; Yuan, TZ; Zhang, HX; Zhao, C, 2022) |
| "Fluorouracil (FU), platinum (PT), and taxane (TAX) therapy was the standard chemotherapy for esophageal squamous cell carcinoma (ESCC) before the era of anti-programmed death-1 antibodies." | 5.51 | A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404). ( Hirota, M; Kawada, J; Kawakami, H; Kii, T; Kurokawa, Y; Matsuyama, J; Nomura, M; Ohta, T; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T, 2022) |
| "Background Early relapse in colorectal cancer (CRC) after curative resection is mainly attributed to the key determinants such as tumor histology, stage, lymphovascular invasion, and the response to chemotherapy." | 5.48 | Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy. ( Ajaj, AR; Al-Hiary, R; Al-Yacoub, S; Kadi, T; Majdalawi, K; Mukred, R; Tantawi, D; Yousef, AM; Yousef, M; Zawiah, M, 2018) |
| "Breast cancer is believed to result from the interplay of genetic and non-genetic risk factors, and individual genetic variation may influence the efficacy of chemotherapy." | 5.43 | A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients. ( Fan, T; Fan, Z; Li, J; Lin, B; Ouyang, T; Wang, T; Wu, L; Xie, Y; Yao, L; Yin, CC; Zhang, H, 2016) |
| " The chemotherapy drugs were administered as follows: 135 mg/m(2) paclitaxel on day 1, 25 mg/m(2)/day cisplatin on days 1-3, followed by continuously infused intravenous fluorouracil for 120 h at a variable dosage from 600 to 800 mg/m(2)/day, depending on prior radiation." | 5.43 | A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. ( Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ, 2016) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 5.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "Patients suffering from triple-negative breast cancer (TNBC) have poor prognosis mainly because no standard treatment is currently available." | 5.38 | Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. ( Jiang, X; Lin, G; Liu, D; Peng, J; Peng, R; Qin, T; Shi, Y; Teng, X; Wang, S; Wang, X; Yuan, Z, 2012) |
| "To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer." | 5.38 | [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012) |
| "Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study." | 5.35 | Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. ( Agrogiannis, G; Arapogiannis, G; Gouveris, P; Kavantzas, N; Kopterides, P; Kosmas, C; Kyriakou, V; Lazaris, A; Papathomas, T; Patsouris, E; Tsavaris, N; Zorzos, H, 2009) |
| "The estimated rate of freedom from recurrence of breast cancer at a distant site in women with an RS of 26 to 100 treated largely with taxane and/or anthracycline-containing adjuvant chemotherapy regimens plus endocrine therapy in the prospective TAILORx trial was 93% at 5 years, an outcome better than expected with endocrine therapy alone in this population." | 5.34 | Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. ( Abrams, J; Albain, KS; Badve, SS; Berenberg, JL; Brufsky, AM; Dees, EC; Desbiens, C; Ellis, MJ; Geyer, CE; Goetz, MP; Goggins, TF; Gomez, HL; Gray, RJ; Hayes, DF; Kaklamani, VG; Keane, MM; Lively, T; Mahalcioiu, C; Makower, DF; Mayer, IA; Olson, JA; Paik, S; Reddy, PS; Saphner, TJ; Sledge, GW; Sparano, JA; Toppmeyer, DL; Wagner, LI; Wood, WC, 2020) |
| "The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival." | 5.34 | Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. ( Banzi, M; Cardellino, GG; Cinieri, S; Ciuffreda, L; Corallo, S; Corsi, D; Galli, F; Labianca, R; Lonardi, S; Maiello, E; Mambrini, A; Marchetti, P; Mattioli, R; Petrelli, F; Pusceddu, V; Rimassa, L; Ronzoni, M; Rosati, G; Rulli, E; Sobrero, A; Zagonel, V; Zampino, M; Zaniboni, A, 2020) |
| "A current recommendation for the treatment of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) is conventional fractionated radiotherapy (RT) with concurrent cisplatin followed by adjuvant cisplatin and 5-fluorouracil (PF)." | 5.34 | NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. ( Chan, ATC; Chappell, R; Cheng, AAC; Choi, HCW; Kwong, DLW; Lee, AWM; Lu, TX; Ng, WT; Ngan, RKC; Sze, HCK; Tung, SY; Wong, FCS; Yiu, HHY; Yuen, KT, 2020) |
| "Induction cisplatin and gemcitabine chemotherapy is a standard treatment for locally advanced nasopharyngeal carcinoma (NPC)." | 5.34 | Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. ( Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K, 2020) |
| " In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules." | 5.34 | [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine]. ( Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007) |
| "Oral capecitabine is an active and well-tolerated agent when used alone as first-line therapy in patients who have relapsed after HDC-ASCS for MBC." | 5.31 | Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support. ( Ball, ED; Bashey, A; Corringham, S; Jones, V; Lancaster, D; Law, P; Silva-Gietzen, J; Sundaram, S, 2001) |
| "We conducted a single-arm phase II trial to evaluate the efficacy and adverse effects (AEs) of an anti-epidermal growth factor receptor monoclonal antibody, nimotuzumab, combined with cisplatin and 5-fluorouracil (PF) as first-line treatment in recurrent metastatic nasopharyngeal carcinoma after radical radiotherapy." | 5.30 | Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. ( Chen, J; Chen, X; Chua, MLK; Han, F; Hu, G; Hu, X; Li, J; Mai, H; Miao, J; Shao, X; Shen, G; Shi, M; Wang, L; Wu, S; Xie, C; Zhang, N; Zhao, C, 2019) |
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 5.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| "Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil." | 5.28 | Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991) |
| "Patients with HER2-negative and endocrine treatment-resistant breast cancer with metastasis or recurrence after surgery were randomly assigned to receive first-line taxane or S-1." | 5.27 | Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer. ( Fukuda, T; Hagiwara, Y; Kawahara, T; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Taira, N; Uemura, Y; Watanabe, T, 2018) |
| "To evaluate, in a phase 2 study, whether induction docetaxel, cisplatin, and fluorouracil (TPF) followed by weekly docetaxel and cetuximab in concurrence with intensity modulated radiation therapy can improve the treatment outcome for patients with advanced locally recurrent nasopharyngeal carcinoma (rNPC)." | 5.27 | Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. ( Chan, LLK; Kam, MKM; Kwong, DLW; Lee, AWM; Lung, ML; Ng, WT; Ngan, RKC; Sze, HCK; Tung, SY; Yiu, HHY; Yuen, KT, 2018) |
| "Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone." | 5.24 | Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). ( Alberts, SR; Berg, DJ; Bjarnason, GA; Ciombor, K; Dragovich, T; Enzinger, PC; Fuchs, CS; Goldberg, RM; Gunderson, LL; Haller, DG; Ilson, D; Mamon, HJ; Mayer, RJ; Meyerhardt, J; Niedzwiecki, D; O'Reilly, E; Swanson, RS; Tepper, JE; Venook, AP; Willett, CG; Ye, X, 2017) |
| "To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) vs bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain." | 5.24 | Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. ( Gea, S; López-Martínez, N; Rivera, F; Valladares, M, 2017) |
| "In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer." | 5.24 | mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design ( Kurosawa, S; Mishima, H; Nagata, N; Oba, K; Sakamoto, J, 2017) |
| "Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status and normal blood and renal function, were treated with capecitabine 825 mg/m(2) bid during radiotherapy associated with a single dose of mitomycin 15 mg/m(2) on day 1." | 5.22 | Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. ( Alex, AK; Bariani, G; Braghirolli, MI; Hoff, PM; Moniz, CM; Nahas, C; Oliveira, SC; Riechelmann, R, 2016) |
| "gov NCT00561470) was to investigate the treatment effect of adding aflibercept to second-line infusional 5-fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) in patients with metastatic colorectal cancer (mCRC) who had failed any prior oxaliplatin-containing regimen." | 5.22 | Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A ( Andria, M; Arnold, D; Cunningham, D; Dochy, E; Grávalos, C; Hoff, PM; Humblet, Y; Joulain, F; Kröning, H; Lakomý, R; Le-Guennec, S; Macarulla, T; McKendrick, J; Mitchell, E; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Tabernero, J; Ten Tije, AJ; Van Cutsem, E; van Hazel, G; Vishwanath, RL, 2016) |
| " Ocular discomfort occurred in 43 of 49 patients in the fluorouracil group versus 36 of 49 in the placebo group, epiphora occurred in 24 versus five, and eyelid skin inflammation occurred in seven versus none." | 5.22 | Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial. ( Burton, MJ; Gichuhi, S; Kabiru, J; Macharia, E; Maina, J; Munene, R; Ollando, E; Onyuma, T; Rono, H; Sagoo, MS; Wachira, J; Weiss, HA; Zindamoyen, AM, 2016) |
| " Women aged 65-79, operated for breast cancer, with average to high risk of recurrence, were allocated 1 : 1 to CMF (cyclophosphamide 600 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m², days 1, 8) or docetaxel (35 mg/m(2) days 1, 8, 15) every 4 weeks, for four or six cycles according to hormone receptor status." | 5.20 | Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. ( Barni, S; Botti, G; Colantuoni, G; D'Aiuto, M; Daniele, B; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Di Maio, M; Di Rella, F; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Iodice, G; Labonia, V; Landi, G; Lauria, R; Montanino, A; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, E; Signoriello, S; Tinessa, V, 2015) |
| "A current recommendation for locoregionally advanced nasopharyngeal carcinoma (NPC) is conventional fractionated radiotherapy with concurrent cisplatin plus adjuvant cisplatin and fluorouracil (PF)." | 5.20 | Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr ( Chan, AT; Chan, LL; Chan, OS; Chappell, R; Cheng, A; Cheung, FY; Choi, H; Kwong, DL; Lee, AW; Lu, TX; Ng, WT; Ngan, RK; Tung, SY; Wong, F; Yau, S; Yiu, H; Yuen, KT, 2015) |
| "CEREBEL compared the incidence of CNS metastases as first site of relapse in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer receiving lapatinib-capecitabine or trastuzumab-capecitabine." | 5.20 | CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. ( Allerton, R; Bidoli, P; Chan, S; Chmielowska, E; Ciruelos, E; Dank, M; DeSilvio, M; Fabi, A; Gori, S; Hornyak, L; Karaszewska, B; Manikhas, A; Margolin, S; Nagi, F; Nusch, A; Parikh, R; Pivot, X; Santillana, S; Semiglazov, V; Swaby, RF; Żurawski, B, 2015) |
| "This study compared the efficacy and toxicity of Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil (5-FU) in patients of recurrent squamous cell carcinoma of head and neck (SCCHN) treated with palliative intent." | 5.20 | Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. ( Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP, 2015) |
| "Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC)." | 5.20 | Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. ( Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D, 2015) |
| "In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3-4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m(2) on days 1-5 and 29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m(2) on days 1-5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m(2) on days 1-14 and 22-35) and oxaliplatin (50 mg/m(2) on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m(2) on days 1 and 15), leucovorin (400 mg/m(2) on days 1 and 15), and infusional fluorouracil (2400 mg/m(2) on days 1-2 and 15-16)." | 5.20 | Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. ( Arnold, D; Fietkau, R; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Hoffmanns, H; Hofheinz, RD; Hohenberger, W; Hothorn, T; Lang-Welzenbach, M; Liersch, T; Lindemann, F; Raab, HR; Rödel, C; Sauer, R; Schlenska-Lange, A; Staib, L; Ströbel, P; Wilhelm, M; Wittekind, C; Wolff, HA, 2015) |
| "Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients." | 5.20 | Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. ( Aftimos, P; Ameye, L; Beauduin, M; Bejarano Hernández, S; Cornez, N; de Azambuja, E; Delhaye, F; Diaz, M; Focan, C; Lemort, M; Paesmans, M; Piccart-Gebhart, M; Shih-Li, C; Suter, T; Vandenbossche, S; Vindevoghel, A, 2015) |
| "Although cisplatin combined with 5-fluorouracil is a common first-line regimen for advanced nasopharyngeal carcinoma (NPC), there are no standard regimens for refractory or relapsed patients." | 5.19 | Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy. ( Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Wang, XX, 2014) |
| "We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea." | 5.19 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. ( Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI, 2014) |
| "The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50." | 5.17 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. ( Begum, R; Cunningham, D; Essapen, S; Falk, S; Glynne-Jones, R; Gollins, S; James, RD; Kadalayil, L; Ledermann, J; Leslie, M; Maughan, T; McDonald, A; Meadows, HM; Myint, AS; Saunders, MP; Sebag-Montefiore, D; Wilson, C, 2013) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 5.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin." | 5.17 | Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. ( Ajani, JA; Benson, AB; Gunderson, LL; Haddock, MG; Mayer, RJ; Moughan, J; Pedersen, JE; Rich, TA; Thomas, CR; Willett, CG; Winter, KA, 2013) |
| "The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer." | 5.17 | FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013) |
| " This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer." | 5.17 | Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. ( Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 5.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| " In the TEX trial, 287 patients with locally advanced or distant metastatic breast cancer were randomized to either epirubicin and paclitaxel (ET) or epirubicin, paclitaxel, and capecitabine (TEX)." | 5.16 | Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. ( Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H, 2012) |
| "To explore the impact of dose intensity (DI) in the adjuvant setting of breast cancer, a randomized phase III trial was conducted comparing postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide, methotrexate and fluorouracil (CMF)in high-risk breast cancer patients." | 5.16 | Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. ( Bafaloukos, D; Batistatou, A; Bobos, M; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Kosmidis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Stathopoulos, GP; Timotheadou, E, 2012) |
| "Therapy-naive patients, age 18-75 years, Karnofsky Performance Status (KPS)>60, gross total resection of stage IB-III pancreatic adenocarcinoma, stratified for center and surgical margins, were randomly assigned to receive either gemcitabine 1 g/m2 weekly on days 1, 8, and 15 (arm A) or the PEFG regimen (cisplatin and epirubicin 40 mg/m2, day 1; gemcitabine 600 mg/m2, days 1, 8; 5-fluorouracil 200 mg/m2 daily, days 1-28) (arm B)." | 5.16 | Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. ( Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A, 2012) |
| "We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC)." | 5.16 | Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. ( Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S, 2012) |
| "005) evaluating first-line bevacizumab plus paclitaxel or capecitabine for locally recurrent or metastatic breast cancer." | 5.16 | Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. ( Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z, 2012) |
| "Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)." | 5.16 | Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial. ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012) |
| "RNA was isolated from 308 formalin-fixed paraffin-embedded primary tumor samples from breast cancer patients enrolled in the HE10/97 trial, evaluating adjuvant dose-dense sequential chemotherapy with epirubicin followed by cyclophosphamide, methotrexate, fluorouracil (CMF) with or without paclitaxel (E-T-CMF versus E-CMF)." | 5.16 | The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology G ( Bafaloukos, D; Christodoulou, C; Fountzilas, G; Gogas, H; Kalogeras, KT; Koutras, AK; Kouvatseas, G; Kronenwett, R; Linardou, H; Pectasides, D; Samantas, E; Wirtz, RM; Zagouri, F, 2012) |
| "The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial." | 5.15 | Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. ( Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA, 2011) |
| "We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer." | 5.15 | XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. ( Cassidy, J; Clarke, S; Díaz-Rubio, E; Figer, A; Gilberg, F; Koski, S; Rittweger, K; Saltz, L; Scheithauer, W; Wong, R, 2011) |
| "We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection." | 5.15 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011) |
| " Capecitabine (CAP) and oxaliplatin (OX) are synergistic with radiotherapy (RT) and active in colorectal neoplasms." | 5.14 | Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. ( Bucci, L; Cannella, L; Carlomagno, C; D'Armiento, FP; D'Armiento, MR; De Placido, S; De Stefano, A; Farella, A; Pacelli, R; Pepe, S; Pesce, G; Solla, R, 2009) |
| "We randomly assigned patients with stage I, II, IIIA, or IIIB breast cancer to standard chemotherapy (either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide plus doxorubicin) or capecitabine." | 5.14 | Adjuvant chemotherapy in older women with early-stage breast cancer. ( Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Cohen, HJ; Dressler, LG; Gralow, JR; Grenier, D; Hart, RD; Hudis, CA; Kartcheske, PA; Kornblith, AB; Magrinat, G; Mahmood, AA; Mauer, AM; Muss, HB; Norton, L; Parker, BA; Partridge, AH; Perez, EA; Theodoulou, M; Wheeler, JD; Winer, EP; Wolff, AC, 2009) |
| "Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) has become a standard regimen for colorectal cancer." | 5.14 | Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. ( Ikeguchi, M; Kanazawa, A; Katano, K; Kidani, A; Makino, M; Ozaki, N; Sugimoto, S; Takeda, H; Tanaka, T; Yoshimura, H, 2009) |
| "Capecitabine is frequently used in the treatment of recurrent/progressive metastatic breast cancer (MBC) after prior anthracycline and taxane therapy." | 5.14 | Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. ( Abdulnabi, R; Clemons, M; Gelmon, K; Iscoe, N; Jordaan, JP; Joy, AA; Kotliar, M; Lynch, J, 2010) |
| "To describe the considerations leading to marketing approval of ixabepilone in combination with capecitabine and as monotherapy for the treatment of advanced breast cancer that is refractory to other chemotherapies." | 5.13 | Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. ( Aziz, R; Booth, B; Bullock, J; Dagher, R; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kasliwal, R; Lechleider, RJ; Leighton, J; Pazdur, R; Pope, S; Sridhara, R, 2008) |
| "To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer." | 5.13 | Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008) |
| "A dose-escalation study was conducted for patients with inoperable or recurrent breast cancer in order to determine the recommended dose (RD) of capecitabine combined with a fixed dose of weekly paclitaxel." | 5.13 | [A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer]. ( Horiguchi, J; Iino, Y; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, R; Odawara, H; Rokutanda, N; Sato, A; Takeyoshi, I; Tokiniwa, H, 2008) |
| "This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen." | 5.13 | Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008) |
| "International Breast Cancer Study Group Trial VI accrued 1475 eligible pre- and perimenopausal women with node-positive breast cancer who were randomly assigned to receive three to nine courses of classical combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.13 | Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. ( Castiglione-Gertsch, M; Coates, AS; Cole, BF; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Gusterson, BA; Holmberg, SB; Lindtner, J; Price, KN; Simoncini, E; Thürlimann, B; Viale, G, 2008) |
| "To evaluate the efficacies of cyclophosphamide, methotrexate, and fluorouracil (CMF) and tegafur-uracil (UFT) as adjuvant therapy in patients with resected stage I-IIIA breast cancer by immunohistochemistry (IHC)-based subtype and to determine the relationships between clinicopathological factors and long-term outcomes." | 5.12 | Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial). ( Akiyama, F; Inaji, H; Kurosumi, M; Masuda, N; Ohashi, Y; Ohno, S; Ohsumi, S; Saji, S; Sato, N; Shimomura, A; Takao, S; Tokuda, Y; Tsuda, H; Watanabe, T, 2021) |
| "To compare two different timings of radiation treatment in patients with breast cancer who underwent conservative surgery and were candidates to receive adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy." | 5.12 | A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. ( Arcangeli, G; Benassi, M; Giannarelli, D; Pinnarò, P; Rambone, R, 2006) |
| "We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)." | 5.12 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006) |
| "Concomitant radiotherapy with adjuvant fluorouracil, mitoxantrone, and cyclophosphamide has significantly better locoregional control in node-positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity." | 5.12 | A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. ( Bertheault-Cvitkovic, F; Castèra, D; Combe, M; de la Lande, B; Demange, L; Garbay, JR; Graïc, Y; Krzisch, C; Leduc, B; Lucas, V; Mouret-Fourme, E; Nguyen, TD; Noguès, C; Rouëssé, J; Serin, D; Villet, R, 2006) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 5.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer." | 5.12 | Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006) |
| "The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer." | 5.12 | Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. ( Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F, 2006) |
| "Based on phase II data in advanced breast cancer (BC), the fluorouracil, epirubicin, and vinorelbine (FEN) combination was assessed as perioperative chemotherapy, integrated in a multidisciplinary treatment for locally advanced BC." | 5.12 | Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. ( Ardavanis, A; Arnogiannaki, N; Chrysochoou, M; Ioannidis, G; Karamouzis, M; Missitzis, I; Orphanos, G; Pissakas, G; Rigatos, G; Scorilas, A; Sotiropoulou, A; Tryfonopoulos, D, 2006) |
| "A phase-I clinical study of a combination therapy of vinorelbine and capecitabine was conducted in anthracycline- and taxane-pretreated patients with advanced/recurrent breast cancer." | 5.12 | [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ( Aogi, K; Fujii, H; Hatake, K; Noguchi, S; Saeki, T; Sano, M; Tabei, T; Tokuda, Y, 2006) |
| " Here, we investigate the prognostic and treatment predictive role of CCND1 and PAK1 gene amplification in postmenopausal breast cancer patients randomized to tamoxifen treatment or no adjuvant treatment." | 5.12 | Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. ( Ahnström Waltersson, M; Bostner, J; Fornander, T; Nordenskjöld, B; Skoog, L; Stål, O, 2007) |
| "This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive breast cancer." | 5.12 | Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. ( Bondar, G; Kossé, V; Lehmann, U; Maubach, L; Meurer, J; Possinger, K; Schmid, P; Tarutinov, V; Untch, M; Vassiljev, L; Wallwiener, D, 2007) |
| "The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma." | 5.12 | Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. ( Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H, 2007) |
| "Tissue samples from patients with pathologic ((p)) stage III colorectal cancer were tested for sensitivity to 5-fluorouracil (5-FU)." | 5.12 | An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Watanabe, T, 2007) |
| "To assess the efficacy and tolerability of combination therapy with capecitabine and cisplatin in patients with recurrent carcinoma of the uterine cervix." | 5.12 | A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. ( Benjapibal, M; Inthasorn, P; Leelaphatanadit, C; Therasakvichya, S; Thirapakawong, C, 2007) |
| "Chemotherapy with fluorouracil and folinic acid could improve survival of patients with stage II colorectal cancer, although the absolute improvements are small: assuming 5-year mortality without chemotherapy is 20%, the relative risk of death seen here translates into an absolute improvement in survival of 3." | 5.12 | Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. ( Barnwell, J; Gray, R; Hills, RK; Kerr, DJ; McConkey, C; Williams, NS, 2007) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "5-Fluorouracil (5-FU), an antitumor agent, is used clinically against a variety of malignancies, including bladder carcinoma." | 5.11 | Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. ( Fukushima, M; Li, YN; Miki, T; Mizutani, Y; Nakanishi, H; Wada, H; Yoshida, O, 2004) |
| "In an earlier study, we have demonstrated a high clinical and pathologic response rate of neoadjuvant paclitaxel (P) and cisplatin (C) for patients with locally advanced breast cancer (LABC)." | 5.11 | Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. ( Ajarim, DS; Al-Malik, OA; Al-Shabanah, M; Ezzat, AA; Ibrahim, EM; Rahal, MM; Raja, MA; Sorbris, R; Tulbah, AM, 2004) |
| "The purpose of this report is to evaluate the efficacy and toxicity (Tx) of a double modulation of 5-fluorouracil (5-FU) by trimetrexate (TMTX) and leucovorin (LV) in patients with advanced recurrent (inoperable) or metastatic colorectal cancer (ACC)." | 5.11 | Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. ( Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004) |
| "A phase I clinical trial was started in order to determine the recommended doses of capecitabine and epirubicin, when administered in combination with a fixed dose of cyclophosphamide (600 mg/m(2) day 1 q3 weeks) in patients with inoperable or recurrent breast cancer." | 5.11 | Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer. ( Hozumi, Y; Ito, Y; Iwata, H; Kobayashi, T; Morita, S; Ohno, S; Sakamoto, J; Toi, M, 2004) |
| "To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse." | 5.11 | Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. ( Bonadonna, G; Gianni, L; Moliterni, A; Valagussa, P; Zambetti, M, 2004) |
| "We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer." | 5.11 | Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004) |
| "The goal of this multicenter, open-label phase II study was the clinical evaluation of combination therapy with the oral fluoropyrimidine capecitabine and the taxane paclitaxel in patients with metastatic breast cancer (MBC)." | 5.11 | Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. ( Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D, 2004) |
| "To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)." | 5.11 | A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004) |
| "To assess patterns of locoregional failure (LRF) in lymph node-positive (LN+) breast cancer patients treated with mastectomy and adjuvant chemotherapy (+/- tamoxifen) and without postmastectomy radiotherapy (PMRT) in five National Surgical Adjuvant Breast and Bowel Project trials." | 5.11 | Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized c ( Anderson, S; Bryant, J; Deutsch, M; Jeong, JH; Mamounas, E; Taghian, A; Wolmark, N, 2004) |
| "Since the need for nonanthracycline-containing chemotherapy regimens increases with the increased use of anthracyclines in earlier stages of breast cancer, we investigated the feasibility of the combination of docetaxel and 5-fluorouracil (5-FU) with folinic acid (FA)." | 5.11 | A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer. ( Nortier, JW; Rodenburg, CJ; Slee, PH; van Bochove, A, 2004) |
| "We randomized 1,475 premenopausal women with node-positive breast cancer to three, six, or nine courses of "classical" CMF (cyclophosphamide, methotrexate, and fluorouracil)." | 5.11 | Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca ( Bonetti, M; Carbone, A; Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Holmberg, SB; Lindtner, J; Nasi, ML; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B, 2005) |
| "Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)." | 5.11 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005) |
| " trastuzumab (8 mg/kg followed by 6 mg/kg) every 3 weeks in combination with chemotherapeutic agents administered in 3-weekly courses (docetaxel, vinorelbine and capecitabine) in 31 patients with HER2-positive recurrent locoregional and/or metastatic breast cancer." | 5.11 | Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. ( Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D, 2005) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 5.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "The purpose of this study was to evaluate the efficacy and tolerance of the bimonthly administration of oxaliplatin in combination with high-dose leucovorin and infusional 5-fluorouracil (5-FU) (FOLFOX2 regimen) in patients with advanced colorectal cancer (ACC) who did not respond or whose disease progressed within 3 months after front-line treatment with CPT-11-containing regimens." | 5.10 | Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). ( Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N, 2002) |
| "Effective adjuvant treatment modalities in premenopausal breast cancer patients today include chemotherapy, ovariectomy, and tamoxifen administration." | 5.10 | Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breas ( Bauernhofer, T; Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Seifert, M; Steger, G; Steindorfer, P; Wette, V, 2002) |
| "The purpose of this study was to evaluate the prognostic value of quantitative dynamic FDG PET studies in patients with metastastic colorectal cancer receiving FOLFOX (fluorouracil, folinic acid and oxaliplatin) chemotherapy." | 5.10 | PET-FDG as predictor of therapy response in patients with colorectal carcinoma. ( Dimitrakopoulou-Strauss, A; Rudi, J; Strauss, LG, 2003) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer." | 5.10 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003) |
| "We randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation." | 5.10 | Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. ( Fetting, J; Gradishar, WJ; Gray, R; Lazarus, HM; LeMaistre, CF; Osborne, CK; Paietta, E; Pisansky, TM; Robert, NJ; Tallman, MS; Vaughan, WP, 2003) |
| "Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine carbamate with high activity in metastatic breast cancer." | 5.10 | Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. ( Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G, 2003) |
| "To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy." | 5.10 | Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003) |
| "Cimetidine has been shown to have beneficial effects in colorectal cancer patients." | 5.10 | Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002) |
| "Twenty-one patients with recurrent or metastatic breast cancer were treated with paclitaxel (Taxol) as a 1-hour infusion on day 1 only of a 14-day cycle." | 5.10 | Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer. ( Amamoo, MA; Collichio, FA; Fogleman, J; Graham, M; Griggs, J, 2002) |
| "Capecitabine, a tumor-selective, oral fluoropyrimidine, has demonstrated significant antitumor activity in patients with metastatic breast cancer." | 5.10 | Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study. ( Bokemeyer, C; Jakob, A; Kanz, L; Knop, S; Mayer, F; Schupp, M, 2002) |
| "Paclitaxel has significant antitumor activity in patients with metastaticbreast cancer who have been previously treated with or exposed to anthracycline-containing chemotherapy." | 5.10 | Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. ( Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R, 2002) |
| "This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 5.09 | Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. ( Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A, 1999) |
| "The aim of this study was to evaluate the toxicity and efficacy of the combination of 5-fluorouracil, bleomycin, epirubicin, and cisplatin (FBEC) in the treatment of patients with undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 5.09 | Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. ( Armand, JP; Azli, N; Chouaki, N; Couteau, C; Cvitkovic, E; Fandi, A; Hasbini, A; Taamma, A; Wibault, P, 1999) |
| "To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival." | 5.09 | Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Manfreda, D; Mittlböck, M; Mlineritsch, B; Samonigg, H; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 5.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer." | 5.09 | Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). ( Abeloff, MD; Hochster, H; Kucuk, O; Pandya, KJ; Skeel, RT, 1999) |
| "Three hundred twenty-eight patients with stage II/IIIA breast cancer who were younger than 66 years of age were randomly allocated to chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC) or FAC plus pretreatment with ethinyl estradiol (EE(2))." | 5.09 | Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer. ( Baggen, MG; Beudeker, M; Bontenbal, M; Braun, JJ; Burghouts, JT; Foekens, JA; Helle, P; Janssen, JT; Klijn, JG; Leisink, M; Ras, GJ; Stiegelis, WF; van der Linden, GH; van der Velden, PC; van Geel, AN; van Putten, WL, 2000) |
| "The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer." | 5.09 | Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000) |
| "In a randomized trial, the authors evaluated the possible adjuvant activity of intraportal chemotherapy (with 5-fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7) administered after surgery to half of the patients who underwent a full resection for Dukes B2 or C colorectal cancer." | 5.09 | Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium). ( Beauduin, M; Brohée, D; Bury, J; Focan, C; Herman, ML; Lecomte, M; Vindevoghel, A, 2000) |
| "QUASAR is a large trial of adjuvant chemotherapy for colorectal cancer in which clinicians could choose to deliver a standard adjuvant cytotoxic chemotherapy regimen, 5-fluorouracil (5-FU) and L-folinic acid (L-FA), in either a once-weekly or a four-weekly schedule." | 5.09 | Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. ( Barnwell, J; Gray, R; Kerr, DJ; McConkey, C, 2000) |
| "Irinotecan (CPT11) has established activity in the treatment of advanced colorectal cancer without cross-resistance with established 5-fluorouracil/folinic acid-based therapy." | 5.09 | Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. ( Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D, 2001) |
| "Standard adjuvant chemotherapy for colorectal cancer consists of 5-fluorouracil with leucovorin or levamisole." | 5.09 | A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results. ( Kerr, DJ, 2001) |
| "The purpose of this investigation was to study the long-term prognosis of breast cancer patients with 10 or more positive lymph nodes after conventional chemotherapy treatment with cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.09 | Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. ( Bastert, G; Bojar, H; Sauerbrei, W; Schmoor, C; Schumacher, M, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | 5.09 | Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "Six hundred ninety-eight breast cancer patients (T1c, T2, T3, T4b, N0 to 1, and M0) were enrolled onto a randomized phase III trial that compared four cycles of fluorouracil, epirubicin, and cyclophosphamide administered preoperatively versus the same regimen administered postoperatively (the first cycle administered within 36 hours after surgery)." | 5.09 | Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. ( Duchateau, L; Julien, JP; Tubiana-Hulin, M; van de Velde, CJ; van der Hage, JA; Vandervelden, C, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| " 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas." | 5.09 | A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001) |
| "Between 1966 and 1983 we selected 209 patients with colorectal adenocarcinomas, stage B (14%) and C (86%) of Dukes, treated with convenient surgery in 100% of cases, 5-fluorouracil in 85% and postoperative radiotherapy with telecobalt in 46." | 5.08 | [Is radiotherapy necessary in the control of colorectal cancer?]. ( Molina Esquivel, J; Rodríguez del Rincón, E; Vargas Sandoval, G; Velázquez López, J, 1995) |
| "Seventy-six patients with bladder cancer Stage T1G3 through T4 N0 M0 were entered in the same chemotherapy regimen (Cisplatin 20 mg/mq and 5-Fluorouracil 200 mg/mq daily for 5 days) alternated with different radiotherapy scheduling, the first 18 patients received two cycles of 20 Gy/10 fractions/12 days each; the second group of 58 patients received two cycles of 25 Gy/10 fractions/12 days each (the last 21 patients received Methotrexate 40 mg/mq instead of 5-Fluorouracil)." | 5.08 | Alternating chemo-radiotherapy in bladder cancer: a conservative approach. ( Boccardo, F; Canobbio, L; Curotto, A; Franzone, P; Giudici, S; Guarneri, D; Martorana, G; Orsatti, M; Scarpati, D; Venturini, M, 1995) |
| "Sixty-two females and 21 males were treated for recurrent HPV infection, with either fluorouracil (Efudex 5%) cream or laser ablation of the lesions." | 5.08 | Interferon as an adjuvant treatment for genital condyloma acuminatum. ( Bergman, A; Klutke, JJ, 1995) |
| "Sixty-one patients with primary node positive stage III breast cancers were randomized to receive postoperative radiotherapy and doxorubicin-based chemotherapy (eight cycles of CAFt: cyclophosphamide, adriamycin, oral ftorafur) with or without tamoxifen as adjuvant treatment." | 5.08 | The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. ( Blomqvist, C; Elomaa, I; Gröhn, P; Rissanen, P; Saarto, T; Tiusanen, K, 1995) |
| "A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks." | 5.08 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 5.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "The effects of medroxyprogesterone acetate (MPA) therapy on advanced or recurrent breast cancer and its influence on blood coagulation and the fibrinolytic system were compared among three different therapy regimens consisting of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) + MPA and CAF or MPA alone." | 5.08 | Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system. ( Abe, O; Aoki, N; Asaishi, K; Enomoto, K; Izuo, M; Koyama, H; Nomura, Y; Ohshima, A; Tominaga, T; Tsukada, T, 1995) |
| "To evaluate ambulatory cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 32 patients with non-curative or recurrent colorectal cancer who were treated by l-Leucovorin (l-LV) plus 5-fluorouracil for the past four years." | 5.08 | [Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer]. ( Kunii, Y; Ota, K; Takahashi, N, 1995) |
| "In order to reduce toxic effects while attaining maximal therapeutic effects, epirubicin 10 mg/day, cyclophosphamide 100 mg/day and prednisolone 10 mg/day were administered through in indwelling catheter inserted into the internal mammary artery and/or subclavian artery for 3-4 weeks, employing the implantable port system for the treatment of unresectable breast cancer and recurrent cancer." | 5.08 | [Intra-arterial infusion chemotherapy for breast cancer]. ( Hamada, E; Ikawa, M; Matsumoto, Y; Miura, T; Murata, M; Nakasato, S; Takaki, S; Terakado, H; Watanabe, Y, 1996) |
| "In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2." | 5.08 | Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996) |
| "Fifty-nine patients with invasive primary gastric adenocarcinoma who were deemed resectable for cure entered a clinical trial that called for 2 cycles of protracted infusion 5-fluorouracil with weekly leucovorin and cisplatin chemotherapy followed by surgery." | 5.08 | Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. ( Baranda, J; Casagrande, Y; Crookes, P; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Silberman, H; Stain, S; Tan, M, 1997) |
| "The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer." | 5.08 | Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. ( Abramson, N; Atkins, JN; Bryant, J; DeCillis, A; Deschenes, L; Dignam, J; Dimitrov, NV; Emir, B; Fisher, B; Margolese, RG; Shibata, H; Wickerham, DL; Wolmark, N, 1997) |
| "The objective of the study was to determine the response rate and associated toxicity of 5-fluorouracil and high-dose leucovorin in patients with recurrent adenocarcinoma of the cervix." | 5.08 | Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. ( Andersen, WA; Blessing, JA; Look, KY; Manetta, A; McGehee, R; Valea, FA; Webster, KD, 1997) |
| "Sixty metastatic and recurrent breast cancer patients who had been given cyclophosphamide, methotrexate and fluorouracil (CMF) therapy previously and were treated at the Oncology Departments of Cukurova and Ege University Medical Schools between March 1992-94, were randomized into 2 groups for the chemotherapy program." | 5.08 | Refractory breast cancer: a comparison of two different chemotherapy regimens. ( Bilkay, BC; Burgut, R; Erkisi, M; Hazar, B; Seyrek, E, 1997) |
| "One hundred ninety-five women (141 eligible) whose disease was in CR or in CR except for bone metastases following six cycles (6 months) of doxorubicin-containing induction treatment were randomized to receive cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, and halotestin [CMF(P)TH] or observation." | 5.08 | Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. ( Abeloff, MD; Cummings, FJ; Falkson, G; Gelman, RS; Osborne, CK; Pandya, KJ; Sledge, GW; Tormey, D, 1998) |
| "To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of 5-fluorouracil (5-FU) in advanced or recurrent breast cancer patients who had been treated previously with at least one chemotherapeutic regimen, patients were treated with docetaxel as a 1-h infusion on day 1 followed by 5-FU as a continuous infusion on days 1 through 5 every 3-4 weeks." | 5.08 | A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. ( Adachi, I; Ando, M; Fujii, H; Igarashi, T; Itoh, K; Katsumata, N; Narabayashi, M; Ohtsu, T; Omuro, Y; Sasaki, Y; Taguchi, T; Tokue, Y; Wakita, H; Watanabe, T; Ying, DF, 1998) |
| "To evaluate ambulatory cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 12 outpatients with recurrent breast cancer who were treated by sequential methotrexate (MTX)/5-FU therapy for the past 2 years." | 5.07 | [Clinical study of ambulatory cancer chemotherapy for recurrent breast cancer]. ( Kunii, Y; Nitta, A; Ota, K; Takahashi, N, 1994) |
| "The usefulness of CAF [cyclophosphamide (CPA)/doxorubicin (ADR)/5-fluorouracil (5-FU)] + medroxyprogesterone acetate (MPA) therapy for advanced/recurrent breast cancer was studied in a randomised trial at 56 institutions." | 5.07 | Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. ( Abe, O; Abe, R; Enomoto, K; Hayasaka, H; Izuo, M; Ohshima, A; Takatani, O; Tominaga, T; Uchino, J; Watanabe, H, 1994) |
| " 414 premenopausal patients with T2-T3 N0-N1 M0 breast cancer were randomised to receive either four cycles of neoadjuvant chemotherapy (cyclophosphamide, doxorubicin, 5-fluorouracil), followed by local-regional treatment (group I) or four cycles of adjuvant chemotherapy after primary irradiation +/- surgery (group II)." | 5.07 | Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. ( Asselain, B; Beuzeboc, P; Dorval, T; Durand, JC; Fourquet, A; Jouve, M; Palangié, T; Pierga, JY; Scholl, SM; Vilcoq, JR, 1994) |
| "The clinical efficacy of "CMF" chemotherapy, (cyclophosphamide, methotrexate, 5-fluorouracil), was evaluated on advanced and recurrent breast cancer." | 5.07 | [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan]. ( Adachi, I; Fukami, A; Koyama, H; Nomura, Y; Tominaga, T, 1994) |
| "In a prospective study of 622 women with breast cancer, those with one to three histologically positive axillary lymph nodes were randomised after mastectomy to receive cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously on days 1 and 8, and fluorouracil 600 mg/m2 intravenously on days 1 and 8 every 28 days for six cycles (CMF x six), or for twelve cycles of the same chemotherapy (CMF x 12)." | 5.07 | Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial. ( Bartolucci, AA; Bass, D; Carpenter, JT; Ketcham, A; Marcial, V; Moore, M; Singh, KP; Smalley, R; Vélez-García, E; Vogel, CL, 1992) |
| "A randomized controlled trial was performed to study the efficiency of adjuvant chemotherapy with early intravesical instillation of Adriamycin and long-term oral administration of 5-fluorouracil in 275 patients with superficial bladder cancer." | 5.07 | Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1992) |
| "To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU." | 5.07 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992) |
| "This phase III prospective, randomized, and stratified trial was undertaken to evaluate the efficacy of four courses of combined fluorouracil (1000 mg per square meter of body-surface area daily for four days) and cisplatin (75 mg per square meter on the first day) plus 5000 cGy of radiation therapy, as compared with 6400 cGy of radiation therapy alone, in patients with squamous-cell carcinoma or adenocarcinoma of the thoracic esophagus." | 5.07 | Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. ( al-Sarraf, M; Brindle, J; Byhardt, R; Cooper, J; Davis, L; Emami, B; Herskovic, A; Leichman, L; Martz, K; Vaitkevicius, V, 1992) |
| "Between 1976 and 1984, 574 patients with operable breast cancer and histologically negative axillary lymph nodes were randomly assigned after mastectomy to receive either no further treatment or chemotherapy with oral LMF (fluorouracil, 500 mg, methotrexate, 25 mg, and chlorambucil, 10 mg, on day 1; fluorouracil, 500 mg, and chlorambucil, 10 mg, on day 2)." | 5.07 | West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. ( Grieve, RJ; Howell, A; Kelly, KA; Monypenny, IJ; Morrison, JM; Walker, RA; Waterhouse, JA, 1992) |
| "A randomised trial has previously been repeated in which 437 women with node positive breast cancer received either a 12-week chemohormonal regimen consisting of cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, adriamycin and tamoxifen or 36 weeks of CMFVP." | 5.07 | The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. ( Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Gent, M; Goodyear, MD; Levine, MN; Skillings, J, 1992) |
| "A randomized trial has been performed in which women with axillary node-positive breast cancer were allocated to either a short intensive 12-week chemohormonal treatment consisting of cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and tamoxifen (CMFVP plus AT) or 36 weeks of CMFVP." | 5.06 | A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. ( Abu-Zahra, H; Arnold, A; Bramwell, V; DePauw, S; Findlay, B; Gent, M; Hryniuk, WM; Levin, L; Levine, MN; Skillings, J, 1990) |
| "Thirty patients with advanced breast cancer, previously treated with anthracycline and 5 fluorouracil in bolus administration, were evaluated with a chemotherapy regimen generally used in head and neck cancer." | 5.06 | [Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]. ( Bastit, P; Bugat, R; Cappelaere, P; Chauvergne, J; Fumoleau, P; Horner, D; Metz, R, 1990) |
| "A prospective controlled randomized trial testing adjuvant postoperative combination chemotherapy (5-fluorouracil, lomustine (CCNU) and vincristine) versus no adjuvant therapy in patients operated on for Dukes' C colorectal cancer is reported." | 5.06 | Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. ( Asklöf, G; Bergman, L; Domellöf, L; Hafström, L; Hansson, K; Kugelberg, C; Nilsson, T; Norryd, C; Rudenstam, CM; Wählby, L, 1990) |
| "On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix." | 5.06 | A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. ( Alberts, DS; Boutselis, JG; Green, S; Hannigan, EV; Surwit, EA; Wallace, DL; Weiss, GR, 1990) |
| "Forty-nine nonpregnant women with extensive condylomata acuminata of the vulva were studied to evaluate the effectiveness of topical 5-fluorouracil (5-FU) for treating vulvar condylomata and to compare the results of continuous use with periodic use of the medication." | 5.06 | Treatment of extensive vulvar condylomata acuminata with topical 5-fluorouracil. ( Krebs, HB, 1990) |
| "We have evaluated the results of salvage systemic therapy in 257 patients with breast cancer recurrent after surgical adjuvant treatment with cyclophosphamide, fluorouracil, and prednisone (CFP) with or without tamoxifen." | 5.06 | Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. ( Ahmann, DL; Buckner, JC; Cullinan, SA; Everson, LK; Ingle, JN; Krook, JE; O'Fallon, JR; Pfeifle, DM, 1989) |
| "The relationship between hormone receptor status and the effect of adjuvant tamoxifen in early breast cancer remains controversial." | 5.06 | The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. ( Cedermark, B; Fornander, T; Glas, U; Johansson, H; Nordenskjöld, B; Rotstein, S; Rutqvist, LE; Skoog, L; Somell, A; Theve, T, 1989) |
| "Thirty-seven patients with poor prognosis, metastatic breast cancer were treated with 5-fluorouracil, vinblastine, and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (FUVA) induction chemotherapy." | 5.06 | Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study. ( Ellis, GK; Goldberg, RS; Green, S; Livingston, RB; Schulman, S; Tranum, BL, 1989) |
| "Postmenopausal women who underwent modified radical mastectomy for Stage II, estrogen receptor (ER)-positive breast cancer were randomized to receive endocrine treatment (tamoxifen [T], 40 mg daily for 3 years) alone versus endocrine treatment plus five-drug chemotherapy (Cytoxan [cyclophosphamide, C], methotrexate [M], 5-fluorouracil [F], vincristine [V], and prednisone [P], CMFVP, for 1 year)." | 5.06 | Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. ( Arafah, BM; Crowe, JP; Gordon, NH; Hubay, CA; Marshall, JS; McGuire, W; Pearson, OH, 1989) |
| "Treatment with tamoxifen (TM), alone or in combination with cyclophosphamide, methotrexate, and fluorouracil (CMF), was used as an adjuvant to surgery in 433 patients with stage I, II, or III(T3a) breast cancer." | 5.06 | Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. ( Bianco, AR; D'Istria, M; De Placido, S; Delrio, G; Gallo, C; Marinelli, A; Pagliarulo, C; Petrella, G, 1988) |
| "Eight hundred eighteen premenopausal or perimenopausal breast cancer patients with axillary node metastases were treated with adjuvant chemotherapy (CMF) with or without endocrine treatment (prednisone, oophorectomy) in two concurrent prospective trials." | 5.06 | Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. ( Castiglione, M; Gelber, RD; Goldhirsch, A, 1988) |
| "A multi-institutional cooperative study of patients with locally advanced, recurrent, or metastatic gastric adenocarcinoma who had not previously received chemotherapy was conducted, prospectively randomizing patients to receive either doxorubicin or the three-drug combination, 5-fluorouracil (5-FU), doxorubicin (Adriamycin; Adria Laboratories, Columbus, Ohio), and BCNU (FAB)." | 5.06 | Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. ( Fox, RM; Gill, G; Levi, JA; Tattersall, MH; Thomson, D; Woods, RL, 1986) |
| "Randomized clinical trials were conducted in patients with advanced/relapsed breast cancer, using CMitF (mitoxantrone, cyclophosphamide, and 5-fluorouracil) regimen in comparison with CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen." | 5.06 | [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer]. ( Sakai, K; Taguchi, T; Terasawa, T; Wada, H, 1986) |
| "Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy." | 5.06 | Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. ( Emrich, LJ; Lele, SB; Patsner, B; Piver, MS, 1986) |
| "This prospective evaluation of 5-fluorouracil (5-FU) and methyl-CCNU administered in combination to patients with surgery for histologically proved gastric adenocarcinoma is based upon 312 patients randomized between August 1974 and May 1980." | 5.05 | Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. ( Amadeo, JH; Higgins, GA; Humphrey, EW; Keehn, RJ; Smith, DE, 1983) |
| "One hundred thirty-six patients with isolated recurrence of breast cancer received regional therapy (surgery and/or irradiation) followed by combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC)." | 5.05 | Combined modality approach in breast cancer with isolated or multiple metastases. ( Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Marcus, CE; Montague, ED; Pinnamaneni, K; Smith, TL; Yap, HY, 1984) |
| "In 1977 the National Surgical Adjuvant Breast and Bowel Project (NSABP) initiated a prospectively randomized clinical trial to evaluate the relative merits of 1-phenylalanine mustard and 5-fluorouracil (PF) with and without tamoxifen (T) as adjuvant therapy for patients with primary breast cancer and positive axillary nodes." | 5.05 | Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. ( Allegra, J; Bowman, D; Brown, A; Fisher, B; Plotkin, D; Redmond, CK; Rockette, HE; Wickerham, DL; Wolter, J, 1983) |
| "A randomized controlled trial envelope method was conducted in 126 cases of recurrent breast cancer to compare the antitumor efficacy and toxicity of spansule (SF-SP) and gastro-soluble tegafur." | 5.05 | [Comparative study on two different types of tegafur for recurrent breast cancer]. ( Taguchi, T, 1984) |
| "The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma." | 5.05 | Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. ( Athens, J; Chen, TT; Costanzi, JJ; Haas, C; Heilbrun, LK; McDonald, B; Oishi, N; Panettiere, FJ; Talley, RW, 1984) |
| "In a controlled clinical trial, 52 patients with ER positive metastatic breast cancer were randomly assigned to receive initial treatment with either tamoxifen alone followed by sequential cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) after tumour progression of concurrent tamoxifen plus CMF, All 52 patients entered are eligible and 50 patients were currently assessable." | 5.05 | Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF. ( Bezwoda, WR; De Moor, NG; Derman, D; Lange, M; Levin, J, 1982) |
| "One hundred seventy-one patients received one year of melphalan or intermittent cyclophosphamide, methotrexate, and fluorouracil after mastectomy for breast cancer with involved axillary nodes." | 5.05 | Favorable factors in the adjuvant therapy of breast cancer. ( Carpenter, JT; Laws, HL; Maddox, WA; Soong, SJ; Wirtschafter, DD, 1982) |
| "In 1977 we reported our results of an ongoing randomized clinical trial evaluating early or delayed adjuvant chemotherapy utilizing 5-flourouracil, cytoxan and prednisone in premenopausal patients with recurrent or advanced breast cancer." | 5.05 | An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Green, SJ; Hahn, RG; Ingle, JN; Lee, RA, 1982) |
| "A prospective, randomized clinical trial of three treatment regimens: (1) Cytoxan, methotrexate, and 5-fluorouracil (CMF), (2) CMF plus the antiestrogen drug, tamoxifen (CMFT), and (3) CMFT plus bacillus Calmette-Guerin (BCG) vaccinations in women with stage 22 breast cancer is reported." | 5.05 | Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary report. ( Debanne, SM; Eckert, C; Flynn, WJ; Hermann, RE; Hubay, CA; Jones, JC; Mansour, EG; Marshall, JS; McGuire, WL; Pearson, OH; Rhodes, RS, 1980) |
| "To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients)." | 5.05 | Prolongation of the disease-free interval in surgically treated rectal carcinoma. ( , 1985) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 5.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 5.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| "To evaluate the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil (5-FU), in preventing postoperative recurrence of bladder cancer, a randomized controlled study with 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) as the reference standard was performed." | 5.05 | [A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer]. ( Hisazumi, H; Kanda, S; Katsumi, T; Kawaguchi, K; Mikawa, I; Misaki, T; Miyagi, T; Nakamura, T; Orito, M; Sakai, A, 1985) |
| "Concomitant external-beam radiochemotherapy (5-fluorouracil-mitomycin C) has become the standard of care in anal cancer since the '90s." | 5.01 | Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). ( Ajani, JA; Bosset, JF; Chakravarthy, AB; Christiaens, M; Collette, L; Glynne-Jones, R; Hannoun-Levi, JM; Haustermans, K; Konski, AA; Maingon, P; Matzinger, O; Meadows, H; Northover, J; Peiffert, D; Puyraveau, M; Rivin Del Campo, E; Winter, KA, 2019) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 4.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "In patients with stage III colorectal cancer (CRC) who have undergone potentially curative resection, adjuvant treatment with 6 months' of 5-fluorouracil (5-FU) plus folinic acid (FA) is generally accepted as standard treatment and leads to a 5% to 10% improvement in absolute survival when compared with a no-chemotherapy control." | 4.82 | Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. ( Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M, 2003) |
| "To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of relapse, on the basis of three successive randomised trials and one observational study conducted from June 1973 to December 1980." | 4.82 | 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. ( Bonadonna, G; Daidone, MG; Gianni, L; Moliterni, A; Pilotti, S; Valagussa, P; Zambetti, M, 2005) |
| " 5-Fluorouracil (5FU) is widely used as the first-line treatment of colorectal cancer (CRC)." | 4.31 | Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids. ( Castañeda-Patlán, MC; Macías-Silva, M; Moreno-Londoño, AP; Robles-Flores, M; Sarabia-Sánchez, MA, 2023) |
| "In Japan, standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) includes preoperative chemotherapy with fluorouracil plus cisplatin followed by esophagectomy." | 4.12 | Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ( Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T, 2022) |
| "To explore the efficacy and safety of gemcitabine (GEM) combined with cisplatin (DDP) in the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC)." | 4.12 | Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma. ( Cai, MB; Li, ZM; Nie, YH; Tan, YR; Yang, Q; Zhu, HB, 2022) |
| "To date, 5-fluorouracil-based chemotherapy is very important for locally advanced or metastatic colorectal cancer (CRC)." | 4.12 | Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness. ( Cheng, J; Jin, M; Lin, Z; Ren, J; Wang, L; Wu, G; Yang, K; Yu, D; Zhang, D; Zhang, T; Zhao, L; Zhou, P, 2022) |
| "Surgically resected colorectal cancer specimens from 89 patients were decellularized to produce patient-derived scaffold, which were seeded with HT29 cells, cultured for 3 weeks, and treated with 5-fluorouracil." | 4.12 | 5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information. ( Bexe Lindskog, E; Holdfeldt, A; Landberg, G; Salerno, S; Ståhlberg, A, 2022) |
| "Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response." | 4.12 | Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022) |
| "To investigate whether the addition of fluorouracil to docetaxel and cisplatin induction chemotherapy (IC) can truly improve the prognosis of patients with locoregionally advanced nasopharyngeal carcinoma (NPC)." | 4.12 | Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis. ( Liao, K; Qiu, WZ; Tao, HY; Yuan, YW; Zhan, ZJ; Zheng, RH, 2022) |
| "The antimetabolite drug, 5-fluorouracil (5-FU), has been suggested as an adjunctive treatment to reduce the recurrence rates of odontogenic keratocysts (OKCs)." | 4.02 | 5-Fluorouracil Is Associated With a Decreased Recurrence Risk in Odontogenic Keratocyst Management: A Retrospective Cohort Study. ( Bradley, G; Caminiti, MF; El-Rabbany, M; Jeon, J, 2021) |
| "Consecutive patients with locally advanced (T2 ≥ 4 cm-T4 or N+) anal cancer scheduled for two cycles of concomitant 5-fluorouracil and mitomycin C chemotherapy were selected from an institutional database (n = 106)." | 4.02 | Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer. ( Johnsson, A; Nilsson, MP; Scherman, J, 2021) |
| "Molecular breast cancer subtypes were centrally assessed on whole tumor sections by IHC in patients of the Austrian Breast and Colorectal Cancer Study Group Trial 5 who had received either 5 years of tamoxifen/3 years of goserelin or six cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF)." | 3.96 | Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. ( Bago-Horvath, Z; Balic, M; Filipits, M; Gnant, M; Greil, R; Hulla, W; Kwasny, W; Lax, SF; Rudas, M; Singer, CF, 2020) |
| "Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC)." | 3.96 | Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil. ( Mertens, LS; Noordzij, A; Pos, F; Schaake, EE; Schuring, N; van de Kamp, MW; van der Heijden, MS; van Rhijn, BWG; Voskuilen, CS, 2020) |
| "The high-budding group demonstrated resistance to 5-fluorouracil-based chemotherapy, whereas the low-budding group exhibited significant survival benefits from adjuvant chemotherapy in stage III colorectal cancer." | 3.91 | Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis. ( Hase, K; Kajiwara, Y; Mochizuki, S; Okamoto, K; Shinto, E; Ueno, H; Yamadera, M; Yamamoto, J, 2019) |
| "The current study suggests that the identification of predictive signatures of fluorouracil (5-FU) response for stage II and III colorectal cancer (CRC) could be confounded by chemotherapy-irrelevant low relapse risk." | 3.91 | Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. ( Ao, L; Cai, H; Guo, Y; Guo, Z; Li, N; Song, K; Song, X; Wang, X; Zhao, W; Zheng, W, 2019) |
| "First-line adjuvant chemotherapy options for early-stage colorectal cancer (CRC) include CapeOx (capecitabine, intravenous oxaliplatin) and FOLFOX (intravenous 5-fluorouracil, leucovorin, oxaliplatin)." | 3.91 | Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. ( Chambers, CR; Chu, MP; Dersch-Mills, D; Ghosh, S; Ha, V; Sawyer, MB; Wong, GG, 2019) |
| "Compared with conventional fluorouracil plus cisplatin (FP) regimen, gemcitabine plus cisplatin (GP) can prolong survival in patients with recurrent or metastatic nasopharyngeal carcinoma, but the economic impact of this practice remains unknown." | 3.91 | Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. ( Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T, 2019) |
| "Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)." | 3.91 | S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019) |
| "This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel." | 3.88 | A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018) |
| "Prosigna assays were performed on the NanoString platform in tumors from participants in Danish Breast Cancer Group (DBCG) 77B, a four-arm trial that randomized premenopausal women with high-risk early breast cancer to no systemic treatment, levamisole, oral cyclophosphamide (C) or cyclophosphamide, methotrexate and fluorouracil (CMF)." | 3.88 | The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. ( Buckingham, W; Ejlertsen, B; Eriksen, JO; Ferree, S; Hood, T; Jensen, MB; Lænkholm, AV; Nielsen, TO; Ram, N; Wehn, P, 2018) |
| "We wished to evaluate the efficacy and safety of liposomal paclitaxel and docetaxel for induction chemotherapy (IC) for nasopharyngeal carcinoma (NPC)." | 3.88 | Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma. ( Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC, 2018) |
| " We conducted a retrospective study to evaluate the efficacy of this protocol with taxene, cisplatin and 5-fluorouracil in Chinese patients with hypopharyngeal cancer that chose preservation strategy." | 3.88 | Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer. ( Bai, Y; Fang, J; Feng, L; Hou, L; Li, P; Lian, M; Liu, S; Ma, H; Meng, L; Zhong, Q, 2018) |
| "The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 3.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
| "This retrospective study enrolled 131 patients with stage III colorectal cancer who underwent curative resection: 72 received 5-fluorouracil-based adjuvant chemotherapy (chemotherapy group) and 59 did not (surgery-alone group)." | 3.85 | Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer. ( Kameyama, H; Kobayashi, T; Kosugi, SI; Okamura, T; Shimada, Y; Tajima, Y; Wakai, T; Yagi, R, 2017) |
| "A total of 132 women with non-metastatic breast cancer receiving FEC (5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)) were prospectively enrolled." | 3.83 | A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. ( Au, HJ; Bies, RR; Carandang, D; Cass, CE; Clemons, M; Damaraju, S; Damaraju, VL; Hanson, J; Joy, AA; King, K; Koski, S; Kuzma, M; Mackey, JR; Pituskin, E; Prado, CM; Sawyer, MB; Scarfe, AG; Smylie, M; Tonkin, K; Vos, LJ, 2016) |
| "We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer." | 3.83 | In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016) |
| "Protein content of ABCC10 and ABCC11 was assessed in tumor tissue blocks of 140 colorectal cancer patients and associated with survival of patients with regard to 5-fluorouracil-based therapy." | 3.83 | Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients. ( Bruha, J; Daum, O; Dubova, M; Krizkova, V; Liska, V; Skala, M; Soucek, P; Susova, S; Vycital, O, 2016) |
| "Perioperative chemotherapy with 5-fluorouracil and cisplatin, with or without epirubicin, improves overall survival in resectable gastroesophageal junction and gastric adenocarcinoma." | 3.83 | Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. ( Afchain, P; Aparicio, T; Artru, P; Bachet, JB; Baumgaertner, I; Benallaoua, M; Boige, V; Boubaya, M; Coriat, R; des Guetz, G; Lecaille, C; Locher, C; Mary, F; Samalin, E; Tougeron, D; Zaanan, A, 2016) |
| "The two key aspects associated with the microsatellite instability (MSI) as genetic phenomenon in colorectal cancer (CRC) are better survival prognosis, and the varying response to 5-fluorouracil (5-FU)-based chemotherapy." | 3.83 | Microsatellite instability & survival in patients with stage II/III colorectal carcinoma. ( Branimir, Z; Daniela, B; Ivan, D; Jadranka, A; Petar, S; Srdjan, M; Velimir, M; Zoran, K, 2016) |
| "To compare the treatment outcomes of concurrent involved-field radiotherapy and XELOX (oxaliplatin and capecitabine) versus XELOX chemotherapy alone in gastric adenocarcinoma patients with locoregional recurrence." | 3.81 | Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. ( Huang, Y; Li, WH; Li, YQ; Liu, N; Liu, SG; Liu, XB; Liu, YH; Wang, FL; Yu, J; Yuan, ST; Zhang, JD; Zhang, Y, 2015) |
| "The MAGIC/UK Medical Research Council (MRC) trial set the standard of care for treatment of resectable gastric and junctional adenocarcinoma, demonstrating that perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (ECF) confers a survival benefit over surgery alone." | 3.81 | Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. ( Kalachand, R; King, S; Mongan, AM; Muldoon, C; O'Byrne, K; O'Farrell, NJ; Power, D; Ravi, N; Reynolds, JV, 2015) |
| "First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine." | 3.81 | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. ( Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I, 2015) |
| "The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma." | 3.81 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015) |
| "Concomitant chemoradiotherapy of 5-fluorouracil and cisplatin with radiotherapy is a highly effective and well-tolerated treatment of anal cancer." | 3.81 | Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2015) |
| "To summarize the experience of the chemotherapy regimen cisplatin + fluorouracil + vincristine (C5V) for hepatoblastoma, and analyze the factors associated the outcome." | 3.81 | [Outcome of hepatoblastoma: experience with 63 patients received chemotherapy with the regimen C5V]. ( Dong, K; Li, K; Liu, B; Liu, G; Xiao, X, 2015) |
| "Colorectal cancer is commonly treated with 5-fluorouracil and 5-formyltetrahydrofolate (leucovorin)." | 3.81 | Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Sondén, A; Wettergren, Y, 2015) |
| "Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse." | 3.80 | AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. ( Arthur, K; Blayney, JK; Dunne, PD; Greer, S; Johnston, PG; Kalimutho, M; Longley, DB; Loughrey, M; McArt, DG; Ong, CW; Redmond, K; Salto-Tellez, M; Srivastava, S; Van Schaeybroeck, S; Wang, T, 2014) |
| "Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal." | 3.80 | Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. ( Chiu, J; Chu, KW; Epstein, RJ; Leung, R; Poon, J; Tang, V; Wong, H; Yau, T, 2014) |
| "We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer." | 3.80 | An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014) |
| "The effectiveness of 5-fluorouracil (5-FU)-based adjuvant chemotherapy is reported in patients with colorectal cancer (CRC), but the usefulness of 5-FU metabolic enzymes as predictive biomarkers of the efficacy of this chemotherapy remains unclear." | 3.80 | Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. ( Hasegawa, H; Ishii, Y; Kitagawa, Y; Okabayashi, K; Shigeta, K, 2014) |
| "Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer." | 3.80 | Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014) |
| " Here, we report an advanced case of breast cancer with vertebra-Th7 metastasis that showed complete response to combined treatments with formalin-fixed autologous tumor vaccine (AFTV), palliative radiation therapy with 36 Gy, and adjuvant chemotherapy with standardized CEF (cyclophosphamide, epirubicin, and 5FU), zoledronic acid, and aromatase inhibitors following mastectomy for the breast tumor." | 3.79 | Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report. ( Kuranishi, F; Ohno, T, 2013) |
| "Tumor control and survival of patient with advanced cholangiocarcinoma treated with gemcitabine-based and 5FU-based chemotherapy do not markedly differ." | 3.79 | Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. ( Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU, 2013) |
| "Our aim was to evaluate the efficacy and toxicity of cisplatin, fluorouracil, and docetaxel chemotherapy plus intensity-modulated radiotherapy (IMRT) for locoregionally advanced nasopharyngeal carcinoma (NPC)." | 3.79 | Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. ( Du, C; Hu, C; Ying, H; Zhang, Y; Zhou, J, 2013) |
| "The prognostic impact of CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) on the treatment outcome of colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) is unclear." | 3.79 | Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ, 2013) |
| "The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy." | 3.78 | Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. ( Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY, 2012) |
| "A combination of 5-fluorouracil plus actinomycin D (5FU plus Act D) is the regimen that has been commonly administered to Chinese and Japanese gestational trophoblastic neoplasia patients as the first or second line of treatment with an excellent outcome." | 3.78 | Resistant gestational trophoblastic neoplasia patients treated with 5-fluorouracil plus actinomycin D. ( Manopunya, M; Suprasert, P, 2012) |
| "To evaluate the effect of anthracycline pirarubicin-based regimen in association with different ways of fluorouracil (5-Fu) as neoadjuvant and adjuvant chemotherapy for primary breast cancer." | 3.78 | [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer]. ( Fan, T; Fan, ZQ; Li, JF; Lin, BY; Ouyang, T; Wang, LZ; Wang, TF; Xie, YT, 2012) |
| "The combination of PLD with cisplatin and infusional fluorouracil (CCF) for 8 courses was investigated in patients with primary or recurrent T2-T4a-d N0-3 M0 breast cancer." | 3.77 | Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. ( Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Iorfida, M; Luini, A; Montagna, E; Scarano, E; Torrisi, R; Veronesi, P; Viale, G, 2011) |
| "When applying the topoisomerase inhibitor irinotecan (CPT) with the infusional fluorouracil/levofolinate (FOLFIRI) ± bevacizumab chemotherapy regimen in cases of advanced colorectal carcinoma, the international standard dose for CPT is 180 mg/m(2)." | 3.77 | Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. ( Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y, 2011) |
| "Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients with metastatic colorectal cancer (mCRC)." | 3.77 | A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. ( Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A, 2011) |
| "After resection of CRC and synchronous metastases, 53 (84%) out of 63 patients without chemotherapy, and 38 (83%) out of 46 that received 5-fluorouracil (5-FU) alone or with leucovorin (LV) developed recurrent tumors." | 3.77 | FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. ( Kanazawa, T; Kawai, K; Kazama, S; Kitayama, J; Mori, K; Nagawa, H; Nozawa, H; Saito, S; Sunami, E; Yazawa, K, 2011) |
| "FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients." | 3.77 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively." | 3.77 | Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. ( Cho, YB; Choi, SH; Chun, HK; Chung, HJ; Kim, HC; Lee, WY; Yun, SH, 2011) |
| "We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma." | 3.76 | [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. ( Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK, 2010) |
| "We examined the pre-treatment tumour biopsies (n=40) obtained from patients with rectal adenocarcinoma (clinical International Union Against Cancer stage ll/III) who were scheduled to receive neoadjuvant 5-fluorouracil-based chemoradiotherapy for EGFR, VEGF and HIF-1 expression by quantitative real-time polymerase chain reaction." | 3.76 | Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg ( Inoue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2010) |
| "Survival and recurrence patterns of 91 patients with adenocarcinoma of the stomach who had received surgery followed by radiotherapy combined with fluorouracil and leucovorin (n = 5), capecitabine (n = 39), or capecitabine and cisplatin (n = 47) were analyzed and compared with survival and recurrence patterns of 694 patients from the DGCT (D1, n = 369; D2, n = 325)." | 3.76 | Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. ( Bakker, B; Boot, H; Cats, A; Dikken, JL; Hartgrink, HH; Jansen, EP; Kranenbarg, EM; Peeters, KC; Putter, H; van de Velde, CJ; Verheij, M, 2010) |
| "A 77-year-old woman treated with capecitabine for late recurrence of breast cancer developed life-threatening toxicity shortly after receiving the second cycle of therapy." | 3.76 | Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer. ( Bozzarelli, S; Carnaghi, C; Colombo, P; De Vincenzo, F; Giorgetti, PL; Rimassa, L; Santoro, A; Sclafani, F, 2010) |
| "Conflicting data exist regarding the relevance of high-frequency microsatellite instability (MSI-H) for predicting the prognosis and benefits of 5-fluorouracil (5-FU)-based chemotherapy." | 3.75 | Chemosensitivity and survival in gastric cancer patients with microsatellite instability. ( Ando, K; Kakeji, Y; Maehara, Y; Masuda, T; Morita, M; Ohgaki, K; Oki, E; Yoshida, R; Zhao, Y, 2009) |
| " We performed retrospective study that examined the efficacy of preventive treatment (granisetron+dexamethasone+domperidone) for delayed emesis induced by FOLFOX4 chemotherapy for advanced and recurrent colorectal cancer." | 3.75 | [Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy]. ( Hama, T; Hatake, K; Imada, H; Kamisugi, K; Kawakami, K; Matsusaka, S; Mizunuma, N; Nakamoto, E; Shinozaki, E; Shirai, T; Shouji, D; Suenaga, M; Suzuki, W; Takahashi, G; Yokokawa, T, 2009) |
| "Data were collected from 1097 consecutive anthracycline-naive patients treated for metastatic breast cancer with epirubicin." | 3.74 | New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. ( Andersen, PK; Cortese, G; Nielsen, D; Nielsen, G; Ryberg, M; Skovsgaard, T, 2008) |
| "To give an update on the long-term outcome of an intensified protocol of combined radiochemotherapy (RCT) with 5-fluorouracil (5-FU) and cisplatin after initial transurethral resection of bladder tumor (TURBT) with selective organ preservation in bladder cancer." | 3.74 | Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. ( Dunst, J; Engehausen, DG; Krause, FS; Papadopoulos, T; Rödel, C; Sauer, R; Weiss, C, 2007) |
| "In 25 consecutive non-metastatic primary breast cancer patients adjuvant fluorouracil/epirubicin/cyclophosphamid (FEC) or EC followed by taxane (EC-T) or cyclophosphamid/methotrexate/fluorouracil (CMF) therapy were given." | 3.74 | An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer. ( Dengler, R; Fröhlich, F; Kroll, T; Lobodasch, K; Pachmann, K; Pachmann, U; Rengsberger, M; Schubert, R, 2008) |
| "Taxanes (TX) were administered to 246 of 292 patients with recurrent/metastatic breast cancer (MBC) who were treated in Hiei Hospital between January 2001 and May 2006." | 3.74 | [Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer]. ( Iguchi, C; Kan, N; Kodama, H; Nio, Y; Yoshikawa, K, 2007) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| "Oxaliplatin, Irinotecan, 5-fluorouracil and leucovorin are commonly used to treat advanced colorectal cancer in Western countries." | 3.74 | Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer. ( Aso, M; Higashi, H; Imamura, S; Kakeji, Y; Katoh, H; Maehara, S; Maehara, Y; Makino, I; Saeki, H; Tanaka, J, 2007) |
| "To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma." | 3.73 | Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. ( Adams, R; Jones, RS; Keene, KS; Penberthy, DR; Rich, TA; Shepard, RC, 2005) |
| "A 55-year-old Asian Indian woman who had recurrent sebaceous gland carcinoma of the left lower eyelid with orbital extension and regional lymph node metastasis was treated with neoadjuvant chemotherapy, using a combination of carboplatin and 5-fluorouracil." | 3.73 | Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. ( Burman, S; Honavar, SG; Murthy, R; Naik, MN; Reddy, VA; Vemuganti, GK, 2005) |
| "The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5'-TSER, 3'-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy." | 3.73 | Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. ( Adleff, V; Budai, B; Czeglédi, F; Gyergyay, F; Hitre, E; Horváth, Z; Kásler, M; Kovács, T; Kralovánszky, J; Láng, I; Lövey, J; Orosz, Z, 2005) |
| "Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer." | 3.73 | Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005) |
| "To report on possible adverse interaction between capecitabine and warfarin in a patient with cancer, who developed subconjunctival and nose bleeding during treatment with these drugs and review of the previously reported five cases in the literature." | 3.73 | Drug interaction between capecitabine and warfarin: a case report and review of the literature. ( Akcali, Z; Basturk, B; Ozyilkan, O; Yildirim, Y, 2006) |
| "The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen." | 3.73 | Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. ( Baehner, FL; Baker, J; Bryant, J; Costantino, JP; Cronin, M; Geyer, CE; Kim, C; Kim, W; Paik, S; Shak, S; Tang, G; Watson, D; Wickerham, DL; Wolmark, N, 2006) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 3.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 3.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 3.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "This study was to investigate the effect of capecitabine on recurrent tumor and metastasis after curative resection of liver cancer, xenograft of a highly metastatic human hepatocellular carcinoma (HCC) tumor (LCI-D20), with special reference to the expression of platelet-derived endothelial cell growth factor (PD-ECGF)." | 3.72 | Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. ( Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J, 2003) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 3.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| " Dihydropyrimidine dehydrogenase (DPD) which catalyzes 5-fluorouracil (5-FU), thymidine phosphorylase (TP), responsible for catalyzing doxifluridine to 5-FU, and thymidylate synthase (TS) were estimated for breast cancer." | 3.72 | [Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer]. ( Koh, M; Morimoto, K, 2004) |
| "Three dogs with advanced-stage adenocarcinoma of the gastrointestinal tract were treated by use of resection, adjuvant chemotherapy with cisplatin and 5-fluorouracil, and second-look laparotomy (SLL)." | 3.72 | Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. ( Gilson, SD; Stanclift, RM, 2004) |
| "One hundred and three patients with recurrent adenocarcinoma of the rectum underwent reirradiation with concurrent 5-fluorouracil-based chemotherapy." | 3.71 | Long-term results of reirradiation for patients with recurrent rectal carcinoma. ( Marks, G; Marks, J; Mohiuddin, M, 2002) |
| "We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously." | 3.71 | [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002) |
| "The clinical relevance of bax and bcl-2 protein expression has been investigated in 84 patients with recurrent or metastatic colorectal cancer submitted to a chemotherapy regimen including methotrexate and fluorouracil/leucovorin." | 3.71 | Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. ( Costa, A; Daidone, MG; Dellapasqua, S; Lacava, J; Lena, MD; Leone, B; Paradiso, A; Simone, G; Vallejo, C, 2001) |
| "One hundred nine patients with stage II or III (T3N1) breast cancer were treated in three prospective trials utilizing four cycles of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC, n = 72) or paclitaxel (n = 37) followed by segmental resection (n = 109) and axillary node dissection (n = 94)." | 3.71 | Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. ( Ames, FC; Buchholz, TA; Buzdar, AU; Hortobagyi, GN; Hunt, KK; Kuerer, HM; Pusztai, L; Ross, MI; Singletary, SE; Valero, V, 2001) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 3.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "Sixteen patients with rectal adenocarcinoma up to 3 cm above the pectineal line with initial indications for abdominoperineal resection (APR) were submitted to a 5040-cGy (28 x 180 cGy) radiotherapy dose and chemotherapy during the first 3 and last 3 days of radiotherapy, using 425 mg/m2/day of 5-fluorouracil (5FU) and 20 mg/m2/day of folinic acid." | 3.70 | Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial. ( Filho, WD; Lopes, A; Nakagawa, WT; Novaes, PE; Rossi, BM, 1998) |
| "Based on these results, we consider the addition of high-dose toremifene to the CAF therapy to be useful in the treatment of advanced and recurrent breast cancer." | 3.70 | Cyclophosphamide, adriamycin, 5-fluorouracil and high-dose toremifene for patients with advanced/recurrent breast cancer. The Japan Toremifene Cooperative Study Group. ( Aoyama, H; Hirata, K; Kimura, M; Kinoshita, H; Koyama, H; Monden, Y; Nomura, Y; Ogawa, M; Takashima, S; Tominaga, T; Uchino, J; Yoshida, M, 1998) |
| "Epirubicin and 5-FU were administered through an indwelling catheter inserted into the internal mammary artery and/or subclavian artery employing an implantable infusion port system for the treatment of unresectable advanced breast cancer and recurrent breast cancer." | 3.70 | [Intra-arterial infusion chemotherapy for unresectable or recurrent breast cancer]. ( An, M; Hamada, E; Idezuki, Y; Ikawa, M; Kishi, T; Kobayashi, M; Matsumoto, Y; Miura, T; Murata, M; Nakasato, S; Takaki, S; Terakado, H; Watanabe, Y, 1998) |
| "We herein report the case of a patient with recurrent breast cancer who showed a remarkable improvement in her quality of life (QOL) as a result of a good response to medroxyprogesterone acetate (MPA)." | 3.70 | Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care. ( Higashi, Y; Iino, Y; Ishiguro, S; Kurihara, T; Morishita, Y; Suemasu, K; Tabei, T; Takeda, F, 1998) |
| "Concurrent 2-drug chemoradiotherapy with cisplatin and 5-fluorouracil is feasible without major toxicity and offers a potentially curative and conservative treatment for patients with localized muscle-invasive bladder cancer." | 3.70 | [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study]. ( Berger, C; Chauvet, B; Davin, JL; Félix-Faure, C; Reboul, F; Vincent, P, 1998) |
| "For almost 40 years, 5-fluorouracil (5-FU) has been the only useful drug with clinically meaningful activity in metastatic colorectal carcinoma." | 3.70 | Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer. ( Au, E; Khoo, KS; Koo, WH; Lim, WT, 1999) |
| "An 83-year-old Caucasian man with cutaneous T-cell lymphoma developed an aggressive squamous cell carcinoma of the left forearm, which recurred and metastasized after Mohs micrographic surgery and systemic chemotherapy with cis-platin and 5-fluorouracil." | 3.70 | Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis. ( Beer, R; Elizeri, Y; Gmyrek, R; Grossman, ME; Oster, MW; Schneiderman, P; Silvers, DN, 1999) |
| "A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)." | 3.70 | [A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000) |
| "(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy." | 3.70 | Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Donehower, RC; Grochow, LB; Hruban, RH; Hurwitz, H; Jaffee, EM; Korman, LT; Lillemoe, KD; O'Reilly, S; Yeo, CJ; Zahurek, ML, 2000) |
| "Continuous systemic infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (500 mg/body/day) was performed for advanced hepatocellular carcinoma (HCC) after hepatectomy with diffuse lung metastases and multiple intrahepatic metastases." | 3.70 | [Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 2000) |
| "The relationship of changes in 3H-thymidine labelling index (TLI) induced by primary chemotherapy to tumor response and relapse rate in 36 patients with previously untreated locally advanced breast cancer (LABC) was analyzed." | 3.69 | Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. ( Alama, A; Camoriano, A; Campora, E; Gardin, G; Meazza, R; Merlini, L; Naso, C; Pronzato, P; Repetto, L; Rosso, R, 1994) |
| "Between 1982 and 1992, 139 patients with epidermoid carcinoma of the anal canal were treated by radiation and chemotherapy with 5-fluorouracil (5-Fu) and mitomycin C (MMC)." | 3.69 | [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients]. ( Budach, V; Döker, R; Grabenbauer, GG; Huber, K; Hültenschmidt, B; Hutter, M; Kuhne-Velte, HJ; Panzer, M; Rühl, U; Wendt, T, 1994) |
| " To improve local control and decrease metastases, a 7-month regimen was used with standard-dose radiotherapy (RT), cisplatin (DDP), and continuous infusion (CI) 5-fluorouracil (5-FU) in patients with locoregional squamous/adenocarcinoma of the esophagus." | 3.69 | Chemoradiotherapy of esophageal carcinoma. ( Cummings, G; Gaspar, LE; Herskovic, AM; Khanuja, PS; Kinzie, JL; Kraut, MJ; Lattin, PB; Poplin, EA; Steiger, Z; Vaitkevicius, VK, 1994) |
| "Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C." | 3.69 | Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy. ( Anderson, PJ; Frost, DB; Kagan, AR; Latino, F; Peddada, AV; Rao, AR; Shah, KH; Smith, DE, 1994) |
| " Adenocarcinoma patients receive mitomycin C and 5-fluorouracil; sarcoma patients receive cisplatin and doxorubicin." | 3.69 | Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. ( Sugarbaker, PH, 1994) |
| "We have investigated the effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) on meningioma cells in two different culture systems, evaluated by the uptake of radiolabelled methionine." | 3.69 | Synergistic inhibitory effects of interferon-alpha and 5-fluorouracil in meningioma cells in vitro. ( Muhr, C; Smits, A; Wang, JL; Zhang, ZJ, 1996) |
| "Frozen tissue from primary tumours of 152 premenopausal breast cancer patients, who participated in a trial comparing radiotherapy with adjuvant chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil, CMF), was analysed for c-erbB-2 protein expression, measured by flow cytometry." | 3.69 | c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. ( Carstensen, JM; Nordenskjöld, B; Rutqvist, LE; Skoog, L; Stål, O; Sullivan, S; Wingren, S, 1995) |
| "Use of chlorhexidine intraperitoneal therapy at the time of the operation for perforated colorectal cancer significantly decreases the frequency of gross tumor recurrence but not total recurrences." | 3.69 | Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model. ( Ong, J; Stabile, B; Stamos, M; Stuntz, M; Wilmoth, G, 1997) |
| " We have treated 18 recurrent glioma patients with high dose methotrexate (HDMTX) plus 5-fluorouracil (5FU)." | 3.68 | Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). ( Boiardi, A; Croci, D; Perego, E; Silvani, A; Solero, CL, 1992) |
| "Previous studies have demonstrated continuous-infusion 5-fluorouracil (CI 5-FU) to be an active single-agent treatment for breast cancer without significant myelotoxicity." | 3.68 | Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide: feasibility study. ( Carey, P; Saphner, T; Tormey, DC, 1992) |
| "50 patients with recurrent cervical carcinoma were included in a phase II study of cisplatinum and 5-fluorouracil." | 3.68 | [A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer]. ( Abeler, V; Kaern, J; Kjørstad, KE; Nordal, R; Sandvei, R; Sundfør, K; Tropé, C; Vergote, I; Vossli, S, 1990) |
| "To evaluate the role of chemotherapy in local control of primary breast cancer, the incidence of local failure was evaluated in 768 patients treated with surgery and adjuvant, combination chemotherapy that contained fluorouracil, doxorubicin, and cyclophosphamide (FAC) at our institute between 1974 and 1982." | 3.68 | Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? ( Ames, F; Buzdar, AU; Ellerbroek, N; Fraschini, G; Holmes, FA; Hortobagyi, GN; Hug, V; Kau, S; McNeese, MD; Smith, TL, 1990) |
| "Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen." | 3.67 | Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989) |
| " cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) after surgery for primary breast cancer was analyzed according to three administration-related factors: total number of cycles received, time elapsed between surgery and start of chemotherapy, and dose intensity of treatment." | 3.67 | Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. ( Amoroso, D; Bertelli, G; Botto, F; Campora, E; Conte, PF; Pronzato, P; Rosso, R; Sertoli, MR, 1989) |
| "We report a case of recurrent adenocarcinoma of the bladder treated by intra-arterial infusion of 5-fluorouracil (5-FU)." | 3.67 | Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder. ( Fuchs, EF; Hatch, TR, 1989) |
| "The influence of several variables on the effectiveness of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy given to 87 patients with stage II breast cancer was retrospectively analyzed." | 3.67 | Adjuvant chemotherapy with and without radiotherapy in stage II breast cancer. ( Biran, S; Brufman, G; Sulkes, A, 1988) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 3.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "In order to further extend the duration of remission induced by high-dose CAF therapy, maintenance therapies based on long-term oral administration of cyclophosphamide and fluorouracil (CF) were applied for patients with advanced and recurrent breast cancer." | 3.67 | [Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast C ( Abe, O; Enomoto, K; Inoue, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1988) |
| "Forty patients with adenocarcinoma of the cecum who underwent right hemicolectomy received regional irradiation for 40-45 Gy/4-5 weeks and weekly 5-Fluorouracil (5-FU)." | 3.67 | Regional adjuvant irradiation for adenocarcinoma of the cecum. ( Cormier, WJ; Jazy, FK; Meyer, RL; Shehata, WM; Welling, RE, 1987) |
| "This study was carried out to evaluate the effects of carmofur (Mifurol), a masked compound of 5-fluorouracil (5-FU), in preventing postoperative recurrence of urogenital carcinoma (especially in bladder cancer)." | 3.67 | [Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent]. ( Funai, K; Hayahara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Nishio, S; Yasumoto, R; Yuki, K, 1987) |
| "25 patients (2 females, 23 males, 20 to 40-year-old) suffering from condylomata acuminata (19 genital, 2 anal, and 4 genitoanal lesions) were locally treated with salicylic acid containing 5-fluorouracil (Verrumal) once a day." | 3.67 | [5-Fluorouracil treatment of condylomata acuminata]. ( Djawari, D, 1986) |
| "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function." | 3.67 | Allergic reaction to 5-fluorouracil infusion. ( Sridhar, KS, 1986) |
| "The efficacy of salvage treatments in 243 patients with operable breast cancer and positive axillary nodes who failed during or after adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate and fluorouracil) was analyzed." | 3.67 | Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. ( Bonadonna, G; Tancini, G; Valagussa, P, 1986) |
| "Twenty-five consecutive cases of inflammatory breast carcinoma were treated with high-dose cyclophosphamide and 5-fluorouracil in 5-day courses every 3 weeks for 2 years, with total mastectomy performed after the third course." | 3.67 | Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. ( Breau, JL; Israël, L; Morere, JF, 1986) |
| "Risk factors for local-regional recurrence of breast cancer were analyzed in a retrospective review of 117 patients treated with adjuvant CMF (Cytoxan [Mead Johnson & Co, Evansville, Ind], methotrexate, 5-fluorouracil) after radical or modified radical mastectomy at the Vincent T." | 3.67 | Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. ( Bachenheimer, L; Beiser, C; Byrne, P; Dritschilo, A; Goldberg, R; Smith, F; Smith, L; Stefanik, D; Ueno, W, 1985) |
| "The effects of combination chemotherapy including mitoxantrone (MXN) "M-VEMFH" for advanced breast cancer were studied." | 3.67 | [Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer]. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sugiura, I, 1985) |
| " A complete regression of pleural, pulmonary parenchymal, cutaneous, and bone metastases was seen following therapy with 5-fluorouracil, Adriamycin, and mitomycin C." | 3.66 | Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy. ( Budd, GT; Groppe, CW, 1983) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 3.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| " Adenocarcinoma related to diethylstilbestrol exposure in utero is a recently recognized type of vaginal lesion, and melanoma and sarcoma occur rarely in the vagina." | 3.66 | Malignant tumors of the vagina. Classification and approach to treatment. ( Gerbie, MV, 1983) |
| "A course of combined therapy (adriablastin, cyclophosphan, vincristine and, in some cases, 5-fluorouracil) was given to 50 breast cancer patients with metastases of different localization." | 3.66 | [Combination chemotherapy including anablastine in disseminated breast cancer]. ( Ass, NIa; Dement'eva, IP; Lipovich, MM, 1981) |
| "Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer." | 3.66 | [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer]. ( Abe, O; Enomoto, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1982) |
| " Following surgical removal of spontaneous mammary adenocarcinomas, phenylalanine mustard, adriamycin, and 5-fluorouracil (PAF) were administered at 4, 2, and 50 mg/kg, respectively, once a week for six injections." | 3.65 | Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. ( Anderson, JC; Fugmann, RA; Martin, DS; Stolfi, RL, 1977) |
| "Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate." | 3.65 | Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. ( Bruckner, HW; Deppe, G, 1977) |
| "Prolonged cyclic combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil was evaluated as adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph nodes." | 3.65 | Combination chemotherapy as an adjuvant treatment in operable breast cancer. ( Bajetta, E; Bonadonna, G; Brambilla, C; Brugnatelli, L; Brusamolino, E; De Lena, M; Musumeci, R; Rossi, A; Tancini, G; Valagussa, P; Veronesi, U, 1976) |
| " Treatment-related adverse events (TRAEs) occurred more frequently in group A vs." | 3.30 | A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). ( Choi, IS; Han, HS; Kim, JW; Kim, KH; Kim, MJ; Ko, YH; Koh, SA; Koo, DH; Lee, KW; Lee, SS; Nam, BH; Park, JH; Ryu, MH; Sohn, BS; Zang, DY, 2023) |
| "Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate." | 3.30 | Preoperative Treatment of Locally Advanced Rectal Cancer. ( Al Baghdadi, T; Basch, E; Chang, GJ; Colgrove, B; Dueck, AC; Farma, JM; George, TJ; Goldberg, J; Gollub, MJ; Goodman, KA; Gordon, V; Kennecke, HF; Mamon, HJ; McWilliams, RR; Meyerhardt, JA; Montemurro, M; Musher, BL; Nelson, GD; O'Reilly, EM; Saltz, LB; Schrag, D; Shergill, A; Shi, Q; Venook, AP; Weiser, MR, 2023) |
| " Secondary endpoints include the DFS of ctDNA positive patients versus ctDNA negative patients, the 2- and 3-year DFS rates, overall survival (OS), the impact of hallmark molecules on the treatment response, adverse events (AEs), and the impact of nutrition status or exercise on recurrence." | 3.30 | Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPL ( Chen, X; Chen, Y; Guo, F; Han, G; Li, W; Ma, L; Pan, L; Shu, Y; Tang, J; Tian, Y; Xie, L; Xu, H; Zhang, J; Zhang, X, 2023) |
| "The estimated cure rates for colon cancer were 0." | 3.11 | Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study. ( Fukuda, T; Hasegawa, J; Ishiguro, M; Masuda, Y; Nakamura, M; Sakamoto, J; Shibahara, H; Shiroiwa, T; Tomita, N; Yamaguchi, S, 2022) |
| "Patients with stage II colon cancer were randomly assigned in a 2:1 ratio to have treatment decisions guided by either ctDNA results or standard clinicopathological features." | 3.11 | Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. ( Burge, M; Cohen, JD; Day, F; Dobbyn, L; Gibbs, P; Harris, M; Harris, S; Hayes, T; Hruban, R; Khattak, A; Kinzler, KW; Kosmider, S; Lahouel, K; Lee, B; Lee, M; Lennon, AM; Lo, SN; Lynam, J; McLachlan, SA; Nott, L; Papadopoulos, N; Popoli, M; Ptak, J; Shapiro, J; Silliman, N; Tie, J; Tomasetti, C; Vogelstein, B; Wang, Y; Wong, R, 2022) |
| "44 patients with metastatic colorectal cancer were enrolled in this study." | 3.11 | Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study). ( Fukazawa, A; Hasegawa, S; Hirata, K; Koda, K; Kosugi, C; Kuramochi, H; Matsuda, A; Matsuoka, H; Ohta, R; Otsuka, T; Sakamoto, K; Sonoda, H; Takahashi, M; Watanabe, T; Yamada, T; Yoshida, H; Yoshida, Y, 2022) |
| "Both LRC and DFS of rectal cancer patients treated with HART vs." | 3.01 | Tumor regression grading after preoperative hyperfractionated radiotherapy/chemoradiotherapy for locally advanced rectal cancers: interim analysis of phase III clinical study. ( Dębosz-Suwińska, I; Galwas-Kliber, K; Idasiak, A; Mrochem-Kwarciak, J; Rajczykowski, M; Stobiecka, E; Suwiński, R; Zeman, M, 2021) |
| "4 Gy) with or without intravenous pembrolizumab administered at a dosage of 200 mg every 3 weeks for up to 6 doses before surgery." | 3.01 | Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. ( Colangelo, LH; Faller, BA; George, S; George, TJ; Gollub, MJ; Hall, WA; Hong, TS; Jacobs, SA; Kachnic, LA; Kainthla, R; Lucas, PC; O'Rourke, MA; Parker, W; Rahma, OE; Russell, MM; Schefter, TE; Sigurdson, E; Stella, PJ; Valicenti, RK; Vijayvergia, N; Wolmark, N; Yothers, G; You, YN, 2021) |
| " Treatment-emergent adverse events of maximum grade 3 or 4 occurred in 61." | 3.01 | First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial. ( Bai, C; Chang, X; Chen, W; Feng, J; Ge, M; Guo, Y; He, X; Huang, X; Li, Z; Lin, T; Liu, Y; Luo, Y; Shen, L; Sun, Y; Wang, L; Xue, K; Yang, K; Zeng, Y; Zhang, Q; Zhu, X, 2021) |
| "Patients with invasive, early stage breast cancer were eligible." | 2.94 | Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. ( Agrawal, RK; Ahmed, I; Bishop, J; Bowden, SJ; Brookes, CL; Brunt, AM; Canney, P; Churn, M; Dunn, J; Fernando, IN; Goodman, A; Grieve, R; Herring, K; Latief, TN; Marshall, A; Poole, CJ; Rea, DW; Ritchie, D; Spooner, D; Stevens, A, 2020) |
| "Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | 2.94 | Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
| "Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy is under debate." | 2.94 | Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). ( Fukunaga, M; Ide, Y; Ikumoto, T; Iwamoto, S; Kanazawa, A; Kato, T; Konishi, K; Kotaka, M; Kudo, T; Kurata, T; Sakai, D; Sano, Y; Satake, H; Satoh, T; Sugimoto, N; Tomita, N; Tsuji, A; Yamanaka, T, 2020) |
| "Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) often requires postoperative chemoradiation with high risk of toxicity." | 2.94 | Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. ( Betz, CS; Binder, M; Boettcher, A; Bokemeyer, C; Busch, CJ; Moeckelmann, N; Muenscher, A; Schafhausen, P; Vettorazzi, E; Zech, HB, 2020) |
| "More than half of the 40,000 incident rectal cancer patients in the United States each year are diagnosed at clinical stage II and III (locally advanced stage)." | 2.90 | Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). ( Basch, E; Gollub, M; Mamon, H; Saltz, L; Schrag, D; Shi, Q; Venook, A; Weiser, M, 2019) |
| "A radical rectal cancer surgery was performed 6 to 8 weeks after the simultaneous chemoradiotherapy." | 2.90 | Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer. ( Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y, 2019) |
| "Patients with cT4 or fixed cT3 rectal cancer were randomized either to preoperative 5 × 5 Gy and three cycles of FOLFOX4 or to chemoradiation (50." | 2.90 | Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. ( Bębenek, M; Bujko, K; Cencelewicz, A; Ciseł, B; Jankiewicz, M; Jankowski, M; Kapturkiewicz, B; Kapuściński, W; Kępka, L; Kosakowska, E; Kładny, J; Las-Jankowska, M; Maciejczyk, A; Majewski, A; Markiewicz, W; Michalski, W; Pietrzak, L; Polkowski, W; Rutkowski, A; Sadowski, J; Socha, J; Spałek, M; Styliński, R; Suwiński, R; Toczko, Z; Wasilewska-Tesluk, E; Wyrwicz, L; Zegarski, W; Żelazowska-Omiotek, U; Zygulska, J, 2019) |
| "Patients with resected stage III colon cancer (CC) from seven adjuvant studies with available data for disease recurrence and MMR and BRAFV600E status were analyzed." | 2.90 | Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. ( Alberts, S; André, T; de Gramont, A; Grothey, A; Kerr, R; Lonardi, S; Pederson, L; Shi, Q; Sinicrope, FA; Taieb, J; Van Cutsem, E; Wolmark, N; Yoshino, T; Yothers, G; Zaanan, A, 2019) |
| "9%) in arm B experienced grade 3/4 adverse events related to bevacizumab; the most frequent were 2 anastomotic fistulas (both in arm A) and abscesses (1 in arm A and 2 in arm B)." | 2.90 | Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. ( Adenis, A; André, T; Azria, D; Bachet, JB; Balosso, J; Ben Abdelghani, M; Borg, C; Boudghène, F; Conroy, T; Coudert, M; François, Y; Ghiringhelli, F; Ionescu-Goga, M; Lakkis, Z; Mantion, G; Mornex, F; Quero, L; Rio, E; Roullet, B; Spaëth, D; Tanang, A; Vendrely, V, 2019) |
| "For stage II/Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic options." | 2.87 | Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. ( Gray, R; Handley, K; Hutchins, GGA; Kerr, D; Magill, L; Quirke, P; Seymour, M; Southward, K; Tinkler-Hundal, E; Treanor, D; Wright, A, 2018) |
| "This study investigated the role of hyperthermia combined with preoperative concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer (LARC) according to hypoxic marker expression." | 2.87 | Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer. ( Gu, MJ; Kang, MK; Kim, JH; Kim, SW; Yea, JW, 2018) |
| "Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population." | 2.87 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. ( Andre, T; Boukovinas, I; Grothey, A; Iveson, T; Kerr, R; Labianca, R; Meyerhardt, JA; Meyers, JP; Niedzwiecki, D; Paul, J; Renfro, LA; Sargent, DJ; Saunders, M; Shi, Q; Shields, AF; Sobrero, AF; Souglakos, J; Taieb, J; Torri, V; Vernerey, D; Watanabe, T; Yamanaka, T; Yoshino, T, 2018) |
| " The objective of this study was to compare outcome measures, adverse effects, and cost of FOLFOX4 and FOLFIRINOX treatments in rectal cancer patients." | 2.87 | Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study. ( Chen, Y; Liu, J; Qi, F; Yan, Q; Zhang, G; Zheng, Z, 2018) |
| "The German rectal cancer trial CAO/ARO/AIO-04 has shown a significant benefit in 3-year disease-free survival (DFS) of adding oxaliplatin to a standard preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) and adjuvant chemotherapy in patients with locally advanced rectal cancer." | 2.87 | Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. ( Arnold, D; Fietkau, R; Fokas, E; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Hofheinz, RD; Hohenberger, W; Hothorn, T; Kaufmann, M; Liersch, T; Rödel, C; Sauer, R, 2018) |
| "In multivariate analysis, breast cancer subtype was a significant predictor of LRR (p < 0." | 2.84 | Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study. ( Bonnefoi, H; Breton-Callu, C; Cameron, D; Gillon, P; Slaets, L; Touati, N, 2017) |
| "For these patients with metastatic esophageal cancer, chemotherapy is generally indicated." | 2.84 | Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. ( Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2017) |
| "This study aims to explore the efficacy and safety of recombinant human adenovirus p53 (rAd-p53) combined with chemoradiotherapy (CRT) in the treatment of recurrent nasopharyngeal carcinoma (NPC)." | 2.84 | Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma. ( Ma, JG; Ma, WS; Xing, LN, 2017) |
| "Patients with resected stage III colon cancers were randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) chemotherapy with or without cetuximab (North Central Cancer Treatment Group N0147 trial) or adjuvant FOLFOX chemotherapy with or without bevacizumab (National Surgical Adjuvant Breast and Bowel Project C-08 trial)." | 2.84 | Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. ( Alberts, SR; Allegra, CJ; Goldberg, RM; Meyers, JP; Pogue-Geile, KL; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Thibodeau, SN; Yothers, G, 2017) |
| "Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression." | 2.82 | MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil. ( Gazouli, M; Lampropoulou, DI; Nemati, M; Pouya, FD; Rasmi, Y, 2022) |
| "Untreated advanced gastric cancer patients randomly received docetaxel and cisplatin at 60 mg/m(2) (day 1) followed by fluorouracil at 600 mg/m(2)/day (days 1-5; mDCF regimen) or cisplatin at 75 mg/m(2) (day 1) followed by fluorouracil at 600 mg/m(2)/day (days 1-5; CF) every 3 weeks." | 2.82 | Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. ( Ba, Y; Bai, Y; Chen, W; Dai, G; Fan, N; Jiao, S; Li, J; Liu, T; Liu, Y; Ma, D; Qin, S; Shen, L; Shu, Y; Wang, J; Xu, J; Xu, R; Zheng, L, 2016) |
| " The primary outcome was all-grade, all-cause treatment-emergent adverse events (TEAEs)." | 2.82 | Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. ( Adkins, D; Aguilar, JL; Bryant, K; Chang, SC; Chen, E; Chin, S; Ernst, S; He, S; Lee, HJ; Misiukiewicz, K; Obasaju, CK; Soulières, D, 2016) |
| "Evidence for the prognostic value of circulating tumor cells (CTCs) in early-stage breast cancer is swiftly increasing." | 2.82 | Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial. ( Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E, 2016) |
| "Two patients with HPV-unrelated HNSCC treated with APF declined CRT and remained free of relapse at 36 and 28months of follow-up." | 2.82 | nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. ( Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Michel, L; Nussenbaum, B; Paniello, R; Rich, J; Thorstad, W; Trinkaus, K; Uppaluri, R; Wildes, TM, 2016) |
| "Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy." | 2.82 | Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. ( Anderson, H; Bengtsson, NO; Bergh, J; Brandberg, Y; Carlsson, L; Egle, D; Fornander, T; Foukakis, T; Gnant, M; Greil, R; Hellström, M; Johansson, H; Karlsson, E; Loibl, S; Malmström, P; Mlineritsch, B; Möbus, V; Schmatloch, S; Singer, CF; Steger, G; Untch, M; von Minckwitz, G; Wallberg, B, 2016) |
| "We genotyped 306 patients with early breast cancer, who were randomised to receive post-operative radiotherapy or CMF chemotherapy, for the RAD51 135G>C polymorphism." | 2.80 | The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer. ( Asklid, A; Fornander, T; Söderlund Leifler, K; Stenmark Askmalm, M, 2015) |
| "Although colon cancer (CC) with microsatellite instability (MSI) has a more favorable prognosis than microsatellite stable (MSS) CC, the impact varies according to clinicopathological parameters." | 2.80 | Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. ( Bosman, FT; Delorenzi, M; Klingbiel, D; Roth, AD; Saridaki, Z; Tejpar, S, 2015) |
| "Dutch Colorectal Cancer group, CKTO 2003-16, ISRCTN36266738." | 2.80 | Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. ( Berglund, Å; Breugom, AJ; Fokstuen, T; Gelderblom, H; Glimelius, B; Kapiteijn, E; Leer, JWH; Marijnen, CAM; Martijn, H; Meershoek-Klein Kranenbarg, E; Muller, EW; Nagtegaal, ID; Påhlman, L; Punt, CJA; Putter, H; Roodvoets, AGH; Rutten, HJT; Steup, WH; van de Velde, CJH; van den Broek, CBM; van Gijn, W, 2015) |
| " We have developed a 2-weekly docetaxel combined with CF regimen and conducted a Phase I/II trial for metastatic or recurrent esophageal cancer (JCOG0807)." | 2.80 | A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods o ( Chin, K; Fukuda, H; Hironaka, S; Kataoka, K; Katayama, H; Kato, K; Kii, T; Kitagawa, Y; Mizusawa, J; Shibuya, Y; Tsubosa, Y; Tsushima, T, 2015) |
| " The safety and dosage of S-1 combined with postoperative radiotherapy have not yet been evaluated." | 2.80 | Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer. ( Bi, F; Cao, D; Chen, Y; Gou, HF; Li, Q; Li, ZP; Liu, JY; Peng, XC; Qiu, M; Shen, YL; Wang, X; Xu, F; Yang, Y; Yi, C; Zhao, YQ, 2015) |
| "1804 rectal cancer patients, staged cT3-4N0-2M0, participated in a multicenter study." | 2.80 | Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12. ( Baek, JY; Chie, EK; Cho, HM; Jang, HS; Jeong, BK; Jeong, JU; Kim, DY; Kim, JH; Kim, JS; Kim, K; Kim, SH; Kim, SY; Kim, TH; Lee, JH; Nam, TK; Oh, JH; Shim, BY; Yoon, MS, 2015) |
| " Preclinical evidence suggests that the scheduling of bevacizumab may be crucial to optimize its combination with chemo-radiotherapy." | 2.80 | Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. ( Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Comella, P; Delrio, P; Granata, V; Iaffaioli, VR; Leone, A; Marone, P; Muto, P; Pecori, B; Petrillo, A; Romano, C; Romano, G; Tatangelo, F, 2015) |
| "Breast cancer is characterized by great molecular heterogeneity demonstrated, e." | 2.79 | Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. ( Alsner, J; Kyndi, M; Myhre, S; Nord, S; Overgaard, J; Sørensen, FB; Sørlie, T; Tramm, T, 2014) |
| "In T3 rectal cancer (RC), preoperative chemoradiotherapy [5-fluorouracil (5-FU-RT)] reduces local recurrences, but does not affect overall survival." | 2.79 | Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. ( Adenis, A; André, T; Azria, D; Borg, C; Bosset, JF; Boudghène, F; Maingon, P; Mantion, G; Mornex, F; Morsli, O; Piutti, M, 2014) |
| "Patients with resected stage III colon cancer who were 18 years of age or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1, from four randomised controlled trials (NSABP C-08, XELOXA, X-ACT, and AVANT; 8734 patients in total) were pooled and analysed." | 2.79 | Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll ( Cartwright, T; Haller, D; Lee, S; McKenna, E; O'Connell, MJ; Saif, M; Schmoll, HJ; Sun, W; Twelves, C; Yothers, G, 2014) |
| "Adults with primary metastasized rectal cancer were enrolled." | 2.78 | Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. ( Beets, GL; Beukema, JC; de Jong, KP; Gelderblom, AJ; Havenga, K; Hospers, GA; Nagtegaal, ID; Rutten, HJ; Tamas, K; van de Velde, CJ; van Dijk, TH; Wiggers, T, 2013) |
| "Between 2001 and 2008, 65 consecutive gastric cancer patients received either 3D-CRT (n = 27) or IMRT (n = 38) following tumor resection." | 2.78 | Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. ( Boda-Heggemann, J; Haneder, S; Hochhaus, A; Hofheinz, RD; Lohr, F; Michaely, H; Ronellenfitsch, U; Schneider, V; Weiss, C; Wenz, F; Wertz, H, 2013) |
| " A multicenter phase II study was conducted to evaluate the efficacy and toxicity of capecitabine combined with nedaplatin for these patients." | 2.78 | Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy. ( Chen, ZB; Liao, H; Lin, Z; Ou, XQ; Peng, PJ; Peng, YL; Wang, SY; Zhang, HY, 2013) |
| " Here we report the first phase 2 study of erlotinib in combination with adjuvant chemoradiation and chemotherapy for resected PDAC." | 2.78 | Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. ( Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L, 2013) |
| "A single-center colorectal cancer database was queried for c-stage II-III rectal cancer patients undergoing neoadjuvant chemoradiation followed by proctectomy between 1997 and 2007." | 2.78 | Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think! ( Buta, M; de Campos-Lobato, LF; de Sousa, JB; Dietz, DW; Fazio, VW; Kalady, MF; Lavery, IC; Stocchi, L, 2013) |
| "The trial was prematurely stopped after the declaration of 15 serious adverse events (SAEs) in 14 out of 16 patients." | 2.78 | Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. ( Azria, D; Becouarn, Y; Conroy, T; Delarochefordiere, A; Deutsch, E; Ezra, P; Juzyna, B; Lemanski, C; Levy, A; Malekzadeh, K; Malka, D; Martel-Lafay, I; Miglianico, L; Paris, E; Pignon, JP; Rio, E, 2013) |
| " The severity of OPN was assessed according to the Common Toxicity Criteria for Adverse Events at baseline, every 2 weeks until the 8th cycle, and every 4 weeks thereafter until the 26th week." | 2.78 | Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. ( Fukunaga, M; Hata, T; Kojima, H; Kono, T; Matsui, T; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Sakamoto, J; Shimada, M; Takemoto, H, 2013) |
| "To select suitable chemotherapy for cervical cancer patients by ATP-tumor chemosensitivity assay." | 2.78 | [ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer]. ( Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q, 2013) |
| " Treatment consisted of paclitaxel at a dose of 135 mg/m(2) on day 1, cisplatin 25 mg/m(2)/day from day 1 to day 3 and 5-FU-continuous infusion for 120 h at a variable dosage from 600 to 1,000 mg/m(2)/day according to prior radiation." | 2.78 | Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. ( An, X; Chen, C; Li, YH; Liang, Y; Luo, HY; Wang, FH; Wang, ZQ; Zhang, L, 2013) |
| "This Phase Ib trial assessed the maximum tolerated dose (MTD) and safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin, and cetuximab (PFE) as first-line palliative treatment in patients with relapsed and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)." | 2.78 | Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( Brümmendorf, TH; Delord, JP; Forssmann, U; Goddemeier, T; Kaminsky, MC; Keller, U; Machiels, JP, 2013) |
| "Capecitabine was administered at 850 mg/m(2) twice daily every day per week radiotherapy (45 Gy in 25 fractions) over the 5 weeks." | 2.77 | Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. ( Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS, 2012) |
| "Patients with stage III-IV HNSCC received hyperfractionated radiation (72-74." | 2.77 | Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. ( Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG, 2012) |
| "We performed a prospective phase II trial to investigate the safety and efficacy of radiotherapy combined with capecitabine in patients suffering from a recurrence of a squamous cell carcinoma of the head and neck (SCCHN) within a previously irradiated field." | 2.77 | Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial. ( Kornek, G; Lemaire, C; Radonjic, D; Selzer, E; Vormittag, L, 2012) |
| "Patients with MSI-H (n=34) colon cancer presented with a significantly lower risk of relapse after 12 months of follow-up compared with MSS (n=189) colon cancer patients (5 year time to relapse: MSI-H 0." | 2.77 | Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. ( Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M, 2012) |
| "Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis (PC) as the only site of metastases." | 2.77 | The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. ( Bertrand, C; Ceelen, W; D'Hoore, A; Fieuws, S; Hompes, D; Kerger, J; Legendre, H; Peeters, M; Van Cutsem, E; Van der Speeten, K, 2012) |
| "Locally advanced head and neck squamous cell carcinoma (HNSCC) has a high rate of recurrence." | 2.77 | Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma. ( Abgral, R; Gouders, D; Keromnes, N; Le Roux, PY; Leleu, C; Mollon, D; Nowak, E; Querellou, S; Rousset, J; Salaün, PY; Valette, G, 2012) |
| " The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer." | 2.77 | Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. ( Abe, K; Ishikawa, Y; Jingu, K; Kubozono, M; Matsushita, H; Nemoto, K; Shirata, Y; Sugawara, T; Takahashi, C; Takeda, K; Tanabe, T; Umezawa, R; Yamamoto, T, 2012) |
| "This study was conducted to determine the optimal dosage of the docetaxel-capecitabine-cisplatin (DXP) regimen and to evaluate its efficacy and safety in patients with advanced gastric cancer." | 2.76 | Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. ( Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH, 2011) |
| "Patients (N = 207) with nonresectable rectal cancer were randomized to preoperative CRT or RT (2 Gy × 25 ± 5-fluorouracil/leucovorin)." | 2.76 | Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. ( Berglund, Å; Bruheim, K; Brændengen, M; Cvancarova, M; Glimelius, B; Tveit, KM, 2011) |
| "In gemcitabine-pretreated pancreatic cancer, salvage chemotherapy has not been established, and the prognostic factors are not completely known." | 2.76 | Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY, 2011) |
| "Of these, 10 (22%) had inflammatory breast cancer (IBC), and 27 (60%) had estrogen receptor (ER)(+) disease." | 2.76 | Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. ( Buyse, ME; Dy, PA; Geyer, CE; Jacobs, SA; Liepman, MK; Mamounas, EP; Melnik, MK; Pajon, ER; Piette, F; Posada, JG; Rastogi, P; Robidoux, A; Swain, SM; Wolmark, N, 2011) |
| "To evaluate the efficacy of late accelerated hyperfractionated conformal radiotherapy (LACF) combined with capecitabine on esophageal carcinoma." | 2.76 | [Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. ( Feng, XZ; Han, JQ; Sheng, W, 2011) |
| "In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival." | 2.75 | Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. ( Cho, BC; Choi, EC; Choi, HJ; Kim, GE; Kim, JH; Lee, CG; Lee, YJ; Sohn, JH, 2010) |
| "Patients with locally advanced head and neck cancer, and who had not previously undergone surgery, were randomly assigned to one of four groups in a 3:2:2:2 ratio, stratified by centre and chemotherapy regimen: radical radiotherapy alone (n=233); radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy (SIM alone; n=166); or 14 and 28 days after completing radiotherapy (SUB alone, n=160); or both (SIM+SUB; n=154)." | 2.75 | Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. ( Glaholm, J; Gupta, N; Hackshaw, A; Hutchison, I; Kadalayil, L; Macdougall, H; Monson, K; Tobias, JS, 2010) |
| "Patients with poor-risk rectal cancer defined by MRI can be at high risk of disease recurrence despite standard chemoradiotherapy and optimum surgery." | 2.75 | Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. ( Barbachano, Y; Brown, G; Chau, I; Chua, YJ; Cunningham, D; Massey, A; Oates, JR; Tait, D; Tebbutt, NC; Wotherspoon, A, 2010) |
| "Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules." | 2.75 | Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. ( Adansa, JC; Cruz, JJ; Gil-Arnaiz, I; Hitt, R; Irigoyen, A; Isla, D; Lambea, J; Lecumberri, MJ; Martinez-Trufero, J, 2010) |
| "Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection." | 2.75 | Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010) |
| "To evaluate the efficacy and safety of weekly or 3-week docetaxel in combination with capecitabine." | 2.75 | [A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer]. ( Bai, YX; Cheng, Y; Jiang, ZF; Jiao, SC; Li, X; Liu, DQ; Liu, JW; Liu, WC; Ren, J; Sun, Q; Tang, LL; Wang, HQ; Wang, Y; Wang, YS; Wei, Y; Xiao, JX; Xie, XD; Zhang, SH, 2010) |
| "Liver perfusion chemotherapy (LPC) for pancreatic cancer has been rarely undertaken in a postoperative adjuvant setting." | 2.74 | Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. ( Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N, 2009) |
| "This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers." | 2.74 | Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, MA; Kim, TY; Kim, WH; Lee, KH; Lee, KW; Lee, MH; Lee, NS; Oh, DY; Park, SR; Song, HS, 2009) |
| "Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks." | 2.74 | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009) |
| "The treatment of peritoneal carcinomatosis is based on cytoreduction followed by hyperthermic intraperitoneal chemotherapy and combined with adjuvant chemotherapy." | 2.73 | 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. ( Boot, H; Bruin, S; van Slooten, G; van Tinteren, H; Verwaal, VJ, 2008) |
| " Oxaliplatin in combination with leucovorin and 5-FU should be considered a feasible chemotherapy regimen for patients with recurrent/metastatic biliary tract carcinoma." | 2.73 | Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. ( Cho, JY; Jeung, HC; Lee, DK; Lee, SJ; Lim, JY; Mun, HS; Paik, YH; Yoon, DS, 2008) |
| "Patients with advanced esophageal squamous cell carcinoma receive neoadjuvant chemotherapy or chemoradiotherapy to improve survival, but benefits are observed only in those with histologic response." | 2.73 | Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. ( Doki, Y; Fujiwara, Y; Fukunaga, H; Hatazawa, J; Higuchi, I; Miyata, H; Monden, M; Takiguchi, S; Tatsumi, M; Yano, M; Yasuda, T, 2008) |
| "Paclitaxel was administered as a 1-h intravenous (i." | 2.73 | A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer. ( Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2008) |
| "Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract." | 2.73 | [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008) |
| "2004, 256 cases with stage III colorectal cancer randomized received de Gramont, modified FOLFOX4 (mFOLFOX4) and XELOX regimens." | 2.73 | [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer]. ( Cheng, RC; Diao, C; Liu, QY; Su, YJ; Wei, XP; Xu, JB; Zhang, JM, 2008) |
| "Irinotecan 180 mg/m2 was administered biweekly on D1, LV 200 mg/m2 by intravenous infusion in 2 hours before bolus intravenous injection of 5-Fu 400 mg/m2, then followed immediately by intravenous infusion of 5-Fu 2." | 2.73 | [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. ( Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD, 2008) |
| " The secondary aim was to evaluate whether distal bowel clearance < or =1 cm is safe after radiation." | 2.73 | Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe? ( Bujko, K; Chmielik, E; Nasierowska-Guttmejer, A; Nowacki, MP; Rutkowski, A; Wojnar, A, 2008) |
| "Since the prognosis of recurrent ovarian cancer patients is still poor, we need to establish a useful treatment strategy to achieve their long-term survival." | 2.73 | Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience. ( Ebina, Y; Hosaka, M; Mitamura, T; Moriwaki, M; Ohba, Y; Sakuragi, N; Takeda, M; Todo, Y; Watari, H, 2008) |
| "We sought to evaluate the efficacy and safety data of a combination regimen using weekly irinotecan in combination with capecitabine and concurrent radiotherapy (CapIri-RT) as neoadjuvant treatment in rectal cancer in a phase-II trial." | 2.73 | A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. ( Grobholz, R; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Leitner, A; Post, S; Wenz, F; Willeke, F; Willer, A, 2007) |
| " The mean area under the curve increased significantly with escalating dosage levels (R = 0." | 2.73 | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. ( Hanazaki, K; Kobayashi, M; Kondo, K; Nagata, N; Namikawa, T; Oba, K; Okabayashi, T; Sakamoto, J, 2007) |
| "The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome." | 2.73 | Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Gelber, S; Goldhirsch, A; Pagani, O; Price, KN; Simoncini, E, 2007) |
| " In locally advanced rectal cancer, preoperative infusional chemotherapy combined with radiation was found to be less toxic than bolus chemotherapy and radiotherapy." | 2.73 | Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. ( Elsaleh, H; Joseph, D; Kaminski, A, 2007) |
| "This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma." | 2.73 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. ( Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH, 2007) |
| "Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field were eligible." | 2.73 | Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. ( Ang, KK; Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2008) |
| "Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only." | 2.73 | A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. ( Gnant, M; Greil, R; Herbst, F; Hofbauer, F; Jagoditsch, M; Jakesz, R; Rabl, H; Samonigg, H; Schaberl-Moser, R; Schippinger, W; Steger, GG; Thaler, J; Thödtmann, R; Tschmelitsch, J; Wohlmuth, P, 2007) |
| "Sites of metastasis were as follows: liver (n = 10), lung (n = 8), skin (n = 1), and non-regional lymph nodes (n = 1)." | 2.73 | Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. ( Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J, 2007) |
| "Chemoradiotherapy of the last phase II study with intermittent capecitabine (1500 mg/m(2)/day, delivered on days 1-14 and 22-35) and irinotecan (4 x 60 mg/m(2)) concurrently to radiotherapy is a safe treatment with low toxicity and high efficacy." | 2.73 | Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. ( Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F; Semrau, S, 2007) |
| "Gemcitabine was given at 1,000 mg/m(2) weekly for 3 weeks followed by 1 week rest then 5-6 weeks of radiotherapy and concurrent CI 5FU (200 mg/m(2)/day)." | 2.73 | 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. ( Borg, M; Carroll, S; Davies, T; Goldstein, D; Graham, P; Harvey, J; Iacopetta, B; Kneebone, A; Macleod, C; Millar, JL; Ngan, SY; Reece, WH; Spry, N; Zissiadis, Y, 2008) |
| "Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined." | 2.73 | Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. ( Baumann, W; Ette, C; Formentini, A; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Sander, S; Staib, L, 2008) |
| "The Adjuvant Colon Cancer End Points (ACCENT) data set was analyzed using univariate and multivariate Cox proportional hazards models, stratified by study." | 2.73 | Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. ( André, T; Benedetti, JK; Campbell, ME; Goldberg, RM; Grothey, A; Haller, DG; O'Connell, MJ; Sargent, DJ; Seitz, JF, 2008) |
| "7%); previous radiotherapy dosage ranged between 30 and 55 Gy (median, 50." | 2.72 | Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. ( Bolzicco, G; Coco, C; Dalla Palma, M; De Paoli, A; Di Russo, A; Doglietto, GB; Gambacorta, MA; Mohiuddin, M; Morganti, AG; Rossi, C; Valentini, V; Valvo, F, 2006) |
| "Patients with invasive ductal pancreatic cancer who underwent radical surgery with clear histological margins at 11 Japanese institutions were enrolled and randomly assigned to one of two groups: surgery-alone group (no further treatment after surgery) and the surgery + chemotherapy group [two courses of postoperative adjuvant systemic chemotherapy with cisplatin (80 mg/m(2), Day 1) and 5-fluorouracil (500 mg/m(2)/day, Days 1-5)]." | 2.72 | A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. ( Kakizoe, T; Kiuchi, T; Kosuge, T; Mukai, K, 2006) |
| " The purpose of the present study was to evaluate the effectiveness and safety of radiotherapy combined with nedaplatin and 5-FU for postoperative locoregional (excluding hematogenous metastasis) recurrent esophageal cancer." | 2.72 | Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. ( Jingu, K; Matsushita, H; Nakata, E; Nemoto, K; Ogawa, Y; Sugawara, T; Takahashi, C; Takai, Y; Yamada, S, 2006) |
| "The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions." | 2.72 | A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. ( Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006) |
| "The 18-year probability of any first breast cancer event was 73% and 59% (P < ." | 2.72 | Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. ( Grau, C; Jensen, AR; Nielsen, HM; Overgaard, J; Overgaard, M, 2006) |
| "Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated." | 2.72 | Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. ( Hirota, T; Kodaira, S; Mori, T; Ohashi, Y, 2006) |
| "To investigate the effect of three-dimensional conformal radiotherapy (3-DCRT) in combination with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer." | 2.72 | Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. ( He, C; Hu, JB; Sun, XN; Wang, Q; Xu, J; Yang, QC, 2006) |
| "Treatment comprised cetuximab (initial dose 400 mg/m2 with subsequent weekly doses of 250 mg/m2) in combination with 3-week cycles of either cisplatin (100 mg/m2) or carboplatin (area under the curve, 5), each in combination with a 5-day infusion of fluorouracil (FU) at escalating doses of 600, 800, and 1,000 mg/m2/d." | 2.72 | Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ( Amellal, N; Awada, A; Borel, C; Bourhis, J; Duck, L; Geoffrois, L; Harstrick, A; Hitt, R; Humblet, Y; Lopez-Pousa, A; Mesia, R; Rivera, F; Rosine, D; Schueler, A; Vega Villegas, ME, 2006) |
| "Twenty-nine colorectal cancer patients with non-resectable hepatic metastases were consecutively enrolled for HAI alternating with systemic chemotherapy (HA + SC group)." | 2.72 | Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer. ( Chang, HM; Ha, HK; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, KH; Lee, MG; Ryu, MH; Yu, CS, 2006) |
| "For patients who have significant residual tumor after resection or relapse after radiation, the proper chemotherapy regimen has not yet been identified." | 2.72 | Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. ( Ahn, SD; Ghim, TT; Goo, HW; Khang, SK; Kim, YJ; Lee, MJ; Park, JB; Ra, YS; Song, JS, 2006) |
| "Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions." | 2.72 | A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). ( Koizumi, W; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S, 2006) |
| "4 Gy/28 fractions) combined with 5-FU (200-225 mg/m(2)/day by continuous venous infusion) and weekly OXA (25-60 mg/m(2))." | 2.72 | 5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results. ( Aschele, C; Bruttocao, A; DeSalvo, GL; Fabris, G; Ferraro, B; Finco, C; Frego, M; Friso, ML; Lise, M; Lonardi, S; Nitti, D; Pucciarelli, S; Rugge, M; Toppan, P; Urso, E, 2006) |
| " A weekly 5 hour-administration of 5-FU (1500 mg) which was repeated for 8 weeks showed a comparable effect to a continuous infusion group with an identical total dosage of 5-FU." | 2.72 | [Prophylactic hepatic arterial infusion chemotherapy after curative surgery of colorectal liver metastases--the viewpoint from patients' quality of life]. ( Hoshino, H; Iwazawa, T; Kanoh, T; Kimura, Y; Matsushita, M; Miyazaki, S; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H, 2006) |
| "After curative resection of a stage III colon cancer, adjuvant treatment with 5-FU plus leucovorin is generally well tolerated." | 2.71 | 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. ( Arkenau, HT; Bermann, A; Porschen, R; Rettig, K; Strohmeyer, G, 2003) |
| "Metastatic gastric cancer is usually treated with cisplatin- and 5-FU-based chemotherapy regimens." | 2.71 | Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion. ( Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2003) |
| "Capecitabine is an effective salvage regimen in patients with recurrent and metastatic NPC." | 2.71 | A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. ( Au, GK; Chua, DT; Sham, JS, 2003) |
| "Capecitabine was suggested to be safe and effective in the treatment of advanced or recurrent gastric cancer." | 2.71 | A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. ( Koizumi, W; Saigenji, K; Sakata, Y; Taguchi, T; Terashima, M; Ujiie, S, 2003) |
| " With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen)." | 2.71 | A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. ( Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Naoi, Y; Tanigawa, T; Yamamoto, H, 2003) |
| "The median dysphagia free time was 9." | 2.71 | A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. ( Glynne-Jones, R; Goodchild, K; Harney, J; Hoskin, PJ; Phillips, H; Saunders, MI, 2003) |
| ") bolus, days 1-5) plus LEV (150 mg/day orally, days 1-3); postoperative RT was delivered during week 2 at the same dosage and schedule as in arm I." | 2.71 | Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report. ( Cafiero, F; Gipponi, M; Lionetto, R, 2003) |
| "Obesity is a risk factor for the development of colon carcinoma." | 2.71 | Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. ( Benson, AB; Catalano, PJ; Fuchs, CS; Haller, DG; Macdonald, JS; Mayer, RJ; Meyerhardt, JA, 2003) |
| "Ten patients with advanced or recurrent cancer of the cervix with no prior chemotherapy were entered in a phase II trial from October 2000 to November 2001." | 2.71 | First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study. ( Behtash, N; Ghaemmaghami, F; Khanafshar, N; Modares, M; Moosavi, A; Toogeh, G; Yarandi, F, 2003) |
| "Patients with gastric cancer staged IB to IV(M0) were treated with chemoradiotherapy after curative resection with extensive (D2) lymph node dissection." | 2.71 | Postoperative chemoradiotherapy for gastric cancer. ( Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, DY; Kim, K; Kim, S; Kim, WS; Kim, YI; Lee, KW; Lee, MH; Lim, DH; Noh, JH; Park, CH; Park, CK; Park, JO; Park, K; Park, SH; Sohn, TS, 2003) |
| "Capecitabine (Xeloda) is an oral fluoropyrimidine that is preferentially activated at the tumoral level, exploiting the higher thymidine phosphorylase activity in tumoral tissue." | 2.71 | Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. ( Chamorey, E; Giroux, B; Guardiola, E; Magné, N; Milano, G; Mouri, Z; Otto, J; Pivot, X; Schneider, M; Thyss, A, 2003) |
| "Attempted surgical salvage of rectal cancer recurrence is performed commonly in the United States." | 2.71 | Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. ( Cooke, E; Hollis, D; Mayer, RJ; Niedzwiecki, D; O'Connell, M; Tepper, JE, 2003) |
| "122 patients with primary squamous cell carcinoma of the lip, the oral cavity and the oropharynx have been treated with 100 mg/m2 cisplatin bolus infusion and 120-h continuous infusion of 1000 mg/m2 5-fluorouracil following radical surgery; 99 patients completed all 3 cycles." | 2.71 | Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results. ( Bitter, K; Ghahremani, MT; Kovács, AF; Stefenelli, U, 2003) |
| "Oral capecitabine is a highly active, well-tolerated and convenient treatment for breast and colorectal cancer." | 2.71 | A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. ( Kaye, SB; McMahon, L; Paul, J; Reed, N; Vasey, PA, 2003) |
| "5-FU/irinotecan is a valuable regimen for second-line treatment in 5-FU/platinum-resistant O-G carcinoma." | 2.71 | Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ( Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS, 2004) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 2.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "Some patients with colon cancer have a high risk of local recurrence postoperatively." | 2.71 | Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. ( Benson, AB; Donohue, JH; Fisher, B; Goldberg, RM; Gunderson, LL; Mailliard, JA; Martenson, JA; Myerson, R; Sargent, DJ; Thomas, CR; Willett, CG, 2004) |
| "Patients with locally advanced squamous cell carcinoma of the esophagus, who respond to preoperative neoadjuvant combined radiochemotherapy, seem to have more benefit from subsequent resection than non-responding patients." | 2.71 | Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. ( Brücher, BL; Busch, R; Dittler, HJ; Fink, U; Molls, M; Sarbia, M; Siewert, JR; Stein, HJ; Werner, M; Zimmermann, F, 2004) |
| "Thirty-eight unresectable small hepatocellular carcinoma patients with diameter | 2.71 | [Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xia, JL; Yang, BW; Yie, SL; Zhang, BH, 2004) |
| "For patients with high-risk breast cancer treated with modified radical mastectomy, treatment with radiation therapy (schedule of 16 fractions) and adjuvant chemotherapy leads to better survival outcomes than chemotherapy alone, and it is well tolerated, with acceptable long-term toxicity." | 2.71 | Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. ( Coldman, AJ; Coppin, CM; Durand, R; Gelmon, K; Jackson, SM; Knowling, MA; Le, N; Manji, M; Olivotto, IA; Phillips, N; Ragaz, J; Spinelli, JJ; Weir, L; Wilson, KS, 2005) |
| "Progression-free and freedom from metastases rates were 29." | 2.71 | Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo ( Bamberg, M; Baumann, M; Budach, V; Budach, W; Geismar, D; Grabenbauer, G; Herrmann, T; Hinkelbein, W; Jahnke, K; Lammert, I; Stueben, G; Stuschke, M; Wernecke, KD; Wust, P, 2005) |
| "Patients with advanced or recurrent gastric cancer were treated with escalating doses of weekly paclitaxel as a 60 min intravenous (i." | 2.71 | Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. ( Araki, K; Hirabayashi, N; Kataoka, M; Kobayashi, M; Kojima, H; Kondo, K; Matsui, T; Miyashita, Y; Nakao, A; Nakazato, H; Sakamoto, J; Takiyama, W, 2005) |
| "Thirty-six patients died because of disease progression, and 3 are alive with progressive disease." | 2.71 | Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A, 2005) |
| "Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy." | 2.70 | Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002) |
| "Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection." | 2.70 | Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. ( Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF, 2001) |
| "The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery." | 2.70 | Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001) |
| "Distant metastases remain the main cause of treatment failure in NPC." | 2.70 | Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study. ( Allam, A; El-Badawi, S; El-Serafi, M; El-Weshi, A; Ibrahim, E; Khafaga, Y; Mosseri, V, 2001) |
| "We evaluated the clinical effect of 5-FU and low-dose Cisplatin (LFP) therapy alone and LFP therapy combined with radiation therapy in patients with advanced or recurrent esophageal cancer." | 2.70 | [Preliminary clinical evaluation of continuous infusion of 5-FU and low-dose Cisplatin (LFP) therapy alone and combined with radiation therapy for treatment of advanced or recurrent esophageal cancer]. ( Horimi, T; Itoh, S; Morita, S; Ohnishi, T; Takamatsu, M; Tsuji, A, 2002) |
| "Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients)." | 2.70 | Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. ( Adak, S; Benson, AB; Gray, B; Kemeny, MM; Lipsitz, S; Macdonald, JS; O'Dwyer, PJ; Sigurdson, ER; Smith, T, 2002) |
| "Exclusive CRT approach is not safe to treat patients with low infiltrative rectal carcinoma." | 2.70 | Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? ( David Filho, WJ; de O Ferreira, F; Ferrigno, R; Lopes, A; Nakagawa, WT; Nishimoto, IN; Rossi, BM; Vieira, RA, 2002) |
| "Paclitaxel is an important new agent in the treatment of esophageal carcinoma, and further evaluation of this agent in combination chemotherapy is warranted." | 2.69 | Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. ( Ajani, J; Bhalla, K; Donegan, J; Forastiere, A; Huang, Y; Ilson, DH; Kelsen, DP; Martin, L; Patel, P; Pazdur, R; Reed, C, 1998) |
| "Between 1984 and 1990, 277 stage I breast cancer patients with tumours negative for both oestrogen and progesterone receptors were randomised to receive either low-dose short-term chemotherapy or no chemotherapy." | 2.69 | Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group. ( Fridrik, M; Gnant, M; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Samonigg, H; Sevelda, P; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, B, 1998) |
| "Patients with advanced and recurrent gastric cancer were treated with this regimen as early phase II trial and its efficacy and toxicity were assessed." | 2.69 | Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer. ( Inada, T; Kikuyama, S; Miyakita, M; Ogata, Y, 1998) |
| " We administered pharmacokinetic modulating chemotherapy, based on the concept that the benefit of a continuous venous 5-fluorouracil (5FU) infusion can be potentiated by low-dose oral UFT, a combination of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil at a molar ratio of 1:4." | 2.69 | Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. ( Kotera, H; Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H, 1998) |
| "Eniluracil is a novel DPD-inactivator designed to prolong the half-life of 5-FU and provide sustained plasma concentrations of 5-FU with oral dosing." | 2.69 | Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. ( Brockstein, B; Dolan, ME; Haraf, DJ; Humerickhouse, RA; Kies, M; Ratain, MJ; Stenson, K; Sulzen, L; Vokes, EE, 1999) |
| "In women with inoperable primary breast cancer or large T2 tumors, preoperative chemotherapy may induce tumor shrinkage, facilitate surgery and possibly improve survival." | 2.69 | Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. ( Billgren, AM; Fornander, T; Rutqvist, LE; Skoog, L; Tani, E; Wilking, N, 1999) |
| "Combination chemotherapy with multiple drugs (FLMP therapy), in which the drugs were determined based on biochemical modulation and the dosing schedule was established in accordance with the circadian rhythms of the human body, was performed in cases of advanced recurrent gastric cancer." | 2.69 | [Effect of combination chemotherapy with multiple drugs (FLMP therapy) based on the circadian rhythms of the human body in advanced recurrent gastric cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Nagaoka, H; Okabe, T; Yokomori, T, 1999) |
| "Paclitaxel has exhibited single-agent activity in patients with this disease." | 2.69 | Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. ( Du, W; Ensley, J; Gadgeel, S; Hussain, M; Kucuk, O; Salwen, W, 1999) |
| "For locally unresectable recurrent squamous cell carcinoma of the head and neck, we investigated two salvage chemotherapy regimens as second-line chemotherapy." | 2.69 | Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck. ( Kawaida, M; Kitahara, S; Kohno, N; Ohmuma, T, 1999) |
| "Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole." | 2.69 | Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. ( , 2000) |
| " Only one patient required a dosage adjustment of cisplatin for a serum creatinine elevation >2." | 2.69 | Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. ( Braly, P; Doroshow, JH; Johnson, D; Kogut, N; Leong, L; Longmate, J; Margolin, K; McNamara, M; Morgan, RJ; Nagasawa, S; Najera, L; Raschko, J; Schinke, S; Shibata, S; Somlo, G, 2000) |
| "To improve survival rate in advanced head and neck cancer, we scheduled 90 patients to receive low dose cisplatin plus 5-fluorouracil regimen as neoadjuvant(NAC), concurrent(CC), adjuvant(AC), and second line chemotherapy (SC) setting." | 2.69 | The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. ( Kawada, M; Kitahara, S; Kohno, N; Nakanoboh, M; Shirasaka, T; Tamura, E; Tanabe, T, 2000) |
| "Forty-two patients with head and neck cancer were treated with tegafur suppository for 7 days preoperatively and clinical value of this treatment was assessed." | 2.68 | [High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories]. ( Itokazu, T; Kochi, A; Koja, S; Maeda, H; Maeshiro, N; Matsumura, J; Noda, Y; Yasuda, S, 1995) |
| "Women with metastatic breast cancer who had measurable disease, required laboratory tests, had received no prior chemotherapy for metastases, had a Cancer and Leukemia Group B (CALGB) performance status < or = 2, and provided informed consent were eligible." | 2.68 | Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. ( Abrams, J; Aisner, J; Budman, D; Cirrincione, C; Citron, M; Holland, J; Muss, H; Panasci, L; Perloff, M; Perry, M, 1995) |
| " These results show that AO-90 in combination with MF therapy is efficacious in the treatment of patients with gastric cancer." | 2.68 | [A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)]. ( Akazawa, S; Kitamura, S; Kosaki, G; Kurihara, M; Nakano, S; Ohtani, T; Sasaki, T; Takahashi, H; Tokunaga, K, 1995) |
| " However, considering the fact that toxicity was still considerable despite reducing the dose of chemotherapy by 50%, we believe that conventionally dosed short-term regimens are preferable in the treatment of node-positive breast cancer." | 2.68 | Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigator ( Clahsen, PC; Sylvester, RJ; van de Velde, CJ; van Driel, OJ; Welvaart, K, 1995) |
| "Studies addressing the sequencing of radiation therapy and chemotherapy will necessarily be large because adverse effects from administering the two modalities simultaneously are not great." | 2.68 | Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer--toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Institution study. ( Ackland, SP; Bonaventura, A; Christie, D; Dady, P; Denham, JW; Hamilton, CS; Lamb, DS; O'Brien, M; Spry, NA; Stewart, JF, 1995) |
| "Combined chemotherapy and radiotherapy in standard dosage is an acceptable approach following mastectomy for patients with extensive nodal involvement at high risk for local recurrence and distant relapse." | 2.68 | Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. ( Barraclough, B; Boyages, J; Langlands, AO; Ung, O, 1995) |
| "All patients had surgically documented minimal residual disease (1." | 2.68 | Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial. ( Averette, H; Berek, JS; Blessing, JA; Braly, PS; Homesley, HD, 1995) |
| "Thirty-one patients with squamous cell carcinoma of the vulva were treated with two courses of combination chemotherapy mitomycin C, 15 mg/m2 intravenously (i." | 2.68 | Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. ( di Re, F; Fontanelli, R; Kenda, R; Lupi, G; Paladini, D; Raspagliesi, F; Zucali, R, 1996) |
| "Thirty-two patients (76%) had no oral mucositis." | 2.68 | Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995) |
| "Sixty-three patients developed distant metastases or local relapse, 30 in the CT + RT group and 33 in the RT group." | 2.68 | Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. ( Bertelsen, K; Högberg, T; Koern, J; Onsrud, M; Simonsen, E; Sundfør, K; Tropé, CG; Westberg, R, 1996) |
| "We identified patients with gastric cancer at high risk for recurrence before therapy using endoscopic ultrasonography (EUS)." | 2.68 | Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. ( Botet, J; Brennan, M; Gerdes, H; Huang, Y; Karpeh, M; Kelsen, D; Klimstra, D; Lauers, G; Lightdale, C; Quan, V; Saltz, L; Schwartz, G, 1996) |
| "Treatment of both Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG-NHL) with bulky presentation at diagnosis frequently results in residual masses detected radiologically." | 2.68 | Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. ( Babini, L; Barbieri, E; Battista, G; Bendandi, M; Canini, R; Fanti, S; Frezza, G; Gherlinzoni, F; Gozzetti, A; Merla, E; Monetti, N; Pisi, P; Rimondi, MR; Tura, S; Zinzani, PL; Zompatori, M, 1996) |
| "To determine whether, when primary breast cancer is treated by local excision supported by systemic therapy appropriate to the oestrogen receptor status (ER) of the tumour, local radiotherapy can be avoided." | 2.68 | Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. ( Everington, D; Forrest, AP; George, WD; Harnett, AN; McArdle, CS; Prescott, RJ; Smith, DC; Stewart, HJ, 1996) |
| "For 27 outpatients with advanced cancer of the digestive system including 15 cases of esophageal cancer, 4 cases of gastric cancer, 3 cases of colon cancer, 4 cases of pancreatic cancer and 1 case of gall bladder cancer, 4 to 6 week home adjuvant chemotherapy was performed." | 2.68 | [Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy]. ( Araki, H; Hiramatsu, Y; Kamiyama, Y; Kojima, Y; Nakagawa, A; Nakagawa, M; Ogura, T; Shirasaka, T, 1995) |
| "Eighty patients with advanced squamous carcinoma of the head and neck were entered into a study using a 2-day, inpatient, intravenous regimen." | 2.68 | Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck. ( Canney, PA; Hatton, MQ; Junor, EJ; McGurk, FM; Paul, J; Robertson, AG; Symonds, RP; Yosef, H, 1996) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 2.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "The head and neck cancer program at the University of Chicago has reported encouraging results with concomitant 5-fluorouracil, hydroxyurea, and radiation administered every other week to patients with locally advanced or recurrent disease." | 2.68 | Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. ( Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME, 1997) |
| "25 horses with 27 T2-stage periocular squamous cell carcinomas." | 2.68 | Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses. ( Carlson, G; Madigan, JE; Metzger, L; Pascoe, JR; Théon, AP, 1997) |
| "The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in chemotherapy naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck." | 2.67 | Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a ( Cappelaere, P; Clavel, M; Clerico, M; Cognetti, F; de Mulder, PH; Schornagel, JH; Tueni, EA; Vermorken, JB; Verweij, J; Wildiers, J, 1994) |
| "Leukopenia was more frequent in the simultaneous than in the sequential arm (p = 0." | 2.67 | A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. ( Carlini, P; Cercato, MC; Cognetti, F; Del Vecchio, MR; Giannarelli, D; Impiombato, FA; Marzetti, F; Milella, M; Pinnarò, P, 1994) |
| "Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
| "Colon cancer is one of the major health problems in industrialized countries, and its incidence appears to be increasing." | 2.67 | Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. ( Aquino, A; Armenio, S; Civitelli, S; Francini, G; Lorenzini, L; Mancini, S; Marsili, S; Marzocca, G; Petrioli, R; Tanzini, G, 1994) |
| "Three had only bone metastases and were evaluable for toxicity and survival." | 2.67 | A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. ( Ang, PT; Au, E, 1994) |
| "Leukocytopenia was more severe in group B." | 2.67 | [Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy] ( Ito, T; Komatsu, Y; Moriya, N; Ogasawara, H; Saito, S; Sakata, Y; Sugimoto, N; Tamura, Y; Tsushima, K; Yamada, Y, 1994) |
| " Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions." | 2.67 | Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. ( Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992) |
| "Women with node-negative breast cancer have a 30% chance of relapse 5 years after mastectomy." | 2.67 | Swiss adjuvant trials in women with node-negative breast cancer. OSAKO. ( Jungi, WF; Senn, HJ, 1992) |
| "Postoperative women with breast cancer but without histopathological evidence of metastases to the axillary lymph nodes or clinical evidence of metastases were studied." | 2.67 | Chemotherapy versus observation in high-risk node-negative breast cancer patients. ( Cooper, MR; Eudey, L; Falkson, G; Gilchrist, KW; Mansour, EG; Osborne, CK; Shatila, AH; Tormey, DC, 1992) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "Significant improvement in dysphagia was recorded in 76% patients with complete response in 47 cases ranging from 6 to 27 months." | 2.67 | The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study. ( Desai, PB; Deshpande, R; Dinshaw, KA; Malliat, MK; Pendse, AM; Sharma, V; Telang, CS; Vege, SS, 1991) |
| "After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy." | 2.67 | [Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]. ( Berres, M; Harder, F; Jäggi, P; Laffer, U; Metzger, U, 1990) |
| "A total of 848 patients with gastric cancer underwent curative resection were eligible." | 2.67 | [Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supp ( Ichihashi, H; Imaizumi, M; Kamei, H; Kondo, T, 1990) |
| "A total of 6501 patients with stage III colon cancer who received adjuvant FOLFOX or FLOX in six randomized trials were included in the analysis." | 2.66 | Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. ( Alberts, SR; Andre, T; De Gramont, A; Goldberg, RM; Grothey, A; Kerr, RS; Lonardi, S; Marshall, JL; Pederson, LD; Salem, ME; Shi, Q; Taieb, J; Wolmark, N; Yin, J; Yoshino, T; Yothers, G, 2020) |
| "Controversial questions in recurrent breast cancer include the magnitude of the survival benefit of combination chemotherapy and the best choice of first line chemotherapy." | 2.66 | Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen. ( Brincker, H, 1988) |
| "Consequently, SLO in the treatment of ovarian cancer is considered to be effective in the extirpation of residual cancer and in the early detection of cancer recurrence." | 2.66 | [Studies of second-look operations (SLO) in ovarian cancer]. ( Yuzawa, H, 1989) |
| " Group A received (2"R)-4'-O-tetrahydropyranyladriamycin (THP) in combination with 5-fluorouracil (5-FU) and cyclophosphamide (CPA), while Group B was administered adriamycin (ADR) together with 5-FU and CPA." | 2.66 | A randomized controlled study of (2"R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tominaga, T, 1989) |
| "Following curative surgery for colorectal cancer 141 patients were randomized to receive a 6 month course of 5-fluorouracil (5FU) with or without postoperative levamisole or supportive treatment only." | 2.66 | Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. ( Bell, PR; Shaw, D; Windle, R, 1987) |
| "From 1973 to 1980, 701 patients with breast cancer measuring less than 2 cm in pathological diameter and with no palpable axillary lymph nodes were randomized to Halsted mastectomy (349) or to "quadrantectomy" with axillary dissection and radiotherapy to the ipsilateral breast tissue (QUART) (352)." | 2.66 | Local control and survival in early breast cancer: the Milan trial. ( Luini, A; Veronesi, U; Zucali, R, 1986) |
| "5-Fluorouracil was administered p." | 2.66 | Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1987) |
| " From the above results, THP in combination with cyclophosphamide and 5-Fluorouracil is comparable to ADR in efficacy and can be regarded as having better safety than ADR for the treatment of breast cancer." | 2.66 | [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer]. ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tanaka, T; Tominaga, T, 1986) |
| "Fifty-eight patients with disseminated breast cancer were randomly divided into 2 study groups." | 2.66 | [Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer]. ( Borisov, AI; Korman, DB; Maslova, IA; Pines, EV, 1985) |
| "Among patients with primary head and neck cancer, the stage of the disease influenced the response rate." | 2.65 | Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. ( Archibald, SD; Browman, GP; Hryniuk, WM; Kiehl, K; Levine, MN; Russell, R; Young, JE, 1983) |
| "Kondo) in Japan." | 2.65 | [Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer]. ( Ichihashi, H; Imaizumi, M; Kamei, H; Kondo, T, 1984) |
| "Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with methotrexate (250 mg/m2) followed 1 hour later by 5-FU (600 mg/m2)." | 2.65 | Use of methotrexate and 5-FU for recurrent head and neck cancer. ( Jacobs, C, 1982) |
| " Both the delay in starting chemotherapy and the significant decrease in percent optimal drug dosage during the first six cycles of therapy are factors that may influence the high frequency of relapse observed in the R." | 2.65 | A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. ( Cooper, MR; Ferree, C; Howard, V; Jackson, DV; Muss, HB; Rhyne, AL; Richards, F; Shore, A; Spurr, CL; Stuart, JJ; White, DR, 1981) |
| "172 patients who had had mastectomy for breast cancer were treated by repeated adjuvant chemotherapy, either with phenylalanine mustard (P." | 2.64 | Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Hahn, RG; Ingle, JN; O'Connell, MJ; O'Fallon, JR; Payne, WS; Rubin, J; Scanlon, PW, 1978) |
| "Omission of radiotherapy in rectal cancer is analyzed in the context of historical findings, as well as more recent data describing risk stratification of stage II-III disease, surgical optimization, imaging limitations, improvement in systemic chemotherapeutic agents, and contemporary studies evaluating selective omission of radiotherapy." | 2.58 | The Selective Use of Radiation Therapy in Rectal Cancer Patients. ( Czito, B; Martella, A; Palta, M; Willett, C, 2018) |
| "Pancreatic cancer is an aggressive cancer that continues to have single-digit 5-year mortality rates despite advancements in the field." | 2.53 | Localized Pancreatic Cancer: Multidisciplinary Management. ( Chiorean, EG; Coveler, AL; Herman, JM; Simeone, DM, 2016) |
| "The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage." | 2.52 | Anal cancer treatment: current status and future perspectives. ( Abdayem, P; Antoun, J; Ghosn, M; Kourie, HR; Nasr, D, 2015) |
| "Chemotherapy-induced diarrhea (CID) is a common and often severe side effect experienced by colorectal cancer (CRC) patients during their treatment." | 2.50 | Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. ( Doherty, GA; Lee, CS; Ryan, EJ, 2014) |
| "In general, people with Bowen's disease have an excellent prognosis because the disease is typically slow-growing and responds favourably to treatment." | 2.49 | Interventions for cutaneous Bowen's disease. ( Bath-Hextall, FJ; Leonardi-Bee, J; Matin, RN; Wilkinson, D, 2013) |
| "Vulvar cancer is a relatively rare gynecological malignancy afflicting elderly women." | 2.48 | Radiation in vulvar cancer. ( Sharma, DN, 2012) |
| "The majority of patients with a squamous cell carcinoma of the head and neck present with locally advanced tumors." | 2.48 | Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. ( Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N, 2012) |
| "Triple-negative breast cancer (TNBC) often grows rapidly and has poor outcomes, with a high recurrence rate and a short interval between recurrence and death." | 2.47 | Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. ( Kajiura, Y; Yagata, H; Yamauchi, H, 2011) |
| "The management of rectal cancer has undergone significant evolution with advances in surgery, radiation therapy, and chemotherapy." | 2.47 | Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy. ( Czito, BG; Willett, CG, 2011) |
| " The question to be addressed is how and when to apply intensified systemic therapy with adequate dosage and intensity as well as acceptable treatment-associated toxicity." | 2.47 | [Rectal cancer: current status of multimodal therapy--when and how?]. ( Becker, H; Gaedcke, J; Ghadimi, BM; Hess, C; Liersch, T; Rödel, C, 2011) |
| "Colorectal cancer is the second leading cause of cancer-related deaths in the world." | 2.47 | Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. ( Crea, F; Danesi, R; Landini, I; Mini, E; Napoli, C; Nobili, S; Paolicchi, E; Perrone, G, 2011) |
| "Risk factors for colorectal cancer are mainly dietary and genetic." | 2.46 | Colorectal cancer treatment. ( Landau, D; Qureshi, A; Ross, P; Verma, A, 2010) |
| "The successful management of rectal cancer requires a multidisciplinary approach, with treatment decisions based on precise patient evaluations by a group of clinicians, including surgeons, gastroenterologists, medical and radiation oncologists, radiologists, and pathologists." | 2.45 | The multidisciplinary management of rectal cancer. ( Hoffe, SE; Meredith, KL; Shibata, D, 2009) |
| "As therapy for locoregionally advanced head and neck cancer (HNC) has evolved, treatment has become increasingly aggressive and cure rates have risen." | 2.44 | Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. ( Posner, M; Vermorken, JB, 2008) |
| "Colon cancer is a public health problem worldwide." | 2.44 | Colon cancer: update on adjuvant therapy. ( Duhoux, F; Mano, MS, 2008) |
| "Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor prognosis." | 2.44 | Recurrent head and neck cancer: current treatment and future prospects. ( Specenier, PM; Vermorken, JB, 2008) |
| "If almost all colorectal cancers (CRC) correspond to the same histopathological type (adenocarcinoma), molecular biology allowed the identification of two different molecular mechanisms of colorectal carcinogenesis: chromosomal instability characterized by recurrent allelic losses on chromosomes 17, 5, 18, 8 and 22 that contribute to the inactivation of tumor suppressor genes, and genetic instability characterized by the instability of microsatellite loci due to an alteration of DNA mismatch repair leading to the accumulation of mutations in genes involved in the control of cell cycle and apoptosis." | 2.43 | [Molecular biology in clinical cancer research: the example of digestive cancers]. ( Laurent-Puig, P; Lièvre, A, 2005) |
| "Because patients with advanced gastric cancers have less than 50% chance of cure after R0 resection, the need for an adjuvant treatment to eradicate residual microscopic disease is clear." | 2.43 | A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy. ( Yu, W, 2006) |
| "Patients with locally recurrent head and neck cancer previously treated with radiation have a poor prognosis." | 2.43 | Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? ( Li, Y; Machtay, M; Wong, SJ, 2006) |
| "5-Fluorouracil has been the mainstay of therapy for the last four decades." | 2.43 | Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. ( Monga, DK; O'Connell, MJ, 2006) |
| "The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease." | 2.42 | Adjuvant radiation therapy of patients with rectal cancer. ( Bechtel, J; Tepper, J, 2003) |
| "Recent advances have been made in the treatment of pancreas cancer." | 2.42 | [Adjuvant and additive therapy for cancer of the pancreas]. ( Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD, 2003) |
| "Selected patients with inflammatory breast cancer have the potential for long-term survival." | 2.42 | Ten-year outcome after combined modality therapy for inflammatory breast cancer. ( Bertsch, H; Fox, K; Glick, J; Harris, EE; Schultz, D; Solin, LJ, 2003) |
| "Adjuvant therapy of rectal cancer follow the progress obtained in colon cancer using adjuvant fluorouracil based chemotherapy and is also based on radiotherapy." | 2.42 | [Adjuvant therapy of rectal cancer]. ( Bouaouina, N; Boussen, H, 2003) |
| "The prognosis of pancreatic cancer is poor at any stage." | 2.42 | [Adjuvant treatment of pancreatic cancer]. ( Oettle, H, 2003) |
| "Adjuvant therapy of colorectal cancer with oral fluorinated pyrimidines is attractive because of its ease of administration and good tolerability." | 2.42 | Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. ( Burzykowski, T; Buyse, M; Hamada, C; Ohashi, Y; Piedbois, P; Sakamoto, J, 2004) |
| "Patients with high-risk resected colon cancer obtain benefit from FU-based therapy across subsets of age, sex, location, T stage, nodal status, and grade." | 2.42 | Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? ( Alberts, SR; Benedetti, J; Cha, SS; Chen, W; Francini, G; Francois Seitz, J; Gill, S; Goldberg, RM; Haller, DG; Heldebrant, MP; Labianca, R; Loprinzi, CL; Sargent, DJ; Shepherd, LE; Thomé, SD, 2004) |
| "Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease." | 2.42 | Adjuvant therapy for rectal cancer in the elderly. ( Cohen, SM; Neugut, AI, 2004) |
| "We observed a case of multiple brain metastases in an EOC patient after complete response of a pelvic recurrence to platinum/paclitaxel chemotherapy." | 2.42 | Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. ( Cesák, T; Kohlová, T; Melichar, B; Nová, M; Urminská, H, 2004) |
| "Adjuvant therapy for colorectal cancer includes chemotherapy, radiotherapy and immunotherapy." | 2.41 | Adjuvant therapy of colorectal cancer: the next step forward. ( Kumar, D; Prabhudesai, AG, 2002) |
| " Fluorodeoxyuridine (FUDR) or 5-fluorouracil (5-FU) was used as the agent and a total dosage of 10-20 g was administered for 6-12 months in most studies." | 2.41 | [The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer]. ( Monden, T; Tono, T, 2000) |
| "Capecitabine is an oral fluoropyrimidine that mimics continuous infusion 5-fluorouracil and generates 5-fluorouracil preferentially at the tumor site." | 2.41 | The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. ( Blum, JL, 2001) |
| "Capecitabine is an excellent treatment option for patients who require symptom palliation and who prefer oral medications." | 2.41 | Clinical status of capecitabine in the treatment of breast cancer. ( Gradishar, WJ, 2001) |
| "Capecitabine has the potential to replace bolus or continuous infusion 5-FU as the standard treatment for rectal cancer and offers a potentially enhanced therapeutic ratio." | 2.41 | Improving chemoradiotherapy in rectal cancer. ( Debus, J; Glynne-Jones, R, 2001) |
| "Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects." | 2.41 | A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. ( Francini, G; Goldberg, RM; Haller, DG; Jacobson, SD; Labianca, R; Macdonald, JS; Sargent, DJ; Seitz, JF; Shepherd, LE, 2001) |
| "Because pancreatic cancer has a poor survival rate and only 20% of patients present with potentially resectable disease, a key goal of therapy is to provide palliation." | 2.41 | Pancreatic cancer: what the oncologist can offer for palliation. ( Moore, MJ, 2002) |
| "Traditionally, the most accepted treatment of vulvar cancer has been and continues to be surgery." | 2.41 | Recurrent vulvar cancer. ( Penalver, M; Salom, EM, 2002) |
| "In patients with Dukes' B or C rectal cancer, combined radiation and FU increase survival and decrease local and distal recurrence." | 2.40 | Adjuvant therapy of colorectal cancer. ( Cohen, A; Kemeny, N; Saltz, L, 1997) |
| "Locally advanced cervical cancer has a poor prognosis, poor survival rate, and high local failure rate." | 2.40 | [Clinical evaluation of chemoradiotherapy for advanced cervical cancer]. ( Kaneyasu, Y; Okawa, MK; Okawa, T, 1997) |
| "Patients with advanced colorectal cancer can only benefit from these important advances, however, if a truly multidisciplinary approach to patient care is adopted which requires integration of the roles of the surgeon, medical oncologist and radiotherapist." | 2.40 | The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon. ( Neoptolemos, JP; Rougier, P, 1997) |
| "The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (< 5% of patients)." | 2.40 | Oral 5-FU alternatives for the treatment of head and neck cancer. ( Brockstein, BE; Haraf, DJ; Humerickhouse, R; Vokes, EE, 1998) |
| "Five-year survival rates were 57% for squamous cell carcinoma, 63% for adenocarcinoma, and 33% for melanoma." | 2.40 | Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. ( Klas, JV; Madoff, RD; Rothenberger, DA; Wong, WD, 1999) |
| "An early diagnosis and treatment of Bowen's disease is important for preventing its progression to invasive epidermoid carcinoma and later dissemination." | 2.39 | [Bowen's disease. A report of 9 cases]. ( Borbujo Martínez, J; de Miguel Sánchez, C; Gázquez Abad, I; Olmos Carrasco, O; Rodríguez García, MD; Sáez-Berlana, A, 1994) |
| "Eighty percent of the patients had squamous cell carcinoma and 20% had adenocarcinoma." | 2.39 | Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. ( Bates, BA; Bernard, SA; Detterbeck, FC; Qaqish, BF; Tepper, JE, 1996) |
| " These include novel dosing and scheduling strategies, newer active agents, fresh biochemical targets, and different combinations of chemotherapy with hormonal therapy." | 2.39 | Adjuvant drug therapy for operable breast cancer. ( Hudis, CA; Norton, L, 1996) |
| "Among studies in recurrent head and neck cancer, the most effective chemotherapy regimens appear to be variations of the program consisting of cisplatin followed by a 5-day infusion of 5-fluorouracil." | 2.38 | Current chemotherapy of head and neck cancer. ( Amrein, P, 1991) |
| "Dystrophic epidermolysis bullosa is associated with a high incidence of cutaneous squamous cell carcinoma." | 2.38 | Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. ( Lentz, SR; Marion, JM; Orlowski, EP; Raish, RJ, 1990) |
| "Conservative procedures to treat rectal cancer are also gaining support because of reduced morbidity and mortality, avoidance of colostomy, and excellent survival figures in selected patients." | 2.38 | Surgical therapy of early rectal carcinoma. ( Curley, SA; Rich, TA; Roh, MS, 1989) |
| "After treatment of early breast carcinoma (stage I, II, and some III), the recurrent lesion can be classified as local, regional, distant, or combinations thereof." | 2.37 | Patterns of metastasis and natural courses of breast carcinoma. ( Lee, YT, 1985) |
| "Anal cancer is a rare form of gastrointestinal malignancy, and treatment is often confined to specialist centres." | 1.91 | Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience. ( Elmasry, A; Giridharan, S; Patel, C, 2023) |
| "Anal squamous cell carcinoma (ASCC) is an uncommon tumor." | 1.91 | Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation. ( Fukuya, A; Kagemoto, K; Kawaguchi, T; Mitsui, Y; Miyamoto, H; Noda, K; Okamoto, K; Sato, Y; Takayama, T; Yamasaki, M, 2023) |
| "Conjunctival papilloma is often resistant to treatment." | 1.91 | Conjunctival papilloma treatment outcomes: a 12-year-retrospective study. ( Galor, A; Karp, CL; Sripawadkul, W; Theotoka, D; Zein, M, 2023) |
| "Using established ovarian cancer cells lines as well as ovarian cancer cells isolated from a patient with high-grade drug-resistant ovarian carcinoma, we demonstrate that ovarian CSCs consistently express lower levels of NKG2D ligands (MICA/B and ULBPs) on their surfaces, a mechanism by which they evade natural killer (NK) cells' surveillance." | 1.91 | Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands. ( Hatefi, A; Li, G; Nikkhoi, SK, 2023) |
| "Because recurrent gastric cancer is often a progressive condition, post-treatment might be promptly transferred to the other posterior regimen without 5-FU as required." | 1.72 | [Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report]. ( Hirano, S; Ichinokawa, M; Kumagai, K; Kuwabara, S; Matsumoto, J; Murakawa, K; Ono, K; Takeuchi, Y; Wada, H, 2022) |
| "Fifteen percent of colorectal cancer (CRC) cells exhibit a mucin hypersecretory phenotype, which is suggested to provide resistance to immune surveillance and chemotherapy." | 1.72 | Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion. ( Alonso-Marañón, J; Cantero-Recasens, G; Espinosa, L; Garrido, M; Iglesias, M; Lobo-Jarne, T; Malhotra, V, 2022) |
| "In patients with esophageal cancer, oxaliplatin appears to have a lower risk of SIADH than cisplatin, suggesting that oxaliplatin can be a therapeutic option for patients with esophageal cancer who are at high risk of SIADH." | 1.72 | Folinic Acid, Fluorouracil, and Oxaliplatin Therapy for Recurrent Esophageal Cancer with Syndrome of Inadequate Antidiuretic Hormone Secretion (SIADH) After Preoperative Cisplatin/5-Fluorouracil Therapy. ( Abe, T; Futai, R; Hayashi, H; Iemoto, T; Inoue, Y; Morikawa, T; Ose, T; Sanuki, T; Sasaki, A; Yoshie, T, 2022) |
| "Our results suggest IMRT-based CRT with concurrent fluoropyrimidine and cisplatin is a safe and feasible option for patient with SCCA and may cause less acute toxicity." | 1.72 | Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. ( Bednarski, BK; Chang, GJ; Das, P; Delclos, ME; Eng, C; Holliday, EB; Jennings, K; Johnson, B; Koay, EJ; Koong, AC; Ludmir, EB; Messick, CA; Minsky, BD; Morris, VK; Rodriguez-Bigas, MA; Skibber, JM; Smith, GL; Taniguchi, C; Tillman, MM; You, YN, 2022) |
| "The selected old colon cancer patients with a high risk of recurrence gained an additional benefit with respect to prognosis from FU + oxaliplatin as AC." | 1.72 | Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis. ( Fukuda, A; Fukuoka, H; Hashimoto, S; Hisanaga, M; Nagayasu, T; Nonaka, T; Oyama, S; Sawai, T; Shiraishi, T; Sumida, Y; Takeshita, H; Tanaka, K; To, K; Tominaga, T, 2022) |
| "Patients with colon cancer who prematurely discontinue postoperative chemotherapy may have an increased risk of disease recurrence and death." | 1.72 | The association of abdominal adiposity with premature discontinuation of postoperative chemotherapy in colon cancer. ( Brown, JC; Caan, BJ; Cespedes Feliciano, EM; Cheng, E; Meyerhardt, JA, 2022) |
| " We followed up these patients and analyzed the relapse-free survival (RFS), overall survival (OS), and chemotherapy-induced adverse events (AEs)." | 1.72 | A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma. ( Dai, H; Feng, W; Tang, C; Yao, L, 2022) |
| "On day 2 of re-treatment, serous retinal detachment recurred and treatment was discontinued." | 1.72 | [A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer]. ( Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K, 2022) |
| "Primary squamous cell carcinoma (SCC) of the liver is a rare disease that is difficult to diagnose until the pathology is confirmed." | 1.72 | Primary Squamous Cell Carcinoma of the Liver with Good Response to Carboplatin and 5-Flurouracil: A Case Report. ( Chen, LM; Chien, LY; Fu, CK; Lee, HL, 2022) |
| "Obstructive colorectal cancer is locally advanced colorectal cancer with a poor prognosis." | 1.72 | A Prospective, Single-arm, Multicenter Trial of Diverting Stoma Followed by Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer: YCOG 1305 (PROBE Study). ( Endo, I; Ishibe, A; Misumi, T; Nakagawa, K; Ota, M; Suwa, H; Suwa, Y; Watanabe, J, 2022) |
| "In stage 3 colon cancer oncologists had an equal decision "to do or not to do" in MSI testing." | 1.72 | The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer. ( Araz, M; Aykan, NF; Baykara, M; Beypinar, I; Demir, H, 2022) |
| "Colon cancer is one of the leading causes of cancer-related deaths worldwide." | 1.72 | Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years. ( Abdelaziz, LA; Gertallah, LM; Harb, OA; Taha, HF, 2022) |
| "We report a case of advanced gastric cancer that was successfully treated with mFOLFOX6 therapy." | 1.62 | [A Case of Advanced Gastric Cancer Successfully Treated with mFOLFOX6 Therapy]. ( Fukada, A; Hashimoto, Y; Hirose, H; Kawada, J; Kidogami, S; Kishimoto, T; Mizuno, M; Mokutani, Y; Murotani, M; Nagano, S; Nakano, M; Sasaki, Y; Tamura, S; Yoneda, N; Yoshioka, S, 2021) |
| "In patients with BR or LA pancreatic cancer, FOLFIRINOX is a valuable neoadjuvant treatment that enables curative surgery in approximately one-quarter of patients and significantly improves overall survival." | 1.62 | Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. ( Choi, YH; Jang, JY; Kim, SW; Kim, YT; Kwon, W; Lee, SH; Paik, WH; Ryu, JK; Shin, BS; You, MS, 2021) |
| "To evaluate somatic mutations, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in patients with Pancreatic ductal adenocarcinoma (PDAC) with pathologic complete response (pCR) to neoadjuvant therapy (NAT) and find their associations with outcome." | 1.62 | Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. ( Miao, Y; Pu, N; Thompson, E; Wolfgang, C; Yin, L; Yu, J, 2021) |
| " There was also no difference in the incidence of grade 3/4 adverse events between groups." | 1.62 | Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. ( Fujiwara, Y; Fukuda, N; Hayashi, N; Mitani, H; Nakano, K; Ohmoto, A; Ono, M; Sato, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yunokawa, M, 2021) |
| "T4N0 colon cancer had similar oncological characteristics and survival outcomes to T3N1 colon cancer." | 1.62 | Staging Paradox and Discrepancy in Adjuvant Chemotherapy in Patients with T4N0, T1-2N1, and T3N1 Colon Cancer. ( Arita, T; Fujiwara, H; Ikoma, H; Kiuchi, J; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Okamoto, K; Otsuji, E; Shimizu, H; Shiozaki, A; Yamamoto, Y, 2021) |
| "Although topical therapies are used to treat extramammary Paget's disease (EMPD), reliable treatment outcomes and the effects of these therapies on subsequent surgical treatments are unclear." | 1.62 | Initial topical monotherapy may increase the risk of recurrence in patients with extramammary Paget's disease. ( Choi, S; Chung, KY; Oh, BH; Oh, Y; Roh, MR, 2021) |
| "In patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) the estimated prognosis is usually poor." | 1.62 | Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study. ( Amorim, C; Domingues, I; Felix, R; Garcia, AR; João Sousa, M; Mariano, M; Pontes, F; Salgueiro, F; Teixeira, M, 2021) |
| "Although the continuation of cetuximab in combination with paclitaxel after EXTREME provides moderate benefit, it could be an interesting option for selected patients." | 1.62 | Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. ( Alfonsi, M; Chevalier, T; Daste, A; Dupuis, C; Fakhry, N; Fayette, J; Huguet, F; Lambert, T; Le Tourneau, C; Loundou, A; Peyrade, F; Peyraud, F; Reure, J; Saada-Bouzid, E; Salas, S; Toullec, C, 2021) |
| "Our study revealed that there was no adverse pathologic or oncological outcome with the concurrent use of PPIs along with Cape-NACRT in the treatment of LARC." | 1.62 | Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: Is it Safe? ( Abraham, AG; Ghosh, S; Joseph, K; Mahfouz, M; Menon, A; Mulder, K; Nijjar, T; Paulson, K; Roa, W; Severin, D; Tankel, K; Thachuthara, JJ; Usmani, N; Warkentin, H, 2021) |
| "Only 50-70% of elderly colon cancer patients could complete the recommended 6 months of postoperative chemotherapy." | 1.62 | Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study. ( Chen, J; Chen, W; Dong, H; Wang, G; Wang, W, 2021) |
| "Of the 881 gastric cancer patients, 88 (10." | 1.56 | Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. ( An, JY; Bae, JM; Byeon, SJ; Choi, MG; Kim, KM; Kim, S; Kim, SM; Lee, J; Lee, JH; Sohn, TS, 2020) |
| "Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54-67), 84% male, and 70% Eastern Cooperative Oncology Group performance status 0-1; 32% had oral cavity and 30% oropharyngeal cancers." | 1.56 | Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. ( Ahn, MJ; Auclair, V; Berrocal, A; Bertolini, F; Castro, G; Cheung, WY; Chirovsky, D; Grünwald, V; Guillaume, X; Harrington, K; Joo, S; Kuyas, H; Shah, R; Sjoquist, K; Yang, MH, 2020) |
| "The objectives of this study were to evaluate survival in 141 patients with stage II-IV oral squamous cell carcinoma (OSCC) treated with preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) via the superficial temporal artery, and to clarify the prognostic factors." | 1.56 | Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma. ( Endo, M; Hasegawa, H; Kaneko, T; Kanno, C; Kano, M; Kitabatake, T; Monma, T; Sato, E; Takeishi, E; Yamazaki, M, 2020) |
| " A modified FOLFOXIRI regimen is also widely used to reduce adverse events." | 1.56 | Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience. ( Adachi, T; Eguchi, S; Enjoji, T; Hidaka, M; Inoue, Y; Ito, S; Kanetaka, K; Kobayashi, K; Kosaka, T; Kuba, S; Okada, S; Takatsuki, M; Tetsuo, H; Torashima, Y; Yamaguchi, S; Yamanouchi, K, 2020) |
| "Endpoints were pathologic response, resection margin and overall survival (OS), disease free survival (DFS), local recurrence free survival (LRFS), and metastasis free survival (MFS)." | 1.56 | Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer. ( Bloemen, JG; Burger, JWA; Creemers, GJM; Kusters, M; Nederend, J; Nieuwenhuijzen, GAP; Peulen, HMU; Roef, MJ; Rutten, HJT; van Lijnschoten, G; van Zoggel, DMGI; Voogt, ELK, 2020) |
| "Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy." | 1.56 | Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. ( Chang, W; Cho, JY; Cho, S; Jheon, S; Kang, SB; Kim, DW; Kim, JH; Kim, JW; Kim, K; Kim, SA; Lee, KW; Oh, HK; Suh, KJ, 2020) |
| "A 68-year-old female with rectal cancer underwent low anterior resection with regional lymph node dissection." | 1.56 | [Long-Term Survival of a Patient with Advanced Recurrent Rectal Cancer Treated with a Multidisciplinary Therapy including Five Operations-A Case Report]. ( Adikrisna, R; Gokita, K; Nara, A; Onishi, I; Sueyoshi, K; Udagawa, M; Watanabe, Y, 2020) |
| "When treating invasive basal cell carcinoma (BCC) with Mohs micrographic surgery (MMS), including infiltrative and nodular subtypes, the goal is complete surgical removal of the tumor." | 1.56 | Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery. ( Housewright, C; Pederson, H; Staples, CJ, 2020) |
| "To evaluate the prognostic value of posttreatment fibrosis in human PDAC patients, and to compare a type I collagen targeted MRI probe, CM-101, to the standard contrast agent, Gd-DOTA, for their abilities to identify FOLFIRINOX-induced fibrosis in a murine model of PDAC." | 1.56 | Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. ( Arora, G; Axtell, AL; Bardeesy, N; Caravan, P; Chawla, A; Chen, YI; Deshpande, V; Erstad, DJ; Farrar, CT; Ferreira, DS; Ferrone, CR; Fuchs, BC; Ghoshal, S; Graham-O'Regan, KA; Humblet, V; Jones, C; Jordan, VC; Kontos, F; Lanuti, M; Li, S; Michelakos, T; Qadan, M; Rotile, NJ; Sojoodi, M; Tanabe, KK; Taylor, MS, 2020) |
| "Acute hematotoxicity (G3, 4, 5 according to Common Terminology Criteria for Adverse Events - CTCAE) was significantly associated with the concomitant chemoradiotherapy (P = 0." | 1.56 | Haematotoxicity in IMRT/VMAT curatively treated anal cancer. ( Drbohlavová, T; Jirkovská, M; Lohynská, R; Malinová, B; Mazaná, E; Nýdlová, A; Stankušová, H; Veselský, T, 2020) |
| "In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed." | 1.56 | Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. ( Alawi, M; David, K; Ewald, F; Fischer, L; Indenbirken, D; Izbicki, JR; Jücker, M; Juhl, H; Molloy, MP; Nashan, B; Omidi, M; Sauter, G; Schlüter, H; Simon, R; Smit, DJ; Spohn, M; Voß, H; Wurlitzer, M, 2020) |
| "Colon cancer is the 4th most common cancer causing death in both male and female equally, mainly caused due to the improper diet plans, consumption of the red meat and lack of exercise." | 1.51 | Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance? ( Karthika, C; Sureshkumar, R, 2019) |
| "As chemotherapy does not target the cancer stem cells, we conclude that the tumor cells recover due to the presence of cancer stem cells." | 1.51 | Modeling the stem cell hypothesis: Investigating the effects of cancer stem cells and TGF-β on tumor growth. ( Elliott, SL; Kose, E; Lewis, AL; Steinfeld, AE; Zollinger, EA, 2019) |
| "We report 2 cases of advanced colorectal cancer achieving complete response by FOLFOXIRI plus bevacizumab." | 1.51 | [Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report]. ( Aizawa, M; Endo, S; Isohata, N; Nemoto, D; Nemoto, T; Oshibe, I; Saito, T; Soeta, N; Takayanagi, D; Togashi, K; Utano, K, 2019) |
| "A total of 118 rectal cancer patients receiving preoperative CRT were enrolled." | 1.51 | Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy. ( Araki, T; Fujikawa, H; Hiro, J; Ide, S; Kusunoki, M; Ohi, M; Okugawa, Y; Saigusa, S; Toiyama, Y; Yamamoto, A; Yasuda, H; Yoshiyama, S, 2019) |
| "The rates of locoregional recurrence (2." | 1.51 | Adjuvant Chemotherapy in Rectal Cancer Patients Treated With Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study. ( Chung, MJ; Jang, HS; Jeong, JU; Jeong, S; Kim, SH; Lee, JH; Nam, TK; Song, JH; Yu, M, 2019) |
| "Adult patients with R/M-HNSCC, who initiated systemic therapy between 1 September 2011 and 31 December 2014 and followed through 31 December 2015, were identified from iKnowMed electronic-health-records database (McKesson Specialty Health) supplemented with manual chart-abstraction." | 1.51 | Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( Black-Shinn, J; Boyd, M; Chirovsky, D; Joo, S; Nadler, E, 2019) |
| "Preoperative radio(chemo)therapy in rectal cancer may irreversibly damage pelvic bone marrow (PBM) and impair the tolerance of subsequent chemotherapy." | 1.51 | Impact of pelvic bone marrow irradiation on the hematological toxicity of subsequent chemotherapy in rectal cancer. ( Michalski, W; Spalek, M; Wyrwicz, L, 2019) |
| "Capecitabine is a safe regimen in terms of oncologic outcomes compared with FL in older patients with stage II colon cancer." | 1.51 | Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study. ( Cho, S; Jeong, SY; Kim, MJ; Kwon, YH; Lee, KY; Park, JW; Park, KJ; Ryoo, SB, 2019) |
| "Examinations revealed advanced rectal cancer involving the anal canal with invasion of the left-sided levator ani muscle." | 1.51 | [Curative Transanal Resection after Neoadjuvant Chemotherapy for Lower Rectal Cancer-A Case Report]. ( Aizawa, M; Endo, K; Endo, S; Isohata, N; Nemoto, D; Nemoto, T; Oshibe, I; Saito, T; Soeta, N; Takayanagi, D; Togashi, K; Utano, K, 2019) |
| "We reported 2 cases of colorectal cancer receiving neoadjuvant chemotherapy(NAC)with the aim of curative resection or anal preservation." | 1.51 | [Two Cases of Locally Advanced Rectal Cancer and Lower Rectal Cancer Resected Successfully That Enabled Anus Preservation after Preoperative Chemotherapy]. ( Chiku, T; Hashiba, T; Sano, W; Shinoda, K; Togawa, Y; Yamashita, K, 2019) |
| "Although hepatectomy for metastatic colorectal cancer (mCRC) prolongs survival in up to 40% of people, recurrence rates approach 70%." | 1.51 | Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study. ( Hanai, T; Hayashi, T; Ikeda, Y; Kato, Y; Katsuno, H; Koide, Y; Maeda, K; Masumori, K; Matsuoka, H; Morise, Z; Nakajima, S; Sugioka, A; Tanahashi, Y; Tanaka, C; Uyama, I, 2019) |
| "Patients with recurrence or metastasis within 6 months after cisplatin administration were considered platinum-resistant and those with no recurrence or metastasis within 6 months were considered platinum-sensitive." | 1.51 | Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. ( Fushimi, C; Hanyu, K; Katsube, Y; Kondo, T; Miura, K; Okada, T; Okamoto, I; Sato, H; Shimizu, A; Tsukahara, K, 2019) |
| "CRT for anal cancer is becoming a standard therapy but local recurrence is possible." | 1.51 | [A Case of Colostomy-Free and Long-Term Survival with 5-FU/CDDP for Local Recurrence of Anal Cancer after Chemoradiation Therapy]. ( Aoyama, Y; Hikosaka, Y; Karamatsu, S; Katada, T; Kato, A; Mita, K; Nishida, T; Nishido, T; Saito, M; Sakamoto, S; Shibata, T; Teranishi, F; Tsuchiya, T, 2019) |
| "To investigate the relationship between treatment-related lymphopenia and pathologic response to neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC)." | 1.51 | Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy. ( Hu, Y; Li, Q; Liu, M; Liu, S; Xi, M; Yang, H; Zhao, L; Zhou, S, 2019) |
| "Recurrence and chemoresistance in colorectal cancer remain important issues for patients treated with conventional therapeutics." | 1.51 | Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. ( Jang, H; Kim, A; Kim, H; Kim, MJ; Kim, YH; Lee, SB; Lee, SJ; Myung, JK; Park, EH; Park, JH; Park, S; Shim, S, 2019) |
| "We report the case of a long-term esophageal cancer survivor treated by esophageal bypass operation for ERF after chemoradiotherapy (CRT)." | 1.51 | Long-term Esophageal Cancer Survivor Treated by Bypass for Esophagobronchial Fistula After Chemoradiotherapy: A Case Report. ( Emi, M; Hamai, Y; Ibuki, Y; Miyata, Y; Ohsawa, M; Okada, M, 2019) |
| "Long-term outcomes of older esophageal cancer patients (70 y and above) selected for treatment with neoadjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy were comparable with the outcomes of their younger counterparts." | 1.48 | Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. ( Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM, 2018) |
| "Superficial basal cell carcinoma is a type of keratinocyte carcinoma that has increasing incidence and substantial morbidity." | 1.48 | Comparing Topical Treatments for Basal Cell Carcinoma. ( Shaw, FM; Weinstock, MA, 2018) |
| "BACKGROUND Triple negative breast cancer (TNBC) has a more aggressive recurrence." | 1.48 | Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis. ( Chang, W; Hu, B; Liang, Y; Wang, S; Zhang, Y, 2018) |
| "Data on patients with cT3/4 and N+ rectal cancer who were treated in our institution from April 2010 to February 2016 were reviewed retrospectively." | 1.48 | Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study. ( Noie, T; Okuyama, T; Ono, Y; Oya, M; Sameshima, S; Tagaya, N; Takeshita, E; Yamagata, Y; Yoshioka, R, 2018) |
| "Human papillomavirus-associated oropharyngeal cancer was associated with a significant improved overall survival, locoregional, distant and overall tumor control rates in multivariate analysis." | 1.48 | Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". ( Baumeister, P; Belka, C; Ganswindt, U; Hess, J; Kirchner, T; Macht, C; Maihoefer, C; Pflugradt, U; Schneider, L; Schüttrumpf, L; Walch, A; Woischke, C; Zitzelsberger, H, 2018) |
| "Background Early relapse in colorectal cancer (CRC) after curative resection is mainly attributed to the key determinants such as tumor histology, stage, lymphovascular invasion, and the response to chemotherapy." | 1.48 | Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy. ( Ajaj, AR; Al-Hiary, R; Al-Yacoub, S; Kadi, T; Majdalawi, K; Mukred, R; Tantawi, D; Yousef, AM; Yousef, M; Zawiah, M, 2018) |
| " We compared tolerability and efficacy of the two different chemotherapy regimens; 5-FU/leucovorin (LV) versus cisplatin with capecitabine (XP) combined with radiotherapy (RT) in the adjuvant therapy of the lymph node positive locally advanced gastric cancer." | 1.48 | Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer. ( Bilici, A; Erkol, B; Figen, M; Surmelioglu, A; Tilki, M; Ustaalioglu, BBO; Uyar, S, 2018) |
| "Patients with rectal cancer treated with chemoradiotherapy and radical surgery from 2003 to 2015 (N = 222) were included." | 1.46 | Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy. ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Tanaka, T; Watanabe, T, 2017) |
| "Distal resection margin (≤5 vs >5 mm) did not show any significant difference in cumulative incidence of locoregional recurrence (P=." | 1.46 | Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis. ( Bae, JM; Jang, HS; Jeong, S; Kim, SH; Lee, JH; Lee, JW; Nam, TK; Song, JH; Sung, S, 2017) |
| "Pancreatic cancer has a high rate of local recurrence and poor prognosis even with adjuvant chemotherapy after curative resection." | 1.46 | Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. ( Jun, E; Kim, SC; Lee, CM; Lee, S; Oh, J; Shim, IK, 2017) |
| "5-fluorouracil was associated with a 74% success rate as the initial treatment modality for high-grade vaginal dysplasia." | 1.46 | Topical 5-Fluorouracil for Women With High-Grade Vaginal Intraepithelial Neoplasia. ( Feldman, S; Fiascone, S; Vitonis, AF, 2017) |
| "Penile squamous cell carcinoma (pSCC) is a relatively rare disease in Western world but is a significant health problem in developing countries like India." | 1.46 | Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery. ( Bunger, D; Gupta, S; Pawar, SS, 2017) |
| "Recurrence of gastric cancer after 10 years of surgical resection is highly rare." | 1.46 | [Gastric Cancer Recurrence in 12 Years after Surgical Resection]. ( Chang, HK; Kim, JH; Ku, KH; Kwon, HJ; Park, JG; Park, SJ, 2017) |
| "Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed." | 1.46 | Usefulness of chemoradiotherapy for inoperable gastric cancer. ( Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K, 2017) |
| "Patients with locally advanced rectal cancer (LARC) receiving neoadjuvant chemoradiation (nCRT) can have a complete pathologic response (pCR), and are given postoperative adjuvant chemotherapy (ACT)." | 1.46 | Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified? ( Church, JM; Gamaleldin, M; Gorgun, E; Kalady, M; Liska, D; Stocchi, L, 2017) |
| "Advanced stage squamous cell carcinoma of the head and neck carries an overall poor prognosis, and survivorship gains have remained relatively stagnant compared to other malignancies due to its complex tumor biology and lack of proven effective targeting agents." | 1.46 | Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma. ( Bhandari, M; Jones, RG; Kang, SY; Seim, NB; Teknos, TN, 2017) |
| "Patients with locally advanced colon cancer (LACC) have a relatively poor prognosis despite radical resection and adjuvant chemotherapy." | 1.46 | Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer. ( Huang, CJ; Huang, CM; Huang, CW; Huang, MY; Ma, CJ; Tsai, HL; Wang, JY; Yeh, Y-, 2017) |
| "In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months." | 1.43 | Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. ( Carp, L; Corthouts, B; Specenier, P; Szturz, P; Van Den Weyngaert, D; Van Laer, C; Van Marck, E; Vanderveken, O; Vermorken, JB, 2016) |
| "Esophageal squamous cell carcinoma (ESCC) contains genomic alterations of undefined clinical significance." | 1.43 | Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. ( Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y, 2016) |
| "Breast cancer is believed to result from the interplay of genetic and non-genetic risk factors, and individual genetic variation may influence the efficacy of chemotherapy." | 1.43 | A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients. ( Fan, T; Fan, Z; Li, J; Lin, B; Ouyang, T; Wang, T; Wu, L; Xie, Y; Yao, L; Yin, CC; Zhang, H, 2016) |
| "To evaluate the impact of the 12-gene Colon Cancer Recurrence Score Assay-a clinically validated prognosticator in stage II colon cancer after surgical resection-on adjuvant treatment decisions in T3 mismatch repair proficient (MMR-P) stage II colon cancer in clinical practice." | 1.43 | Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients. ( Beny, A; Brenner, B; Chao, C; Dror, Y; Geva, R; Gluzman, A; Hubert, A; Idelevich, E; Liebermann, N; Man, S; Mishaeli, M; Purim, O; Rothney, M; Shacham-Shmueli, E; Shani, A; Shulman, K; Soussan-Gutman, L; Steiner, M; Tezcan, H, 2016) |
| "A pathologic cervical residual tumor was observed in 16 patients (35." | 1.43 | [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy]. ( Ballester, M; Daraï, E; Huguet, F; Lauratet, B; Lefranc, JP; Monnier, L; Touboul, E, 2016) |
| "Of them, 315 node-negative stage II colorectal cancer cases were enrolled." | 1.43 | Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial. ( Doki, Y; Fukunaga, M; Ikeda, M; Kato, T; Matsuura, N; Miyake, Y; Mizushima, T; Monden, M; Mori, M; Murata, K; Nakamura, Y; Nezu, R; Noura, S; Ohnishi, T; Ohtsuka, M; Ohue, M; Sekimoto, M; Takemasa, I; Yamamoto, H, 2016) |
| "Resection of exocrine pancreatic cancer is necessary for cure, but locoregional and distant relapse is common." | 1.43 | Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. ( Haddock, MG; Hallemeier, CL; Harmsen, WS; Kendrick, ML; Merrell, KW; Miller, RC; Quevedo, JF, 2016) |
| "Distant metastasis occurred in 86." | 1.43 | [Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy]. ( Chi, P; Huang, S; Huang, Y; Lin, H; Lu, X; Sun, Y; Wang, X; Xu, Z; Ye, D, 2016) |
| "Between 2006 and 2015, patients with rectal cancer, stages I-III, without metastasis, treated with neoadjuvant CRT/CT, who had clinical complete response were included." | 1.43 | Non-surgical management of rectal cancer. Series of 68 cases, long follow up in two leading centres in Argentina. ( Chacon, M; Coraglio, M; Dieguez, A; Huertas, E; Iseas, S; Mariani, J; Mendez, G; O'Connor, JM; Pairola, A; Roca, E; Sanchez Loria, F, 2016) |
| " The chemotherapy drugs were administered as follows: 135 mg/m(2) paclitaxel on day 1, 25 mg/m(2)/day cisplatin on days 1-3, followed by continuously infused intravenous fluorouracil for 120 h at a variable dosage from 600 to 800 mg/m(2)/day, depending on prior radiation." | 1.43 | A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. ( Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ, 2016) |
| "Locally advanced hepatocellular carcinoma (HCC) with portal vein thrombosis carries a 1-year survival rate <10%." | 1.43 | Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. ( Choi, GH; Choi, JS; Han, DH; Han, KH; Joo, DJ; Kim, MS; Kim, SI; Park, YN; Seong, J, 2016) |
| "45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included." | 1.43 | Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival. ( Behrendt, FF; Eble, MJ; Heinzel, A; Mohammadkhani Shali, S; Mottaghy, FM; Schmitt, V; Verburg, FA; Winz, OH, 2016) |
| "After local excision of early rectal cancer, revision radical resection is recommended for patients with high-risk pathologic stage T1 (pT1) or pT2 cancer, but the revision procedure has high morbidity rates." | 1.43 | Adjuvant chemoradiotherapy instead of revision radical resection after local excision for high-risk early rectal cancer. ( Ahn, SJ; Chung, WK; Jeong, JU; Kim, HR; Kim, YH; Nam, TK; Shim, HJ; Song, JY; Yoon, MS, 2016) |
| "The incidence of young-age gastric cancer (GC) is increasing worldwide, but clinical behavior of young-age GC patients is not well established." | 1.43 | Clinical characteristics of young-age onset gastric cancer in Korea. ( Kim, IH; Lee, J; Lee, MA; Roh, SY, 2016) |
| "We herein describe a case of gastric cancer during pregnancy." | 1.43 | Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report. ( Chin, HM; Jo, YS; Jun, KH; Jung, JH; Kim, EY, 2016) |
| "Anal cancer was diagnosed in a 36-year-old nulliparous woman." | 1.43 | Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level. ( Biel, P; Cordes, T; Köhler, C; Marnitz, S, 2016) |
| "BACKGROUND Hepatocellular carcinoma (HCC) causes many deaths worldwide every year, especially in Asia." | 1.43 | Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. ( He, B; Hu, X; Liu, J; Liu, S; Wang, H, 2016) |
| "Nine days after CAF treatment, residual tumors showed features of regressive alterations and were composed of mesenchymal-like tumor cells, infiltrating immune cells and some tumor-associated fibroblasts with an intense deposition of collagen." | 1.42 | Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination. ( Alves, F; Deppert, W; Jannasch, K; Lenfert, E; Maenz, C; Wegwitz, F, 2015) |
| "In the multivariable analysis, stage II colon cancer patients with at least one G allele for ITGB3 rs4642 had higher risk of recurrence (hazard ratio (HR)=4." | 1.42 | Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. ( Benhaim, L; Bohanes, P; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; LaBonte, MJ; Lenz, C; Lenz, F; Lenz, HJ; Loupakis, F; Ning, Y; Wakatsuki, T; Yang, D; Zhang, W, 2015) |
| "For patients with locally advanced rectal cancer, higher radiation dose may contribute to the improvement of both LC and disease-free survival, without significantly increasing the incidence of acute and long-term complications compared with adjuvant chemoradiotherapy alone." | 1.42 | Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer. ( Fu, S; Huang, G; Li, P; Lu, JJ; Peng, L; Tey, J; Xiong, F; Yang, Z; Zhang, Q, 2015) |
| "The clinicopathological parameters and adverse effects were similar between the 2 groups (P > 0." | 1.42 | Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. ( Burns, M; Hong, Y; Lei, X; Li, JL; Li, QL; Li, YG; Liu, C; Liu, HC; Liu, JS; Qiu, XX; Wang, XH; Wu, QF; Xia, M; Xiao, H; Xu, RC; Zhu, HZ; Zuo, CH, 2015) |
| "Finally, using a human colon cancer xenograft murine model, we found that the combined 5-FU and 10058-F4 treatment significantly decreased tumorigenicity in nude mice compared with 5-FU or 10058-F4 treatment alone." | 1.42 | The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells. ( Enoki, T; Hamano, K; Hosoyama, T; Kugimiya, N; Li, TS; Nishimoto, A; Ueno, K, 2015) |
| " Most adverse events were mild (grade 1-2) (Common Terminology Criteria for Adverse Events, version 3." | 1.42 | Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ( Kumita, S; Mine, T; Murata, S; Onozawa, S; Sakamoto, A; Sugihara, F; Ueda, T; Yamaguchi, H; Yasui, D, 2015) |
| "To explore the clinical efficacy and toxic and side effects of recombinant human endostatin (rh- endostatin/endostar) combined with chemotherapy in the treatment of advanced gastric cancer." | 1.42 | Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer. ( Gao, SR; Li, LM; Wang, AR; Wang, GM; Xia, HP; Xu, HY, 2015) |
| "Primary rectal cancer patients with synchronous distant metastases between September 2001 and August 2011 were enrolled." | 1.42 | Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2015) |
| "Information about 209 esophageal cancer patients with stage III or T3 disease, who underwent NAC consisting of CF with or without docetaxel, was reviewed." | 1.42 | Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. ( Abe, T; Andoh, M; Ishihara, M; Kadowaki, S; Kawai, R; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tajika, M; Tanaka, T; Taniguchi, H; Uemura, N; Ura, T, 2015) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 1.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "The clinicopathological data of 110 gastric cancer patients who developed recurrence or second primary malignancies after radical gastrectomy and adjuvant chemotherapy with FOLFOX4 regimen or docetaxel plus FOLFOX4 regimen were analyzed retrospectively." | 1.42 | [Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy]. ( Du, C; Guo, C; Wang, J; Xu, Q; Zhou, A, 2015) |
| "In the clinic, predicting metastasis and chemoresistance takes high priority, but has not been well established." | 1.40 | Predicting distant metastasis and chemoresistance using plasma miRNAs. ( Chen, J; Chen, Y; Hu, T; Wang, W; Zhang, Y, 2014) |
| "Despite curative surgery for colorectal cancer, some patients experience tumor recurrence." | 1.40 | Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. ( Chang, SC; Chen, WS; Chiou, SH; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Lin, TC; Wang, HS; Yang, SH, 2014) |
| "Recurrent rectal cancer appears radioresistant compared with primary tumors for tumor size after CRT." | 1.40 | Chemoradiotherapy response in recurrent rectal cancer. ( Bhangu, A; Brown, G; Tait, DM; Tekkis, P; Wotherspoon, A; Yu, SK, 2014) |
| "Metastasized rectal cancer has long been considered incurable." | 1.40 | A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach. ( Albertsson, M; Holmqvist, A; Jung, M; Sun, XF, 2014) |
| "Patients with cT2-4N0-2M0 distal rectal cancer treated with CRT (50." | 1.40 | Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. ( Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; Sabbagh, C; São Julião, GP, 2014) |
| "A total of 100 gastric cancer patients who received curative D2 gastrectomy were enrolled in this study and were randomly assigned to either XELOX group (oral capecitabine combined with intravenous oxaliplatin chemotherapy) or the control group (surgery alone)." | 1.40 | [Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis]. ( He, Y; Huang, C; Ji, J; Liang, H; Liu, Y; Shi, Y; Sun, Y; Wu, A; Yan, M; Ye, Y; Zhan, Y, 2014) |
| "Fibrolamellar variant of hepatocellular carcinoma (FLHCC) does not have a favorable prognosis than conventional HCC, and there is no difference regarding the response to chemotherapy and the degree of surgical resectability." | 1.40 | Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. ( Akdemir, ÜÖ; Akyol, G; Boyunağa, Ö; Dalgiç, A; Demiroğullari, B; Eser, EP; Karadeniz, C; Oğuz, A; Okur, A; Pinarli, FG; Yilmaz, G, 2014) |
| "Distant metastasis accounted for the predominant cause of death." | 1.40 | [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment]. ( Guo, Y; Ji, Q; Qian, W; Wang, Y; Zhu, G, 2014) |
| "Inguinal lymph node metastasis is predictive of locoregional recurrence and poor overall survival in anal carcinoma." | 1.40 | Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma. ( Blinde, SE; Mens, JW; Nuyttens, JJ; Olofsen, M; Schasfoort, R; Verhoef, C, 2014) |
| "Patients with T3/T4 and or N+ rectal cancer (n = 65) were treated with preoperative concomitant boost radiotherapy (55 Gy/25 fractions) associated to concurrent chemotherapy with oral capecitabine." | 1.40 | Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients. ( Agolli, L; Bracci, S; De Sanctis, V; Falco, T; Masoni, L; Maurizi Enrici, R; Osti, MF; Valeriani, M, 2014) |
| "Three and five years survival of gastric cancer patients subjected to adjuvant chemoradiotherapy was 53 and 41% respectively." | 1.40 | [Adjuvant chemoradiotherapy in advanced gastric cancer: experience in 168 patients]. ( Isa O, N; López V, H; Russo N, M, 2014) |
| "Esophageal squamous cell carcinoma (ESCC) patients with regional lymph node metastases have poor prognosis after surgery." | 1.40 | Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? ( Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J, 2014) |
| "Locally recurrent rate of advanced head and neck squamous cell carcinoma (HNSCC) still remains high and the treatment is controversial." | 1.40 | Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma. ( Chen, CH; Lin, SF; Liu, YC; Sun, Y; Tang, JY; Wu, CF; Yang, WC, 2014) |
| "Patients with locally advanced rectal cancer (LARC) have a dismal prognosis." | 1.40 | Post-chemoradiation intraoperative electron-beam radiation therapy boost in resected locally advanced rectal cancer: long-term results focused on topographic pattern of locoregional relapse. ( Alvarez, E; Calvo, FA; Del Valle, E; Deutsch, E; Garcia-Alfonso, P; García-Sabrido, JL; Muñoz-Calero, A; Peligros, I; Rivera, S; Rodriguez, M; Serrano, J; Sole, CV; Turégano, F, 2014) |
| "Adjuvant chemotherapy use in stage II colorectal cancer (CRC) is debated." | 1.40 | The role of adjuvant chemotherapy in stage II colorectal cancer patients. ( Chang, SC; Chang, YY; Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Lin, JK; Lin, TC; Wang, HS; Yang, SH, 2014) |
| "Lung cancer is one of the leading causes of cancer-related death in developed countries." | 1.40 | SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. ( Feng, Y; Lu, W; Zhang, M; Zuo, Y, 2014) |
| "FuOx-resistant (chemoresistant; CR) colon cancer cells, highly enriched in CSCs, were used for this study." | 1.40 | Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. ( Banerjee, S; Dyson, G; Farhana, L; Levi, E; Maddipati, KR; Majumdar, AP; Nangia-Makker, P; Patel, A; Rajendra, SG; Vasudevan, A; Woods, J; Yu, Y, 2014) |
| "In practice, patients with metastatic colorectal cancer in treatment failure or relapse after first-line therapy should not expect too much from the addition of aflibercept or bevacizumab to a second-line protocol." | 1.40 | Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab. ( , 2014) |
| "The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009." | 1.40 | Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014) |
| "Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy for which no standard treatment algorithm exists." | 1.40 | The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. ( Chang, GJ; Crane, CH; Das, P; Eng, C; Ohinata, A; Pathak, P; Phillips, JK; Rodriguez-Bigas, M; Rogers, JE; Sethi, S; Vauthey, JN; Wolff, RA; Xing, Y; You, YN, 2014) |
| "Among them, 3 patients with bladder metastasis received intravesical chemotherapy of fluorouracil." | 1.40 | [Analysis of the treatment and prognosis for gestational trophoblastic neoplasia patients with urinary system and adrenal glands metastasis]. ( Feng, F; Ren, T; Wan, X; Wang, D; Xiang, Y; Yang, J, 2014) |
| "Their prognostic impact on colon cancer patients receiving adjuvant chemotherapy has not been well established." | 1.40 | LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. ( Chang, WC; Chen, CW; Fan, YC; Hsu, WH; Huang, CW; Lou, YT; Lu, CY; Wang, JY; Wu, IC, 2014) |
| "The aim is to evaluate the preliminary efficacy and side effects of paclitaxel, 5-fluorouracil, and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) as postoperative adjuvant therapy for patients of locally advanced gastric cancer (GC) at high risk for recurrence after curative resection." | 1.40 | Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer. ( Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z, 2014) |
| "Stage III rectal cancer was found in 64." | 1.39 | Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. ( Arbea, L; Arredondo, J; Baixauli, J; Beorlegui, C; Chopitea, A; Hernández-Lizoáin, JL; Rodríguez, J; Sola, JJ, 2013) |
| "Our findings suggest that BCS after NCT in clinical stage III patients is oncologically safe in terms of LR if breast tumor size is ≤4 cm after NCT and Ki-67 is a predictor of LR after NCT." | 1.39 | Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. ( Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC, 2013) |
| " Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer." | 1.39 | Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ( Chen, H; Cohen, MH; Fuchs, C; He, K; Keegan, P; Pazdur, R; Shord, S; Sickafuse, S; Zhao, H, 2013) |
| "We retrospectively analyzed esophageal squamous cell carcinoma (SCC) patients with e-CR after nCRT between 1999 and 2006." | 1.39 | Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy. ( Chang, HK; Chang, WC; Chao, YK; Chiu, CT; Liu, YH; Tseng, CK; Wan, YL; Wen, YW, 2013) |
| "Oral squamous cell carcinoma (OSCC) is a common malignant tumor of the head and neck, and recurrence is an important prognostic factor in patients with OSCC." | 1.39 | The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases. ( Wang, B; Wang, XD; Yue, K; Zhang, S, 2013) |
| "5-Fluorouracil (5-FU) was suspended in an ethyl acetate solution of poly D,L-lactide-co-glycolic acid (PLGA) and a vacuum drying method was applied." | 1.39 | Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors. ( Chen, Y; Sun, W; Yuan, W, 2013) |
| "The survival rates of esophageal cancer treated with DCRT in North West of Iran is poor; therefore, early detection and improved treatment methods, with clinical trials are a high priority." | 1.39 | Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran. ( Ghojazadeh, M; Jangjoo, AG; Mirinezhad, SK; Mohammadzadeh, M; Naseri, AR; Nasiri, B; Seyednezhad, F; Somi, MH, 2013) |
| "Management of locally advanced rectal cancer is complex because curative treatment routinely involves administration of surgery, chemotherapy, and radiation." | 1.39 | Evolving role of neoadjuvant therapy in rectal cancer. ( Schrag, D, 2013) |
| "We report a case of advanced relapsed colon cancer, which had multiple liver and spleen metastasis, controlled for about two years by capecitabine therapy." | 1.39 | [A case of relapsed colon cancer successfully treated by capecitabine]. ( Hashimoto, T; Kimura, S; Toyono, M; Usuba, O; Yokoyama, M, 2013) |
| "A total of 507 patients with rectal cancer underwent RT at HKL." | 1.39 | Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience. ( Lau, FN; Lee, WC; Phua, VC; Yusof, MM, 2013) |
| "We retrospectively studied 276 esophageal cancer patients treated with nCRT and surgery between 2002 and 2008." | 1.39 | Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? ( Chan, SC; Chang, HK; Chao, YK; Chen, WH; Chiu, CH; Liu, YH; Tseng, CK, 2013) |
| "Fecal incontinence was assessed by patient self-reported data without the use of a validated score." | 1.39 | Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer. ( Buchner, S; Dinnewitzer, A; Jäger, T; Nawara, C; Öfner, D; Wolfgang, H, 2013) |
| "Metastatectomy in colorectal cancer (CRC) is now a standard of care with improved survival reported." | 1.39 | Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. ( Beeke, C; Bishnoi, S; Karapetis, CS; Maddern, G; Padbury, R; Padman, S; Price, TJ; Townsend, AR, 2013) |
| "Contrarily, patients with colon cancer stage III are routinely offered chemotherapy, but due to expected adverse effects and frailty, elderly patients are often excluded from standard protocols." | 1.39 | Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving? ( Ågesen, TH; Guren, MG; Lothe, RA; Nesbakken, A; Skotheim, RI; Sveen, A; Tveit, KM, 2013) |
| "The 3-year local recurrence and distant metastasis rates in the adjuvant chemotherapy group were 4." | 1.39 | [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy]. ( Chang, H; Chen, L; Du, XJ; Gao, YH; Liu, MZ; Peng, HH; Wen, BX; Xiao, L; You, KY; Zeng, ZF; Zhou, GQ, 2013) |
| "By this stage of esophageal cancer, surgery, although very invasive, is the standard radical therapy for the patients." | 1.39 | Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer. ( Kameda, Y; Ohkawa, S; Tamai, S; Yoshii, T, 2013) |
| "A 57-year-old male with lower esophageal cancer underwent subtotal esophagectomy with lymphadenectomy." | 1.39 | Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case. ( Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T, 2013) |
| "These results suggest that HR + RFA after effective chemotherapy is a safe procedure with low local recurrence at the RFA site and is a potentially effective treatment option for patients with initially unresectable CRLM." | 1.39 | Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Kikuchi, K; Kuroki, H; Mima, K; Miyamoto, Y; Nakagawa, S; Okabe, H; Sakamoto, Y; Watanabe, M, 2013) |
| "In patients with HER2-overexpressed breast cancer, the positive rate of HER2ECD was significantly higher (24." | 1.39 | Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer. ( Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H, 2013) |
| " CRT combined with 5-fluorouracil (5-FU) and cisplatin (CDDP) was administered to all patients." | 1.39 | Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer. ( Hayashi, R; Ikematsu, H; Ito, M; Kaneko, K; Kojima, T; Minashi, K; Ohtsu, A; Onozawa, M; Oono, Y; Satake, H; Yajima, Y; Yano, T; Yoda, Y, 2013) |
| "Patients with small residual tumors (≤3 cm) radiologically staged ycT0-2N0 were treated by transanal endoscopic microsurgery." | 1.39 | Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. ( Bianchi, R; Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2013) |
| "To assess the outcome of esophageal cancer according to therapeutic strategy." | 1.39 | [Esophageal cancer: outcome according to therapeutic strategy]. ( Capitain, O; Cellier, P; Denis, F; Girault, S; Hamy, A; Mahé, MA; Mesgouez-Nebout, N; Paumier, A; Poirier, AL; Rousseau, D, 2013) |
| "Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008." | 1.39 | Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. ( Beukema, JC; Burgerhof, JG; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Muller, K; Paardekooper, G; Plukker, JT; Smit, JK; Timmer, PR; van Dijk, BA; Woutersen, D, 2013) |
| "Locoregional treatment of inflammatory breast cancer (IBC) is crucial because local relapses may be highly symptomatic and are commonly associated with distant metastasis." | 1.38 | Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up. ( Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C, 2012) |
| "Patients with early breast cancer with highly proliferative (S-phase fraction >4%) operable tumors of >3 cm received 4 cycles of intensified neoadjuvant chemotherapy with high-dose cyclophosphamide (doxorubicin 70 mg/m d1, cyclophosphamide 700 mg/m d1/d8, and 5 FU 700 mg/m d1-d5) every 3 weeks." | 1.38 | Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer. ( Alran, S; Beuzeboc, P; Dettwiler, S; Diéras, V; Fréneaux, P; Laurence, V; Le Tourneau, C; Pierga, JY; Sigal-Zafrani, B; Vincent-Salomon, A, 2012) |
| "To evaluate the efficacy and treatment-related toxicity of accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer (LRIRC)." | 1.38 | Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. ( Dai, Y; Li, L; Shao, ZY; Sun, DS; Yu, JM; Zhang, JD, 2012) |
| "Patients suffering from triple-negative breast cancer (TNBC) have poor prognosis mainly because no standard treatment is currently available." | 1.38 | Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. ( Jiang, X; Lin, G; Liu, D; Peng, J; Peng, R; Qin, T; Shi, Y; Teng, X; Wang, S; Wang, X; Yuan, Z, 2012) |
| "Locally advanced breast cancer (LABC) remains a clinical challenge as the majority of patients with this diagnosis develop distant metastases despite appropriate therapy." | 1.38 | Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women. ( Bhatnagar, D; Chakraborty, A; Chintamani, C; Devi, TR; Kapur, S; Mishra, AK; Saxena, S; Singh, LC; Sugandhi, N, 2012) |
| "Sixty-eight patients with metastatic rectal cancer were enrolled and analyzed." | 1.38 | The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer. ( Chang, CY; Cho, YB; Choi, DH; Chun, HK; Kim, HC; Lee, WY; Park, HC; Park, JO; Park, YS; Yun, SH, 2012) |
| "We obtained total RNA from residual cancer cells using microdissection from a total of 52 rectal cancer specimens from patients who underwent preoperative CRT." | 1.38 | Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. ( Fujikawa, H; Inoue, Y; Kusunoki, M; Matsushita, K; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Uchida, K, 2012) |
| "Survival for patients with pancreatic cancer remains poor." | 1.38 | Intensity-modulated radiotherapy for pancreatic adenocarcinoma. ( Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC, 2012) |
| "Superficial bladder cancer is often multifocal, has high recurrences after surgical resection and recurs after intravesical live Bacillus Calmette-Guérin." | 1.38 | Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. ( Annels, NE; Coffin, RS; Harrington, KJ; Horvath, A; Melcher, AA; Metcalf, S; Mostafid, H; Pandha, HS; Pencavel, T; Peschard, P; Price, T; Seth, R; Simpson, GR, 2012) |
| "RFA combined with chemotherapy is a promising treatment for NPC metastatic liver disease with improved local response, PFS, and OS compared to current chemotherapy protocols." | 1.38 | Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes. ( Cai, XY; Cai, YC; Cao, Y; Jiang, WQ; Jin, Y; Shi, YX; Tan, YT, 2012) |
| "In pN0 gastric cancers, prognostic factors differed significantly between early stage and advanced stage." | 1.38 | Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. ( Kang, WM; Ma, ZQ; Wang, J; Yu, JC, 2012) |
| "After nCRT for rectal cancer, postsurgery CEA level may have more prognostic value than pretreatment level." | 1.38 | Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. ( Chang, DT; Hong, JC; Koong, AC; Liauw, SL; McDonnell, SE; Minsky, BD; Song, S, 2012) |
| "However, its role for advanced gastric cancer remains unclear." | 1.38 | Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection. ( Conrad, T; Jacks, L; Kassam, Z; Khalili, I; MacKay, HJ; MacLellan, SJ; Okrainec, A; Ringash, J, 2012) |
| "Capecitabine seems to be an active and well-tolerated regimen, even in heavily pretreated, frail patients." | 1.38 | Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma. ( Ceruse, P; Fayette, J; Girodet, D; Péron, J; Poupart, M; Ramade, A; Zrounba, P, 2012) |
| "In early-stage breast cancer, radiotherapy delivered after conservative surgery leads to a reduction in the risk of local recurrences by approximately two thirds." | 1.38 | [A case of cutaneous mammary re-irradiation]. ( Bollet, MA; Fourchotte, V; Jacob, J; Kirova, YM; Pierga, JY, 2012) |
| "The relevant literature regarding treatment of liver cirrhosis complicated with HCC and synchronous colon Ca reveals poor and controversial outcomes." | 1.38 | How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer? ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012) |
| "A 71 years old Italian man had type 3 gastric cancer of the greater curvature." | 1.38 | Local recurrence of gastric cancer after total gastrectomy: an unusual presentation. ( Amato, B; Cardin, F; Lorenzetti, R; Martella, B; Militello, C; Terranova, C, 2012) |
| "To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer." | 1.38 | [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012) |
| "Topical 5-FU, as a sole or combined therapy, must be considered a long-term safe and effective treatment for patients affected by OSSN." | 1.37 | Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study. ( Alemany-Rubio, E; Lazzarini, D; Midena, E; Parrozzani, R; Urban, F, 2011) |
| "To update our experience in treating squamous cell carcinoma of the anal margin with definitive radiotherapy (RT)." | 1.37 | Squamous cell carcinoma of the anal margin: the university of Florida experience. ( Balamucki, CJ; George, TJ; Kirwan, JM; Mendenhall, WM; Morris, CG; Newlin, HE; Rout, WR; Zlotecki, RA, 2011) |
| "All of the patients had squamous cell carcinoma." | 1.37 | Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. ( Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM, 2011) |
| "Even after curative resection of pancreatic cancer, there is a high probability of systemic recurrence." | 1.37 | Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. ( Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y, 2011) |
| "Chemoradiotherapy (CRT) for esophageal cancer is disadvantageous because of a high locoregional failure rate." | 1.37 | Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. ( Horimatsu, T; Ishikura, S; Minashi, K; Muto, M; Nihei, K; Ohtsu, A; Onozawa, M; Taku, K; Tu, CH; Yano, T; Yoshida, S, 2011) |
| "Adjuvant chemotherapy in rectal cancer is not well defined." | 1.37 | Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. ( Alfonso, R; Corona, J; Custodio, A; de las Heras, M; Dıaz-Rubio, E; Ortega, L; Puente, J; Rodriguez, L; Sanchez, JC; Sastre, J, 2011) |
| "Head and neck squamous cell carcinoma (HNSCC) is one prevalent human cancer worldwide." | 1.37 | Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. ( Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH, 2011) |
| "Major forms of oral candidiasis are pseudomembranous and atrophic form, but chronic hyperplastic candidiasis (CHC) is rarely seen." | 1.37 | Oral candidiasis mimicking tongue cancer. ( Hasegawa, S; Hashikawa, K; Nibu, K; Otsuki, N; Saito, M; Shibata, T; Tahara, S; Yamashita, D, 2011) |
| "A cohort of 148 patients with esophageal cancer received cisplatin-based CCRT (concurrently combined with 40 Gy irradiation) and subsequent esophagectomy." | 1.37 | Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. ( Chen, JS; Cheng, JC; Chuang, TH; Hsu, CH; Hsu, HH; Huang, PM; Kuo, SW; Lee, JM; Lee, YC; Lin, CC; Shun, CT; Wang, YH; Wu, MT; Yang, PW; Yang, SY, 2011) |
| "Patients with mucinous rectal cancer experienced a lower rate of T-downstaging after PCRT and had a poorer prognosis than did patients with nonmucinous cancer." | 1.37 | Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. ( Kim, CW; Kim, JC; Kim, JH; Kim, TW; Lim, SB; Shin, US; Yoon, SN; Yoon, YS; Yu, CS, 2011) |
| "In 10-24% of patients with rectal cancer who are treated with neoadjuvant chemoradiation, no residual tumor is found after surgery (ypT0)." | 1.37 | Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. ( Bakers, FC; Barbaro, B; Beets, GL; Beets-Tan, RG; Haustermans, K; Lambrecht, M; Lambregts, DM; Maas, M; Valentini, V; Vandecaveye, V, 2011) |
| "We retrospectively evaluated 333 rectal cancer patients who received preoperative CRT followed by surgery with curative intent between January 2000 and December 2006." | 1.37 | Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. ( Kim, CW; Kim, JC; Kim, KH; Lim, SB; Yang, SS; Yoon, SN; Yoon, YS; Yu, CS, 2011) |
| "Patients with dMMR colon cancers have reduced rates of tumor recurrence, delayed TTR, and improved survival rates, compared with pMMR colon cancers." | 1.37 | DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. ( Allegra, C; Foster, NR; Gallinger, S; Kim, GP; Labianca, R; Marsoni, S; Monges, G; Moore, MJ; Sargent, DJ; Sinicrope, FA; Thibodeau, SN; Yothers, G, 2011) |
| "From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors." | 1.37 | Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. ( Blair, EA; Cohen, EE; Haraf, DJ; Pederson, AW; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Witt, ME, 2011) |
| "For patients with HER2-overexpressing gastric cancer, there is an improved prognosis with additional trastuzumab to chemotherapy with a platinum compound and a fluoropyrimidin in first-line therapy." | 1.37 | Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). ( Dumke, K; Krüger, M; Reymond, M; Weissinger, F, 2011) |
| "The outcomes and management of colorectal cancer (CRC) hepatic metastasis have undergone many evolutionary changes." | 1.37 | Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment. ( Chan, KM; Chen, JS; Chiang, JM; Lee, CF; Lee, WC; Wang, JY; Yu, MC, 2011) |
| "Patients who had clinical Stage I-IVA esophageal cancer and received definitive CRT between 2001 and 2007 were retrospectively analyzed." | 1.36 | Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. ( Higashino, K; Iishi, H; Imai, A; Ishihara, R; Nishiyama, K; Sugimoto, N; Takeuchi, Y; Tatsuta, M; Uedo, N; Yamamoto, S; Yano, M, 2010) |
| "Pelvic recurrent rectal cancer is still a challenging clinical problem, and patients generally have a dismal prognosis and a poor quality of life." | 1.36 | Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy. ( Bossola, M; Doglietto, GB; Pacelli, F; Papa, V; Rosa, F; Sanchez, AM; Tortorelli, AP; Valentini, V, 2010) |
| "We established 2 HIF-1alpha knockdown gastric cancer cell lines in order to clarify the role of HIF-1alpha in chemo-resistance against 5-FU." | 1.36 | HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. ( Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Miyazaki, K; Nakamura, J; Noshiro, H, 2010) |
| "From April, 2007 to February, 2009, 23 colorectal cancer patients were treated with Bevacizumab." | 1.36 | [Evaluation of bevacizumab for advanced colorectal cancer]. ( Hoshino, S; Matsuo, K; Naito, M; Nakano, M; Noda, N; Shinohara, T; Tanaka, S; Yamashita, Y; Yamauchi, Y, 2010) |
| "Using a comprehensive esophageal cancer database, we identified patients who underwent esophagectomy between 1994 and 2008." | 1.36 | Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. ( Hoffe, S; Karl, R; Kelley, S; Marcovalerio, M; McLoughlin, J; Meredith, KL; Shah, N; Siegel, EM; Turaga, KK; Weber, JM, 2010) |
| "Adjuvant chemo-radiation for gastric cancer is a standard at our institution and has resulted in few relapses and an interesting median survival." | 1.36 | Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience. ( Aftimos, PG; Chahine, GY; El Helou, JA; Ghosn, MG; Nasr, DI; Nasr, EA; Nasr, FL; Noun, RJ, 2010) |
| "Patients with gallbladder cancer at T2N0M0, T2N1M0, T3N0M0, and T3N1M0 stages were enrolled in this study." | 1.36 | Adjuvant chemoradiation therapy in gallbladder cancer. ( Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM, 2010) |
| "2 Gy/f, 2 f/d plus concurrent capecitabine at an oral dosage of 825 mg/m2 bid on each day of radiotherapy period." | 1.36 | [Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer]. ( Dai, Y; Shao, ZY; Yu, JM; Zhang, JD, 2010) |
| "Twenty men with primary rectal cancer clinically involving the lower urinary tract organs underwent extended colorectal resection combined with radical prostatectomy." | 1.36 | Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract. ( Ito, M; Kobayashi, A; Minagawa, N; Nishizawa, Y; Saito, N; Sugito, M; Suzuki, T; Tanaka, T; Watanabe, K, 2010) |
| "Frequently advanced or recurrent esophageal cancer was invasive trachea and often causing hemoptysis, stenosis and dyspnea." | 1.36 | [A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, Y; Kurokawa, T; Nagahama, T; Tei, S; Watayou, Y, 2010) |
| "We report here a case of recurrent esophageal cancer successfully treated by cervical lymph node dissection and chemo-radiation therapy." | 1.36 | [A case of recurrent esophageal cancer successfully treated by combined therapies]. ( Andoh, S; Kitamura, Y; Tokunou, K; Toshimitsu, H; Tsushimi, K; Yamamoto, T, 2010) |
| "It is important to understand that gastric cancer diagnosed poorly differentiated adenocarcinoma pathologically sometimes occurs duodenal invasion and obstructive jaundice." | 1.36 | [A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy]. ( Fukuda, S; Hiraki, S; Kawaoka, T; Matsukuma, S; Nagashima, A, 2010) |
| "Sigmoidectomy was performed for sigmoid colon cancer in January 2002." | 1.36 | [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]. ( Doki, Y; Hirose, H; Ikeda, M; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S, 2010) |
| "Local therapy for early rectal cancer is a valid alternative to the classical radical operation, which has a higher morbidity and mortality rate." | 1.35 | Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience. ( Baldarelli, M; Bartolacci, S; Grillo Ruggeri, F; Guerrieri, M; Lezoche, E; Mantello, G; Organetti, L, 2008) |
| "For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0." | 1.35 | Platinum-based chemotherapy in triple-negative breast cancer. ( Arnedos, M; Ashley, S; Johnston, S; Nerurkar, A; Popat, S; Sirohi, B; Smith, IE; Walsh, G, 2008) |
| "Recurrent lymph node metastasis was detected in 68 patients with thoracic esophageal carcinoma after curative esophagectomy (R0, International Union Against Cancer criteria)." | 1.35 | Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. ( Mitsuhashi, N; Nakamura, T; Narumiya, K; Ohki, T; Ota, M; Sato, T; Yamamoto, M, 2008) |
| "Patients with localized esophageal cancer (LEC) have diverse outcomes (post-therapy pathologic response, disease-free survival [DFS], and overall survival [OS]) after preoperative chemoradiation (P-CTRT), dictated also by inherent molecular heterogeneity." | 1.35 | Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. ( Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG, 2008) |
| "Patients with locally advanced breast carcinoma (LABC) receive preoperative chemotherapy to provide early systemic treatment and assess in vivo tumor response." | 1.35 | Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. ( Barlow, WE; Doot, RK; Dunnwald, LK; Ellis, GK; Gralow, JR; Kurland, BF; Lawton, TJ; Linden, HM; Livingston, RB; Mankoff, DA; Schubert, EK; Specht, JM, 2008) |
| "CRP was associated with disease progression and factors reflecting nutritional depletion such as serum albumin, lymphocyte count and body weight loss ratio." | 1.35 | Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. ( Inoue, Y; Koike, Y; Kusunoki, M; Miki, C; Okugawa, Y; Tanaka, K; Toiyama, Y; Yokoe, T, 2008) |
| "We report two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia." | 1.35 | [Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia]. ( Kobayashi, Y; Matsuzaki, A; Terauchi, F; Washino, S, 2008) |
| "However, few studies examining oral squamous cell carcinomas (OSCCs) have been reported." | 1.35 | Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy. ( Morishita, K; Ohno, S; Tateishi, Y; Tatemoto, Y; Ueta, E; Yamamoto, T, 2009) |
| "Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study." | 1.35 | Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. ( Agrogiannis, G; Arapogiannis, G; Gouveris, P; Kavantzas, N; Kopterides, P; Kosmas, C; Kyriakou, V; Lazaris, A; Papathomas, T; Patsouris, E; Tsavaris, N; Zorzos, H, 2009) |
| " This case was deemed in operable, and one-shot bolus of 5-FU was administered through the tumor feeding arteries: the left 3rd, 4th lumbar, and ilio -- lumbar arteries at a dosage of 250 mg/body from each artery." | 1.35 | Arterial infusion chemotherapy in patient with repeated recurrent tumor of cecal cancer: report of a case. ( Anazawa, S; Eto, K; Ogawa, M; Takao, Y; Ushigome, T; Watanabe, M; Yamagata, T; Yanaga, K, 2008) |
| "Sixty-eight consecutive patients with pancreatic cancer who underwent pancreatic resection were included." | 1.35 | Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. ( Kitade, H; Kwon, AH; Matsui, Y; Mergental, H; Satoi, S; Takahashi, K; Takai, S; Tanigawa, N; Toyokawa, H; Yanagimoto, H, 2009) |
| " Chemotherapy with cisplatin plus 5-FU (PF) is widely used, but the standard dosage, PF (100/1000; cisplatin 100 mg/m(2) day 1 and 5-FU 1000 mg/m(2)/24 h by continuous intravenous infusion on days 1 through 4), is relatively toxic for palliative use, and PF (80/800; cisplatin 80 mg/m(2) day 1 and 5-FU 800 mg/m(2)/24 h by continuous intravenous infusion on days 1 through 5) is more commonly used in Japan, albeit without clear comparative data." | 1.35 | Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. ( Doi, T; Fuse, N; Kadowaki, S; Kiyota, N; Minami, H; Ohtsu, A; Tahara, M, 2009) |
| "Five patients had less than one-third residual tumor cells in resected specimens histopathologically; eight had more than two-thirds residual tumor cells." | 1.35 | Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer. ( Kusunoki, M; Miki, C; Mohri, Y; Ohi, M; Otake, K; Tanaka, K; Toiyama, Y; Tonouchi, H; Yokoe, T, 2009) |
| "Esophageal adenosquamous carcinoma is a rare esophageal disease and prone to be misdiagnosed as esophageal squamous cell carcinoma." | 1.35 | [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma]. ( Fu, JH; Lin, P; Long, H; Ma, GW; Rong, TH; Su, XD; Zhang, DK; Zhang, LJ, 2009) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used in a number of solid malignancies, including colorectal cancer." | 1.35 | A case of 5-fluorouracil-induced acute psychosis. ( Alabsi, E; Fakih, M; Fora, A, 2009) |
| "Thirty-three patients with rectal cancer underwent preoperative CRT." | 1.35 | Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. ( Ioue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| "Approximately 20% of rectal cancer patients undergoing neoadjuvant chemoradiation achieve pCR, which has been associated with decreased local recurrence and improved recurrence-free survival." | 1.35 | Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. ( de Campos-Lobato, LF; Dietz, D; Fazio, VW; Geisler, DP; Kalady, MF; Lavery, IC; Stocchi, L, 2009) |
| "For patients with T3N0M0 colon cancer without known risk factors, the necessity of chemotherapy has no definite consensus." | 1.35 | The necessity of chemotherapy in T3N0M0 colon cancer without risk factors. ( Cho, YB; Chun, HK; Kim, HC; Lee, WY; Yun, HR; Yun, SH, 2009) |
| "Forty patients with rectal cancer underwent 5-fluorouracil based chemoradiotherapy followed by curative surgery." | 1.35 | Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues. ( Inoue, Y; Kusunoki, M; Miki, C; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| "The presence of ECE in breast cancer is positively related with tumor size and the number of positive lymph nodes." | 1.35 | [Clinical impact of extracapsular extension of axillary lymph node metastases in breast cancer]. ( Cao, WF; Cao, XC; Hao, XS; Ning, LS; Niu, Y; Song, YQ; Zhang, B; Zhao, HM, 2009) |
| "We have experienced a case of advanced esophageal cancer that has come back eight years after combined modality therapy, and after that, the patient could obtain a long-term survival with a marked effect of chemotherapy." | 1.35 | [A case of advanced esophageal cancer that has come back eight years after combined modality therapy]. ( Aoyama, N; Minamide, J; Ota, Y; Takata, K, 2009) |
| "Previously irradiated recurrent rectal cancer is a formidable patient threat with limited treatment options." | 1.35 | Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. ( Begossi, G; Belliveau, J; DiSiena, M; Gustafson, E; Wanebo, HJ, 2008) |
| "Early relapse in colorectal cancer (CRC) patients is attributed mainly to the higher malignant entity (such as an unfavorable genotype, deeper tumor invasion, lymph node metastasis and advance cancer stage) and poor response to chemotherapy." | 1.35 | ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. ( Cheng, TL; Fang, WY; Huang, MY; Lee, SC; Lin, SR; Wang, JY, 2008) |
| "From 1998 to 2006, 370 primary breast cancer patients underwent curative surgical treatment after NAC containing both anthracycline and taxane at the National Cancer Center Hospital." | 1.35 | Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. ( Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C, 2009) |
| "5-fluorouracil was given as continuous infusion 350 mg/m(2)/day five times weekly, and RHT (BSD-2000 system) was applied twice a week within 1 h after radiotherapy." | 1.35 | Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. ( Buecklein, V; Duehmke, E; Issels, RD; Milani, V; Pazos, M; Rahman, S; Schaffer, M; Schaffer, P; Tschoep, K; Wilkowski, R, 2008) |
| "Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome." | 1.35 | Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. ( Au, GK; Chua, D; Sham, JS; Wei, WI, 2008) |
| "4-year local-regional control, distant metastasis-free survival, disease-free survival and overall survival rates were 76." | 1.35 | Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings. ( Chan, KY; Chen, YH; Cheng, JC; Cheng, SH; Jian, JJ; Tsai, SY; Yen, KC, 2008) |
| "Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute." | 1.34 | A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. ( Anderson, WF; Berman, AW; Lippman, ME; Steinberg, SM; Swain, SM; Vatas, U; Walshe, JM, 2007) |
| "Breast cancer is a heterogeneous disease and it is of importance to select patients with regard to different prognosis and treatment sensitivity to individualize treatment regimes." | 1.34 | Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy. ( Fernö, M; Johnsson, A; Malmström, J; Marko-Varga, G; Niméus, E, 2007) |
| "Two hundred and four patients with breast cancer were treated with neoadjuvant chemotherapy between 1996 and April 2005." | 1.34 | Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. ( Chaturvedi, A; Drew, PJ; Fox, JN; Garimella, V; Long, ED; Qutob, O; Turnbull, LW, 2007) |
| "The rate of distant metastases increased from 18." | 1.34 | Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. ( Eriksen, MT; Haffner, J; Wibe, A; Wiig, JN, 2007) |
| "Of the 223 patients, 32 had distant metastases but palliative gastrectomy (resected metastatic), 82 had recurrent disease after previous curative gastrectomy (recurrent), and 109 had distant metastases without gastrectomy (initially metastatic)." | 1.34 | Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. ( Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Kim, WK; Lee, JL; Lee, JS; Lee, SS; Ryu, MH, 2007) |
| " In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules." | 1.34 | [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine]. ( Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007) |
| "The prognosis of recurrent metastatic cervical cancer is extremely poor." | 1.34 | Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series. ( Abu-Rustum, NR; Aghajanian, C; Bowes, RJ; Jhamb, N; Khoury-Collado, F, 2007) |
| "Resection of locally recurrent rectal cancer (LRRC) after curative resection represents a difficult problem and a surgical challenge." | 1.34 | Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience. ( Asoglu, O; Emek, E; Igci, A; Kapran, Y; Karanlik, H; Kecer, M; Muslumanoglu, M; Ozmen, V; Parlak, M, 2007) |
| "After 10 years, second primary cancer (seven cases) became as important an issue as recurrence of primary gastric cancer (six cases)." | 1.34 | Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. ( Chung, HC; Jeung, HC; Kim, BS; Moon, YW; Noh, SH; Rha, SY; Roh, JK; Yoo, NC, 2007) |
| "Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease." | 1.34 | Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. ( Arita, S; Ariyama, H; Baba, E; Kusaba, H; Miki, R; Mitsugi, K; Nakano, S; Noshiro, H; Ogami, N; Qin, B; Shibata, Y; Yao, T, 2007) |
| "All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed." | 1.34 | [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. ( Chen, L; Fan, Y; Fu, L; Guo, XJ; Lang, RG; Sun, YL, 2007) |
| "Treatment with capecitabine and erlotinib in gemcitabine-refractory patients was associated with an overall objective radiologic response rate of 10% and a median survival duration of 6." | 1.34 | Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. ( Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX, 2007) |
| "Patients with esophageal cancer often develop metastatic disease after esophageal resection and generally receive cisplatin-based chemotherapy or chemoradiotherapy." | 1.34 | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. ( Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H, 2007) |
| " The adverse effect included grade 3 or grade 4 leukopenia in 12." | 1.34 | [Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers]. ( Bai, P; Li, XG; Ma, SK; Wu, LY; Zhang, R; Zhang, WH, 2007) |
| "Twenty-six patients with non-metastatic rectal cancer >T1 on pathologic TNM staging who underwent primary laparoscopic surgery were considered for comparison." | 1.34 | Laparoscopic total mesorectal excision after neoadjuvant chemoradiotherapy. ( Bona, S; Elmore, U; Furlan, N; Romario, UF; Rosati, R, 2007) |
| "Surgery was performed for sigmoid colon cancer on September 29, 2004." | 1.34 | [A patient with recurrent sigmoid colon cancer in whom pleural effusion and ascites resolved after FOLFOX 4 therapy]. ( Akamatsu, M; Katamoto, T; Matsubara, S; Nakata, W; Ohata, K; Ohmae, T; Tsuji, Y, 2007) |
| "In contrast, locally advanced rectal cancers in cUICC-II/-III stages (T3/T4 or N(+)) should receive long-term, 5-FU-based, neoadjuvant chemoradiotherapy according to the excellent results of the CAO/AIO/ARO-94 trial of the German Rectal Cancer Study Group." | 1.33 | [Present treatment strategies for rectal carcinoma]. ( Becker, H; Ghadimi, BM; Langer, C; Liersch, T, 2005) |
| "Patients with rectal cancer treated by preoperative chemoradiation showed a surprisingly low rate of micrometastasis detection (7%), even in high-risk patients (T3 and T4 tumors)." | 1.33 | Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. ( Coelho Siqueira, SA; Gama-Rodrigues, JJ; Habr-Gama, A; Kiss, DR; Nishida Arazawa, ST; Perez, RO; Rawet, V, 2005) |
| "An in situ human hepatocellular carcinoma model was established in mice livers orthotopically." | 1.33 | Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. ( Lin, RX; Lü, QJ; Tuo, CW; Wang, SQ; Zhang, W, 2005) |
| "We present the first reported case of a squamous cell carcinoma recurrence on a reconstructed flap in the pharynx treated successfully with topical chemotherapy." | 1.33 | Recurrent squamous cell carcinoma in the neopharynx treated successfully with topical 5-fluorouracil. ( Banga, R; Cox, G; Ramsden, J, 2005) |
| "Patients with a locally advanced rectal cancer, treated by pre-operative CRT were studied." | 1.33 | Response to neoadjuvant therapy for rectal cancer: influence on long-term results. ( Arriola, E; Biondo, S; Cambray, M; Del Rio, C; Marti-Rague, J; Navarro, M; Novell, V; Pares, D, 2005) |
| "Fifty-eight patients with advanced laryngeal cancer (T3/T4N0/N + M0) were treated with curative intent with accelerated RT during the period 1990-1998." | 1.33 | Accelerated radiotherapy for advanced laryngeal cancer. ( Edström, S; Ejnell, H; Haugen, H; Johansson, KA; Mercke, C, 2005) |
| "Most cervical cancer patients with pelvic recurrent or persistent disease are not candidates for exenteration, therefore, they only receive palliative chemotherapy." | 1.33 | Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer. ( Brom, R; Candelaria, M; Cantu, D; Cetina, L; Chanona, J; de la Garza, J; Dolores, R; Duenas-Gonzalez, A; Gonzalez, A; Lopez-Graniel, C; Uribe, J, 2005) |
| "Pancreatic cancer is the fifth leading cause of cancer-related death worldwide." | 1.33 | Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. ( Incrocci, L; Jeekel, J; Kazemier, G; Smeenk, HG; Tran, KT; van Dekken, H; van Eijck, CH, 2005) |
| " A decrease of dosage or abundance of continuation was done during the course due to complications." | 1.33 | [Five cases of locally advanced rectal cancer or local recurrence performed intra-arterial infusion chemotherapy via the internal iliac artery]. ( Agata, T; Aoyama, H; Funabashi, M; Hanai, T; Kamano, T; Katsuno, H; Koide, Y; Maeda, K; Masumori, K; Noro, T; Sato, H, 2005) |
| "This is the first study investigating neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with chemotherapy in patients with breast cancer." | 1.33 | Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer. ( Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N, 2006) |
| "Eighteen consecutive pancreatic cancer patients presenting with isolated locoregional recurrence after surgical resection." | 1.33 | Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. ( Bruns, C; Dühmke, E; Heinemann, V; Thoma, M; Wilkowski, R, 2006) |
| "Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemotherapy were included in the present study." | 1.33 | Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. ( Alberti, S; Angelucci, D; Cianchetti, E; Ficorella, C; Iacobelli, S; Lattanzio, R; Marchetti, P; Natoli, C; Piantelli, M; Ricevuto, E; Tinari, N, 2006) |
| "Capecitabine is a new chemotherapeutic agent considered highly specific for sensitive tumour cells, which convert the drug to 5-fluorouracil." | 1.33 | Coronary artery spasm induced by capecitabine. ( Barone, C; Cassano, A; Crea, F; Lanza, GA; Pozzo, C; Sestito, A; Sgueglia, GA, 2006) |
| "Histologic tumor regression (TR) in rectal cancer after preoperative chemoradiotherapy (CT/RT) may be useful as a surrogate end point for early treatment efficacy, but little is known about its prognostic value." | 1.33 | Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. ( Aust, DE; Baretton, GB; Becker, H; Häusler, P; Jakob, C; Kulle, B; Liersch, T; Meyer, W; Schwabe, W, 2006) |
| "Twenty-three patients died of breast cancer (11." | 1.33 | Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome. ( Galimberti, V; Gandini, S; Gentilini, O; Goldhirsch, A; Intra, M; Luini, A; Peruzzotti, G; Veronesi, P; Veronesi, U; Winnikow, E, 2006) |
| "A large proportion of breast cancer patients are treated with adjuvant chemotherapy after the primary operation, but some will recur in spite of this treatment." | 1.33 | Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. ( Edén, P; Fernö, M; Johnsson, A; Niméus-Malmström, E; Ohlsson, M; Ostberg, G; Peterson, C; Ritz, C; Strand, C, 2006) |
| "Docetaxel and nedaplatin are active for esophageal cancer." | 1.33 | Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Miyazaki, S; Nemoto, K; Ohtsuka, K; Sakata, Y; Sakayori, M; Shibata, H; Shimodaira, H; Yoshioka, T, 2006) |
| "Initial treatments of locally advanced rectal cancers focus on local control, as local relapse of a rectal cancer is correlated with a high morbidity and mortality." | 1.32 | A favourable pathological stage after neoadjuvant radiochemotherapy in patients with initially irresectable rectal cancer correlates with a favourable prognosis. ( Hospers, GA; Mulder, NH; Reerink, O; Szabo, BG; Verschueren, RC, 2003) |
| "Patients with unresectable distant metastasis are not suitable candidates for surgical resection and intraoperative radiation therapy, whereas those with resectable metastasis are potential candidates." | 1.32 | Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer. ( Hashiguchi, Y; Kato, S; Kazumoto, T; Nishimura, Y; Sakamoto, H; Sakura, M; Sekine, T; Tanaka, Y, 2003) |
| "From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days)." | 1.32 | Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. ( Britton, KR; Matsushita, H; Miyata, T; Miyazaki, S; Nemoto, K; Ogawa, Y; Takahashi, C; Takai, Y; Takeda, K; Yamada, S, 2003) |
| "The local recurrence rate of colorectal cancer has been significantly reduced due to the use of combined radiochemotherapy." | 1.32 | Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer--preliminary results. ( Abdel-Rahman, S; D hmke, E; Ertl-Wagner, B; Issels, RD; Krych, M; Pachmann, S; Schaffer, M; Schaffer, PM, 2003) |
| "Twenty-five cases with head and neck cancers in Guangzhou Tumor Hospital from January 1999 to June 2002 were reviewed." | 1.32 | [Combined usage of taxotere in induction chemotherapy of head and neck neoplasms]. ( Liu, WW; Yu, QW; Zeng, J; Zeng, ZY, 2003) |
| "The study reviewed Stage II and III rectal cancer patients treated with preoperative chemoradiation and resected for cure." | 1.32 | Response to preoperative chemoradiation in stage II and III rectal cancer. ( Blatchford, GJ; Brown, CL; Christensen, MA; Haynatzki, GR; Shashidharan, M; Ternent, CA; Thorson, AG, 2003) |
| "Curative surgery for rectal cancer seldom requires urinary tract resections." | 1.32 | Total cystectomies in the surgical treatment of rectal cancer with prior chemoradiation: analysis of postoperative morbidity and survival. ( Chwaliński, M; Nowacki, MP; Oledzki, J; Rogowski, W; Sopyło, R, 2004) |
| "A total of 5 breast cancer patients, 2 with far advanced primary breast tumor and 3 with local recurrent tumors on their anterior chest wall, underwent multimodal therapy in which cryosurgery was performed in combination with local injection of the non-specific immunopotentiator OK-432." | 1.32 | [Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer]. ( Kawaguchi, Y; Saji, S; Sugiyama, Y, 2003) |
| "The murine AT-84 orthotopic model of oral cancer was assessed to find how similar it is to human oral cancer." | 1.32 | Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. ( Hutchison, R; Kellman, RM; Lou, E; Shillitoe, EJ, 2003) |
| "Ten patients with recurrent esophageal cancer were treated with the combination of docetaxel 60 mg/m2 (day 1), CDDP 10 mg/body (days 1-5) and 5-FU 500 mg/body (days 1-5) at intervals of 2-3 weeks." | 1.32 | [Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study]. ( Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H, 2003) |
| "In stage II (T3-4N0) and III (TxN1-2) rectal cancer, adjuvant radiochemotherapy improves overall survival and decreases the rate of local failure compared to only surgical therapy and is regarded as standard for patients with carcinoma of the lower and intermediate rectum." | 1.32 | [Principles of postoperative therapy in rectal carcinoma]. ( Folprecht, G; Köhne, CH, 2004) |
| " For both men and women, overweight and obese patients experience less toxicity associated with adjuvant chemoradiotherapy, suggesting that actual body weight dosing of fluorouracil for obese patients is justified." | 1.32 | Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. ( Benson, AB; Brady, D; Cummings, B; Fuchs, CS; Hollis, DR; Macdonald, JS; Mayer, RJ; McCollum, AD; Meyerhardt, JA; Niedzwiecki, D; O'Connell, MJ; Tepper, JE; Willett, C, 2004) |
| "A total of 145 rectal cancer patients were treated with surgery and postoperative radiochemotherapy." | 1.32 | Extracapsular spread of nodal metastasis as a prognostic factor in rectal cancer. ( Berger, J; Heide, J; Krüll, A, 2004) |
| "Colon and rectal cancer are in France a challenging problem in public health, reaching the second place in cancer related deaths." | 1.32 | [Colorectal cancer: what should be the management of primary tumour?]. ( Delpero, JR; Lelong, B; Moutardier, V, 2004) |
| "The deleted in colorectal cancer (DCC) gene predicts a poor outcome for patients with colorectal carcinoma." | 1.32 | Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. ( Gal, R; Klein, B; Koren, R; Sadikov, E; Sulkes, J, 2004) |
| "To evaluate the effects of 3-dimensional conformal radiation therapy combined with chemotherapy for rectal cancer of postoperative local recurrence." | 1.32 | [Effecting observation of 3-dimensional conformal radiotherapy combined with chemotherapy for rectal cancer of postoperative local recurrence]. ( Chen, LH; Wu, DH, 2004) |
| "Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy." | 1.32 | Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. ( Campos, FG; Gama-Rodrigues, J; Habr-Gama, A; Kiss, DR; Nadalin, W; Perez, RO; Ribeiro, U; Sabbaga, J; Silva e Sousa, AH, 2004) |
| "To explore the change of T cell subsets in patients suffered from hepatocellular carcinoma (HCC) before and after hepatectomy, and study the value of Roferon-A (interferon alpha-2a) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of HCC for preventing recurrence." | 1.32 | [The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence]. ( Chen, JS; Duan, ZH; Li, HH; Wang, J; Zhang, HW, 2004) |
| "Surgical specimens were assessed for rectal cancer regression grade." | 1.32 | Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. ( Cunningham, C; Dodds, E; George, BD; Jones, AC; Mortensen, NJ; Warren, BF; Wheeler, JM, 2004) |
| "Postoperative complications were anastomosis leakage in 1 patient, and anastomosis stenosis in 2 and esophagobronchial fistula in 1." | 1.31 | [Salvage operation for esophageal cancer after radical chemoradiotherapy]. ( Boku, N; Gotohda, N; Nagai, K; Nishimura, M; Ohtsu, A; Yoshida, J, 2002) |
| "The life-table estimates for breast cancer-specific survival in women with local recurrences were 84." | 1.31 | Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women. ( Arnesson, LG; Emdin, SO; Fornander, T; Fredriksson, I; Frisell, J; Holmberg, L; Holmqvist, M; Liljegren, G; Palm-Sjövall, M, 2002) |
| "During the follow-up, an elevated squamous cell carcinoma antigen (SCC Ag) level led to restaging computed tomography scans, which confirmed recurrent metastatic disease in the liver." | 1.31 | Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy. ( Bolton, M; Copur, S; Frankforter, S; Fruehling, RM; Ledakis, P; Mleczko, KL; Muhvic, J; Norvell, M; Novinski, D; VanWie, E, 2001) |
| "Thirteen patients with locally advanced esophageal cancer (T4 cases) and 3 with recurrence of esophageal cancer were treated with radiotherapy (40-70 Gy) and 5-FU combined with cisplatin/nedaplatin concurrently." | 1.31 | [Chemoradiotherapy using platinum analogs/5-FU for advanced esophageal cancer]. ( Kawasaki, H; Matsuya, H; Morita, T; Morohashi, H; Nakai, M; Sasaki, M; Shibata, S; Yamada, K, 2002) |
| "We report a recurrent case of breast cancer successfully treated with intra-arterial infusion of doxorubicin hydrochloride (ADM) combined with systemic CAF therapy." | 1.31 | [Recurrence of right breast cancer at the thoracic wall successfully treated with intra-arterial infusion of doxorubicin hydrochloride--a case report]. ( Hasegawa, S; Ishiwa, N; Matsumoto, A; Morinaga, S; Nishimura, J; Noguchi, Y; Okoshi, T; Yamamoto, Y; Yoshikawa, T, 2002) |
| "We report a case of primary liver carcinoid." | 1.31 | [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes]. ( Hasuike, Y; Takeda, Y; Tujinaka, T; Ueda, S; Yoshida, K, 2002) |
| "Eight patients affected by conjunctival squamous cell carcinoma (three recurrent cases, three incompletely excised, and two untreated cases) were treated with 1% 5-FU eye drops." | 1.31 | Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. ( Angeli, CD; Boccato, P; de Belvis, V; Midena, E; Valenti, M, 2000) |
| "It is possible to cure oesophageal cancer with chemo-radiotherapy and selective oesophagectomy, and achieve organ preservation in the majority of long term survivors." | 1.31 | Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation. ( Lim, JT; Wilson, KS, 2000) |
| "Of 69 patients with laryngeal cancer, 14 were treated by partial laryngectomy and 19 by radiation therapy; of 46 patients with piriform sinus cancer, 8 were treated by partial surgery and 12 by radiation therapy; the other patients were treated as was initially planned (total laryngectomy with partial pharyngectomy)." | 1.31 | Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy. ( Angelard, B; Lecanu, JB; Monceaux, G; Périé, S; St Guily, JL, 2000) |
| "The regimen appears active against rectal cancer, and appears to warrant further consideration as a treatment option for this patient population." | 1.31 | A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. ( Anscher, MS; Dewhirst, MW; Hurwitz, H; Jowell, P; Lee, C; Prosnitz, LR; Rosner, G; Samulski, T; Tyler, D, 2000) |
| "A continuous, 24-hour 5-fluorouracil administration was made through the bilateral internal iliac artery at a dosage of 250 mg/m2/day by the subcutaneous reservoir located at both upper legs using a Baxter infusor." | 1.31 | Continuous intra-arterial 5-FU chemotherapy in a patient with a repeated recurrence of rectal cancer: report of a case. ( Araki, Y; Inuzuka, K; Isomoto, H; Matsumoto, A; Ogoh, Y; Ozaki, K; Shirouzu, K; Toh, U; Yasunaga, M, 2000) |
| "225 patients with squamous cell carcinoma of the oesophagus were prospectively studied." | 1.31 | Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. ( Busch, R; Roder, RJ; Rosenberg, R; Thorban, S, 2000) |
| "The prognosis of upper thoracic esophageal cancer is poor when compared with middle and lower thoracic esophageal cancer because the tumor easily infiltrates the respiratory tract and surgical en-bloc resection is difficult." | 1.31 | Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. ( Doki, Y; Fujiwara, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yano, M, 2000) |
| "We found that the hazard function of metastasis in time presented two peaks of incidence at 20 and 60 months, respectively." | 1.31 | Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. ( Biganzoli, E; Bonoldi, E; Boracchi, P; Fanelli, M; Gasparini, G; Morabito, A, 2001) |
| "In node-positive colon cancer, we assessed the S-phase fraction (SPF) index, the vascular endothelial growth factor (VEGF) expression and the TS levels." | 1.31 | Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. ( Baldelli, AM; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Graziano, F; Grianti, C; Muretto, P; Rossi, C; Staccioli, MP; Valentini, M, 2001) |
| "Oral capecitabine is an active and well-tolerated agent when used alone as first-line therapy in patients who have relapsed after HDC-ASCS for MBC." | 1.31 | Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support. ( Ball, ED; Bashey, A; Corringham, S; Jones, V; Lancaster, D; Law, P; Silva-Gietzen, J; Sundaram, S, 2001) |
| "Some degree of aneuploidy was detected in all primary carcinomas." | 1.31 | Markers of drug resistance in relapsing colon cancer. ( Davaris, PS; Kavantzas, NG; Lazaris, AC; Tsavaris, NV; Zorzos, HS, 2002) |
| "If hepatic reserve is satisfactory, an aggressive surgical approach combined with chemotherapy seems to be of benefit for patients having HCC with tumor thrombus in the MPV, IVC, or EBD." | 1.31 | Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. ( Aoyagi, S; Eriguchi, N; Fukuda, S; Imamura, I; Imamura, M; Okuda, K, 2002) |
| "The failure to reduce distant metastasis and improve survival may have related in part to the more advanced disease stage in our patients and the relatively low compliance rate of adjuvant chemotherapy." | 1.31 | Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis. ( Au, GK; Choy, D; Chua, DT; Sham, JS, 2002) |
| " Patients in the P+M group who received a 5-fluorouracil (5-FU) dosage of more than 3500 mg had a better 5-year local control rate than patients who received a 5-FU dosage of less than 3500 mg (p = 0." | 1.31 | Trimodal combination therapy for maxillary sinus carcinoma. ( Amagasa, T; Enomoto, S; Kishimoto, S; Miura, M; Ogura, I; Shibuya, H; Yoshimura, R, 2002) |
| "A 50-year-old man with gallbladder cancer was treated by extended cholecystectomy and regional lymph node dissection." | 1.30 | [A case of recurrent gallbladder cancer with marked response to arterial infusion chemotherapy and transarterial embolization]. ( Ino, M; Noda, H; Takahashi, S; Takeuchi, S; Tanaka, T; Tateoka, H; Yokoyama, M, 1997) |
| "A 59-year-old man with colon cancer was diagnosed as having a local recurrence of the disease, forming a huge intra pelvic tumor, accompanied by pulmonary metastasis 16 months after hemicolectomy." | 1.30 | [A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin]. ( Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Tabata, H; Takasaki, S, 1997) |
| "Advanced gastric cancer was found in 12 cases (operation performed in 9 cases and 7 cases resectable) and recurrent in 5 cases." | 1.30 | [Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer]. ( Katsumata, K; Kohno, M; Koyanagi, Y; Moriwaki, R; Ohno, M; Shibata, K; Tadatomo, H; Yamamoto, K; Yamashita, S, 1997) |
| "For locally advanced primary colorectal cancer, our institution has combined intraoperative electron irradiation (IOERT) with external beam irradiation (EBRT) +/- 5-fluorouracil (5-FU) and surgical resection." | 1.30 | Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU. ( Cha, S; Devine, R; Dozois, R; Fieck, JM; Gunderson, LL; Haddock, M; Martenson, JA; Nelson, H; O'Connell, MJ; Wolff, B, 1997) |
| "5-Fluorouracil was administered at an initial daily dose of 125 mg/m2, with dose escalation planned in 25-mg increments, depending on patient tolerance." | 1.30 | Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer. ( Burch, PA; Garton, GR; Kugler, JW; Martenson, JA; Pitot, HC; Santala, RG; Schroeder, G; Stella, PJ; Swaminathan, R; Wright, K, 1997) |
| "We retrospectively examined the acute toxicity of (neo-)adjuvant combined treatment for rectal cancer in an attempt to evaluate potential factors that influence the severity of toxic side effects." | 1.30 | [The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma]. ( Fietkau, R; Grabenbauer, GG; Keilholz, L; Kessler, H; Martus, P; Rödel, C; Sauer, R, 1997) |
| "He was diagnosed as rectal cancer with multiple liver metastases." | 1.30 | [A case of multiple liver metastasis and local recurrence from rectal cancer effectively treated by arterial infusion chemotherapy using low-dose 5-fluorouracil, cisplatin and LV]. ( Endo, Y; Kodama, M; Naitoh, H; Okauchi, H; Tani, T; Yamasaki, M, 1997) |
| "The International Breast Cancer Study Group (IBCSG) prospectively explored the efficacy of retreatment for patients upon relapse using the same therapy administered during the adjuvant programme." | 1.30 | Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. ( Castiglione-Gertsch, M; Coates, A; Collins, J; Gelber, RD; Goldhirsch, A; Gudgeon, A; Hacking, A; Isley, M; Lindtner, J; Rudenstam, CM; Senn, HJ; Tattersall, M, 1997) |
| "Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread." | 1.30 | [How I treat colorectal cancer. I. Prevention and adjuvant treatment]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "Locally advanced breast carcinoma is associated with a poor prognosis." | 1.30 | Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications. ( Bengtsson, NO; Bergh, JC; Fornander, TG; Hatschek, T; Jansson, TE; Karlsson, YA; Malmström, PO; Sjöberg, SM; Söderberg, M, 1998) |
| "Reirradiation of head and neck cancer with 5-fluorouracil and hydroxyurea offers acceptable acute toxicity and minimal late effects." | 1.30 | Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. ( Beenken, SW; Conner, W; Meredith, RF; Peters, GE; Salter, MM; Smith, J; Spencer, SA; Wheeler, RH, 1999) |
| "Advanced gastric, colon and esophageal cancers (n = 21) were treated with 5-FU (250 mg) modulated by CDDP (5 mg)." | 1.30 | [Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis]. ( Hisano, H; Kida, H; Nomura, M; Shibasaki, S; Shinkai, K; Yano, H, 1999) |
| "In stade II and III breast cancer, neoadjuvant chemotherapy with FEC-HD obtains an important histological response with an acceptable toxicity." | 1.30 | [Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer]. ( Arnoud, L; Belichard, C; Coudert, B; Darut-Jouve, A; Guerrin, J; Jolimoy, G, 1999) |
| "Mitomycin C (20 mg) was injected through out the induced hypertension (1." | 1.30 | [A case of liver metastases from gastric cancer responding to induced hypertensive chemotherapy with angiotensin II]. ( Arai, K; Iwasaki, Y; Kitamura, M; Nakajima, Y, 1999) |
| "Fifty-three patients with localized esophageal cancer received concurrent chemoradiotherapy followed by brachytherapy." | 1.30 | High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. ( Dokiya, T; Oki, Y; Yorozu, A, 1999) |
| "The role in colorectal cancer is less clear, although there are some reports that suggest a benefit." | 1.30 | Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999) |
| "Local control of esophageal cancer is excellent following neoadjuvant chemotherapy and radiation therapy." | 1.30 | Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy. ( Adelstein, DJ; Becker, M; Chidel, MA; Kupelian, PA; Rice, TW; Suh, JH, 1999) |
| "A total of 1309 women with Stage I/II breast cancer underwent full axillary dissection and either mastectomy (n = 894) or breast-conserving surgery (n = 415)." | 1.30 | Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: value of adjuvant irradiation. ( Fodor, J; Major, T; Nemeth, G; Polgar, C; Toth, J, 1999) |
| "Patients with hepatic metastases from rectal cancer treated with hepatic artery (HA) chemotherapy have a life expectancy great enough to be at risk for pelvic failure." | 1.29 | Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases. ( Andrews, JC; Cha, C; Ensminger, WD; Lawrence, TS; Robertson, JM, 1996) |
| "Chemotherapy for cervical cancer patients with recurrent and/or advanced disease has been complicated by excessive toxicity and short duration of responses, leading to little or no improvement in survival." | 1.29 | Chemotherapy of recurrent/advanced cervical cancer: results of the Yale University PBM-PFU protocol. ( Chambers, JT; Chambers, SK; Kohorn, EI; Lamb, L; Schwartz, PE, 1994) |
| "Primary hepatocellular carcinoma is a very rare disease, especially in association with a pregnancy." | 1.29 | [Hepatocellular carcinoma in pregnancy]. ( Brucker, C; Debus-Thiede, G; Genz, T; Maassen, V; Schweiberer, L; Weiss, M, 1994) |
| "5-Fluorouracil was given as a continuous infusion during therapy." | 1.29 | Whole abdominal radiotherapy and concomitant 5-fluorouracil as adjuvant therapy in advanced colon cancer. ( Ben-Josef, E; Court, WS, 1995) |
| "The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR." | 1.29 | Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. ( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995) |
| "Four hundred five patients with anal cancer were identified by computer search, and 204 (51%) were evaluable; 164 of 204 (80%) had squamous cell carcinoma, 137 of whom (84%) were treated with sphincter-preserving procedures, and 27 of whom (16%) were treated by by radical surgery." | 1.29 | Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. ( Coplin, MA; Johnson, FE; Longo, WE; Vernava, AM; Virgo, KS; Wade, TP, 1994) |
| "FLP therapy for advanced or recurrent stomach cancer in outpatients was expected to improve the QOL." | 1.29 | [Effects of combination chemotherapy using 5-FU, leucovorin, and CDDP (FLP therapy) for noncurative resected or recurrent stomach cancer in outpatients]. ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Onodera, S; Rino, Y; Sairenji, M, 1994) |
| " Increasing the dosage by boost technique above 50." | 1.29 | [Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2]. ( Renner, H; van Kampen, M, 1994) |
| "A total of 1216 patients with resected colon cancer, 1017 (84%) of whom had CEA monitoring." | 1.29 | An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. ( Fleming, TR; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tangen, C, 1993) |
| "Eighty-one laryngeal cancer patients treated at our clinic during the past ten years were studied clinically." | 1.29 | Results of treatment of laryngeal cancer. ( Hasegawa, T; Kim, Y; Sano, R; Suzuki, H, 1994) |
| "Recently, in the treatment of gastric cancer this biochemical modulation has been introduced into clinical practice and has also achieved good antitumor activity." | 1.29 | [Clinical effect and characteristics of low dose leucovorin and high dose 5-FU therapy in patients with recurrent gastric cancer--a new method of biochemical modulation]. ( Akiyama, H; Kajiyama, Y; Matsuda, M; Ono, Y; Suzuki, M; Tsurumaru, M; Udagawa, H; Watanabe, G, 1993) |
| "Twenty-six patients with advanced squamous carcinoma of the head and neck or local recurrence after surgery and/or radiotherapy received carboplatin 300 mg/m2 intravenously on day 1 and 5-fluorouracil 1 gm/m2 by continuous intravenous infusion for 4 days." | 1.29 | Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck. ( Canney, P; Junor, E; Yosef, H, 1993) |
| "Radically excised ovarian cancers present an unsolved problem with regard to the value of routine second-look operation." | 1.29 | Second-look laparotomy in the management of patients after radical surgery for ovarian cancer. ( Hansen, M; Hansen, OP; Lund, B; Tuxen, MK, 1993) |
| "Because DNA aneuploidy is an indirect measure of the proliferative activity of a cell population, a study was conducted to examine differences in tumor response to induction chemotherapy based on aDI values." | 1.29 | DNA content and tumor response to induction chemotherapy in patients with advanced laryngeal squamous cell carcinoma. ( Beals, TE; Fisher, SG; Gregg, CM; McClatchy, KM; Wolf, GT, 1993) |
| "Patients with inflammatory breast cancer have a high risk of developing a local recurrence and/or distant metastases." | 1.29 | Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. ( Arriagada, R; Fontaine, F; Le Chevalier, T; Mouriesse, H; Spielmann, M; Thomas, F; Tursz, T, 1995) |
| " The aim of this study was to evaluate intraoperative radiation therapy (IORT) (flab technique) combined with preoperative or postoperative radiochemotherapy." | 1.29 | Locally advanced rectal cancer: resection and intraoperative radiotherapy using the flab method combined with preoperative or postoperative radiochemotherapy. ( Fink, U; Huber, FT; Molls, M; Siewert, JR; Stepan, R; Zimmermann, F, 1996) |
| " In CCR managed with EC, the independent factors of age, tumor classification, exact tumor location, true vocal cord motion, arytenoid cartilage motion, total dosage of drugs delivered, and number of courses received were tested for potential correlation with survival, local recurrence, nodal recurence, and distant metastasis." | 1.29 | Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. ( Bassot, V; Brasnu, D; Khayat, D; Laccourreye, H; Laccourreye, O; Ménard, M, 1996) |
| "A-68-year-old man had hepatocellular carcinoma (HCC) in the area of S6 segment which was resected surgically." | 1.29 | [A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer]. ( Fukuzawa, Y; Ikeda, H; Kato, K; Murata, K; Sawada, T; Tagaya, T; Takahashi, K; Takiya, S, 1996) |
| "To identify appropriate candidates with rectal cancer for preoperative chemoradiation therapy, the local recurrence rate and clinicopathological characteristics of 232 patients with rectal cancer undergoing curative resection in our department were investigated." | 1.29 | [Preoperative chemoradiation therapy for lower rectal cancer]. ( Iihara, K; Kimura, M; Kitada, M; Murotani, M; Niinobu, T; Nose, T; Ogawa, M; Shibata, T; Takada, T; Takami, M; Tsujinaka, T; Tsukahara, Y; Tsukamoto, F, 1996) |
| " Our preliminary data indicate that postradiation adjuvant chemotherapy with a weekly FP regimen at our dosage is not recommended for high-risk NPC." | 1.29 | Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma. ( Hsu, CY; Jan, JS; Lin, JC, 1996) |
| "In 56 patients with a 3d stage gastric cancer regional intraarterial chemotherapy with 5-fluorouracil was used pre- and postoperatively." | 1.29 | [The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy]. ( Makarkin, NA; Tikhonov, VI; Tuzikov, SA; Zyrianov, BN, 1996) |
| "Palliative treatment of recurrent rectal cancer remains to be a challenge." | 1.28 | Intraarterial 5-FU-infusion and simultaneous radiotherapy as palliative treatment of recurrent rectal cancer. ( Kolotas, C; Kuhn, FP; Schmitt, G; Schnabel, T; Zamboglou, N, 1992) |
| " After right lobectomy of the liver which contained the tumors of S6 2 cm and S8 3 cm in diameter 7 months before, the patient was treated with hepatic arterial embolization (TAE) combined with infusion of anti-cancer drug (ADM, CDDP) four times since June 1990." | 1.28 | [A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE]. ( Imai, Y; Ito, J; Kobayashi, K; Okamoto, M; Tagawa, K; Taniguchi, M; Tanzawa, Y; Toda, N; Unuma, T; Uta, Y, 1992) |
| "We reported a case of locally advanced breast cancer who was cannulated into the right internal thoracic artery through the right femoral artery by Seldinger's method for intra-arterial chemotherapy and obtained good results." | 1.28 | [A case of complete response of locally advanced breast cancer to arterial infusion chemotherapy: cannulation through the right femoral artery and combined use of G-CSF]. ( Miura, T; Murata, M; Seki, M; Shinohara, K; Takagi, S; Tezuka, T, 1992) |
| "Twenty patients with rectal cancer underwent the preoperative regimen that consisted of 3,000 cGy delivered in 10 fractions over 12 days with concomitant 5-fluorouracil and mitomycin-C." | 1.28 | Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma. ( Broadwater, JR; Gocio, JC; Hutchins, LF; Klimberg, VS; Lang, NP; Langston, JD; Maners, A; Westbrook, KC, 1992) |
| "Twenty-two cases of early squamous cell carcinoma of the arytenoid cartilage staged as T1 according to the 1983 American Joint Committee for Cancer Staging Classification system were reviewed." | 1.28 | T1 squamous cell carcinoma of the arytenoid. ( Brasnu, D; Chabardes, E; Housset, M; Laccourreye, H; Laccourreye, O; Weinstein, G, 1992) |
| "Mitomycin C was given on Day 1 (dose: 15 mg/m2 i." | 1.28 | Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer. ( Dobrowsky, W, 1992) |
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 1.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| "Head and neck cancer locally recurrent after previous irradiation and surgery presents a difficult management problem." | 1.28 | Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. ( Kim, RY; Meredith, RF; Peters, GE; Salter, MM; Spencer, SA; Weppelmann, B; Wheeler, RH, 1992) |
| "Intra-abdominal panniculitis can result in mass lesions in the mesentery and omentum." | 1.28 | Intra-abdominal panniculitis can mimic recurrent stomach carcinoma. ( Cunningham, D; Husband, JE; MacVicar, D; Menzies-Gow, N; Taylor, R, 1992) |
| "Fourteen patients with relapsing ovarian cancer were treated with Mitomycin C (Mit C) and 5 Fluorouracil (5-FU)." | 1.28 | Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer. ( Covens, A; Mazurka, J; O'Connell, G; Rusthoven, J, 1992) |
| "The records of patients with esophageal cancer who were treated with a combined modality therapy were reviewed to determine the effects of simultaneously administered chemotherapy and radiotherapy (RT) at sites of recurrence and the relationship between treatment outcome and clinicopathologic variables." | 1.28 | Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . ( Denham, JW; Devitt, PG; Gill, PG; Jamieson, GG; Olweny, C; Yeoh, E, 1992) |
| "Hydroxyurea is an active single agent in squamous cell cancer of the head and neck." | 1.28 | Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992) |
| "Between 1979 and 1988, 33 patients with squamous cell carcinoma of the anal canal were treated with chemoradiation." | 1.28 | Squamous cell carcinoma of the anal canal. ( Fleshman, JW; Fry, RD; Halverson, JD; Kodner, IJ; Lopez, MJ; Monafo, WW; Myerson, RJ; Shapiro, SJ, 1991) |
| "We report a case of recurrent squamous cell carcinoma of the renal pelvis." | 1.28 | [Successful treatment of recurrent kidney pelvic squamous cell cancer with chemotherapy and radiotherapy: a case report]. ( Miyagawa, I; Nemoto, R; Yamane, A, 1991) |
| "Therapeutic results in advanced cervical cancer have not been showing any progress for more than 30 years." | 1.28 | [Systemic therapy in recurrent and primary advanced cervix cancer]. ( Bastert, G; Junkermann, H; Kaufmann, M; Schmid, H; Schönig, T; von Fournier, D, 1991) |
| "Eighty-three rats with isolated colon cancer underwent total colectomy; 40 of these rats with no metastases were randomized into two groups: surgery alone or surgery plus 5-FU (5 mg/kg body weight/day) for 5 days after surgery." | 1.28 | Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy. ( Ballet, F; Delelo, R; Herve, JP; Nordlinger, B; Panis, Y; Puts, JP, 1991) |
| " Single-agent and combined dose-response patterns consisting of decreasing viability with increasing drug concentration were observed consistently." | 1.28 | Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. ( Averette, HE; Gerhardt, RT; Guerra, L; Perras, JP; Petru, E; Ramos, R; Sevin, BU, 1991) |
| "Stage II patients with breast carcinoma who had undergone lumpectomy." | 1.28 | Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial. ( Allen, S; Bosworth, H; Budman, D; Lehrman, D; Lichtman, SM; Schulman, P; Vinciguerra, V; Weiselberg, L; Weiss, R, 1991) |
| "Seventeen patients with colorectal cancer metastatic to the liver underwent hepatic resection." | 1.28 | Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis. ( Furusawa, M; Kakeji, Y; Maehara, Y; Sugimachi, K; Tomoda, H; Tsujitani, S; Watanabe, A, 1991) |
| "Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil." | 1.28 | Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991) |
| "These two cases showed no recurrent liver cancers." | 1.28 | [Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
| "Thirty-five patients with nonmetastatic squamous cell carcinoma of the esophagus were treated with chemotherapy (5-fluorouracil, cisplatin) and concomitant split-course radiation therapy." | 1.28 | Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. ( Carcassonne, Y; Fuentes, P; Gauthier, AP; Giovannini, M; Giudicelli, R; Padaut-Cesana, J; Seitz, JF, 1990) |
| "A 62-year-old female with anal cancer underwent Miles operation in November, 1987." | 1.28 | [Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer]. ( Amino, K; Mieno, K; Miura, S; Satoi, Y; Shikata, J; Takeda, Y, 1989) |
| "Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer." | 1.28 | [Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer." | 1.28 | [Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. ( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989) |
| "A patient with ovarian cancer recurrent in the pelvis showed partial response to consecutive intraarterial (IA) cisplatin (CDDP) combined with continuous IA 5FU treatment and received third look operation in which the recurrent tumor could not be completely removed." | 1.28 | [Successful treatment of a patient with recurrent ovarian cancer by lentinan combined with intraarterial 5FU]. ( Chen, JT; Fujimoto, I; Hamada, T; Hasumi, K; Hirai, Y; Masubuchi, K; Nakayama, K; Shimizu, Y; Teshima, H; Yamauchi, K, 1989) |
| "5-fluorouracil (5-FU) was administered by arterial continuous infusion, and adriamycin (ADM) and mitomycin C (MMC) by bolus infusion." | 1.28 | [Clinical effectiveness of arterial infusion chemotherapy in advanced and recurrent gastric cancer]. ( Odaka, Y; Oikawa, K; Saito, K; Sato, M; Takagane, A; Terashima, M, 1989) |
| "A 24-year-old man with hepatocellular carcinoma presented with recurrent obstructive jaundice caused by bile duct invasion and distal migration of necrotic tumor fragments." | 1.27 | Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma. ( Albaugh, JS; Keeffe, EB; Krippaehne, WW, 1984) |
| "Large dosage of 5-fluorouracil given by slow intravenous infusion has proved to be very effective in the treatment of gestational trophoblastic neoplasms." | 1.27 | Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms. ( Sung, HC; Wu, PC; Yang, HY, 1984) |
| "Patients with inoperable rectal cancer have a remote chance of 5-year survival." | 1.27 | Ten years' experience with a multimodality treatment of advanced stages of rectal cancer. ( Wassif, SB, 1983) |
| "Of 55 patients with esophageal squamous cell carcinoma, 30 with localized disease were treated with a combined modality for curative intent." | 1.27 | Combined modality therapy for esophageal squamous cell carcinoma. ( Asfaw, I; Franklin, R; Hoschner, J; Loh, J; Miller, P; Rosenberg, J; Steiger, Z; Vaishampayan, G, 1983) |
| "A retrospective study of 56 patients treated for carcinoma in situ of the vulva over a 24-year period has shown a relative increase in the occurrence of this neoplasm." | 1.27 | Wide local excision in the treatment of vulvar carcinoma in situ: a reappraisal. ( Gallup, DG; Wolcott, HD, 1984) |
| "Melphalan (L-PAM) was compared to (C) cyclophosphamide, (M) methotrexate, and (F) 5-fluorouracil (CMF) in 413 patients with advanced ovarian carcinoma." | 1.27 | Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer. ( Bauer, M; Brodovsky, HS; Elson, PJ; Horton, J, 1984) |
| "Two cases of primary advanced breast cancer and 4 cases of recurrent breast cancer were treated with cyclophosphamide, Adriamycin and FT-207 combined with hormone therapy." | 1.27 | [Effect of CAF'-endocrine therapy on advanced and recurrent breast cancer]. ( Kagaya, H; Matsuoka, S; Miyata, S; Sato, Y; Uchino, J; Une, Y; Yakura, Y, 1984) |
| "Distant metastases developed in 40% of patients." | 1.27 | Multimodal treatment of locoregionally advanced breast cancer. ( Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Montague, ED; Schell, F; Spanos, W; Yap, HY, 1983) |
| "Ninety-one patients with malignant epithelial tumors of the nasopharynx seen in our department from 1970 to 1982 were evaluated." | 1.27 | Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches. ( Barzilay, J; Rahima, M; Rakowsky, E; Sidi, J, 1986) |
| "Forty patients with advanced squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, 5-FU (by continuous 5-day infusion), and allopurinol; 37 are evaluable for response." | 1.27 | Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. ( Cartei, G; De Besi, P; Fiorentino, M; Fosser, V; Paccagnella, A; Peracchia, A; Salvagno, L; Sileni, VC; Tremolada, C, 1986) |
| " The drug sensitivity of the cultured cancer cells was investigated with a colony forming assay, and a dose-response curve was obtained for the time-dependent anticancer drug." | 1.27 | [Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment]. ( Maeda, T, 1986) |
| " At these dosage levels, diarrhea was not a limiting toxicity." | 1.27 | High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer. ( Arnold, DJ; Balcueva, EP; Dimitrov, NV; Scholnik, AP; Schwenke, P; Suhrland, LG; Walker, WS, 1988) |
| "Esophageal cancer was treated with sequential intravenous cisplatin 100 mg/m2 (day 1) and 5-fluorouracil (5-FU) 40 mg/m2/hour X 120 (days 2-7)." | 1.27 | Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy. ( Barreras, L; Manten, H; Saldana, MJ; Sridhar, KS, 1988) |
| " Chemotherapy consisted of two cycles of CF (cyclophosphamide at a dosage of 100 mg/m2 orally on days 1-14+5-fluorouracil at 600 mg/m2 iv on days 1 and 8) during concurrent radiotherapy, followed by six cycles of CMFP (same CF dosages+methotrexate at 40 mg/m2 iv on days 1 and 8+prednisone at 40 mg/m2 orally on days 1-14)." | 1.27 | Integration of full-dose adjuvant chemotherapy with definitive radiotherapy for primary breast cancer: four-year update. ( Fowble, BL; Fox, KR; Glick, JH; Glover, DJ; Goodman, RL; Haller, DG; Hurwitz, S; Mackie, JA; Rosato, EF; Weiler, C, 1988) |
| "For the treatment of recurrent breast cancer, surgical treatment of the local lesion is only of limited significance, leaving a major role for systemic treatment such as chemotherapy and endocrine therapy." | 1.27 | [Local treatment of locally recurrent breast cancers]. ( Asaishi, K; Hayasaka, H; Okazaki, M, 1988) |
| "Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with an outpatient schedule: cisplatin (100 mg/m2) day 1 and an 8-hour infusion of 5-fluorouracil (1000 mg/m2) on days 1-4 every 28 days." | 1.27 | Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1988) |
| "Six patients with an upper gastrointestinal hemorrhage or a small bowel obstruction all had local recurrence." | 1.27 | Results in the management of locally unresectable pancreatic carcinoma. ( Parker, RG; Selch, MT, 1986) |
| "Colorectal cancer is one of the most resistant tumors to chemotherapy." | 1.27 | [Chemotherapy of advanced and recurrent colorectal cancer]. ( Tominaga, T, 1986) |
| "Patients with metastatic breast carcinoma and similar presentations should be considered for prophylactic therapy with allopurinol and hydration before chemotherapy." | 1.27 | Fatal acute tumor lysis syndrome with metastatic breast carcinoma. ( Coonley, CJ; Dyer, MC; Stark, ME, 1987) |
| "A 51-year-old man with recurrent gastric cancer was treated by combined administration of Cisplatin and Carmofur." | 1.27 | [A case of recurrent gastric cancer successfully treated with a combination of cisplatin and carmofur]. ( Abe, S; Akazawa, S; Fujiki, T; Futatsuki, K; Kanda, Y; Kuwatsuru, R; Saifuku, K; Yamamoto, K; Yoon, S; Yoshida, K, 1987) |
| "no amenorrhea), or family history of breast cancer." | 1.27 | Significance of plasma retinol binding protein levels in recurrence of breast tumors in women. ( Beattie, CW; Das Gupta, TK; Hart, G; Mehta, RR, 1987) |
| "Among 30 patients with squamous cell carcinoma, five achieved complete response (CR) (17%) and 13 achieved partial response (PR) (43%)." | 1.27 | Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study. ( DeConti, RC; Marsh, JC; Milner, LM; O'Donnell, MR; Rowland, KM; Showel, J; Spiers, AS; Stott, PB; Taylor, SG, 1986) |
| "14 patient with breast cancer of loco regional diffusion (M0), 4 of whom had negative axillary lymph nodes, were administered precautional chemotherapy with CMF, on the basis of anatomo-clinical prognostic elements (size of the neoplasia, grading (tumoral limits, neoplastic embolisation etc." | 1.27 | Our experience regarding precautional chemotherapy in breast cancer. ( Cherchi, PL; Dessole, S; Fadda, G; Piras, G; Sardu, GM, 1985) |
| "Sixteen patients with dermal lymphatic carcinomatosis and 10 patients with negative skin biopsies had median RFS of 31 and 46 months, respectively (p = 0." | 1.27 | Management of inflammatory carcinoma of the breast. A combined modality approach. ( Blumenschein, GR; Buzdar, AU; Fastenberg, NA; Hortobagyi, GN; Jessup, JM; Martin, RG; Montague, ED, 1985) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| ", CAF (CPA + ADM + 5-FU), and AC (ADM + CPA) are well known, but the dosage and administration schedule differ somewhat with the researcher." | 1.27 | [Chemotherapy for recurrent breast carcinoma]. ( Taguchi, T, 1985) |
| " The mean half-life of 5-FU in the isolated circuit was 18." | 1.27 | Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. ( Abramson, IS; Andrews, PA; Howell, SB; Murphy, MP; Stemmer, EA; Wile, AG, 1985) |
| "Twenty-nine patients with advanced colorectal cancer were treated with methotrexate (MTX) 200 mg/m2 followed 1 h later by fluorouracil (FU) (1000 mg/m2) and 24 h later by oral leucovorin 20 mg every 6 h for six doses." | 1.27 | A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. ( Ford, J; Margolese, R; Panasci, L, 1985) |
| "Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of cisplatin (20 mg/m2) and 5-FU (400-200 mg/m2) by iv push on Days 1-5 every 21 days." | 1.27 | Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule. ( Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Tatarek, R, 1985) |
| "Treatment of colorectal cancer beyond surgical resection has had only minimal success in the past." | 1.27 | Colorectal cancer: speculations on the role of intraperitoneal therapy. ( Muggia, FM, 1985) |
| " They received 5FU and cisplatin in the same dosage every 28 days for either recurrent or metastatic disease." | 1.27 | A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. ( Citrin, P; Dasmahapatra, KS; Hill, GJ; Mohit-Tabatabai, MA; Rush, BF; Yee, R, 1985) |
| "Twenty-five patients with advanced squamous cell carcinoma of the head and neck were entered into this study." | 1.26 | Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A. ( Blackledge, G; Crowther, D; Thatcher, N, 1980) |
| "Seventeen patients with adenocystic carcinoma have received 34 adequate trials of chemotherapy at Princess Margaret Hospital since 1969." | 1.26 | Chemotherapy for adenocystic carcinoma. ( Sutherland, DJ; Tannock, IF, 1980) |
| "Patients without lymph node metastases were not treated." | 1.26 | [Ancillary chemotherapy with trofosfamid, methotrexate and fluoro-uracil in cancer of the breast (author's transl)]. ( Albrecht, M; Jepsen, G; Thomsen, K; Trams, G, 1981) |
| "Further subclassification of the tumors based on elements suggestive of tumor differentiation detected on light and electron microscopic examination was possible in 22 of the 35 patients." | 1.26 | Anaplastic malignant neoplasms: diagnosis and treatment. ( Bedikian, AY; Luna, M; Mackay, B; Valdivieso, M, 1981) |
| "Sixty-two patients with breast cancer treated with Adriamycin-containing adjuvant chemotherapy developed recurrent disease." | 1.26 | Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. ( Barnes, BC; Blumenschein, GR; Buzdar, AU; Campos, LT; Distefano, A; Hortobagyi, GN; Legha, SS; Schell, FC; Wiseman, CL; Yap, HY, 1981) |
| "Relief of pain was noted in two-thirds of the patients." | 1.26 | Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer. ( Hafström, L; Jönsson, PE; Landberg, T; Owman, T; Sundkvist, K, 1979) |
| "Eight patients with squamous cell carcinoma in situ of the vagina were treated with monthly 5 day courses of 20% 5-fluorouracil cream applied to the vagina." | 1.26 | Postirradiation squamous cell carcinoma in situ of the vagina: treatment by topical 20 percent 5-fluorouracil cream. ( Barlow, JJ; Gamarra, M; Piver, MS; Sandecki, A; Tsukada, Y, 1979) |
| "Sixty-six confirmed cases of Bowen's disease (intraepidermal squamous cell carcinoma) were seen from 1965 through 1976: twenty-four cases were treated surgically-four by excision (two recurrences) and twenty by desiccation and curettage (four recurrences); one was treated with x-ray radiation; and forty-one were treated with topical 5-fluorouracil (5-FU) (three recurrences)." | 1.26 | Bowen's disease and 5-fluorouracil. ( Sturm, HM, 1979) |
| "Four cases of Bowen's disease of the finger have been treated, three during the past two years." | 1.26 | Bowen's Disease of the Finger. ( Kern, AB; Schiff, BL, 1977) |
| "A therapeutical method of inoperable squamous cell carcinomas based on cell kinetics has been applied since 1969 by using 5-fluorine-uracil." | 1.25 | [Radiotherapy of inoperable orofacial squamous epithelial carcinomas following pharmacologically induced partial synchronization]. ( Esser, E; Schumann, J; Wannenmacher, M, 1975) |
| "Although breast cancer presents as localized disease and is treated with local modalities, i." | 1.25 | Chemotherapy in the treatment strategy of breast cancer. ( Carbone, PP, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 475 (17.76) | 18.7374 |
| 1990's | 487 (18.21) | 18.2507 |
| 2000's | 744 (27.81) | 29.6817 |
| 2010's | 772 (28.86) | 24.3611 |
| 2020's | 197 (7.36) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, NS | 1 |
| Baxter, LA | 1 |
| Goel, A | 1 |
| Arnold, R | 1 |
| Kaur, B | 1 |
| Liu, W | 2 |
| Pirrie, SJ | 1 |
| Hussain, S | 1 |
| Viney, R | 1 |
| Ford, D | 1 |
| Zarkar, A | 2 |
| Wood, MA | 1 |
| Mitin, T | 2 |
| Thompson, RF | 1 |
| James, ND | 3 |
| Ward, DG | 1 |
| Bryan, RT | 1 |
| Takashima, T | 1 |
| Nishimura, S | 3 |
| Kawajiri, H | 1 |
| Mizuyama, Y | 1 |
| Nishimori, T | 1 |
| Yamagata, S | 2 |
| Tokunaga, S | 1 |
| Tezuka, K | 1 |
| Tei, S | 2 |
| Sunami, T | 1 |
| Ikeda, K | 3 |
| Ogawa, Y | 4 |
| Kashiwagi, S | 1 |
| Noda, S | 1 |
| Onoda, N | 3 |
| Ishikawa, T | 2 |
| Kudoh, S | 1 |
| Takada, M | 1 |
| Hirakawa, K | 1 |
| Ohira, M | 1 |
| Okunaka, M | 1 |
| Kotani, D | 1 |
| Demachi, K | 1 |
| Fujiwara, H | 6 |
| Sakashita, S | 1 |
| Yoshino, T | 10 |
| Fujita, T | 3 |
| Kojima, T | 10 |
| Peng, H | 2 |
| Chen, L | 5 |
| Mao, YP | 1 |
| Tian, L | 1 |
| Liu, LZ | 2 |
| Kawada, J | 2 |
| Mizuno, M | 1 |
| Fukada, A | 1 |
| Nakano, M | 5 |
| Murotani, M | 2 |
| Nagano, S | 1 |
| Yoneda, N | 1 |
| Kidogami, S | 1 |
| Mokutani, Y | 1 |
| Kishimoto, T | 4 |
| Hashimoto, Y | 2 |
| Hirose, H | 2 |
| Yoshioka, S | 2 |
| Tamura, S | 2 |
| Sasaki, Y | 4 |
| Kadono, T | 1 |
| Okuyama, Y | 3 |
| Nakatsugawa, Y | 1 |
| Yamada, S | 7 |
| Nishimura, T | 1 |
| Fujii, H | 8 |
| Tomatsuri, N | 1 |
| Sato, H | 4 |
| Kimura, H | 1 |
| Urata, Y | 1 |
| Okadome, K | 1 |
| Baba, Y | 2 |
| Yasuda-Yoshihara, N | 1 |
| Nomoto, D | 1 |
| Yagi, T | 1 |
| Toihata, T | 1 |
| Ogawa, K | 2 |
| Sawayama, H | 1 |
| Ishimoto, T | 1 |
| Iwatsuki, M | 1 |
| Iwagami, S | 1 |
| Miyamoto, Y | 4 |
| Yoshida, N | 1 |
| Watanabe, M | 8 |
| Komohara, Y | 1 |
| Baba, H | 8 |
| Oneda, E | 1 |
| Zaniboni, A | 7 |
| Goerling, U | 1 |
| Gauler, T | 1 |
| Dietz, A | 1 |
| Grünwald, V | 2 |
| Knipping, S | 1 |
| Guntinas-Lichius, O | 1 |
| Frickhofen, N | 1 |
| Lindeman, HW | 1 |
| Fietkau, R | 10 |
| Haxel, B | 1 |
| Große-Thie, C | 1 |
| Maschmeyer, G | 1 |
| Zipfel, M | 1 |
| Martus, P | 4 |
| Knoedler, M | 1 |
| Keilholz, U | 2 |
| Klinghammer, K | 1 |
| Miyajima, N | 1 |
| Ragab Eissa, I | 1 |
| Abdelmoneim, M | 1 |
| Naoe, Y | 1 |
| Ichinose, T | 1 |
| Matsumura, S | 2 |
| Bustos-Villalobos, I | 1 |
| Mukoyama, N | 1 |
| Morimoto, D | 1 |
| Shibata, M | 1 |
| Takeuchi, D | 1 |
| Tsunoda, N | 1 |
| Kikumori, T | 1 |
| Tanaka, M | 1 |
| Kodera, Y | 3 |
| Kasuya, H | 1 |
| Pumpalova, Y | 1 |
| Rogers, AM | 1 |
| Tan, SX | 1 |
| Herbst, CL | 1 |
| Ruff, P | 2 |
| Neugut, AI | 2 |
| Hur, C | 2 |
| Ichikawa, N | 1 |
| Homma, S | 1 |
| Funakoshi, T | 1 |
| Hattori, M | 2 |
| Sato, M | 2 |
| Kamiizumi, Y | 1 |
| Omori, K | 1 |
| Nomura, M | 4 |
| Yokota, R | 1 |
| Koike, M | 1 |
| Kon, H | 1 |
| Takeda, K | 6 |
| Ishizu, H | 1 |
| Matsuoka, S | 2 |
| Hirose, K | 1 |
| Murata, R | 1 |
| Iijima, H | 1 |
| Yoshida, T | 4 |
| Minagawa, N | 2 |
| Takahashi, N | 5 |
| Taketomi, A | 1 |
| Kuwabara, S | 1 |
| Murakawa, K | 1 |
| Kumagai, K | 1 |
| Takeuchi, Y | 2 |
| Wada, H | 5 |
| Ichinokawa, M | 1 |
| Matsumoto, J | 1 |
| Ono, K | 1 |
| Hirano, S | 1 |
| Sato, Y | 13 |
| Kobayashi, M | 12 |
| Karasawa, H | 1 |
| Ichikawa, H | 2 |
| Kajiwara, T | 2 |
| Kohyama, A | 1 |
| Watanabe, K | 2 |
| Kamei, T | 4 |
| Ohnuma, S | 1 |
| Unno, M | 3 |
| Kagawa, Y | 1 |
| Inoue, A | 1 |
| Nishizawa, Y | 4 |
| Kawai, K | 3 |
| Ohta, T | 2 |
| Hata, T | 6 |
| Naito, A | 2 |
| Komatsu, H | 2 |
| Miyazaki, Y | 1 |
| Tomokuni, A | 2 |
| Motoori, M | 3 |
| Fujitani, K | 2 |
| Kato, T | 12 |
| Takeda, Y | 4 |
| Murata, K | 4 |
| Mori, Y | 1 |
| Kikuchi, O | 1 |
| Horimatsu, T | 3 |
| Hara, H | 5 |
| Hironaka, S | 4 |
| Kato, K | 8 |
| Tsushima, T | 2 |
| Ishihara, R | 3 |
| Mukai, K | 2 |
| Uozumi, R | 2 |
| Tada, H | 1 |
| Kasai, H | 1 |
| Kawaguchi, A | 1 |
| Muto, M | 5 |
| Shibahara, H | 1 |
| Shiroiwa, T | 2 |
| Ishiguro, M | 2 |
| Nakamura, M | 8 |
| Hasegawa, J | 4 |
| Yamaguchi, S | 10 |
| Masuda, Y | 1 |
| Sakamoto, J | 17 |
| Tomita, N | 5 |
| Fukuda, T | 3 |
| Cantero-Recasens, G | 1 |
| Alonso-Marañón, J | 1 |
| Lobo-Jarne, T | 1 |
| Garrido, M | 1 |
| Iglesias, M | 1 |
| Espinosa, L | 1 |
| Malhotra, V | 1 |
| Liu, Z | 3 |
| Liu, L | 2 |
| Weng, S | 1 |
| Guo, C | 3 |
| Dang, Q | 1 |
| Xu, H | 5 |
| Wang, L | 8 |
| Lu, T | 1 |
| Zhang, Y | 9 |
| Sun, Z | 2 |
| Han, X | 3 |
| Ishikawa, Y | 4 |
| Suzuki, M | 4 |
| Yamaguchi, H | 3 |
| Seto, I | 1 |
| Machida, M | 1 |
| Takagawa, Y | 1 |
| Jingu, K | 5 |
| Kikuchi, Y | 2 |
| Murakami, M | 4 |
| Futai, R | 1 |
| Yoshie, T | 1 |
| Sanuki, T | 1 |
| Inoue, Y | 9 |
| Abe, T | 3 |
| Sasaki, A | 1 |
| Iemoto, T | 1 |
| Hayashi, H | 7 |
| Ose, T | 1 |
| Morikawa, T | 2 |
| Ayyoub, S | 1 |
| Sultan, I | 1 |
| Pouya, FD | 1 |
| Gazouli, M | 1 |
| Rasmi, Y | 1 |
| Lampropoulou, DI | 1 |
| Nemati, M | 1 |
| Zhu, X | 3 |
| Cao, Y | 2 |
| Ju, X | 1 |
| Zhao, X | 1 |
| Jiang, L | 1 |
| Ye, Y | 3 |
| Jin, G | 1 |
| Zhang, H | 4 |
| Holliday, EB | 1 |
| Morris, VK | 1 |
| Johnson, B | 1 |
| Eng, C | 5 |
| Ludmir, EB | 2 |
| Das, P | 5 |
| Minsky, BD | 10 |
| Taniguchi, C | 1 |
| Smith, GL | 1 |
| Koay, EJ | 1 |
| Koong, AC | 4 |
| Delclos, ME | 4 |
| Skibber, JM | 6 |
| Rodriguez-Bigas, MA | 5 |
| You, YN | 3 |
| Bednarski, BK | 1 |
| Tillman, MM | 1 |
| Chang, GJ | 6 |
| Jennings, K | 1 |
| Messick, CA | 1 |
| Li, WZ | 2 |
| Lv, X | 3 |
| Hu, D | 1 |
| Lv, SH | 1 |
| Liu, GY | 2 |
| Liang, H | 3 |
| Ye, YF | 2 |
| Yang, W | 1 |
| Zhang, HX | 1 |
| Yuan, TZ | 1 |
| Wang, DS | 2 |
| Lu, N | 1 |
| Ke, LR | 2 |
| Tang, WB | 1 |
| Tong, LH | 1 |
| Chen, ZJ | 1 |
| Liu, T | 3 |
| Cao, KJ | 1 |
| Mo, HY | 3 |
| Guo, L | 2 |
| Zhao, C | 3 |
| Chen, MY | 1 |
| Chen, QY | 2 |
| Huang, PY | 2 |
| Sun, R | 1 |
| Qiu, F | 1 |
| Luo, DH | 2 |
| Hua, YJ | 1 |
| Tang, LQ | 2 |
| Qian, CN | 1 |
| Mai, HQ | 3 |
| Guo, X | 3 |
| Xiang, YQ | 2 |
| Xia, WX | 2 |
| Mehta, R | 1 |
| Frakes, J | 1 |
| Kim, J | 2 |
| Nixon, A | 1 |
| Liu, Y | 10 |
| Howard, L | 1 |
| Martinez Jimenez, ME | 1 |
| Carballido, E | 1 |
| Imanirad, I | 1 |
| Sanchez, J | 1 |
| Dessureault, S | 1 |
| Xie, H | 1 |
| Felder, S | 1 |
| Sahin, I | 1 |
| Hoffe, S | 2 |
| Malafa, M | 1 |
| Kim, R | 3 |
| Katsumata, K | 4 |
| Sumi, T | 1 |
| Ishizaki, T | 2 |
| Enomoto, M | 2 |
| Shigoka, M | 2 |
| Wada, T | 3 |
| Kuwabara, H | 2 |
| Mazaki, J | 2 |
| Kasahara, K | 1 |
| Tago, T | 1 |
| Udo, R | 1 |
| Nagakawa, Y | 2 |
| Kawachi, S | 2 |
| Tsuchida, A | 2 |
| Kitazume, Y | 1 |
| Kawazoe, H | 1 |
| Yoshizawa, T | 1 |
| Iihara, H | 1 |
| Takahashi, M | 7 |
| Arai, T | 2 |
| Murachi, Y | 1 |
| Mikami, T | 1 |
| Hashiguchi, K | 2 |
| Yamazaki, T | 2 |
| Takahashi, K | 12 |
| Fujita, Y | 4 |
| Hosokawa, Y | 1 |
| Morozumi, I | 1 |
| Tsuchiya, M | 1 |
| Yokoyama, A | 1 |
| Hashimoto, H | 1 |
| Yamaguchi, M | 1 |
| Ishii, M | 2 |
| Itano, O | 1 |
| Morinaga, J | 1 |
| Shirakawa, H | 1 |
| Itano, S | 1 |
| Jimenez-Fonseca, P | 1 |
| Salazar, R | 2 |
| Valenti, V | 2 |
| Msaouel, P | 1 |
| Carmona-Bayonas, A | 1 |
| Tominaga, T | 13 |
| Nonaka, T | 2 |
| Oyama, S | 2 |
| Shiraishi, T | 3 |
| Takeshita, H | 1 |
| Hisanaga, M | 1 |
| Fukuoka, H | 1 |
| Fukuda, A | 3 |
| Sumida, Y | 1 |
| Hashimoto, S | 3 |
| To, K | 1 |
| Tanaka, K | 14 |
| Sawai, T | 2 |
| Nagayasu, T | 2 |
| Yang, Q | 2 |
| Nie, YH | 1 |
| Cai, MB | 1 |
| Li, ZM | 1 |
| Zhu, HB | 1 |
| Tan, YR | 1 |
| Zhao, L | 3 |
| Lin, Z | 3 |
| Yu, D | 1 |
| Jin, M | 1 |
| Zhou, P | 1 |
| Ren, J | 2 |
| Cheng, J | 1 |
| Yang, K | 2 |
| Wu, G | 1 |
| Zhang, T | 3 |
| Zhang, D | 1 |
| Salerno, S | 1 |
| Ståhlberg, A | 1 |
| Holdfeldt, A | 1 |
| Bexe Lindskog, E | 1 |
| Landberg, G | 1 |
| Maruyama, K | 1 |
| Moriyama, M | 1 |
| Tie, J | 1 |
| Cohen, JD | 1 |
| Lahouel, K | 1 |
| Lo, SN | 1 |
| Wang, Y | 7 |
| Kosmider, S | 1 |
| Wong, R | 4 |
| Shapiro, J | 1 |
| Lee, M | 3 |
| Harris, S | 1 |
| Khattak, A | 1 |
| Burge, M | 2 |
| Harris, M | 1 |
| Lynam, J | 1 |
| Nott, L | 1 |
| Day, F | 1 |
| Hayes, T | 1 |
| McLachlan, SA | 1 |
| Lee, B | 1 |
| Ptak, J | 1 |
| Silliman, N | 1 |
| Dobbyn, L | 1 |
| Popoli, M | 1 |
| Hruban, R | 1 |
| Lennon, AM | 1 |
| Papadopoulos, N | 1 |
| Kinzler, KW | 1 |
| Vogelstein, B | 1 |
| Tomasetti, C | 1 |
| Gibbs, P | 1 |
| Saada-Bouzid, E | 2 |
| Peyrade, F | 5 |
| Guigay, J | 3 |
| Brown, JC | 1 |
| Meyerhardt, JA | 9 |
| Cespedes Feliciano, EM | 1 |
| Cheng, E | 1 |
| Caan, BJ | 1 |
| Yao, L | 2 |
| Tang, C | 1 |
| Feng, W | 1 |
| Dai, H | 2 |
| Kii, T | 3 |
| Hirota, M | 2 |
| Matsuyama, J | 1 |
| Sakai, D | 2 |
| Shimokawa, T | 1 |
| Kurokawa, Y | 3 |
| Kawakami, H | 3 |
| Tsujinaka, T | 4 |
| Satoh, T | 3 |
| Lohynská, R | 2 |
| Pechačová, Z | 1 |
| Nishiwaki, N | 1 |
| Noma, K | 1 |
| Kunitomo, T | 1 |
| Hashimoto, M | 2 |
| Maeda, N | 1 |
| Tanabe, S | 2 |
| Sakurama, K | 1 |
| Shirakawa, Y | 1 |
| Fujiwara, T | 1 |
| Ak Aksoy, S | 1 |
| Tunca, B | 1 |
| Erçelik, M | 1 |
| Tezcan, G | 1 |
| Ozturk, E | 1 |
| Cecener, G | 1 |
| Ugras, N | 1 |
| Yilmazlar, T | 1 |
| Yerci, O | 1 |
| Fu, JY | 1 |
| Yue, XH | 1 |
| Dong, MJ | 1 |
| Li, J | 17 |
| Zhang, CP | 2 |
| Ito, R | 1 |
| Nakamura, Y | 3 |
| Sunakawa, H | 1 |
| Hojo, H | 1 |
| Nakamura, N | 1 |
| Yano, T | 5 |
| Daiko, H | 4 |
| Akimoto, T | 1 |
| Conroy, T | 4 |
| Castan, F | 3 |
| Lopez, A | 2 |
| Turpin, A | 2 |
| Ben Abdelghani, M | 3 |
| Wei, AC | 1 |
| Mitry, E | 1 |
| Biagi, JJ | 1 |
| Evesque, L | 1 |
| Artru, P | 3 |
| Lecomte, T | 2 |
| Assenat, E | 1 |
| Bauguion, L | 1 |
| Ychou, M | 4 |
| Bouché, O | 7 |
| Monard, L | 1 |
| Lambert, A | 1 |
| Hammel, P | 2 |
| Wang, D | 2 |
| Cao, Q | 1 |
| Pérez-García, P | 1 |
| Burgos-Blasco, B | 1 |
| Gómez-Calleja, V | 1 |
| Vidal-Villegas, B | 1 |
| Méndez-Fernández, R | 1 |
| Gegúndez-Fernández, JA | 1 |
| Díaz-Valle, D | 1 |
| Monzer, A | 1 |
| Wakimian, K | 1 |
| Ballout, F | 1 |
| Al Bitar, S | 1 |
| Yehya, A | 1 |
| Kanso, M | 1 |
| Saheb, N | 1 |
| Tawil, A | 1 |
| Doughan, S | 1 |
| Hussein, M | 1 |
| Mukherji, D | 1 |
| Faraj, W | 1 |
| Gali-Muhtasib, H | 1 |
| Abou-Kheir, W | 1 |
| Yu, X | 2 |
| Su, X | 2 |
| Fang, L | 1 |
| Chen, X | 10 |
| Pu, Y | 1 |
| Liu, H | 8 |
| Guo, R | 1 |
| Mohanty, S | 1 |
| Mohapatra, P | 1 |
| Shriwas, O | 1 |
| Ansari, SA | 1 |
| Priyadarshini, M | 1 |
| Priyadarsini, S | 1 |
| Rath, R | 1 |
| Sultania, M | 1 |
| Das Majumdar, SK | 1 |
| Swain, RK | 1 |
| Dash, R | 1 |
| Sugase, T | 1 |
| Sugimura, K | 1 |
| Kanemura, T | 1 |
| Takeoka, T | 1 |
| Yamamoto, M | 5 |
| Shinno, N | 1 |
| Omori, T | 1 |
| Fujii, Y | 2 |
| Mukai, Y | 1 |
| Mikamori, M | 2 |
| Hasegawa, S | 6 |
| Haraguchi, N | 2 |
| Akita, H | 1 |
| Nishimura, J | 4 |
| Matsuda, C | 2 |
| Yasui, M | 2 |
| Miyata, H | 3 |
| Matsuoka, H | 3 |
| Yamada, T | 3 |
| Ohta, R | 1 |
| Yoshida, Y | 5 |
| Watanabe, T | 10 |
| Kosugi, C | 1 |
| Fukazawa, A | 1 |
| Kuramochi, H | 1 |
| Matsuda, A | 2 |
| Sonoda, H | 1 |
| Yoshida, H | 3 |
| Sakamoto, K | 4 |
| Otsuka, T | 2 |
| Hirata, K | 7 |
| Koda, K | 1 |
| Takahashi, S | 8 |
| Oridate, N | 1 |
| Shimizu, Y | 3 |
| Fujimoto, Y | 4 |
| Matsumoto, K | 1 |
| Yokota, T | 2 |
| Ueda, T | 4 |
| Hanai, N | 3 |
| Yoshizaki, T | 1 |
| Yasumatsu, R | 1 |
| Nakayama, M | 1 |
| Shiga, K | 1 |
| Fujii, T | 4 |
| Mitsugi, K | 5 |
| Nohata, N | 1 |
| Gumuscu, B | 1 |
| Swaby, RF | 2 |
| Tahara, M | 7 |
| Patel, C | 1 |
| Elmasry, A | 1 |
| Giridharan, S | 1 |
| Kono, T | 4 |
| Miyata, R | 1 |
| Yoshimatsu, K | 4 |
| Koike, T | 2 |
| Shiozawa, S | 4 |
| Hanada, M | 1 |
| Ajihara, T | 1 |
| Naritomi, T | 1 |
| Fukuya, Y | 1 |
| Santos, A | 1 |
| Cristóbal, I | 1 |
| Rubio, J | 1 |
| Caramés, C | 1 |
| Luque, M | 1 |
| Sanz-Álvarez, M | 1 |
| Zazo, S | 1 |
| Madoz-Gúrpide, J | 1 |
| Rojo, F | 1 |
| García-Foncillas, J | 1 |
| Breadner, D | 1 |
| Loree, JM | 1 |
| Cheung, WY | 3 |
| Gipson, M | 1 |
| Lakkunarajah, S | 1 |
| Mulder, KE | 1 |
| Spartlin, JL | 1 |
| Kong, S | 1 |
| Ding, PQ | 1 |
| Gill, S | 2 |
| Welch, SA | 1 |
| Yamasaki, M | 5 |
| Okamoto, K | 8 |
| Fukuya, A | 3 |
| Kawaguchi, T | 5 |
| Noda, K | 5 |
| Kagemoto, K | 3 |
| Mitsui, Y | 3 |
| Miyamoto, H | 6 |
| Takayama, T | 4 |
| Sripawadkul, W | 4 |
| Theotoka, D | 2 |
| Zein, M | 4 |
| Galor, A | 7 |
| Karp, CL | 7 |
| Wylegala, A | 2 |
| Alvarez, OP | 2 |
| Al Bayyat, G | 2 |
| Kumar, V | 2 |
| Bansal, S | 2 |
| Badola, A | 2 |
| Nautiyal, V | 2 |
| Gupta, M | 2 |
| Ahmad, M | 2 |
| Saini, S | 2 |
| Lee, HL | 1 |
| Fu, CK | 1 |
| Chien, LY | 1 |
| Chen, LM | 2 |
| Oguma, J | 2 |
| Ishiyama, K | 1 |
| Kurita, D | 1 |
| Kanematsu, K | 1 |
| Kubo, K | 3 |
| Utsunomiya, D | 1 |
| Yamamoto, S | 5 |
| Honma, Y | 2 |
| Aoyama, R | 1 |
| Hida, K | 1 |
| Yamaguchi, T | 8 |
| Manaka, D | 4 |
| Kato, S | 3 |
| Yamada, M | 1 |
| Yamanokuchi, S | 1 |
| Kyogoku, T | 1 |
| Kanazawa, A | 5 |
| Kawada, K | 4 |
| Sakamoto, T | 2 |
| Goto, S | 1 |
| Sakai, Y | 2 |
| Obama, K | 1 |
| Oiki, H | 1 |
| Kawabata, R | 1 |
| Izutani, Y | 1 |
| Kitagawa, A | 1 |
| Ushimaru, Y | 1 |
| Ohhara, N | 1 |
| Miyake, Y | 2 |
| Maeda, S | 3 |
| Nakata, K | 1 |
| Nishikawa, K | 1 |
| Miyamoto, A | 2 |
| Kuhara, K | 1 |
| Usui, T | 2 |
| Shimojima, Y | 1 |
| Nishiguchi, R | 1 |
| Okayama, S | 2 |
| Asaka, S | 1 |
| Yokomizo, H | 2 |
| Shimakawa, T | 2 |
| Ohigashi, S | 1 |
| Li, G | 4 |
| Nikkhoi, SK | 1 |
| Hatefi, A | 1 |
| Liu, X | 1 |
| Peng, S | 1 |
| Tang, G | 2 |
| Xu, G | 2 |
| Xie, Y | 2 |
| Shen, D | 1 |
| Zhu, M | 1 |
| Huang, Y | 12 |
| Wang, X | 11 |
| Yu, H | 1 |
| Huang, M | 2 |
| Luo, Y | 2 |
| Okano, M | 2 |
| Hara, T | 1 |
| Tanizaki, K | 1 |
| Takayama, O | 1 |
| Kim, Y | 2 |
| Imamoto, H | 1 |
| Ide, Y | 2 |
| Shimokawa, M | 1 |
| Koga, F | 1 |
| Ueda, Y | 3 |
| Nakazawa, J | 1 |
| Komori, A | 2 |
| Otsu, S | 1 |
| Arima, S | 1 |
| Fukahori, M | 1 |
| Makiyama, A | 2 |
| Shinohara, Y | 2 |
| Ueno, S | 1 |
| Taguchi, H | 1 |
| Honda, T | 1 |
| Shibuki, T | 1 |
| Nio, K | 1 |
| Ureshino, N | 1 |
| Mizuta, T | 1 |
| Shirakawa, T | 2 |
| Moreno-Londoño, AP | 1 |
| Castañeda-Patlán, MC | 1 |
| Sarabia-Sánchez, MA | 1 |
| Macías-Silva, M | 1 |
| Robles-Flores, M | 1 |
| Fu, Q | 1 |
| Chen, Y | 9 |
| Huang, D | 1 |
| Zhang, X | 2 |
| Xiao, W | 2 |
| Xue, X | 1 |
| Zhang, Q | 5 |
| Li, X | 10 |
| Gao, S | 3 |
| Que, R | 1 |
| Shen, Y | 3 |
| Wu, J | 2 |
| Zhang, M | 2 |
| Bai, X | 1 |
| Liang, T | 1 |
| Mahdavi, H | 1 |
| Le Tourneau, C | 4 |
| Ghiani, M | 1 |
| Cau, MC | 1 |
| Depenni, R | 1 |
| Ronzino, G | 1 |
| Bonomo, P | 2 |
| Montesarchio, V | 2 |
| Leo, L | 1 |
| Schulten, J | 1 |
| Salmio, S | 1 |
| Messinger, D | 2 |
| Sbrana, A | 1 |
| Borcoman, E | 1 |
| Ghi, MG | 1 |
| Zong, JF | 2 |
| Lin, PJ | 2 |
| Tsou, HH | 1 |
| Guo, Q | 1 |
| Liu, YC | 3 |
| Twu, CW | 2 |
| Zheng, W | 3 |
| Jiang, RS | 2 |
| Liang, KL | 2 |
| Lin, TY | 2 |
| Pan, JJ | 3 |
| Lin, SJ | 3 |
| Lin, JC | 4 |
| Lee, KW | 7 |
| Zang, DY | 4 |
| Ryu, MH | 9 |
| Han, HS | 1 |
| Kim, KH | 5 |
| Kim, MJ | 3 |
| Koh, SA | 1 |
| Lee, SS | 2 |
| Koo, DH | 2 |
| Ko, YH | 1 |
| Sohn, BS | 1 |
| Kim, JW | 6 |
| Park, JH | 5 |
| Nam, BH | 3 |
| Choi, IS | 3 |
| Schrag, D | 4 |
| Shi, Q | 9 |
| Weiser, MR | 3 |
| Gollub, MJ | 2 |
| Saltz, LB | 5 |
| Musher, BL | 1 |
| Goldberg, J | 1 |
| Al Baghdadi, T | 1 |
| Goodman, KA | 3 |
| McWilliams, RR | 1 |
| Farma, JM | 2 |
| George, TJ | 3 |
| Kennecke, HF | 2 |
| Shergill, A | 1 |
| Montemurro, M | 1 |
| Nelson, GD | 1 |
| Colgrove, B | 1 |
| Gordon, V | 1 |
| Venook, AP | 4 |
| O'Reilly, EM | 1 |
| Dueck, AC | 1 |
| Basch, E | 2 |
| Mamon, HJ | 2 |
| Satake, M | 2 |
| Ito, Y | 9 |
| Tanaka, H | 6 |
| Higashida, M | 2 |
| Okada, T | 5 |
| Endo, S | 4 |
| Fujiwara, Y | 9 |
| Ueno, T | 1 |
| Pesántez, D | 1 |
| Ten Hoorn, S | 1 |
| Machado, I | 1 |
| García-Albéniz, X | 1 |
| Rodríguez-Salas, N | 1 |
| Heredia-Soto, V | 1 |
| Viñal, D | 1 |
| Pericay, C | 2 |
| García-Carbonero, R | 1 |
| Losa, F | 1 |
| Alonso, V | 2 |
| Vera, R | 1 |
| Feliu Batlle, J | 1 |
| Gallego, J | 1 |
| Salud, A | 1 |
| Nogué, M | 1 |
| Layos, L | 1 |
| Montagut, C | 1 |
| Capdevila, J | 1 |
| Vermeulen, L | 2 |
| Maurel, J | 2 |
| Fernandez-Martos, C | 1 |
| Azman, AA | 1 |
| Siok-Fong, C | 1 |
| Rajab, NF | 1 |
| Md Zin, RR | 1 |
| Ahmad Daud, NN | 1 |
| Mohamad Hanif, EA | 1 |
| Luu, W | 1 |
| McRae, MY | 1 |
| Mihara, Y | 1 |
| Hirasaki, M | 1 |
| Horita, Y | 2 |
| Fujino, T | 1 |
| Fukushima, H | 2 |
| Kamakura, Y | 1 |
| Uranishi, K | 1 |
| Hirano, Y | 1 |
| Ryozawa, S | 1 |
| Yasuda, M | 1 |
| Makino, Y | 1 |
| Shibazaki, S | 1 |
| Hamaguchi, T | 3 |
| Zhang, J | 6 |
| Han, G | 1 |
| Tang, J | 1 |
| Guo, F | 2 |
| Li, W | 1 |
| Xie, L | 1 |
| Tian, Y | 2 |
| Pan, L | 1 |
| Shu, Y | 2 |
| Ma, L | 1 |
| Taniguchi, SH | 1 |
| Komine, K | 1 |
| Takenaga, N | 1 |
| Sasaki, K | 6 |
| Kawamura, Y | 1 |
| Kasahara, Y | 1 |
| Ouchi, K | 1 |
| Imai, H | 1 |
| Saijo, K | 2 |
| Shirota, H | 1 |
| Ishioka, C | 2 |
| Okumura, S | 1 |
| Goumard, C | 1 |
| Gayet, B | 2 |
| Fuks, D | 1 |
| Scatton, O | 1 |
| Karthika, C | 1 |
| Sureshkumar, R | 1 |
| Jia, AY | 1 |
| Narang, A | 1 |
| Safar, B | 1 |
| Zaheer, A | 1 |
| Murphy, A | 1 |
| Azad, NS | 1 |
| Gearhart, S | 1 |
| Fang, S | 1 |
| Efron, J | 1 |
| Warczynski, T | 1 |
| Hacker-Prietz, A | 2 |
| Meyer, J | 1 |
| Manceau, G | 1 |
| Margot, N | 1 |
| Augustin, J | 1 |
| Bardier, A | 1 |
| Simon, JM | 1 |
| Bachet, JB | 8 |
| Spano, JP | 1 |
| Maingon, P | 5 |
| Vaillant, JC | 4 |
| Karoui, M | 3 |
| Nougaret, S | 1 |
| de Forges, H | 1 |
| Vargas, HA | 1 |
| Gallix, B | 1 |
| Gourgou, S | 2 |
| Rouanet, P | 1 |
| Kim, SM | 2 |
| An, JY | 4 |
| Byeon, SJ | 1 |
| Lee, J | 14 |
| Kim, KM | 4 |
| Choi, MG | 6 |
| Lee, JH | 18 |
| Sohn, TS | 9 |
| Bae, JM | 11 |
| Kim, S | 15 |
| Eba, S | 1 |
| Notsuda, H | 1 |
| Hoshi, F | 1 |
| Oishi, H | 2 |
| Matsuda, Y | 1 |
| Sado, T | 1 |
| Noda, M | 2 |
| Sakurada, A | 1 |
| Okoshi, A | 1 |
| Tanaka, N | 5 |
| Okada, Y | 1 |
| Chen, J | 6 |
| Yin, W | 1 |
| Yao, H | 1 |
| Gu, W | 1 |
| Kotaka, M | 3 |
| Shinozaki, K | 2 |
| Touyama, T | 2 |
| Matsui, T | 6 |
| Ishigure, K | 1 |
| Inoue, K | 5 |
| Munemoto, Y | 4 |
| Takagane, A | 3 |
| Ishikawa, H | 1 |
| Ishida, H | 2 |
| Ogata, Y | 3 |
| Oba, K | 9 |
| Goto, K | 1 |
| Maehara, Y | 9 |
| Ohtsu, A | 12 |
| Rodriguez-Galindo, C | 1 |
| Krailo, MD | 1 |
| Krasin, MJ | 1 |
| Huang, L | 2 |
| McCarville, MB | 1 |
| Hicks, J | 1 |
| Pashankar, F | 1 |
| Pappo, AS | 1 |
| Martin Huertas, R | 1 |
| Fernández Abad, M | 1 |
| Corral de la Fuente, E | 1 |
| Serrano Domingo, JJ | 1 |
| Martínez Jáñez, N | 1 |
| Sparano, JA | 1 |
| Gray, RJ | 1 |
| Makower, DF | 1 |
| Albain, KS | 1 |
| Saphner, TJ | 1 |
| Badve, SS | 1 |
| Wagner, LI | 1 |
| Kaklamani, VG | 1 |
| Keane, MM | 1 |
| Gomez, HL | 1 |
| Reddy, PS | 1 |
| Goggins, TF | 1 |
| Mayer, IA | 1 |
| Toppmeyer, DL | 1 |
| Brufsky, AM | 1 |
| Goetz, MP | 1 |
| Berenberg, JL | 2 |
| Mahalcioiu, C | 1 |
| Desbiens, C | 1 |
| Hayes, DF | 1 |
| Dees, EC | 1 |
| Geyer, CE | 4 |
| Olson, JA | 1 |
| Wood, WC | 1 |
| Lively, T | 1 |
| Paik, S | 3 |
| Ellis, MJ | 1 |
| Abrams, J | 2 |
| Sledge, GW | 2 |
| Yamadera, M | 1 |
| Shinto, E | 1 |
| Kajiwara, Y | 1 |
| Mochizuki, S | 1 |
| Hase, K | 1 |
| Yamamoto, J | 1 |
| Ueno, H | 3 |
| Rivin Del Campo, E | 2 |
| Matzinger, O | 1 |
| Haustermans, K | 2 |
| Peiffert, D | 3 |
| Glynne-Jones, R | 11 |
| Winter, KA | 4 |
| Konski, AA | 2 |
| Ajani, JA | 10 |
| Bosset, JF | 7 |
| Hannoun-Levi, JM | 2 |
| Puyraveau, M | 2 |
| Chakravarthy, AB | 1 |
| Meadows, H | 2 |
| Northover, J | 1 |
| Collette, L | 2 |
| Christiaens, M | 1 |
| Sano, M | 2 |
| Imaizumi, R | 1 |
| Maeda, H | 3 |
| Ida, A | 1 |
| Yamada, Y | 5 |
| Katsube, T | 1 |
| Sawazaki, S | 1 |
| Numata, M | 1 |
| Ju, M | 1 |
| Morita, J | 1 |
| Komori, K | 1 |
| Maezawa, Y | 1 |
| Amano, S | 1 |
| Aoyama, T | 2 |
| Tamagawa, H | 2 |
| Sato, T | 5 |
| Oshima, T | 1 |
| Mushiake, H | 1 |
| Yukawa, N | 1 |
| Masuda, M | 2 |
| Rino, Y | 2 |
| Elliott, SL | 1 |
| Kose, E | 1 |
| Lewis, AL | 1 |
| Steinfeld, AE | 1 |
| Zollinger, EA | 1 |
| Chikhladze, S | 1 |
| Lederer, AK | 1 |
| Kousoulas, L | 1 |
| Reinmuth, M | 1 |
| Sick, O | 1 |
| Fichtner-Feigl, S | 1 |
| Wittel, UA | 1 |
| Fernando, IN | 1 |
| Bowden, SJ | 1 |
| Herring, K | 1 |
| Brookes, CL | 1 |
| Ahmed, I | 1 |
| Marshall, A | 1 |
| Grieve, R | 1 |
| Churn, M | 1 |
| Spooner, D | 2 |
| Latief, TN | 1 |
| Agrawal, RK | 1 |
| Brunt, AM | 1 |
| Stevens, A | 1 |
| Goodman, A | 1 |
| Canney, P | 2 |
| Bishop, J | 1 |
| Ritchie, D | 1 |
| Dunn, J | 1 |
| Poole, CJ | 2 |
| Rea, DW | 2 |
| de Meric de Bellefon, M | 1 |
| Lemanski, C | 3 |
| Samalin, E | 5 |
| Mazard, T | 1 |
| Lenglet, A | 1 |
| Demontoy, S | 1 |
| Riou, O | 1 |
| Llacer-Moscardo, C | 1 |
| Fenoglietto, P | 2 |
| Aillères, N | 1 |
| Thezenas, S | 1 |
| Debrigode, C | 1 |
| Vieillot, S | 2 |
| Azria, D | 6 |
| Alwers, E | 1 |
| Jansen, L | 1 |
| Bläker, H | 1 |
| Kloor, M | 2 |
| Tagscherer, KE | 1 |
| Roth, W | 1 |
| Boakye, D | 1 |
| Herpel, E | 1 |
| Grüllich, C | 1 |
| Chang-Claude, J | 1 |
| Brenner, H | 1 |
| Hoffmeister, M | 1 |
| Abdel Raouf, SM | 1 |
| Ibrahim, TR | 1 |
| Abdelaziz, LA | 2 |
| Farid, MI | 1 |
| Mohamed, SY | 1 |
| Akiyoshi, T | 2 |
| Toda, S | 1 |
| Tomizawa, K | 1 |
| Hanaoka, Y | 1 |
| Nagasaki, T | 2 |
| Konishi, T | 5 |
| Matoba, S | 1 |
| Fukunaga, Y | 2 |
| Ueno, M | 3 |
| Kuroyanagi, H | 1 |
| Shao, YW | 1 |
| Tong, X | 1 |
| Wu, X | 4 |
| Pang, J | 1 |
| Feng, A | 1 |
| Yang, Z | 4 |
| Lu, W | 2 |
| Fu, D | 1 |
| Kong, X | 1 |
| Huang, Z | 1 |
| Hwang, M | 1 |
| Zhu, Y | 3 |
| Jiang, K | 1 |
| Wu, Y | 1 |
| Yuan, Y | 1 |
| Ding, K | 1 |
| Randrian, V | 1 |
| Adenis, A | 3 |
| Desrame, J | 3 |
| Barbier, E | 3 |
| Di Fiore, F | 4 |
| Lièvre, A | 3 |
| Dahan, L | 3 |
| Laurent-Puig, P | 4 |
| Mineur, L | 1 |
| Breysacher, G | 1 |
| Roquin, G | 1 |
| Louafi, S | 1 |
| Louvet, C | 3 |
| Borg, C | 7 |
| Metges, JP | 1 |
| Faroux, R | 2 |
| Gaba, L | 1 |
| Manfredi, S | 2 |
| Tougeron, D | 5 |
| Rosati, G | 7 |
| Galli, F | 5 |
| Cantore, M | 4 |
| Bergamo, F | 2 |
| Banzi, M | 5 |
| Zampino, MG | 5 |
| Mattioli, R | 2 |
| Cardellino, GG | 2 |
| Ronzoni, M | 5 |
| Di Bartolomeo, M | 3 |
| Tamberi, S | 1 |
| Marchetti, P | 5 |
| Rimassa, L | 5 |
| Corsi, D | 3 |
| Bochicchio, AM | 2 |
| Artioli, F | 1 |
| Labianca, R | 11 |
| Rulli, E | 4 |
| Bilancia, D | 3 |
| Bregni, G | 1 |
| de Boo, L | 1 |
| Cimino-Mathews, A | 1 |
| Lubeck, Y | 1 |
| Daletzakis, A | 1 |
| Opdam, M | 1 |
| Sanders, J | 1 |
| Hooijberg, E | 1 |
| van Rossum, A | 1 |
| Loncova, Z | 1 |
| Rieder, D | 1 |
| Trajanoski, Z | 1 |
| Vollebergh, M | 1 |
| Sobral-Leite, M | 1 |
| van de Vijver, K | 1 |
| Broeks, A | 1 |
| van der Wiel, R | 1 |
| van Tinteren, H | 3 |
| Linn, S | 1 |
| Horlings, HM | 1 |
| Kok, M | 1 |
| Barbour, AP | 2 |
| Walpole, ET | 3 |
| Mai, GT | 1 |
| Barnes, EH | 1 |
| Watson, DI | 1 |
| Ackland, SP | 2 |
| Martin, JM | 1 |
| Finch, R | 1 |
| Karapetis, CS | 2 |
| Shannon, J | 2 |
| Nott, LM | 1 |
| Varma, S | 1 |
| Marx, G | 2 |
| Falk, GL | 2 |
| Gebski, V | 1 |
| Oostendorp, M | 1 |
| Wilson, K | 1 |
| Thomas, J | 2 |
| Lampe, G | 1 |
| Zalcberg, JR | 2 |
| Simes, J | 1 |
| Smithers, BM | 4 |
| Chirovsky, D | 2 |
| Bertolini, F | 1 |
| Ahn, MJ | 1 |
| Yang, MH | 3 |
| Castro, G | 1 |
| Berrocal, A | 1 |
| Sjoquist, K | 1 |
| Kuyas, H | 1 |
| Auclair, V | 1 |
| Guillaume, X | 1 |
| Joo, S | 2 |
| Shah, R | 1 |
| Harrington, K | 1 |
| Petrelli, F | 2 |
| Lonardi, S | 8 |
| Corallo, S | 1 |
| Mambrini, A | 3 |
| Ciuffreda, L | 5 |
| Pusceddu, V | 3 |
| Maiello, E | 3 |
| Zampino, M | 1 |
| Zagonel, V | 3 |
| Cinieri, S | 1 |
| Sobrero, A | 4 |
| Hasegawa, H | 3 |
| Kaneko, T | 2 |
| Kanno, C | 1 |
| Endo, M | 3 |
| Yamazaki, M | 1 |
| Kitabatake, T | 1 |
| Monma, T | 1 |
| Takeishi, E | 1 |
| Sato, E | 1 |
| Kano, M | 1 |
| Kobayashi, K | 9 |
| Ito, S | 4 |
| Torashima, Y | 3 |
| Okada, S | 2 |
| Enjoji, T | 1 |
| Tetsuo, H | 1 |
| Kuba, S | 2 |
| Kosaka, T | 4 |
| Adachi, T | 2 |
| Hidaka, M | 2 |
| Yamanouchi, K | 1 |
| Kanetaka, K | 3 |
| Takatsuki, M | 3 |
| Eguchi, S | 4 |
| Nishibeppu, K | 1 |
| Komatsu, S | 2 |
| Imamura, T | 1 |
| Kiuchi, J | 2 |
| Arita, T | 2 |
| Kosuga, T | 1 |
| Konishi, H | 2 |
| Kubota, T | 3 |
| Shiozaki, A | 3 |
| Otsuji, E | 4 |
| Salem, ME | 1 |
| Yin, J | 1 |
| Goldberg, RM | 12 |
| Pederson, LD | 1 |
| Wolmark, N | 12 |
| Alberts, SR | 9 |
| Taieb, J | 12 |
| Marshall, JL | 1 |
| Kerr, RS | 1 |
| Yothers, G | 11 |
| Grothey, A | 5 |
| Andre, T | 14 |
| De Gramont, A | 4 |
| Chen, Q | 1 |
| Gao, P | 1 |
| Song, Y | 1 |
| Huang, X | 4 |
| Xiao, Q | 1 |
| Wang, Z | 2 |
| Nemoto, T | 2 |
| Isohata, N | 2 |
| Takayanagi, D | 2 |
| Nemoto, D | 2 |
| Aizawa, M | 2 |
| Utano, K | 2 |
| Togashi, K | 2 |
| Oshibe, I | 2 |
| Soeta, N | 2 |
| Saito, T | 4 |
| Yoshida, S | 5 |
| Suzuki, N | 1 |
| Takahashi, T | 9 |
| Tokuno, K | 1 |
| Harada, E | 1 |
| Hamano, K | 3 |
| Nagano, H | 2 |
| Hayashi, Y | 1 |
| Nakatsuka, R | 1 |
| Miyazaki, S | 4 |
| Komori, T | 2 |
| Iwase, K | 1 |
| Qiu, S | 1 |
| He, J | 3 |
| Peng, Y | 1 |
| Feng, Z | 1 |
| Huang, H | 2 |
| Du, Y | 1 |
| Zhou, Y | 2 |
| Nie, Y | 2 |
| Keum, J | 1 |
| Lee, HS | 2 |
| Kang, H | 1 |
| Jo, JH | 1 |
| Chung, MJ | 2 |
| Park, JY | 2 |
| Park, SW | 1 |
| Song, SY | 3 |
| Bang, S | 1 |
| Voogt, ELK | 1 |
| van Zoggel, DMGI | 1 |
| Kusters, M | 1 |
| Nieuwenhuijzen, GAP | 1 |
| Bloemen, JG | 1 |
| Peulen, HMU | 1 |
| Creemers, GJM | 1 |
| van Lijnschoten, G | 1 |
| Nederend, J | 1 |
| Roef, MJ | 1 |
| Burger, JWA | 1 |
| Rutten, HJT | 2 |
| Choi, YH | 2 |
| Lee, SH | 5 |
| You, MS | 1 |
| Shin, BS | 1 |
| Paik, WH | 2 |
| Ryu, JK | 2 |
| Kim, YT | 2 |
| Kwon, W | 2 |
| Jang, JY | 7 |
| Kim, SW | 7 |
| Buecher, B | 2 |
| Jary, M | 3 |
| Bidard, FC | 3 |
| Ghiringhelli, F | 2 |
| François, É | 4 |
| Smith, D | 2 |
| de la Fouchardière, C | 3 |
| Parzy, A | 2 |
| Baba-Hamed, N | 2 |
| El Hajbi, F | 3 |
| Jacquin, M | 2 |
| Rebucci-Peixoto, M | 1 |
| Spehner, L | 2 |
| Vendrely, V | 4 |
| Vernerey, D | 3 |
| Ma, WJ | 1 |
| Jin, YW | 1 |
| Wu, ZR | 1 |
| Wang, JK | 1 |
| Liu, F | 2 |
| Shi, YJ | 1 |
| Li, QS | 2 |
| Cheng, NS | 1 |
| Kim, SA | 1 |
| Suh, KJ | 1 |
| Chang, W | 2 |
| Oh, HK | 1 |
| Cho, JY | 4 |
| Kim, DW | 2 |
| Cho, S | 2 |
| Kim, JH | 22 |
| Kim, K | 12 |
| Kang, SB | 3 |
| Jheon, S | 1 |
| Okuno, M | 1 |
| Hatano, E | 1 |
| Toda, R | 1 |
| Nishino, H | 5 |
| Nakamura, K | 4 |
| Ishii, T | 2 |
| Seo, S | 1 |
| Taura, K | 1 |
| Yasuchika, K | 1 |
| Yazawa, T | 1 |
| Zaima, M | 1 |
| Terajima, H | 1 |
| Kaihara, S | 1 |
| Adachi, Y | 2 |
| Inoue, N | 3 |
| Furumoto, K | 1 |
| Tokuka, A | 1 |
| Furuyama, H | 1 |
| Doi, K | 2 |
| Hirose, T | 1 |
| Matsumoto, S | 4 |
| Uemoto, S | 1 |
| Nara, A | 1 |
| Udagawa, M | 1 |
| Onishi, I | 1 |
| Sueyoshi, K | 1 |
| Gokita, K | 1 |
| Watanabe, Y | 4 |
| Adikrisna, R | 1 |
| Roseweir, AK | 1 |
| Hoorn, ST | 1 |
| Powell, AG | 1 |
| Aherne, S | 1 |
| Roxburgh, CS | 1 |
| McMillan, DC | 1 |
| Horgan, PG | 1 |
| Ryan, E | 1 |
| Sheahan, K | 1 |
| Paul, J | 4 |
| Harkin, A | 1 |
| Graham, J | 2 |
| Sansom, O | 1 |
| Church, DN | 1 |
| Tomlinson, I | 1 |
| Saunders, M | 3 |
| Iveson, TJ | 2 |
| Edwards, J | 1 |
| Iwamoto, S | 2 |
| Satake, H | 2 |
| Kudo, T | 1 |
| Fukunaga, M | 3 |
| Konishi, K | 2 |
| Ikumoto, T | 1 |
| Tsuji, A | 3 |
| Sano, Y | 1 |
| Sugimoto, N | 3 |
| Kurata, T | 1 |
| Yamanaka, T | 2 |
| Brouquet, A | 2 |
| Huguet, F | 6 |
| Sabbagh, C | 2 |
| Lefèvre, JH | 2 |
| Mariette, C | 3 |
| Vicaut, E | 1 |
| Benoist, S | 3 |
| Pederson, H | 1 |
| Staples, CJ | 1 |
| Housewright, C | 1 |
| Lee, AWM | 2 |
| Ngan, RKC | 2 |
| Ng, WT | 3 |
| Tung, SY | 3 |
| Cheng, AAC | 1 |
| Kwong, DLW | 2 |
| Lu, TX | 3 |
| Chan, ATC | 1 |
| Sze, HCK | 2 |
| Yiu, HHY | 2 |
| Wong, FCS | 1 |
| Yuen, KT | 3 |
| Chappell, R | 2 |
| Choi, HCW | 1 |
| Owen, D | 1 |
| Lukovic, J | 1 |
| Hosni, A | 1 |
| Crane, CH | 10 |
| Hong, TS | 4 |
| Dawson, LA | 1 |
| Velec, M | 1 |
| Lawrence, TS | 2 |
| Yoneda, A | 1 |
| Kobayashi, S | 4 |
| Maruya, Y | 1 |
| Isagawa, Y | 1 |
| Yoshimoto, T | 2 |
| Migita, K | 1 |
| Kawaguchi, Y | 4 |
| Morita, M | 5 |
| Bago-Horvath, Z | 1 |
| Rudas, M | 1 |
| Singer, CF | 2 |
| Greil, R | 5 |
| Balic, M | 1 |
| Lax, SF | 1 |
| Kwasny, W | 2 |
| Hulla, W | 1 |
| Gnant, M | 7 |
| Filipits, M | 1 |
| Sakr, A | 1 |
| Elsherbiny, M | 1 |
| Abdel Moneim, R | 1 |
| Shaaban, S | 1 |
| Aldaly, M | 1 |
| Erstad, DJ | 1 |
| Sojoodi, M | 1 |
| Taylor, MS | 1 |
| Jordan, VC | 2 |
| Farrar, CT | 1 |
| Axtell, AL | 1 |
| Rotile, NJ | 1 |
| Jones, C | 1 |
| Graham-O'Regan, KA | 1 |
| Ferreira, DS | 1 |
| Michelakos, T | 1 |
| Kontos, F | 1 |
| Chawla, A | 1 |
| Li, S | 2 |
| Ghoshal, S | 1 |
| Chen, YI | 1 |
| Arora, G | 1 |
| Humblet, V | 1 |
| Deshpande, V | 2 |
| Qadan, M | 1 |
| Bardeesy, N | 1 |
| Ferrone, CR | 3 |
| Lanuti, M | 1 |
| Tanabe, KK | 1 |
| Caravan, P | 1 |
| Fuchs, BC | 1 |
| Oguz, S | 1 |
| Kucukaslan, H | 1 |
| Topaloglu, S | 1 |
| Ones, T | 1 |
| Baltacioglu, F | 1 |
| Cobanoglu, U | 1 |
| Calik, A | 1 |
| Barnes, CA | 1 |
| Aldakkak, M | 1 |
| Christians, KK | 1 |
| Clarke, CN | 1 |
| Dua, K | 1 |
| George, B | 1 |
| Ritch, PS | 1 |
| Kamgar, M | 1 |
| Hall, WA | 2 |
| Kulkarni, N | 1 |
| Erickson, BA | 1 |
| Evans, DB | 3 |
| Tsai, S | 1 |
| Diefenhardt, M | 1 |
| Hofheinz, RD | 7 |
| Ghadimi, M | 4 |
| Rödel, C | 10 |
| Fokas, E | 3 |
| El Sissy, C | 1 |
| Kirilovsky, A | 1 |
| Van den Eynde, M | 1 |
| Muşină, AM | 1 |
| Anitei, MG | 1 |
| Romero, A | 1 |
| Marliot, F | 1 |
| Junca, A | 1 |
| Doyen, J | 1 |
| Mlecnik, B | 1 |
| Haicheur, N | 1 |
| Fredriksen, T | 1 |
| Lagorce, C | 1 |
| Jouret-Mourin, A | 1 |
| Leonard, D | 1 |
| Bibeau, F | 4 |
| Iseas, S | 2 |
| Roca, EL | 1 |
| Cabanne, AM | 1 |
| Vaccaro, CA | 1 |
| Santino, JP | 1 |
| Huertas, E | 2 |
| Carvalho, C | 1 |
| Figueiredo, N | 1 |
| Perez, RO | 9 |
| Habr-Gama, A | 10 |
| Scripcariu, V | 1 |
| Gerard, JP | 2 |
| Galon, J | 1 |
| Zeitoun, G | 1 |
| Pagès, F | 1 |
| Ye, W | 1 |
| Shi, L | 3 |
| Qian, L | 1 |
| Sun, Y | 6 |
| Sun, X | 1 |
| Groehs, RV | 1 |
| Negrao, MV | 1 |
| Hajjar, LA | 1 |
| Jordão, CP | 1 |
| Carvalho, BP | 1 |
| Toschi-Dias, E | 1 |
| Andrade, AC | 1 |
| Hodas, FP | 1 |
| Alves, MJNN | 1 |
| Sarmento, AO | 1 |
| Testa, L | 1 |
| Hoff, PMG | 1 |
| Negrao, CE | 1 |
| Filho, RK | 1 |
| Voskuilen, CS | 1 |
| van de Kamp, MW | 1 |
| Schuring, N | 1 |
| Mertens, LS | 1 |
| Noordzij, A | 1 |
| Pos, F | 1 |
| van Rhijn, BWG | 1 |
| van der Heijden, MS | 1 |
| Schaake, EE | 1 |
| Hӧllhumer, R | 2 |
| Williams, S | 2 |
| Michelow, P | 2 |
| Chong, WQ | 1 |
| Lim, CM | 1 |
| Sinha, AK | 1 |
| Tan, CS | 2 |
| Chan, GHJ | 1 |
| Kumarakulasinghe, NB | 1 |
| Sundar, R | 1 |
| Jeyasekharan, AD | 1 |
| Loh, WS | 1 |
| Tay, JK | 1 |
| Yadav, K | 1 |
| Wong, AL | 1 |
| Kong, LR | 1 |
| Soo, RA | 1 |
| Lau, JA | 1 |
| Soon, YY | 2 |
| Goh, RM | 1 |
| Ho, FCH | 1 |
| Chong, SM | 1 |
| Lee, SC | 2 |
| Loh, KS | 1 |
| Tai, BC | 1 |
| Lim, YC | 1 |
| Goh, BC | 1 |
| Choi, YJ | 3 |
| Byun, Y | 1 |
| Kang, JS | 1 |
| Kim, HS | 5 |
| Han, Y | 1 |
| Kim, H | 9 |
| Oh, DY | 11 |
| Lee, K | 2 |
| Chie, EK | 7 |
| Huang, CW | 4 |
| Ma, CJ | 3 |
| Su, WC | 1 |
| Chen, YT | 1 |
| Tsai, HL | 4 |
| Yeh, YS | 3 |
| Chang, TK | 1 |
| Hsu, WH | 2 |
| Yu, FJ | 1 |
| Wang, JY | 8 |
| Caminiti, MF | 1 |
| El-Rabbany, M | 1 |
| Jeon, J | 1 |
| Bradley, G | 1 |
| Nýdlová, A | 1 |
| Drbohlavová, T | 1 |
| Mazaná, E | 1 |
| Jirkovská, M | 1 |
| Veselský, T | 1 |
| Malinová, B | 1 |
| Stankušová, H | 1 |
| Zech, HB | 1 |
| Moeckelmann, N | 1 |
| Boettcher, A | 1 |
| Muenscher, A | 1 |
| Binder, M | 1 |
| Vettorazzi, E | 1 |
| Bokemeyer, C | 4 |
| Schafhausen, P | 1 |
| Betz, CS | 1 |
| Busch, CJ | 1 |
| Shi, X | 2 |
| Cheng, Y | 4 |
| Wang, J | 15 |
| Chen, H | 4 |
| Tan, W | 1 |
| Tan, Z | 1 |
| Ishibe, A | 1 |
| Watanabe, J | 1 |
| Suwa, Y | 1 |
| Nakagawa, K | 6 |
| Suwa, H | 1 |
| Misumi, T | 1 |
| Ota, M | 3 |
| Endo, I | 2 |
| Kobayashi, N | 2 |
| Omae, K | 1 |
| Mizuno, N | 1 |
| Uesugi, K | 1 |
| Sudo, K | 1 |
| Ozaka, M | 2 |
| Okano, N | 1 |
| Kamei, K | 1 |
| Yamaguchi, A | 1 |
| Suzuki, S | 4 |
| Ishihara, S | 4 |
| Uchiyama, T | 1 |
| Todaka, A | 1 |
| Fukutomi, A | 2 |
| Srouji, RM | 1 |
| Narayan, RR | 1 |
| Boerner, T | 1 |
| Buisman, FE | 1 |
| Seier, K | 1 |
| Gonen, M | 3 |
| Balachandran, VP | 1 |
| Drebin, JA | 1 |
| Jarnagin, WR | 1 |
| Kingham, TP | 1 |
| Wei, A | 1 |
| Kemeny, NE | 5 |
| D'Angelica, MI | 1 |
| Koizumi, M | 1 |
| Shinji, S | 1 |
| Yokoyama, Y | 2 |
| Takahashi, G | 2 |
| Iwai, T | 1 |
| Hara, K | 3 |
| Rossini, D | 1 |
| Antoniotti, C | 1 |
| Santini, D | 1 |
| Tomasello, G | 1 |
| Ermacora, P | 1 |
| Germani, MM | 1 |
| Ricci, V | 1 |
| Caponnetto, S | 1 |
| Moretto, R | 2 |
| Pietrantonio, F | 2 |
| Buonadonna, A | 1 |
| Ritorto, G | 1 |
| Masi, G | 2 |
| Latiano, TP | 1 |
| Rapisardi, S | 1 |
| Falcone, A | 5 |
| Cremolini, C | 1 |
| Ng, SP | 1 |
| Chu, J | 1 |
| Chander, S | 1 |
| Bressel, M | 1 |
| McKendrick, J | 3 |
| Steel, M | 1 |
| Murray, WK | 1 |
| Leong, T | 2 |
| Heriot, A | 1 |
| Michael, M | 1 |
| Ngan, SY | 3 |
| Yin, L | 1 |
| Pu, N | 1 |
| Thompson, E | 1 |
| Miao, Y | 1 |
| Wolfgang, C | 1 |
| Yu, J | 2 |
| Dotti, K | 1 |
| Pella, N | 1 |
| Yasmina, M | 1 |
| Ferrari, D | 3 |
| Voß, H | 1 |
| Wurlitzer, M | 1 |
| Smit, DJ | 1 |
| Ewald, F | 1 |
| Alawi, M | 1 |
| Spohn, M | 1 |
| Indenbirken, D | 1 |
| Omidi, M | 1 |
| David, K | 1 |
| Juhl, H | 1 |
| Simon, R | 1 |
| Sauter, G | 1 |
| Fischer, L | 1 |
| Izbicki, JR | 2 |
| Molloy, MP | 1 |
| Nashan, B | 1 |
| Schlüter, H | 1 |
| Jücker, M | 1 |
| Beypinar, I | 1 |
| Demir, H | 1 |
| Araz, M | 1 |
| Baykara, M | 1 |
| Aykan, NF | 1 |
| Park, SJ | 4 |
| Joo, I | 1 |
| Lee, KB | 1 |
| Han, JK | 1 |
| Nassar, A | 1 |
| Phelip, JM | 1 |
| Goéré, D | 2 |
| Loriau, J | 1 |
| Gallois, C | 3 |
| Michel, P | 3 |
| Penna, C | 1 |
| Garant, A | 1 |
| Kavan, P | 1 |
| Martin, AG | 1 |
| Azoulay, L | 1 |
| Lavoie, C | 1 |
| Vasilevsky, CA | 1 |
| Boutros, M | 1 |
| Faria, J | 1 |
| Nguyen, TN | 1 |
| Ferland, E | 1 |
| Des Groseilliers, S | 1 |
| Cloutier, AS | 1 |
| Diec, H | 1 |
| Drolet, S | 1 |
| Richard, C | 1 |
| Batist, G | 1 |
| Vuong, T | 2 |
| Ohno, S | 4 |
| Saji, S | 6 |
| Masuda, N | 2 |
| Tsuda, H | 1 |
| Akiyama, F | 1 |
| Kurosumi, M | 1 |
| Shimomura, A | 1 |
| Sato, N | 4 |
| Takao, S | 1 |
| Ohsumi, S | 1 |
| Tokuda, Y | 2 |
| Inaji, H | 1 |
| Ohashi, Y | 8 |
| Park, SH | 14 |
| Lim, DH | 7 |
| Kim, ST | 4 |
| Kang, JH | 4 |
| Oh, SY | 5 |
| Hwang, IG | 2 |
| Ji, JH | 2 |
| Shin, DB | 4 |
| Yu, JI | 1 |
| Hong, JY | 1 |
| Park, JO | 13 |
| Park, YS | 11 |
| Lim, HY | 7 |
| Kang, WK | 14 |
| Ouali, K | 1 |
| Neuzillet, C | 1 |
| Rousseau, B | 1 |
| Garcia-Larnicol, ML | 1 |
| Tournigand, C | 2 |
| Cohen, R | 1 |
| Shim, HJ | 2 |
| Kim, HJ | 9 |
| Hwang, JE | 1 |
| Bae, WK | 1 |
| Chung, IJ | 2 |
| Lee, DH | 1 |
| Mi, YT | 1 |
| Lee, JK | 2 |
| Lim, SC | 1 |
| Chung, JW | 1 |
| Cho, SH | 4 |
| Fukuda, N | 1 |
| Yunokawa, M | 1 |
| Ohmoto, A | 1 |
| Hayashi, N | 2 |
| Urasaki, T | 1 |
| Nakano, K | 2 |
| Ono, M | 2 |
| Tomomatsu, J | 1 |
| Mitani, H | 2 |
| Schmocker, RK | 1 |
| Delitto, D | 1 |
| Wright, MJ | 1 |
| Ding, D | 1 |
| Cameron, JL | 5 |
| Lafaro, KJ | 1 |
| Burns, WR | 1 |
| Wolfgang, CL | 4 |
| Burkhart, RA | 1 |
| Cabel, L | 1 |
| Ii, T | 1 |
| Rikiyama, N | 1 |
| Noguchi, A | 1 |
| Aoki, Y | 1 |
| Sato, J | 1 |
| Kikuchi, D | 1 |
| Yamanami, H | 1 |
| Kaizaki, R | 1 |
| Inoue, T | 5 |
| Nishiyama, T | 1 |
| Nobori, C | 1 |
| Kunimoto, T | 1 |
| Okazaki, Y | 1 |
| Takatsuka, S | 1 |
| Tsukamoto, T | 1 |
| Nishiguchi, Y | 1 |
| Iwamoto, K | 1 |
| Ohtsuka, M | 2 |
| Imasato, M | 1 |
| Inui, M | 1 |
| Zenitani, S | 1 |
| Wada, R | 1 |
| Nakahara, Y | 1 |
| Furukawa, K | 1 |
| Moon, J | 2 |
| Asaoka, T | 1 |
| Kishi, K | 2 |
| Akamatsu, H | 1 |
| Shimizu, H | 3 |
| Kuriu, Y | 2 |
| Yamamoto, Y | 9 |
| Morimura, R | 1 |
| Ikoma, H | 2 |
| Song, SH | 1 |
| Park, JS | 3 |
| Kang, MK | 3 |
| Choi, GS | 2 |
| Park, SY | 1 |
| Kim, JG | 3 |
| Kang, BW | 2 |
| Baek, JH | 4 |
| Baek, DW | 1 |
| Kim, JC | 12 |
| Seo, AN | 1 |
| Zou, J | 2 |
| Li, Z | 4 |
| Piessen, G | 1 |
| Legoux, JL | 1 |
| De Chaisemartin, C | 2 |
| Lecaille, C | 3 |
| Ammarguellat, H | 1 |
| Brunetti, F | 1 |
| Prudhomme, M | 1 |
| Regimbeau, JM | 1 |
| Glehen, O | 1 |
| Portier, G | 1 |
| Hartwig, J | 1 |
| Goujon, G | 1 |
| Romain, B | 1 |
| Lepage, C | 2 |
| Idasiak, A | 1 |
| Galwas-Kliber, K | 1 |
| Rajczykowski, M | 1 |
| Dębosz-Suwińska, I | 1 |
| Zeman, M | 1 |
| Stobiecka, E | 1 |
| Mrochem-Kwarciak, J | 1 |
| Suwiński, R | 2 |
| Choi, S | 1 |
| Oh, Y | 1 |
| Roh, MR | 1 |
| Chung, KY | 1 |
| Oh, BH | 1 |
| Zhu, H | 1 |
| Ye, J | 1 |
| Simone, CB | 1 |
| Zhu, Z | 1 |
| Zhao, W | 2 |
| Amini, A | 1 |
| Zhou, J | 5 |
| Wu, C | 3 |
| Tang, H | 2 |
| Fan, M | 1 |
| Li, L | 2 |
| Lin, Q | 1 |
| Xia, Y | 3 |
| Li, Y | 6 |
| Mo, M | 1 |
| Jia, H | 1 |
| Lu, S | 1 |
| Wu, S | 2 |
| Hamaji, M | 1 |
| Haque, W | 1 |
| Jeong, BK | 2 |
| Shridhar, R | 1 |
| Zhang, Z | 2 |
| Zhao, K | 2 |
| Nahm, WJ | 1 |
| Shen, J | 1 |
| Zito, PM | 1 |
| Gonzalez, AM | 1 |
| Nagrani, N | 1 |
| Moore, K | 1 |
| Badiavas, EV | 1 |
| Kirsner, RS | 1 |
| Nichols, AJ | 1 |
| Gottlieb, S | 1 |
| O'Grady, C | 1 |
| Gliksberg, A | 1 |
| Kent, P | 1 |
| Pasini, F | 2 |
| Bozzarelli, S | 2 |
| Garattini, SK | 1 |
| Carlomagno, C | 3 |
| Bidoli, P | 2 |
| Amoroso, D | 2 |
| Frassineti, L | 1 |
| Pastorino, A | 1 |
| De Stefano, A | 3 |
| Mitachi, K | 2 |
| Ariake, K | 2 |
| Shima, H | 1 |
| Sato, S | 3 |
| Miura, T | 5 |
| Ishida, M | 1 |
| Mizuma, M | 2 |
| Ohtsuka, H | 2 |
| Igarashi, K | 2 |
| Kurokawa, T | 3 |
| Kanemoto, Y | 1 |
| Azuma, Y | 1 |
| Iimura, Y | 1 |
| Kuroda, S | 1 |
| Yazawa, K | 2 |
| Tsurita, G | 1 |
| Akabane, S | 1 |
| Shimizu, W | 1 |
| Takakura, Y | 1 |
| Kochi, M | 3 |
| Taguchi, K | 2 |
| Nakashima, I | 1 |
| Sato, K | 3 |
| Egi, H | 1 |
| Sentani, K | 1 |
| Yasui, W | 1 |
| Ohdan, H | 1 |
| Pontes, F | 1 |
| Garcia, AR | 1 |
| Domingues, I | 1 |
| João Sousa, M | 1 |
| Felix, R | 5 |
| Amorim, C | 1 |
| Salgueiro, F | 1 |
| Mariano, M | 1 |
| Teixeira, M | 1 |
| Mie, T | 1 |
| Sasaki, T | 7 |
| Takeda, T | 1 |
| Fukuda, K | 3 |
| Furukawa, T | 1 |
| Kasuga, A | 1 |
| Matsuyama, M | 1 |
| Sasahira, N | 1 |
| Tao, HY | 1 |
| Zhan, ZJ | 1 |
| Qiu, WZ | 2 |
| Liao, K | 1 |
| Yuan, YW | 1 |
| Zheng, RH | 1 |
| Chen, PH | 1 |
| Wu, YY | 1 |
| Lee, CH | 1 |
| Chung, CH | 1 |
| Chen, YG | 1 |
| Huang, TC | 1 |
| Yeh, RH | 1 |
| Chang, PY | 1 |
| Dai, MS | 1 |
| Lai, SW | 1 |
| Ho, CL | 1 |
| Chen, JH | 1 |
| Chen, YC | 1 |
| Hu, JM | 1 |
| Yang, SS | 2 |
| Chien, WC | 1 |
| Fujisawa, A | 1 |
| Takahara, H | 1 |
| Kondo, Y | 1 |
| Akagami, M | 1 |
| Yokoyama, T | 1 |
| Takahara, N | 1 |
| Chevalier, T | 1 |
| Daste, A | 1 |
| Loundou, A | 1 |
| Peyraud, F | 1 |
| Lambert, T | 1 |
| Dupuis, C | 1 |
| Alfonsi, M | 1 |
| Fayette, J | 4 |
| Reure, J | 1 |
| Fakhry, N | 1 |
| Toullec, C | 1 |
| Salas, S | 1 |
| Mas, L | 1 |
| Meirovitz, A | 1 |
| Bergerson, S | 1 |
| Hirshoren, N | 1 |
| Weinberger, JM | 1 |
| Bersudski, E | 1 |
| Daniel, S | 1 |
| Sheva, K | 1 |
| Perez, CA | 3 |
| Rahma, OE | 1 |
| Russell, MM | 1 |
| Parker, W | 1 |
| Jacobs, SA | 2 |
| Colangelo, LH | 1 |
| Lucas, PC | 1 |
| Kachnic, LA | 1 |
| Vijayvergia, N | 1 |
| O'Rourke, MA | 2 |
| Faller, BA | 1 |
| Valicenti, RK | 1 |
| Schefter, TE | 1 |
| George, S | 1 |
| Kainthla, R | 1 |
| Stella, PJ | 2 |
| Sigurdson, E | 1 |
| Bennardo, L | 1 |
| Bennardo, F | 1 |
| Giudice, A | 1 |
| Passante, M | 1 |
| Dastoli, S | 1 |
| Morrone, P | 1 |
| Provenzano, E | 1 |
| Patruno, C | 1 |
| Nisticò, SP | 1 |
| Iqbal, MS | 1 |
| Kovarik, J | 1 |
| Patil, R | 1 |
| Kelly, CG | 1 |
| Menon, A | 1 |
| Abraham, AG | 1 |
| Mahfouz, M | 1 |
| Thachuthara, JJ | 1 |
| Usmani, N | 1 |
| Warkentin, H | 1 |
| Ghosh, S | 2 |
| Nijjar, T | 1 |
| Severin, D | 1 |
| Tankel, K | 1 |
| Paulson, K | 1 |
| Mulder, K | 1 |
| Roa, W | 1 |
| Joseph, K | 1 |
| Taha, HF | 1 |
| Harb, OA | 1 |
| Gertallah, LM | 1 |
| Chen, W | 4 |
| Dong, H | 1 |
| Wang, G | 1 |
| Wang, W | 3 |
| Kanai, M | 1 |
| Eto, T | 1 |
| Mizushima, T | 4 |
| Mori, M | 7 |
| Matsuda, F | 1 |
| Nakazawa, N | 1 |
| Sohda, M | 1 |
| Ide, M | 3 |
| Shimoda, Y | 1 |
| Ubukata, Y | 1 |
| Kuriyama, K | 1 |
| Sano, A | 1 |
| Sakai, M | 1 |
| Yokobori, T | 1 |
| Ogawa, H | 2 |
| Oyama, T | 2 |
| Shirabe, K | 2 |
| Saeki, H | 3 |
| Nilsson, MP | 1 |
| Johnsson, A | 4 |
| Scherman, J | 1 |
| Guo, Y | 4 |
| Shen, L | 3 |
| Feng, J | 2 |
| Ge, M | 1 |
| He, X | 1 |
| Bai, C | 1 |
| Xue, K | 1 |
| Zeng, Y | 1 |
| Chang, X | 1 |
| Lin, T | 1 |
| Makino, S | 1 |
| Takahashi, H | 4 |
| Ikenaga, M | 1 |
| Yamamoto, H | 5 |
| Doki, Y | 6 |
| Tanaka, T | 10 |
| Kiyomatsu, T | 1 |
| Hata, K | 1 |
| Nozawa, H | 2 |
| Burgy, M | 2 |
| Barthélémy, P | 1 |
| Lefevre, F | 1 |
| Dupret-Bories, A | 1 |
| Truntzer, P | 1 |
| Korenbaum, C | 1 |
| Flesch, H | 1 |
| Bronner, G | 1 |
| Borel, C | 3 |
| Sclafani, F | 3 |
| Brown, G | 5 |
| Cunningham, D | 11 |
| Rao, S | 1 |
| Tekkis, P | 2 |
| Tait, D | 4 |
| Morano, F | 1 |
| Baratelli, C | 1 |
| Kalaitzaki, E | 1 |
| Rasheed, S | 1 |
| Watkins, D | 1 |
| Starling, N | 1 |
| Wotherspoon, A | 3 |
| Chau, I | 7 |
| Antonios, A | 1 |
| Gharios, J | 1 |
| Tohme, C | 1 |
| Gillon, P | 1 |
| Touati, N | 1 |
| Breton-Callu, C | 1 |
| Slaets, L | 1 |
| Cameron, D | 1 |
| Bonnefoi, H | 1 |
| Baechmann, S | 1 |
| Ormanns, S | 1 |
| Haas, M | 1 |
| Kruger, S | 1 |
| Remold, A | 1 |
| Modest, DP | 2 |
| Kirchner, T | 2 |
| Jung, A | 1 |
| Werner, J | 2 |
| Heinemann, V | 6 |
| Boeck, S | 1 |
| Nakajima, Y | 4 |
| Tokairin, Y | 2 |
| Hoshino, A | 2 |
| Kawano, T | 3 |
| Coen, M | 1 |
| Rigamonti, F | 1 |
| Roth, A | 1 |
| Koessler, T | 1 |
| Sung, S | 1 |
| Kim, SH | 13 |
| Nam, TK | 4 |
| Jeong, S | 2 |
| Jang, HS | 3 |
| Song, JH | 2 |
| Lee, JW | 3 |
| Takayoshi, K | 1 |
| Kusaba, H | 2 |
| Uenomachi, M | 1 |
| Makiyama, C | 1 |
| Uchino, K | 1 |
| Shibata, Y | 2 |
| Inadomi, K | 1 |
| Tsuchihashi, K | 1 |
| Arita, S | 2 |
| Ariyama, H | 2 |
| Esaki, T | 3 |
| Akashi, K | 1 |
| Baba, E | 2 |
| Il Yu, J | 1 |
| Chul Park, H | 1 |
| Hoon Lim, D | 1 |
| Oh Park, J | 1 |
| Suk Park, Y | 1 |
| Tae Kim, S | 1 |
| Ho Choi, S | 1 |
| Wook Choi, D | 1 |
| Woong Han, I | 1 |
| Seok Heo, J | 1 |
| Magnes, T | 1 |
| Melchardt, T | 1 |
| Hufnagl, C | 1 |
| Weiss, L | 1 |
| Mittermair, C | 1 |
| Neureiter, D | 1 |
| Klieser, E | 1 |
| Rinnerthaler, G | 1 |
| Roesch, S | 1 |
| Gaggl, A | 1 |
| Egle, A | 1 |
| Urushibara, S | 1 |
| Tsubota, T | 1 |
| Asai, R | 1 |
| Azumi, J | 1 |
| Ashida, K | 1 |
| Shiota, G | 1 |
| Hutchins, GGA | 1 |
| Treanor, D | 1 |
| Wright, A | 1 |
| Handley, K | 1 |
| Magill, L | 1 |
| Tinkler-Hundal, E | 1 |
| Southward, K | 1 |
| Seymour, M | 1 |
| Kerr, D | 2 |
| Gray, R | 7 |
| Quirke, P | 1 |
| Voncken, FEM | 1 |
| van der Kaaij, RT | 1 |
| Sikorska, K | 1 |
| van Werkhoven, E | 1 |
| van Dieren, JM | 1 |
| Grootscholten, C | 1 |
| Snaebjornsson, P | 1 |
| van Sandick, JW | 2 |
| Aleman, BMP | 1 |
| Ohue, M | 3 |
| Kanemitsu, Y | 1 |
| Kobatake, T | 1 |
| Ito, M | 3 |
| Moriya, Y | 4 |
| Saito, N | 2 |
| Thavaneswaran, S | 1 |
| Kok, PS | 1 |
| Price, T | 2 |
| Vellayappan, BA | 1 |
| Ku, GY | 1 |
| Leong, CN | 2 |
| Lu, JJ | 3 |
| Tey, JC | 1 |
| Dumont, S | 1 |
| Pernot, S | 2 |
| Zoubir, M | 1 |
| Nguyen, T | 2 |
| Abdelghani, MB | 1 |
| Aparicio, T | 5 |
| Bennouna, J | 1 |
| Gornet, JM | 1 |
| Bonnetain, F | 3 |
| Markovina, S | 1 |
| Youssef, F | 1 |
| Roy, A | 1 |
| Aggarwal, S | 1 |
| Khwaja, S | 1 |
| DeWees, T | 1 |
| Tan, B | 1 |
| Hunt, S | 1 |
| Myerson, RJ | 3 |
| Chang, DT | 4 |
| Parikh, PJ | 1 |
| Olsen, JR | 1 |
| Kim, D | 1 |
| Park, M | 1 |
| Jang, H | 4 |
| Hyun, H | 1 |
| Lim, W | 1 |
| Jun, E | 1 |
| Kim, SC | 1 |
| Lee, CM | 1 |
| Oh, J | 1 |
| Lee, S | 4 |
| Shim, IK | 1 |
| Kim, HB | 1 |
| Park, SG | 1 |
| Fuchs, CS | 7 |
| Niedzwiecki, D | 5 |
| Tepper, JE | 4 |
| Ye, X | 1 |
| Swanson, RS | 1 |
| Enzinger, PC | 3 |
| Haller, DG | 16 |
| Dragovich, T | 2 |
| Bjarnason, GA | 2 |
| Willett, CG | 11 |
| Gunderson, LL | 11 |
| Ilson, D | 1 |
| O'Reilly, E | 1 |
| Ciombor, K | 1 |
| Berg, DJ | 1 |
| Meyerhardt, J | 1 |
| Mayer, RJ | 10 |
| Berger, MD | 1 |
| Stintzing, S | 4 |
| Yang, D | 9 |
| Cao, S | 1 |
| Sunakawa, Y | 3 |
| Ning, Y | 6 |
| Matsusaka, S | 3 |
| Okazaki, S | 1 |
| Suenaga, M | 4 |
| Schirripa, M | 1 |
| Soni, S | 1 |
| Zhang, W | 13 |
| Loupakis, F | 4 |
| Lenz, HJ | 14 |
| Ghaneh, P | 2 |
| Kleeff, J | 1 |
| Halloran, CM | 1 |
| Raraty, M | 1 |
| Jackson, R | 2 |
| Melling, J | 1 |
| Jones, O | 1 |
| Palmer, DH | 1 |
| Cox, TF | 1 |
| Smith, CJ | 1 |
| O'Reilly, DA | 1 |
| Scarfe, AG | 2 |
| Valle, JW | 1 |
| McDonald, AC | 2 |
| Carter, R | 1 |
| Tebbutt, NC | 2 |
| Goldstein, D | 3 |
| Padbury, R | 2 |
| Dervenis, C | 2 |
| Glimelius, B | 7 |
| Deakin, M | 1 |
| Anthoney, A | 1 |
| Lerch, MM | 1 |
| Mayerle, J | 1 |
| Oláh, A | 1 |
| Rawcliffe, CL | 1 |
| Campbell, F | 1 |
| Strobel, O | 1 |
| Büchler, MW | 4 |
| Neoptolemos, JP | 4 |
| Yeom, SS | 1 |
| Park, IJ | 3 |
| Jung, SW | 1 |
| Oh, SH | 1 |
| Lee, JL | 6 |
| Yoon, YS | 4 |
| Kim, CW | 4 |
| Lim, SB | 6 |
| Kim, N | 1 |
| Yu, CS | 10 |
| Fiascone, S | 1 |
| Vitonis, AF | 1 |
| Feldman, S | 1 |
| Gupta, S | 2 |
| Pawar, SS | 1 |
| Bunger, D | 1 |
| Yea, JW | 1 |
| Gu, MJ | 1 |
| Kawahara, T | 1 |
| Shimozuma, K | 1 |
| Hagiwara, Y | 1 |
| Uemura, Y | 1 |
| Taira, N | 1 |
| Mukai, H | 1 |
| Tseng, MSF | 1 |
| Zheng, H | 1 |
| Ng, IWS | 1 |
| Leong, YH | 1 |
| Yong, WP | 1 |
| Cheong, WK | 1 |
| Tey, JCS | 1 |
| Ströbel, P | 2 |
| Liersch, T | 9 |
| Grabenbauer, GG | 9 |
| Hartmann, A | 1 |
| Kaufmann, M | 5 |
| Sauer, R | 17 |
| Graeven, U | 3 |
| Hoffmanns, H | 2 |
| Raab, HR | 2 |
| Hothorn, T | 3 |
| Wittekind, C | 4 |
| Ku, KH | 1 |
| Kwon, HJ | 1 |
| Chang, HK | 5 |
| Park, JG | 3 |
| Shida, T | 1 |
| Endo, Y | 3 |
| Yoshioka, T | 2 |
| Suzuki, K | 6 |
| Kobayashi, Y | 2 |
| Ono, Y | 3 |
| Ito, T | 5 |
| Ryu, H | 1 |
| Song, IC | 1 |
| Choi, YS | 1 |
| Yun, HJ | 1 |
| Jo, DY | 1 |
| Kim, JM | 1 |
| Ko, YB | 1 |
| Lee, HJ | 4 |
| Shaw, FM | 1 |
| Weinstock, MA | 1 |
| Kam, MKM | 1 |
| Chan, LLK | 1 |
| Lung, ML | 1 |
| Leblanc, J | 1 |
| Chu, NS | 1 |
| Wu, IC | 2 |
| Chen, LT | 3 |
| Chin, YY | 1 |
| Mayanagi, S | 1 |
| Kashiwabara, K | 1 |
| Honda, M | 1 |
| Kanda, M | 2 |
| Hamada, C | 4 |
| Sadahiro, S | 1 |
| Yoshikawa, T | 2 |
| Sobrero, AF | 2 |
| Shields, AF | 1 |
| Souglakos, J | 4 |
| Kerr, R | 2 |
| Boukovinas, I | 2 |
| Meyers, JP | 2 |
| Renfro, LA | 2 |
| Torri, V | 1 |
| Sargent, DJ | 12 |
| Iveson, T | 2 |
| Wang, S | 4 |
| Liang, Y | 4 |
| Hu, B | 1 |
| Qi, F | 1 |
| Zheng, Z | 2 |
| Yan, Q | 1 |
| Liu, J | 6 |
| Zhang, G | 1 |
| Ettrich, TJ | 1 |
| Ebert, M | 1 |
| Lorenzen, S | 2 |
| Moehler, M | 1 |
| Vogel, A | 1 |
| Witkowski, L | 1 |
| Seufferlein, T | 1 |
| Reinacher-Schick, A | 1 |
| Martella, A | 1 |
| Willett, C | 3 |
| Palta, M | 2 |
| Czito, B | 1 |
| Mnejja, W | 1 |
| Toumi, N | 2 |
| Fourati, N | 1 |
| Bouzguenda, R | 1 |
| Ghorbel, A | 2 |
| Frikha, M | 2 |
| Siala, W | 1 |
| Daoud, J | 2 |
| Greally, M | 1 |
| Pilson, K | 1 |
| Linehan, A | 1 |
| O'Keane, C | 1 |
| Shields, CJ | 1 |
| Conneely, JB | 1 |
| McCaffrey, JA | 1 |
| Wawok, P | 1 |
| Polkowski, W | 2 |
| Richter, P | 2 |
| Szczepkowski, M | 1 |
| Olędzki, J | 2 |
| Wierzbicki, R | 1 |
| Gach, T | 1 |
| Rutkowski, A | 3 |
| Dziki, A | 1 |
| Kołodziejski, L | 1 |
| Sopyło, R | 2 |
| Pietrzak, L | 2 |
| Kryński, J | 1 |
| Wiśniowska, K | 1 |
| Spałek, M | 2 |
| Pawlewicz, K | 1 |
| Polkowski, M | 1 |
| Kowalska, T | 1 |
| Paprota, K | 1 |
| Jankiewicz, M | 2 |
| Radkowski, A | 1 |
| Chalubińska-Fendler, J | 1 |
| Michalski, W | 3 |
| Bujko, K | 4 |
| Wu, YS | 1 |
| Mao, MJ | 1 |
| Yu, YH | 1 |
| Yang, J | 4 |
| Huang, XJ | 1 |
| Retornaz, F | 1 |
| Kirscher, S | 1 |
| Etienne, PL | 2 |
| Khemissa Akouz, F | 1 |
| Locher, C | 3 |
| Rinaldi, Y | 1 |
| Lavau-Denes, S | 1 |
| Baconnier, M | 1 |
| Oden-Gangloff, A | 1 |
| Genet, D | 2 |
| Bedenne, L | 1 |
| Paillaud, E | 1 |
| Chen, EY | 1 |
| Blanke, CD | 3 |
| Benson, AB | 13 |
| Robles, C | 1 |
| Li, H | 3 |
| Mattek, N | 1 |
| Sanborn, RE | 1 |
| Lopez, CD | 1 |
| Jang, BS | 1 |
| Park, HJ | 3 |
| Okuyama, T | 2 |
| Sameshima, S | 1 |
| Takeshita, E | 1 |
| Yoshioka, R | 1 |
| Yamagata, Y | 1 |
| Tagaya, N | 1 |
| Noie, T | 1 |
| Oya, M | 1 |
| Arnold, D | 4 |
| Folprecht, G | 5 |
| Hohenberger, W | 7 |
| Le Corre, D | 1 |
| Le Malicot, K | 2 |
| Tabernero, J | 4 |
| Mulot, C | 1 |
| Seitz, JF | 7 |
| Mini, E | 5 |
| Van Laethem, JL | 1 |
| Emile, JF | 3 |
| Song, K | 1 |
| Cai, H | 1 |
| Li, N | 2 |
| Song, X | 2 |
| Ao, L | 1 |
| Guo, Z | 1 |
| Maihoefer, C | 1 |
| Schüttrumpf, L | 1 |
| Macht, C | 1 |
| Pflugradt, U | 1 |
| Hess, J | 1 |
| Schneider, L | 1 |
| Woischke, C | 1 |
| Walch, A | 1 |
| Baumeister, P | 1 |
| Zitzelsberger, H | 1 |
| Belka, C | 1 |
| Ganswindt, U | 1 |
| Pittman, ME | 1 |
| Milsom, J | 1 |
| Yantiss, RK | 1 |
| Jensen, MB | 3 |
| Lænkholm, AV | 1 |
| Nielsen, TO | 1 |
| Eriksen, JO | 1 |
| Wehn, P | 1 |
| Hood, T | 1 |
| Ram, N | 1 |
| Buckingham, W | 1 |
| Ferree, S | 1 |
| Ejlertsen, B | 2 |
| Lavin, VJ | 1 |
| Mehta, S | 2 |
| Sumra, P | 1 |
| Bhatt, L | 1 |
| Jackson, AS | 1 |
| Sheikh, HY | 1 |
| Jiang, ZC | 1 |
| Chi, Y | 1 |
| Zawiah, M | 1 |
| Yousef, AM | 1 |
| Kadi, T | 1 |
| Yousef, M | 1 |
| Majdalawi, K | 1 |
| Al-Yacoub, S | 1 |
| Al-Hiary, R | 1 |
| Tantawi, D | 1 |
| Mukred, R | 1 |
| Ajaj, AR | 1 |
| Li, PJ | 1 |
| Hu, WH | 1 |
| Jin, T | 1 |
| Yamamoto, A | 3 |
| Toiyama, Y | 8 |
| Okugawa, Y | 6 |
| Saigusa, S | 6 |
| Ide, S | 1 |
| Fujikawa, H | 2 |
| Hiro, J | 2 |
| Yasuda, H | 2 |
| Yoshiyama, S | 1 |
| Ohi, M | 2 |
| Araki, T | 1 |
| Kusunoki, M | 9 |
| Yu, M | 1 |
| Jeong, JU | 3 |
| Ustaalioglu, BBO | 1 |
| Bilici, A | 1 |
| Tilki, M | 1 |
| Surmelioglu, A | 1 |
| Erkol, B | 1 |
| Figen, M | 1 |
| Uyar, S | 1 |
| Saba, NF | 1 |
| Mendenhall, WM | 4 |
| Hutcheson, K | 2 |
| Suárez, C | 1 |
| Wolf, G | 1 |
| Ferlito, A | 1 |
| Jung, YH | 2 |
| Yoo, JY | 1 |
| Mondaca, S | 1 |
| Chatila, WK | 1 |
| Bates, D | 1 |
| Hechtman, JF | 1 |
| Cercek, A | 2 |
| Segal, NH | 1 |
| Stadler, ZK | 1 |
| Varghese, AM | 1 |
| Kundra, R | 1 |
| Capanu, M | 1 |
| Shia, J | 3 |
| Schultz, N | 1 |
| Saltz, L | 8 |
| Yaeger, R | 2 |
| Kina, S | 1 |
| Nakasone, T | 1 |
| Kinjo, T | 1 |
| Nimura, F | 1 |
| Sunagawa, N | 1 |
| Arasaki, A | 1 |
| Eder-Czembirek, C | 1 |
| Rechinger, S | 1 |
| Kornek, G | 4 |
| Selzer, E | 4 |
| Seemann, R | 2 |
| Rhoades, K | 1 |
| Smith, B | 1 |
| Honaker, MD | 1 |
| Venkateswaran, N | 1 |
| Mercado, C | 2 |
| Nadler, E | 1 |
| Boyd, M | 1 |
| Black-Shinn, J | 1 |
| Bastit, V | 1 |
| Bon-Mardion, N | 1 |
| Picquenot, JM | 1 |
| Rainville, V | 1 |
| Moldovan, C | 1 |
| François, A | 1 |
| Loeb, A | 1 |
| Thureau, S | 1 |
| Manu, D | 1 |
| Jardin, F | 1 |
| Marie, JP | 1 |
| Clatot, F | 1 |
| Wong, GG | 1 |
| Ha, V | 1 |
| Chu, MP | 1 |
| Dersch-Mills, D | 1 |
| Chambers, CR | 1 |
| Sawyer, MB | 2 |
| Choi, JG | 1 |
| Nipp, RD | 1 |
| Tramontano, A | 1 |
| Ali, A | 1 |
| Zhan, T | 2 |
| Pandharipande, P | 1 |
| Dowling, EC | 1 |
| Fernandez-Del Castillo, C | 2 |
| Ryan, DP | 6 |
| Kong, CY | 1 |
| Spalek, M | 1 |
| Wyrwicz, L | 2 |
| Liu, SL | 1 |
| Sun, XS | 1 |
| Li, XY | 1 |
| Lin, HX | 3 |
| Wen, YF | 1 |
| Guo, SS | 1 |
| Liu, LT | 1 |
| Xie, HJ | 1 |
| Tang, QN | 1 |
| Liang, YJ | 1 |
| Yan, JJ | 1 |
| Lin, C | 2 |
| Yang, ZC | 1 |
| Wasserman, I | 1 |
| Lee, LH | 1 |
| Ogino, S | 2 |
| Marco, MR | 1 |
| Datta, J | 1 |
| Sadot, E | 1 |
| Szeglin, B | 1 |
| Guillem, JG | 2 |
| Paty, PB | 4 |
| Nash, GM | 1 |
| Barlas, A | 1 |
| Manova-Todorova, K | 1 |
| Uppada, SPB | 1 |
| Elghouayel, AE | 1 |
| Ntiamoah, P | 1 |
| Glickman, JN | 1 |
| Hamada, T | 2 |
| Kosumi, K | 1 |
| Inamura, K | 1 |
| Chan, AT | 4 |
| Nishihara, R | 1 |
| Ganesh, K | 1 |
| Dhawan, P | 1 |
| Sawyers, CL | 1 |
| Garcia-Aguilar, J | 1 |
| Giannakis, M | 1 |
| Smith, JJ | 1 |
| Haddad, RI | 3 |
| Massarelli, E | 1 |
| Lee, JJ | 2 |
| Lin, HY | 2 |
| Lewis, J | 1 |
| Garden, AS | 2 |
| Blumenschein, GR | 6 |
| William, WN | 2 |
| Pharaon, RR | 1 |
| Tishler, RB | 1 |
| Glisson, BS | 2 |
| Pickering, C | 1 |
| Gold, KA | 1 |
| Johnson, FM | 2 |
| Rabinowits, G | 2 |
| Ginsberg, LE | 1 |
| Williams, MD | 1 |
| Myers, J | 1 |
| Kies, MS | 3 |
| Papadimitrakopoulou, V | 2 |
| Yasuno, M | 3 |
| Uetake, H | 1 |
| Mizunuma, N | 3 |
| Miyata, G | 2 |
| Shiomi, A | 1 |
| Kagimura, T | 1 |
| Sugihara, K | 5 |
| Lee, H | 1 |
| Min, BH | 1 |
| Kim, JJ | 1 |
| Jeong, WK | 1 |
| Choi, DI | 1 |
| Kim, M | 1 |
| Seo, SW | 1 |
| Lee, KY | 5 |
| Park, JW | 2 |
| Kwon, YH | 1 |
| Ryoo, SB | 1 |
| Jeong, SY | 5 |
| Park, KJ | 5 |
| Liu, S | 4 |
| Fang, J | 1 |
| Ma, H | 1 |
| Meng, L | 1 |
| Bai, Y | 3 |
| Feng, L | 2 |
| Lian, M | 1 |
| Li, P | 2 |
| Zhong, Q | 1 |
| Hou, L | 1 |
| Weiser, M | 1 |
| Mamon, H | 1 |
| Gollub, M | 1 |
| Venook, A | 2 |
| Miao, J | 1 |
| Shen, G | 2 |
| Shi, M | 3 |
| Zhang, N | 3 |
| Hu, G | 2 |
| Hu, X | 3 |
| Shao, X | 1 |
| Han, F | 1 |
| Mai, H | 1 |
| Chua, MLK | 1 |
| Xie, C | 1 |
| Aoto, K | 1 |
| Kono, K | 1 |
| Matsui, S | 1 |
| Kajiyama, D | 1 |
| Kawaguchi, M | 1 |
| Ohira, K | 1 |
| Amagasa, H | 2 |
| Noguchi, T | 2 |
| Sugita, H | 1 |
| Ganno, H | 2 |
| Imai, K | 3 |
| Ami, K | 2 |
| Ando, M | 4 |
| Hotta, S | 1 |
| Kameyama, H | 2 |
| Shimada, Y | 4 |
| Tajima, Y | 2 |
| Hanyu, T | 1 |
| Takizawa, K | 1 |
| Nagahashi, M | 1 |
| Sakata, J | 1 |
| Kobayashi, T | 5 |
| Wakai, T | 2 |
| Laccourreye, O | 7 |
| Marret, G | 1 |
| Rubin, F | 1 |
| Fabre, E | 1 |
| Badoual, C | 1 |
| Oudard, S | 1 |
| Bonfils, P | 1 |
| Lisan, Q | 1 |
| Endo, K | 1 |
| Yamashita, K | 3 |
| Chiku, T | 1 |
| Sano, W | 1 |
| Hashiba, T | 1 |
| Shinoda, K | 1 |
| Togawa, Y | 1 |
| Morise, Z | 1 |
| Tanaka, C | 3 |
| Hayashi, T | 4 |
| Ikeda, Y | 2 |
| Maeda, K | 4 |
| Masumori, K | 2 |
| Koide, Y | 3 |
| Katsuno, H | 2 |
| Tanahashi, Y | 1 |
| Nakajima, S | 1 |
| Hanai, T | 2 |
| Kato, Y | 3 |
| Sugioka, A | 1 |
| Uyama, I | 1 |
| Tsukahara, K | 1 |
| Okamoto, I | 1 |
| Katsube, Y | 1 |
| Shimizu, A | 1 |
| Kondo, T | 3 |
| Hanyu, K | 1 |
| Fushimi, C | 1 |
| Miura, K | 1 |
| Akhter, K | 1 |
| Enamur Rashid, M | 1 |
| Yang, Y | 4 |
| Liu, Q | 1 |
| Jia, B | 1 |
| Du, X | 1 |
| Dai, G | 2 |
| Zeng, M | 1 |
| Wen, K | 1 |
| Xiao, D | 1 |
| Zhan, P | 1 |
| Verma, V | 1 |
| Ly, QP | 1 |
| Lazenby, A | 1 |
| Sasson, A | 1 |
| Schwarz, JK | 1 |
| Meza, JL | 1 |
| Are, C | 1 |
| Hahn, SM | 1 |
| Grem, JL | 1 |
| Harada, K | 1 |
| Okamoto, W | 1 |
| Mimaki, S | 1 |
| Kawamoto, Y | 1 |
| Bando, H | 1 |
| Yamashita, R | 1 |
| Yuki, S | 1 |
| Komatsu, Y | 2 |
| Sakamoto, N | 1 |
| Tsuchihara, K | 1 |
| Kim, C | 2 |
| Chon, HJ | 2 |
| Jung, M | 4 |
| Nam, CM | 2 |
| Kang, B | 2 |
| Chung, HC | 7 |
| Rha, SY | 6 |
| Aoyama, Y | 1 |
| Katada, T | 1 |
| Saito, M | 3 |
| Tsuchiya, T | 1 |
| Nishido, T | 1 |
| Kato, A | 1 |
| Shibata, T | 7 |
| Teranishi, F | 2 |
| Sakamoto, S | 1 |
| Mita, K | 1 |
| Karamatsu, S | 1 |
| Hikosaka, Y | 1 |
| Nishida, T | 1 |
| Shinozaki, E | 2 |
| Murofushi, K | 1 |
| Taguchi, S | 1 |
| Nagayama, S | 1 |
| Chino, A | 1 |
| Kawachi, H | 1 |
| Yamamoto, N | 3 |
| Oguchi, M | 1 |
| Ishizuka, N | 2 |
| Yamaguchi, K | 3 |
| Li, Q | 4 |
| Zhou, S | 1 |
| Yang, H | 2 |
| Liu, M | 4 |
| Hu, Y | 1 |
| Xi, M | 1 |
| Maskell, D | 1 |
| Buckley, H | 1 |
| Sission, K | 1 |
| Roques, T | 1 |
| Geropantas, K | 1 |
| Lee, DW | 4 |
| Han, SW | 11 |
| Cha, Y | 1 |
| Kim, HP | 1 |
| Lyu, J | 1 |
| Han, H | 2 |
| Bang, D | 2 |
| Won, JK | 1 |
| Kang, GH | 5 |
| Kim, TY | 17 |
| Ishibashi, Y | 2 |
| Liang, W | 1 |
| Wan, N | 1 |
| Zhang, L | 7 |
| Jiang, J | 2 |
| Ozawa, S | 3 |
| Koyanagi, K | 1 |
| Kazuno, A | 1 |
| Ninomiya, Y | 1 |
| Yatabe, K | 1 |
| Ciseł, B | 1 |
| Kosakowska, E | 1 |
| Cencelewicz, A | 1 |
| Styliński, R | 1 |
| Bębenek, M | 1 |
| Kapturkiewicz, B | 1 |
| Maciejczyk, A | 1 |
| Sadowski, J | 1 |
| Zygulska, J | 1 |
| Zegarski, W | 1 |
| Jankowski, M | 1 |
| Las-Jankowska, M | 1 |
| Toczko, Z | 1 |
| Żelazowska-Omiotek, U | 1 |
| Kępka, L | 1 |
| Socha, J | 1 |
| Wasilewska-Tesluk, E | 1 |
| Markiewicz, W | 1 |
| Kładny, J | 1 |
| Majewski, A | 1 |
| Kapuściński, W | 1 |
| Hirano, H | 1 |
| Shoji, H | 2 |
| Okita, N | 1 |
| Iwasa, S | 1 |
| Takashima, A | 2 |
| Boku, N | 5 |
| Motoi, F | 1 |
| Naitoh, T | 1 |
| Pederson, L | 1 |
| Alberts, S | 1 |
| Van Cutsem, E | 6 |
| Sinicrope, FA | 4 |
| Zaanan, A | 2 |
| Kim, YH | 4 |
| Park, EH | 1 |
| Lee, SJ | 5 |
| Kim, A | 1 |
| Lee, SB | 1 |
| Shim, S | 1 |
| Myung, JK | 1 |
| Park, S | 1 |
| Mantion, G | 2 |
| Boudghène, F | 2 |
| Mornex, F | 5 |
| Balosso, J | 1 |
| François, Y | 1 |
| Rio, E | 2 |
| Roullet, B | 1 |
| Spaëth, D | 1 |
| Quero, L | 1 |
| Lakkis, Z | 2 |
| Coudert, M | 1 |
| Ionescu-Goga, M | 1 |
| Tanang, A | 1 |
| Seto, A | 1 |
| Shimbashi, W | 1 |
| Yonekawa, H | 2 |
| Ohsawa, M | 1 |
| Hamai, Y | 1 |
| Ibuki, Y | 1 |
| Emi, M | 1 |
| Miyata, Y | 1 |
| Okada, M | 1 |
| Hamamoto, Y | 3 |
| Tsubosa, Y | 2 |
| Ura, T | 6 |
| Chin, K | 2 |
| Kojima, Y | 3 |
| Akutsu, Y | 1 |
| Matsushita, H | 4 |
| Kawakami, K | 2 |
| Mori, K | 4 |
| Makiuchi, T | 1 |
| Nagumo, R | 1 |
| Kitagawa, Y | 4 |
| Faivre, S | 3 |
| Albert, S | 1 |
| Raymond, E | 3 |
| Haddad, R | 1 |
| O'Neill, A | 1 |
| Tishler, R | 3 |
| Khuri, F | 2 |
| Adkins, D | 3 |
| Clark, J | 3 |
| Sarlis, N | 2 |
| Lorch, J | 1 |
| Beitler, JJ | 1 |
| Limaye, S | 1 |
| Riley, S | 1 |
| Posner, M | 2 |
| Dou, H | 1 |
| Lam, C | 1 |
| Miyazaki, T | 1 |
| Hasegawa, Y | 5 |
| Ozawa, T | 2 |
| Hirakawa, H | 2 |
| Suzuki, A | 2 |
| Okamoto, H | 1 |
| Harata, I | 1 |
| Arredondo, J | 3 |
| Baixauli, J | 3 |
| Beorlegui, C | 2 |
| Arbea, L | 2 |
| Rodríguez, J | 3 |
| Sola, JJ | 3 |
| Chopitea, A | 2 |
| Hernández-Lizoáin, JL | 3 |
| Monden, N | 2 |
| Homma, A | 1 |
| Okami, K | 1 |
| Onozawa, Y | 3 |
| Fujii, M | 3 |
| Taguchi, T | 10 |
| de Blas, B | 1 |
| Beier, F | 1 |
| Shin, HC | 1 |
| Han, W | 1 |
| Moon, HG | 1 |
| Im, SA | 11 |
| Moon, WK | 1 |
| Park, IA | 1 |
| Noh, DY | 2 |
| Ando, N | 2 |
| Seki, S | 1 |
| Mukaida, H | 1 |
| Fukuda, H | 4 |
| van Dijk, TH | 1 |
| Tamas, K | 1 |
| Beukema, JC | 2 |
| Beets, GL | 3 |
| Gelderblom, AJ | 1 |
| de Jong, KP | 1 |
| Nagtegaal, ID | 2 |
| Rutten, HJ | 1 |
| van de Velde, CJ | 5 |
| Wiggers, T | 1 |
| Hospers, GA | 3 |
| Havenga, K | 1 |
| Min, HS | 1 |
| Bang, YJ | 10 |
| Jang, JJ | 1 |
| Ha, SW | 4 |
| Kobayashi, R | 2 |
| Yamashita, H | 3 |
| Okuma, K | 2 |
| Shiraishi, K | 1 |
| Ohtomo, K | 2 |
| Lin, SC | 1 |
| Chen, PC | 1 |
| Lee, CT | 1 |
| Tsai, HM | 1 |
| Lin, PC | 1 |
| Chen, HH | 1 |
| Wu, YH | 1 |
| Lin, BW | 1 |
| Su, WP | 1 |
| Lee, JC | 1 |
| Boda-Heggemann, J | 1 |
| Weiss, C | 2 |
| Schneider, V | 1 |
| Haneder, S | 1 |
| Michaely, H | 1 |
| Wertz, H | 1 |
| Ronellenfitsch, U | 1 |
| Hochhaus, A | 4 |
| Wenz, F | 2 |
| Lohr, F | 1 |
| Absenger, G | 2 |
| Benhaim, L | 4 |
| Szkandera, J | 3 |
| Labonte, MJ | 5 |
| Pichler, M | 2 |
| Stotz, M | 2 |
| Samonigg, H | 7 |
| Renner, W | 3 |
| Gerger, A | 7 |
| Arnheim, K | 1 |
| Engelen, SM | 1 |
| Maas, M | 2 |
| Lahaye, MJ | 1 |
| Leijtens, JW | 1 |
| van Berlo, CL | 1 |
| Jansen, RL | 1 |
| Breukink, SO | 1 |
| Dejong, CH | 1 |
| Beets-Tan, RG | 2 |
| Cohen, MH | 1 |
| Shord, S | 1 |
| Fuchs, C | 1 |
| He, K | 2 |
| Zhao, H | 1 |
| Sickafuse, S | 1 |
| Keegan, P | 1 |
| Pazdur, R | 5 |
| James, RD | 1 |
| Meadows, HM | 3 |
| Myint, AS | 2 |
| Saunders, MP | 2 |
| Maughan, T | 3 |
| McDonald, A | 1 |
| Essapen, S | 2 |
| Leslie, M | 2 |
| Falk, S | 3 |
| Wilson, C | 1 |
| Gollins, S | 4 |
| Begum, R | 1 |
| Ledermann, J | 2 |
| Kadalayil, L | 2 |
| Sebag-Montefiore, D | 4 |
| Chao, YK | 3 |
| Tseng, CK | 3 |
| Wen, YW | 2 |
| Liu, YH | 4 |
| Wan, YL | 1 |
| Chiu, CT | 1 |
| Chang, WC | 2 |
| Wang, B | 1 |
| Zhang, S | 1 |
| Yue, K | 1 |
| Wang, XD | 1 |
| Yuan, ST | 1 |
| Wang, FL | 1 |
| Liu, N | 1 |
| Liu, SG | 1 |
| Li, YQ | 1 |
| Liu, XB | 1 |
| Li, WH | 1 |
| Zhang, JD | 4 |
| Bondar', GV | 2 |
| Basheev, VKh | 1 |
| Zolotukhin, SÉ | 1 |
| Sovpel', IV | 1 |
| Sovpel', OV | 1 |
| Kua, VF | 1 |
| Ismail, F | 1 |
| Chee Ee Phua, V | 1 |
| Aslan, NM | 1 |
| Sun, W | 2 |
| Yuan, W | 1 |
| Le Fur, E | 1 |
| Chatellier, G | 1 |
| Berger, A | 3 |
| Dousset, B | 4 |
| Nordlinger, B | 7 |
| Berges, O | 1 |
| Deberne, M | 1 |
| Dessard-Diana, B | 1 |
| Henni, M | 1 |
| Giraud, P | 1 |
| Housset, M | 3 |
| Durdux, C | 2 |
| Motoyama, S | 1 |
| Nanjo, H | 1 |
| Yoshino, K | 1 |
| Kuribayashi, K | 1 |
| Nagaki, Y | 1 |
| Saito, H | 3 |
| Minamiya, Y | 1 |
| Ogawa, J | 1 |
| Goto, Y | 1 |
| Kodaira, T | 3 |
| Furutani, K | 1 |
| Tachibana, H | 3 |
| Ito, J | 3 |
| Suzuki, H | 5 |
| Mirinezhad, SK | 1 |
| Somi, MH | 1 |
| Seyednezhad, F | 1 |
| Jangjoo, AG | 1 |
| Ghojazadeh, M | 1 |
| Mohammadzadeh, M | 1 |
| Naseri, AR | 1 |
| Nasiri, B | 1 |
| Tai, CJ | 1 |
| Pan, CK | 1 |
| Chen, CS | 1 |
| Hung, CS | 1 |
| Wu, CH | 2 |
| Chiou, HY | 1 |
| Peng, PJ | 1 |
| Ou, XQ | 1 |
| Chen, ZB | 1 |
| Liao, H | 2 |
| Peng, YL | 1 |
| Wang, SY | 1 |
| Zhang, HY | 1 |
| Martín, M | 2 |
| Ruiz, A | 1 |
| Ruiz Borrego, M | 1 |
| Barnadas, A | 1 |
| González, S | 1 |
| Calvo, L | 1 |
| Margelí Vila, M | 1 |
| Antón, A | 3 |
| Rodríguez-Lescure, A | 1 |
| Seguí-Palmer, MA | 1 |
| Muñoz-Mateu, M | 1 |
| Dorca Ribugent, J | 1 |
| López-Vega, JM | 1 |
| Jara, C | 1 |
| Espinosa, E | 1 |
| Mendiola Fernández, C | 1 |
| Andrés, R | 2 |
| Ribelles, N | 1 |
| Plazaola, A | 1 |
| Sánchez-Rovira, P | 1 |
| Salvador Bofill, J | 1 |
| Crespo, C | 1 |
| Carabantes, FJ | 1 |
| Servitja, S | 1 |
| Chacón, JI | 1 |
| Rodríguez, CA | 1 |
| Hernando, B | 1 |
| Álvarez, I | 1 |
| Carrasco, E | 1 |
| Lluch, A | 4 |
| Kuranishi, F | 1 |
| Ohno, T | 1 |
| Chua, TC | 3 |
| Quinn, LE | 1 |
| Zhao, J | 2 |
| Morris, DL | 4 |
| Vermorken, JB | 9 |
| Stöhlmacher-Williams, J | 1 |
| Davidenko, I | 1 |
| Licitra, L | 2 |
| Winquist, E | 1 |
| Villanueva, C | 1 |
| Foa, P | 1 |
| Rottey, S | 4 |
| Skladowski, K | 1 |
| Pai, VR | 1 |
| Blajman, CR | 1 |
| Forastiere, AA | 3 |
| Stein, BN | 1 |
| Oliner, KS | 1 |
| Pan, Z | 2 |
| Bach, BA | 1 |
| Herman, JM | 4 |
| Fan, KY | 1 |
| Wild, AT | 1 |
| Wood, LD | 1 |
| Blackford, AL | 1 |
| Ellsworth, S | 1 |
| Zheng, L | 2 |
| Le, DT | 1 |
| De Jesus-Acosta, A | 1 |
| Hidalgo, M | 1 |
| Donehower, RC | 3 |
| Schulick, RD | 3 |
| Edil, BH | 2 |
| Choti, MA | 3 |
| Hruban, RH | 2 |
| Pawlik, TM | 3 |
| Laheru, DA | 2 |
| Ohchi, T | 2 |
| Akagi, Y | 1 |
| Kinugasa, T | 1 |
| Fujino, S | 1 |
| Kibe, S | 1 |
| Yuge, K | 1 |
| Sasatomi, T | 1 |
| Mizobe, T | 1 |
| Oka, Y | 1 |
| Hong, KD | 1 |
| Shirouzu, K | 5 |
| Bath-Hextall, FJ | 1 |
| Matin, RN | 1 |
| Wilkinson, D | 1 |
| Leonardi-Bee, J | 1 |
| Gerber, N | 1 |
| Ilson, DH | 2 |
| Wu, AJ | 1 |
| Janjigian, YY | 1 |
| Kelsen, DP | 4 |
| Zheng, J | 2 |
| Bains, MS | 1 |
| Rizk, N | 1 |
| Rusch, VW | 1 |
| Castoro, C | 1 |
| Scarpa, M | 1 |
| Cagol, M | 1 |
| Alfieri, R | 1 |
| Ruol, A | 1 |
| Cavallin, F | 1 |
| Michieletto, S | 1 |
| Zanchettin, G | 1 |
| Chiarion-Sileni, V | 2 |
| Corti, L | 1 |
| Ancona, E | 1 |
| O'Connell, M | 2 |
| Cassidy, J | 2 |
| Kerr, DJ | 5 |
| Meyers, J | 1 |
| de Campos-Lobato, LF | 3 |
| Stocchi, L | 4 |
| de Sousa, JB | 1 |
| Buta, M | 1 |
| Lavery, IC | 3 |
| Fazio, VW | 3 |
| Dietz, DW | 2 |
| Kalady, MF | 3 |
| Páez, D | 3 |
| Benhanim, L | 1 |
| Kahn, M | 2 |
| Lenz, F | 2 |
| Lenz, C | 2 |
| Wakatsuki, T | 3 |
| Hashimoto, T | 1 |
| Yokoyama, M | 3 |
| Kimura, S | 2 |
| Usuba, O | 1 |
| Toyono, M | 1 |
| Butthongkomvong, K | 1 |
| Sirachainan, E | 1 |
| Jhankumpha, S | 1 |
| Kumdang, S | 1 |
| Sukhontharot, OU | 1 |
| Lee, WC | 2 |
| Yusof, MM | 1 |
| Lau, FN | 1 |
| Phua, VC | 1 |
| Kim, SY | 4 |
| Baek, SK | 1 |
| Shin, SJ | 2 |
| Kim, TI | 1 |
| Kang, DR | 1 |
| Hur, H | 1 |
| Min, BS | 2 |
| Kim, NK | 7 |
| Roh, JK | 5 |
| Ahn, JB | 4 |
| Huddart, RA | 2 |
| Hall, E | 1 |
| Hussain, SA | 2 |
| Jenkins, P | 1 |
| Rawlings, C | 1 |
| Tremlett, J | 1 |
| Crundwell, M | 1 |
| Adab, FA | 1 |
| Sheehan, D | 1 |
| Syndikus, I | 1 |
| Hendron, C | 1 |
| Lewis, R | 1 |
| Waters, R | 1 |
| Curigliano, G | 1 |
| Pivot, X | 3 |
| Cortés, J | 2 |
| Elias, A | 1 |
| Cesari, R | 1 |
| Khosravan, R | 1 |
| Collier, M | 1 |
| Cataruozolo, PE | 1 |
| Kern, KA | 1 |
| Goldhirsch, A | 10 |
| Chiu, CH | 2 |
| Chan, SC | 1 |
| Chen, WH | 2 |
| Hamilton, SR | 1 |
| Bot, BM | 1 |
| Twelves, C | 2 |
| Benedetti, JK | 2 |
| O'Connell, MJ | 10 |
| Woo, IS | 2 |
| Kim, MY | 1 |
| Han, CW | 1 |
| Rha, EY | 1 |
| Nishina, T | 3 |
| Takano, Y | 3 |
| Denda, T | 4 |
| Yasui, H | 4 |
| Kondo, K | 7 |
| Takahashi, Y | 4 |
| Sugiyama, Y | 3 |
| Muro, K | 6 |
| Sabbaga, J | 3 |
| Gama-Rodrigues, J | 7 |
| São Julião, GP | 4 |
| Proscurshim, I | 4 |
| Bailão Aguilar, P | 1 |
| Nadalin, W | 6 |
| Dinnewitzer, A | 1 |
| Jäger, T | 1 |
| Nawara, C | 1 |
| Buchner, S | 1 |
| Wolfgang, H | 1 |
| Öfner, D | 1 |
| Deutsch, E | 2 |
| Pignon, JP | 1 |
| Levy, A | 1 |
| Delarochefordiere, A | 1 |
| Martel-Lafay, I | 1 |
| Malka, D | 4 |
| Miglianico, L | 1 |
| Becouarn, Y | 1 |
| Malekzadeh, K | 1 |
| Paris, E | 1 |
| Juzyna, B | 1 |
| Ezra, P | 1 |
| Hayashi, R | 3 |
| Ebihara, M | 1 |
| Miyazaki, M | 2 |
| Shinozaki, T | 1 |
| Sakuraba, M | 1 |
| Zenda, S | 1 |
| Fujii, S | 2 |
| Korytova, LI | 2 |
| Masliukova, EA | 1 |
| Korytov, OV | 2 |
| Gopta, EV | 1 |
| Oltarzhevskaia, ND | 1 |
| Korotina, MA | 1 |
| Moughan, J | 1 |
| Pedersen, JE | 1 |
| Thomas, CR | 3 |
| Haddock, MG | 5 |
| Rich, TA | 7 |
| Akiyama, Y | 1 |
| Aoki, T | 1 |
| Hagiwara, K | 1 |
| Hironaka, K | 1 |
| Osuka, F | 1 |
| Takeuchi, M | 1 |
| Nakajima, T | 4 |
| Aitchison, M | 1 |
| Bray, CA | 1 |
| Van Poppel, H | 1 |
| Sylvester, R | 1 |
| Innes, C | 1 |
| McMahon, L | 2 |
| Vasey, PA | 2 |
| Beretta, GD | 1 |
| Mosconi, S | 1 |
| Mandalà, M | 1 |
| Cervantes, A | 3 |
| Padman, S | 1 |
| Beeke, C | 1 |
| Bishnoi, S | 1 |
| Townsend, AR | 1 |
| Maddern, G | 1 |
| Price, TJ | 1 |
| Gross, E | 1 |
| Meul, C | 1 |
| Raab, S | 1 |
| Propping, C | 1 |
| Avril, S | 1 |
| Aubele, M | 1 |
| Gkazepis, A | 1 |
| Schuster, T | 1 |
| Grebenchtchikov, N | 1 |
| Schmitt, M | 1 |
| Kiechle, M | 1 |
| Meijer, J | 1 |
| Vijzelaar, R | 1 |
| Meindl, A | 1 |
| van Kuilenburg, AB | 2 |
| Madbouly, KM | 1 |
| Abbas, KS | 1 |
| Hussein, AM | 2 |
| Mansi, L | 1 |
| Benzidane, B | 1 |
| Cazorla, A | 1 |
| Demarchi, M | 1 |
| Kaliski, A | 1 |
| Delabrousse, E | 1 |
| Letondal, P | 1 |
| Valmary-Degano, S | 1 |
| Morita, S | 6 |
| Kojima, H | 3 |
| Takemoto, H | 2 |
| Nagata, N | 6 |
| Shimada, M | 1 |
| Mishima, H | 8 |
| Strojan, P | 2 |
| Grašič Kuhar, C | 1 |
| Žumer, B | 1 |
| Kadivec, M | 1 |
| Karner, K | 1 |
| Fajdiga, I | 1 |
| Jančar, B | 1 |
| Gale, N | 1 |
| Poljak, M | 1 |
| Kocjan, BJ | 1 |
| Zakotnik, B | 1 |
| Mirza, A | 1 |
| Pritchard, S | 1 |
| Welch, I | 1 |
| Sveen, A | 1 |
| Nesbakken, A | 1 |
| Ågesen, TH | 1 |
| Guren, MG | 2 |
| Tveit, KM | 7 |
| Skotheim, RI | 1 |
| Lothe, RA | 1 |
| Dunne, PD | 1 |
| McArt, DG | 1 |
| Blayney, JK | 1 |
| Kalimutho, M | 1 |
| Greer, S | 1 |
| Wang, T | 5 |
| Srivastava, S | 1 |
| Ong, CW | 1 |
| Arthur, K | 1 |
| Loughrey, M | 1 |
| Redmond, K | 1 |
| Longley, DB | 1 |
| Salto-Tellez, M | 1 |
| Johnston, PG | 4 |
| Van Schaeybroeck, S | 1 |
| Hanna, DL | 1 |
| Winder, T | 2 |
| Volz, N | 1 |
| Stremitzer, S | 2 |
| El-Khoueiry, R | 3 |
| Kim, EY | 3 |
| Yechieli, R | 1 |
| Kim, JK | 1 |
| Mikkelsen, T | 1 |
| Kalkanis, SN | 1 |
| Rock, J | 1 |
| Rosenblum, M | 1 |
| Ryu, S | 1 |
| Bendell, JC | 3 |
| Swieboda-Sadlej, A | 1 |
| Barone, C | 5 |
| Wainberg, ZA | 1 |
| Pastorelli, D | 1 |
| Tarazi, J | 1 |
| Rosbrook, B | 1 |
| Bloom, J | 1 |
| Ricart, AD | 1 |
| Lopatin, M | 1 |
| Clark-Langone, KM | 1 |
| Millward, C | 1 |
| Sharif, S | 1 |
| Shak, S | 2 |
| Curtis, NJ | 1 |
| Noble, F | 2 |
| Bailey, IS | 2 |
| Kelly, JJ | 2 |
| Byrne, JP | 2 |
| Underwood, TJ | 2 |
| Gao, Y | 2 |
| Huang, HQ | 2 |
| Bai, B | 1 |
| Cai, QC | 1 |
| Wang, XX | 1 |
| Cai, QQ | 2 |
| Stiekema, J | 1 |
| Trip, AK | 1 |
| Jansen, EP | 2 |
| Boot, H | 4 |
| Cats, A | 2 |
| Ponz, OB | 1 |
| Verheij, M | 2 |
| Hu, T | 1 |
| Kajiura, S | 1 |
| Hosokawa, A | 1 |
| Yoshita, H | 1 |
| Ueda, A | 2 |
| Mihara, H | 1 |
| Ando, T | 4 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Leone, JP | 1 |
| Leone, J | 1 |
| Vallejo, CT | 2 |
| Pérez, JE | 2 |
| Romero, AO | 2 |
| Machiavelli, MR | 2 |
| Romero Acuña, L | 1 |
| Domínguez, ME | 2 |
| Langui, M | 1 |
| Fasce, HM | 1 |
| Leone, BA | 2 |
| Ortiz, E | 1 |
| Iturbe, J | 1 |
| Zwenger, AO | 1 |
| You, KY | 1 |
| Peng, HH | 1 |
| Gao, YH | 1 |
| Zhou, GQ | 1 |
| Chang, H | 1 |
| Du, XJ | 1 |
| Xiao, L | 1 |
| Zeng, ZF | 1 |
| Wen, BX | 1 |
| Liu, MZ | 4 |
| Ubink, I | 1 |
| van der Sluis, P | 1 |
| Schipper, M | 1 |
| Reerink, O | 2 |
| Voest, E | 1 |
| Borel-Rinkes, I | 1 |
| Wijrdeman, H | 1 |
| Vleggaar, F | 1 |
| Agterof, M | 1 |
| Overkleeft, E | 1 |
| Siersema, P | 1 |
| van Hillegersberg, R | 1 |
| Lolkema, MP | 1 |
| Lan, YT | 2 |
| Chang, SC | 3 |
| Yang, SH | 3 |
| Lin, CC | 4 |
| Wang, HS | 3 |
| Jiang, JK | 3 |
| Chen, WS | 3 |
| Lin, TC | 3 |
| Chiou, SH | 1 |
| Lin, JK | 4 |
| Chiu, J | 1 |
| Tang, V | 1 |
| Leung, R | 1 |
| Wong, H | 2 |
| Chu, KW | 1 |
| Poon, J | 1 |
| Epstein, RJ | 1 |
| Yau, T | 1 |
| Zhao, Q | 1 |
| Jiang, Y | 2 |
| Yuan, Z | 2 |
| Yang, L | 1 |
| Yu, SK | 1 |
| Bhangu, A | 1 |
| Tait, DM | 1 |
| Andoh, H | 1 |
| Hazama, S | 1 |
| Suzuki, G | 1 |
| Yamazaki, H | 1 |
| Ogo, E | 1 |
| Hayabuchi, N | 1 |
| Umeno, H | 1 |
| Nakashima, T | 1 |
| Nakamura, S | 5 |
| Yoshida, K | 6 |
| Li, XF | 2 |
| Li, YH | 5 |
| Gao, YN | 1 |
| Li, CL | 1 |
| Yue, HZ | 1 |
| Li, DM | 1 |
| Nolan, L | 1 |
| Bateman, AC | 1 |
| Sharland, DM | 1 |
| Rees, CN | 1 |
| Bateman, AR | 1 |
| Tanis, E | 1 |
| Mauer, M | 1 |
| Sorbye, H | 1 |
| van Coevorden, F | 2 |
| Gruenberger, T | 4 |
| Schlag, PM | 2 |
| Punt, CJ | 4 |
| Ruers, TJ | 2 |
| Ruf, C | 1 |
| Thomusch, O | 1 |
| Goos, M | 1 |
| Makowiec, F | 1 |
| Illerhaus, G | 1 |
| Ruf, G | 1 |
| Nangia-Makker, P | 2 |
| Yu, Y | 2 |
| Vasudevan, A | 2 |
| Farhana, L | 2 |
| Rajendra, SG | 2 |
| Levi, E | 2 |
| Majumdar, AP | 2 |
| Holmqvist, A | 3 |
| Sun, XF | 3 |
| Albertsson, M | 3 |
| Morizane, C | 1 |
| Hiraoka, N | 1 |
| Kondo, S | 1 |
| Ohno, I | 1 |
| Shimizu, S | 1 |
| Mitsunaga, S | 1 |
| Ikeda, M | 5 |
| Okusaka, T | 1 |
| Lynn, PB | 2 |
| Miger, J | 1 |
| Jamshed, A | 1 |
| Hussain, R | 1 |
| Iqbal, H | 1 |
| Ji, J | 2 |
| Zhan, Y | 1 |
| He, Y | 3 |
| Huang, C | 1 |
| Yan, M | 1 |
| Shi, Y | 3 |
| Wu, A | 1 |
| Xing, L | 1 |
| Wu, P | 1 |
| Xu, D | 1 |
| Jiang, Z | 1 |
| Zang, Q | 1 |
| Wu, CE | 1 |
| Chen, SC | 1 |
| Lin, YC | 1 |
| Lo, YF | 1 |
| Hsueh, S | 1 |
| Okur, A | 1 |
| Eser, EP | 1 |
| Yilmaz, G | 1 |
| Dalgiç, A | 1 |
| Akdemir, ÜÖ | 1 |
| Oğuz, A | 1 |
| Karadeniz, C | 1 |
| Akyol, G | 1 |
| Demiroğullari, B | 1 |
| Boyunağa, Ö | 1 |
| Pinarli, FG | 1 |
| Gomez-Millan, J | 1 |
| Perez, L | 1 |
| Aroca, I | 1 |
| Del Mar Delgado, M | 1 |
| De Luque, V | 1 |
| Román, A | 1 |
| Torres, E | 1 |
| Ramos, S | 1 |
| Perez, S | 1 |
| Bayo, E | 1 |
| Medina, JA | 1 |
| Matsuda, N | 1 |
| Ohde, S | 1 |
| Yagata, H | 2 |
| Kajiura, Y | 2 |
| Yoshida, A | 1 |
| Tsunoda, H | 1 |
| Yamauchi, H | 2 |
| Yang, A | 1 |
| Pan, J | 1 |
| Hu, C | 2 |
| Luo, R | 1 |
| Zhou, L | 2 |
| Lüpfert, C | 1 |
| Cai, J | 1 |
| Dorth, JA | 1 |
| Pura, JA | 1 |
| Uronis, HE | 1 |
| D'Amico, TA | 1 |
| Czito, BG | 4 |
| Kasliwal, MK | 1 |
| Tan, LA | 1 |
| O'Toole, JE | 1 |
| Wang, WY | 2 |
| Chen, CC | 1 |
| Wu, CT | 1 |
| Shih, YT | 1 |
| Okumura, H | 3 |
| Uchikado, Y | 2 |
| Omoto, I | 2 |
| Kita, Y | 2 |
| Arigami, T | 1 |
| Uenosono, Y | 1 |
| Matsushita, D | 2 |
| Hiraki, Y | 2 |
| Owaki, T | 2 |
| Ishigami, S | 3 |
| Natsugoe, S | 2 |
| van den Berg, MW | 1 |
| Sloothaak, DA | 1 |
| Dijkgraaf, MG | 1 |
| van der Zaag, ES | 1 |
| Bemelman, WA | 1 |
| Tanis, PJ | 1 |
| Bosker, RJ | 1 |
| Fockens, P | 1 |
| ter Borg, F | 1 |
| van Hooft, JE | 1 |
| Lee, CS | 1 |
| Ryan, EJ | 1 |
| Doherty, GA | 1 |
| De Bari, B | 1 |
| Buglione, M | 1 |
| Maddalo, M | 1 |
| Lestrade, L | 1 |
| Spiazzi, L | 1 |
| Vitali, P | 1 |
| Barbera, F | 1 |
| Magrini, SM | 1 |
| Qian, W | 1 |
| Zhu, G | 1 |
| Ji, Q | 1 |
| Etienne-Grimaldi, MC | 1 |
| Mahamat, A | 1 |
| Chazal, M | 1 |
| Olschwang, S | 1 |
| Gaub, MP | 1 |
| Formento, JL | 1 |
| Formento, P | 1 |
| Sudaka, A | 2 |
| Boige, V | 5 |
| Abderrahim-Ferkoune, A | 1 |
| Benchimol, D | 1 |
| Houry, S | 4 |
| Faucheron, JL | 1 |
| Letoublon, C | 2 |
| Gilly, FN | 1 |
| Delpero, JR | 6 |
| Lasser, P | 5 |
| Pradere, B | 1 |
| Pezet, D | 1 |
| Penault-Llorca, F | 2 |
| Milano, G | 5 |
| Blinde, SE | 1 |
| Schasfoort, R | 1 |
| Mens, JW | 2 |
| Verhoef, C | 2 |
| Olofsen, M | 1 |
| Nuyttens, JJ | 1 |
| Osti, MF | 1 |
| Agolli, L | 1 |
| Bracci, S | 1 |
| Masoni, L | 1 |
| Valeriani, M | 1 |
| Falco, T | 1 |
| De Sanctis, V | 1 |
| Maurizi Enrici, R | 1 |
| Yana, I | 1 |
| Otani, S | 2 |
| Céruse, P | 3 |
| Cosmidis, A | 1 |
| Belot, A | 1 |
| Rabilloud, M | 1 |
| Fuchsmann, C | 1 |
| Poupart, M | 3 |
| Ramade, A | 3 |
| Tartas, S | 1 |
| Favrel, V | 1 |
| Pommier, P | 1 |
| Zrounba, P | 3 |
| Mongan, AM | 1 |
| Kalachand, R | 1 |
| King, S | 1 |
| O'Farrell, NJ | 1 |
| Power, D | 1 |
| Ravi, N | 1 |
| Muldoon, C | 1 |
| O'Byrne, K | 1 |
| Reynolds, JV | 2 |
| Tashiro, J | 1 |
| Kondo, H | 1 |
| Morita, Y | 2 |
| Koyama, I | 1 |
| Thind, G | 1 |
| Johal, B | 1 |
| Follwell, M | 1 |
| Kim, KJ | 1 |
| Rhee, YY | 2 |
| Cho, NY | 3 |
| Lee, KH | 12 |
| Eikesdal, HP | 1 |
| Knappskog, S | 1 |
| Aas, T | 1 |
| Lønning, PE | 1 |
| Wang, SS | 1 |
| Xie, X | 2 |
| Wong, CS | 3 |
| Choi, Y | 1 |
| Fung, MC | 1 |
| Takada, T | 3 |
| Sutoh, T | 1 |
| Morita, H | 2 |
| Yajima, R | 2 |
| Tsutsumi, S | 2 |
| Asao, T | 2 |
| Kuwano, H | 3 |
| Huang, MY | 6 |
| Chen, CF | 1 |
| Huang, CM | 3 |
| Lu, CY | 2 |
| Chai, CY | 2 |
| Huang, CJ | 3 |
| Isa O, N | 1 |
| Russo N, M | 1 |
| López V, H | 1 |
| Tramm, T | 1 |
| Kyndi, M | 1 |
| Myhre, S | 1 |
| Nord, S | 1 |
| Alsner, J | 1 |
| Sørensen, FB | 1 |
| Sørlie, T | 1 |
| Overgaard, J | 5 |
| Liu, HC | 2 |
| Yen, LC | 1 |
| Chang, JY | 2 |
| Huang, JJ | 1 |
| Lin, SR | 2 |
| Niwa, K | 1 |
| Ishiyama, S | 1 |
| Sugimoto, K | 1 |
| Komiyama, H | 1 |
| Yaginuma, Y | 1 |
| Goto, M | 2 |
| Okuzawa, A | 1 |
| Tomiki, Y | 1 |
| Lyu, X | 1 |
| Huang, J | 1 |
| Mao, Y | 1 |
| Feng, Q | 1 |
| Shao, K | 1 |
| Yang, WC | 1 |
| Chen, CH | 1 |
| Tang, JY | 1 |
| Wu, CF | 1 |
| Lin, SF | 1 |
| Sole, CV | 1 |
| Calvo, FA | 1 |
| Serrano, J | 1 |
| Del Valle, E | 1 |
| Rodriguez, M | 1 |
| Muñoz-Calero, A | 1 |
| Turégano, F | 1 |
| García-Sabrido, JL | 1 |
| Garcia-Alfonso, P | 1 |
| Peligros, I | 1 |
| Rivera, S | 1 |
| Alvarez, E | 1 |
| Péron, J | 2 |
| Polivka, V | 1 |
| Chabaud, S | 1 |
| Girodet, D | 2 |
| Sudarshan, M | 1 |
| Alcindor, T | 1 |
| Ades, S | 1 |
| Aloraini, A | 1 |
| van Huyse, M | 1 |
| Asselah, J | 1 |
| David, M | 1 |
| Frechette, D | 1 |
| Brisson, S | 1 |
| Thirlwell, M | 1 |
| Ferri, L | 1 |
| Lin, HH | 1 |
| Chang, YY | 1 |
| Marthey, L | 1 |
| Sa-Cunha, A | 1 |
| Blanc, JF | 1 |
| Gauthier, M | 1 |
| Cueff, A | 1 |
| Trouilloud, I | 1 |
| Coriat, R | 3 |
| Terrebonne, E | 1 |
| Solub, D | 1 |
| Thirot Bidault, A | 1 |
| Carbonnel, F | 1 |
| Goddard, L | 1 |
| Mollet, T | 1 |
| Blalock, T | 1 |
| Zuo, Y | 1 |
| Feng, Y | 2 |
| Bucci, L | 2 |
| Pepe, S | 2 |
| Romano, FJ | 1 |
| Cella, AC | 1 |
| Attademo, L | 1 |
| Rosanova, M | 1 |
| De Falco, S | 1 |
| Fiore, G | 1 |
| Raimondo, L | 1 |
| De Placido, S | 4 |
| Jeung, HC | 8 |
| Hong, MH | 2 |
| Lim, S | 1 |
| Yang, WI | 2 |
| Piutti, M | 1 |
| Morsli, O | 1 |
| Shigeta, K | 1 |
| Ishii, Y | 1 |
| Okabayashi, K | 2 |
| Kaytan Saglam, E | 1 |
| Yucel, S | 1 |
| Balik, E | 1 |
| Saglam, S | 1 |
| Asoglu, O | 2 |
| Yamaner, S | 1 |
| Bugra, D | 1 |
| Oral, EN | 1 |
| Kizir, A | 1 |
| Kapran, Y | 2 |
| Sakar, B | 1 |
| Akyuz, A | 1 |
| Gulluoglu, M | 1 |
| Cienfuegos, JA | 1 |
| Rotellar, F | 1 |
| Pastor, C | 2 |
| Banerjee, S | 1 |
| Woods, J | 1 |
| Patel, A | 1 |
| Dyson, G | 1 |
| Maddipati, KR | 1 |
| Goff, LW | 1 |
| Thakkar, N | 1 |
| Du, L | 1 |
| Chan, E | 1 |
| Tan, BR | 3 |
| Cardin, DB | 1 |
| McLeod, HL | 1 |
| Berlin, JD | 3 |
| Zehnbauer, B | 1 |
| Fournier, C | 1 |
| Picus, J | 3 |
| Wang-Gillam, A | 1 |
| Lee, W | 1 |
| Lockhart, AC | 3 |
| Zhao, S | 1 |
| Jiang, T | 1 |
| Cui, F | 1 |
| Liu, C | 2 |
| Lu, H | 1 |
| Xue, Y | 2 |
| Jiang, W | 1 |
| Peng, Z | 1 |
| Yan, D | 1 |
| Soon, SS | 1 |
| Chia, WK | 1 |
| Chan, ML | 1 |
| Ho, GF | 1 |
| Jian, X | 1 |
| Deng, YH | 1 |
| Sharma, A | 1 |
| Segelov, E | 1 |
| Ali, R | 1 |
| Toh, HC | 1 |
| Wee, HL | 1 |
| Nagai, Y | 1 |
| Beppu, T | 3 |
| Sakamoto, Y | 3 |
| Nitta, H | 1 |
| Masuda, T | 3 |
| Okabe, H | 2 |
| Hirashima, K | 1 |
| Imamura, Y | 1 |
| Chikamoto, A | 2 |
| Errico, A | 1 |
| Richter, I | 1 |
| Dvořák, J | 1 |
| Blüml, A | 1 |
| Cermáková, E | 1 |
| Bartoš, J | 1 |
| Urbanec, M | 1 |
| Sitorová, V | 1 |
| Ryška, A | 1 |
| Sirák, I | 1 |
| Buka, D | 1 |
| Ferko, A | 1 |
| Melichar, B | 2 |
| Petera, J | 1 |
| Gori, S | 4 |
| Lunardi, G | 1 |
| Inno, A | 1 |
| Magarotto, R | 1 |
| Duranti, S | 1 |
| Messa, MG | 1 |
| Mucchino, C | 1 |
| Cirillo, M | 1 |
| Lin, J | 1 |
| Xie, B | 1 |
| Xu, T | 1 |
| Lynggaard, CD | 1 |
| Therkildsen, MH | 1 |
| Kristensen, CA | 1 |
| Specht, L | 1 |
| Söderlund Leifler, K | 1 |
| Asklid, A | 1 |
| Fornander, T | 6 |
| Stenmark Askmalm, M | 2 |
| Klingbiel, D | 1 |
| Saridaki, Z | 1 |
| Roth, AD | 4 |
| Bosman, FT | 1 |
| Delorenzi, M | 1 |
| Tejpar, S | 1 |
| Pardini, B | 1 |
| Rosa, F | 2 |
| Naccarati, A | 1 |
| Vymetalkova, V | 1 |
| di Gaetano, C | 1 |
| Buchler, T | 1 |
| Novotny, J | 1 |
| Matullo, G | 1 |
| Vodicka, P | 1 |
| Rodriguez-Bigas, M | 1 |
| Xing, Y | 1 |
| Vauthey, JN | 5 |
| Rogers, JE | 1 |
| Ohinata, A | 1 |
| Pathak, P | 1 |
| Sethi, S | 1 |
| Phillips, JK | 1 |
| Wolff, RA | 7 |
| Wang, CC | 2 |
| Liang, JT | 1 |
| Tsai, CL | 1 |
| Chen, YH | 2 |
| Lin, YL | 1 |
| Shun, CT | 2 |
| Cheng, JC | 3 |
| Wang, H | 4 |
| Xu, Y | 2 |
| Shi, J | 1 |
| Gao, X | 1 |
| Geng, L | 1 |
| Patkowski, W | 1 |
| Stankiewicz, R | 1 |
| Grąt, M | 1 |
| Krasnodębski, M | 1 |
| Kornasiewicz, O | 1 |
| Krawczyk, M | 1 |
| Boni, C | 2 |
| Massuti, B | 1 |
| Middleton, G | 2 |
| Dane, F | 2 |
| Reichardt, P | 3 |
| Pimentel, FL | 1 |
| Cohn, A | 1 |
| Follana, P | 1 |
| Clemens, M | 1 |
| Moiseyenko, V | 1 |
| Harrison, M | 2 |
| Richards, DA | 1 |
| Prenen, H | 1 |
| Ecstein-Fraisse, E | 1 |
| Hitier, S | 1 |
| Rougier, P | 5 |
| Hoshino, S | 3 |
| Aisu, N | 1 |
| Mogi, A | 1 |
| Kojima, D | 1 |
| Tanimura, S | 1 |
| Yamashita, Y | 6 |
| Rashidi, A | 1 |
| Amarillo, I | 1 |
| Fisher, SI | 1 |
| Ng, K | 1 |
| Chan, JA | 1 |
| Schaefer, PL | 1 |
| Whittom, R | 1 |
| Hantel, A | 1 |
| Giovannucci, EL | 1 |
| Jannasch, K | 1 |
| Wegwitz, F | 1 |
| Lenfert, E | 1 |
| Maenz, C | 1 |
| Deppert, W | 1 |
| Alves, F | 1 |
| Schmoll, HJ | 3 |
| Cartwright, T | 1 |
| McKenna, E | 1 |
| Saif, M | 1 |
| Haller, D | 2 |
| Lam, SW | 1 |
| de Groot, SM | 1 |
| Honkoop, AH | 1 |
| Jager, A | 2 |
| ten Tije, AJ | 2 |
| Bos, MM | 1 |
| Linn, SC | 1 |
| van den Bosch, J | 1 |
| Kroep, JR | 1 |
| Braun, JJ | 2 |
| Boven, E | 1 |
| León, X | 2 |
| Agüero, A | 1 |
| López, M | 2 |
| García, J | 1 |
| Farré, N | 1 |
| López-Pousa, A | 3 |
| Quer, M | 2 |
| Omori, M | 1 |
| Takenaka, R | 1 |
| Breugom, AJ | 1 |
| van Gijn, W | 1 |
| Muller, EW | 1 |
| Berglund, Å | 3 |
| van den Broek, CBM | 1 |
| Fokstuen, T | 1 |
| Gelderblom, H | 2 |
| Kapiteijn, E | 1 |
| Leer, JWH | 1 |
| Marijnen, CAM | 1 |
| Martijn, H | 1 |
| Meershoek-Klein Kranenbarg, E | 1 |
| Påhlman, L | 4 |
| Punt, CJA | 1 |
| Putter, H | 2 |
| Roodvoets, AGH | 1 |
| Steup, WH | 1 |
| van de Velde, CJH | 1 |
| Bohanes, P | 2 |
| El-Khoueiry, A | 3 |
| Perrone, F | 1 |
| Nuzzo, F | 2 |
| Di Rella, F | 1 |
| Gravina, A | 1 |
| Iodice, G | 1 |
| Labonia, V | 1 |
| Landi, G | 1 |
| Pacilio, C | 1 |
| Rossi, E | 1 |
| De Laurentiis, M | 1 |
| D'Aiuto, M | 1 |
| Botti, G | 2 |
| Forestieri, V | 1 |
| Lauria, R | 1 |
| Tinessa, V | 1 |
| Daniele, B | 1 |
| Colantuoni, G | 1 |
| Barni, S | 3 |
| Riccardi, F | 1 |
| De Maio, E | 1 |
| Montanino, A | 1 |
| Morabito, A | 2 |
| Daniele, G | 1 |
| Di Maio, M | 1 |
| Piccirillo, MC | 1 |
| Signoriello, S | 1 |
| Gallo, C | 2 |
| de Matteis, A | 2 |
| Sherman, WH | 1 |
| Chu, K | 1 |
| Chabot, J | 1 |
| Allendorf, J | 1 |
| Schrope, BA | 1 |
| Hecht, E | 1 |
| Jin, B | 1 |
| Leung, D | 1 |
| Remotti, H | 1 |
| Addeo, G | 1 |
| Postolov, I | 1 |
| Tsai, W | 1 |
| Fine, RL | 1 |
| Leon, O | 1 |
| Guren, M | 1 |
| Hagberg, O | 1 |
| Dahl, O | 3 |
| Havsteen, H | 1 |
| Naucler, G | 1 |
| Svensson, C | 1 |
| Jakobsen, A | 4 |
| Pfeiffer, P | 2 |
| Wanderås, E | 1 |
| Ekman, T | 1 |
| Lindh, B | 1 |
| Balteskard, L | 2 |
| Frykholm, G | 3 |
| Park, P | 1 |
| Lück, HJ | 2 |
| Lübbe, K | 1 |
| Reinisch, M | 1 |
| Maass, N | 1 |
| Feisel-Schwickardi, G | 1 |
| Tomé, O | 1 |
| Janni, W | 2 |
| Aydogdu, M | 1 |
| Neunhöffer, T | 1 |
| Ober, A | 1 |
| Aktas, B | 1 |
| Park-Simon, TW | 1 |
| Schumacher, C | 2 |
| Höffkes, HG | 1 |
| Illmer, T | 1 |
| Wagner, H | 1 |
| Mehta, K | 1 |
| von Minckwitz, G | 3 |
| Nekljudova, V | 1 |
| Loibl, S | 2 |
| Lee, AW | 1 |
| Ngan, RK | 1 |
| Cheng, A | 1 |
| Kwong, DL | 2 |
| Chan, LL | 1 |
| Yiu, H | 1 |
| Wong, F | 1 |
| Yau, S | 1 |
| Cheung, FY | 1 |
| Chan, OS | 1 |
| Choi, H | 1 |
| Ren, T | 1 |
| Feng, F | 1 |
| Wan, X | 3 |
| Xiang, Y | 5 |
| Lin, CH | 1 |
| Desurmont, T | 1 |
| Skrypek, N | 1 |
| Duhamel, A | 1 |
| Jonckheere, N | 1 |
| Millet, G | 1 |
| Leteurtre, E | 2 |
| Gosset, P | 1 |
| Duchene, B | 1 |
| Ramdane, N | 1 |
| Hebbar, M | 1 |
| Van Seuningen, I | 3 |
| Pruvot, FR | 1 |
| Huet, G | 2 |
| Truant, S | 2 |
| Xu, R | 2 |
| Jiao, S | 1 |
| Xu, J | 2 |
| Fan, N | 1 |
| Ba, Y | 1 |
| Ma, D | 1 |
| Qin, S | 1 |
| Manikhas, A | 1 |
| Żurawski, B | 1 |
| Chmielowska, E | 1 |
| Karaszewska, B | 1 |
| Allerton, R | 1 |
| Chan, S | 1 |
| Fabi, A | 1 |
| Ciruelos, E | 1 |
| Dank, M | 1 |
| Hornyak, L | 1 |
| Margolin, S | 1 |
| Nusch, A | 1 |
| Parikh, R | 1 |
| Nagi, F | 1 |
| DeSilvio, M | 1 |
| Santillana, S | 1 |
| Semiglazov, V | 2 |
| Tey, J | 2 |
| Peng, L | 2 |
| Fu, S | 2 |
| Huang, G | 1 |
| Xiong, F | 2 |
| Yossi, S | 1 |
| El Alouani, C | 1 |
| Pointreau, Y | 1 |
| Laccourreye, L | 2 |
| Capitain, O | 2 |
| Gustin, P | 1 |
| Peyraga, G | 1 |
| Septans, AL | 1 |
| Jadaud, É | 1 |
| Vinchon-Petit, S | 1 |
| Cellier, P | 2 |
| Autret, D | 1 |
| Tuchais, C | 1 |
| Zhang, WW | 1 |
| Zhu, YJ | 1 |
| Wang, QX | 1 |
| Wang, XH | 2 |
| Xiao, WW | 1 |
| Li, QQ | 3 |
| Hu, YH | 3 |
| Zuo, CH | 1 |
| Xia, M | 1 |
| Liu, JS | 1 |
| Qiu, XX | 1 |
| Lei, X | 1 |
| Xu, RC | 1 |
| Li, JL | 2 |
| Li, YG | 1 |
| Li, QL | 1 |
| Xiao, H | 1 |
| Hong, Y | 1 |
| Zhu, HZ | 1 |
| Wu, QF | 1 |
| Burns, M | 1 |
| Kataoka, K | 1 |
| Mizusawa, J | 2 |
| Shibuya, Y | 1 |
| Katayama, H | 1 |
| Herzog, S | 1 |
| Stiegelbauer, V | 1 |
| Schaberl-Moser, R | 3 |
| Asslaber, M | 1 |
| Lax, S | 1 |
| Leitner, G | 1 |
| Berghold, A | 1 |
| Colussi, O | 1 |
| Voron, T | 1 |
| Pozet, A | 1 |
| Sauvanet, A | 2 |
| Paye, F | 1 |
| Cojean Zeleck, D | 1 |
| Tchinou, L | 1 |
| Kozak, MM | 1 |
| von Eyben, R | 1 |
| Pai, J | 1 |
| Vossler, SR | 1 |
| Limaye, M | 1 |
| Jayachandran, P | 1 |
| Anderson, EM | 1 |
| Shaffer, JL | 1 |
| Longacre, T | 1 |
| Pai, RK | 1 |
| Kugimiya, N | 1 |
| Nishimoto, A | 1 |
| Hosoyama, T | 1 |
| Ueno, K | 2 |
| Enoki, T | 1 |
| Li, TS | 1 |
| Kawamura, M | 1 |
| Kawamoto, A | 1 |
| Mohri, Y | 2 |
| Xu, C | 2 |
| Xie, J | 1 |
| Liang, N | 1 |
| Qiao, L | 1 |
| Luo, H | 1 |
| Zhang, JX | 1 |
| Cao, C | 1 |
| Li, D | 1 |
| Feng, H | 1 |
| Luo, J | 1 |
| Tang, Z | 1 |
| Liu, P | 1 |
| Lu, K | 1 |
| Ju, H | 1 |
| Marks, E | 1 |
| Rizvi, SM | 1 |
| Sarwani, N | 1 |
| El-Deiry, WS | 1 |
| Coradini, D | 1 |
| Biganzoli, E | 2 |
| Ardoino, I | 1 |
| Ambrogi, F | 1 |
| Boracchi, P | 3 |
| Demicheli, R | 1 |
| Daidone, MG | 4 |
| Moliterni, A | 3 |
| Cho, H | 1 |
| Nishiike, S | 1 |
| Takenaka, Y | 1 |
| Nakahara, S | 1 |
| Yasui, T | 1 |
| Hanamoto, A | 1 |
| Inohara, H | 1 |
| Zhao, B | 1 |
| Shang, D | 1 |
| Zhong, M | 1 |
| Deng, C | 1 |
| Jia, X | 1 |
| Hishida, T | 1 |
| Tsuboi, M | 1 |
| Shukuya, T | 1 |
| Takamochi, K | 1 |
| Sakurai, H | 1 |
| Yoh, K | 1 |
| Kunitoh, H | 1 |
| Ghosn, M | 2 |
| Kourie, HR | 1 |
| Abdayem, P | 1 |
| Antoun, J | 1 |
| Nasr, D | 1 |
| Kushwaha, VS | 1 |
| Husain, N | 1 |
| Khan, H | 1 |
| Negi, MP | 1 |
| Jamal, N | 1 |
| Ghatak, A | 1 |
| Murata, S | 1 |
| Onozawa, S | 1 |
| Sugihara, F | 1 |
| Sakamoto, A | 1 |
| Yasui, D | 1 |
| Mine, T | 2 |
| Kumita, S | 1 |
| Troussier, I | 1 |
| Servagi-Vernat, S | 2 |
| Benahim, C | 1 |
| Khalifa, J | 1 |
| Darmon, I | 1 |
| Ortholan, C | 1 |
| Krebs, L | 1 |
| Dejean, C | 1 |
| Bensadoun, RJ | 2 |
| Thariat, J | 1 |
| McDonald, AM | 1 |
| Dulaney, CR | 1 |
| López-Araujo, J | 1 |
| Posey, JA | 1 |
| Keene, KS | 2 |
| Christein, JD | 1 |
| Heslin, MJ | 1 |
| Wood, TE | 1 |
| Jacob, R | 1 |
| El-Hadaad, HA | 1 |
| Wahba, HA | 1 |
| Roshdy, S | 1 |
| Hassan, AS | 1 |
| Naicker, M | 1 |
| Yusof, KH | 1 |
| Wan Ishak, WZ | 1 |
| Hacibekiroglu, I | 1 |
| Kodaz, H | 1 |
| Erdogan, B | 1 |
| Turkmen, E | 1 |
| Esenkaya, A | 1 |
| Uzunoglu, S | 1 |
| Cicin, I | 1 |
| Yamamoto, D | 1 |
| Iwase, S | 1 |
| Tsubota, Y | 1 |
| Ariyoshi, K | 1 |
| Miyaji, T | 1 |
| Sueoka, N | 1 |
| Yamamoto, C | 1 |
| Teramoto, S | 1 |
| Odagiri, H | 2 |
| Kitamura, K | 2 |
| Nagumo, Y | 1 |
| Nakanoko, T | 1 |
| Kasagi, Y | 1 |
| Tsuda, Y | 1 |
| Zaitsu, Y | 1 |
| Ando, K | 2 |
| Nakashima, Y | 1 |
| Imamura, YU | 1 |
| Ohgaki, K | 2 |
| Oki, E | 2 |
| Ohga, S | 1 |
| Liu, G | 1 |
| Liu, B | 2 |
| Li, K | 1 |
| Dong, K | 1 |
| Xiao, X | 1 |
| Ikeda, J | 1 |
| Nishisaki, H | 1 |
| Bartlett, JM | 1 |
| McConkey, CC | 1 |
| Munro, AF | 1 |
| Desmedt, C | 1 |
| Dunn, JA | 3 |
| Larsimont, DP | 1 |
| O'Malley, FP | 1 |
| Cameron, DA | 2 |
| Earl, HM | 1 |
| Shepherd, LE | 3 |
| Cardoso, F | 1 |
| Caldas, C | 1 |
| Twelves, CJ | 1 |
| Di Leo, A | 1 |
| Pritchard, KI | 1 |
| Inukai, M | 1 |
| Kunieda, K | 2 |
| Kurachi, K | 1 |
| Ina, K | 2 |
| Ooshiro, M | 1 |
| Shimoyama, T | 1 |
| Xie, Q | 1 |
| Liang, J | 2 |
| Rao, Q | 1 |
| Li, R | 1 |
| Zhou, H | 1 |
| Han, J | 1 |
| Yao, T | 3 |
| Lou, YT | 1 |
| Chen, CW | 1 |
| Fan, YC | 1 |
| Landry, JC | 1 |
| Prabhu, RS | 1 |
| Cohen, SJ | 1 |
| Staley, CA | 2 |
| Whittington, R | 2 |
| Sigurdson, ER | 4 |
| Nimeiri, H | 1 |
| Verma, U | 1 |
| Ruiz, ES | 1 |
| Cohen, JL | 1 |
| Friedman, A | 1 |
| Wang, Q | 2 |
| Lei, Z | 1 |
| Wu, D | 1 |
| Si, A | 1 |
| Wang, K | 2 |
| Yan, Z | 2 |
| Lau, WY | 1 |
| Wu, M | 2 |
| Shen, F | 2 |
| Uchihara, T | 1 |
| Hualin, W | 1 |
| Takeishi, K | 1 |
| Itoh, S | 2 |
| Harimoto, N | 1 |
| Yoshizumi, T | 1 |
| Aishima, S | 1 |
| Ayez, N | 1 |
| van der Stok, EP | 1 |
| Grünhagen, DJ | 1 |
| Rothbarth, J | 1 |
| van Meerten, E | 1 |
| Eggermont, AM | 1 |
| Gao, SR | 1 |
| Li, LM | 1 |
| Xia, HP | 1 |
| Wang, GM | 1 |
| Xu, HY | 1 |
| Wang, AR | 1 |
| Kidane, B | 1 |
| Coughlin, S | 1 |
| Vogt, K | 1 |
| Malthaner, R | 1 |
| Luc, G | 1 |
| Gronnier, C | 1 |
| Lebreton, G | 1 |
| Brigand, C | 1 |
| Mabrut, JY | 1 |
| Bail, JP | 1 |
| Meunier, B | 2 |
| Collet, D | 1 |
| Sandalevskaya, AG | 1 |
| Krasnikoval, VG | 1 |
| Meshechkin, AV | 1 |
| Qiu, M | 1 |
| Peng, XC | 1 |
| Bi, F | 1 |
| Xu, F | 2 |
| Li, ZP | 1 |
| Shen, YL | 1 |
| Liu, JY | 1 |
| Zhao, YQ | 1 |
| Cao, D | 1 |
| Gou, HF | 1 |
| Yi, C | 1 |
| Xu, YJ | 1 |
| Qiu, SF | 1 |
| Huang, LL | 1 |
| Huang, CB | 1 |
| Wen, B | 1 |
| Wang, C | 2 |
| Huang, R | 2 |
| Dong, J | 1 |
| Zeng, Z | 1 |
| Szturz, P | 1 |
| Specenier, P | 1 |
| Van Laer, C | 1 |
| Van Den Weyngaert, D | 1 |
| Corthouts, B | 1 |
| Carp, L | 1 |
| Van Marck, E | 1 |
| Vanderveken, O | 1 |
| Ueda, S | 2 |
| Nishina, S | 1 |
| Sakiyama, T | 1 |
| Nonagase, Y | 1 |
| Okabe, T | 2 |
| Tamura, T | 3 |
| Lam, JY | 1 |
| McConnell, YJ | 1 |
| Rivard, JD | 1 |
| Temple, WJ | 1 |
| Mack, LA | 1 |
| Kim, DY | 6 |
| Kim, HC | 6 |
| Kim, HR | 5 |
| Oh, ST | 5 |
| Oh, JH | 2 |
| Lee, WY | 7 |
| Lee, JB | 1 |
| Jung, SH | 2 |
| Oze, I | 1 |
| Narita, Y | 1 |
| Masuishi, T | 1 |
| Taniguchi, H | 2 |
| Kadowaki, S | 2 |
| Andoh, M | 1 |
| Kawai, R | 1 |
| Uemura, N | 1 |
| Ishihara, M | 1 |
| Tajika, M | 3 |
| Niwa, Y | 3 |
| Zhong, LP | 2 |
| Ren, GX | 1 |
| Guo, W | 1 |
| Hong, CS | 1 |
| Sun, J | 1 |
| Zhu, HG | 1 |
| Tu, WY | 1 |
| Cai, YL | 1 |
| Yin, QM | 1 |
| Wang, LZ | 2 |
| Wang, ZH | 2 |
| Hu, YJ | 1 |
| Ji, T | 1 |
| Yang, WJ | 1 |
| Ye, WM | 1 |
| Wang, YA | 1 |
| Xu, LQ | 1 |
| Zhuang, Z | 1 |
| Myers, JN | 2 |
| Zhang, ZY | 2 |
| Wu, Z | 1 |
| Ma, S | 1 |
| Jing, S | 1 |
| Deng, Q | 1 |
| Wu, K | 1 |
| Chen, S | 1 |
| Tang, R | 1 |
| Yeh, CJ | 1 |
| Wolff, HA | 3 |
| Lang-Welzenbach, M | 1 |
| Staib, L | 3 |
| Wilhelm, M | 1 |
| Lindemann, F | 1 |
| Schlenska-Lange, A | 1 |
| Odin, E | 1 |
| Sondén, A | 1 |
| Gustavsson, B | 4 |
| Carlsson, G | 3 |
| Wettergren, Y | 1 |
| Kun, M | 1 |
| Xinxin, Z | 1 |
| Feifan, Z | 1 |
| Lin, M | 1 |
| Dartigues, P | 1 |
| Ruffier-Loubière, A | 1 |
| Janoray, G | 1 |
| Chapet, S | 2 |
| de Calan, L | 1 |
| Dumont, P | 1 |
| Dorval, É | 1 |
| Orain, I | 1 |
| Calais, G | 7 |
| De Divitiis, C | 1 |
| Cassata, A | 1 |
| Nasti, G | 1 |
| Ottaiano, A | 1 |
| Nappi, A | 1 |
| Barretta, ML | 1 |
| Iaffaioli, RV | 1 |
| Lépinoy, A | 1 |
| Lescut, N | 1 |
| Caubet, M | 1 |
| Boustani, J | 1 |
| Fantoli, M | 1 |
| Buffet-Miny, J | 1 |
| Bednarek, C | 1 |
| Créhange, G | 2 |
| Cho, HM | 1 |
| Shim, BY | 2 |
| Kim, TH | 3 |
| Baek, JY | 1 |
| Yoon, MS | 2 |
| Kim, JS | 3 |
| Avallone, A | 1 |
| Pecori, B | 1 |
| Bianco, F | 1 |
| Aloj, L | 1 |
| Tatangelo, F | 1 |
| Romano, C | 1 |
| Granata, V | 1 |
| Marone, P | 1 |
| Leone, A | 1 |
| Petrillo, A | 1 |
| Caracò, C | 1 |
| Iaffaioli, VR | 1 |
| Muto, P | 1 |
| Romano, G | 1 |
| Comella, P | 1 |
| Budillon, A | 1 |
| Delrio, P | 1 |
| de Azambuja, E | 1 |
| Ameye, L | 1 |
| Diaz, M | 1 |
| Vandenbossche, S | 1 |
| Aftimos, P | 1 |
| Bejarano Hernández, S | 1 |
| Shih-Li, C | 1 |
| Delhaye, F | 1 |
| Focan, C | 3 |
| Cornez, N | 1 |
| Vindevoghel, A | 2 |
| Beauduin, M | 3 |
| Lemort, M | 2 |
| Paesmans, M | 1 |
| Suter, T | 1 |
| Piccart-Gebhart, M | 1 |
| Adriaensen, GF | 1 |
| van der Hout, MW | 1 |
| Reinartz, SM | 1 |
| Georgalas, C | 1 |
| Fokkens, WJ | 1 |
| Sebio, A | 2 |
| Yamauchi, S | 1 |
| Gotoh, M | 1 |
| Kawai, H | 1 |
| Nakayama, N | 2 |
| Amagai, K | 1 |
| Shirao, K | 3 |
| Okada, N | 1 |
| Kanamori, J | 1 |
| Mayer, B | 1 |
| Sander, S | 2 |
| Paschke, S | 1 |
| Henne-Bruns, D | 5 |
| Link, KH | 4 |
| Kornmann, M | 5 |
| Pituskin, E | 1 |
| Damaraju, S | 1 |
| Bies, RR | 1 |
| Vos, LJ | 1 |
| Prado, CM | 1 |
| Kuzma, M | 1 |
| Clemons, M | 2 |
| Tonkin, K | 1 |
| Au, HJ | 1 |
| Koski, S | 2 |
| Joy, AA | 2 |
| Smylie, M | 1 |
| King, K | 1 |
| Carandang, D | 1 |
| Damaraju, VL | 1 |
| Hanson, J | 1 |
| Cass, CE | 1 |
| Mackey, JR | 1 |
| El-Serafi, M | 2 |
| Buzaid, A | 1 |
| Tibiche, C | 1 |
| Zaman, N | 1 |
| Trifiro, M | 1 |
| O'Connor-McCourt, M | 1 |
| Wang, E | 1 |
| Matsumoto, H | 4 |
| Murakami, H | 1 |
| Kubota, H | 1 |
| Tsuruta, A | 1 |
| Tohyama, K | 1 |
| Hirai, T | 1 |
| Franco, P | 1 |
| Potenza, I | 1 |
| Schena, M | 3 |
| Riva, G | 1 |
| Pecorari, G | 1 |
| Garzino Demo, P | 1 |
| Fasolis, M | 1 |
| Moretto, F | 1 |
| Garzaro, M | 1 |
| Di Muzio, J | 1 |
| Melano, M | 1 |
| Airoldi, M | 7 |
| Ragona, R | 2 |
| Rampino, M | 1 |
| Ricardi, U | 1 |
| Kwon, HY | 1 |
| Kim, IK | 1 |
| Kang, J | 2 |
| Sohn, SK | 1 |
| Pei, H | 1 |
| Qiang, W | 1 |
| Xu, B | 2 |
| Ji, M | 1 |
| Lu, Q | 1 |
| Song, B | 1 |
| Cui, H | 1 |
| Cheng, C | 1 |
| Yang, B | 1 |
| Wang, F | 2 |
| Kong, P | 1 |
| Jia, Z | 1 |
| Bi, Y | 1 |
| Zhao, Z | 1 |
| Shi, R | 1 |
| Yan, T | 1 |
| Xu, E | 1 |
| Qian, Y | 1 |
| Xi, Y | 1 |
| Guo, S | 1 |
| Jia, J | 1 |
| Guo, J | 2 |
| Cheng, X | 1 |
| Zhan, Q | 1 |
| Cui, Y | 1 |
| Vernmark, K | 1 |
| Björnsson, B | 1 |
| Gasslander, T | 1 |
| Sandström, P | 1 |
| Wu, L | 1 |
| Ouyang, T | 2 |
| Fan, Z | 1 |
| Fan, T | 2 |
| Lin, B | 1 |
| Yin, CC | 1 |
| Driessen, CM | 1 |
| de Boer, JP | 1 |
| Rasch, CR | 1 |
| de Jong, MA | 1 |
| Verbist, BM | 1 |
| Melchers, WJ | 1 |
| Tesselaar, ME | 1 |
| van der Graaf, WT | 1 |
| Kaanders, JH | 1 |
| van Herpen, CM | 1 |
| Oliveira, SC | 1 |
| Moniz, CM | 1 |
| Riechelmann, R | 1 |
| Alex, AK | 1 |
| Braghirolli, MI | 1 |
| Bariani, G | 1 |
| Nahas, C | 1 |
| Hoff, PM | 5 |
| George, A | 1 |
| Zietman, AL | 1 |
| Heney, NM | 1 |
| Kaufman, DS | 2 |
| Uzzo, RG | 1 |
| Dreicer, R | 1 |
| Wallace, HJ | 1 |
| Souhami, L | 1 |
| Dobelbower, MC | 1 |
| Sandler, HM | 1 |
| Shipley, WU | 1 |
| Renehan, AG | 1 |
| Malcomson, L | 1 |
| Emsley, R | 1 |
| Maw, A | 1 |
| Rooney, PS | 1 |
| Susnerwala, S | 2 |
| Blower, A | 1 |
| Wilson, MS | 1 |
| Scott, N | 1 |
| O'Dwyer, ST | 1 |
| Joulain, F | 1 |
| Mitchell, E | 1 |
| Lakomý, R | 1 |
| Prausová, J | 1 |
| Moiseyenko, VM | 1 |
| van Hazel, G | 1 |
| Kröning, H | 1 |
| Humblet, Y | 4 |
| Grávalos, C | 1 |
| Le-Guennec, S | 1 |
| Andria, M | 1 |
| Dochy, E | 1 |
| Vishwanath, RL | 1 |
| Macarulla, T | 1 |
| Du, C | 2 |
| Xu, Q | 1 |
| Zhou, A | 1 |
| Ojima, T | 2 |
| Nakamori, M | 3 |
| Katsuda, M | 2 |
| Hayata, K | 2 |
| Iwahashi, M | 3 |
| Yamaue, H | 4 |
| Jeannin, G | 1 |
| Merle, P | 1 |
| Janicot, H | 1 |
| Thibonnier, L | 1 |
| Kwiatkowski, F | 1 |
| Naame, A | 1 |
| Chadeyras, JB | 1 |
| Galvaing, G | 1 |
| Belliere, A | 1 |
| Filaire, M | 1 |
| Verrelle, P | 2 |
| Soulières, D | 1 |
| Aguilar, JL | 1 |
| Chen, E | 1 |
| Misiukiewicz, K | 1 |
| Ernst, S | 2 |
| Bryant, K | 1 |
| He, S | 1 |
| Obasaju, CK | 1 |
| Chin, S | 1 |
| Brenner, B | 1 |
| Geva, R | 1 |
| Rothney, M | 1 |
| Beny, A | 1 |
| Dror, Y | 1 |
| Steiner, M | 1 |
| Hubert, A | 1 |
| Idelevich, E | 1 |
| Gluzman, A | 2 |
| Purim, O | 1 |
| Shacham-Shmueli, E | 1 |
| Shulman, K | 1 |
| Mishaeli, M | 1 |
| Man, S | 1 |
| Soussan-Gutman, L | 1 |
| Tezcan, H | 1 |
| Chao, C | 1 |
| Shani, A | 1 |
| Liebermann, N | 1 |
| Shah, MA | 1 |
| Allegra, CJ | 3 |
| Monnier, L | 1 |
| Touboul, E | 5 |
| Daraï, E | 1 |
| Lefranc, JP | 1 |
| Lauratet, B | 1 |
| Ballester, M | 1 |
| Ohnishi, T | 3 |
| Noura, S | 2 |
| Takemasa, I | 3 |
| Sekimoto, M | 2 |
| Nezu, R | 1 |
| Matsuura, N | 1 |
| Monden, M | 4 |
| Kitadani, J | 1 |
| Tabata, H | 2 |
| Takeuchi, A | 1 |
| Bozec, A | 1 |
| Benezery, K | 2 |
| Ettaiche, M | 1 |
| Chamorey, E | 3 |
| Vandersteen, C | 1 |
| Dassonville, O | 2 |
| Poissonnet, G | 2 |
| Riss, JC | 1 |
| Chand, ME | 1 |
| Leysalle, A | 1 |
| Saada, E | 1 |
| Demard, F | 4 |
| Santini, J | 4 |
| Merrell, KW | 1 |
| Quevedo, JF | 1 |
| Harmsen, WS | 1 |
| Kendrick, ML | 1 |
| Miller, RC | 2 |
| Hallemeier, CL | 1 |
| Go, SI | 2 |
| Kim, YS | 2 |
| Song, HN | 1 |
| Ahn, D | 1 |
| Sohn, JH | 3 |
| Lee, JE | 5 |
| Miyawaki, Y | 1 |
| Joag, MG | 1 |
| Sise, A | 1 |
| Murillo, JC | 1 |
| Sayed-Ahmed, IO | 1 |
| Wong, JR | 1 |
| Boupaijit, K | 1 |
| Suprasert, P | 2 |
| Chen, D | 1 |
| Wen, X | 1 |
| Song, YS | 2 |
| Lee, TH | 1 |
| Dang, RP | 1 |
| LE, VH | 1 |
| Miles, BA | 1 |
| Teng, MS | 1 |
| Genden, EM | 1 |
| Bakst, RL | 1 |
| Gupta, V | 1 |
| Zhang, DY | 1 |
| Demicco, EG | 1 |
| Posner, MR | 3 |
| Misiukiewicz, KJ | 1 |
| Chi, P | 1 |
| Lin, H | 1 |
| Lu, X | 1 |
| Xu, Z | 1 |
| Huang, S | 2 |
| Ye, D | 1 |
| Roozeboom, MH | 1 |
| Arits, AHMM | 1 |
| Mosterd, K | 1 |
| Sommer, A | 1 |
| Essers, BAB | 1 |
| de Rooij, MJM | 1 |
| Quaedvlieg, PJF | 1 |
| Steijlen, PM | 1 |
| Nelemans, PJ | 1 |
| Kelleners-Smeets, NWJ | 1 |
| Lan, WG | 1 |
| Xu, DH | 1 |
| Ding, CL | 1 |
| Ning, FL | 1 |
| Zhou, YL | 1 |
| Ma, LB | 1 |
| Liu, CM | 1 |
| van Erning, FN | 1 |
| Vissers, PA | 1 |
| Lemmens, VE | 1 |
| Jung, SM | 1 |
| Kim, TW | 13 |
| Gichuhi, S | 1 |
| Macharia, E | 1 |
| Kabiru, J | 1 |
| Zindamoyen, AM | 1 |
| Rono, H | 1 |
| Ollando, E | 1 |
| Wachira, J | 1 |
| Munene, R | 1 |
| Maina, J | 1 |
| Onyuma, T | 1 |
| Sagoo, MS | 1 |
| Weiss, HA | 1 |
| Burton, MJ | 1 |
| Coveler, AL | 1 |
| Simeone, DM | 1 |
| Chiorean, EG | 1 |
| Sanchez Loria, F | 1 |
| O'Connor, JM | 1 |
| Pairola, A | 1 |
| Chacon, M | 1 |
| Mendez, G | 1 |
| Coraglio, M | 1 |
| Mariani, J | 1 |
| Dieguez, A | 1 |
| Roca, E | 1 |
| Lewis, C | 1 |
| Xun, P | 1 |
| Wang, ZQ | 2 |
| Jiang, YX | 1 |
| Wang, FH | 2 |
| Luo, HY | 2 |
| Peng, J | 2 |
| Han, DH | 1 |
| Joo, DJ | 1 |
| Kim, MS | 1 |
| Choi, GH | 1 |
| Choi, JS | 1 |
| Park, YN | 1 |
| Seong, J | 1 |
| Han, KH | 2 |
| Kim, SI | 1 |
| Mohammadkhani Shali, S | 1 |
| Schmitt, V | 1 |
| Behrendt, FF | 1 |
| Winz, OH | 1 |
| Heinzel, A | 1 |
| Mottaghy, FM | 1 |
| Eble, MJ | 2 |
| Verburg, FA | 1 |
| Stanisavljević, L | 1 |
| Myklebust, MP | 1 |
| Leh, S | 1 |
| Krizkova, V | 1 |
| Dubova, M | 1 |
| Susova, S | 1 |
| Vycital, O | 1 |
| Bruha, J | 1 |
| Skala, M | 1 |
| Liska, V | 1 |
| Daum, O | 1 |
| Soucek, P | 1 |
| González, I | 1 |
| A-Cienfuegos, J | 1 |
| Martínez, P | 1 |
| Corvaisier, M | 1 |
| Bauzone, M | 1 |
| Corfiotti, F | 1 |
| Renaud, F | 1 |
| El Amrani, M | 1 |
| Monté, D | 1 |
| Formstecher, P | 1 |
| Gespach, C | 1 |
| Aprile, G | 2 |
| Massida, B | 1 |
| Scartozzi, M | 1 |
| Song, JY | 1 |
| Ahn, SJ | 1 |
| Chung, WK | 1 |
| Lee, MA | 2 |
| Kim, IH | 1 |
| Roh, SY | 1 |
| Killander, F | 1 |
| Karlsson, P | 2 |
| Anderson, H | 2 |
| Mattsson, J | 1 |
| Holmberg, E | 1 |
| Lundstedt, D | 1 |
| Holmberg, L | 2 |
| Malmström, P | 2 |
| Mary, F | 1 |
| Boubaya, M | 1 |
| Benallaoua, M | 1 |
| Afchain, P | 1 |
| Baumgaertner, I | 1 |
| des Guetz, G | 1 |
| Hepp, P | 1 |
| Andergassen, U | 1 |
| Jäger, B | 1 |
| Trapp, E | 1 |
| Alunni-Fabbroni, M | 1 |
| Friedl, TW | 1 |
| Hecker, N | 1 |
| Lorenz, R | 1 |
| Fasching, P | 1 |
| Schneeweiss, A | 1 |
| Fehm, T | 1 |
| Rack, B | 1 |
| Jun, KH | 1 |
| Jung, JH | 1 |
| Jo, YS | 1 |
| Chin, HM | 1 |
| Taki, T | 1 |
| Hoya, Y | 1 |
| Watanabe, A | 3 |
| Nakayoshi, T | 1 |
| Okamoto, T | 2 |
| Sekine, H | 1 |
| Mitsumori, N | 1 |
| Yanaga, K | 2 |
| Köhler, C | 2 |
| Marnitz, S | 1 |
| Biel, P | 1 |
| Cordes, T | 1 |
| Ley, J | 1 |
| Michel, L | 1 |
| Wildes, TM | 1 |
| Thorstad, W | 1 |
| Gay, HA | 1 |
| Daly, M | 1 |
| Rich, J | 1 |
| Paniello, R | 1 |
| Uppaluri, R | 1 |
| Trinkaus, K | 1 |
| Nussenbaum, B | 1 |
| Kim, CG | 1 |
| Beom, SH | 1 |
| Heo, SJ | 1 |
| Kim, YJ | 6 |
| Koom, WS | 2 |
| Roh, YH | 1 |
| Ma, BG | 1 |
| Gemici, C | 1 |
| Yaprak, G | 1 |
| Batirel, HF | 1 |
| Ilhan, M | 1 |
| Mayadagli, A | 1 |
| He, B | 2 |
| Srdjan, M | 1 |
| Jadranka, A | 1 |
| Ivan, D | 1 |
| Branimir, Z | 1 |
| Daniela, B | 1 |
| Petar, S | 1 |
| Velimir, M | 1 |
| Zoran, K | 1 |
| Krug, D | 1 |
| Häfner, MF | 1 |
| Ma, WS | 1 |
| Ma, JG | 1 |
| Xing, LN | 1 |
| Foukakis, T | 1 |
| Bengtsson, NO | 2 |
| Brandberg, Y | 2 |
| Wallberg, B | 1 |
| Mlineritsch, B | 4 |
| Schmatloch, S | 1 |
| Steger, G | 5 |
| Egle, D | 1 |
| Karlsson, E | 1 |
| Carlsson, L | 1 |
| Untch, M | 2 |
| Hellström, M | 1 |
| Johansson, H | 3 |
| Möbus, V | 2 |
| Bergh, J | 1 |
| Chai, Y | 1 |
| Zhou, Z | 1 |
| Gamaleldin, M | 1 |
| Church, JM | 1 |
| Kalady, M | 1 |
| Liska, D | 1 |
| Gorgun, E | 1 |
| Smyrk, TC | 1 |
| Thibodeau, SN | 2 |
| Pogue-Geile, KL | 1 |
| Hong, S | 2 |
| Shimizu, D | 1 |
| Kobayashi, D | 1 |
| Hayashi, M | 1 |
| Iwata, N | 1 |
| Sugimoto, H | 1 |
| Murotani, K | 1 |
| Fujiwara, M | 1 |
| Luc Van Laethem, J | 1 |
| Laurent Puig, P | 1 |
| Seim, NB | 1 |
| Kang, SY | 1 |
| Bhandari, M | 1 |
| Jones, RG | 1 |
| Teknos, TN | 1 |
| Yagi, R | 1 |
| Okamura, T | 1 |
| Kosugi, SI | 1 |
| Rivera, F | 6 |
| Valladares, M | 1 |
| Gea, S | 1 |
| López-Martínez, N | 1 |
| Hosoda, K | 1 |
| Moriya, H | 1 |
| Katada, C | 1 |
| Sugawara, M | 1 |
| Mieno, H | 1 |
| Komori, S | 1 |
| Katada, N | 1 |
| Byer, J | 1 |
| Kothari, N | 1 |
| Mahipal, A | 1 |
| Chang, YD | 1 |
| Kim, RD | 1 |
| Ohman, KA | 1 |
| Linehan, DC | 1 |
| Tan, MC | 1 |
| Fields, RC | 1 |
| Strasberg, SM | 1 |
| Hawkins, WG | 1 |
| Yeh, Y- | 1 |
| Kurosawa, S | 1 |
| Christou, N | 1 |
| Perraud, A | 1 |
| Blondy, S | 1 |
| Jauberteau, MO | 1 |
| Battu, S | 1 |
| Mathonnet, M | 1 |
| Verwaal, VJ | 3 |
| Bruin, S | 1 |
| van Slooten, G | 1 |
| Lim, JY | 3 |
| Mun, HS | 1 |
| Lee, DK | 2 |
| Paik, YH | 2 |
| Yoon, DS | 3 |
| Greenberg, JA | 1 |
| Shibata, D | 2 |
| Herndon, JE | 1 |
| Steele, GD | 1 |
| Mayer, R | 1 |
| Bleday, R | 1 |
| Lurje, G | 1 |
| Schultheis, AM | 1 |
| Groshen, S | 4 |
| Hendifar, AE | 1 |
| Husain, H | 1 |
| Gordon, MA | 1 |
| Nagashima, F | 1 |
| Chang, HM | 10 |
| Guerrieri, M | 1 |
| Baldarelli, M | 1 |
| Organetti, L | 1 |
| Grillo Ruggeri, F | 1 |
| Mantello, G | 1 |
| Bartolacci, S | 1 |
| Lezoche, E | 1 |
| Sirohi, B | 1 |
| Arnedos, M | 1 |
| Popat, S | 1 |
| Ashley, S | 3 |
| Nerurkar, A | 1 |
| Walsh, G | 5 |
| Johnston, S | 1 |
| Smith, IE | 2 |
| Nakamura, T | 7 |
| Narumiya, K | 1 |
| Ohki, T | 1 |
| Mitsuhashi, N | 2 |
| Higuchi, I | 1 |
| Yasuda, T | 5 |
| Yano, M | 4 |
| Tatsumi, M | 1 |
| Fukunaga, H | 1 |
| Takiguchi, S | 2 |
| Hatazawa, J | 1 |
| Izzo, L | 1 |
| Pietrasanta, D | 1 |
| Izzo, P | 1 |
| Caputo, M | 1 |
| Di Cello, P | 1 |
| Meloni, P | 1 |
| Bolognese, A | 1 |
| Liang, C | 1 |
| Hata, F | 2 |
| Yamamitsu, S | 1 |
| Shirasaka, T | 5 |
| Bazarbashi, S | 1 |
| El-Bassiouni, M | 1 |
| Abdelsalam, M | 1 |
| Soudy, H | 1 |
| Sanea, NA | 1 |
| Jabbar, AA | 1 |
| Manji, M | 2 |
| Fagih, M | 1 |
| Ajarim, D | 1 |
| Mano, MS | 1 |
| Duhoux, F | 1 |
| Javeri, H | 1 |
| Arora, R | 1 |
| Correa, AM | 1 |
| Hofstetter, WL | 2 |
| Liao, Z | 2 |
| McAleer, MF | 1 |
| Maru, D | 1 |
| Bhutani, MS | 1 |
| Swisher, SG | 3 |
| Izzo, JG | 1 |
| Dunnwald, LK | 1 |
| Gralow, JR | 2 |
| Ellis, GK | 2 |
| Livingston, RB | 3 |
| Linden, HM | 1 |
| Specht, JM | 1 |
| Doot, RK | 1 |
| Lawton, TJ | 1 |
| Barlow, WE | 1 |
| Kurland, BF | 1 |
| Schubert, EK | 1 |
| Mankoff, DA | 1 |
| Matsubara, J | 1 |
| Takahari, D | 3 |
| Hirashima, Y | 1 |
| Okita, NT | 1 |
| Nakajima, TE | 2 |
| Lechleider, RJ | 1 |
| Kaminskas, E | 1 |
| Jiang, X | 2 |
| Aziz, R | 1 |
| Bullock, J | 1 |
| Kasliwal, R | 1 |
| Harapanhalli, R | 1 |
| Pope, S | 1 |
| Sridhara, R | 1 |
| Leighton, J | 2 |
| Booth, B | 1 |
| Dagher, R | 1 |
| Justice, R | 1 |
| Sakaeda, T | 1 |
| Yamamori, M | 1 |
| Kuwahara, A | 1 |
| Hiroe, S | 1 |
| Okumura, K | 1 |
| Okuno, T | 1 |
| Miki, I | 1 |
| Chayahara, N | 1 |
| Okamura, N | 1 |
| Yu, ZY | 1 |
| Ouyang, XN | 1 |
| Chen, ZS | 1 |
| Xie, FW | 1 |
| Diao, C | 1 |
| Cheng, RC | 1 |
| Zhang, JM | 1 |
| Wei, XP | 1 |
| Su, YJ | 1 |
| Liu, QY | 1 |
| Xu, JB | 1 |
| Chang, PM | 1 |
| Teng, HW | 1 |
| Chen, PM | 2 |
| Chang, SY | 2 |
| Chu, PY | 2 |
| Tsai, TL | 2 |
| Tai, SK | 2 |
| Wang, YF | 2 |
| Huang, JL | 1 |
| Ryberg, M | 1 |
| Nielsen, D | 1 |
| Cortese, G | 1 |
| Nielsen, G | 1 |
| Skovsgaard, T | 2 |
| Andersen, PK | 1 |
| Kang, YK | 9 |
| Kang, HJ | 4 |
| Ryoo, BY | 1 |
| Park, SR | 3 |
| Min, YJ | 1 |
| Braendengen, M | 1 |
| Birkemeyer, E | 1 |
| Wiig, JN | 3 |
| Byström, P | 1 |
| Goldsmith, YB | 1 |
| Roistacher, N | 1 |
| Baum, MS | 1 |
| Button, MR | 1 |
| Morgan, CA | 1 |
| Croydon, ES | 1 |
| Roberts, SA | 2 |
| Crosby, TD | 2 |
| Xu, JM | 1 |
| Zhang, XD | 1 |
| Chu, YP | 1 |
| Wang, YH | 3 |
| Liu, DQ | 2 |
| Jin, ML | 1 |
| Overman, MJ | 1 |
| Kopetz, S | 1 |
| Wen, S | 1 |
| Fogelman, D | 1 |
| Morris, J | 3 |
| Abbruzzese, JL | 4 |
| Nowacki, MP | 2 |
| Chmielik, E | 1 |
| Nasierowska-Guttmejer, A | 1 |
| Wojnar, A | 1 |
| Hattori, S | 1 |
| Minashi, K | 4 |
| Onozawa, M | 3 |
| Nihei, K | 4 |
| Ishikura, S | 2 |
| Mesia, R | 7 |
| Remenar, E | 2 |
| Kawecki, A | 3 |
| Erfan, J | 2 |
| Zabolotnyy, D | 2 |
| Kienzer, HR | 1 |
| Cupissol, D | 3 |
| Benasso, M | 8 |
| Vynnychenko, I | 1 |
| De Raucourt, D | 2 |
| Schueler, A | 2 |
| Amellal, N | 2 |
| Hitt, R | 6 |
| Lin, XB | 1 |
| Wang, AL | 1 |
| Bu, Q | 1 |
| Hu, XH | 1 |
| Pan, ZH | 1 |
| Shuang, YR | 1 |
| Guan, ZZ | 1 |
| Kurosaki, I | 1 |
| Kawachi, Y | 1 |
| Tsuchiya, Y | 1 |
| Aono, T | 1 |
| Yokoyama, N | 1 |
| Shimizu, T | 3 |
| Hatakeyama, K | 2 |
| Suto, R | 1 |
| Miyamoto, S | 3 |
| Kaneda, Y | 1 |
| Zenpo, N | 1 |
| Kurata, S | 1 |
| Nakayasu, K | 1 |
| Osaki, Y | 1 |
| Tokudome, N | 1 |
| Sugihara, T | 1 |
| Iwase, T | 1 |
| Hatake, K | 3 |
| Kinsella, TJ | 2 |
| Seo, Y | 1 |
| Willis, J | 1 |
| Stellato, TA | 1 |
| Siegel, CT | 1 |
| Harpp, D | 1 |
| Willson, JK | 1 |
| Gibbons, J | 1 |
| Sanabria, JR | 1 |
| Hardacre, JM | 1 |
| Schulak, JP | 1 |
| Hiramatsu, M | 2 |
| Kawai, M | 2 |
| Sumiyoshi, K | 1 |
| Nishimura, H | 1 |
| Tanigawa, N | 3 |
| Tomoda, T | 1 |
| Nakahara, R | 1 |
| Inokuchi, H | 1 |
| Mizoguchi, N | 1 |
| Takada, A | 1 |
| Fuwa, N | 4 |
| Recchia, F | 1 |
| Candeloro, G | 1 |
| Necozione, S | 1 |
| Bratta, M | 1 |
| Bisegna, R | 1 |
| Rea, S | 1 |
| Koike, Y | 1 |
| Miki, C | 5 |
| Yokoe, T | 6 |
| Washino, S | 1 |
| Terauchi, F | 1 |
| Matsuzaki, A | 1 |
| Chen, Z | 1 |
| Li, CZ | 1 |
| Sheng, LJ | 1 |
| Zhou, DG | 1 |
| Wang, QC | 1 |
| Zhang, EN | 1 |
| Lee, YC | 2 |
| Tateishi, Y | 1 |
| Tatemoto, Y | 1 |
| Morishita, K | 1 |
| Ueta, E | 1 |
| Yamamoto, T | 5 |
| Seol, YM | 1 |
| Song, MK | 1 |
| Kim, GH | 1 |
| Shin, HJ | 3 |
| Song, GA | 1 |
| Chung, JS | 1 |
| Cho, GJ | 1 |
| Chen, EX | 1 |
| Horiguchi, J | 2 |
| Koibuchi, Y | 2 |
| Rokutanda, N | 1 |
| Nagaoka, R | 1 |
| Kikuchi, M | 2 |
| Sato, A | 1 |
| Odawara, H | 1 |
| Tokiniwa, H | 1 |
| Iino, Y | 5 |
| Takeyoshi, I | 1 |
| Yarney, J | 1 |
| Vanderpuye, V | 1 |
| Kitcher, ED | 1 |
| Nobili, S | 3 |
| Checcacci, D | 1 |
| Filippelli, F | 1 |
| Del Buono, S | 1 |
| Mazzocchi, V | 1 |
| Mazzei, T | 2 |
| Lorizzo, K | 1 |
| Fazio, N | 1 |
| Radice, D | 1 |
| Boselli, S | 1 |
| Ariu, L | 1 |
| Nolè, F | 1 |
| Magni, E | 1 |
| Ardito, R | 1 |
| Minchella, I | 1 |
| Rocca, A | 1 |
| Di Meglio, G | 1 |
| Squadroni, M | 1 |
| de Braud, F | 1 |
| Prunotto, M | 1 |
| Bosco, M | 1 |
| Daniele, L | 1 |
| Macri', L | 1 |
| Bonello, L | 1 |
| Schirosi, L | 1 |
| Rossi, G | 2 |
| Filosso, P | 1 |
| Mussa, B | 1 |
| Sapino, A | 1 |
| Tsavaris, N | 4 |
| Lazaris, A | 1 |
| Kosmas, C | 4 |
| Gouveris, P | 3 |
| Kavantzas, N | 1 |
| Kopterides, P | 1 |
| Papathomas, T | 1 |
| Agrogiannis, G | 1 |
| Arapogiannis, G | 1 |
| Zorzos, H | 1 |
| Kyriakou, V | 1 |
| Patsouris, E | 2 |
| Asiyanbola, B | 1 |
| Gleisner, A | 1 |
| Swartz, M | 1 |
| Ogawa, M | 9 |
| Takao, Y | 1 |
| Eto, K | 1 |
| Yamagata, T | 1 |
| Ushigome, T | 1 |
| Anazawa, S | 1 |
| Pozzo, C | 2 |
| Watari, H | 1 |
| Hosaka, M | 1 |
| Mitamura, T | 1 |
| Moriwaki, M | 1 |
| Ohba, Y | 1 |
| Todo, Y | 1 |
| Takeda, M | 2 |
| Ebina, Y | 1 |
| Sakuragi, N | 1 |
| Song, HS | 1 |
| Lee, NS | 1 |
| Lee, MH | 3 |
| Kim, MA | 1 |
| Kim, WH | 1 |
| Satoi, S | 1 |
| Yanagimoto, H | 1 |
| Toyokawa, H | 1 |
| Matsui, Y | 1 |
| Kitade, H | 1 |
| Mergental, H | 1 |
| Takai, S | 1 |
| Kwon, AH | 1 |
| Farella, A | 1 |
| D'Armiento, FP | 1 |
| Pesce, G | 1 |
| Cannella, L | 1 |
| Pacelli, R | 1 |
| Solla, R | 1 |
| D'Armiento, MR | 1 |
| Gou, HY | 1 |
| Han, JS | 1 |
| Li, SM | 1 |
| Yang, R | 1 |
| Qiao, J | 1 |
| Shao, ZY | 3 |
| Meredith, KL | 2 |
| Hoffe, SE | 1 |
| Kiyota, N | 1 |
| Fuse, N | 1 |
| Doi, T | 4 |
| Minami, H | 1 |
| Huh, JW | 3 |
| Wang, ML | 1 |
| Foo, KF | 1 |
| Tamandl, D | 3 |
| Gruenberger, B | 3 |
| Herberger, B | 2 |
| Kaczirek, K | 2 |
| Outlaw, ED | 1 |
| Chang, A | 1 |
| Birnbaum, EH | 1 |
| Fleshman, JW | 2 |
| Grigsby, PW | 2 |
| Kodner, IJ | 2 |
| Malayapa, RS | 1 |
| Mutch, MG | 1 |
| Parikh, P | 1 |
| Kim, MK | 2 |
| Cho, KJ | 1 |
| Park, SI | 2 |
| Song, HY | 1 |
| Shin, JH | 1 |
| Jung, HY | 1 |
| Lee, GH | 1 |
| Choi, KD | 1 |
| Song, HJ | 1 |
| Ryu, JS | 1 |
| Kim, SB | 2 |
| Shimamura, T | 1 |
| Sato, R | 1 |
| Cho, N | 1 |
| Highley, MS | 1 |
| Griffiths, GO | 1 |
| Uscinska, BM | 1 |
| Barber, JB | 1 |
| Parmar, MK | 1 |
| Harper, PG | 1 |
| Ono, A | 1 |
| Yamazaki, K | 1 |
| Taku, K | 2 |
| Lahmer, G | 1 |
| Croner, RS | 1 |
| Merkel, S | 2 |
| Göhl, J | 1 |
| Iishi, H | 1 |
| Higashino, K | 1 |
| Uedo, N | 1 |
| Tatsuta, M | 1 |
| Imai, A | 1 |
| Nishiyama, K | 2 |
| Livi, L | 3 |
| Borghesi, S | 2 |
| Saieva, C | 3 |
| Fambrini, M | 1 |
| Iannalfi, A | 1 |
| Greto, D | 2 |
| Paiar, F | 3 |
| Scoccianti, S | 2 |
| Simontacchi, G | 1 |
| Bianchi, S | 2 |
| Cataliotti, L | 2 |
| Biti, G | 2 |
| Kim, DH | 1 |
| Wang-Chesebro, A | 1 |
| Weinberg, V | 1 |
| Pouliot, J | 1 |
| Speight, J | 1 |
| Littell, R | 1 |
| Hsu, IC | 1 |
| Otake, K | 1 |
| Tonouchi, H | 1 |
| Kovács, AF | 2 |
| Eberlein, K | 1 |
| Hülsmann, T | 1 |
| Muss, HB | 3 |
| Berry, DA | 2 |
| Cirrincione, CT | 2 |
| Theodoulou, M | 1 |
| Mauer, AM | 1 |
| Kornblith, AB | 1 |
| Partridge, AH | 1 |
| Dressler, LG | 1 |
| Cohen, HJ | 1 |
| Becker, HP | 1 |
| Kartcheske, PA | 1 |
| Wheeler, JD | 1 |
| Perez, EA | 1 |
| Wolff, AC | 1 |
| Burstein, HJ | 1 |
| Mahmood, AA | 1 |
| Magrinat, G | 2 |
| Parker, BA | 1 |
| Hart, RD | 1 |
| Grenier, D | 1 |
| Norton, L | 3 |
| Hudis, CA | 2 |
| Winer, EP | 1 |
| Vaishampayan, UN | 1 |
| Marur, S | 1 |
| Heilbrun, LK | 3 |
| Cher, ML | 1 |
| Dickow, B | 1 |
| Smith, DW | 1 |
| Al Hasan, SA | 1 |
| Eliason, J | 1 |
| Oh, KJ | 2 |
| Choi, SH | 6 |
| Lee, SI | 2 |
| Yokouchi, J | 1 |
| Le Scodan, R | 2 |
| Girard, N | 1 |
| Mercier, C | 2 |
| Valette, PJ | 2 |
| Roy, P | 2 |
| Scoazec, JY | 2 |
| Partensky, C | 2 |
| Hogg, ME | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Klug, C | 2 |
| Berzaczy, D | 1 |
| Voracek, M | 2 |
| Nell, C | 1 |
| Ploder, O | 1 |
| Millesi, W | 2 |
| Ewers, R | 3 |
| Valentini, V | 10 |
| Massaccesi, M | 1 |
| Balducci, M | 2 |
| Mantini, G | 3 |
| Micciché, F | 2 |
| Mattiucci, GC | 3 |
| Dinapoli, N | 1 |
| Meduri, B | 1 |
| D'Agostino, GR | 1 |
| Salvi, G | 1 |
| Nardone, L | 1 |
| Holsinger, FC | 1 |
| Bassot, V | 5 |
| Kakeji, Y | 4 |
| Zhao, Y | 1 |
| Yoshida, R | 1 |
| Lee, YJ | 2 |
| Lee, CG | 2 |
| Cho, BC | 1 |
| Kim, GE | 1 |
| Choi, HJ | 1 |
| Choi, EC | 1 |
| Turrini, O | 1 |
| Viret, F | 2 |
| Moureau-Zabotto, L | 3 |
| Guiramand, J | 1 |
| Moutardier, V | 2 |
| Lelong, B | 3 |
| Giovannini, M | 4 |
| Zhang, DK | 1 |
| Su, XD | 1 |
| Lin, P | 1 |
| Long, H | 1 |
| Fu, JH | 1 |
| Zhang, LJ | 1 |
| Ma, GW | 1 |
| Rong, TH | 2 |
| Tay, E | 1 |
| Cree, IA | 1 |
| Hungerford, J | 1 |
| Franks, W | 1 |
| Fora, A | 1 |
| Alabsi, E | 1 |
| Fakih, M | 1 |
| Yokokawa, T | 1 |
| Shouji, D | 1 |
| Imada, H | 1 |
| Nakamoto, E | 1 |
| Kamisugi, K | 1 |
| Suzuki, W | 1 |
| Shirai, T | 1 |
| Hama, T | 1 |
| Ioue, Y | 1 |
| Sugimoto, S | 1 |
| Katano, K | 1 |
| Yoshimura, H | 1 |
| Kidani, A | 1 |
| Takeda, H | 2 |
| Makino, M | 1 |
| Ozaki, N | 1 |
| Ikeguchi, M | 1 |
| Tardío, JC | 1 |
| Nájera, L | 2 |
| Alemany, I | 1 |
| Martín, T | 2 |
| Castaño, A | 1 |
| Pérez-Regadera, JF | 1 |
| Eliason, M | 1 |
| Bowen, G | 1 |
| Bowen, A | 1 |
| Hazard, L | 1 |
| Samlowski, W | 2 |
| Feig, BW | 3 |
| Bedi, M | 1 |
| Krishnan, S | 3 |
| Milman, S | 1 |
| Kim, AW | 1 |
| Warren, WH | 1 |
| Liptay, MJ | 1 |
| Miller, C | 1 |
| Basu, S | 1 |
| Faber, LP | 4 |
| Geisler, DP | 1 |
| Dietz, D | 2 |
| Yun, HR | 1 |
| Cho, YB | 4 |
| Yun, SH | 5 |
| Chun, HK | 4 |
| Power, DG | 1 |
| Kim, BG | 3 |
| Kwon, HC | 2 |
| Lee, DM | 1 |
| Kim, SG | 1 |
| Kim, DK | 1 |
| Jang, JS | 2 |
| Kim, MC | 2 |
| Verweij, J | 3 |
| Sleijfer, S | 1 |
| Küronya, Z | 1 |
| Bodrogi, I | 1 |
| Lövey, J | 2 |
| Plótár, V | 1 |
| Manninger, S | 1 |
| Pápai, Z | 1 |
| Khademi, B | 1 |
| Moradi, A | 1 |
| Hoseini, S | 1 |
| Mohammadianpanah, M | 1 |
| García-Castaño, A | 1 |
| Vega, N | 1 |
| Vega-Villegas, ME | 1 |
| Gutiérrez-Sanz, L | 1 |
| Pacelli, F | 3 |
| Tortorelli, AP | 2 |
| Bossola, M | 3 |
| Sanchez, AM | 2 |
| Papa, V | 1 |
| Doglietto, GB | 4 |
| Jones, J | 2 |
| Takeda, A | 3 |
| Picot, J | 1 |
| von Keyserlingk, C | 1 |
| Clegg, A | 1 |
| Tobias, JS | 1 |
| Monson, K | 1 |
| Gupta, N | 1 |
| Macdougall, H | 1 |
| Glaholm, J | 1 |
| Hutchison, I | 1 |
| Hackshaw, A | 1 |
| Arimura, Y | 1 |
| Okahara, S | 1 |
| Tanuma, T | 1 |
| Kodaira, J | 1 |
| Hokari, K | 1 |
| Tsukagoshi, H | 1 |
| Shinomura, Y | 1 |
| Hosokawa, M | 1 |
| Kim, JY | 3 |
| Chang, DK | 1 |
| Rhee, PL | 1 |
| Kim, DS | 1 |
| Yun, H | 1 |
| Nakamura, J | 1 |
| Kitajima, Y | 1 |
| Kai, K | 1 |
| Hiraki, M | 1 |
| Noshiro, H | 3 |
| Miyazaki, K | 1 |
| Zhang, B | 1 |
| Cao, WF | 1 |
| Zhao, HM | 1 |
| Song, YQ | 1 |
| Ning, LS | 1 |
| Niu, Y | 1 |
| Hao, XS | 1 |
| Cao, XC | 1 |
| Tsukuda, M | 2 |
| Ishitoya, J | 1 |
| Matsuda, H | 1 |
| Horiuchi, C | 1 |
| Nishimura, G | 1 |
| Kawakami, M | 1 |
| Niho, T | 1 |
| Sakuma, Y | 1 |
| Shiono, O | 1 |
| Komatsu, M | 2 |
| Ota, Y | 1 |
| Minamide, J | 1 |
| Takata, K | 1 |
| Aoyama, N | 2 |
| Lee, GW | 1 |
| Kim, HG | 1 |
| Jacot, W | 1 |
| Gourgou-Bourgade, S | 1 |
| Gutowski, M | 1 |
| Colombo, PE | 1 |
| Bleuse, JP | 1 |
| Kramar, A | 2 |
| Romieu, G | 1 |
| Wilkinson, NW | 1 |
| Lopa, S | 1 |
| Costantino, JP | 3 |
| Petrelli, NJ | 1 |
| Naito, M | 1 |
| Noda, N | 1 |
| Matsuo, K | 4 |
| Yamauchi, Y | 1 |
| Shinohara, T | 1 |
| Tanaka, S | 3 |
| Nobuhara, Y | 1 |
| Kubo, N | 1 |
| Matuoka, T | 1 |
| Yo, T | 1 |
| Tans, L | 1 |
| Ansink, AC | 1 |
| van Rooij, PH | 1 |
| Kleijnen, C | 1 |
| Hsu, CC | 1 |
| Corsini, MM | 1 |
| Winter, JM | 1 |
| Callister, MD | 1 |
| Farnell, MB | 1 |
| Swartz, MJ | 1 |
| Kang, SH | 2 |
| Kim, JI | 2 |
| Moon, HS | 2 |
| Sung, JK | 1 |
| Lee, BS | 2 |
| Jeong, HY | 2 |
| Chua, YJ | 1 |
| Barbachano, Y | 1 |
| Oates, JR | 2 |
| Massey, A | 2 |
| Boxberger, F | 1 |
| Albrecht, H | 1 |
| Konturek, PC | 1 |
| Reulbach, U | 1 |
| Maennlein, G | 1 |
| Meyer, T | 1 |
| Hahn, EG | 1 |
| Wein, A | 1 |
| Weber, JM | 1 |
| Turaga, KK | 1 |
| Siegel, EM | 1 |
| McLoughlin, J | 1 |
| Marcovalerio, M | 1 |
| Shah, N | 1 |
| Kelley, S | 1 |
| Karl, R | 1 |
| Kara, O | 1 |
| Ozdemir, E | 1 |
| Arslan, C | 1 |
| Dogan, E | 1 |
| Altundag, K | 3 |
| Lu, JC | 1 |
| Kong, C | 1 |
| Tao, H | 1 |
| Palmero, R | 1 |
| Cos, M | 1 |
| Vilajosana, E | 1 |
| Vázquez, S | 1 |
| Seront, E | 1 |
| Marot, L | 1 |
| Coche, E | 1 |
| Gala, JL | 1 |
| Sempoux, C | 1 |
| Larsen, SG | 1 |
| Dueland, S | 1 |
| Flatmark, K | 1 |
| Giercksky, KE | 1 |
| Min, N | 1 |
| He, BF | 1 |
| Zhang, LS | 1 |
| Jia, YZ | 1 |
| Kienzer, H | 1 |
| Koralewski, P | 1 |
| Delord, JP | 2 |
| Curran, D | 1 |
| Gross, A | 1 |
| Ghorbel, L | 1 |
| Ben Salah, H | 1 |
| Khabir, A | 1 |
| Karray, H | 1 |
| Gargouri, R | 1 |
| Boudawara, T | 1 |
| Wright, JL | 1 |
| Patil, SM | 1 |
| Temple, LK | 1 |
| Dikken, JL | 1 |
| Bakker, B | 1 |
| Hartgrink, HH | 1 |
| Kranenbarg, EM | 1 |
| Peeters, KC | 1 |
| Gao, J | 2 |
| Hu, JY | 1 |
| Xia, YF | 2 |
| Yi, W | 1 |
| Tao, YL | 2 |
| Abrous-Anane, S | 3 |
| Savignoni, A | 3 |
| Daveau, C | 3 |
| Pierga, JY | 9 |
| Gautier, C | 3 |
| Reyal, F | 3 |
| Dendale, R | 3 |
| Campana, F | 4 |
| Kirova, YM | 4 |
| Fourquet, A | 8 |
| Bollet, MA | 5 |
| Spanos, CP | 1 |
| Syrakos, T | 1 |
| Martinez-Trufero, J | 2 |
| Isla, D | 3 |
| Adansa, JC | 1 |
| Irigoyen, A | 1 |
| Gil-Arnaiz, I | 1 |
| Lambea, J | 2 |
| Lecumberri, MJ | 1 |
| Cruz, JJ | 1 |
| Choi, EK | 2 |
| Ahn, SD | 5 |
| Lee, SW | 3 |
| Yoon, SM | 2 |
| Lee, YS | 3 |
| Lee, SG | 1 |
| Hwang, S | 1 |
| Park, KM | 1 |
| Aftimos, PG | 1 |
| Nasr, EA | 1 |
| Nasr, DI | 1 |
| Noun, RJ | 1 |
| Nasr, FL | 1 |
| Ghosn, MG | 1 |
| El Helou, JA | 1 |
| Chahine, GY | 1 |
| Chen, MH | 1 |
| Tzeng, CH | 1 |
| Wang, WS | 1 |
| Mallmann, P | 1 |
| Nitschmann, S | 1 |
| Carnaghi, C | 1 |
| Colombo, P | 1 |
| De Vincenzo, F | 1 |
| Giorgetti, PL | 1 |
| Santoro, A | 1 |
| Napoli, C | 2 |
| Landini, I | 2 |
| Morganti, M | 1 |
| Cianchi, F | 1 |
| Valanzano, R | 1 |
| Tonelli, F | 2 |
| Cortesini, C | 1 |
| Moon, YW | 3 |
| Cho, SY | 1 |
| Han, SS | 1 |
| Kim, YK | 1 |
| Lee, WJ | 1 |
| Woo, SM | 1 |
| Nicolini, A | 1 |
| Conte, M | 1 |
| Ferrari, P | 1 |
| Carpi, A | 1 |
| Miccoli, P | 1 |
| Urba, S | 1 |
| Foster, J | 1 |
| Worden, F | 1 |
| Qiu, Y | 1 |
| Xi, T | 1 |
| Raus, I | 1 |
| Jung, K | 1 |
| Schüler, P | 1 |
| Herrmann, MK | 1 |
| Hennies, S | 1 |
| Vorwerk, H | 1 |
| Hille, A | 1 |
| Hess, CF | 2 |
| Christiansen, H | 2 |
| Ramani, VS | 1 |
| Sun Myint, A | 2 |
| Montazeri, A | 2 |
| Torrisi, R | 1 |
| Montagna, E | 1 |
| Scarano, E | 1 |
| Dellapasqua, S | 2 |
| Cancello, G | 1 |
| Iorfida, M | 1 |
| Luini, A | 3 |
| Veronesi, P | 2 |
| Viale, G | 2 |
| Colleoni, M | 3 |
| Dai, Y | 2 |
| Yu, JM | 2 |
| Walbert, T | 1 |
| Gilbert, MR | 1 |
| Groves, MD | 1 |
| Puduvalli, VK | 1 |
| Yung, WK | 2 |
| Conrad, CA | 1 |
| Bobustuc, GC | 1 |
| Colman, H | 1 |
| Hsu, SH | 1 |
| Bekele, BN | 1 |
| Qiao, W | 1 |
| Levin, VA | 6 |
| Parrozzani, R | 1 |
| Lazzarini, D | 1 |
| Alemany-Rubio, E | 1 |
| Urban, F | 1 |
| Midena, E | 2 |
| Park, NH | 1 |
| Chung, HH | 1 |
| Kim, YB | 2 |
| Cole, BF | 2 |
| Roncadin, M | 1 |
| Chua, BH | 1 |
| Murray, E | 1 |
| Price, KN | 5 |
| Castiglione-Gertsch, M | 5 |
| Gruber, G | 3 |
| Yoo, C | 1 |
| Yook, JH | 3 |
| Kim, BS | 7 |
| Suzuki, T | 3 |
| Sugito, M | 1 |
| Kobayashi, A | 1 |
| Abdulnabi, R | 1 |
| Kotliar, M | 1 |
| Lynch, J | 1 |
| Jordaan, JP | 1 |
| Iscoe, N | 1 |
| Gelmon, K | 2 |
| Ferrandina, G | 2 |
| Margariti, PA | 2 |
| Smaniotto, D | 2 |
| Petrillo, M | 2 |
| Salerno, MG | 1 |
| Fagotti, A | 1 |
| Macchia, G | 4 |
| Morganti, AG | 6 |
| Cellini, N | 6 |
| Scambia, G | 2 |
| Matsuoka, M | 2 |
| Oriuchi, N | 1 |
| Klinger, M | 1 |
| Eipeldauer, S | 1 |
| Martoni, AA | 1 |
| Di Fabio, F | 1 |
| Pinto, C | 1 |
| Castellucci, P | 1 |
| Pini, S | 1 |
| Ceccarelli, C | 1 |
| Cuicchi, D | 1 |
| Iacopino, B | 1 |
| Di Tullio, P | 1 |
| Giaquinta, S | 1 |
| Tardio, L | 1 |
| Lombardi, R | 1 |
| Fanti, S | 2 |
| Cola, B | 1 |
| Kim, JA | 1 |
| Han, B | 1 |
| Balamucki, CJ | 1 |
| Zlotecki, RA | 1 |
| Rout, WR | 1 |
| Newlin, HE | 1 |
| Morris, CG | 1 |
| Kirwan, JM | 1 |
| Ahn, JH | 2 |
| Kim, WK | 3 |
| Lee, JS | 8 |
| Brændengen, M | 1 |
| Bruheim, K | 1 |
| Cvancarova, M | 1 |
| Has, C | 1 |
| Burger, B | 1 |
| Volz, A | 1 |
| Kohlhase, J | 1 |
| Bruckner-Tuderman, L | 1 |
| Itin, P | 1 |
| Podolsky, L | 1 |
| Oh, M | 1 |
| Subbarayan, PR | 1 |
| Francheschi, D | 1 |
| Livingstone, A | 1 |
| Ardalan, B | 2 |
| Aguayo-Leiva, IR | 1 |
| Ríos-Buceta, L | 1 |
| Jaén-Olasolo, P | 1 |
| Zhang, SH | 2 |
| Jiang, ZF | 2 |
| Xie, XD | 1 |
| Wei, Y | 1 |
| Liu, JW | 1 |
| Liu, WC | 1 |
| Bai, YX | 1 |
| Jiao, SC | 1 |
| Sun, Q | 1 |
| Xiao, JX | 1 |
| Wang, HQ | 1 |
| Tang, LL | 1 |
| Wang, YS | 1 |
| Takamori, H | 1 |
| Kanemitsu, K | 1 |
| Ikeda, O | 1 |
| Oya, N | 1 |
| Störkel, S | 1 |
| Senger, S | 1 |
| Stroh, C | 1 |
| Choi, CH | 2 |
| Lee, YY | 1 |
| Kim, TJ | 2 |
| Nam, HR | 3 |
| Huh, SJ | 3 |
| Bae, DS | 2 |
| Burmeister, BH | 3 |
| Thomas, JM | 1 |
| Burmeister, EA | 2 |
| Harvey, JA | 1 |
| Thomson, DB | 1 |
| Gotley, DC | 2 |
| Tu, CH | 1 |
| Kogashiwa, Y | 1 |
| Yamauchi, K | 2 |
| Nagafuji, H | 1 |
| Matsuda, T | 3 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Maruyama, T | 1 |
| Kohno, N | 5 |
| Fernandez, KS | 1 |
| Baum, R | 1 |
| Fung, B | 1 |
| Yeager, N | 1 |
| Leonis, MA | 1 |
| Wagner, LM | 1 |
| Tiao, G | 1 |
| Ross, ME | 1 |
| Kwon, KA | 1 |
| Maejima, K | 1 |
| Tokunaga, A | 1 |
| Kiyama, T | 1 |
| Kanno, H | 1 |
| Bou, H | 1 |
| Uchida, E | 1 |
| Inoue, H | 1 |
| Yano, H | 4 |
| Shimabukuro, R | 1 |
| Takahashi, I | 3 |
| Nishizaki, T | 2 |
| da Luz Moreira, A | 1 |
| Geisler, D | 1 |
| Samaras, P | 1 |
| Breitenstein, S | 1 |
| Haile, SR | 1 |
| Stenner-Liewen, F | 1 |
| Heinrich, S | 1 |
| Feilchenfeldt, J | 1 |
| Renner, C | 1 |
| Knuth, A | 1 |
| Pestalozzi, BC | 1 |
| Clavien, PA | 1 |
| Hirst, J | 1 |
| Barbour, A | 1 |
| Sastre, J | 1 |
| Custodio, A | 1 |
| Sanchez, JC | 1 |
| Ortega, L | 1 |
| Rodriguez, L | 1 |
| Puente, J | 1 |
| Corona, J | 1 |
| Alfonso, R | 1 |
| de las Heras, M | 1 |
| Dıaz-Rubio, E | 2 |
| Chang, YC | 1 |
| Li, WY | 1 |
| Hsieh, SL | 1 |
| Nagahama, T | 1 |
| Watayou, Y | 1 |
| Hataji, K | 1 |
| Kawasaki, Y | 1 |
| Arai, K | 7 |
| Yamaoka, K | 1 |
| Inatsugi, N | 1 |
| Yoshikawa, S | 1 |
| Uchida, H | 1 |
| Kuge, H | 1 |
| Yokotani, T | 1 |
| Kawaguchi, C | 1 |
| Shimobayashi, T | 1 |
| Inagaki, M | 2 |
| Tatsumi, K | 1 |
| Saraya, T | 1 |
| Otsuji, T | 1 |
| Yamochi, Y | 1 |
| Yamanishi, K | 1 |
| Enomoto, Y | 1 |
| Nonomura, A | 1 |
| Sho, M | 1 |
| Tokunou, K | 1 |
| Toshimitsu, H | 1 |
| Kitamura, Y | 1 |
| Andoh, S | 1 |
| Tsushimi, K | 1 |
| Kawaoka, T | 1 |
| Matsukuma, S | 1 |
| Nagashima, A | 1 |
| Hiraki, S | 1 |
| Fukuda, S | 2 |
| Kim, HM | 1 |
| Miyoshi, N | 1 |
| Yamashita, S | 3 |
| Yamashita, D | 1 |
| Otsuki, N | 1 |
| Hashikawa, K | 1 |
| Tahara, S | 1 |
| Nibu, K | 1 |
| Lorch, JH | 1 |
| Goloubeva, O | 1 |
| Cullen, K | 1 |
| Tan, M | 2 |
| Fasciano, J | 1 |
| Sammartino, DE | 1 |
| Giovaninni, M | 1 |
| Bories, E | 1 |
| Pesenti, C | 1 |
| Caillol, F | 1 |
| Minsat, M | 1 |
| Monges, G | 2 |
| Sarran, A | 1 |
| Resbeut, M | 2 |
| Rudkin, AK | 1 |
| Muecke, JS | 1 |
| Haylock, B | 1 |
| Wise, M | 1 |
| Neupane, R | 1 |
| Samuel, L | 2 |
| Dougal, M | 1 |
| Lloyd, A | 1 |
| Topham, C | 2 |
| Errihani, H | 1 |
| M'rabti, H | 1 |
| Ismaili, N | 1 |
| Inrhaoun, H | 1 |
| Elghissassi, I | 1 |
| Boscolo-Rizzo, P | 1 |
| Gava, A | 1 |
| Marchiori, C | 1 |
| Baggio, V | 1 |
| Da Mosto, MC | 1 |
| Bourgier, C | 2 |
| Pessoa, EL | 1 |
| Dunant, A | 1 |
| Heymann, S | 1 |
| Spielmann, M | 3 |
| Uzan, C | 1 |
| Mathieu, MC | 1 |
| Arriagada, R | 4 |
| Marsiglia, H | 1 |
| Lee, JM | 2 |
| Yang, SY | 1 |
| Yang, PW | 1 |
| Wu, MT | 1 |
| Hsu, CH | 4 |
| Chuang, TH | 1 |
| Chen, JS | 4 |
| Hsu, HH | 1 |
| Huang, PM | 1 |
| Kuo, SW | 1 |
| Svensson, H | 1 |
| Hatschek, T | 2 |
| Einbeigi, Z | 1 |
| Lim, KH | 1 |
| Lee, HN | 1 |
| Park, EK | 1 |
| Uncu, D | 2 |
| Ozdemir, NY | 1 |
| Aksoy, S | 3 |
| Abali, H | 1 |
| Oksuzoglu, BC | 1 |
| Budakoglu, B | 1 |
| Yildiz, R | 1 |
| Aslan, N | 1 |
| Zengin, N | 1 |
| Shin, US | 1 |
| Yoon, SN | 2 |
| Conradi, LC | 1 |
| Bleckmann, A | 1 |
| Schirmer, M | 1 |
| Sprenger, T | 1 |
| Jo, P | 1 |
| Homayounfar, K | 1 |
| Rothe, H | 1 |
| Middel, P | 1 |
| Becker, H | 5 |
| Ghadimi, MB | 1 |
| Beissbarth, T | 1 |
| Lambregts, DM | 1 |
| Vandecaveye, V | 1 |
| Barbaro, B | 1 |
| Bakers, FC | 1 |
| Lambrecht, M | 1 |
| Ott, K | 2 |
| Rachakonda, PS | 1 |
| Panzram, B | 1 |
| Keller, G | 1 |
| Lordick, F | 2 |
| Becker, K | 1 |
| Langer, R | 1 |
| Buechler, M | 1 |
| Hemminki, K | 1 |
| Kumar, R | 1 |
| Dettwiler, S | 1 |
| Beuzeboc, P | 6 |
| Alran, S | 1 |
| Laurence, V | 1 |
| Fréneaux, P | 1 |
| Sigal-Zafrani, B | 1 |
| Diéras, V | 3 |
| Vincent-Salomon, A | 1 |
| Maithel, SK | 1 |
| Coban, I | 1 |
| Kneuertz, PJ | 1 |
| Kooby, DA | 1 |
| El-Rayes, BF | 1 |
| Kauh, JS | 1 |
| Sarmiento, J | 1 |
| Volkan Adsay, N | 1 |
| Sun, DS | 1 |
| Klaver, YL | 2 |
| de Hingh, IH | 2 |
| Nishi, T | 2 |
| Warita, E | 1 |
| Miyamoto, J | 1 |
| Akutsu, N | 1 |
| Yamanaka, Y | 1 |
| Nagase, M | 1 |
| Mücke, T | 1 |
| Konen, M | 1 |
| Wagenpfeil, S | 1 |
| Kesting, MR | 1 |
| Wolff, KD | 1 |
| Hölzle, F | 1 |
| McCaffrey, R | 1 |
| Bahtiyar, M | 1 |
| Kohorn, EI | 2 |
| Chambers, JT | 3 |
| Schwartz, PE | 3 |
| Chambers, SK | 2 |
| Lin, PH | 1 |
| Chiu, CF | 1 |
| Lu, YS | 2 |
| Leibold, T | 1 |
| Akhurst, TJ | 1 |
| Chessin, DB | 1 |
| Yeung, HW | 1 |
| Macapinlac, H | 1 |
| Riedel, E | 1 |
| Mazumdar, M | 1 |
| Wong, WD | 2 |
| Larson, SM | 1 |
| Giorda, G | 1 |
| Boz, G | 1 |
| Gadducci, A | 1 |
| Lucia, E | 1 |
| De Piero, G | 1 |
| De Paoli, A | 2 |
| Innocente, R | 1 |
| Trovò, M | 1 |
| Sorio, R | 1 |
| Campagnutta, E | 1 |
| Regine, WF | 2 |
| Abrams, R | 1 |
| Safran, H | 1 |
| Hoffman, JP | 3 |
| Konski, A | 2 |
| Macdonald, JS | 12 |
| Hyodo, I | 1 |
| Arai, Y | 1 |
| Takiuchi, H | 2 |
| Yoshida, M | 3 |
| Koizumi, W | 4 |
| Iwase, H | 1 |
| Komaki, RU | 1 |
| Wu, TT | 2 |
| Hofmann, G | 1 |
| Langsenlehner, U | 1 |
| Langsenlehner, T | 1 |
| Glehr, M | 1 |
| Fuerst, F | 1 |
| Krippl, P | 1 |
| Strassburg, J | 1 |
| Ruppert, R | 1 |
| Ptok, H | 1 |
| Maurer, C | 1 |
| Junginger, T | 1 |
| Hermanek, P | 1 |
| Showalter, TN | 1 |
| Anne, PR | 1 |
| Chervoneva, I | 1 |
| Mitchell, EP | 1 |
| Yeo, CJ | 2 |
| Rosato, EL | 1 |
| Kennedy, EP | 1 |
| Berger, AC | 1 |
| Liu, D | 1 |
| Peng, R | 1 |
| Teng, X | 1 |
| Qin, T | 1 |
| Lin, G | 1 |
| Singh, LC | 1 |
| Chakraborty, A | 1 |
| Mishra, AK | 1 |
| Devi, TR | 1 |
| Sugandhi, N | 1 |
| Chintamani, C | 1 |
| Bhatnagar, D | 1 |
| Kapur, S | 1 |
| Saxena, S | 1 |
| Zheng, M | 1 |
| Liu, JH | 1 |
| Xiong, Y | 1 |
| Li, JD | 1 |
| He, L | 1 |
| Ren, YF | 1 |
| Wang, HY | 3 |
| Trigo, JM | 1 |
| Kerber, A | 1 |
| Bethe, U | 1 |
| Picard, M | 1 |
| Brummendorf, TH | 2 |
| Nakajima, K | 1 |
| Okada, K | 3 |
| Foster, NR | 1 |
| Marsoni, S | 1 |
| Kim, GP | 1 |
| Allegra, C | 1 |
| Moore, MJ | 2 |
| Gallinger, S | 1 |
| Lee, KT | 1 |
| Heo, JS | 4 |
| Choi, DW | 1 |
| Jang, KT | 1 |
| Park, HC | 2 |
| Necchi, A | 1 |
| Nicolai, N | 1 |
| Colecchia, M | 1 |
| Catanzaro, M | 1 |
| Torelli, T | 1 |
| Piva, L | 1 |
| Salvioni, R | 1 |
| Marcuello, E | 1 |
| Paré, L | 1 |
| Salazar, J | 1 |
| del Rio, E | 1 |
| Baiget, M | 1 |
| Miyagi, K | 1 |
| Suzuki, O | 1 |
| Choe, KS | 1 |
| Haraf, DJ | 13 |
| Solanki, A | 1 |
| Cohen, EE | 3 |
| Seiwert, TY | 1 |
| Stenson, KM | 5 |
| Blair, EA | 2 |
| Portugal, L | 3 |
| Villaflor, VM | 2 |
| Witt, ME | 6 |
| Vokes, EE | 18 |
| Salama, JK | 4 |
| Clarke, S | 1 |
| Scheithauer, W | 6 |
| Figer, A | 2 |
| Rittweger, K | 1 |
| Gilberg, F | 1 |
| Kitayama, J | 1 |
| Sunami, E | 1 |
| Saito, S | 3 |
| Kanazawa, T | 5 |
| Kazama, S | 1 |
| Nagawa, H | 1 |
| Kobunai, T | 1 |
| Matsuda, K | 1 |
| Nozawa, K | 1 |
| Iinuma, H | 1 |
| Horie, H | 2 |
| Ikeuchi, H | 1 |
| Eshima, K | 1 |
| Muto, T | 3 |
| Rastogi, P | 1 |
| Buyse, ME | 1 |
| Swain, SM | 3 |
| Robidoux, A | 2 |
| Liepman, MK | 1 |
| Pajon, ER | 1 |
| Dy, PA | 1 |
| Posada, JG | 2 |
| Melnik, MK | 1 |
| Piette, F | 1 |
| Mamounas, EP | 2 |
| Katz, MH | 2 |
| Wolff, R | 2 |
| Varadhachary, G | 2 |
| Javle, M | 1 |
| Lin, E | 2 |
| Fleming, JB | 2 |
| Pisters, PW | 4 |
| Qureshi, A | 1 |
| Verma, A | 1 |
| Ross, P | 1 |
| Landau, D | 1 |
| Giessen, C | 1 |
| Laubender, RP | 1 |
| Ankerst, DP | 1 |
| Schulz, C | 1 |
| Moosmann, N | 1 |
| Schalhorn, A | 2 |
| von Weikersthal, LF | 1 |
| Bolton, JS | 2 |
| Mahoney, MR | 2 |
| Farr, GH | 1 |
| Fitch, TR | 1 |
| Maples, WJ | 1 |
| Nagorney, DM | 2 |
| Rubin, J | 4 |
| Fuloria, J | 1 |
| Steen, PD | 1 |
| Kawaguchi, K | 2 |
| Yamada, H | 2 |
| Horie, A | 1 |
| Nomura, T | 2 |
| Iketani, S | 1 |
| Kanai, I | 1 |
| Nakatani, Y | 1 |
| Hamada, Y | 1 |
| Cohen, DJ | 1 |
| Newman, E | 1 |
| Iqbal, S | 2 |
| Chang, RY | 1 |
| Potmesil, M | 1 |
| Ryan, T | 1 |
| Donahue, B | 1 |
| Chandra, A | 1 |
| Utate, M | 1 |
| Hiotis, S | 1 |
| Pachter, LH | 1 |
| Hochster, H | 3 |
| Muggia, F | 1 |
| Pederson, AW | 1 |
| Seiwert, T | 1 |
| Zhou, N | 1 |
| An, X | 2 |
| Zang, Y | 1 |
| Zou, W | 1 |
| Shen, ZY | 1 |
| Kim, SJ | 1 |
| Nakayama, S | 1 |
| Shimazu, K | 1 |
| Tamaki, Y | 4 |
| Akazawa, K | 1 |
| Tsukamoto, F | 2 |
| Torikoshi, Y | 1 |
| Matsushima, T | 1 |
| Shibayama, M | 1 |
| Ishihara, H | 1 |
| Noguchi, S | 2 |
| Liauw, W | 1 |
| Gaedcke, J | 1 |
| Hess, C | 1 |
| Ghadimi, BM | 2 |
| Zhao, M | 1 |
| Wang, JP | 1 |
| Wu, PH | 2 |
| Kato, H | 4 |
| Igaki, H | 1 |
| Shinoda, M | 1 |
| Yabusaki, H | 1 |
| Kurita, A | 1 |
| Kanda, T | 2 |
| Yun, T | 1 |
| Han, JY | 1 |
| Choi, HL | 1 |
| Kim, HY | 1 |
| Kim, HT | 2 |
| Ji, JF | 1 |
| Cai, Y | 1 |
| Wu, H | 1 |
| Dou, FY | 1 |
| Li, ZY | 1 |
| Bu, ZD | 1 |
| Wu, AW | 1 |
| Tham, IW | 1 |
| Zhuchenko, AP | 1 |
| Kalganov, ID | 1 |
| Filon, AF | 1 |
| Wilson, PM | 1 |
| Lam, VW | 1 |
| Spiro, C | 1 |
| Laurence, JM | 1 |
| Johnston, E | 1 |
| Hollands, MJ | 1 |
| Pleass, HC | 1 |
| Richardson, AJ | 1 |
| Muratore, A | 1 |
| Zimmitti, G | 1 |
| Ribero, D | 1 |
| Mellano, A | 1 |
| Viganò, L | 1 |
| Capussotti, L | 1 |
| Crea, F | 2 |
| Paolicchi, E | 1 |
| Perrone, G | 1 |
| Danesi, R | 1 |
| Kokubu, A | 1 |
| Narisawa-Saito, M | 1 |
| Sasaki, H | 2 |
| Aoyagi, K | 1 |
| Yoshimatsu, Y | 1 |
| Tachimori, Y | 1 |
| Kushima, R | 1 |
| Kiyono, T | 1 |
| Weissinger, F | 1 |
| Reymond, M | 1 |
| Dumke, K | 1 |
| Krüger, M | 1 |
| Chang, CY | 1 |
| Choi, DH | 1 |
| Okamoto, N | 1 |
| Nagashima, K | 1 |
| Shimoda, T | 1 |
| Masutomi, K | 1 |
| Balachandran, A | 1 |
| Bhosale, P | 1 |
| Abdalla, EK | 1 |
| Abbruzzese, J | 2 |
| Chopin-Laly, X | 1 |
| Charnsangavej, C | 1 |
| Ahn, SH | 1 |
| Kim, SU | 1 |
| Choi, SB | 1 |
| Park, MS | 1 |
| Lee, DY | 1 |
| Kim, KS | 1 |
| Matsushita, K | 2 |
| Uchida, K | 1 |
| Ariga, H | 1 |
| Nemoto, K | 5 |
| Narazaki, K | 1 |
| Umezawa, R | 2 |
| Koto, M | 1 |
| Sugawara, T | 3 |
| Kubozono, M | 2 |
| Onodera, K | 1 |
| Chung, HJ | 1 |
| Tabe, Y | 1 |
| Suto, T | 1 |
| Shioya, M | 1 |
| Saito, J | 2 |
| Nakano, T | 1 |
| Scotté, M | 1 |
| Hamidou, H | 1 |
| Paillot, B | 2 |
| Michot, F | 1 |
| Soltys, SG | 1 |
| Choi, CY | 1 |
| Fee, WE | 2 |
| Pinto, HA | 1 |
| Le, QT | 1 |
| Sharma, DN | 1 |
| Jiang, R | 1 |
| Rodriguez, CP | 2 |
| Adelstein, DJ | 6 |
| Rybicki, LA | 2 |
| Saxton, JP | 4 |
| Lorenz, RR | 1 |
| Wood, BG | 3 |
| Scharpf, J | 1 |
| Ives, DI | 2 |
| Noh, JH | 4 |
| Ahn, YC | 2 |
| Sohn, I | 1 |
| Park, CK | 4 |
| Gogas, H | 2 |
| Dafni, U | 1 |
| Karina, M | 1 |
| Papadimitriou, C | 1 |
| Batistatou, A | 1 |
| Bobos, M | 1 |
| Kalofonos, HP | 1 |
| Eleftheraki, AG | 1 |
| Timotheadou, E | 1 |
| Bafaloukos, D | 2 |
| Christodoulou, C | 2 |
| Markopoulos, C | 1 |
| Briasoulis, E | 1 |
| Papakostas, P | 1 |
| Samantas, E | 2 |
| Kosmidis, P | 3 |
| Stathopoulos, GP | 1 |
| Karanikiotis, C | 1 |
| Pectasides, D | 2 |
| Dimopoulos, MA | 1 |
| Fountzilas, G | 3 |
| Abelson, JA | 1 |
| Murphy, JD | 1 |
| Minn, AY | 1 |
| Chung, M | 1 |
| Fisher, GA | 1 |
| Ford, JM | 1 |
| Kunz, P | 1 |
| Norton, JA | 1 |
| Visser, BC | 1 |
| Poultsides, GA | 1 |
| Chan, KM | 1 |
| Chiang, JM | 1 |
| Lee, CF | 1 |
| Yu, MC | 1 |
| Hsia, Y | 1 |
| Luo, S | 1 |
| Xu, M | 1 |
| Xiao, F | 1 |
| Fu, X | 1 |
| Zhou, B | 1 |
| Long, X | 1 |
| Xu, BQ | 1 |
| Tu, ZW | 1 |
| Liu, ZG | 1 |
| Zeng, MS | 1 |
| Reni, M | 1 |
| Balzano, G | 1 |
| Cereda, S | 1 |
| Passoni, P | 1 |
| Zerbi, A | 1 |
| Tronconi, MC | 1 |
| Milandri, C | 1 |
| Saletti, P | 1 |
| Rognone, A | 1 |
| Fugazza, C | 1 |
| Magli, A | 1 |
| Di Muzio, N | 1 |
| Di Carlo, V | 1 |
| Villa, E | 1 |
| Ziras, N | 2 |
| Kakolyris, S | 2 |
| Kentepozidis, N | 1 |
| Makrantonakis, P | 1 |
| Xynogalos, S | 1 |
| Christophyllakis, Ch | 1 |
| Kouroussis, Ch | 1 |
| Vamvakas, L | 2 |
| Georgoulias, V | 4 |
| Polyzos, A | 3 |
| Simpson, GR | 1 |
| Horvath, A | 1 |
| Annels, NE | 1 |
| Pencavel, T | 1 |
| Metcalf, S | 1 |
| Seth, R | 1 |
| Peschard, P | 1 |
| Coffin, RS | 1 |
| Mostafid, H | 1 |
| Melcher, AA | 1 |
| Harrington, KJ | 1 |
| Pandha, HS | 1 |
| Vestermark, LW | 1 |
| Jensen, HA | 1 |
| Jin, Y | 1 |
| Cai, YC | 1 |
| Cai, XY | 1 |
| Tan, YT | 1 |
| Shi, YX | 1 |
| Jiang, WQ | 1 |
| Karasawa, K | 3 |
| Hirowatari, H | 1 |
| Izawa, H | 1 |
| Furuya, T | 1 |
| Ito, K | 4 |
| An, HJ | 1 |
| Yun, SC | 1 |
| Hong, YS | 3 |
| Moretones, C | 1 |
| León, D | 1 |
| Navarro, A | 1 |
| Santacruz, O | 1 |
| Boladeras, AM | 1 |
| Macià, M | 1 |
| Cambray, M | 2 |
| Navarro, V | 1 |
| Modolell, I | 1 |
| Guedea, F | 1 |
| Miyashiro, I | 1 |
| Shingai, T | 2 |
| Ohigashi, H | 3 |
| Ishikawa, O | 3 |
| Yu, JC | 1 |
| Kang, WM | 1 |
| Ma, ZQ | 1 |
| Vormittag, L | 1 |
| Lemaire, C | 1 |
| Radonjic, D | 1 |
| Song, S | 1 |
| Hong, JC | 1 |
| McDonnell, SE | 1 |
| Liauw, SL | 1 |
| Sheng, W | 1 |
| Feng, XZ | 1 |
| Han, JQ | 1 |
| Matsumoto, M | 1 |
| Sakurai, T | 2 |
| Setoyama, T | 1 |
| Nabeki, B | 1 |
| Nakajo, M | 1 |
| MacLellan, SJ | 1 |
| MacKay, HJ | 1 |
| Ringash, J | 2 |
| Jacks, L | 1 |
| Kassam, Z | 1 |
| Conrad, T | 1 |
| Khalili, I | 1 |
| Okrainec, A | 1 |
| Tikidzhieva, A | 1 |
| Benner, A | 1 |
| Michel, S | 1 |
| Formentini, A | 4 |
| Dippold, W | 1 |
| von Knebel Doeberitz, M | 1 |
| Oonk, AMM | 1 |
| van Rijn, C | 1 |
| Smits, MM | 1 |
| Mulder, L | 1 |
| Laddach, N | 1 |
| Savola, SP | 1 |
| Wesseling, J | 1 |
| Rodenhuis, S | 1 |
| Imholz, ALT | 1 |
| Lips, EH | 1 |
| Buehrlen, M | 1 |
| Zwaan, CM | 1 |
| Granzen, B | 1 |
| Lassay, L | 1 |
| Deutz, P | 1 |
| Vorwerk, P | 1 |
| Staatz, G | 1 |
| Gademann, G | 1 |
| Oldenburger, F | 1 |
| Tamm, M | 1 |
| Mertens, R | 1 |
| Shitara, K | 2 |
| Mizota, A | 1 |
| Kondo, C | 2 |
| Kucukoner, M | 1 |
| Isikdogan, A | 1 |
| Arpaci, E | 1 |
| Bilici, M | 1 |
| Cetin, B | 1 |
| Inane, M | 1 |
| Kaplan, MA | 1 |
| Cayir, K | 1 |
| Yetisyigit, T | 1 |
| Ozdemir, N | 1 |
| Inal, A | 1 |
| Alkis, N | 1 |
| Tekin, SB | 1 |
| Eroglu, C | 1 |
| Turhal, S | 1 |
| Benekli, M | 1 |
| Buyukberber, S | 1 |
| Shanmugan, S | 1 |
| Arrangoiz, R | 1 |
| Nitzkorski, JR | 1 |
| Yu, JQ | 1 |
| Li, T | 1 |
| Cooper, H | 1 |
| Blank, S | 1 |
| Siewert, JR | 3 |
| Hompes, D | 1 |
| D'Hoore, A | 1 |
| Fieuws, S | 1 |
| Ceelen, W | 1 |
| Peeters, M | 1 |
| Van der Speeten, K | 1 |
| Bertrand, C | 1 |
| Legendre, H | 1 |
| Kerger, J | 1 |
| Arvold, ND | 1 |
| Clark, JW | 4 |
| Blaszkowsky, LS | 2 |
| Niemierko, A | 1 |
| Allen, JN | 1 |
| Kwak, EL | 2 |
| Wadlow, RC | 1 |
| Zhu, AX | 3 |
| Warshaw, AL | 2 |
| Bentzen, AG | 1 |
| Wanderås, EH | 1 |
| Wilsgaard, T | 1 |
| Kurzweg, T | 1 |
| Möckelmann, N | 1 |
| Laban, S | 1 |
| Knecht, R | 1 |
| Makhson, A | 1 |
| Gligorov, J | 1 |
| Lichinitser, M | 1 |
| Scotto, N | 1 |
| Mitchell, L | 1 |
| Tjulandin, S | 1 |
| Koca, D | 1 |
| Oztop, I | 1 |
| Yavuzsen, T | 1 |
| Ellidokuz, H | 1 |
| Yilmaz, U | 1 |
| Jang, SM | 1 |
| Lee, WS | 1 |
| Cho, TH | 1 |
| Zhao, HY | 2 |
| Hu, ZH | 2 |
| Lin, SX | 1 |
| Manopunya, M | 1 |
| Ying, H | 1 |
| Sawaki, A | 1 |
| Lang, I | 2 |
| Inbar, MJ | 1 |
| Kahán, Z | 1 |
| Beslija, S | 1 |
| Stemmer, SM | 1 |
| Kaufman, B | 1 |
| Zvirbule, Z | 1 |
| Steger, GG | 2 |
| Brodowicz, T | 1 |
| Zielinski, C | 2 |
| Filleron, T | 1 |
| Dalenc, F | 1 |
| Fumoleau, P | 2 |
| Kerbrat, P | 1 |
| Martin, AL | 1 |
| Roché, H | 1 |
| Varol, U | 1 |
| Karaca, B | 1 |
| Cakar, B | 1 |
| Sezgin, C | 1 |
| Karabulut, B | 1 |
| Uslu, R | 1 |
| Phillips, BE | 1 |
| Tubbs, RR | 1 |
| Rice, TW | 2 |
| Plesec, T | 1 |
| Videtic, GM | 1 |
| Yoshii, T | 1 |
| Ohkawa, S | 1 |
| Tamai, S | 1 |
| Kameda, Y | 1 |
| Oellers, P | 1 |
| Kao, AA | 1 |
| Abdelaziz, A | 1 |
| Feuer, W | 1 |
| Dubovy, SR | 1 |
| Peled, Y | 1 |
| Levavi, H | 1 |
| Krissi, H | 1 |
| Weill, Y | 1 |
| Sabah, G | 1 |
| Eitan, R | 1 |
| Peng, F | 1 |
| Zhu, J | 1 |
| Gong, Y | 1 |
| Mochinaga, S | 1 |
| Okahashi, T | 1 |
| Koga, S | 1 |
| Nakano, Y | 2 |
| Yakabe, T | 1 |
| Sumi, K | 1 |
| Kitahara, K | 1 |
| Fujito, H | 1 |
| Ohishi, T | 1 |
| Hisa, A | 1 |
| Takanosawa, M | 1 |
| Ichimura, K | 3 |
| Nakazawa, M | 1 |
| Giacchetti, S | 2 |
| Dugué, PA | 1 |
| Innominato, PF | 1 |
| Garufi, C | 1 |
| Tumolo, S | 2 |
| Coudert, B | 2 |
| Iacobelli, S | 2 |
| Smaaland, R | 1 |
| Tampellini, M | 2 |
| Adam, R | 3 |
| Moreau, T | 1 |
| Lévi, F | 2 |
| Legge, F | 1 |
| Lucidi, A | 1 |
| Iannone, V | 1 |
| Carone, V | 1 |
| Iitaka, D | 1 |
| Ichikawa, D | 3 |
| Murayama, Y | 2 |
| Nakanishi, M | 2 |
| Ochiai, T | 4 |
| Kokuba, Y | 1 |
| Sonoyama, T | 2 |
| Wang, TF | 1 |
| Xie, YT | 2 |
| Fan, ZQ | 1 |
| Lin, BY | 1 |
| Li, JF | 1 |
| Novarino, AM | 1 |
| Satolli, MA | 1 |
| Chiappino, I | 1 |
| Giacobino, A | 1 |
| Napoletano, R | 1 |
| Ceccarelli, M | 1 |
| Ciccone, G | 1 |
| Bertetto, O | 3 |
| Ma, J | 2 |
| Huang, XL | 1 |
| Neskey, DM | 1 |
| Giráldez, MD | 1 |
| Lozano, JJ | 1 |
| Cuatrecasas, M | 1 |
| Alonso-Espinaco, V | 1 |
| Mármol, M | 1 |
| Hörndler, C | 1 |
| Ortego, J | 1 |
| Escudero, P | 2 |
| Ramírez, G | 3 |
| Petry, C | 1 |
| Lasalvia, L | 1 |
| Bohmann, K | 1 |
| Wirtz, R | 1 |
| Mira, A | 1 |
| Castells, A | 1 |
| Minato, T | 1 |
| Seike, J | 1 |
| Yamai, H | 1 |
| Takechi, H | 1 |
| Yuasa, Y | 1 |
| Furukita, Y | 1 |
| Bando, Y | 1 |
| Tangoku, A | 3 |
| Schneider, BJ | 1 |
| Hayman, JA | 1 |
| Chang, AC | 1 |
| Orringer, MB | 1 |
| Pickens, A | 1 |
| Pan, CC | 1 |
| Merajver, SD | 1 |
| Urba, SG | 2 |
| Cacheux, W | 1 |
| Servois, V | 1 |
| Zefkili, S | 1 |
| Farkhondeh, F | 1 |
| Baranger, B | 1 |
| Mariani, P | 1 |
| Kwak, JY | 1 |
| Jang, SJ | 1 |
| Abgral, R | 1 |
| Le Roux, PY | 1 |
| Keromnes, N | 1 |
| Rousset, J | 1 |
| Valette, G | 1 |
| Gouders, D | 1 |
| Leleu, C | 1 |
| Mollon, D | 1 |
| Nowak, E | 1 |
| Querellou, S | 1 |
| Salaün, PY | 1 |
| Yao, W | 1 |
| Jiang, GL | 1 |
| Oh, SC | 1 |
| Nam, SH | 1 |
| Song, EK | 1 |
| Yim, CY | 1 |
| Perisanidis, C | 1 |
| Sulzbacher, I | 1 |
| Mittlböck, M | 3 |
| Mitchell, D | 1 |
| Czembirek, C | 1 |
| Schopper, C | 1 |
| Mima, K | 1 |
| Nakagawa, S | 2 |
| Kuroki, H | 1 |
| Kikuchi, K | 3 |
| Ryu, KW | 1 |
| Kim, YW | 1 |
| Choi, IJ | 1 |
| Choi, JJ | 1 |
| Lee, I | 1 |
| Cho, JH | 1 |
| Keum, KC | 1 |
| Collura, A | 1 |
| Marisa, L | 1 |
| Trojan, D | 1 |
| Buhard, O | 1 |
| Lagrange, A | 1 |
| Saget, A | 1 |
| Bombled, M | 1 |
| Méchighel, P | 1 |
| Ayadi, M | 1 |
| Muleris, M | 1 |
| de Reynies, A | 1 |
| Svrcek, M | 1 |
| Fléjou, JF | 1 |
| Florent, JC | 1 |
| Mahuteau-Betzer, F | 1 |
| Faussat, AM | 1 |
| Duval, A | 1 |
| Jacob, J | 1 |
| Fourchotte, V | 1 |
| Golden, DW | 1 |
| Rudra, S | 1 |
| Nwizu, T | 1 |
| Blair, E | 1 |
| Clavier, JB | 1 |
| Antoni, D | 1 |
| Atlani, D | 1 |
| Dufour, P | 1 |
| Kurtz, JE | 1 |
| Noel, G | 1 |
| Wiegel, T | 2 |
| Kron, M | 2 |
| Kontani, K | 1 |
| Kuroda, N | 1 |
| Murazawa, C | 1 |
| Norimura, S | 1 |
| Ohtani, M | 1 |
| Fujiwara-Honjo, N | 1 |
| Kushida, Y | 1 |
| Date, M | 1 |
| Haba, R | 1 |
| Houchi, H | 1 |
| Yamauchi, A | 1 |
| Yokomise, H | 1 |
| Kaneko, K | 1 |
| Yajima, Y | 1 |
| Yoda, Y | 1 |
| Ikematsu, H | 1 |
| Oono, Y | 1 |
| Chen, C | 1 |
| Linardou, H | 1 |
| Kalogeras, KT | 1 |
| Kronenwett, R | 1 |
| Kouvatseas, G | 1 |
| Wirtz, RM | 1 |
| Zagouri, F | 1 |
| Koutras, AK | 1 |
| Antoniou, E | 1 |
| Mantas, D | 1 |
| Paraskeva, P | 1 |
| Dimitroulis, D | 1 |
| Smyrnis, A | 1 |
| Nikitakis, N | 1 |
| Labadariou, A | 1 |
| Vernicos, P | 1 |
| Kostakis, A | 1 |
| Folkert, MR | 1 |
| Shih, KK | 1 |
| Abu-Rustum, NR | 2 |
| Jewell, E | 1 |
| Kollmeier, MA | 1 |
| Makker, V | 1 |
| Barakat, RR | 1 |
| Alektiar, KM | 2 |
| Takahashi, C | 3 |
| Abe, K | 2 |
| Tanabe, T | 3 |
| Shirata, Y | 1 |
| Xue, C | 1 |
| Yu, QT | 1 |
| Song, XQ | 1 |
| Wu, JX | 1 |
| Zhang, JW | 1 |
| Liu, JL | 1 |
| Zhao, LP | 1 |
| Zhao, YY | 1 |
| Ma, YX | 1 |
| Martella, B | 1 |
| Cardin, F | 1 |
| Lorenzetti, R | 1 |
| Terranova, C | 1 |
| Amato, B | 1 |
| Militello, C | 1 |
| Dewas, CV | 1 |
| Dalban, C | 1 |
| Petitfils, A | 1 |
| Peignaux, K | 1 |
| Truc, G | 1 |
| Martin, E | 1 |
| Khoury, C | 1 |
| Dewas, S | 1 |
| Bianchi, R | 1 |
| Bonnet, S | 1 |
| Faron, M | 1 |
| Elias, D | 5 |
| Deschamps, F | 1 |
| Dromain, C | 1 |
| Dumont, F | 1 |
| De Baere, T | 1 |
| Ducreux, M | 5 |
| Kang, EJ | 1 |
| Rousseau, D | 1 |
| Denis, F | 1 |
| Girault, S | 1 |
| Poirier, AL | 1 |
| Paumier, A | 1 |
| Hamy, A | 1 |
| Mahé, MA | 1 |
| Mesgouez-Nebout, N | 1 |
| Beriwal, S | 2 |
| Shukla, G | 1 |
| Shinde, A | 1 |
| Heron, DE | 2 |
| Kelley, JL | 2 |
| Edwards, RP | 2 |
| Sukumvanich, P | 2 |
| Richards, S | 1 |
| Olawaiye, AB | 1 |
| Krivak, TC | 2 |
| Smit, JK | 1 |
| Muijs, CT | 1 |
| Burgerhof, JG | 1 |
| Paardekooper, G | 1 |
| Timmer, PR | 1 |
| Muller, K | 1 |
| Woutersen, D | 1 |
| Mul, VE | 1 |
| van Dijk, BA | 1 |
| Langendijk, JA | 1 |
| Plukker, JT | 2 |
| Hua, XD | 1 |
| He, ZY | 1 |
| Kilic, D | 1 |
| Yalman, D | 1 |
| Aksu, G | 1 |
| Atasoy, BM | 1 |
| Igdem, S | 1 |
| Dincbas, FO | 1 |
| Yalcin, S | 3 |
| Tian, YF | 1 |
| Chen, TJ | 1 |
| Lin, CY | 1 |
| Lin, LC | 1 |
| Hsing, CH | 1 |
| Sheu, MJ | 1 |
| Lee, HH | 1 |
| Shiue, YL | 1 |
| Huang, HY | 1 |
| Pan, HY | 1 |
| Li, CF | 1 |
| Chen, SH | 2 |
| Covino, M | 2 |
| Gambacorta, MA | 4 |
| Galardi, A | 1 |
| Mangoni, M | 1 |
| Agresti, B | 1 |
| Franceschini, D | 1 |
| Scotti, V | 1 |
| Detti, B | 1 |
| Valeri, A | 1 |
| Messerini, L | 1 |
| Habermehl, D | 1 |
| Brecht, IC | 1 |
| Bergmann, F | 1 |
| Welzel, T | 1 |
| Rieken, S | 1 |
| Schirmacher, P | 1 |
| Debus, J | 3 |
| Combs, SE | 1 |
| Bisagni, G | 2 |
| Musolino, A | 1 |
| Panebianco, M | 1 |
| Ardizzoni, A | 1 |
| Gamucci, T | 1 |
| Passalacqua, R | 1 |
| Gnoni, R | 1 |
| Moretti, G | 1 |
| Machiels, JP | 1 |
| Kaminsky, MC | 1 |
| Keller, U | 1 |
| Goddemeier, T | 1 |
| Forssmann, U | 1 |
| Yaremko, BP | 1 |
| Palma, DA | 1 |
| Erickson, AL | 1 |
| Pierce, G | 1 |
| Malthaner, RA | 1 |
| Inculet, RI | 1 |
| Dar, AR | 1 |
| Rodrigues, GB | 1 |
| Yu, E | 1 |
| Kumamoto, Y | 1 |
| Kuratomi, Y | 1 |
| Toh, S | 1 |
| Shinokuma, A | 1 |
| Chujo, K | 1 |
| Komiyama, S | 3 |
| Wong, ZW | 2 |
| Tan, EH | 3 |
| Yap, SP | 2 |
| Tan, T | 2 |
| Leong, SS | 2 |
| Fong, KW | 2 |
| Wee, J | 2 |
| Robertson, JM | 1 |
| Cha, C | 1 |
| Andrews, JC | 1 |
| Ensminger, WD | 1 |
| Hartung, G | 1 |
| Samel, S | 1 |
| Pichlmeier, U | 1 |
| Post, S | 2 |
| Hehlmann, R | 2 |
| Queisser, W | 4 |
| Alonso, O | 1 |
| Delgado, L | 1 |
| Núñez, M | 1 |
| Vargas, C | 1 |
| Lopera, J | 1 |
| Andruskevicius, P | 1 |
| Sabini, G | 1 |
| Gaudiano, J | 1 |
| Musé, IM | 1 |
| Roca, R | 1 |
| Chen, CL | 1 |
| Hong, RL | 2 |
| Chen, KL | 1 |
| Lin, JF | 2 |
| Cheng, AL | 3 |
| Gotohda, N | 1 |
| Nishimura, M | 1 |
| Yoshida, J | 1 |
| Nagai, K | 1 |
| Lee, KD | 1 |
| Liu, TW | 1 |
| Wu, CW | 2 |
| Tiu, CM | 1 |
| Liu, JM | 1 |
| Chung, TR | 1 |
| Whang-Peng, J | 1 |
| Fredriksson, I | 1 |
| Liljegren, G | 1 |
| Arnesson, LG | 1 |
| Emdin, SO | 1 |
| Palm-Sjövall, M | 1 |
| Holmqvist, M | 1 |
| Frisell, J | 1 |
| Mawdsley, S | 2 |
| Hall, M | 1 |
| Matsui, H | 1 |
| Suzuka, K | 1 |
| Iitsuka, Y | 1 |
| Yamazawa, K | 1 |
| Mitsuhashi, A | 1 |
| Seki, K | 2 |
| Sekiya, S | 1 |
| Mohiuddin, M | 3 |
| Marks, G | 1 |
| Marks, J | 1 |
| Matsukuma, A | 1 |
| Araki, K | 2 |
| Kawaguchi, H | 1 |
| Kusumoto, H | 1 |
| Haraguchi, M | 1 |
| Prabhudesai, AG | 1 |
| Kumar, D | 1 |
| Nagy, A | 1 |
| Douillard, JY | 1 |
| Monson, J | 1 |
| Riess, H | 4 |
| Moylan, E | 2 |
| Jones, D | 1 |
| Dethling, J | 1 |
| Colman, J | 1 |
| Coward, L | 1 |
| MacGregor, S | 1 |
| Amano, H | 2 |
| Nimura, Y | 1 |
| Matsushiro, T | 1 |
| Nagakawa, T | 1 |
| Nakayama, T | 3 |
| Kitahara, S | 3 |
| Tamura, E | 2 |
| Calvo, E | 1 |
| González-Cao, M | 1 |
| Aramendía, JM | 1 |
| Fernández-Hidalgo, O | 1 |
| Martín-Algarra, S | 1 |
| Salgado, JE | 1 |
| Martínez-Monge, R | 2 |
| de Irala, J | 1 |
| Brugarolas, A | 1 |
| Katsuramaki, T | 1 |
| Furuhata, T | 1 |
| Kimura, Y | 6 |
| Ohmura, T | 2 |
| Mukaiya, M | 1 |
| Brown, TA | 1 |
| Ridge, JA | 2 |
| Goldberg, M | 1 |
| Fu, QG | 1 |
| Meng, FD | 1 |
| Shen, XD | 1 |
| Guo, RX | 1 |
| Bilchik, AJ | 2 |
| Wood, TF | 1 |
| Chawla, SP | 1 |
| Rose, DM | 1 |
| Chung, MH | 1 |
| Stern, SS | 1 |
| Foshag, LJ | 1 |
| Ramming, KP | 1 |
| Copur, S | 1 |
| Ledakis, P | 1 |
| Novinski, D | 1 |
| Mleczko, KL | 1 |
| Frankforter, S | 1 |
| Bolton, M | 1 |
| Fruehling, RM | 1 |
| VanWie, E | 1 |
| Norvell, M | 1 |
| Muhvic, J | 1 |
| Kouroussis, C | 1 |
| Mavroudis, D | 2 |
| Papadouris, S | 1 |
| Agelaki, S | 2 |
| Kalbakis, K | 2 |
| Panopoulos, C | 1 |
| Vardakis, N | 2 |
| Sarra, E | 1 |
| Shibata, S | 2 |
| Kawasaki, H | 1 |
| Nakai, M | 1 |
| Morohashi, H | 2 |
| Matsuya, H | 1 |
| Yamada, K | 1 |
| Morita, T | 2 |
| Sasaki, M | 2 |
| Takeuchi, I | 1 |
| Ohsawa, T | 1 |
| Nakada, H | 1 |
| Inokuma, S | 1 |
| Odaka, A | 1 |
| Hoshino, T | 1 |
| Murata, N | 1 |
| Hashimoto, D | 1 |
| Matsumoto, Y | 3 |
| Ishiwa, N | 1 |
| Morinaga, S | 2 |
| Noguchi, Y | 2 |
| Matsumoto, A | 3 |
| Okoshi, T | 1 |
| Hasuike, Y | 3 |
| Tujinaka, T | 1 |
| Jakesz, R | 5 |
| Hausmaninger, H | 4 |
| Kubista, E | 3 |
| Menzel, C | 1 |
| Bauernhofer, T | 1 |
| Seifert, M | 1 |
| Haider, K | 2 |
| Steindorfer, P | 5 |
| Fridrik, M | 3 |
| Wette, V | 1 |
| Shimizu, C | 2 |
| Chiba, N | 2 |
| Spencer, S | 1 |
| Wheeler, R | 1 |
| Peters, G | 1 |
| Meredith, R | 2 |
| Beenken, S | 1 |
| Nabel, L | 1 |
| Wooten, A | 1 |
| Soong, SJ | 2 |
| Salter, M | 1 |
| Verschueren, RC | 1 |
| Szabo, BG | 1 |
| Mulder, NH | 2 |
| Akbulut, H | 1 |
| Altuntas, F | 1 |
| Akbulut, KG | 1 |
| Ozturk, G | 1 |
| Cindoruk, M | 1 |
| Unal, E | 1 |
| Icli, F | 1 |
| Hashiguchi, Y | 1 |
| Sekine, T | 1 |
| Sakamoto, H | 1 |
| Nishimura, Y | 2 |
| Kazumoto, T | 1 |
| Sakura, M | 1 |
| Tanaka, Y | 5 |
| Yamada, R | 2 |
| Nakai, S | 1 |
| Morimoto, Y | 1 |
| Kitagawa, T | 1 |
| Kurihara, Y | 1 |
| Papagikos, M | 1 |
| Skibber, J | 2 |
| Janjan, NA | 7 |
| Feig, B | 2 |
| Hung, A | 1 |
| Delclos, M | 1 |
| Cleary, K | 3 |
| Britton, KR | 1 |
| Takai, Y | 2 |
| Miyata, T | 1 |
| Myerson, R | 3 |
| Zobeiri, I | 1 |
| Birnbaum, E | 1 |
| Fleshman, J | 1 |
| Kodner, I | 1 |
| Ratkin, G | 1 |
| Arkenau, HT | 1 |
| Bermann, A | 2 |
| Rettig, K | 2 |
| Strohmeyer, G | 2 |
| Porschen, R | 3 |
| Datta, NR | 1 |
| Nagar, YS | 1 |
| Singh, S | 1 |
| Naryan, L | 1 |
| Catalano, P | 1 |
| Rao, MS | 1 |
| O'Dwyer, PJ | 2 |
| Khan, Z | 1 |
| Misra, G | 1 |
| Fiander, AN | 1 |
| Dallimore, NS | 1 |
| Bechtel, J | 1 |
| Tepper, J | 1 |
| Thuss-Patience, PC | 2 |
| Kretzschmar, A | 1 |
| Krenn, V | 1 |
| Dörken, B | 1 |
| Raraty, MG | 1 |
| Hickey, H | 2 |
| Stocken, DD | 4 |
| Friess, H | 2 |
| Harris, EE | 1 |
| Schultz, D | 1 |
| Bertsch, H | 1 |
| Fox, K | 1 |
| Glick, J | 3 |
| Solin, LJ | 1 |
| Suzuki, E | 2 |
| Hirai, R | 1 |
| Ota, T | 2 |
| Shimizu, N | 1 |
| Chua, DT | 4 |
| Sham, JS | 5 |
| Au, GK | 4 |
| Andreadis, C | 1 |
| Vahtsevanos, K | 1 |
| Sidiras, T | 1 |
| Thomaidis, I | 1 |
| Antoniadis, K | 1 |
| Mouratidou, D | 1 |
| Schechter, BA | 1 |
| Nagler, RS | 1 |
| Kwong, PW | 1 |
| Hung, KN | 1 |
| Leung, LH | 1 |
| Saigenji, K | 2 |
| Ujiie, S | 1 |
| Terashima, M | 2 |
| Sakata, Y | 4 |
| Bouaouina, N | 1 |
| Boussen, H | 3 |
| Noh, SH | 3 |
| Min, JS | 3 |
| Jang, WI | 1 |
| Dimitrakopoulou-Strauss, A | 1 |
| Strauss, LG | 1 |
| Rudi, J | 1 |
| Weiss, RB | 2 |
| Woolf, SH | 1 |
| Demakos, E | 1 |
| Holland, JF | 2 |
| Falkson, G | 10 |
| Robbins, A | 1 |
| Bothun, S | 1 |
| Henderson, IC | 2 |
| Mohamed, F | 2 |
| Chang, D | 1 |
| Sugarbaker, PH | 10 |
| Schache, D | 2 |
| Bell, A | 1 |
| Poulsen, MG | 1 |
| Mackintosh, J | 1 |
| Schaffer, M | 2 |
| Krych, M | 1 |
| Pachmann, S | 1 |
| Abdel-Rahman, S | 1 |
| Schaffer, PM | 1 |
| Ertl-Wagner, B | 1 |
| D hmke, E | 1 |
| Issels, RD | 2 |
| Weisser, A | 1 |
| Willer, A | 2 |
| Emi, Y | 1 |
| Sakurai, M | 1 |
| Yonemura, Y | 2 |
| Kikkawa, N | 7 |
| Iijima, S | 2 |
| Naoi, Y | 2 |
| Tanigawa, T | 1 |
| Kurokawa, E | 2 |
| Fusai, G | 1 |
| Davidson, BR | 1 |
| Jan, JS | 2 |
| Chen, KY | 2 |
| Hsu, CY | 2 |
| Liang, WM | 1 |
| Makhnova, EV | 1 |
| Gershanovich, ML | 1 |
| Saini, A | 1 |
| Norman, AR | 5 |
| Hill, M | 5 |
| Hickish, T | 1 |
| Lofts, F | 1 |
| Jodrell, D | 1 |
| Ross, PJ | 4 |
| Oates, J | 3 |
| Denham, JW | 4 |
| Steigler, A | 1 |
| Kilmurray, J | 1 |
| Wratten, C | 1 |
| Burmeister, B | 1 |
| Lamb, DS | 2 |
| Joseph, D | 5 |
| Delaney, G | 1 |
| Christie, D | 2 |
| Jamieson, G | 1 |
| Ackland, S | 1 |
| Walpole, E | 1 |
| Harney, J | 1 |
| Goodchild, K | 1 |
| Phillips, H | 1 |
| Hoskin, PJ | 1 |
| Saunders, MI | 1 |
| Ulutin, HC | 1 |
| Ash, D | 1 |
| Dodwell, D | 1 |
| Nashimoto, A | 1 |
| Furukawa, H | 3 |
| Kitamura, M | 5 |
| Kinoshita, T | 3 |
| Yamamura, Y | 3 |
| Sasako, M | 1 |
| Kunii, Y | 3 |
| Motohashi, H | 2 |
| Samur, M | 1 |
| Bozcuk, HS | 1 |
| Kohli, M | 1 |
| Khan, MA | 1 |
| Mehta, P | 1 |
| Hutchins, L | 1 |
| Cascinu, S | 6 |
| Oettle, H | 2 |
| Cafiero, F | 1 |
| Gipponi, M | 1 |
| Lionetto, R | 1 |
| Graf, R | 1 |
| Wust, P | 5 |
| Hildebrandt, B | 3 |
| Gögler, H | 1 |
| Ullrich, R | 1 |
| Herrmann, R | 3 |
| Loré, JM | 1 |
| Kaufman, S | 1 |
| Sundquist, N | 2 |
| Chary, KK | 1 |
| Tallman, MS | 1 |
| Robert, NJ | 1 |
| LeMaistre, CF | 1 |
| Osborne, CK | 4 |
| Vaughan, WP | 1 |
| Gradishar, WJ | 3 |
| Pisansky, TM | 1 |
| Fetting, J | 1 |
| Paietta, E | 1 |
| Lazarus, HM | 1 |
| Snyder, ME | 1 |
| Catalano, PJ | 2 |
| Ghaemmaghami, F | 1 |
| Behtash, N | 1 |
| Yarandi, F | 1 |
| Moosavi, A | 1 |
| Modares, M | 1 |
| Toogeh, G | 1 |
| Khanafshar, N | 1 |
| Jonat, W | 1 |
| Kölbl, H | 1 |
| Jänicke, F | 1 |
| Kieback, DG | 1 |
| Kuhn, W | 1 |
| Schindler, AE | 1 |
| Mohrmann, S | 1 |
| Deniaud-Alexandre, E | 3 |
| Tiret, E | 4 |
| Sezeur, A | 3 |
| Gallot, D | 3 |
| Parc, R | 4 |
| Qu, SH | 1 |
| Pène, F | 4 |
| Schlienger, M | 4 |
| Zeng, J | 1 |
| Yu, QW | 1 |
| Liu, WW | 1 |
| Zeng, ZY | 2 |
| An, FS | 1 |
| Huang, JQ | 1 |
| Yoshizawa, H | 1 |
| Tanaka, J | 2 |
| Kagamu, H | 1 |
| Maruyama, Y | 1 |
| Miyao, H | 1 |
| Iwashima, A | 1 |
| Gejyo, F | 1 |
| Koike, R | 1 |
| Nakamatsu, K | 1 |
| Kanamori, S | 1 |
| Shigeoka, H | 1 |
| Shiozaki, H | 3 |
| Yeoh, C | 1 |
| Kim, YI | 6 |
| Kim, WS | 3 |
| Jung, CW | 2 |
| Im, YH | 4 |
| Park, K | 4 |
| Park, CH | 4 |
| Flieger, D | 1 |
| Keller, R | 1 |
| Fischbach, W | 1 |
| Brown, CL | 1 |
| Ternent, CA | 1 |
| Thorson, AG | 1 |
| Christensen, MA | 1 |
| Blatchford, GJ | 1 |
| Shashidharan, M | 1 |
| Haynatzki, GR | 1 |
| CAVANAGH, D | 1 |
| MARTIN, DS | 3 |
| HERNANDEZ-ROMAN, P | 1 |
| Guardiola, E | 1 |
| Magné, N | 3 |
| Thyss, A | 2 |
| Otto, J | 1 |
| Giroux, B | 1 |
| Mouri, Z | 1 |
| Schneider, M | 4 |
| Giannakakis, T | 1 |
| Vadiaka, M | 2 |
| Dimitrakopoulos, A | 3 |
| Karadima, D | 1 |
| Rokana, S | 1 |
| Papalambros, E | 3 |
| Papastratis, G | 3 |
| Margaris, H | 2 |
| Tsipras, H | 2 |
| Hollis, D | 1 |
| Cooke, E | 1 |
| Lorenz, M | 2 |
| Müller, HH | 1 |
| Schramm, H | 1 |
| Gassel, HJ | 1 |
| Hauss, J | 1 |
| Ridwelski, K | 1 |
| Schäfer, H | 1 |
| Long, HJ | 1 |
| Dummer, R | 1 |
| Beyeler, M | 1 |
| Morcinek, J | 1 |
| Burg, G | 1 |
| Chwaliński, M | 1 |
| Rogowski, W | 1 |
| Shimoyama, S | 1 |
| Kataoka, M | 2 |
| Mori, T | 11 |
| Iwasaki, Y | 6 |
| Katayanagi, S | 3 |
| Kaji, M | 1 |
| Mizuta, M | 1 |
| Akazawa, S | 3 |
| Yamashina, T | 1 |
| Murakami, T | 1 |
| Nakazima, T | 1 |
| Kotake, K | 1 |
| Koyama, Y | 3 |
| Stippel, DL | 1 |
| Töx, U | 1 |
| Gossmann, A | 1 |
| Beckurts, KT | 1 |
| Hölscher, AH | 1 |
| Semiglazov, VF | 3 |
| Maksimov, SIa | 1 |
| Semiglazov, VV | 1 |
| Kosnikov, AG | 1 |
| Ghahremani, MT | 1 |
| Stefenelli, U | 1 |
| Bitter, K | 1 |
| Reed, N | 1 |
| Kaye, SB | 3 |
| Tsujie, M | 1 |
| Handa, R | 1 |
| Oshima, S | 1 |
| Tamesa, T | 2 |
| Mori, N | 3 |
| Takemoto, N | 1 |
| Yamasaki, T | 1 |
| Oka, M | 2 |
| Balart, J | 1 |
| Balmaña, J | 1 |
| Rius, X | 1 |
| Gallen, M | 1 |
| Navarro, S | 1 |
| Arcusa, A | 1 |
| Gallardo, E | 1 |
| Brunet, J | 1 |
| Lou, E | 1 |
| Kellman, RM | 1 |
| Hutchison, R | 1 |
| Shillitoe, EJ | 1 |
| Sueyoshi, S | 2 |
| Sasahara, H | 2 |
| Matono, S | 1 |
| Yamana, H | 2 |
| Fujita, H | 3 |
| Ring, A | 1 |
| Webb, A | 2 |
| Allum, WH | 1 |
| Ebbs, S | 2 |
| Gui, G | 1 |
| Sacks, NP | 1 |
| Okabe, S | 1 |
| Tang, ZY | 3 |
| Fan, J | 1 |
| Wu, ZQ | 1 |
| Ji, Y | 1 |
| Xiao, YS | 1 |
| Shi, YH | 1 |
| Li, XM | 1 |
| Sun, QM | 1 |
| Liu, YK | 1 |
| Ye, SL | 2 |
| Assersohn, L | 1 |
| Ward, C | 1 |
| Waters, JS | 3 |
| Hill, ME | 1 |
| Schüll, B | 1 |
| Kornek, GV | 3 |
| Argiris, A | 2 |
| Murphy, BA | 1 |
| Langer, CJ | 2 |
| Köhne, CH | 1 |
| Peyromaure, M | 1 |
| Slama, J | 1 |
| Ponvert, D | 1 |
| Debré, B | 1 |
| Zerbib, M | 1 |
| Buyse, M | 5 |
| Burzykowski, T | 1 |
| Piedbois, P | 5 |
| Mizutani, Y | 1 |
| Fukushima, M | 1 |
| Yoshida, O | 1 |
| Nakanishi, H | 1 |
| Li, YN | 1 |
| Miki, T | 1 |
| Ernst, MF | 1 |
| Voogd, AC | 1 |
| Coebergh, JW | 1 |
| Poortmans, PM | 1 |
| Roukema, JA | 1 |
| Hollis, DR | 1 |
| McCollum, AD | 1 |
| Brady, D | 1 |
| Cummings, B | 2 |
| Heide, J | 1 |
| Krüll, A | 1 |
| Berger, J | 1 |
| Hong, TJ | 1 |
| Cohen, DP | 1 |
| Tyler, DS | 3 |
| Anscher, MS | 3 |
| Ludwig, KA | 1 |
| Seigler, HF | 2 |
| Mantyh, C | 1 |
| Morse, MA | 2 |
| Petros, WP | 1 |
| Honeycutt, W | 1 |
| Spector, NL | 1 |
| Ertel, PJ | 1 |
| Mangum, SG | 1 |
| Hurwitz, HI | 2 |
| Ezzat, AA | 1 |
| Ibrahim, EM | 1 |
| Ajarim, DS | 1 |
| Rahal, MM | 1 |
| Raja, MA | 1 |
| Tulbah, AM | 1 |
| Al-Malik, OA | 1 |
| Al-Shabanah, M | 1 |
| Sorbris, R | 1 |
| Allen, MJ | 1 |
| Ford, HE | 1 |
| Tebbutt, N | 1 |
| Mulligan, ED | 1 |
| Dunne, B | 1 |
| Griffin, M | 1 |
| Keeling, N | 1 |
| Bassi, C | 1 |
| Beger, H | 1 |
| Fernandez-Cruz, L | 1 |
| Lacaine, F | 1 |
| Falconi, M | 1 |
| Pederzoli, P | 1 |
| Pap, A | 1 |
| Francis, DL | 1 |
| Visvikis, D | 1 |
| Costa, DC | 1 |
| Croasdale, I | 1 |
| Arulampalam, TH | 1 |
| Luthra, SK | 1 |
| Taylor, I | 2 |
| Ell, PJ | 1 |
| Bellon, JR | 1 |
| Shulman, LN | 1 |
| Come, SE | 1 |
| Gelman, RS | 6 |
| Silver, BJ | 1 |
| Harris, JR | 2 |
| Recht, A | 3 |
| Gething, S | 1 |
| Haiba, M | 1 |
| Brun, EA | 1 |
| Salum, G | 1 |
| Ortiz, EH | 1 |
| Bologna, F | 1 |
| Lacava, JA | 1 |
| Loprinzi, CL | 1 |
| Thomé, SD | 1 |
| Benedetti, J | 1 |
| Francini, G | 3 |
| Francois Seitz, J | 1 |
| Cha, SS | 3 |
| Heldebrant, MP | 1 |
| Toi, M | 4 |
| Hozumi, Y | 1 |
| Iwata, H | 1 |
| Hooiveld, EA | 1 |
| Haanen, JB | 1 |
| Westermann, AM | 1 |
| Petit, T | 1 |
| Claude, L | 1 |
| Carrie, C | 1 |
| Machtay, M | 4 |
| Rosenthal, DI | 2 |
| Chalian, AA | 1 |
| Lustig, R | 1 |
| Hershock, D | 1 |
| Miller, L | 1 |
| Weinstein, GS | 1 |
| Weber, RS | 2 |
| Sideris, L | 1 |
| Pocard, M | 1 |
| Edè, C | 1 |
| Ben Hassouna, D | 1 |
| Côté, JF | 1 |
| Morimoto, K | 1 |
| Koh, M | 1 |
| Bonadonna, G | 12 |
| Zambetti, M | 5 |
| Gianni, L | 3 |
| Valagussa, P | 12 |
| Lerouge, D | 1 |
| Laugier, A | 2 |
| Cohen, SM | 1 |
| Osaki, A | 1 |
| Tanabe, K | 1 |
| Toge, T | 1 |
| Gal, R | 1 |
| Sadikov, E | 1 |
| Sulkes, J | 1 |
| Klein, B | 1 |
| Koren, R | 1 |
| Peake, DR | 1 |
| Glaholm, JG | 1 |
| Wallace, DM | 1 |
| Komaki, R | 2 |
| Putnam, JB | 2 |
| Lynch, PM | 3 |
| Smythe, R | 2 |
| Vaporciyan, A | 2 |
| Faust, J | 1 |
| Cohen, DS | 1 |
| Nivers, R | 1 |
| Roth, JA | 2 |
| Joh, JW | 1 |
| Park, YJ | 1 |
| Park, W | 1 |
| Pall, A | 1 |
| Mahajan, BB | 1 |
| Puri, KP | 1 |
| Gupta, RR | 1 |
| Meza, LA | 1 |
| Amin, B | 1 |
| Samid, D | 1 |
| Hill, T | 1 |
| Chen, YM | 1 |
| Lower, EE | 1 |
| Marcom, PK | 1 |
| Dräger, J | 1 |
| Lüdemann, L | 1 |
| Sreenivasa, G | 1 |
| Tullius, SG | 1 |
| Amthauer, H | 1 |
| Neuhaus, P | 1 |
| Kaçar, S | 1 |
| Kahya, M | 1 |
| Gürkan, A | 1 |
| Karaca, C | 1 |
| Varilsüha, C | 1 |
| Uslu, A | 1 |
| Askmalm, MS | 1 |
| Carstensen, J | 2 |
| Nordenskjöld, B | 5 |
| Olsson, B | 1 |
| Rutqvist, LE | 5 |
| Skoog, L | 6 |
| Stål, O | 4 |
| Bathe, OF | 1 |
| Dowden, S | 1 |
| Sutherland, F | 1 |
| Dixon, E | 1 |
| Butts, C | 1 |
| Bigam, D | 1 |
| Walley, B | 1 |
| Ruether, D | 1 |
| Martenson, JA | 4 |
| Mailliard, JA | 2 |
| Donohue, JH | 2 |
| Fisher, B | 9 |
| Poon, D | 1 |
| Cheung, YB | 1 |
| Chua, ET | 1 |
| Costamagna, G | 1 |
| Deodato, F | 1 |
| Luzi, S | 1 |
| Barbi, S | 1 |
| Perri, V | 1 |
| Trodella, L | 2 |
| Garcea, G | 1 |
| Polemonivi, N | 1 |
| O'Leary, E | 1 |
| Lloyd, TD | 1 |
| Dennison, AR | 1 |
| Berry, DP | 1 |
| Urminská, H | 1 |
| Kohlová, T | 1 |
| Nová, M | 1 |
| Cesák, T | 1 |
| Harting, MT | 1 |
| Blakely, ML | 1 |
| Herzog, CE | 1 |
| Lally, KP | 1 |
| Andrassy, RJ | 1 |
| Song, ST | 1 |
| Yu, JX | 1 |
| Tucci, A | 1 |
| Rinaldi, A | 1 |
| Colarusso, D | 1 |
| Pizza, C | 1 |
| Reggiardo, G | 2 |
| Manzione, L | 2 |
| Wu, DH | 1 |
| Chen, LH | 1 |
| Katopodis, R | 1 |
| Stewart, G | 1 |
| Gennatas, K | 2 |
| Skopelitis, HM | 1 |
| Zacharakis, M | 1 |
| Kouraklis, G | 1 |
| Vasiliou, J | 1 |
| Felekouras, E | 1 |
| Voros, D | 1 |
| Zografos, G | 1 |
| Balafouta, M | 1 |
| Paraskevaidis, M | 1 |
| Safioleas, M | 1 |
| Fotiadis, K | 1 |
| Karatzas, G | 1 |
| Birtle, AJ | 2 |
| Newby, JC | 1 |
| Harland, SJ | 1 |
| Delvart, V | 1 |
| Pascal, G | 1 |
| Valeanu, A | 1 |
| Castaing, D | 2 |
| Azoulay, D | 1 |
| Paule, B | 1 |
| Kunstlinger, F | 1 |
| Ghémard, O | 1 |
| Bismuth, H | 2 |
| Ribeiro, U | 2 |
| Silva e Sousa, AH | 2 |
| Campos, FG | 3 |
| Kiss, DR | 3 |
| Taghian, A | 1 |
| Jeong, JH | 1 |
| Mamounas, E | 2 |
| Anderson, S | 1 |
| Bryant, J | 3 |
| Deutsch, M | 1 |
| Gullu, I | 2 |
| Altundag, O | 2 |
| Ozyar, E | 2 |
| Cengiz, M | 2 |
| Akyol, F | 2 |
| Taillier, G | 1 |
| Triboulet, JP | 1 |
| O'Boyle, K | 1 |
| Medinger, M | 1 |
| Steinbild, S | 1 |
| Mross, K | 1 |
| Tschmelitsch, J | 2 |
| Hager, E | 1 |
| Karstens, JH | 1 |
| Schmidberger, H | 1 |
| Raab, R | 2 |
| Madoff, RD | 2 |
| Brücher, BL | 1 |
| Stein, HJ | 1 |
| Zimmermann, F | 2 |
| Werner, M | 1 |
| Sarbia, M | 1 |
| Busch, R | 2 |
| Dittler, HJ | 1 |
| Molls, M | 2 |
| Fink, U | 2 |
| Yucel, T | 1 |
| Hosal, S | 1 |
| Sozeri, B | 1 |
| Hirabayashi, K | 1 |
| Numa, F | 1 |
| Stanclift, RM | 1 |
| Gilson, SD | 1 |
| Matsumoto, G | 1 |
| Tsuruta, K | 1 |
| Okamoto, A | 1 |
| Hara, Y | 3 |
| Irie, T | 1 |
| Arii, S | 2 |
| Nakashima, S | 1 |
| Araki, Y | 2 |
| Kikuchi, S | 1 |
| Sakakura, C | 1 |
| Hagiwara, A | 2 |
| Yamagishi, H | 1 |
| Inaba, S | 1 |
| Yoshitani, S | 1 |
| Imaizumi, H | 1 |
| Kuroda, M | 1 |
| Yokoi, M | 1 |
| Harada, H | 1 |
| Takashima, S | 3 |
| Kiyonaga, H | 1 |
| Miyashita, K | 1 |
| Okumura, N | 1 |
| Morioka, N | 1 |
| Aizawa, K | 1 |
| Tsuchida, M | 1 |
| Sakon, M | 1 |
| Kondo, M | 1 |
| Ota, H | 1 |
| Damdinsuren, B | 1 |
| Marubashi, S | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Nakamori, S | 3 |
| Li, HH | 1 |
| Duan, ZH | 1 |
| Zhang, HW | 1 |
| Gan, YH | 2 |
| Yie, SL | 1 |
| Ren, ZG | 2 |
| Xia, JL | 2 |
| Zhang, BH | 1 |
| Ge, NL | 2 |
| Yang, BW | 1 |
| Birocco, N | 1 |
| Dongiovanni, D | 1 |
| Numico, G | 4 |
| Colantonio, I | 1 |
| Bontemps, P | 1 |
| Bourgeois, H | 1 |
| Dutin, JP | 1 |
| Philippi, MH | 1 |
| Bendahmane, B | 1 |
| Mallard-Carre, M | 1 |
| Tubiana-Mathieu, N | 2 |
| Lee, HR | 2 |
| Park, J | 1 |
| Lee, KE | 2 |
| Chung, CW | 1 |
| Cadron, I | 1 |
| Vergote, I | 2 |
| Frassineti, G | 1 |
| Dogliotti, L | 2 |
| Rosso, R | 10 |
| Di Costanzo, F | 1 |
| Costanzo, FD | 1 |
| Bruzzi, P | 1 |
| Pucciarelli, S | 2 |
| Toppan, P | 2 |
| Friso, ML | 3 |
| Russo, V | 1 |
| Pasetto, L | 1 |
| Urso, E | 2 |
| Marino, F | 1 |
| Ambrosi, A | 1 |
| Lise, M | 2 |
| Nahas, SC | 1 |
| Slee, PH | 1 |
| Rodenburg, CJ | 1 |
| Nortier, JW | 1 |
| van Bochove, A | 1 |
| Pilotti, S | 1 |
| Sohn, HJ | 1 |
| Papadopoulou-Zekeridou, P | 1 |
| Alexandridis, E | 1 |
| Delithanasis, I | 1 |
| Zekeridis, T | 1 |
| Lagra, F | 1 |
| Krokidis, X | 1 |
| Lazaridis, N | 1 |
| Ragaz, J | 3 |
| Olivotto, IA | 2 |
| Spinelli, JJ | 2 |
| Phillips, N | 1 |
| Jackson, SM | 1 |
| Wilson, KS | 2 |
| Knowling, MA | 1 |
| Coppin, CM | 1 |
| Weir, L | 1 |
| Le, N | 1 |
| Durand, R | 1 |
| Coldman, AJ | 1 |
| Wheeler, JM | 1 |
| Dodds, E | 1 |
| Warren, BF | 2 |
| Cunningham, C | 1 |
| George, BD | 1 |
| Jones, AC | 1 |
| Mortensen, NJ | 1 |
| Wutzl, A | 1 |
| Kermer, C | 1 |
| Glaser, C | 1 |
| Poeschl, PW | 1 |
| Sikora, SS | 1 |
| Balachandran, P | 1 |
| Dimri, K | 1 |
| Rastogi, N | 1 |
| Kumar, A | 1 |
| Saxena, R | 1 |
| Kapoor, VK | 1 |
| Marti, A | 1 |
| Rixe, O | 1 |
| Janot, F | 4 |
| Julieron, M | 1 |
| Gatineau, M | 1 |
| Temam, S | 1 |
| Armand, JP | 10 |
| Domenge, C | 5 |
| Luboinski, B | 2 |
| Park, DJ | 2 |
| Lu, B | 1 |
| Yang, DY | 1 |
| Gordon, M | 1 |
| Yun, J | 1 |
| Press, OA | 1 |
| Vallböhmer, D | 1 |
| Rhodes, K | 1 |
| Chan, AK | 1 |
| Wong, A | 2 |
| Jenken, D | 1 |
| Heine, J | 1 |
| Buie, D | 1 |
| Johnson, D | 2 |
| Gibson, MK | 1 |
| Holcroft, CA | 1 |
| Kvols, LK | 2 |
| Budach, V | 3 |
| Stuschke, M | 1 |
| Budach, W | 1 |
| Baumann, M | 1 |
| Geismar, D | 1 |
| Grabenbauer, G | 1 |
| Lammert, I | 1 |
| Jahnke, K | 1 |
| Stueben, G | 1 |
| Herrmann, T | 1 |
| Bamberg, M | 1 |
| Hinkelbein, W | 1 |
| Wernecke, KD | 1 |
| Garcia, AA | 2 |
| Blessing, JA | 7 |
| Darcy, KM | 2 |
| Mannel, RS | 1 |
| Miller, DS | 1 |
| Husseinzadeh, N | 1 |
| Langer, C | 1 |
| Milano, MT | 2 |
| Kao, J | 2 |
| Mittal, BB | 2 |
| Weichselbaum, RR | 9 |
| Ferrigno, R | 2 |
| Nakamura, RA | 1 |
| Dos Santos Novaes, PE | 1 |
| Pellizzon, AC | 1 |
| Maia, MA | 1 |
| Fogarolli, RC | 1 |
| Salvajoli, JV | 1 |
| Filho, WJ | 1 |
| Lopes, A | 3 |
| Nishida Arazawa, ST | 1 |
| Rawet, V | 1 |
| Coelho Siqueira, SA | 1 |
| Gama-Rodrigues, JJ | 1 |
| Chen, EC | 2 |
| Cai, L | 2 |
| Cui, NJ | 3 |
| Brinkmann, OA | 1 |
| Bruns, F | 1 |
| Gosheger, G | 1 |
| Micke, O | 2 |
| Hertle, L | 1 |
| Penberthy, DR | 1 |
| Shepard, RC | 1 |
| Adams, R | 1 |
| Jones, RS | 1 |
| Schippinger, W | 2 |
| Jagoditsch, M | 2 |
| Sorré, C | 1 |
| Mischinger, HJ | 2 |
| Hofbauer, F | 2 |
| Holzberger, P | 1 |
| Mermershtain, W | 2 |
| Gusakova, I | 1 |
| Walfish, S | 1 |
| Cohen, Y | 3 |
| Ariad, S | 1 |
| Bonneterre, J | 2 |
| Bercez, C | 1 |
| Bonneterre, ME | 1 |
| Lenne, X | 1 |
| Dervaux, B | 1 |
| Hundahl, SA | 1 |
| Fisher, R | 1 |
| Mackay, J | 2 |
| Kneebone, A | 2 |
| McClure, B | 1 |
| Rischin, D | 2 |
| Lin, RX | 1 |
| Tuo, CW | 1 |
| Lü, QJ | 1 |
| Wang, SQ | 1 |
| Banga, R | 1 |
| Ramsden, J | 1 |
| Cox, G | 1 |
| Hirabayashi, N | 2 |
| Takiyama, W | 1 |
| Miyashita, Y | 2 |
| Nakazato, H | 4 |
| Nakao, A | 3 |
| Palmer, G | 1 |
| Martling, A | 1 |
| Blomqvist, L | 1 |
| Cedermark, B | 2 |
| Holm, T | 1 |
| Kessler, H | 2 |
| Matzel, KE | 1 |
| Schneider, IH | 2 |
| Gellermann, J | 2 |
| Wlodarczyk, W | 1 |
| Ganter, H | 1 |
| Nicolau, A | 1 |
| Rau, B | 2 |
| Tilly, W | 2 |
| Fähling, H | 1 |
| Nadobny, J | 1 |
| Hishinuma, S | 1 |
| Tomikawa, M | 1 |
| Ozawa, I | 1 |
| Katano, S | 1 |
| Tsukiyama, I | 1 |
| Mayordomo, JI | 1 |
| Lara, R | 1 |
| Lastra, R | 1 |
| Ortega, E | 1 |
| Polo, E | 1 |
| Saenz-Cusi, A | 1 |
| Tres, A | 1 |
| Herbst, RS | 1 |
| Arquette, M | 1 |
| Shin, DM | 2 |
| Dicke, K | 1 |
| Azarnia, N | 1 |
| Hong, WK | 7 |
| Cho, EK | 1 |
| Lee, WK | 1 |
| Lee, SN | 1 |
| Bang, SM | 2 |
| Park, DK | 1 |
| Park, YH | 1 |
| Windschall, A | 1 |
| Ott, OJ | 1 |
| Strnad, V | 1 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Hanyu, F | 1 |
| Murthy, R | 1 |
| Honavar, SG | 1 |
| Burman, S | 1 |
| Vemuganti, GK | 1 |
| Naik, MN | 1 |
| Reddy, VA | 1 |
| Guadagnolo, BA | 1 |
| Weeks, L | 1 |
| Wirth, LJ | 1 |
| Norris, CM | 1 |
| Sullivan, CA | 1 |
| Goguen, L | 1 |
| Busse, PM | 1 |
| Yom, SS | 1 |
| Biel, MA | 1 |
| Sinard, RJ | 1 |
| El-Naggar, AK | 1 |
| Puri, DR | 1 |
| Chou, W | 1 |
| Lee, N | 1 |
| Yeh, KH | 2 |
| Hsu, C | 2 |
| Kuo, SH | 1 |
| Li, SJ | 1 |
| Biondo, S | 1 |
| Navarro, M | 1 |
| Marti-Rague, J | 1 |
| Arriola, E | 1 |
| Pares, D | 1 |
| Del Rio, C | 1 |
| Novell, V | 1 |
| Lin, ZY | 1 |
| Li, LX | 1 |
| Shen, YF | 1 |
| Haugen, H | 1 |
| Johansson, KA | 1 |
| Ejnell, H | 1 |
| Edström, S | 1 |
| Mercke, C | 1 |
| Mitsuyama, S | 3 |
| Anan, K | 1 |
| Hitre, E | 1 |
| Budai, B | 1 |
| Adleff, V | 1 |
| Czeglédi, F | 1 |
| Horváth, Z | 1 |
| Gyergyay, F | 1 |
| Kovács, T | 1 |
| Orosz, Z | 1 |
| Kásler, M | 1 |
| Kralovánszky, J | 1 |
| Rahman, M | 1 |
| Kodaira, S | 3 |
| Yasutomi, M | 2 |
| Sorscher, SM | 1 |
| Kosugi, S | 1 |
| Ohashi, M | 1 |
| Nishimaki, T | 1 |
| Lopez-Graniel, C | 1 |
| Dolores, R | 1 |
| Cetina, L | 1 |
| Gonzalez, A | 1 |
| Cantu, D | 1 |
| Chanona, J | 1 |
| Uribe, J | 1 |
| Candelaria, M | 1 |
| Brom, R | 1 |
| de la Garza, J | 1 |
| Duenas-Gonzalez, A | 1 |
| Shim, YM | 1 |
| Bonetti, M | 1 |
| Nasi, ML | 1 |
| Rudenstam, CM | 5 |
| Holmberg, SB | 2 |
| Lindtner, J | 4 |
| Golouh, R | 2 |
| Collins, J | 4 |
| Crivellari, D | 3 |
| Carbone, A | 1 |
| Thürlimann, B | 2 |
| Simoncini, E | 3 |
| Fey, MF | 2 |
| Gelber, RD | 8 |
| Coates, AS | 4 |
| Sanuki-Fujimoto, N | 1 |
| Palmer, JL | 1 |
| Morrison, W | 1 |
| Clayman, G | 1 |
| Goepfert, H | 3 |
| Ang, KK | 2 |
| Grainger, J | 1 |
| Richman, P | 1 |
| Makris, A | 1 |
| Ashford, R | 1 |
| Harrison, RA | 1 |
| Osborne, M | 1 |
| Livingstone, JI | 1 |
| MacDonald, P | 1 |
| Mitchell, IC | 1 |
| Meyrick-Thomas, J | 1 |
| Northover, JM | 1 |
| Windsor, A | 1 |
| Novell, R | 1 |
| Wallace, M | 1 |
| Chmura, SJ | 1 |
| Nijdam, W | 1 |
| Levendag, P | 1 |
| Noever, I | 1 |
| Groot, CU | 1 |
| Agthoven, Mv | 1 |
| Arcangeli, G | 3 |
| Pinnarò, P | 2 |
| Rambone, R | 1 |
| Giannarelli, D | 2 |
| Benassi, M | 1 |
| Horvath, WL | 1 |
| Sternfeld, WC | 1 |
| Dakhil, SR | 2 |
| Levitt, R | 1 |
| Rowland, K | 2 |
| Nair, S | 1 |
| Wiltshire, KL | 1 |
| Ward, IG | 1 |
| Swallow, C | 1 |
| Oza, AM | 1 |
| Pond, GR | 1 |
| Catton, P | 1 |
| Siu, LL | 1 |
| Moore, M | 2 |
| Brierley, J | 1 |
| Papadoupolos, T | 1 |
| Füzesi, L | 1 |
| Klimpfinger, M | 2 |
| Ardavanis, A | 2 |
| Tryfonopoulos, D | 2 |
| Orfanos, G | 1 |
| Karamouzis, M | 2 |
| Scorilas, A | 2 |
| Alexopoulos, A | 1 |
| Rigatos, G | 2 |
| Smeenk, HG | 1 |
| Incrocci, L | 1 |
| Kazemier, G | 1 |
| van Dekken, H | 1 |
| Tran, KT | 1 |
| Jeekel, J | 1 |
| van Eijck, CH | 1 |
| Farrell, PJ | 1 |
| Mukai, M | 2 |
| Tajima, T | 2 |
| Ninomiya, H | 2 |
| Wakui, K | 2 |
| Komatsu, N | 2 |
| Tsuchiya, K | 2 |
| Nakasaki, H | 2 |
| Makuuchi, H | 2 |
| Escrig, V | 1 |
| Carles, J | 1 |
| Rizo, A | 1 |
| Vega, ME | 1 |
| Martí, JL | 1 |
| Lobo, F | 1 |
| Pastor, P | 1 |
| Belón, J | 1 |
| Sánchez, MA | 1 |
| Chaib, C | 1 |
| Pallarés, C | 1 |
| Paz-Ares, L | 1 |
| Cortés-Funes, H | 3 |
| Kharatishvili, TK | 1 |
| Tiuliandin, SA | 1 |
| Khatyrëv, SA | 1 |
| Sobolevskiĭ, VA | 1 |
| Tkachev, SI | 1 |
| Ivanov, SI | 1 |
| Vishnevskaia, IaV | 1 |
| Karapetian, RM | 1 |
| Kovalevskiĭ, EE | 1 |
| Byun, JH | 2 |
| Lee, KS | 2 |
| Chang, SK | 1 |
| Choi, SI | 1 |
| Lee, DS | 1 |
| Frontiera, MS | 1 |
| Jackson, DV | 2 |
| Takada, J | 1 |
| Katsuki, Y | 4 |
| Hamada, H | 1 |
| Tsuji, Y | 5 |
| Aoyama, H | 2 |
| Funabashi, M | 1 |
| Kamano, T | 1 |
| Agata, T | 1 |
| Noro, T | 1 |
| Shiba, Y | 1 |
| Umekita, N | 3 |
| Marutaka, M | 1 |
| Suguri, T | 1 |
| Miyake, M | 1 |
| Yoshimura, K | 1 |
| Cupini, S | 1 |
| Marcucci, L | 1 |
| Cerri, E | 1 |
| Allegrini, G | 1 |
| Brunetti, IM | 1 |
| Pfanner, E | 1 |
| Viti, M | 1 |
| Goletti, O | 1 |
| Filipponi, F | 1 |
| Ramaïoli, A | 2 |
| Bourdin, S | 2 |
| Tortochaux, J | 1 |
| Marcy, PY | 2 |
| Vallicioni, J | 3 |
| Seng, H | 1 |
| Alzieu, C | 1 |
| Géry, B | 1 |
| Chauvel, P | 3 |
| Roddiger, SJ | 1 |
| Kolotas, C | 3 |
| Filipowicz, I | 1 |
| Kurek, R | 1 |
| Kuner, RP | 1 |
| Baltas, D | 1 |
| Rogge, B | 1 |
| Kontova, M | 1 |
| Hoffmann, G | 1 |
| Pollow, B | 1 |
| Zamboglou, N | 3 |
| Wilkowski, R | 3 |
| Thoma, M | 2 |
| Bruns, C | 2 |
| Dühmke, E | 1 |
| Coco, C | 3 |
| Rossi, C | 2 |
| Di Russo, A | 1 |
| Valvo, F | 1 |
| Bolzicco, G | 1 |
| Dalla Palma, M | 1 |
| Iguchi, H | 1 |
| Kusuki, M | 1 |
| Nakamura, A | 1 |
| Hachiya, K | 1 |
| Yamane, H | 1 |
| Pergolizzi, S | 1 |
| Adamo, V | 1 |
| Russi, E | 1 |
| Santacaterina, A | 1 |
| Maisano, R | 1 |
| Palazzolo, C | 1 |
| Ferraù, F | 2 |
| Settineri, N | 1 |
| Altavilla, G | 1 |
| Girlando, A | 1 |
| Spadaro, P | 1 |
| Manno, A | 1 |
| Mattana, C | 1 |
| Verbo, A | 1 |
| Pedretti, G | 1 |
| Petito, L | 1 |
| Rizzo, G | 1 |
| Cosimelli, M | 1 |
| Impiombato, FA | 2 |
| Picciocchi, A | 2 |
| Cheng, SH | 2 |
| Horng, CF | 1 |
| Clarke, JL | 1 |
| Tsou, MH | 1 |
| Tsai, SY | 2 |
| Chen, CM | 1 |
| Jian, JJ | 2 |
| Liu, MC | 1 |
| West, M | 1 |
| Huang, AT | 1 |
| Prosnitz, LR | 2 |
| Mimae, T | 1 |
| Ninomiya, M | 2 |
| Kubo, Y | 1 |
| Umeoka, T | 1 |
| Takakura, N | 2 |
| Raguse, JD | 1 |
| Gath, HJ | 1 |
| Bier, J | 1 |
| Kosuge, T | 1 |
| Kiuchi, T | 1 |
| Kakizoe, T | 1 |
| Yildirim, Y | 1 |
| Ozyilkan, O | 1 |
| Akcali, Z | 1 |
| Basturk, B | 1 |
| Rouëssé, J | 1 |
| de la Lande, B | 1 |
| Bertheault-Cvitkovic, F | 1 |
| Serin, D | 3 |
| Graïc, Y | 1 |
| Combe, M | 1 |
| Leduc, B | 1 |
| Lucas, V | 1 |
| Demange, L | 1 |
| Nguyen, TD | 1 |
| Castèra, D | 1 |
| Krzisch, C | 1 |
| Villet, R | 1 |
| Mouret-Fourme, E | 1 |
| Garbay, JR | 1 |
| Noguès, C | 1 |
| Nakata, E | 1 |
| Saeki, T | 3 |
| Kimura, T | 1 |
| Tinari, N | 1 |
| Lattanzio, R | 1 |
| Natoli, C | 1 |
| Cianchetti, E | 1 |
| Angelucci, D | 1 |
| Ricevuto, E | 1 |
| Ficorella, C | 1 |
| Alberti, S | 1 |
| Piantelli, M | 1 |
| Toledano, A | 2 |
| Garaud, P | 2 |
| Breteau, N | 1 |
| Body, G | 2 |
| Le Floch, O | 3 |
| Felici, A | 1 |
| Loos, WJ | 1 |
| Cirillo, I | 1 |
| de Bruijn, P | 1 |
| Nooter, K | 1 |
| Mathijssen, RH | 1 |
| de Jonge, MJ | 1 |
| Ponzanelli, A | 1 |
| Merlano, M | 8 |
| Ricci, I | 3 |
| Vigo, V | 1 |
| Grossi, F | 1 |
| Amadori, D | 2 |
| Cavallo, G | 1 |
| Capaccetti, B | 1 |
| Taveggia, P | 1 |
| Boni, L | 1 |
| Islam, S | 1 |
| Cole, CV | 1 |
| Hoffman, GR | 1 |
| Brennan, PA | 1 |
| Stewart, AA | 1 |
| Rush, B | 1 |
| Davis, E | 1 |
| Yu, W | 1 |
| Nielsen, HM | 2 |
| Overgaard, M | 4 |
| Grau, C | 1 |
| Jensen, AR | 1 |
| Kulke, MH | 2 |
| Earle, CC | 1 |
| Vincitore, M | 1 |
| Michelini, A | 1 |
| Sheehan, S | 1 |
| Hirota, T | 1 |
| Zhang, XQ | 1 |
| Li, DP | 1 |
| Sheng, XG | 1 |
| Du, XL | 1 |
| Song, QQ | 1 |
| Sestito, A | 1 |
| Sgueglia, GA | 1 |
| Cassano, A | 1 |
| Lanza, GA | 1 |
| Hu, JB | 1 |
| Sun, XN | 1 |
| Yang, QC | 1 |
| He, C | 1 |
| Ait Menguellet, S | 1 |
| Collinet, P | 1 |
| Houfflin Debarge, V | 1 |
| Nayama, M | 1 |
| Vinatier, D | 1 |
| Leroy, JL | 1 |
| Bourhis, J | 2 |
| Awada, A | 2 |
| Geoffrois, L | 1 |
| Vega Villegas, ME | 1 |
| Duck, L | 1 |
| Rosine, D | 1 |
| Harstrick, A | 1 |
| Baker, J | 1 |
| Kim, W | 1 |
| Cronin, M | 1 |
| Baehner, FL | 1 |
| Watson, D | 1 |
| Wickerham, DL | 5 |
| Lamberti, C | 1 |
| Lundin, S | 1 |
| Bogdanow, M | 1 |
| Pagenstecher, C | 1 |
| Friedrichs, N | 1 |
| Büttner, R | 1 |
| Sauerbruch, T | 1 |
| Ha, HK | 1 |
| Lee, MG | 1 |
| Lauwers, GY | 1 |
| Wain, JC | 1 |
| Yang, X | 1 |
| Levy, LB | 1 |
| Ellis, LM | 2 |
| Gebbia, V | 4 |
| Verderame, F | 1 |
| Bordonaro, R | 1 |
| Callari, A | 1 |
| Caruso, M | 1 |
| Tirrito, ML | 1 |
| Valenza, R | 1 |
| Cicero, G | 1 |
| Borsellino, N | 1 |
| Tralongo, P | 1 |
| Wan, XR | 3 |
| Yang, XY | 3 |
| Colevas, AD | 1 |
| Wong, SJ | 1 |
| Ogino, K | 1 |
| Hiroyoshi, M | 1 |
| Itoh, T | 2 |
| Toyama, H | 1 |
| Kawai, Y | 1 |
| Makita, D | 1 |
| Tsunemi, K | 1 |
| Moritomo, H | 1 |
| Copcu, E | 1 |
| Sivrioglu, N | 1 |
| Baytekin, C | 1 |
| Er, S | 1 |
| Koc, B | 1 |
| Worden, FP | 1 |
| Clark, JI | 1 |
| Williamson, S | 1 |
| Ensley, J | 5 |
| Hussain, MH | 2 |
| Orphanos, G | 1 |
| Missitzis, I | 1 |
| Chrysochoou, M | 1 |
| Sotiropoulou, A | 1 |
| Arnogiannaki, N | 1 |
| Ioannidis, G | 1 |
| Pissakas, G | 1 |
| Lee, MJ | 1 |
| Ra, YS | 1 |
| Park, JB | 1 |
| Goo, HW | 1 |
| Khang, SK | 1 |
| Song, JS | 1 |
| Ghim, TT | 1 |
| Wagner, A | 1 |
| Goto, A | 1 |
| Ueda, M | 1 |
| Miura, Y | 1 |
| Ichikawa, Y | 2 |
| Togo, S | 2 |
| Shimada, H | 3 |
| Gohongi, T | 1 |
| Iida, H | 1 |
| Nakai, R | 1 |
| Gunji, N | 1 |
| Orii, K | 1 |
| Schneider, S | 1 |
| Sherrod, A | 1 |
| Streeter, O | 1 |
| Danenberg, KD | 1 |
| An, R | 1 |
| Zhu, K | 1 |
| Benzoni, E | 1 |
| Terrosu, G | 1 |
| Bresadola, V | 1 |
| Cerato, F | 1 |
| Cojutti, A | 1 |
| Milan, E | 1 |
| Dado, G | 1 |
| Bresadola, F | 1 |
| Chau, GY | 1 |
| Lui, WY | 1 |
| Tsay, SH | 1 |
| Chao, Y | 1 |
| King, KL | 1 |
| Monga, DK | 1 |
| Aogi, K | 1 |
| Tabei, T | 2 |
| Jakob, C | 1 |
| Meyer, W | 1 |
| Baretton, GB | 1 |
| Schwabe, W | 1 |
| Häusler, P | 1 |
| Kulle, B | 1 |
| Aust, DE | 1 |
| Majem, M | 1 |
| Mañós, M | 1 |
| Gomez, J | 1 |
| Galiana, R | 1 |
| Cardenal, F | 1 |
| Juan, A | 1 |
| Montes, A | 1 |
| Perez, FJ | 1 |
| Nogues, J | 1 |
| Llluch, JR | 1 |
| Gentilini, O | 1 |
| Intra, M | 1 |
| Gandini, S | 1 |
| Peruzzotti, G | 1 |
| Winnikow, E | 1 |
| Galimberti, V | 1 |
| Veronesi, U | 8 |
| DeSalvo, GL | 1 |
| Aschele, C | 2 |
| Rugge, M | 1 |
| Bruttocao, A | 1 |
| Fabris, G | 1 |
| Ferraro, B | 1 |
| Frego, M | 1 |
| Finco, C | 1 |
| Nitti, D | 1 |
| Kwon, JM | 1 |
| Park, BB | 1 |
| Han, MJ | 1 |
| Jackisch, C | 1 |
| Ratto, C | 2 |
| Ricci, R | 1 |
| Castri, F | 1 |
| Parello, A | 1 |
| Vecchio, FM | 1 |
| Hou, MF | 1 |
| Lin, SD | 1 |
| Chuang, HY | 1 |
| Fu, OY | 1 |
| Lian, SL | 1 |
| Kodama, H | 2 |
| Nio, Y | 3 |
| Iguchi, C | 2 |
| Kan, N | 2 |
| Niméus-Malmström, E | 1 |
| Ritz, C | 1 |
| Edén, P | 1 |
| Ohlsson, M | 1 |
| Strand, C | 1 |
| Ostberg, G | 1 |
| Fernö, M | 2 |
| Peterson, C | 1 |
| Iyama, S | 1 |
| Shintani, N | 1 |
| Fujikawa, K | 1 |
| Ohkubo, S | 1 |
| Ohnuma, K | 1 |
| Niitsu, Y | 1 |
| Shiiki, S | 1 |
| Sonoo, H | 2 |
| Seki, M | 2 |
| Hironou, M | 1 |
| Ookubo, S | 1 |
| Udagawa, K | 1 |
| Nakashima, K | 4 |
| Kurebayashi, J | 1 |
| Walshe, JM | 1 |
| Berman, AW | 1 |
| Vatas, U | 1 |
| Steinberg, SM | 2 |
| Anderson, WF | 1 |
| Lippman, ME | 2 |
| Hannigan, E | 1 |
| Moore, DH | 1 |
| Dequanter, D | 1 |
| Lothaire, P | 1 |
| Lalami, Y | 1 |
| Hien Nguyen, T | 1 |
| Vandevelde, L | 1 |
| Andry, G | 1 |
| Lin, EH | 1 |
| Bhatia, S | 1 |
| Rubbia-Brandt, L | 2 |
| Giostra, E | 2 |
| Brezault, C | 1 |
| Andres, A | 2 |
| Audard, V | 1 |
| Sartoretti, P | 1 |
| Majno, PE | 2 |
| Soubrane, O | 2 |
| Chaussade, S | 1 |
| Mentha, G | 2 |
| Terris, B | 1 |
| Klautke, G | 2 |
| Kalykaki, A | 1 |
| Androulakis, N | 1 |
| Tzardi, M | 1 |
| Kotsakis, AP | 1 |
| Gioulbasanis, J | 1 |
| Tsetis, D | 1 |
| Sfakiotaki, G | 1 |
| Chatzidaki, D | 1 |
| Niméus, E | 1 |
| Malmström, J | 1 |
| Marko-Varga, G | 1 |
| Garimella, V | 1 |
| Qutob, O | 1 |
| Fox, JN | 1 |
| Long, ED | 1 |
| Chaturvedi, A | 1 |
| Turnbull, LW | 1 |
| Drew, PJ | 1 |
| Bentzen, JD | 1 |
| Hansen, HS | 2 |
| Hannoun, L | 1 |
| de Geus-Oei, LF | 1 |
| Leer, JW | 1 |
| Corstens, FH | 1 |
| Oyen, WJ | 1 |
| Antonini, N | 2 |
| Jones, H | 1 |
| Horiot, JC | 1 |
| Poortmans, P | 1 |
| Struikmans, H | 1 |
| Van den Bogaert, W | 1 |
| Barillot, I | 1 |
| Jager, J | 1 |
| Hoogenraad, W | 1 |
| Pierart, M | 1 |
| Hart, G | 3 |
| Bartelink, H | 1 |
| Sadighi, S | 1 |
| Mohagheghi, MA | 1 |
| Sadighi, Z | 1 |
| Tytherleigh, MG | 1 |
| Cohen, CE | 1 |
| Livingstone, J | 1 |
| Gilbert, J | 1 |
| Kiss, D | 1 |
| Eriksen, MT | 1 |
| Wibe, A | 1 |
| Haffner, J | 1 |
| Sakayori, M | 1 |
| Shibata, H | 3 |
| Shimodaira, H | 1 |
| Ohtsuka, K | 2 |
| Kakudo, Y | 1 |
| Yang, JJ | 2 |
| Hattori, T | 2 |
| Okuno, K | 2 |
| Kokubu, T | 1 |
| Itoh, K | 2 |
| Tono, T | 6 |
| Kanoh, T | 1 |
| Shiozaki, K | 1 |
| Matsushita, M | 1 |
| Hoshino, H | 1 |
| Iwazawa, T | 1 |
| Monden, T | 2 |
| Ogata, K | 1 |
| Matsuo, A | 1 |
| Kudo, K | 1 |
| Otao, R | 1 |
| Muranaka, T | 1 |
| Uno, T | 1 |
| Isobe, K | 1 |
| Ueno, N | 1 |
| Matsubara, H | 2 |
| Okazumi, S | 1 |
| Nabeya, Y | 1 |
| Shiratori, T | 1 |
| Kawata, T | 1 |
| Ito, H | 2 |
| Falo, C | 1 |
| Moreno, A | 1 |
| Varela, M | 1 |
| Lloveras, B | 1 |
| Figueras, A | 1 |
| Escobedo, A | 1 |
| Oblak, I | 1 |
| Velenik, V | 1 |
| Anderluh, F | 1 |
| Maughan, TS | 1 |
| Miny-Buffet, J | 1 |
| Favre, A | 1 |
| Aballéa, S | 1 |
| Chancellor, JV | 1 |
| Raikou, M | 1 |
| Drummond, MF | 1 |
| Weinstein, MC | 1 |
| Jourdan, S | 1 |
| Bridgewater, J | 1 |
| Leijte, JA | 1 |
| Kerst, JM | 1 |
| Bais, E | 1 |
| Horenblas, S | 1 |
| Pizzocaro, G | 1 |
| Truong, PT | 1 |
| Woodward, WA | 1 |
| Thames, HD | 1 |
| Buchholz, TA | 2 |
| Willeke, F | 1 |
| Horisberger, K | 1 |
| Kraus-Tiefenbacher, U | 1 |
| Leitner, A | 1 |
| Grobholz, R | 1 |
| Kähler, G | 1 |
| Li, JG | 1 |
| Okabayashi, T | 1 |
| Namikawa, T | 1 |
| Hanazaki, K | 1 |
| Kamoshita, N | 2 |
| Makita, F | 1 |
| Matsuzaki, Y | 1 |
| Kabeya, K | 1 |
| Akahane, T | 1 |
| Chiba, T | 1 |
| Khoury-Collado, F | 1 |
| Bowes, RJ | 1 |
| Jhamb, N | 1 |
| Aghajanian, C | 1 |
| Kim, WY | 1 |
| Karanlik, H | 1 |
| Muslumanoglu, M | 1 |
| Igci, A | 1 |
| Emek, E | 1 |
| Ozmen, V | 1 |
| Kecer, M | 1 |
| Parlak, M | 1 |
| Gelber, S | 1 |
| Pagani, O | 1 |
| Engehausen, DG | 1 |
| Krause, FS | 1 |
| Papadopoulos, T | 2 |
| Dunst, J | 5 |
| Parks, R | 1 |
| Kemeny, N | 3 |
| Jarnagin, W | 1 |
| D'Angelica, M | 1 |
| DeMatteo, R | 1 |
| Garden, OJ | 1 |
| Blumgart, LH | 1 |
| Fong, Y | 1 |
| Bostner, J | 1 |
| Ahnström Waltersson, M | 1 |
| Chen, YW | 1 |
| Yen, SH | 2 |
| Chen, SY | 2 |
| Huang, PI | 1 |
| Shiau, CY | 1 |
| Liu, YM | 1 |
| Wang, LW | 1 |
| Bijelic, L | 2 |
| Yan, TD | 2 |
| Kaminski, A | 1 |
| Elsaleh, H | 2 |
| Brizzi, MP | 1 |
| Bitossi, R | 1 |
| Alabiso, I | 1 |
| Sculli, CM | 1 |
| Chiusa, L | 1 |
| Papotti, M | 1 |
| Schmid, P | 1 |
| Kossé, V | 1 |
| Bondar, G | 1 |
| Vassiljev, L | 1 |
| Tarutinov, V | 1 |
| Lehmann, U | 1 |
| Maubach, L | 1 |
| Meurer, J | 1 |
| Wallwiener, D | 1 |
| Possinger, K | 1 |
| Tsuburaya, A | 1 |
| Germano, D | 1 |
| Dinota, A | 1 |
| Romano, R | 1 |
| Sautter-Bihl, ML | 1 |
| Pachmann, K | 1 |
| Dengler, R | 1 |
| Lobodasch, K | 1 |
| Fröhlich, F | 1 |
| Kroll, T | 1 |
| Rengsberger, M | 1 |
| Schubert, R | 1 |
| Pachmann, U | 1 |
| Yoo, NC | 2 |
| Yoshikawa, K | 1 |
| Murakami, S | 1 |
| Gardner-Thorpe, J | 1 |
| Hardwick, RH | 1 |
| Dwerryhouse, SJ | 1 |
| Miki, R | 1 |
| Ogami, N | 1 |
| Qin, B | 1 |
| Nakano, S | 5 |
| Higashi, H | 2 |
| Maehara, S | 1 |
| Makino, I | 1 |
| Imamura, S | 1 |
| Aso, M | 1 |
| Katoh, H | 1 |
| Seki, H | 1 |
| Kurihara, E | 1 |
| Iwata, K | 1 |
| Kelsey, CR | 1 |
| Nelson, JW | 1 |
| Chino, JP | 1 |
| Clough, RW | 1 |
| Clary, BM | 2 |
| Pappas, TN | 1 |
| Morohashi, S | 1 |
| Quinaux, E | 1 |
| Colin, P | 1 |
| Gamelin, E | 1 |
| Achille, E | 1 |
| Boutan-Laroze, A | 1 |
| Flesch, M | 1 |
| Lledo, G | 1 |
| Raoul, Y | 1 |
| Debrix, I | 1 |
| Fan, Y | 1 |
| Lang, RG | 1 |
| Guo, XJ | 1 |
| Sun, YL | 1 |
| Fu, L | 1 |
| Yang, CH | 1 |
| Tsai, YC | 1 |
| Hsu, WL | 1 |
| Spencer, SA | 3 |
| Harris, J | 2 |
| Wheeler, RH | 3 |
| Schultz, C | 1 |
| Spanos, W | 2 |
| Rotman, M | 1 |
| Kawamura, S | 1 |
| Musha, N | 1 |
| Konno, H | 2 |
| Usuki, H | 1 |
| Jeong, WJ | 1 |
| Jung, EJ | 1 |
| Hah, JH | 1 |
| Kwon, TK | 1 |
| Wu, HG | 2 |
| Heo, DS | 4 |
| Sung, MW | 2 |
| Goh, PG | 1 |
| Hwang, SW | 1 |
| Kwon, DS | 1 |
| Nam, KW | 1 |
| Kang, HM | 1 |
| Kang, YS | 1 |
| Seong, JK | 1 |
| Thödtmann, R | 1 |
| Herbst, F | 1 |
| Rabl, H | 1 |
| Wohlmuth, P | 1 |
| Thaler, J | 1 |
| Nguyen, F | 1 |
| Bosset, M | 1 |
| Sedrati, A | 1 |
| Lorgis, V | 1 |
| Morgan, MA | 1 |
| Lewis, WG | 1 |
| Escofet, X | 1 |
| Brewster, AE | 1 |
| Harvard, TJ | 1 |
| Clark, GW | 1 |
| Zabel-du Bois, A | 1 |
| Milker-Zabel, S | 1 |
| Wannenmacher, M | 4 |
| Morel, P | 2 |
| Gervaz, P | 1 |
| Terraz, S | 1 |
| Allal, AS | 2 |
| Hasegawa, N | 1 |
| Kawabata, M | 1 |
| Abeshima, S | 1 |
| Ichimura, T | 1 |
| Kaneko, H | 1 |
| Chang, AY | 1 |
| Lopes, G | 1 |
| Hsin, KW | 1 |
| Lim, R | 1 |
| Fong, FK | 1 |
| Wong, J | 2 |
| Muzikansky, A | 1 |
| Lawrence, C | 1 |
| Sujendran, V | 1 |
| Wheeler, J | 1 |
| Baron, R | 1 |
| Maynard, N | 1 |
| Nagano, T | 1 |
| Bai, P | 1 |
| Zhang, R | 1 |
| Li, XG | 1 |
| Ma, SK | 1 |
| Wu, LY | 1 |
| Zhang, WH | 1 |
| Isogai, A | 1 |
| Nagaya, M | 1 |
| Tsukikawa, S | 1 |
| Kubota, S | 1 |
| Benjapibal, M | 1 |
| Thirapakawong, C | 1 |
| Leelaphatanadit, C | 1 |
| Therasakvichya, S | 1 |
| Inthasorn, P | 1 |
| Küchenmeister, U | 1 |
| Foitzik, T | 1 |
| Ludwig, K | 1 |
| Semrau, S | 1 |
| Prall, F | 1 |
| Klar, E | 1 |
| Rosati, R | 1 |
| Bona, S | 1 |
| Romario, UF | 1 |
| Elmore, U | 1 |
| Furlan, N | 1 |
| Gong, ZJ | 1 |
| Ren, JQ | 1 |
| Kong, G | 1 |
| Qing, DJ | 1 |
| Liang, YQ | 1 |
| Lin, D | 1 |
| Glastonbury, CM | 1 |
| Rafaelian, O | 1 |
| Eisele, DW | 1 |
| Wang, SJ | 1 |
| Akamatsu, M | 1 |
| Nakata, W | 1 |
| Ohmae, T | 1 |
| Ohata, K | 1 |
| Matsubara, S | 1 |
| Katamoto, T | 1 |
| Barnwell, J | 2 |
| McConkey, C | 2 |
| Hills, RK | 1 |
| Williams, NS | 1 |
| Takeuchi, S | 2 |
| Mera, K | 1 |
| Mohile, SG | 1 |
| Schleicher, L | 1 |
| Petrylak, DP | 1 |
| Wanebo, HJ | 2 |
| DiSiena, M | 1 |
| Begossi, G | 1 |
| Belliveau, J | 1 |
| Gustafson, E | 1 |
| Spry, N | 1 |
| Harvey, J | 1 |
| Macleod, C | 2 |
| Borg, M | 1 |
| Millar, JL | 1 |
| Graham, P | 1 |
| Zissiadis, Y | 1 |
| Carroll, S | 1 |
| Davies, T | 1 |
| Reece, WH | 1 |
| Iacopetta, B | 1 |
| Paoletti, L | 1 |
| Meattini, I | 1 |
| Rampini, A | 1 |
| Petrucci, A | 1 |
| Leonulli, BG | 1 |
| Biti, GP | 1 |
| Char, DH | 1 |
| Crawford, JB | 1 |
| Song, CH | 1 |
| Park, CI | 1 |
| Chu, ST | 1 |
| Chou, P | 1 |
| Lee, CC | 1 |
| Fang, WY | 1 |
| Cheng, TL | 1 |
| Belmonte-Montes, C | 1 |
| Cosme-Reyes, C | 1 |
| Charúa-Guindic, L | 1 |
| Thürmann, PA | 1 |
| Bergsland, E | 1 |
| Rothenberg, M | 1 |
| Rosen, L | 1 |
| Shien, T | 1 |
| Hojo, T | 1 |
| Kohno, T | 1 |
| Katsumata, N | 2 |
| Akashi-Tanaka, S | 1 |
| Brizi, MG | 1 |
| Alfieri, S | 1 |
| Sofo, L | 1 |
| Doglietto, G | 1 |
| Ette, C | 1 |
| Baumann, W | 1 |
| Kreuser, ED | 1 |
| Milani, V | 1 |
| Pazos, M | 1 |
| Buecklein, V | 1 |
| Rahman, S | 1 |
| Tschoep, K | 1 |
| Schaffer, P | 1 |
| Duehmke, E | 1 |
| Hau, P | 1 |
| Kunz-Schughart, L | 1 |
| Bogdahn, U | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
| Tani, M | 1 |
| Miyazawa, M | 1 |
| Hirono, S | 1 |
| Ina, S | 1 |
| Nishioka, R | 1 |
| Uchiyama, K | 1 |
| Specenier, PM | 1 |
| Gusterson, BA | 1 |
| Chua, D | 1 |
| Wei, WI | 1 |
| Punzengruber, R | 1 |
| Coon, D | 1 |
| Zorn, KK | 1 |
| Campbell, ME | 1 |
| Wan, S | 1 |
| Levine, E | 1 |
| Myint, S | 1 |
| Su, YR | 1 |
| Wu, GH | 1 |
| Guo, ZM | 1 |
| Chen, WK | 1 |
| Wei, MW | 1 |
| Chen, YF | 1 |
| Chan, KY | 1 |
| Yen, KC | 1 |
| Furuta, R | 1 |
| Kataoka, T | 1 |
| Nagao, S | 1 |
| Kayukawa, S | 1 |
| Mori, F | 1 |
| Masaki, A | 1 |
| Goto, H | 1 |
| Stehlin, JS | 1 |
| Hills, WJ | 1 |
| Rufino, C | 1 |
| Blokhina, NG | 4 |
| Blokhin, NN | 1 |
| Lehnert, M | 5 |
| Jakse, R | 5 |
| Seewann, HL | 1 |
| Al-Sarraf, M | 7 |
| Albaugh, JS | 1 |
| Keeffe, EB | 1 |
| Krippaehne, WW | 1 |
| Mortimer, JE | 2 |
| Hewlett, JS | 1 |
| Bay, J | 1 |
| Sung, HC | 1 |
| Wu, PC | 1 |
| Yang, HY | 1 |
| Thatcher, N | 1 |
| Blackledge, G | 1 |
| Crowther, D | 2 |
| Cortes, EP | 1 |
| Kalra, J | 1 |
| Amin, VC | 1 |
| Attie, J | 1 |
| Eisenbud, L | 1 |
| Khafif, R | 1 |
| Wolk, D | 1 |
| Aral, I | 1 |
| Sciubba, J | 1 |
| Akbiyik, N | 1 |
| Heller, K | 1 |
| Grage, TB | 1 |
| Moss, SE | 1 |
| Hafström, L | 5 |
| Arnott, SJ | 3 |
| Sakai, S | 2 |
| Hohki, A | 1 |
| Fuchihata, H | 1 |
| Veronesi, A | 1 |
| Magri, MD | 1 |
| Tirelli, U | 1 |
| Galligioni, E | 1 |
| Frustaci, S | 1 |
| Grigoletto, E | 1 |
| Wassif, SB | 2 |
| Evans, RG | 2 |
| Burgert, EO | 1 |
| Gilchrist, GS | 1 |
| Smithson, WA | 1 |
| Pritchard, DJ | 1 |
| Bruckman, JE | 1 |
| Kusama, S | 2 |
| Furue, H | 2 |
| Toriyama, K | 2 |
| Wakiya, M | 2 |
| Tannock, IF | 2 |
| Sutherland, DJ | 1 |
| Inuyama, Y | 1 |
| Horiuchi, M | 1 |
| Mashino, S | 1 |
| Ozu, R | 1 |
| Asaoka, K | 1 |
| Budd, GT | 1 |
| Groppe, CW | 1 |
| Brooks, JL | 1 |
| Ryan, JA | 1 |
| Bauermeister, DE | 1 |
| Steele, G | 2 |
| Osteen, RT | 1 |
| Wilson, RE | 1 |
| Brooks, DC | 1 |
| Zamcheck, N | 1 |
| Ravikumar, TS | 1 |
| Papaioannou, A | 1 |
| Lissaios, B | 1 |
| Vasilaros, S | 1 |
| Miligos, S | 1 |
| Papadimitriou, G | 1 |
| Kondilis, D | 1 |
| Polychronis, A | 1 |
| Kozonis, J | 1 |
| Papageorgiou, G | 1 |
| Plataniotis, G | 1 |
| Razis, D | 1 |
| Stathopoulos, G | 1 |
| Tsiliakos, S | 1 |
| Throuvhlas, N | 1 |
| Papavasiliou, K | 1 |
| Tsarouhas, C | 1 |
| Papaevangelou, G | 1 |
| Richards, B | 1 |
| Bastable, JR | 1 |
| Freedman, L | 1 |
| Glashan, RW | 1 |
| Harris, G | 1 |
| Newling, DW | 1 |
| Robinson, MR | 1 |
| Smith, PH | 1 |
| Higgins, GA | 2 |
| Amadeo, JH | 1 |
| Smith, DE | 2 |
| Humphrey, EW | 1 |
| Keehn, RJ | 1 |
| Buzdar, AU | 12 |
| Montague, ED | 4 |
| Hortobagyi, GN | 8 |
| Yap, HY | 3 |
| Pinnamaneni, K | 1 |
| Marcus, CE | 1 |
| Smith, TL | 5 |
| Redmond, CK | 1 |
| Rockette, HE | 1 |
| Brown, A | 1 |
| Allegra, J | 1 |
| Bowman, D | 1 |
| Plotkin, D | 2 |
| Wolter, J | 2 |
| Tancini, G | 5 |
| Marchini, S | 1 |
| Browman, GP | 1 |
| Archibald, SD | 1 |
| Young, JE | 1 |
| Hryniuk, WM | 2 |
| Russell, R | 1 |
| Kiehl, K | 1 |
| Levine, MN | 3 |
| Soloway, MS | 1 |
| Tormey, DC | 11 |
| Weinberg, VE | 1 |
| Leone, LA | 1 |
| Glidewell, OJ | 1 |
| Perloff, M | 2 |
| Kennedy, BJ | 2 |
| Cortes, E | 1 |
| Silver, RT | 1 |
| Aisner, J | 2 |
| Hine, KR | 1 |
| Dykes, PW | 1 |
| Rabadi, SJ | 1 |
| Haid, M | 1 |
| Scanlon, EF | 2 |
| Khandekar, JD | 2 |
| Caprini, JA | 2 |
| Oviedo, MA | 2 |
| Cunningham, MP | 2 |
| Grizenko, KK | 1 |
| Cohen, E | 2 |
| Jungi, WF | 5 |
| Mouridsen, HT | 3 |
| Palshof, T | 1 |
| Alberto, P | 2 |
| Brunner, KW | 1 |
| Mermillod, B | 1 |
| Barrelet, L | 1 |
| Cavalli, F | 1 |
| Howell, A | 2 |
| Rubens, RD | 1 |
| Bush, H | 1 |
| George, WD | 2 |
| Howat, JM | 1 |
| Sellwood, RA | 1 |
| Hayward, JL | 1 |
| Knight, RK | 1 |
| Bulbrook, RD | 2 |
| Michaelson, RA | 1 |
| Magill, GB | 1 |
| Quan, SH | 1 |
| Leaming, RH | 1 |
| Nikrui, M | 1 |
| Stearns, MW | 1 |
| Franklin, R | 1 |
| Steiger, Z | 3 |
| Vaishampayan, G | 1 |
| Asfaw, I | 2 |
| Rosenberg, J | 1 |
| Loh, J | 1 |
| Hoschner, J | 1 |
| Miller, P | 1 |
| Flam, MS | 2 |
| John, M | 1 |
| Lovalvo, LJ | 2 |
| Mills, RJ | 1 |
| Ramalho, LD | 2 |
| Prather, C | 1 |
| Mowry, PA | 2 |
| Morgan, DR | 1 |
| Lau, BP | 1 |
| Hainsworth, JD | 2 |
| Malcolm, A | 2 |
| Johnson, DH | 1 |
| Burnett, LS | 1 |
| Jones, HW | 1 |
| Greco, FA | 1 |
| Imaizumi, M | 2 |
| Kamei, H | 2 |
| Ichihashi, H | 2 |
| Akiyama, J | 1 |
| Sagara, Y | 1 |
| Boulis-Wassif, S | 1 |
| Gerard, A | 1 |
| Loygue, J | 1 |
| Camelot, D | 1 |
| Duez, N | 1 |
| Uyama, T | 1 |
| Aga, Y | 1 |
| Yonezawa, M | 1 |
| Sumiyoshi, Y | 1 |
| Fujita, J | 1 |
| Panettiere, FJ | 1 |
| Haas, C | 2 |
| McDonald, B | 1 |
| Costanzi, JJ | 1 |
| Talley, RW | 1 |
| Athens, J | 1 |
| Oishi, N | 1 |
| Chen, TT | 2 |
| Negishi, T | 1 |
| Owada, F | 1 |
| Ajima, J | 1 |
| Satake, I | 1 |
| Tari, K | 1 |
| Tiver, KW | 1 |
| Langlands, AO | 3 |
| Duprat, G | 1 |
| Chalaoui, J | 1 |
| Sylvestre, J | 1 |
| Simard, P | 1 |
| Potvin, C | 1 |
| Cantin, J | 1 |
| Schmidt, JD | 2 |
| Scott, WW | 2 |
| Gibbons, R | 1 |
| Johnson, DE | 3 |
| Prout, GR | 2 |
| Loening, S | 1 |
| Soloway, M | 1 |
| deKernion, JB | 1 |
| Pontes, JE | 1 |
| Slack, NH | 3 |
| Murphy, GP | 3 |
| Bean, DJ | 1 |
| Rees, RS | 1 |
| O'Leary, JP | 1 |
| Lynch, JB | 1 |
| Renner, H | 2 |
| Lang, C | 1 |
| Ziegler, K | 1 |
| Moertel, CG | 5 |
| Childs, DS | 1 |
| O'Fallon, JR | 4 |
| Holbrook, MA | 2 |
| Schutt, AJ | 3 |
| Reitemeier, RJ | 1 |
| Wolcott, HD | 1 |
| Gallup, DG | 2 |
| Ferenczy, A | 1 |
| Kish, JA | 3 |
| Weaver, A | 1 |
| Jacobs, J | 1 |
| Cummings, G | 2 |
| Conte, PF | 3 |
| Tatarek, R | 2 |
| Scarsi, P | 1 |
| Barbieri, A | 1 |
| Benedetti, G | 2 |
| Brodovsky, HS | 1 |
| Bauer, M | 1 |
| Horton, J | 1 |
| Elson, PJ | 1 |
| Dymarskiĭ, LIu | 1 |
| Sanchakova, AV | 1 |
| Aleksandrova, GI | 1 |
| Trishkina, EA | 1 |
| Une, Y | 2 |
| Kagaya, H | 1 |
| Miyata, S | 1 |
| Uchino, J | 5 |
| Yakura, Y | 1 |
| Swanson, NA | 1 |
| Meyerowitz, BE | 1 |
| Watkins, IK | 1 |
| Sparks, FC | 1 |
| Watanabe, H | 3 |
| Tomita, K | 1 |
| Jinguh, K | 1 |
| Seniukov, MV | 1 |
| Goldobenko, GV | 2 |
| Mardynskiĭ, IuS | 1 |
| Lushnikov, EF | 1 |
| Skoropad, IuD | 1 |
| Tashiro, K | 1 |
| Machida, T | 2 |
| Masuda, F | 1 |
| Ohishi, Y | 1 |
| Gerbie, MV | 1 |
| Schell, F | 1 |
| Cetti, NE | 1 |
| Bedikian, AY | 2 |
| Khankhanian, N | 2 |
| McBride, CM | 2 |
| McMurtrey, MJ | 1 |
| Bodey, GP | 1 |
| Leissner, KH | 1 |
| Arndt, D | 1 |
| Higi, M | 1 |
| Heuser, L | 1 |
| Schmitt, G | 3 |
| Yanagita, T | 1 |
| Kuwano, M | 1 |
| Hiroto, I | 1 |
| Schnitzler, G | 1 |
| Heim, ME | 3 |
| König, H | 1 |
| Katz, R | 1 |
| Fritze, D | 2 |
| Arnold, H | 2 |
| Henss, H | 2 |
| Trux, F | 1 |
| Hubay, CA | 4 |
| Gordon, NH | 3 |
| Crowe, JP | 3 |
| Guyton, SP | 1 |
| Pearson, OH | 4 |
| Marshall, JS | 4 |
| Mansour, EG | 5 |
| Hermann, RE | 2 |
| Jones, JC | 2 |
| Flynn, WJ | 2 |
| Albright, SD | 1 |
| Bezwoda, WR | 1 |
| Derman, D | 1 |
| De Moor, NG | 1 |
| Lange, M | 1 |
| Levin, J | 2 |
| Jacobs, C | 3 |
| Konnak, JW | 1 |
| Britsis, FA | 1 |
| Zakenfel'd, GK | 1 |
| Krampe, RA | 1 |
| Berzinia, VIu | 1 |
| Purkalne, TS | 1 |
| Kovalenko, AV | 1 |
| Rossi, A | 5 |
| Dement'eva, IP | 1 |
| Ass, NIa | 1 |
| Lipovich, MM | 1 |
| Murosaki, S | 1 |
| Inagaki, J | 1 |
| Horikoshi, N | 2 |
| Esaki, K | 1 |
| Nagura, E | 1 |
| Ueoka, H | 1 |
| Okabe, K | 1 |
| Anderson, JM | 1 |
| Rainer, H | 1 |
| Kovats, E | 2 |
| Lehmann, HG | 1 |
| Micksche, M | 1 |
| Rauhs, R | 1 |
| Sedlacek, HH | 1 |
| Seidl, W | 1 |
| Schemper, M | 1 |
| Schiessel, R | 1 |
| Schweiger, B | 1 |
| Wunderlich, M | 1 |
| Gropp, C | 1 |
| Havemann, K | 2 |
| Kunitomo, K | 1 |
| Kuwashima, T | 1 |
| Korematsu, H | 1 |
| Yoshikawa, H | 1 |
| Toyosaki, M | 1 |
| Komi, N | 1 |
| Bitran, JD | 1 |
| Desser, RK | 1 |
| Shapiro, CM | 1 |
| Michel, A | 1 |
| Kozloff, MF | 1 |
| Billings, AA | 1 |
| Recent, W | 1 |
| Bedwinek, JM | 1 |
| Ratkin, GA | 1 |
| Philpott, GW | 1 |
| Wallack, M | 1 |
| Tess, JD | 1 |
| Banfi, A | 1 |
| Hsieh, T | 1 |
| Malkasian, GD | 4 |
| Decker, DG | 4 |
| Green, SJ | 2 |
| Edmonson, JH | 4 |
| Jefferies, JA | 1 |
| Webb, MJ | 1 |
| Jamieson, GG | 2 |
| Gill, PG | 2 |
| Cooper, MR | 3 |
| Rhyne, AL | 1 |
| Ferree, C | 1 |
| Richards, F | 1 |
| White, DR | 1 |
| Stuart, JJ | 1 |
| Howard, V | 1 |
| Shore, A | 1 |
| Spurr, CL | 1 |
| Fournier, DV | 1 |
| Sievers, H | 1 |
| Staib, I | 1 |
| Wöllgens, P | 1 |
| Nedden, R | 1 |
| Lochbühler, H | 1 |
| Christmann, D | 1 |
| Bühner, R | 1 |
| Pfuhl, PJ | 1 |
| Henningsen, B | 1 |
| Kuttig, H | 1 |
| Wysocki, S | 1 |
| Thüre, D | 1 |
| Drings, P | 1 |
| Senn, HJ | 4 |
| Amgwerd, R | 2 |
| Hochuli, E | 1 |
| Robinson, B | 1 |
| Knox, KL | 1 |
| Carpenter, JT | 2 |
| Maddox, WA | 1 |
| Laws, HL | 1 |
| Wirtschafter, DD | 1 |
| Logothetis, CJ | 1 |
| Samuels, ML | 1 |
| Wallace, S | 1 |
| Chuang, V | 1 |
| Trindade, A | 1 |
| Grant, C | 1 |
| Haynie, TP | 1 |
| Wilson, CB | 2 |
| Vestnys, PS | 1 |
| Ahmann, DL | 4 |
| Bisel, HF | 3 |
| Ingle, JN | 5 |
| Hahn, RG | 3 |
| Lee, RA | 1 |
| Scanlon, PW | 2 |
| Payne, WS | 2 |
| Frytak, S | 2 |
| Creagan, ET | 1 |
| Robinson, E | 2 |
| Bartal, A | 1 |
| Haim, N | 2 |
| Mohilever, J | 1 |
| Mekori, T | 1 |
| Costanza, ME | 1 |
| Kumar, AA | 1 |
| Oda, Y | 1 |
| Tsuda, E | 1 |
| Tokuriki, Y | 1 |
| Tsuda, T | 1 |
| Abe, O | 6 |
| Izuo, M | 4 |
| Enomoto, K | 7 |
| Koyama, H | 8 |
| Sakai, K | 4 |
| Terasawa, T | 3 |
| Nomura, Y | 8 |
| Albrecht, M | 1 |
| Jepsen, G | 1 |
| Trams, G | 1 |
| Thomsen, K | 1 |
| Mackay, B | 1 |
| Luna, M | 1 |
| Valdivieso, M | 1 |
| Foster, DC | 1 |
| Woodruff, JD | 1 |
| Savran, VR | 1 |
| Shiian, DN | 1 |
| Legha, SS | 3 |
| Wiseman, CL | 1 |
| Distefano, A | 1 |
| Schell, FC | 1 |
| Barnes, BC | 1 |
| Campos, LT | 1 |
| Caglar, H | 2 |
| Hertzog, RW | 1 |
| Hreshchyshyn, MM | 2 |
| Lokich, J | 2 |
| Kinsella, T | 1 |
| Perri, J | 1 |
| Clouse, M | 1 |
| Chlebowski, RT | 3 |
| Weiner, JM | 2 |
| Luce, J | 2 |
| Hestorff, R | 1 |
| Lang, JE | 1 |
| Reynolds, R | 2 |
| Godfrey, T | 1 |
| Ryden, VM | 1 |
| Bateman, JR | 2 |
| Rhodes, RS | 1 |
| Debanne, SM | 1 |
| Eckert, C | 1 |
| McGuire, WL | 2 |
| Glidewell, O | 1 |
| Cooper, RG | 1 |
| Park, RC | 1 |
| Blom, J | 1 |
| Disaia, PJ | 3 |
| Lagasse, LD | 2 |
| Melchert, F | 1 |
| Kreienberg, R | 2 |
| von Nathusius, U | 1 |
| Piver, MS | 6 |
| Lele, S | 1 |
| Barlow, JJ | 4 |
| Casson, P | 1 |
| Stenson, K | 4 |
| Stupp, R | 2 |
| Malone, D | 1 |
| Gonzales-de Léon, C | 1 |
| Lippman, SM | 2 |
| Kudelka, AP | 2 |
| Edwards, CL | 2 |
| Kavanagh, JJ | 3 |
| Lamb, L | 1 |
| Brucker, C | 1 |
| Weiss, M | 1 |
| Schweiberer, L | 1 |
| Genz, T | 1 |
| Maassen, V | 1 |
| Debus-Thiede, G | 1 |
| Clavel, M | 1 |
| Cognetti, F | 3 |
| Cappelaere, P | 2 |
| de Mulder, PH | 1 |
| Schornagel, JH | 1 |
| Tueni, EA | 1 |
| Wildiers, J | 1 |
| Clerico, M | 1 |
| Kuriyama, M | 2 |
| Takeuchi, T | 2 |
| Ozeki, S | 1 |
| Taniguchi, M | 2 |
| Nagatani, Y | 1 |
| Ben-Josef, E | 1 |
| Court, WS | 1 |
| Jacquet, P | 1 |
| Averbach, AM | 1 |
| Stephens, AD | 1 |
| Raoul, JL | 1 |
| Le Prisé, E | 1 |
| Julienne, V | 1 |
| Gosselin, M | 1 |
| Launois, B | 1 |
| Teo, PM | 2 |
| Leung, TW | 1 |
| Leung, SF | 2 |
| Yeo, W | 1 |
| Choi, PH | 2 |
| Johnson, PJ | 2 |
| Austin, JR | 1 |
| Wong, FC | 1 |
| Kim, EE | 1 |
| Aramaki, M | 2 |
| Kawano, K | 2 |
| Kitano, S | 1 |
| Nishimura, A | 3 |
| Hanada, H | 1 |
| Maeshiro, T | 2 |
| Yamada, F | 2 |
| Awane, Y | 2 |
| Yagyu, T | 4 |
| Shin, E | 5 |
| Yoshioka, Y | 1 |
| Iizuka, R | 1 |
| Sawai, K | 1 |
| Itoh, Y | 2 |
| Tenawa, A | 1 |
| Muramoto, H | 1 |
| Katoh, E | 1 |
| Wingren, S | 2 |
| Ferraud, L | 1 |
| Sullivan, S | 2 |
| Benoit, G | 1 |
| Di Palma, M | 1 |
| Blanchet, P | 1 |
| Lecouturier, S | 1 |
| Yataghene, Y | 1 |
| Decroix, Y | 1 |
| Misset, JL | 1 |
| Jardin, A | 1 |
| Berns, EM | 1 |
| Foekens, JA | 3 |
| van Staveren, IL | 1 |
| van Putten, WL | 2 |
| de Koning, HY | 1 |
| Portengen, H | 1 |
| Klijn, JG | 3 |
| Koja, S | 1 |
| Itokazu, T | 1 |
| Maeshiro, N | 1 |
| Matsumura, J | 1 |
| Yasuda, S | 1 |
| Kochi, A | 1 |
| Noda, Y | 1 |
| Hiraishi, M | 2 |
| Makuuchi, M | 2 |
| Prager, D | 1 |
| Grundfest-Broniatowski, S | 1 |
| Lerner, HJ | 1 |
| Margolese, RG | 3 |
| Dimitrov, N | 1 |
| Silverman, P | 1 |
| Molina Esquivel, J | 1 |
| Vargas Sandoval, G | 1 |
| Rodríguez del Rincón, E | 1 |
| Velázquez López, J | 1 |
| Orsatti, M | 1 |
| Curotto, A | 1 |
| Canobbio, L | 1 |
| Guarneri, D | 1 |
| Scarpati, D | 2 |
| Venturini, M | 1 |
| Franzone, P | 1 |
| Giudici, S | 1 |
| Martorana, G | 1 |
| Boccardo, F | 1 |
| Klutke, JJ | 1 |
| Bergman, A | 1 |
| Kito, T | 2 |
| Turk, PS | 1 |
| Belliveau, JF | 1 |
| Darnowski, JW | 1 |
| Weinberg, MC | 1 |
| Leenen, L | 1 |
| Zerillo, G | 1 |
| Restivo, G | 2 |
| Speciale, R | 2 |
| Cupido, G | 1 |
| Lo Bue, P | 1 |
| Ingria, F | 1 |
| Gallina, S | 1 |
| Spatafora, G | 1 |
| Testa, A | 1 |
| Abram, AC | 1 |
| Nabizadeh, S | 1 |
| Feldman, PS | 1 |
| Cantrell, RW | 1 |
| Levine, PA | 1 |
| Jardines, L | 1 |
| Callans, LS | 1 |
| Torosian, MH | 1 |
| Takenaka, K | 2 |
| Korenaga, D | 2 |
| Hiroshige, K | 1 |
| Ikeda, T | 2 |
| Sugimachi, K | 6 |
| Wahlen, SA | 1 |
| Slater, JD | 1 |
| Wagner, RJ | 1 |
| Wang, WA | 1 |
| Keeney, ED | 1 |
| Hocko, JM | 1 |
| King, A | 1 |
| Slater, JM | 1 |
| Saarto, T | 1 |
| Blomqvist, C | 1 |
| Tiusanen, K | 1 |
| Gröhn, P | 1 |
| Rissanen, P | 1 |
| Elomaa, I | 1 |
| Kallinowski, F | 1 |
| Buhr, HJ | 1 |
| Herfarth, C | 1 |
| Naunheim, KS | 1 |
| Petruska, PJ | 1 |
| Roy, TS | 1 |
| Schlueter, JM | 1 |
| Baue, AE | 1 |
| Kattan, J | 1 |
| Culine, S | 1 |
| Theodore, C | 1 |
| Droz, JP | 1 |
| Fabian, C | 2 |
| Giri, S | 2 |
| Estes, N | 1 |
| Tangen, CM | 3 |
| Poplin, E | 1 |
| Vogel, S | 1 |
| Goodwin, W | 1 |
| Rivkin, S | 1 |
| Fleming, TR | 6 |
| Leichman, CG | 3 |
| Muggia, FM | 3 |
| Doroshow, JH | 2 |
| Meyers, FJ | 2 |
| Holcombe, RF | 1 |
| Weiss, GR | 2 |
| Mangalik, A | 1 |
| Conti, JA | 1 |
| Knopf, K | 1 |
| Cirrincione, C | 1 |
| Perry, M | 1 |
| Budman, D | 2 |
| Panasci, L | 3 |
| Muss, H | 1 |
| Citron, M | 1 |
| Holland, J | 1 |
| Kosaki, G | 3 |
| Onodera, T | 1 |
| Nakagawara, G | 1 |
| Sano, K | 1 |
| Kaibara, N | 1 |
| Kakegawa, T | 2 |
| Kurihara, M | 2 |
| Kitamura, S | 1 |
| Ohtani, T | 1 |
| Tokunaga, K | 1 |
| Olthoff, KM | 1 |
| Rosove, MH | 1 |
| Shackleton, CR | 1 |
| Imagawa, DK | 1 |
| Farmer, DG | 1 |
| Northcross, P | 1 |
| Pakrasi, AL | 1 |
| Martin, P | 1 |
| Goldstein, LI | 1 |
| Shaked, A | 1 |
| Chari, RS | 1 |
| Russell, L | 1 |
| Hathorn, J | 1 |
| Neuberg, D | 1 |
| Tester, WJ | 1 |
| Clahsen, PC | 1 |
| Welvaart, K | 1 |
| van Driel, OJ | 1 |
| Sylvester, RJ | 1 |
| Nitta, A | 1 |
| Ota, K | 2 |
| Shirotani, N | 1 |
| Seshimo, A | 1 |
| Kameoka, S | 1 |
| Zabudkin, AF | 1 |
| Bukhteev, SV | 1 |
| Satoh, Y | 1 |
| Fujisawa, J | 1 |
| Sawaguchi, Y | 1 |
| Muranaga, S | 1 |
| Obara, M | 1 |
| Tamura, K | 1 |
| Tsubono, M | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Araya, S | 1 |
| Imamura, M | 2 |
| Massad, LS | 1 |
| Wagley, E | 1 |
| Winkelman, L | 1 |
| Lincoln, S | 1 |
| Yordan, EL | 1 |
| de Geest, K | 1 |
| Wilbanks, GD | 1 |
| Hamilton, CS | 1 |
| O'Brien, M | 2 |
| Bonaventura, A | 1 |
| Stewart, JF | 1 |
| Spry, NA | 1 |
| Dady, P | 1 |
| Ung, O | 1 |
| Barraclough, B | 1 |
| Boyages, J | 5 |
| Look, KY | 3 |
| Morris, M | 2 |
| Fried, G | 1 |
| Tsalik, M | 1 |
| Stein, M | 1 |
| Dale, J | 1 |
| Gardin, G | 2 |
| Alama, A | 1 |
| Campora, E | 2 |
| Repetto, L | 1 |
| Pronzato, P | 2 |
| Merlini, L | 1 |
| Naso, C | 1 |
| Camoriano, A | 1 |
| Meazza, R | 1 |
| Sataloff, DM | 1 |
| Mason, BA | 1 |
| Prestipino, AJ | 1 |
| Seinige, UL | 1 |
| Lieber, CP | 1 |
| Baloch, Z | 1 |
| Lévy, E | 1 |
| Kusama, M | 1 |
| Abe, R | 5 |
| Braly, PS | 1 |
| Berek, JS | 1 |
| Homesley, HD | 1 |
| Averette, H | 1 |
| Fanning, J | 1 |
| Ladd, C | 1 |
| Hilgers, RD | 1 |
| Huber, MH | 1 |
| Shirinian, M | 1 |
| Dimery, IW | 5 |
| Frankenthaler, RA | 1 |
| Stewart, DJ | 1 |
| Dahrouge, S | 1 |
| Soltys, KM | 1 |
| Evans, WK | 1 |
| Castiglione, M | 2 |
| Hacking, A | 2 |
| Marini, G | 1 |
| Cercato, MC | 1 |
| Carlini, P | 1 |
| Del Vecchio, MR | 1 |
| Marzetti, F | 1 |
| Milella, M | 1 |
| Cohen, AM | 5 |
| Yao, TJ | 1 |
| Enker, W | 1 |
| Tong, W | 1 |
| Tao, Y | 1 |
| Bertino, JR | 1 |
| Kabuto, T | 2 |
| Kameyama, M | 2 |
| Hiratsuka, M | 2 |
| Imaoka, S | 2 |
| Hoshino, M | 1 |
| Igarashi, W | 1 |
| Ohtake, T | 1 |
| Ono, T | 3 |
| Hatakeyama, Y | 2 |
| Nakagawa, H | 1 |
| Cho, G | 1 |
| Takatsuka, Y | 4 |
| Takano, S | 1 |
| Moriguchi, M | 1 |
| Seki, N | 1 |
| Higaki, T | 1 |
| Nakata, Y | 1 |
| Kono, S | 1 |
| Imamura, H | 1 |
| Okamura, Y | 1 |
| Ohshima, A | 2 |
| Hayasaka, H | 2 |
| Takatani, O | 1 |
| Schofield, JB | 1 |
| Lorentzos, A | 1 |
| Moore, J | 1 |
| Atkinson, H | 1 |
| Henk, JM | 1 |
| MacLennan, KA | 1 |
| Gore, ME | 1 |
| Weinstein, G | 2 |
| Brasnu, D | 6 |
| Cauchois, R | 1 |
| Jouffre, V | 1 |
| Garcia, D | 1 |
| Laccourreye, H | 3 |
| Stornes, I | 1 |
| Mejlholm, I | 1 |
| Takamuro, T | 1 |
| Konishi, Y | 1 |
| Takada, Y | 1 |
| Weiden, PL | 2 |
| Piantadosi, S | 2 |
| Obata, K | 1 |
| Akaza, H | 1 |
| Isaka, S | 1 |
| Kagawa, S | 1 |
| Koiso, K | 1 |
| Kotake, T | 1 |
| Matsumura, Y | 1 |
| Niijima, T | 1 |
| Longo, WE | 1 |
| Vernava, AM | 1 |
| Wade, TP | 1 |
| Coplin, MA | 1 |
| Virgo, KS | 1 |
| Johnson, FE | 1 |
| Frasci, G | 1 |
| Leone, F | 1 |
| Monaco, M | 1 |
| Cremone, L | 1 |
| Sapio, U | 1 |
| Faiella, F | 1 |
| Espinosa, A | 1 |
| Persico, G | 1 |
| Okugawa, T | 1 |
| Onodera, S | 1 |
| Kobayashi, O | 1 |
| Sairenji, M | 1 |
| Hartsell, WF | 1 |
| Murthy, AK | 3 |
| Taylor, SG | 6 |
| Haselow, RE | 1 |
| Panzer, M | 1 |
| Hültenschmidt, B | 1 |
| Döker, R | 1 |
| Huber, K | 1 |
| Kuhne-Velte, HJ | 1 |
| Hutter, M | 1 |
| Rühl, U | 2 |
| Wendt, T | 1 |
| Poplin, EA | 1 |
| Khanuja, PS | 1 |
| Kraut, MJ | 1 |
| Herskovic, AM | 1 |
| Lattin, PB | 2 |
| Gaspar, LE | 2 |
| Kinzie, JL | 1 |
| Vaitkevicius, VK | 1 |
| Berger, C | 2 |
| Descamps, P | 1 |
| Reynaud-Bougnoux, A | 1 |
| Bougnoux, P | 1 |
| Lansac, J | 1 |
| Scholl, SM | 4 |
| Asselain, B | 2 |
| Vilcoq, JR | 2 |
| Durand, JC | 2 |
| Dorval, T | 4 |
| Palangié, T | 6 |
| Jouve, M | 4 |
| van Kampen, M | 1 |
| Adachi, I | 2 |
| Fukami, A | 1 |
| Teshima, K | 1 |
| Sugawa, T | 1 |
| Okamura, S | 1 |
| Kubo, H | 1 |
| Sugimoto, O | 1 |
| Nakajima, H | 1 |
| Yamabe, T | 1 |
| Yu, KH | 1 |
| Nonami, T | 1 |
| Harada, A | 1 |
| Kajikawa, M | 1 |
| Hiraoka, E | 1 |
| Takagi, H | 1 |
| Laurie, JA | 3 |
| Tangen, C | 1 |
| Petrioli, R | 1 |
| Lorenzini, L | 1 |
| Mancini, S | 1 |
| Armenio, S | 1 |
| Tanzini, G | 1 |
| Marsili, S | 1 |
| Aquino, A | 1 |
| Marzocca, G | 1 |
| Civitelli, S | 1 |
| Shah, KH | 1 |
| Rao, AR | 1 |
| Frost, DB | 1 |
| Latino, F | 1 |
| Anderson, PJ | 1 |
| Peddada, AV | 1 |
| Kagan, AR | 1 |
| Depisch, D | 3 |
| Pidlich, J | 2 |
| Rosen, H | 1 |
| Karall, M | 1 |
| Prochaska, M | 1 |
| Ernst, A | 1 |
| Sebesta, C | 1 |
| Eckhardt, S | 1 |
| Buffat, L | 1 |
| Lefkopoulos, D | 1 |
| Malafosse, M | 1 |
| Velikova, M | 1 |
| Tsvekova, V | 1 |
| Koĭnov, K | 1 |
| Au, E | 3 |
| Ang, PT | 2 |
| Wils, J | 1 |
| Wagener, DJ | 1 |
| Burghouts, JT | 2 |
| Fickers, MM | 1 |
| de Graeff, A | 1 |
| Lalisang, FM | 1 |
| de Miguel Sánchez, C | 1 |
| Olmos Carrasco, O | 1 |
| Sáez-Berlana, A | 1 |
| Rodríguez García, MD | 1 |
| Gázquez Abad, I | 1 |
| Borbujo Martínez, J | 1 |
| Valente, G | 1 |
| Vercellino, V | 2 |
| Corradi, L | 1 |
| Tardy, A | 1 |
| Pomatto, E | 1 |
| Palestro, G | 1 |
| Hasegawa, T | 1 |
| Sano, R | 1 |
| Tsushima, K | 2 |
| Ogasawara, H | 2 |
| Tamura, Y | 2 |
| Moriya, N | 1 |
| Morrison, WH | 1 |
| Ota, D | 1 |
| Levin, B | 1 |
| Hojyo, M | 1 |
| Maruo, H | 1 |
| Kosaka, A | 1 |
| Bertelsen, K | 2 |
| Dalmark, M | 1 |
| Gadeberg, CC | 2 |
| von der Maase, H | 1 |
| Sell, A | 1 |
| Mäenpää, JU | 1 |
| Heinonen, E | 1 |
| Karnani, P | 1 |
| Kauppila, A | 1 |
| Kuoppala, T | 1 |
| Salmi, T | 1 |
| Sipilä, P | 1 |
| Nieminen, U | 1 |
| Hata, Y | 1 |
| Sasaki, F | 1 |
| Ogita, M | 1 |
| Ohira, S | 1 |
| Konno, T | 1 |
| Yasutake, T | 1 |
| Etoh, T | 1 |
| Ishimaru, T | 1 |
| Niho, Y | 2 |
| Fedeli, A | 2 |
| Luzi Fedeli, S | 2 |
| Catalano, G | 4 |
| Tani, C | 1 |
| Yamamoto, K | 3 |
| Kimura, K | 1 |
| Gall, FP | 1 |
| Tomio, L | 1 |
| Zorat, PL | 1 |
| Paccagnella, A | 3 |
| Segati, R | 2 |
| Loreggian, L | 1 |
| Lora, O | 1 |
| Favaretto, A | 1 |
| Fede, A | 1 |
| Shinohara, M | 1 |
| Kajiyama, Y | 1 |
| Tsurumaru, M | 1 |
| Udagawa, H | 1 |
| Watanabe, G | 1 |
| Matsuda, M | 1 |
| Akiyama, H | 1 |
| Foo, ML | 1 |
| McLlrath, DC | 1 |
| van Heerden, JA | 1 |
| Robinow, JS | 1 |
| Garton, GR | 2 |
| O'Shaughnessy, JA | 1 |
| Cowan, KH | 1 |
| Tanum, G | 2 |
| Karlsen, KO | 1 |
| Junor, E | 1 |
| Yosef, H | 2 |
| Paula, J | 1 |
| Beck, T | 1 |
| Crombach, G | 1 |
| Tuxen, MK | 1 |
| Lund, B | 1 |
| Hansen, OP | 1 |
| Hansen, M | 1 |
| Brockmann, WP | 1 |
| Sommer, K | 1 |
| Steiner, P | 1 |
| Hübener, KH | 1 |
| Carstensen, JM | 2 |
| Burcharth, F | 1 |
| Mercier, M | 1 |
| Arrigoni, F | 1 |
| Ventriglia, L | 1 |
| Saturno, F | 1 |
| Poletti, EM | 1 |
| Sacco, R | 1 |
| Enker, WE | 2 |
| Frankel, J | 1 |
| Shumate, CR | 1 |
| Ota, DM | 2 |
| Fung, CY | 1 |
| Efird, J | 1 |
| Shellito, PC | 2 |
| Falkson, HC | 2 |
| Gilchrist, K | 2 |
| Abeloff, MD | 5 |
| Suh, C | 1 |
| Park, KC | 1 |
| Gregg, CM | 1 |
| Beals, TE | 1 |
| McClatchy, KM | 1 |
| Fisher, SG | 3 |
| Wolf, GT | 3 |
| Asaishi, K | 2 |
| Aoki, N | 1 |
| Tsukada, T | 1 |
| Ungerleider, JS | 1 |
| Emerson, WA | 1 |
| Glick, JH | 2 |
| Bovo, G | 1 |
| Brivio, F | 1 |
| Brenna, A | 2 |
| Fumagalli, L | 1 |
| Perego, P | 1 |
| Brivio, O | 1 |
| Uggeri, F | 1 |
| Lavorato, F | 1 |
| Bratina, G | 1 |
| Singh, G | 1 |
| Singh, DP | 1 |
| Gupta, D | 1 |
| Muralikrishna, BV | 1 |
| Plasswilm, L | 2 |
| Paraiso, D | 1 |
| Garcia-Giralt, E | 3 |
| Pouillart, P | 4 |
| Bates, BA | 1 |
| Detterbeck, FC | 1 |
| Bernard, SA | 1 |
| Qaqish, BF | 1 |
| Remvikos, Y | 1 |
| Peterson, RF | 1 |
| McClure, S | 1 |
| Chapman, RA | 1 |
| Eyre, HJ | 1 |
| Solanki, D | 1 |
| Cruz, AB | 1 |
| Gagliano, R | 1 |
| Vikram, B | 1 |
| Tashiro, H | 1 |
| Koga, T | 2 |
| Shimazu, H | 1 |
| Tomita, M | 1 |
| Lupi, G | 1 |
| Raspagliesi, F | 1 |
| Zucali, R | 3 |
| Fontanelli, R | 1 |
| Paladini, D | 1 |
| Kenda, R | 2 |
| di Re, F | 1 |
| Zhang, ZJ | 1 |
| Wang, JL | 1 |
| Muhr, C | 1 |
| Smits, A | 1 |
| Lönn, U | 1 |
| Lönn, S | 1 |
| Nilsson, B | 1 |
| Stenkvist, B | 1 |
| Johnson, JT | 3 |
| Wagner, RL | 2 |
| Myers, EN | 3 |
| Chi, KH | 1 |
| Chan, WK | 1 |
| Shu, CH | 1 |
| Law, CK | 1 |
| Thomas, F | 1 |
| Mouriesse, H | 1 |
| Le Chevalier, T | 2 |
| Fontaine, F | 1 |
| Tursz, T | 1 |
| Sundfør, K | 2 |
| Tropé, CG | 1 |
| Högberg, T | 1 |
| Onsrud, M | 1 |
| Koern, J | 1 |
| Simonsen, E | 1 |
| Westberg, R | 1 |
| Bensmaine, ME | 1 |
| Azli, N | 4 |
| Cvitkovic, E | 10 |
| Estes, NC | 2 |
| Kelsen, D | 1 |
| Karpeh, M | 1 |
| Schwartz, G | 1 |
| Gerdes, H | 1 |
| Lightdale, C | 1 |
| Botet, J | 1 |
| Lauers, G | 1 |
| Klimstra, D | 1 |
| Quan, V | 1 |
| Brennan, M | 1 |
| Naudo, P | 1 |
| Roux, FX | 3 |
| Sugahara, K | 1 |
| Tobe, T | 1 |
| Dozois, RR | 3 |
| Devine, RM | 3 |
| Nelson, H | 4 |
| Weaver, AL | 1 |
| Ilstrup, DM | 1 |
| Huber, FT | 1 |
| Stepan, R | 1 |
| Guillot, T | 1 |
| Bernal, ET | 1 |
| Sigal, R | 1 |
| Wibault, P | 5 |
| Seegenschmiedt, MH | 1 |
| Ganssauge, F | 1 |
| Saint-Marc, O | 1 |
| Pitre, J | 1 |
| Houssin, D | 1 |
| Chapuis, Y | 1 |
| Dignam, J | 2 |
| Redmond, C | 2 |
| Dimitrov, NV | 4 |
| Bowman, DM | 1 |
| Glass, AG | 2 |
| Atkins, JN | 3 |
| Abramson, N | 2 |
| Sutherland, CM | 1 |
| Aron, BS | 1 |
| Bolla, M | 4 |
| Vincent, P | 2 |
| Benabid, A | 1 |
| Mousseau, M | 1 |
| de Rougemont, J | 1 |
| Vrousos, C | 3 |
| Kolodié, H | 3 |
| Vincent, F | 3 |
| Pasquier, B | 1 |
| Ménard, M | 2 |
| Khayat, D | 2 |
| Zinzani, PL | 1 |
| Zompatori, M | 1 |
| Bendandi, M | 1 |
| Battista, G | 1 |
| Barbieri, E | 1 |
| Gherlinzoni, F | 1 |
| Rimondi, MR | 1 |
| Frezza, G | 1 |
| Pisi, P | 1 |
| Merla, E | 1 |
| Gozzetti, A | 1 |
| Canini, R | 1 |
| Monetti, N | 1 |
| Babini, L | 1 |
| Tura, S | 1 |
| Mantovani, G | 1 |
| Agostara, B | 1 |
| Contu, A | 1 |
| Farris, A | 1 |
| Colucci, G | 1 |
| Ferrero, B | 1 |
| Takiya, S | 1 |
| Sawada, T | 4 |
| Tagaya, T | 1 |
| Fukuzawa, Y | 1 |
| Ikeda, H | 1 |
| Chrétien, Y | 1 |
| Mejean, A | 1 |
| Dufour, B | 1 |
| Kaern, J | 4 |
| Tropé, C | 4 |
| Sundfoer, K | 1 |
| Kristensen, GB | 1 |
| Forrest, AP | 1 |
| Stewart, HJ | 2 |
| Everington, D | 1 |
| Prescott, RJ | 2 |
| McArdle, CS | 1 |
| Harnett, AN | 1 |
| Smith, DC | 1 |
| Lentz, SS | 1 |
| White, RM | 1 |
| Tsavaris, NB | 2 |
| Tentas, K | 1 |
| Mylonakis, N | 1 |
| Sakelaropoulos, N | 1 |
| Lisaios, B | 1 |
| Soumilas, A | 1 |
| Mandrekois, D | 1 |
| Tsetis, A | 1 |
| Klonaris, C | 1 |
| Ogura, T | 1 |
| Hiramatsu, Y | 1 |
| Araki, H | 1 |
| Nakagawa, A | 1 |
| Nakagawa, M | 1 |
| Kamiyama, Y | 1 |
| Ichikawa, W | 1 |
| Nihei, Z | 1 |
| Kawamura, N | 1 |
| Sawai, S | 1 |
| Miyanaga, T | 1 |
| Hirayama, R | 1 |
| Mishima, Y | 1 |
| Yanagi, I | 1 |
| Koga, A | 1 |
| Okuda, K | 2 |
| Nishio, T | 1 |
| Shibata, J | 1 |
| Aso, K | 1 |
| Matuo, H | 1 |
| Nagashima, J | 1 |
| So, H | 1 |
| Takami, M | 1 |
| Kitada, M | 1 |
| Tsukahara, Y | 1 |
| Niinobu, T | 1 |
| Iihara, K | 1 |
| Kimura, M | 2 |
| Nose, T | 1 |
| Kaneyasu, Y | 3 |
| Okawa, MK | 3 |
| Kokubo, N | 2 |
| Takemoto, M | 1 |
| Fukuhara, N | 2 |
| Toda, J | 2 |
| Okawa, T | 3 |
| Terakado, H | 2 |
| Ikawa, M | 2 |
| Hamada, E | 2 |
| Nakasato, S | 2 |
| Takaki, S | 2 |
| Murata, M | 3 |
| Nakano, H | 1 |
| Iwanaga, T | 1 |
| Amos, EH | 1 |
| McCarty, PJ | 1 |
| Gage, JO | 1 |
| Emlet, JL | 1 |
| Lowrey, GC | 1 |
| Peterson, CA | 1 |
| Amos, WR | 1 |
| Cummings, BJ | 2 |
| Balat, O | 1 |
| Verschraegen, C | 1 |
| Skarlatos, J | 1 |
| Kosma, L | 1 |
| Koukourakis, M | 1 |
| Zambatis, C | 1 |
| Kapsoritakis, A | 1 |
| Mouder, N | 1 |
| Yannakakis, D | 1 |
| Doci, R | 1 |
| La Monica, G | 1 |
| Meroni, E | 1 |
| Eboli, M | 1 |
| Lozza, L | 1 |
| Hatton, MQ | 1 |
| Junor, EJ | 1 |
| Canney, PA | 1 |
| Robertson, AG | 1 |
| McGurk, FM | 1 |
| Symonds, RP | 1 |
| Gabra, H | 1 |
| Lee, LE | 1 |
| Leonard, RC | 2 |
| Asano, M | 1 |
| Tateoka, H | 1 |
| Ino, M | 1 |
| Noda, H | 1 |
| Takasaki, S | 1 |
| Masumoto, N | 1 |
| Fandi, A | 3 |
| Taamma, A | 3 |
| Bachouchi, M | 2 |
| Yanes, B | 1 |
| Deeb, LS | 1 |
| Yamout, BI | 1 |
| Shamseddine, AI | 1 |
| Shabb, NS | 1 |
| Uthman, SM | 1 |
| List, M | 2 |
| Ohno, M | 1 |
| Shibata, K | 1 |
| Moriwaki, R | 1 |
| Kohno, M | 1 |
| Tadatomo, H | 1 |
| Koyanagi, Y | 1 |
| Giralt, J | 1 |
| Rubio, D | 1 |
| Maldonado, X | 1 |
| Naval, J | 1 |
| Casado, S | 1 |
| Lara, F | 1 |
| Roselló, JM | 1 |
| Armengol, M | 1 |
| Théon, AP | 1 |
| Pascoe, JR | 1 |
| Madigan, JE | 1 |
| Carlson, G | 1 |
| Metzger, L | 1 |
| Cha, S | 2 |
| Haddock, M | 1 |
| Devine, R | 1 |
| Fieck, JM | 2 |
| Wolff, B | 1 |
| Dozois, R | 1 |
| Swaminathan, R | 1 |
| Burch, PA | 1 |
| Santala, RG | 1 |
| Schroeder, G | 1 |
| Pitot, HC | 1 |
| Wright, K | 1 |
| Kugler, JW | 2 |
| Willers, H | 1 |
| Würschmidt, F | 1 |
| Janik, I | 1 |
| Bünemann, H | 1 |
| Heilmann, HP | 1 |
| Crookes, P | 1 |
| Leichman, L | 3 |
| Laine, L | 1 |
| Stain, S | 1 |
| Baranda, J | 1 |
| Casagrande, Y | 1 |
| Silberman, H | 1 |
| Beauvillain, C | 1 |
| Mahé, M | 1 |
| Peuvrel, P | 1 |
| Bergerot, P | 1 |
| Rivière, A | 2 |
| Vignoud, J | 1 |
| Deraucourt, D | 1 |
| Wesoluch, M | 1 |
| Nagasue, N | 2 |
| Kohno, H | 2 |
| Uchida, M | 1 |
| Yukaya, H | 1 |
| Yamanoi, A | 2 |
| Zyrianov, BN | 1 |
| Makarkin, NA | 1 |
| Tikhonov, VI | 1 |
| Tuzikov, SA | 1 |
| Iannace, C | 1 |
| De Cristofano, L | 1 |
| Caracciolo, F | 1 |
| Ferrero, JM | 2 |
| Namer, M | 3 |
| Dufour, JF | 1 |
| Largillier, R | 2 |
| Creisson, A | 1 |
| Teissier, E | 1 |
| Machiavello, JC | 1 |
| Lallement, M | 1 |
| Monticelli, J | 1 |
| Abbes, M | 1 |
| Chung, YS | 1 |
| Matsuoka, T | 1 |
| Nakata, B | 2 |
| Sowa, M | 2 |
| Zidan, J | 1 |
| Kuten, A | 1 |
| Rosenblatt, E | 1 |
| Wolf, MK | 1 |
| Schellhammer, PF | 1 |
| Einstein, AB | 1 |
| Crawford, ED | 1 |
| Wolff, BG | 2 |
| Lee, HD | 1 |
| Koo, JY | 1 |
| Suh, CO | 1 |
| Jung, WH | 1 |
| Oh, KK | 1 |
| Law, S | 1 |
| Fok, M | 1 |
| Chow, S | 1 |
| Chu, KM | 1 |
| Bretel, JJ | 1 |
| Baldeyrou, P | 1 |
| Grunenwald, D | 1 |
| Le Péchoux, C | 1 |
| Pellae-Cosset, B | 1 |
| Ruffié, P | 1 |
| Guldvog, I | 1 |
| Hagen, S | 1 |
| Trondsen, E | 1 |
| Harbitz, T | 1 |
| Nygaard, K | 1 |
| Nilsen, JB | 1 |
| Wist, E | 1 |
| Hannisdal, E | 1 |
| Keilholz, L | 2 |
| Hugosson, J | 1 |
| Bergdahl, S | 1 |
| Frösing, R | 1 |
| Norlén, L | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Tuğ, T | 1 |
| Karaayvaz, M | 1 |
| Akgül, H | 1 |
| Stuntz, M | 1 |
| Wilmoth, G | 1 |
| Ong, J | 1 |
| Stabile, B | 1 |
| Stamos, M | 1 |
| Pitman, KT | 1 |
| Cohen, A | 1 |
| Eliachar, I | 2 |
| Van Kirk, MA | 1 |
| Lavertu, P | 2 |
| Secic, M | 1 |
| Wanamaker, JR | 1 |
| Strome, M | 1 |
| Iop, A | 2 |
| Cartei, G | 3 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Mansutti, M | 1 |
| Sibau, AM | 1 |
| Solano, C | 1 |
| Sola, C | 1 |
| Hornedo, J | 1 |
| López, J | 1 |
| García-Conde, J | 2 |
| Hartmann, KA | 1 |
| Audretsch, W | 1 |
| Carl, UM | 1 |
| Gripp, S | 1 |
| Muskalla, K | 1 |
| Rezai, M | 1 |
| Schnabel, T | 2 |
| Waap, I | 1 |
| Naitoh, H | 1 |
| Okauchi, H | 1 |
| Tani, T | 1 |
| Kodama, M | 1 |
| Isogai, K | 1 |
| Kanematsu, M | 1 |
| Fujihiro, S | 1 |
| Ehara, H | 1 |
| Itoh, F | 1 |
| Horie, M | 1 |
| Matsuda, S | 1 |
| Tei, KH | 1 |
| Kawada, Y | 1 |
| Jibiki, M | 2 |
| Taniguchi, Y | 1 |
| Matsuo, T | 1 |
| Ikari, H | 1 |
| Ishibashi, T | 1 |
| Sugamura, Y | 1 |
| Kunizaki, T | 1 |
| Hirao, K | 1 |
| DeCillis, A | 1 |
| Emir, B | 1 |
| Deschenes, L | 1 |
| Hansen, PS | 1 |
| Rose, C | 2 |
| Andersson, M | 1 |
| Bach, F | 1 |
| Kjaer, M | 1 |
| Zedeler, K | 1 |
| Fiorentini, G | 1 |
| Cavazzini, G | 1 |
| Molani, L | 1 |
| Morandi, C | 1 |
| Caforio, M | 1 |
| Caleffi, G | 1 |
| Zamagni, D | 1 |
| Smerieri, F | 1 |
| Hussain, M | 2 |
| Salwen, W | 2 |
| Kucuk, O | 4 |
| Gentile, A | 1 |
| Ellis, P | 1 |
| Smith, I | 1 |
| Baum, M | 1 |
| Sacks, N | 1 |
| McKinna, J | 1 |
| Valea, FA | 1 |
| McGehee, R | 1 |
| Manetta, A | 1 |
| Webster, KD | 1 |
| Andersen, WA | 1 |
| Surico, N | 1 |
| Ribaldone, R | 1 |
| Micheli, A | 1 |
| D'Angelo, L | 1 |
| Giovinazzo, G | 1 |
| Tersigni, R | 1 |
| Comandini, E | 1 |
| Scala, T | 1 |
| Mauri, M | 1 |
| D'Aprile, M | 1 |
| Erkisi, M | 1 |
| Bilkay, BC | 1 |
| Seyrek, E | 1 |
| Hazar, B | 1 |
| Burgut, R | 1 |
| Ishida, K | 1 |
| Koeda, K | 1 |
| Aoki, K | 1 |
| Ogasawara, S | 1 |
| Iwaya, T | 1 |
| Saito, K | 2 |
| Schrijvers, D | 1 |
| Johnson, J | 1 |
| Jiminez, U | 1 |
| Gore, M | 2 |
| Szpirglas, H | 1 |
| Robbins, K | 1 |
| Oliveira, J | 1 |
| Lewensohn, R | 1 |
| Schüller, J | 1 |
| Arvay, C | 1 |
| Langecker, P | 1 |
| Jacob, H | 1 |
| Vokes, E | 1 |
| Chao, MW | 1 |
| Byram, D | 1 |
| Bell, R | 1 |
| Bond, R | 1 |
| Vaughan, S | 1 |
| McLennan, R | 1 |
| Lim-Joon, M | 1 |
| Wada, M | 1 |
| Rossi, BM | 2 |
| Nakagawa, WT | 2 |
| Novaes, PE | 1 |
| Filho, WD | 1 |
| Hongo, H | 1 |
| Akamine, T | 1 |
| Hanada, N | 1 |
| Toyota, N | 1 |
| Yoshioka, M | 1 |
| Tabira, Y | 1 |
| Hiraoka, T | 1 |
| Kitamura, N | 1 |
| LeBlanc, M | 1 |
| Giri, PG | 1 |
| Fu, KK | 2 |
| Cooper, J | 2 |
| Adams, G | 1 |
| Sakr, WA | 1 |
| Schuller, DE | 1 |
| Ensley, JF | 2 |
| Isaia, A | 1 |
| Ayzac, L | 1 |
| Hun, D | 1 |
| Romestaing, P | 1 |
| Coquard, R | 1 |
| Ardiet, JM | 1 |
| Marczell, A | 1 |
| Karner, J | 1 |
| Salem, G | 1 |
| Greiner, R | 1 |
| Burger, D | 1 |
| Stöger, F | 1 |
| Ritschel, J | 1 |
| Vischer, HM | 1 |
| Schneeweiss, B | 1 |
| Pandya, KJ | 3 |
| Tormey, D | 1 |
| Cummings, FJ | 4 |
| Ajani, J | 2 |
| Bhalla, K | 1 |
| Forastiere, A | 1 |
| Patel, P | 1 |
| Martin, L | 1 |
| Donegan, J | 1 |
| Reed, C | 1 |
| Koning, C | 1 |
| Gottwald, T | 1 |
| Köveker, G | 1 |
| Büsing, M | 1 |
| Lauchart, W | 1 |
| Becker, HD | 1 |
| Schulz-Wendtland, R | 1 |
| Krämer, S | 1 |
| Säbel, M | 1 |
| Heller, F | 1 |
| Jäger, W | 1 |
| Lang, N | 1 |
| Bautz, W | 1 |
| Tattersall, M | 1 |
| Gudgeon, A | 1 |
| Coates, A | 1 |
| Isley, M | 1 |
| Sevelda, P | 1 |
| Tschurtschenthaler, B | 1 |
| Stierer, M | 2 |
| Kolb, R | 2 |
| Numico, GM | 1 |
| Danova, M | 1 |
| Santelli, A | 1 |
| Ameli, F | 1 |
| Blengio, F | 1 |
| Rosso, M | 1 |
| Bours, V | 1 |
| Jerusalem, G | 1 |
| Fillet, G | 1 |
| Kinoshita, H | 1 |
| Monden, Y | 1 |
| Schaebler, D | 1 |
| Sauter, E | 1 |
| DeMaria, D | 1 |
| Johnson, C | 1 |
| Reilly, DM | 1 |
| Aks, C | 1 |
| Litwin, S | 1 |
| Ying, DF | 1 |
| Omuro, Y | 1 |
| Narabayashi, M | 1 |
| Tokue, Y | 1 |
| Igarashi, T | 1 |
| Wakita, H | 1 |
| Ohtsu, T | 1 |
| Fujieda, S | 1 |
| Sunaga, H | 1 |
| Tsuzuki, H | 1 |
| Chung, KH | 1 |
| Yanagawa, K | 1 |
| Muguruma, K | 1 |
| An, M | 1 |
| Kishi, T | 1 |
| Idezuki, Y | 2 |
| Kikuyama, S | 1 |
| Inada, T | 1 |
| Miyakita, M | 1 |
| Miyazaki, I | 1 |
| Tanemura, H | 2 |
| Hamajima, N | 1 |
| Karlsson, YA | 1 |
| Malmström, PO | 1 |
| Fornander, TG | 1 |
| Söderberg, M | 1 |
| Jansson, TE | 1 |
| Sjöberg, SM | 1 |
| Bergh, JC | 1 |
| Yanagi, H | 1 |
| Kotera, H | 1 |
| Yamamura, T | 1 |
| Kurihara, T | 1 |
| Higashi, Y | 1 |
| Suemasu, K | 1 |
| Ishiguro, S | 1 |
| Morishita, Y | 2 |
| Takeda, F | 1 |
| Fowble, B | 2 |
| Hanlon, AL | 1 |
| Patchefsky, A | 1 |
| Freedman, G | 1 |
| Goldstein, LJ | 1 |
| Chauvet, B | 1 |
| Félix-Faure, C | 1 |
| Davin, JL | 1 |
| Reboul, F | 1 |
| Smith, TJ | 1 |
| Ryan, LM | 1 |
| Douglass, HO | 2 |
| Dayal, Y | 1 |
| Kirkwood, J | 1 |
| Hinson, J | 1 |
| Sischy, B | 1 |
| Harrison, LB | 1 |
| Mychalczak, B | 1 |
| Guillem, J | 2 |
| Anderson, L | 1 |
| White, C | 1 |
| Ishikawa, K | 3 |
| Miyata, M | 3 |
| Brockstein, BE | 1 |
| Humerickhouse, R | 1 |
| Chevallier, P | 1 |
| Rogopoulos, A | 1 |
| Bruneton, JN | 2 |
| Varia, MA | 1 |
| Bundy, BN | 1 |
| Deppe, G | 2 |
| Mannel, R | 1 |
| Averette, HE | 2 |
| Rose, PG | 1 |
| Connelly, P | 1 |
| Bulkley, GB | 1 |
| Matiakin, EG | 1 |
| Uvarov, AA | 1 |
| Kropotov, MA | 1 |
| Azizian, RI | 1 |
| Seow-Choen, F | 1 |
| Soo, KC | 1 |
| Low, CH | 1 |
| Chng, HC | 1 |
| Ng, BK | 1 |
| Hudes, GR | 1 |
| Lipsitz, S | 2 |
| Grem, J | 1 |
| Morrisey, M | 1 |
| Weiner, L | 1 |
| Benson, A | 1 |
| Peters, GE | 2 |
| Beenken, SW | 1 |
| Meredith, RF | 2 |
| Smith, J | 1 |
| Conner, W | 1 |
| Salter, MM | 2 |
| Maekawa, S | 1 |
| Humerickhouse, RA | 1 |
| Dolan, ME | 1 |
| Brockstein, B | 2 |
| Kies, M | 1 |
| Sulzen, L | 1 |
| Ratain, MJ | 1 |
| Shinkai, K | 1 |
| Kida, H | 2 |
| Hisano, H | 1 |
| Shibasaki, S | 1 |
| Darut-Jouve, A | 1 |
| Jolimoy, G | 1 |
| Belichard, C | 1 |
| Arnoud, L | 1 |
| Guerrin, J | 1 |
| Rothenberg, ML | 2 |
| Cox, JV | 1 |
| DeVore, RF | 1 |
| Rivkin, SE | 1 |
| Sandbach, J | 1 |
| Wolf, DL | 1 |
| Mohrland, JS | 1 |
| Elfring, GL | 1 |
| Miller, LL | 2 |
| Von Hoff, DD | 2 |
| Mikhak, B | 1 |
| Zahurak, M | 1 |
| Fetting, JH | 1 |
| Davidson, NE | 1 |
| Waterfield, W | 1 |
| Kennedy, MJ | 1 |
| Blajman, C | 1 |
| Balbiani, L | 1 |
| Block, J | 1 |
| Coppola, F | 1 |
| Chacon, R | 1 |
| Fein, L | 1 |
| Bonicatto, S | 1 |
| Alvarez, A | 1 |
| Schmilovich, A | 1 |
| Delgado, FM | 1 |
| González Barón, M | 1 |
| Paulsen, T | 1 |
| Klas, JV | 1 |
| Rothenberger, DA | 1 |
| Nathu, RM | 1 |
| Parsons, JT | 1 |
| Mancuso, AA | 1 |
| Carroll, RR | 1 |
| Kallel, N | 1 |
| Khomsi, F | 1 |
| Jerbi, G | 1 |
| Dhouib, R | 1 |
| Ben Safta, Z | 1 |
| Ben Abdesselem, M | 1 |
| el May, M | 1 |
| Gammoudi, A | 1 |
| Benna, F | 1 |
| Hamza, H | 1 |
| Dziri, C | 1 |
| Najah, N | 1 |
| Zaouche, A | 1 |
| Rahal, K | 1 |
| Ben Ayed, F | 1 |
| Tominaga, K | 1 |
| Arakawa, T | 1 |
| Imano, M | 1 |
| Kato, M | 1 |
| Hamaguchi, Y | 1 |
| Takaishi, O | 1 |
| Higuchi, K | 1 |
| Osugi, H | 1 |
| Chono, S | 1 |
| Kuroki, T | 1 |
| Hasbini, A | 2 |
| Mahjoubi, R | 2 |
| Chouaki, N | 2 |
| Lianes, P | 1 |
| Alonso, S | 1 |
| Billgren, AM | 1 |
| Tani, E | 1 |
| Wilking, N | 1 |
| Doidy, L | 1 |
| Lusinchi, A | 2 |
| Sabourin, JC | 1 |
| Bonvalot, S | 1 |
| Fukuda, M | 1 |
| Nakayama, Y | 1 |
| Ogata, H | 1 |
| Shimizu, K | 1 |
| Nishikawa, T | 1 |
| Fukuma, E | 1 |
| Umehara, A | 1 |
| Haga, S | 1 |
| Khoo, VS | 1 |
| Dubrow, R | 1 |
| Goswitz, MS | 1 |
| Evetts, PA | 1 |
| Allen, PK | 2 |
| Ping, B | 1 |
| Maghfoor, I | 1 |
| Ambiru, S | 1 |
| Nakajima, N | 2 |
| Görlich, M | 1 |
| Jandrig, B | 1 |
| Maneo, A | 1 |
| Landoni, F | 1 |
| Cormio, G | 1 |
| Colombo, A | 1 |
| Placa, F | 1 |
| Pellegrino, A | 1 |
| Mangioni, C | 1 |
| Debernardis, D | 1 |
| Baldo, C | 1 |
| Tunesi, G | 1 |
| Catalano, V | 2 |
| Staccioli, MP | 2 |
| Muretto, P | 2 |
| Chaney, AW | 1 |
| Eifel, PJ | 1 |
| Logsdon, MD | 1 |
| Wharton, JT | 1 |
| Iwagaki, H | 1 |
| Jikuhara, A | 1 |
| Tagashira, H | 1 |
| Nagao, A | 1 |
| Isozaki, H | 1 |
| Hizuta, A | 1 |
| Yorozu, A | 1 |
| Dokiya, T | 1 |
| Oki, Y | 1 |
| Kuroda, Y | 1 |
| Okamoto, Y | 1 |
| Mizowaki, T | 1 |
| Kusumi, F | 1 |
| Hajiro, K | 1 |
| Matsusue, S | 1 |
| Lim, WT | 1 |
| Koo, WH | 1 |
| Khoo, KS | 1 |
| Couteau, C | 1 |
| Paulino, AC | 1 |
| Grogan, M | 1 |
| Thomas, GM | 2 |
| Melamed, I | 1 |
| Wong, FL | 1 |
| Pearcey, RG | 1 |
| Joseph, PK | 1 |
| Portelance, L | 1 |
| Crook, J | 1 |
| Jones, KD | 1 |
| Horsell, KW | 1 |
| Merten, S | 1 |
| Clingan, P | 1 |
| King, DW | 1 |
| Levitt, M | 2 |
| House, A | 1 |
| Robbins, P | 1 |
| Chidel, MA | 1 |
| Kupelian, PA | 1 |
| Suh, JH | 1 |
| Becker, M | 1 |
| Gmyrek, R | 1 |
| Beer, R | 1 |
| Elizeri, Y | 1 |
| Oster, MW | 1 |
| Silvers, DN | 1 |
| Schneiderman, P | 1 |
| Grossman, ME | 1 |
| Rockette, H | 1 |
| Wieand, S | 1 |
| Bear, HD | 1 |
| Fisher, ER | 2 |
| Kashiwagi, H | 1 |
| Konishi, F | 1 |
| Furuta, K | 1 |
| Ozawa, A | 1 |
| Kanazawa, K | 1 |
| Masui, H | 1 |
| Ike, H | 1 |
| Oki, S | 1 |
| Katsumoto, Y | 1 |
| Furukawa, J | 1 |
| Morimoto, T | 1 |
| Takekuni, K | 1 |
| Azama, T | 1 |
| Nakaguchi, K | 1 |
| Okajima, S | 1 |
| Sue, F | 1 |
| Manfreda, D | 1 |
| Tschurtschenthaler, G | 1 |
| Haie-Meder, C | 1 |
| Fervers, B | 1 |
| Chauvergne, J | 3 |
| Fondrinier, E | 1 |
| Lhommé, C | 1 |
| Guastalla, JP | 1 |
| Maiman, M | 1 |
| Watts, DH | 1 |
| Andersen, J | 1 |
| Clax, P | 1 |
| Merino, M | 1 |
| Kendall, MA | 1 |
| Yamashita, J | 1 |
| Ogawa, N | 1 |
| Yokomori, T | 1 |
| Iesato, H | 1 |
| Nagaoka, H | 1 |
| Gadgeel, S | 1 |
| Du, W | 1 |
| Anderson, N | 2 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| De Franco, A | 1 |
| Battista Doglietto, G | 1 |
| Ziccarelli, L | 1 |
| Skeel, RT | 1 |
| Hall, TC | 2 |
| Shokeir, MO | 1 |
| Taylor, MA | 1 |
| Wreggit, GR | 1 |
| Crabo, L | 1 |
| Kawaida, M | 1 |
| Ohmuma, T | 1 |
| Samli, B | 1 |
| Celik, S | 1 |
| Evrensel, T | 1 |
| Orhan, B | 1 |
| Tasdelen, I | 1 |
| Sakaihara, M | 1 |
| Kataoka, S | 1 |
| Tabata, M | 1 |
| Hanatani, K | 1 |
| Hareyama, H | 1 |
| Bontenbal, M | 1 |
| Baggen, MG | 1 |
| Ras, GJ | 1 |
| Stiegelis, WF | 1 |
| Beudeker, M | 1 |
| Janssen, JT | 1 |
| van der Linden, GH | 1 |
| van der Velden, PC | 1 |
| van Geel, AN | 1 |
| Helle, P | 1 |
| Leisink, M | 1 |
| Angeli, CD | 1 |
| Valenti, M | 1 |
| de Belvis, V | 1 |
| Boccato, P | 1 |
| Corry, J | 1 |
| Smith, JG | 1 |
| D'Costa, IA | 1 |
| Huges, PG | 1 |
| Sexton, MA | 1 |
| Sizeland, A | 1 |
| Lyons, B | 1 |
| Peters, LJ | 1 |
| Lim, JT | 1 |
| Winter, K | 1 |
| Kocha, WI | 1 |
| Coia, LR | 1 |
| Herskovic, A | 3 |
| Graham, M | 2 |
| Lecanu, JB | 1 |
| Monceaux, G | 1 |
| Périé, S | 1 |
| Angelard, B | 1 |
| St Guily, JL | 1 |
| Ohzato, H | 1 |
| Deuffic, S | 1 |
| Arnaud, JP | 1 |
| Pelissier, E | 1 |
| Favre, JP | 1 |
| Jaeck, D | 1 |
| Fourtanier, G | 1 |
| Grandjean, JP | 1 |
| Marre, P | 1 |
| Jabro, G | 1 |
| Wazer, DE | 1 |
| Ruthazer, R | 1 |
| Lum, R | 1 |
| Sklar, N | 1 |
| Goldman, D | 1 |
| Enegess, D | 1 |
| Erban, J | 1 |
| Fodor, J | 1 |
| Toth, J | 1 |
| Major, T | 1 |
| Polgar, C | 1 |
| Nemeth, G | 1 |
| Takiguchi, N | 1 |
| Saitoh, N | 1 |
| Fujimoto, S | 1 |
| Choy, D | 2 |
| Lavrenkov, K | 1 |
| Kawasaki, T | 1 |
| Yabata, E | 1 |
| Gen, T | 1 |
| Kudoh, A | 1 |
| Noguchi, N | 1 |
| Morgan, RJ | 1 |
| Braly, P | 2 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Somlo, G | 1 |
| McNamara, M | 1 |
| Longmate, J | 1 |
| Schinke, S | 1 |
| Raschko, J | 1 |
| Nagasawa, S | 1 |
| Kogut, N | 1 |
| Lee, C | 1 |
| Hurwitz, H | 2 |
| Tyler, D | 1 |
| Jowell, P | 1 |
| Rosner, G | 1 |
| Samulski, T | 1 |
| Dewhirst, MW | 1 |
| Manivit, P | 1 |
| Polo, R | 1 |
| Tabary, D | 1 |
| Nabet, M | 1 |
| Polo, M | 1 |
| Adamy, M | 1 |
| Rubini, B | 1 |
| Fromaget, JM | 1 |
| Chipponi, PN | 1 |
| Untereiner, M | 1 |
| Toh, U | 1 |
| Isomoto, H | 1 |
| Yasunaga, M | 1 |
| Ogoh, Y | 1 |
| Inuzuka, K | 1 |
| Ozaki, K | 1 |
| Horvath, CM | 1 |
| Waxman, S | 1 |
| Thorban, S | 1 |
| Rosenberg, R | 1 |
| Roder, RJ | 1 |
| Strom, EA | 1 |
| Singletary, SE | 4 |
| Hunt, K | 2 |
| McNeese, MD | 5 |
| Horimi, T | 2 |
| Takasaki, M | 1 |
| Nakanoboh, M | 1 |
| Kawada, M | 1 |
| Silvestrini, R | 1 |
| Luisi, A | 1 |
| Cipriani, S | 1 |
| Schaefer, U | 1 |
| Schueller, P | 1 |
| Willich, N | 1 |
| Zelefsky, MJ | 1 |
| Khuri, FR | 1 |
| Nemunaitis, J | 2 |
| Ganly, I | 1 |
| Arseneau, J | 1 |
| Romel, L | 1 |
| Ironside, J | 1 |
| MacDougall, RH | 1 |
| Heise, C | 1 |
| Randlev, B | 1 |
| Gillenwater, AM | 1 |
| Bruso, P | 1 |
| Kirn, DH | 1 |
| Shiga, H | 1 |
| Rasmussen, AA | 1 |
| Langmacher, M | 1 |
| Baylor, A | 1 |
| Cullen, KJ | 1 |
| Shevrin, DH | 1 |
| Bonomi, PD | 2 |
| Harder, C | 1 |
| Rangan, AM | 1 |
| Ahern, V | 1 |
| Yip, D | 1 |
| Boronow, RC | 1 |
| Lamont, JP | 1 |
| Kuhn, JA | 1 |
| Landers, SA | 1 |
| McCarty, TM | 1 |
| Hung, WK | 1 |
| Lau, Y | 1 |
| Chan, CM | 1 |
| Yip, AW | 1 |
| Uchida, N | 1 |
| Tsuzuki, Y | 1 |
| Mochida, Y | 1 |
| Yoshikawa, M | 1 |
| Sekihara, M | 1 |
| Ohno, Y | 1 |
| Park, JK | 1 |
| Noh, JK | 1 |
| Bury, J | 1 |
| Herman, ML | 1 |
| Brohée, D | 1 |
| Lecomte, M | 1 |
| Tassinari, D | 1 |
| Arcangeli, V | 1 |
| Panzini, I | 1 |
| Sartori, S | 1 |
| Ravaioli, A | 1 |
| Fujisawa, Y | 1 |
| Hayne, M | 1 |
| Hanna, N | 1 |
| Hagihara, PF | 1 |
| McGrath, P | 1 |
| Marks, GM | 1 |
| Chakravarthy, A | 1 |
| Abrams, RA | 1 |
| Korman, LT | 1 |
| Zahurek, ML | 1 |
| Grochow, LB | 1 |
| O'Reilly, S | 1 |
| Jaffee, EM | 1 |
| Lillemoe, KD | 1 |
| Takao, T | 1 |
| Nisida, M | 1 |
| Maeda, Y | 1 |
| Berney, CR | 1 |
| Rohner, S | 1 |
| Marti, MC | 1 |
| Aapro, MS | 1 |
| Inoue, M | 1 |
| Choe, KJ | 1 |
| Kim, SR | 1 |
| Bleeker, WA | 1 |
| Hermans, J | 1 |
| Otter, R | 1 |
| Brown, RS | 1 |
| McCormack, M | 1 |
| Lankester, KJ | 1 |
| Spittle, MF | 1 |
| Rashidi, B | 1 |
| An, Z | 1 |
| Sun, FX | 1 |
| Moossa, AR | 1 |
| Hoffman, RM | 1 |
| Blum, JL | 1 |
| Lindel, K | 1 |
| Ott, MJ | 1 |
| Grossbard, M | 1 |
| Ryan, D | 1 |
| Ancukiewicz, M | 1 |
| Hennequin, C | 1 |
| Blazy, A | 1 |
| Perniceni, T | 1 |
| Panis, Y | 2 |
| Mal, F | 1 |
| Sarfati, E | 1 |
| Valleur, P | 1 |
| Belghiti, J | 1 |
| Fekete, F | 1 |
| Maylin, C | 1 |
| Kumar, SK | 1 |
| Foa, C | 1 |
| Bondiau, PY | 1 |
| Min, HQ | 1 |
| Mao, ZD | 1 |
| Gil-Delgado, MA | 1 |
| Guinet, F | 1 |
| Coeffic, D | 1 |
| Durrani, AK | 1 |
| Paradiso, A | 1 |
| Simone, G | 1 |
| Lena, MD | 1 |
| Leone, B | 1 |
| Vallejo, C | 1 |
| Lacava, J | 1 |
| Costa, A | 1 |
| Gasparini, G | 1 |
| Bonoldi, E | 1 |
| Fanelli, M | 1 |
| Romain, S | 1 |
| Look, MP | 1 |
| Martin, PM | 1 |
| Löffler, T | 1 |
| Haack, G | 1 |
| Anger, Y | 1 |
| Witte, RS | 1 |
| Cnaan, A | 1 |
| Barylak, E | 1 |
| Harris, JE | 1 |
| Breslin, TM | 1 |
| Hess, KR | 2 |
| Harbison, DB | 1 |
| Jean, ME | 1 |
| Cleary, KR | 1 |
| Dackiw, AP | 1 |
| Witkamp, AJ | 1 |
| de Bree, E | 1 |
| Kaag, MM | 1 |
| van Slooten, GW | 1 |
| Zoetmulder, FA | 1 |
| Rosen, F | 1 |
| Chung, T | 1 |
| Pelzer, H | 1 |
| Rademaker, A | 1 |
| Weichselbaum, R | 1 |
| Müller, H | 1 |
| Guadagni, S | 1 |
| Takei, H | 1 |
| Maemura, M | 1 |
| Graziano, F | 1 |
| Valentini, M | 1 |
| Giordani, P | 1 |
| Baldelli, AM | 1 |
| Grianti, C | 1 |
| Kamiya, K | 1 |
| Baba, M | 1 |
| Oota, M | 1 |
| Shouji, T | 1 |
| Igarashi, A | 1 |
| Wang, HM | 1 |
| Ng, SH | 1 |
| Wang, CH | 1 |
| Liaw, CT | 1 |
| Yang, TS | 1 |
| Chen, IH | 1 |
| Huguier, M | 1 |
| Schultze, J | 1 |
| Kimmig, B | 1 |
| Schmoor, C | 1 |
| Sauerbrei, W | 1 |
| Bastert, G | 2 |
| Bojar, H | 1 |
| Schumacher, M | 1 |
| De Crevoisier, R | 1 |
| Koscielny, S | 1 |
| Bobin, S | 1 |
| Eschwege, F | 1 |
| De Stefani, A | 1 |
| Marchionatti, S | 1 |
| Pedani, F | 6 |
| Gabriele, P | 4 |
| Cortesina, G | 1 |
| Bumma, C | 1 |
| Nazmy El Assal, O | 1 |
| Sekikawa, K | 2 |
| Anzai, K | 2 |
| Ishihata, R | 1 |
| Yamaki, T | 2 |
| Ohki, S | 1 |
| Kimijima, I | 2 |
| Takenoshita, S | 2 |
| Figueras, J | 1 |
| Valls, C | 1 |
| Rafecas, A | 1 |
| Fabregat, J | 1 |
| Ramos, E | 1 |
| Jaurrieta, E | 1 |
| Blot, F | 1 |
| El Otmany, A | 1 |
| Antoun, S | 1 |
| Nesbitt, J | 1 |
| Lahoti, S | 1 |
| Raijman, I | 1 |
| Swisher, S | 1 |
| Martin, FD | 1 |
| Momma, T | 1 |
| Ando, Y | 1 |
| Sassa, M | 1 |
| Honda, K | 1 |
| Abzumanov, AS | 1 |
| Bozhok, AA | 1 |
| Ivanov, VG | 1 |
| Ivanova, OA | 2 |
| Barash, NIu | 1 |
| Topuzov, EE | 2 |
| Seleznev, IK | 2 |
| Migmanova, NSh | 1 |
| Popova, RT | 1 |
| Nurgaziev, KSh | 1 |
| Sanfilippo, NJ | 1 |
| Curley, S | 1 |
| Hoff, P | 1 |
| Brown, TD | 1 |
| Phan, T | 1 |
| Böhm, B | 1 |
| Helfritzsch, H | 1 |
| Thiele, M | 1 |
| Altendorf-Hofmann, A | 1 |
| Scheele, J | 1 |
| Jurado, M | 1 |
| Aristu, JJ | 1 |
| Moreno, M | 1 |
| Cambeiro, M | 1 |
| Pérez-Ochoa, A | 1 |
| López-García, G | 1 |
| Alcazar, JL | 1 |
| Knowling, M | 1 |
| Browman, G | 1 |
| Siu, L | 1 |
| Khoo, K | 1 |
| Cooke, A | 1 |
| Tannock, I | 1 |
| Klaassen, D | 1 |
| Cripps, C | 1 |
| Goss, G | 1 |
| Matthews, S | 1 |
| Clarke, R | 1 |
| Seymour, L | 1 |
| Archer, VR | 1 |
| Mulholland, PJ | 1 |
| Darnton, SJ | 1 |
| Ferry, DR | 1 |
| Ferguson, MJ | 1 |
| Dewar, JA | 1 |
| Wong, ET | 1 |
| Jaeckle, KA | 1 |
| Kyritsis, AP | 1 |
| Prados, MD | 2 |
| Jacobson, SD | 1 |
| El-Weshi, A | 1 |
| Khafaga, Y | 1 |
| Allam, A | 1 |
| Mosseri, V | 1 |
| Ibrahim, E | 1 |
| El-Badawi, S | 1 |
| Ulrich-Pur, H | 1 |
| Fiebiger, W | 1 |
| Gedlicka, C | 1 |
| Raderer, M | 1 |
| Lenauer, A | 1 |
| Lang, F | 1 |
| Bae, HS | 1 |
| Mochizuki, F | 1 |
| Kasakura, Y | 1 |
| Wakabayashi, K | 1 |
| Eguchi, T | 1 |
| Tsuneda, Y | 1 |
| Kanamori, N | 1 |
| Kaiga, T | 1 |
| van der Hage, JA | 1 |
| Julien, JP | 1 |
| Tubiana-Hulin, M | 1 |
| Vandervelden, C | 1 |
| Duchateau, L | 1 |
| Norman, A | 1 |
| Ting, LL | 1 |
| Ko, JY | 1 |
| Hsu, MM | 1 |
| Sheen, TS | 1 |
| Lou, PJ | 1 |
| Chung, NN | 1 |
| Lui, LT | 1 |
| Haensgen, G | 1 |
| Duffaud, F | 1 |
| Ries, P | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Berlin, J | 1 |
| Hsieh, YC | 1 |
| Bashey, A | 1 |
| Sundaram, S | 1 |
| Corringham, S | 1 |
| Jones, V | 1 |
| Lancaster, D | 1 |
| Silva-Gietzen, J | 1 |
| Law, P | 1 |
| Ball, ED | 1 |
| Shirasawa, H | 1 |
| Manziuk, LV | 1 |
| Artamonova, EV | 1 |
| Sholokhov, VN | 1 |
| Strygina, EA | 1 |
| Kuerer, HM | 1 |
| Ames, FC | 1 |
| Valero, V | 2 |
| Ross, MI | 1 |
| Pusztai, L | 1 |
| Hunt, KK | 1 |
| Kühn, R | 1 |
| Schrott, KM | 1 |
| Lazaris, AC | 1 |
| Kavantzas, NG | 1 |
| Zorzos, HS | 1 |
| Tsavaris, NV | 1 |
| Davaris, PS | 1 |
| Takamatsu, M | 1 |
| Imaeda, Y | 1 |
| Umemoto, S | 1 |
| Imamura, I | 1 |
| Eriguchi, N | 1 |
| Aoyagi, S | 1 |
| Kemeny, MM | 2 |
| Adak, S | 1 |
| Gray, B | 1 |
| Smith, T | 1 |
| Hartman, AR | 1 |
| Fleming, GF | 1 |
| Dillon, JJ | 1 |
| Bahng, H | 1 |
| Collichio, FA | 1 |
| Amamoo, MA | 1 |
| Fogleman, J | 1 |
| Griggs, J | 1 |
| Dizon, DS | 1 |
| Orús, C | 1 |
| Morán, J | 1 |
| Recher, K | 1 |
| Shinohara, H | 1 |
| Toyoda, M | 1 |
| Sako, S | 1 |
| Jakob, A | 1 |
| Knop, S | 1 |
| Schupp, M | 1 |
| Mayer, F | 1 |
| Kanz, L | 1 |
| Booser, DJ | 1 |
| Ibrahim, NK | 1 |
| Rahman, Z | 1 |
| Theriault, RL | 1 |
| Walters, R | 1 |
| Rivera, E | 1 |
| Holmes, FA | 2 |
| Hoy, E | 1 |
| Frye, DK | 1 |
| Manuel, N | 1 |
| Kau, SW | 2 |
| Strom, E | 1 |
| Thomas, E | 1 |
| Ames, F | 2 |
| Berry, D | 1 |
| Stemmler, J | 1 |
| Kosmas, Ch | 1 |
| Macheras, A | 1 |
| Giannopoulos, A | 1 |
| Koufos, Ch | 1 |
| Butterworth, SA | 1 |
| Panton, ON | 1 |
| Klaassen, DJ | 2 |
| Shah, AM | 1 |
| McGregor, GI | 1 |
| Matumoto, A | 1 |
| Asano, A | 1 |
| Morita, K | 1 |
| Salom, EM | 1 |
| Penalver, M | 1 |
| Taylor, ME | 1 |
| Raut, V | 1 |
| Golchin, K | 1 |
| Primrose, WJ | 1 |
| Yoshimura, R | 1 |
| Shibuya, H | 1 |
| Ogura, I | 1 |
| Miura, M | 1 |
| Amagasa, T | 1 |
| Enomoto, S | 1 |
| Kishimoto, S | 1 |
| de O Ferreira, F | 1 |
| David Filho, WJ | 1 |
| Nishimoto, IN | 1 |
| Vieira, RA | 1 |
| El-Domeiri, AA | 1 |
| Chaudhuri, P | 1 |
| Esser, E | 1 |
| Schumann, J | 1 |
| Forney, JP | 1 |
| Morrow, CP | 1 |
| Futoran, RJ | 1 |
| Mavligit, GM | 1 |
| Gutterman, JU | 1 |
| Burgess, MA | 1 |
| Seibert, GB | 1 |
| Speer, JF | 1 |
| Jubert, AV | 1 |
| Martin, RC | 1 |
| Copeland, EM | 1 |
| Gehan, EA | 1 |
| Hersh, EM | 1 |
| Ryan, RF | 2 |
| Zeitoun, P | 1 |
| Martin, F | 1 |
| Nasca, S | 1 |
| Hartmann, M | 1 |
| Körner, F | 1 |
| Lo, TC | 1 |
| Wiley, AL | 1 |
| Ansfield, FJ | 4 |
| Brandenburg, JH | 1 |
| Davis, HL | 1 |
| Gollin, FF | 1 |
| Johnson, RO | 1 |
| Vermund, H | 1 |
| Zollinger, RM | 1 |
| Martin, EW | 1 |
| Carey, LC | 1 |
| Sparks, J | 1 |
| Minton, JP | 1 |
| Glass, A | 1 |
| Barton, B | 1 |
| Such, E | 1 |
| Carbone, P | 1 |
| Economou, S | 1 |
| Foster, R | 1 |
| Frelick, R | 1 |
| Lerner, H | 1 |
| Margolese, R | 3 |
| MacFarlane, J | 1 |
| Volk, H | 1 |
| Fukawa, O | 1 |
| Hori, S | 1 |
| Sprenger, F | 1 |
| Hochueli, R | 1 |
| Engelhart, G | 1 |
| Heinz, C | 1 |
| Wick, A | 1 |
| Enderlin, F | 1 |
| Creux, G | 1 |
| Simeon, B | 1 |
| Lanz, R | 1 |
| Bigler, R | 1 |
| Korman, DB | 2 |
| Berdov, BA | 1 |
| Aleksanian, AZ | 1 |
| Gapaniuk, ON | 1 |
| Sidorchenkov, VO | 1 |
| Reymann, F | 2 |
| Krauss, S | 1 |
| Sonoda, T | 1 |
| Solomon, A | 1 |
| Jönsson, PE | 2 |
| Landberg, T | 1 |
| Owman, T | 1 |
| Sundkvist, K | 1 |
| Ballon, SC | 1 |
| Roberts, JA | 1 |
| Connolly, JG | 1 |
| Anderson, C | 1 |
| Johnson, I | 1 |
| Tsukada, Y | 1 |
| Gamarra, M | 1 |
| Sandecki, A | 1 |
| Mitrov, G | 1 |
| Penchev, P | 1 |
| Khristov, K | 1 |
| Mushmov, M | 1 |
| Pandova, V | 1 |
| Sturm, HM | 1 |
| Lele, SB | 3 |
| Stephens, RL | 1 |
| Hoogstraten, B | 1 |
| Clark, G | 1 |
| Denck, H | 1 |
| Mohs, FE | 1 |
| Jones, DL | 1 |
| Bloom, RF | 1 |
| Dietz, R | 1 |
| Mootz, W | 1 |
| Giles, GR | 1 |
| Lawton, JO | 1 |
| Woolley, PV | 1 |
| Schein, PS | 2 |
| Cohen, D | 1 |
| Yron, I | 1 |
| Grover, NB | 1 |
| Weiss, DW | 1 |
| Poser, H | 1 |
| Quäck, J | 1 |
| Jacobsen, J | 1 |
| Karrer, K | 2 |
| Pridun, N | 2 |
| Zwintz, E | 2 |
| Fugmann, RA | 1 |
| Anderson, JC | 1 |
| Stolfi, RL | 2 |
| Kern, AB | 1 |
| Schiff, BL | 1 |
| Bruckner, HW | 2 |
| Jorgensen, EO | 1 |
| Gibbons, RP | 1 |
| Saroff, J | 1 |
| Schwarzenberg, L | 1 |
| Belpomme, D | 1 |
| Mathé, G | 1 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Gautier, H | 1 |
| Laparre, C | 1 |
| Baron, A | 1 |
| Benson, JW | 1 |
| Sturm, JT | 1 |
| Christenson, CE | 1 |
| Uecker, JH | 1 |
| Perry, JF | 1 |
| Carbone, PP | 4 |
| Lee, FJ | 1 |
| Vongtama, V | 1 |
| Brusamolino, E | 1 |
| Brugnatelli, L | 1 |
| Brambilla, C | 4 |
| De Lena, M | 1 |
| Bajetta, E | 1 |
| Musumeci, R | 1 |
| Carter, SK | 1 |
| Avant, WH | 1 |
| Huff, RC | 1 |
| Cooperman, EM | 1 |
| Kuhn, FP | 1 |
| Karaseva, VV | 1 |
| Stepanov, VG | 1 |
| Korolev, VV | 1 |
| Bavli, IaL | 1 |
| Golubeva, OM | 1 |
| Orlov, AA | 1 |
| Chepik, OF | 1 |
| Imai, Y | 1 |
| Tanzawa, Y | 1 |
| Toda, N | 1 |
| Okamoto, M | 2 |
| Uta, Y | 1 |
| Tagawa, K | 1 |
| Unuma, T | 1 |
| Kuusk, U | 1 |
| Basco, V | 1 |
| Rebbeck, P | 1 |
| Iwao, Y | 1 |
| Aikawa, H | 1 |
| Nagy-Mignotte, H | 1 |
| Moro, D | 1 |
| Paramelle, B | 1 |
| Fritz, P | 1 |
| Schraube, P | 1 |
| Oberle, J | 1 |
| Friedl, P | 1 |
| Amrein, PC | 2 |
| Fabian, RL | 1 |
| Takagi, S | 1 |
| Tezuka, T | 1 |
| Shinohara, K | 1 |
| Vélez-García, E | 2 |
| Vogel, CL | 1 |
| Marcial, V | 1 |
| Ketcham, A | 1 |
| Singh, KP | 1 |
| Bass, D | 1 |
| Bartolucci, AA | 1 |
| Smalley, R | 1 |
| Naito, S | 1 |
| Iguchi, A | 2 |
| Sagiyama, K | 2 |
| Osada, Y | 2 |
| Ariyoshi, A | 2 |
| Omoto, T | 2 |
| Kumazawa, J | 2 |
| Uekado, Y | 1 |
| Hirano, A | 1 |
| Shinka, T | 1 |
| Ohkawa, T | 1 |
| Fowler, WC | 1 |
| Eisenberg, BL | 1 |
| Salvadori, B | 1 |
| Rovini, D | 1 |
| Squicciarini, P | 1 |
| Conti, R | 1 |
| Cusumano, F | 1 |
| Grassi, M | 1 |
| Boiardi, A | 1 |
| Silvani, A | 1 |
| Croci, D | 1 |
| Perego, E | 1 |
| Solero, CL | 1 |
| Klimberg, VS | 1 |
| Langston, JD | 1 |
| Maners, A | 1 |
| Gocio, JC | 1 |
| Hutchins, LF | 1 |
| Lang, NP | 1 |
| Westbrook, KC | 1 |
| Broadwater, JR | 1 |
| Falkson, CI | 2 |
| Sfedj, D | 1 |
| Houvenaeghel, G | 2 |
| Chabardes, E | 1 |
| Mauriac, L | 1 |
| Durand, M | 1 |
| Dilhuydy, JM | 1 |
| Bonichon, F | 1 |
| McGinn, CJ | 1 |
| Okuyama, K | 1 |
| Awano, T | 1 |
| Tohnosu, N | 1 |
| Nakaichi, H | 1 |
| Funami, Y | 1 |
| Yokoyama, I | 1 |
| Ishii, S | 1 |
| Nohga, K | 1 |
| Dobrowsky, W | 4 |
| Wada, S | 1 |
| Yasumoto, R | 2 |
| Kashihara, N | 1 |
| Maekawa, M | 2 |
| Hayahara, N | 2 |
| Kawakita, J | 2 |
| Nishijima, T | 2 |
| Morikawa, Y | 2 |
| Horii, A | 1 |
| Weppelmann, B | 1 |
| Kim, RY | 1 |
| Martz, K | 1 |
| Brindle, J | 1 |
| Vaitkevicius, V | 1 |
| Byhardt, R | 1 |
| Davis, L | 1 |
| Emami, B | 1 |
| MacVicar, D | 1 |
| Husband, JE | 1 |
| Taylor, R | 1 |
| Menzies-Gow, N | 1 |
| Covens, A | 1 |
| O'Connell, G | 1 |
| Rusthoven, J | 1 |
| Mazurka, J | 1 |
| Devitt, PG | 1 |
| Yeoh, E | 1 |
| Olweny, C | 1 |
| Saphner, T | 1 |
| Carey, P | 1 |
| Lindeman, GJ | 1 |
| Driessen, C | 1 |
| Morrison, JM | 1 |
| Kelly, KA | 1 |
| Grieve, RJ | 1 |
| Monypenny, IJ | 1 |
| Walker, RA | 1 |
| Waterhouse, JA | 1 |
| Eudey, L | 1 |
| Shatila, AH | 2 |
| Gilchrist, KW | 2 |
| Sener, SF | 1 |
| Imperato, JP | 1 |
| Ragin, A | 1 |
| Beck, J | 1 |
| Merkel, DE | 1 |
| Panje, WR | 5 |
| Schilsky, RL | 4 |
| Mizuguchi, N | 1 |
| Ohyama, Y | 1 |
| Itoh, M | 1 |
| Mukojima, T | 1 |
| Kumagai, T | 1 |
| Iwasaki, H | 1 |
| Lopez, MJ | 1 |
| Shapiro, SJ | 1 |
| Fry, RD | 1 |
| Halverson, JD | 1 |
| Monafo, WW | 1 |
| Tellez-Bernal, E | 2 |
| Belehradek, M | 2 |
| Recondo, G | 3 |
| Leridant, AM | 1 |
| Vericel, R | 1 |
| Tohma, H | 1 |
| Shikama, T | 1 |
| De Vathaire, F | 1 |
| Richard, JM | 2 |
| Wendling, JL | 1 |
| Kalifa, C | 1 |
| Schwaab, G | 2 |
| Yamane, A | 1 |
| Nemoto, R | 1 |
| Miyagawa, I | 1 |
| Schmid, H | 1 |
| Junkermann, H | 1 |
| Schönig, T | 1 |
| von Fournier, D | 1 |
| Lyman, G | 1 |
| Sridhar, KS | 4 |
| Knight, W | 1 |
| Goodnough, LT | 1 |
| Einhorn, LH | 1 |
| Schacter, L | 1 |
| Bramwell, V | 2 |
| Abu-Zahra, H | 2 |
| Goodyear, MD | 1 |
| Arnold, A | 2 |
| Findlay, B | 2 |
| Skillings, J | 2 |
| Gent, M | 2 |
| Boogerd, W | 1 |
| Dalesio, O | 1 |
| Bais, EM | 1 |
| van der Sande, JJ | 1 |
| Lacau St-Guily, J | 1 |
| Trotoux, J | 1 |
| Adorno, G | 1 |
| Girelli, G | 1 |
| Perrone, MP | 1 |
| Arista, MC | 1 |
| Coluzzi, S | 1 |
| Masi, M | 1 |
| Giudiceandrea, P | 1 |
| Papa, G | 1 |
| Puts, JP | 1 |
| Herve, JP | 1 |
| Delelo, R | 1 |
| Ballet, F | 1 |
| Pflüger, KH | 1 |
| Rothmund, M | 1 |
| Hartmann, LC | 1 |
| Marschke, RF | 1 |
| Schaid, DJ | 1 |
| Gerhardt, RT | 1 |
| Perras, JP | 1 |
| Sevin, BU | 1 |
| Petru, E | 1 |
| Ramos, R | 1 |
| Guerra, L | 1 |
| Takemori, S | 1 |
| Arai, H | 1 |
| Tazawa, K | 1 |
| Fujimaki, M | 1 |
| Dobrowsky, E | 2 |
| Strassl, H | 2 |
| Braun, O | 1 |
| Gritzmann, N | 1 |
| Scheiber, V | 1 |
| Braun, SD | 1 |
| Gemer, LS | 1 |
| McIntee, RA | 1 |
| Baugh, R | 1 |
| Thomas, JH | 1 |
| Nigro, ND | 1 |
| Lichtman, SM | 1 |
| Bosworth, H | 1 |
| Allen, S | 1 |
| Schulman, P | 1 |
| Weiselberg, L | 1 |
| Weiss, R | 1 |
| Lehrman, D | 1 |
| Vinciguerra, V | 1 |
| Hojo, K | 2 |
| Tsujitani, S | 1 |
| Tomoda, H | 1 |
| Furusawa, M | 1 |
| Keane, TJ | 1 |
| O'Sullivan, B | 1 |
| Catton, CN | 1 |
| Raabe, NK | 1 |
| Schreer, I | 1 |
| Frischbier, HJ | 1 |
| Maass, H | 1 |
| Stegner, HE | 1 |
| Krook, JE | 3 |
| Wieand, HS | 2 |
| Collins, RT | 1 |
| Beart, RW | 1 |
| Kubista, TP | 1 |
| Poon, MA | 1 |
| Meyers, WC | 1 |
| Abbott, RL | 1 |
| Palmieri, G | 1 |
| Gridelli, C | 1 |
| Airoma, G | 1 |
| Pepe, R | 1 |
| Incoronato, P | 1 |
| Caponigro, F | 1 |
| Bianco, AR | 2 |
| Hillman, R | 1 |
| Spaulding, M | 2 |
| Laramore, GE | 1 |
| Endicott, JW | 1 |
| McClatchey, K | 1 |
| Henderson, WG | 1 |
| Grégoire, V | 1 |
| Hamoir, M | 1 |
| Longueville, J | 1 |
| Majois, F | 1 |
| Remacle, FM | 1 |
| Rousseau, F | 1 |
| Salamon, E | 1 |
| Wambersie, A | 1 |
| Amrein, P | 1 |
| Dinshaw, KA | 1 |
| Sharma, V | 1 |
| Pendse, AM | 1 |
| Telang, CS | 1 |
| Vege, SS | 1 |
| Malliat, MK | 1 |
| Deshpande, R | 1 |
| Desai, PB | 1 |
| Weh, HJ | 1 |
| Walter, TA | 1 |
| Garbrecht, M | 1 |
| Kremer, B | 1 |
| Crone-Muenzebrock, LS | 1 |
| Hossfeld, DK | 1 |
| Harder, F | 1 |
| Laffer, U | 1 |
| Berres, M | 1 |
| Jäggi, P | 1 |
| Metzger, U | 1 |
| Andrysek, O | 1 |
| Horák, J | 1 |
| Vítek, P | 1 |
| Ota, J | 1 |
| Fujita, M | 1 |
| Sugimoto, T | 1 |
| Kawano, N | 1 |
| Houjo, K | 1 |
| O'Brien, ME | 1 |
| Bayliss, EJ | 1 |
| Stewart, ME | 1 |
| Smyth, JF | 1 |
| Rodger, A | 1 |
| Auther, C | 1 |
| Mori, S | 1 |
| Nishihira, T | 1 |
| Matsumoto, T | 1 |
| Ishikawa, M | 1 |
| Davis, RK | 1 |
| Gibbs, FA | 1 |
| Sapozink, MD | 1 |
| Farver, M | 1 |
| Harker, G | 1 |
| Chen, MC | 1 |
| Recine, D | 1 |
| Reddy, S | 3 |
| Lee, MS | 3 |
| Bonomi, P | 3 |
| Taylor, S | 1 |
| Warren, W | 1 |
| Kittle, CF | 2 |
| Hendrickson, FR | 1 |
| Hamilton, JM | 1 |
| Sznol, M | 1 |
| Friedman, MA | 1 |
| Cocconi, G | 2 |
| di Blasio, B | 1 |
| Alberti, G | 1 |
| Botti, E | 1 |
| Anghinoni, E | 1 |
| DePauw, S | 1 |
| Levin, L | 1 |
| Lentz, SR | 1 |
| Raish, RJ | 1 |
| Orlowski, EP | 1 |
| Marion, JM | 1 |
| Bastit, P | 1 |
| Horner, D | 1 |
| Metz, R | 1 |
| Bugat, R | 1 |
| Theve, T | 2 |
| Kjørstad, KE | 1 |
| Nordal, R | 1 |
| Vossli, S | 1 |
| Abeler, V | 2 |
| Sandvei, R | 1 |
| Stremmel, W | 1 |
| Domellöf, L | 2 |
| Norryd, C | 1 |
| Bergman, L | 1 |
| Nilsson, T | 1 |
| Hansson, K | 1 |
| Wählby, L | 1 |
| Asklöf, G | 1 |
| Kugelberg, C | 1 |
| Polonowski, JM | 1 |
| Kau, S | 1 |
| Fraschini, G | 1 |
| Hug, V | 1 |
| Ellerbroek, N | 1 |
| Benedetto, P | 1 |
| Bacigalupo, A | 1 |
| Grimaldi, A | 4 |
| Toma, S | 1 |
| Comella, G | 1 |
| Cacace, F | 1 |
| Iversen, T | 1 |
| Kjørstad, K | 1 |
| Pappagallo, GL | 1 |
| Zorat, P | 1 |
| Cavaniglia, G | 1 |
| Fosser, VP | 1 |
| De Besi, P | 2 |
| Fornasiero, A | 1 |
| Fiorentino, MV | 1 |
| Green, S | 2 |
| Hannigan, EV | 1 |
| Boutselis, JG | 1 |
| Surwit, EA | 1 |
| Wallace, DL | 1 |
| Alberts, DS | 1 |
| Pride, GL | 1 |
| Amato, R | 1 |
| Schmidt, S | 1 |
| Raber, MN | 1 |
| Frost, P | 1 |
| Stryker, JA | 1 |
| Harvey, HA | 1 |
| Houck, JR | 1 |
| Manders, EK | 1 |
| Bradfield, JJ | 1 |
| Padaut-Cesana, J | 1 |
| Fuentes, P | 1 |
| Giudicelli, R | 1 |
| Gauthier, AP | 1 |
| Carcassonne, Y | 2 |
| Krebs, HB | 4 |
| Grage, T | 1 |
| Woll, JE | 1 |
| Gravenor, D | 1 |
| Black, M | 1 |
| Frenkiel, S | 1 |
| Weitzman, SA | 1 |
| Ziegler, P | 1 |
| Klotch, D | 1 |
| Khan, A | 1 |
| Lore, J | 1 |
| Ask, A | 1 |
| Kallum, B | 1 |
| Lunderquist, A | 1 |
| Rahima, M | 1 |
| Rakowsky, E | 1 |
| Barzilay, J | 1 |
| Sidi, J | 1 |
| Sileni, VC | 1 |
| Salvagno, L | 1 |
| Tremolada, C | 1 |
| Fosser, V | 1 |
| Peracchia, A | 1 |
| Fiorentino, M | 1 |
| Tapazoglou, E | 2 |
| Rosenberg, JC | 1 |
| Arbulu, A | 1 |
| Kinzie, J | 1 |
| Tsuji, H | 1 |
| Tsujii, H | 1 |
| Kamada, T | 1 |
| Takamura, A | 1 |
| Shirato, H | 1 |
| Matsuoka, Y | 1 |
| Irie, G | 1 |
| Taylor, RE | 1 |
| Kerr, GR | 1 |
| Campbell, JB | 1 |
| Dorman, EB | 1 |
| Helliwell, TR | 1 |
| McCormick, M | 1 |
| Miles, J | 1 |
| Morton, RP | 1 |
| Rugman, F | 1 |
| Stell, PM | 1 |
| Stoney, PJ | 1 |
| Vauhan, ED | 1 |
| Germann, R | 2 |
| Schneider, G | 1 |
| Rehak, P | 1 |
| Hardy, JR | 1 |
| Maclean, GD | 1 |
| Foote, GA | 1 |
| Harvey, VJ | 1 |
| Al-Kourainy, K | 1 |
| Crissman, J | 1 |
| Kish, J | 2 |
| Kelly, J | 1 |
| Brincker, H | 2 |
| Dziambor, U | 1 |
| Sarembe, B | 1 |
| Lotze, W | 1 |
| Hottenrott, C | 1 |
| Brando, V | 3 |
| Giordano, C | 2 |
| Mieno, K | 1 |
| Satoi, Y | 1 |
| Amino, K | 1 |
| Miura, S | 2 |
| Shikata, J | 1 |
| Scherlacher, A | 3 |
| Haas, J | 2 |
| Benhamed, M | 1 |
| Marandas, P | 1 |
| Oberlin, P | 1 |
| Crickx, B | 1 |
| Picard, C | 1 |
| Benhamou, G | 1 |
| Vilotte, J | 1 |
| Vissuzaine, C | 1 |
| Bilbault, P | 1 |
| Belaïch, S | 1 |
| Thoms, WW | 1 |
| Fletcher, GH | 1 |
| Oswald, MJ | 2 |
| Braun, OM | 1 |
| Neumeister, B | 1 |
| Popp, W | 1 |
| Scherrer, R | 1 |
| Rausch, EM | 1 |
| Krisch, K | 1 |
| Holzner, JH | 1 |
| da Silva e Sousa Júnior, AH | 1 |
| Gansl, R | 1 |
| da Silva, JH | 1 |
| Pinotti, HW | 1 |
| Thomas, G | 1 |
| Dembo, A | 1 |
| DePetrillo, A | 1 |
| Pringle, J | 1 |
| Ackerman, I | 1 |
| Bryson, P | 1 |
| Balogh, J | 1 |
| Osborne, R | 1 |
| Rosen, B | 1 |
| Fyles, A | 1 |
| Wolf, N | 1 |
| Furukohri, N | 1 |
| Saitoh, S | 1 |
| Baba, T | 1 |
| Munakata, A | 1 |
| Fujimori, M | 2 |
| Masuda, H | 1 |
| Sugenoya, A | 1 |
| Senga, O | 2 |
| Iida, F | 2 |
| Tada, I | 1 |
| Mitarai, Y | 1 |
| Koike, H | 1 |
| Mafune, K | 1 |
| Hirata, T | 1 |
| Miyama, T | 1 |
| Forrest, PA | 1 |
| Ganzer, U | 1 |
| Grant, HR | 1 |
| Clifford, P | 1 |
| Bertelli, G | 1 |
| Botto, F | 1 |
| Sertoli, MR | 2 |
| Palmeri, S | 1 |
| Russo, A | 1 |
| Gebbia, N | 1 |
| Oliveri, D | 1 |
| Rausa, L | 1 |
| Markman, M | 1 |
| Reichman, B | 1 |
| Hakes, T | 1 |
| Hoskins, W | 1 |
| Rubin, S | 1 |
| Jones, W | 1 |
| Lewis, JL | 1 |
| Connolly, J | 1 |
| Schnitt, S | 1 |
| Rose, MA | 2 |
| Silver, B | 2 |
| Aubert, C | 1 |
| Guerinel, G | 1 |
| Christiansen, NP | 1 |
| Curley, SA | 1 |
| Roh, MS | 1 |
| Mukaiyama, T | 1 |
| Kuraishi, Y | 1 |
| Yuzawa, H | 1 |
| Buckner, JC | 1 |
| Everson, LK | 1 |
| Cullinan, SA | 1 |
| Pfeifle, DM | 1 |
| Marangolo, M | 1 |
| Pezzuoli, G | 1 |
| Marubini, E | 1 |
| Cunsolo, A | 1 |
| Garcea, D | 1 |
| Germiniani, R | 1 |
| Luporini, G | 1 |
| Petrelli, N | 1 |
| Herrera, L | 1 |
| Russell, D | 1 |
| Stablein, DM | 1 |
| Schinella, R | 1 |
| Green, MD | 1 |
| Glas, U | 1 |
| Rotstein, S | 1 |
| Somell, A | 1 |
| Fujimoto, M | 2 |
| Schulman, S | 1 |
| Tranum, BL | 1 |
| Goldberg, RS | 1 |
| Kuske, RR | 1 |
| Lovett, RD | 1 |
| Jacobs, AJ | 1 |
| Galakatos, AE | 1 |
| Camel, HM | 1 |
| Kao, MS | 1 |
| Jinushi, K | 1 |
| Saeki, K | 1 |
| Yoshinaka, K | 1 |
| Yanagawa, E | 1 |
| Niimoto, M | 1 |
| Sinha, PP | 1 |
| Lindeløv, B | 1 |
| Erpenbach, K | 1 |
| Derschum, W | 1 |
| von Vietsch, H | 1 |
| Reis, M | 1 |
| Marx, JL | 1 |
| Lackey, VL | 1 |
| Reagan, MT | 1 |
| Smith, RA | 1 |
| Anderson, WJ | 1 |
| Blessing, J | 1 |
| Ball, H | 1 |
| Hanjani, P | 1 |
| Hasumi, K | 2 |
| Chen, JT | 1 |
| Hirai, Y | 1 |
| Nakayama, K | 1 |
| Teshima, H | 1 |
| Fujimoto, I | 1 |
| Masubuchi, K | 2 |
| Teo, P | 1 |
| Tsao, SY | 1 |
| Shiu, W | 1 |
| Leung, WT | 1 |
| Tsang, V | 1 |
| Yu, P | 1 |
| Lui, C | 1 |
| Gelman, R | 1 |
| Gore, SM | 1 |
| Come, S | 1 |
| Connolly, JL | 1 |
| Schnitt, SJ | 1 |
| Leigh, JE | 1 |
| McCormack, GW | 1 |
| Gerstner, JB | 1 |
| Malliard, J | 1 |
| Odaka, Y | 1 |
| Oikawa, K | 1 |
| Guaspari, A | 1 |
| Guarnieri, CM | 3 |
| Whaling, SM | 1 |
| Arafah, BM | 1 |
| McGuire, W | 1 |
| Kanematsu, T | 1 |
| Matsumata, T | 1 |
| Mathisen, DJ | 2 |
| Paredes, J | 1 |
| Felder, TB | 1 |
| Choksi, AJ | 2 |
| Newman, RA | 1 |
| Castellanos, AM | 1 |
| Robbins, KT | 1 |
| McCarthy, K | 1 |
| Atkinson, N | 1 |
| Hansen, R | 1 |
| Helm, J | 1 |
| Wilson, JF | 1 |
| Wilson, S | 1 |
| Pagliarulo, C | 1 |
| Marinelli, A | 1 |
| Petrella, G | 1 |
| D'Istria, M | 1 |
| Delrio, G | 1 |
| Hatch, TR | 1 |
| Fuchs, EF | 1 |
| Borgel, J | 2 |
| Winckel, P | 1 |
| Swiercz, P | 1 |
| Goodman, HM | 1 |
| Dottino, PR | 1 |
| Kredenster, D | 1 |
| Mark, M | 1 |
| Runowicz, C | 1 |
| Cohen, CJ | 1 |
| Ayoub, J | 1 |
| Audet-Lapointe, P | 1 |
| Méthot, Y | 1 |
| Hanley, J | 1 |
| Beaulieu, R | 1 |
| Chemaly, R | 1 |
| Cormier, A | 1 |
| Déry, JP | 1 |
| Drouin, P | 1 |
| Gauthier, P | 1 |
| Sawada, M | 2 |
| Trybula, M | 1 |
| Maffey, SC | 1 |
| Jensik, RJ | 1 |
| Sorace, RA | 1 |
| Bagley, CS | 1 |
| Danforth, DN | 1 |
| Bader, J | 1 |
| Wesley, MN | 1 |
| Sauter, ER | 1 |
| Farley, PC | 1 |
| McFaden, KH | 1 |
| Yokozawa, T | 1 |
| Hanamura, N | 1 |
| Terai, N | 1 |
| Kaneko, G | 1 |
| Kasuga, Y | 1 |
| Ueda, H | 1 |
| Yano, K | 1 |
| Maeda, T | 1 |
| Louie, KG | 1 |
| Ozols, RF | 1 |
| Myers, CE | 2 |
| Ostchega, Y | 1 |
| Jenkins, J | 1 |
| Howser, D | 1 |
| Young, RC | 1 |
| Morphis, JG | 1 |
| Hornback, NB | 1 |
| Jewell, WR | 2 |
| Secco, GB | 1 |
| Marino, G | 1 |
| Fardelli, R | 1 |
| Nobile, MT | 1 |
| Corvò, R | 2 |
| Flechtner, H | 1 |
| Fritsch, H | 1 |
| Fritz, M | 1 |
| Trux, FA | 1 |
| John, MJ | 1 |
| Wade, J | 1 |
| Dembo, AJ | 1 |
| Black, B | 1 |
| Bean, HA | 1 |
| Beale, FA | 1 |
| Pringle, JR | 1 |
| Rawlings, G | 1 |
| Depetrillo, D | 1 |
| Kitahara, M | 1 |
| Katakura, R | 1 |
| Kanno, M | 1 |
| Niizuma, H | 1 |
| Suzuki, J | 1 |
| Sakuyama, T | 1 |
| Kimura, A | 1 |
| Yanagisawa, S | 1 |
| Soji, K | 1 |
| Hano, H | 1 |
| Nagao, F | 1 |
| Takao, H | 1 |
| Miya, K | 1 |
| Azuma, S | 1 |
| Furuta, T | 1 |
| Sakata, K | 1 |
| Shimokawa, K | 1 |
| Brickner, TJ | 1 |
| Gilbertson, GF | 1 |
| Stone, WC | 1 |
| Moran, WJ | 2 |
| Awan, AM | 1 |
| Goodman, R | 1 |
| Jacobs, JR | 1 |
| Binns, P | 1 |
| Chiara, S | 1 |
| Consoli, R | 1 |
| Bruzzone, M | 1 |
| Foglia, G | 1 |
| Ragni, N | 1 |
| Brufman, G | 1 |
| Sulkes, A | 1 |
| Biran, S | 1 |
| Harding, MJ | 1 |
| Soukop, M | 1 |
| Ferguson, JC | 1 |
| Dusková, M | 1 |
| Iwamuro, S | 1 |
| Kondo, I | 1 |
| Choi, KE | 1 |
| Scholnik, AP | 1 |
| Arnold, DJ | 1 |
| Walker, WS | 1 |
| Schwenke, P | 1 |
| Suhrland, LG | 1 |
| Balcueva, EP | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Chalmers, TC | 1 |
| Windle, R | 1 |
| Bell, PR | 1 |
| Shaw, D | 1 |
| Goffinet, DR | 1 |
| Goffinet, L | 1 |
| Kohler, M | 1 |
| Antunez, AR | 1 |
| Rank, F | 1 |
| Dombernowsky, P | 1 |
| Panduro, J | 1 |
| Andersen, KW | 1 |
| Barreras, L | 1 |
| Saldana, MJ | 1 |
| Manten, H | 1 |
| James, P | 1 |
| Guillamondegui, OM | 1 |
| Byers, RM | 1 |
| Rotmensch, J | 1 |
| Senekjian, EK | 1 |
| Javaheri, G | 1 |
| Herbst, AL | 1 |
| Ahmann, FR | 1 |
| Jones, SE | 1 |
| Moon, TE | 1 |
| Fowble, BL | 1 |
| Rosato, EF | 1 |
| Mackie, JA | 1 |
| Weiler, C | 1 |
| Glover, DJ | 1 |
| Fox, KR | 1 |
| Hurwitz, S | 1 |
| Goodman, RL | 1 |
| Dionet, C | 1 |
| Rozan, R | 1 |
| Achard, JL | 1 |
| Dumesnil, Y | 1 |
| Russier, M | 1 |
| Lemesle, P | 1 |
| Theron, H | 1 |
| de Latour, M | 1 |
| Mondie, JM | 1 |
| Russell, KJ | 1 |
| Boileau, MA | 1 |
| Ireton, RC | 1 |
| Higano, CS | 1 |
| Collins, C | 1 |
| Koh, WJ | 1 |
| Griffin, BR | 1 |
| Chapman, WH | 1 |
| Griffin, TW | 1 |
| Okudaira, Y | 1 |
| Rodriguez, LA | 1 |
| Prados, M | 1 |
| Fulton, D | 1 |
| Edwards, MS | 1 |
| Silver, P | 1 |
| Levin, V | 1 |
| Carpiniello, VL | 1 |
| Malloy, TR | 1 |
| Sedlacek, TV | 1 |
| Zderic, SA | 1 |
| Okazaki, M | 1 |
| Iwasa, Z | 1 |
| Matsunami, N | 1 |
| Saeki, Y | 1 |
| Kurooka, K | 1 |
| Yamato, M | 1 |
| Sagara, N | 1 |
| Mizusawa, H | 1 |
| Orecchia, R | 1 |
| Selch, MT | 1 |
| Parker, RG | 1 |
| Bulcavage, L | 1 |
| Levi, JA | 1 |
| Fox, RM | 1 |
| Tattersall, MH | 1 |
| Woods, RL | 1 |
| Thomson, D | 1 |
| Gill, G | 1 |
| Irvin, T | 1 |
| Vowles, KD | 1 |
| Golby, MG | 1 |
| Shehata, WM | 1 |
| Meyer, RL | 1 |
| Jazy, FK | 1 |
| Cormier, WJ | 1 |
| Welling, RE | 1 |
| Wolter, JM | 1 |
| Tseng, A | 1 |
| Silverberg, I | 1 |
| Boles, R | 1 |
| Jacobs, CD | 1 |
| Nishio, S | 1 |
| Funai, K | 1 |
| Yuki, K | 1 |
| Stark, ME | 1 |
| Dyer, MC | 1 |
| Coonley, CJ | 1 |
| Ozaki, M | 1 |
| Hongo, J | 1 |
| Hirota, Y | 1 |
| Pascual, A | 1 |
| Martínez Agulló, A | 1 |
| Aviñó, J | 1 |
| Alberola, V | 1 |
| Gershenson, D | 1 |
| Copeland, L | 1 |
| Roberts, WS | 1 |
| Kuwatsuru, R | 1 |
| Yoon, S | 1 |
| Saifuku, K | 1 |
| Abe, S | 1 |
| Fujiki, T | 1 |
| Kanda, Y | 1 |
| Futatsuki, K | 1 |
| Wile, A | 1 |
| Smolin, M | 1 |
| Mercier, RJ | 1 |
| Neal, GD | 1 |
| Mattox, DE | 1 |
| Gates, GA | 1 |
| Pomeroy, TC | 1 |
| Schmidt-Gollwitzer, K | 1 |
| Schönegg, W | 1 |
| Scheiber, A | 1 |
| Wessel, J | 1 |
| Mehta, RR | 1 |
| Beattie, CW | 1 |
| Das Gupta, TK | 1 |
| Rowland, KM | 1 |
| Spiers, AS | 1 |
| DeConti, RC | 1 |
| O'Donnell, MR | 1 |
| Showel, J | 1 |
| Stott, PB | 1 |
| Milner, LM | 1 |
| Marsh, JC | 1 |
| Djawari, D | 1 |
| Praest, J | 1 |
| Klem, V | 1 |
| Zweig, JI | 1 |
| Kabakow, B | 1 |
| Delgado, G | 2 |
| Ritzi, EM | 1 |
| Pretorius, FJ | 1 |
| Khater, R | 2 |
| Frenay, M | 1 |
| Bourry, J | 2 |
| Yuasa, M | 1 |
| Kawanishi, Y | 1 |
| Numata, A | 1 |
| Imagawa, A | 1 |
| Sefi, A | 1 |
| Guenons, A | 1 |
| Lebeau, J | 1 |
| Doroshow, J | 1 |
| Hoff, S | 1 |
| Margarino, G | 2 |
| Scasso, F | 1 |
| Cascinelli, N | 1 |
| Greco, M | 1 |
| Di Fronzo, G | 1 |
| Oriana, R | 1 |
| Merson, M | 1 |
| Galluzzo, D | 1 |
| Bufalino, R | 1 |
| Belli, F | 1 |
| Sacchini, V | 1 |
| Clark, JL | 1 |
| Berger, SH | 1 |
| Mittelman, A | 1 |
| Berger, FG | 1 |
| Fazio, M | 2 |
| Gandolfo, S | 2 |
| Ozzello, F | 2 |
| Camoletto, D | 1 |
| Negri, L | 1 |
| Cherchi, PL | 1 |
| Dessole, S | 1 |
| Fadda, G | 1 |
| Piras, G | 1 |
| Sardu, GM | 1 |
| Fastenberg, NA | 1 |
| Martin, RG | 1 |
| Jessup, JM | 1 |
| Srodes, CH | 1 |
| Mayernik, DG | 1 |
| Sigler, BA | 1 |
| Schramm, VL | 1 |
| Nolan, TA | 1 |
| Kalish, LA | 1 |
| Olson, JE | 1 |
| Cummings, F | 1 |
| Bennett, JM | 1 |
| Lathrop, JC | 1 |
| Ree, HJ | 1 |
| McDuff, HC | 1 |
| Gough, MH | 1 |
| Durrant, KR | 1 |
| Giraud-Saunders, AM | 1 |
| Paine, CH | 1 |
| McPherson, K | 1 |
| Vessey, MP | 1 |
| Prorokov, VV | 1 |
| Ozhiganov, EL | 1 |
| Abramova, NA | 1 |
| Lee, YT | 1 |
| Gianola, FJ | 2 |
| Speyer, JC | 1 |
| Wesley, R | 2 |
| Barofsky, I | 2 |
| Meyers, CE | 1 |
| Speyer, JL | 1 |
| Rominger, CJ | 1 |
| Conner, N | 1 |
| Marantz, AB | 1 |
| Yeung, KY | 1 |
| Smith, FP | 1 |
| Edwards, BK | 1 |
| Marcus, C | 1 |
| Borisov, AI | 1 |
| Maslova, IA | 1 |
| Pines, EV | 1 |
| Showel, JL | 1 |
| Caldarelli, DD | 1 |
| Hutchinson, JC | 1 |
| Holinger, LD | 1 |
| Kramer, T | 1 |
| Kiel, K | 1 |
| Misaki, T | 1 |
| Hisazumi, H | 1 |
| Sakai, A | 1 |
| Kanda, S | 1 |
| Mikawa, I | 1 |
| Miyagi, T | 1 |
| Katsumi, T | 1 |
| Orito, M | 1 |
| Israël, L | 1 |
| Breau, JL | 1 |
| Morere, JF | 1 |
| Patsner, B | 1 |
| Emrich, LJ | 1 |
| Goldberg, DA | 1 |
| Browning, S | 1 |
| Metter, GE | 1 |
| Miner, PJ | 1 |
| Terz, JJ | 1 |
| Epstein, E | 1 |
| Danjoux, CE | 1 |
| Catton, GE | 1 |
| Seifart, W | 1 |
| Stefanik, D | 1 |
| Goldberg, R | 1 |
| Byrne, P | 1 |
| Smith, F | 1 |
| Ueno, W | 1 |
| Smith, L | 1 |
| Bachenheimer, L | 1 |
| Beiser, C | 1 |
| Dritschilo, A | 1 |
| Wile, AG | 1 |
| Stemmer, EA | 1 |
| Andrews, PA | 1 |
| Murphy, MP | 1 |
| Abramson, IS | 1 |
| Howell, SB | 1 |
| Boublil, JL | 1 |
| Renée, N | 1 |
| Philip, C | 1 |
| Heasman, KZ | 1 |
| Sutherland, HJ | 1 |
| Campbell, JA | 1 |
| Elhakim, T | 1 |
| Boyd, NF | 1 |
| Ford, J | 1 |
| Ohara, K | 1 |
| Kamiya, O | 1 |
| Nagata, K | 1 |
| Sugiura, I | 1 |
| Dasmahapatra, KS | 1 |
| Citrin, P | 1 |
| Hill, GJ | 2 |
| Yee, R | 1 |
| Mohit-Tabatabai, MA | 1 |
| Rush, BF | 3 |
| Hughes, RR | 1 |
| Gardner, B | 1 |
| Southwick, HW | 1 |
| Sancho, H | 1 |
| Simmonds, WP | 1 |
| Curreri, AR | 2 |
| Mackman, S | 3 |
| Uemura, T | 1 |
| Amba, T | 1 |
| Hamada, M | 1 |
| Griffen, WO | 1 |
| Humphrey, L | 2 |
| Sosin, H | 1 |
| Sokolova, VD | 1 |
| Sharoukhova, KS | 1 |
| Goncharova, MG | 1 |
| Murav'eva, NI | 1 |
| Smirnova, KD | 1 |
| Bissada, NK | 1 |
| Redman, JF | 1 |
| Sulieman, JS | 1 |
| Wise, L | 1 |
| Watt, J | 1 |
| Furnari, S | 1 |
| Pavone-Macaluso, M | 1 |
| Veroux, G | 1 |
| Mattea, E | 1 |
| Fetherston, WC | 1 |
| Friedrich, EG | 1 |
| Gründer, K | 1 |
| Leyh, F | 1 |
| Faulkner, SL | 1 |
| Adkins, RB | 1 |
| Reynolds, VH | 1 |
| Majima, S | 1 |
| Matsushige, H | 1 |
| Ellis, H | 1 |
| Jesse, RH | 2 |
| Lindberg, RD | 2 |
| Donaldson, GA | 1 |
| Welch, JP | 1 |
| Larsen, RR | 1 |
| Humphrey, LJ | 2 |
| Watne, AL | 1 |
| Covey, TH | 1 |
| Garin, AM | 2 |
| Voznyĭ, EK | 1 |
| Moroz, LV | 2 |
| Karev, NI | 1 |
| Nordman, E | 1 |
| Kauppinen, C | 1 |
| Lapsa, RKh | 1 |
| Kaulen-Becker, L | 1 |
| Johnson, A | 1 |
| Lewis, GC | 1 |
| Peck, GL | 1 |
| Lenhard, RE | 1 |
| Baker, RR | 1 |
| Dean, RE | 1 |
| Taylor, ES | 1 |
| Weisbrod, DM | 1 |
| Martin, JW | 1 |
| Edelstyn, GA | 1 |
| Marcrae, KD | 1 |
| Mussey, E | 2 |
| Johnson, CE | 2 |
| Lopes, CF | 1 |
| Armond, S | 1 |
| Smith, JP | 1 |
| Rutledge, F | 1 |
| Burns, BC | 1 |
| Soffar, S | 1 |
| Ravdin, RG | 1 |
| Ausman, RK | 1 |
| Moore, GE | 1 |
| Noer, RJ | 1 |
| Cohn, I | 1 |
| Blumenson, LE | 1 |
| Bross, ID | 1 |
| Moore, FT | 1 |
| Andrews, NC | 1 |
| Pershin, MP | 1 |
| Chumakina, SI | 1 |
| Gunka, II | 1 |
| Pantophel, AM | 1 |
| Steklenev, NA | 1 |
| Zirin, MA | 1 |
| Grjaznova, IN | 1 |
| Shain, AA | 1 |
| Pecherskaja, BG | 1 |
| Saveliev, NP | 1 |
| Bashirova, NG | 1 |
| Kuzmin, VP | 1 |
| Budarina, EM | 1 |
| Svedencov, EP | 1 |
| Phateeva, KV | 1 |
| Iunusmetov, IR | 1 |
| Silitrin, NP | 1 |
| Shklovskii, GS | 1 |
| Balas, AN | 1 |
| Ushivceva, AE | 1 |
| Litwin, MS | 1 |
| Reed, RJ | 1 |
| Krementz, ET | 1 |
| Spira, M | 1 |
| Freeman, RF | 1 |
| Arfai, P | 1 |
| Gerow, FJ | 1 |
| Hardy, SB | 1 |
| Ott, F | 1 |
| Storck, H | 1 |
| Meriwether, WD | 1 |
| Ramsey, HE | 1 |
| Ward, SP | 1 |
| Tindel, S | 1 |
| Williams, AC | 1 |
| Klein, E | 1 |
| Takahashi, HO | 1 |
| Watanabe, N | 1 |
| Kirikae, I | 1 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Jacobs, EM | 1 |
| Luce, JK | 1 |
| Wood, DA | 1 |
| Rowe, C | 1 |
| Gasparri, F | 1 |
| Periti, P | 1 |
| De Laurentiis, G | 1 |
| Nozaki, H | 1 |
| Kanamaru, R | 1 |
| Isono, S | 1 |
| Kurobane, T | 1 |
| Johnson, RH | 1 |
| Kaufman, JJ | 1 |
| Lee, TC | 1 |
| Lowenfels, AN | 1 |
| Rohmans, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stereotactic Body Radiation Therapy Plus Pembrolizumab and Trametinib vs. Stereotactic Body Radiation Therapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: an Open-label, Randomized, Controlled, Phase 2 Trial[NCT02704156] | Phase 2 | 170 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma, a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial[NCT02940925] | Phase 3 | 241 participants (Actual) | Interventional | 2016-10-20 | Completed | ||
| Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma[NCT02935309] | Phase 1 | 20 participants (Actual) | Interventional | 2016-10-14 | Completed | ||
| Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.[NCT01558921] | Phase 3 | 920 participants (Actual) | Interventional | 2011-06-21 | Active, not recruiting | ||
| Observation of MRD Detection for Preoperative Sensitivity and Postoperative Positive Rate in Common Risk Stage II Colorectal Cancer[NCT05795010] | 60 participants (Anticipated) | Observational | 2023-03-30 | Not yet recruiting | |||
| Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients With Locally Advanced Cholangiocarcinoma and Discovery of Biomarkers[NCT05677217] | 100 participants (Anticipated) | Observational | 2023-03-20 | Recruiting | |||
| Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma[NCT01526135] | Phase 3 | 493 participants (Actual) | Interventional | 2012-04-16 | Completed | ||
| A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma[NCT02358031] | Phase 3 | 882 participants (Actual) | Interventional | 2015-03-19 | Completed | ||
| Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy[NCT04749108] | Phase 2/Phase 3 | 1,075 participants (Anticipated) | Interventional | 2021-11-26 | Recruiting | ||
| Treatment of Childhood Nasopharyngeal Carcinoma With Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study[NCT00274937] | Phase 3 | 111 participants (Actual) | Interventional | 2006-02-20 | Completed | ||
| Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial[NCT00310180] | Phase 3 | 10,273 participants (Actual) | Interventional | 2006-04-07 | Active, not recruiting | ||
| Sequencing of Chemotherapy and Radiotherapy in Adjuvant Breast Cancer[NCT00003893] | Phase 3 | 2,250 participants (Anticipated) | Interventional | 1998-07-31 | Completed | ||
| Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study[NCT03719924] | Phase 2 | 106 participants (Actual) | Interventional | 2019-03-07 | Active, not recruiting | ||
| Follow-up and Registration Study of Anlotinib Combined With Adjuvant Chemotherapy in the Treatment of Locally Advanced Gastrointestinal Tumors[NCT05742620] | 100 participants (Anticipated) | Interventional | 2023-06-20 | Not yet recruiting | |||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer[NCT00275210] | Phase 3 | 2,246 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811] | Phase 3 | 2,559 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931] | Phase 3 | 2,472 participants (Anticipated) | Interventional | 2000-02-29 | Completed | ||
| A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regime[NCT00112918] | Phase 3 | 3,451 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Therapeutic Efficacy and Safety of Concurrent FOLFIRINOX Plus HIFU for Locally Advanced/Borderline Resectable Pancreatic Cancer: A Prospective Single-center, Single-arm, Investigator-initiated, Open-labeled, Exploratory Clinical Trial[NCT05262452] | 60 participants (Anticipated) | Interventional | 2021-08-09 | Recruiting | |||
| Spartalizumab, mDCF (Docetaxel, Cisplatin and 5-fluorouracil) and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma. A Phase IIA Study[NCT04894370] | Phase 2 | 34 participants (Anticipated) | Interventional | 2022-06-09 | Recruiting | ||
| A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma[NCT03519295] | Phase 2 | 99 participants (Anticipated) | Interventional | 2018-07-22 | Active, not recruiting | ||
| Safety and Efficacy of mFOLFOX6+ Bevacizumab+PD-1 Monoclonal Antibody Treatment Combinations in Patients With Local Advanced Microsatellite Stability Colorectal Cancer --an Open Label, Multicenter, Prospective Phase Ⅱ Study (BASKETII)[NCT04895137] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Non Inferiority Multicenter Phase III Randomized Trial Comparing Preoperative Chemotherapy Only to Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Resectable Rectal Cancer (Intergroup FRENCH-GRECCAR- PRODIGE)[NCT03875781] | Phase 3 | 540 participants (Anticipated) | Interventional | 2019-06-05 | Recruiting | ||
| Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rect[NCT00349076] | Phase 3 | 1,256 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy[NCT03700905] | Phase 3 | 276 participants (Anticipated) | Interventional | 2018-08-21 | Active, not recruiting | ||
| Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer: a Prospective Phase II Study[NCT06148402] | Phase 2 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Recruiting | ||
| PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer[NCT01675999] | Phase 2 | 186 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial.[NCT01814969] | Phase 3 | 260 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer[NCT02921256] | Phase 2 | 363 participants (Actual) | Interventional | 2017-01-11 | Completed | ||
| A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With[NCT02383966] | Phase 3 | 243 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| MAgnetic Resonance Imaging Guided LAteral Lymph Node Dissection in Lower REctal Cancer - A Multicenter, Prospective, Registry Study (MALAREC)[NCT04850027] | 268 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Recruiting | |||
| Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.[NCT02402842] | Phase 2 | 70 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Immunomonitoring and Biomarker Research Based on Tumor and Blood Samples in Patients With Squamous Cell Anal Carcinoma[NCT03942900] | 0 participants (Actual) | Observational | 2020-04-01 | Withdrawn (stopped due to Study not submitted to regulatory authorities) | |||
| European Study Group For Pancreatic Cancer - Trial 3[NCT00058201] | Phase 3 | 1,030 participants (Anticipated) | Interventional | 2001-07-31 | Completed | ||
| Incidence of The Bowel, Bladder, and Sexual Dysfunction Following Surgery for Colorectal Malignancy[NCT04134104] | 38 participants (Actual) | Observational [Patient Registry] | 2014-12-31 | Completed | |||
| A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)[NCT05527782] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Exci[NCT01515787] | Phase 2/Phase 3 | 1,194 participants (Anticipated) | Interventional | 2012-06-12 | Active, not recruiting | ||
| Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma[NCT01616849] | Phase 2 | 39 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer[NCT01068327] | Phase 1 | 46 participants (Actual) | Interventional | 2007-11-05 | Completed | ||
| Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study[NCT00833131] | Phase 3 | 540 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Preoperative Short Course Radiotherapy With Consolidation Chemotherapies and Camrelizumab Followed by Delayed Surgery in Locally Advanced Rectal Cancer[NCT04231552] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2019-11-10 | Active, not recruiting | ||
| Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer[NCT00026273] | Phase 3 | 0 participants | Interventional | 2001-01-31 | Completed | ||
| A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma [NCT00096278] | Phase 3 | 2,710 participants (Actual) | Interventional | 2004-09-15 | Completed | ||
| A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274] | Phase 3 | 3,397 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Randomized Phase III Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatinum-Based Chemoradiotherapy [PARADIGM TRIAL][NCT00095875] | Phase 3 | 145 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02460887] | Phase 3 | 236 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | ||
| Neoadjuvant Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-1 Trial)[NCT05517330] | Phase 2 | 23 participants (Anticipated) | Interventional | 2022-12-20 | Recruiting | ||
| Open-label, Single-arm, Multicenter, Phase II Study Investigating Cetuximab in Combination With Chemotherapy in the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Japanese Subjects[NCT00971932] | Phase 2 | 33 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Prospective Clinical Trial to Assess a Mini-invasive Pre-surgical Procedure to Detect Residual Breast or Axillary Disease in Patients With cT1-T2-T3 cN0/N1 Breast Cancer in Complete Clinical/Radiological Remission After Primary Chemotherapy[NCT05951699] | 105 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma[NCT02325986] | Phase 2 | 46 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT)[NCT03870607] | Phase 2 | 75 participants (Anticipated) | Interventional | 2019-03-13 | Recruiting | ||
| Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal[NCT05019235] | 154 participants (Actual) | Observational | 2021-08-05 | Active, not recruiting | |||
| Tumor Recurrence After Abdominal-perineal Amputation in Squamous Cell Carcinoma of the Anus[NCT05201105] | 43 participants (Actual) | Observational | 2021-10-15 | Completed | |||
| Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients[NCT05060471] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-09-08 | Enrolling by invitation | ||
| A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252] | Phase 3 | 102 participants (Anticipated) | Interventional | 2022-05-07 | Recruiting | ||
| A Multi-institutional, Randomized Controlled, Phase II Clinical Trial on Comparison of Efficacy and Safety of Nedaplatin Plus 5-Fu Combined With and Without Endostar® Continuous Intravenous Infusion in Refractory Nasopharyngeal Carcinoma[NCT02590133] | Phase 2 | 328 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Multicenter Randomized Phase III Trial to Compare 6 FAC Cycles vs 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients[NCT00129389] | Phase 3 | 1,925 participants (Actual) | Interventional | 2003-09-19 | Completed | ||
| A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00460265] | Phase 3 | 658 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer[NCT00313560] | Phase 2 | 48 participants (Actual) | Interventional | 2006-03-16 | Completed | ||
| Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial[NCT03909646] | Phase 4 | 250 participants (Anticipated) | Interventional | 2019-05-27 | Recruiting | ||
| A Retrospective Study for Evaluation of Real-world Efficacy and Safety of Ramucirumab Plus Paclitaxel in Patients With Locally-advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04192734] | 1,063 participants (Actual) | Observational | 2019-12-18 | Completed | |||
| A Prospective Study for Real-world Data (RWD) of Ramucirumab Plus Paclitaxel in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04915807] | 222 participants (Anticipated) | Observational [Patient Registry] | 2021-06-30 | Not yet recruiting | |||
| A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer[NCT00246571] | Phase 2 | 217 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| PATHOS Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.[NCT04925154] | 192 participants (Anticipated) | Observational [Patient Registry] | 2021-12-13 | Recruiting | |||
| Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer Patients as Predictive Factors for Systemic Therapy Outcome[NCT04543019] | 50 participants (Anticipated) | Observational | 2020-12-31 | Not yet recruiting | |||
| Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab[NCT00827671] | Phase 2 | 12 participants (Actual) | Interventional | 2009-03-31 | Terminated (stopped due to Experimental treatment not feasible due to high rate of drop out) | ||
| "Radical External Beam Chemoradiation in Patients With Rectal Cancer: a Wait-and-see Approach"[NCT03001362] | 48 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | |||
| Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator：A Prospective Phase 2 Trial[NCT05338866] | 58 participants (Anticipated) | Observational | 2022-01-01 | Enrolling by invitation | |||
| A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
| A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372] | 196 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036] | Phase 3 | 249 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the He[NCT01177956] | Phase 3 | 73 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111] | Phase 3 | 406 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | ||
| Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma[NCT03925090] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-12-08 | Active, not recruiting | ||
| Phase Ⅲ Trial of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (GP Versus PF) in Patients With N2-3 Nasopharyngeal Carcinoma[NCT03321539] | Phase 3 | 216 participants (Anticipated) | Interventional | 2017-10-30 | Active, not recruiting | ||
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| Randomized Phase III Clinical Trial of Hypofractionated Radiotherapy in Breast Cancer Patients With Immediate Prosthetic Reconstruction: PROMART Trial[NCT05491395] | 120 participants (Anticipated) | Interventional | 2022-06-27 | Recruiting | |||
| Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in Locally Advanced Resectable Rectal Cancer: A Randomized, Non-Comparative Phase II Study[NCT00865189] | Phase 2 | 91 participants (Actual) | Interventional | 2007-10-23 | Completed | ||
| Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study[NCT00515216] | Phase 2 | 26 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers[NCT02296671] | Phase 2 | 0 participants (Actual) | Interventional | 2015-02-28 | Withdrawn (stopped due to Was unable to accrue any patients) | ||
| A Randomized Phase II Study of Docetaxel in Combination With Oxaliplatin With or Without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease[NCT00382720] | Phase 2 | 275 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195] | Phase 3 | 286 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Prospective, Randomized Study Aiming to Assess the Benefit of Autohypnosis Learning in the Care of Patients Treated by Adjuvant Chemotherapy for Colorectal or Breast Cancer.[NCT03429296] | 120 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| Adjuvant Chemotherapy in Elderly Patients With Breast Cancer: Weekly Docetaxel vs. CMF[NCT00331097] | Phase 3 | 300 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma[NCT01065870] | Phase 2/Phase 3 | 64 participants (Anticipated) | Interventional | 2009-12-31 | Recruiting | ||
| Randomized Phase 3 Trial of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy Versus Concurrent Chemotherapy Alone in High Risk Nasopharyngeal Carcinoma Patients Treated With Intensity-modulated Radiotherapy[NCT02621970] | Phase 3 | 534 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Phase 2 Trial[NCT04870905] | Phase 2 | 100 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| Induction Chemotherapy of Docetaxel, Cisplatin and Xeloda in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02786641] | Phase 3 | 235 participants (Anticipated) | Interventional | 2016-08-31 | Not yet recruiting | ||
| Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced NPC： a Phase 3, Multicentre, Non-inferiority, Randomised Factorial Trial[NCT03503136] | Phase 3 | 632 participants (Anticipated) | Interventional | 2018-06-30 | Not yet recruiting | ||
| Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System[NCT05165602] | 30 participants (Anticipated) | Observational | 2022-01-01 | Not yet recruiting | |||
| A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer[NCT00820222] | Phase 3 | 540 participants (Actual) | Interventional | 2009-04-14 | Completed | ||
| The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer[NCT05673343] | 100 participants (Anticipated) | Observational | 2023-01-04 | Not yet recruiting | |||
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer[NCT00321685] | Phase 2 | 57 participants (Actual) | Interventional | 2006-07-25 | Completed | ||
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. A Prospective Phase II Pilot Trial of the German Rectal Cancer Study Group[NCT03561142] | Phase 2 | 94 participants (Anticipated) | Interventional | 2018-06-15 | Recruiting | ||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial[NCT03038256] | Phase 2 | 244 participants (Anticipated) | Interventional | 2018-01-31 | Recruiting | ||
| Late Cardiac Evaluation of the Three Arm Belgian Trial A Phase III Randomized Trial Involving Node-positive Early Breast Cancer Patients With a Long Median Follow-up (~ 15 Years)[NCT01554943] | Phase 2 | 73 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Measurement of the Distance Between the Corresponding Anatomical Landmarks in the Thoracic Cavity and the Incisors[NCT03720405] | 520 participants (Anticipated) | Observational [Patient Registry] | 2018-07-31 | Recruiting | |||
| A Randomised Study of TPF as Neoadjuvant Chemotherapy Followed by Concomitant Chemoradiotherapy (CRT) With Conventional Radiotherapy (RT) Versus Concomitant CRT With Accelerated RT in Patients With Locally Advanced Head and Neck Squamous Cell Cancer (HNSC[NCT00774319] | Phase 2 | 70 participants (Anticipated) | Interventional | 2008-12-31 | Recruiting | ||
| Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Therapy in Rectal Cancers: Focus on Cyclomodulin-producing Escherichia Coli[NCT04103567] | 220 participants (Anticipated) | Interventional | 2020-01-14 | Recruiting | |||
| A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470] | Phase 3 | 1,226 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally R[NCT01081041] | Phase 2 | 187 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| A Randomized Trial Investigating the Role of FOLFOX-4 Regimen Duration (3 Versus 6 Months) and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer[NCT00646607] | Phase 3 | 3,756 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia Induced by Targeted Therapy and Immunotherapy Combination Treatment[NCT04896528] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-06-06 | Recruiting | ||
| PANTHER. A Randomized Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel (dtEC→dtT) Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel (FEC→T) in Lymph [NCT00798070] | Phase 3 | 2,017 participants (Actual) | Interventional | 2007-02-28 | Active, not recruiting | ||
| A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-[NCT02337946] | Phase 2 | 164 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Risk of Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy[NCT04941625] | 150 participants (Anticipated) | Observational | 2018-02-23 | Recruiting | |||
| An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer[NCT01818063] | Phase 2 | 9 participants (Actual) | Interventional | 2013-04-25 | Completed | ||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy (SCPRT) Followed by Consolidation Chemotherapy Versus Long Course Chemoradiation for Unresectable Rectal Cancer[NCT03714490] | Phase 2 | 200 participants (Anticipated) | Interventional | 2018-10-23 | Recruiting | ||
| Resource-Sparing Curative Treatment for Rectal Cancer[NCT01459328] | Phase 3 | 350 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck[NCT04107103] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-03-19 | Recruiting | ||
| A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831] | Phase 2 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Industry decline to supply study drug) | ||
| TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)[NCT06163534] | 500 participants (Anticipated) | Observational [Patient Registry] | 2024-01-30 | Not yet recruiting | |||
| The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Esophageal or Head and Neck Squamous Cell Carcinoma：A Phase 1 Trial[NCT06109207] | Phase 1 | 12 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)[NCT05459415] | 54 participants (Anticipated) | Interventional | 2022-06-22 | Active, not recruiting | |||
| Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies[NCT06061705] | 100 participants (Anticipated) | Interventional | 2023-12-30 | Not yet recruiting | |||
| 1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK[NCT04150900] | Phase 2 | 7 participants (Actual) | Interventional | 2020-01-13 | Active, not recruiting | ||
| A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion [NCT03356223] | Phase 2 | 25 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck[NCT00122460] | Phase 3 | 442 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial[NCT02912052] | Phase 3 | 240 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver[NCT01785212] | 40 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract[NCT00003175] | Phase 2 | 45 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
| A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Bre[NCT00024102] | Phase 3 | 633 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With Gem-based Doublets and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer[NCT02416609] | 44 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer[NCT00002476] | Phase 3 | 0 participants | Interventional | 1990-01-31 | Completed | ||
| Induction Chemotherapy, Preoperative Radiochemotherapy, Consolidation Chemotherapy, Operation and Adjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer- OIGIT 5-01 Phase II Trial[NCT01489332] | Phase 2 | 60 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer[NCT01613469] | Phase 2 | 5 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to Re-eval of patient population) | ||
| A Clinical Trial to Evaluate Postoperative Immunotherapy and Postoperative Systemic Chemotherapy in the Management of Resectable Colon Cancer[NCT00427570] | Phase 3 | 0 participants | Interventional | 1977-09-30 | Completed | ||
| A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon[NCT00427310] | Phase 3 | 1,158 participants (Actual) | Interventional | 1984-03-31 | Completed | ||
| A Phase II Study of Oxaliplatin (Eloxatin) Capecitabine (Xeloda) and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer.[NCT00220051] | Phase 2 | 109 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Double-Blind, Randomized, Phase 2 Trial of Capecitabine Plus Enzastaurin Versus Capecitabine Plus Placebo in Patients With Metastatic or Recurrent Breast Cancer Previously Treated With an Anthracycline and a Taxane[NCT00437294] | Phase 2 | 86 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of efficacy) | ||
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| [NCT02603159] | Phase 3 | 200 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408] | Phase 3 | 184 participants (Actual) | Interventional | 2014-10-01 | Completed | ||
| A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial[NCT03001596] | 264 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy[NCT03734952] | 537 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| Phase II Study Comparing Gemcitabine Plus Cisplatin to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT02016417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma: A Randomized Phase III Trial[NCT04898374] | Phase 3 | 120 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Randomized Trial of Comparing One Cycle With Three Cycles Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02096380] | 120 participants (Anticipated) | Observational [Patient Registry] | 2014-05-31 | Not yet recruiting | |||
| A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progressio[NCT00273546] | Phase 3 | 500 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study[NCT01433614] | Phase 3 | 304 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Follow up and Functional Outcome of Organ Saving Treatment in Patients With Good Response to Neo-adjuvant (Chemo)Radiation for Rectal Cancer[NCT02278653] | 100 participants (Anticipated) | Observational [Patient Registry] | 2014-03-31 | Active, not recruiting | |||
| Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer[NCT01721785] | 307 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| A Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms[NCT03121599] | 3 participants (Actual) | Interventional | 2017-06-11 | Terminated (stopped due to Delayed study materials, poor recruitment) | |||
| A Study of 18F-FLT Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Cases of Prefibrotic/Early Primary Myelofibrosis (PMF) and Essential Thrombocythemia (ET)[NCT03116542] | 21 participants (Anticipated) | Interventional | 2017-05-07 | Recruiting | |||
| Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial[NCT04289792] | Phase 2 | 27 participants (Anticipated) | Interventional | 2020-05-09 | Recruiting | ||
| A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma[NCT00003216] | Phase 3 | 518 participants (Anticipated) | Interventional | 1998-07-31 | Completed | ||
| A Phase II Study Of Paclitaxel-Based Chemoradiotherapy Regimen With Selective Surgical Salvage For Resectable Locoregionally Advanced Carcinoma Of The Esophagus[NCT00069953] | Phase 2 | 43 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212] | Phase 3 | 456 participants (Anticipated) | Interventional | 2019-10-22 | Recruiting | ||
| A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer[NCT00453323] | Phase 2 | 33 participants (Actual) | Interventional | 2006-06-30 | Active, not recruiting | ||
| Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER[NCT02268006] | Phase 2 | 50 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response[NCT03515941] | Early Phase 1 | 6 participants (Actual) | Interventional | 2018-06-22 | Terminated (stopped due to The PI has decided to close the study due to the outdated study design.) | ||
| A Randomized Phase III Trial of Postoperative Chemotherapy or Chemo-radiotherapy for Locally Advanced Gastric Cancer After D2 Resection[NCT03601988] | Phase 3 | 408 participants (Anticipated) | Interventional | 2018-07-28 | Recruiting | ||
| Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | ||
| A Randomized Phase II Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)[NCT04793932] | Phase 2 | 261 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer[NCT00469443] | Phase 3 | 330 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Phase II Study of TPF Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT03020329] | Phase 2 | 37 participants (Anticipated) | Interventional | 2016-11-14 | Recruiting | ||
| A Single Arm Open-label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-line Treatment of Patients With HER2-positive Locally Recurrent or Metastatic Breast Cancer[NCT00811135] | Phase 2 | 88 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480] | Phase 2 | 63 participants (Actual) | Interventional | 2020-02-01 | Completed | ||
| Phase Ⅲ Trial of Induction Chemotherapy（TPF） Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (PF) in Patients With High Risk Nasopharyngeal Carcinoma[NCT03306121] | Phase 3 | 322 participants (Anticipated) | Interventional | 2017-11-13 | Active, not recruiting | ||
| Feasibility Clinical Trial of Intraoperative Radiotherapy (IORT) and Second Breast-conserving-surgery After Local Recurrence of Breast Carcinoma[NCT02386371] | 66 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Randomized Controlled Trial Comparing Adjuvant Chemotherapy Vs. no Chemotherapy for Patients With Carcinoma of Gallbladder Undergoing Curative Resection.[NCT02778308] | 100 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449] | Phase 2 | 58 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723] | 441 participants (Actual) | Observational | 2011-08-01 | Completed | |||
| A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.[NCT00851110] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-10-31 | Terminated | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Clinical Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin in Patients With Unresectable Locally Advanced Pancreatic Cancer[NCT03585062] | Phase 2 | 40 participants (Actual) | Interventional | 2017-11-20 | Terminated (stopped due to The paclitaxel-albumin halt production.) | ||
| A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)[NCT04787991] | Phase 1 | 45 participants (Anticipated) | Interventional | 2021-08-09 | Active, not recruiting | ||
| An Open-Label Combination Study of Capecitabine and Standard Paclitaxel Therapy as First or Second Line Therapy in Women With Metastatic Breast Carcinoma[NCT00005649] | Phase 2 | 0 participants | Interventional | 1998-07-31 | Completed | ||
| Phase II Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil Followed by Weekly Docetaxel and Cetuximab in Concurrence With Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma (NPC)[NCT01326559] | Phase 2 | 33 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Phase Ib Study of the Safety and Pharmacokinetics of Chemoembolization With Irinotecan-Eluting Beads for the Treatment of Hepatic Metastases[NCT01336985] | Phase 1 | 5 participants (Actual) | Interventional | 2011-03-28 | Terminated | ||
| Complete Pathologic Response Rectal Cancers EYSAC.1 Study[NCT03351959] | 1,000 participants (Anticipated) | Observational | 2018-01-01 | Recruiting | |||
| Prediction of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.[NCT02439086] | 20 participants (Anticipated) | Interventional | 2015-09-30 | Not yet recruiting | |||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| A Phase III, Multi-institutional Randomised Trial Comparing Neoadjuvant Chemoradiotherapy (NARCT) and Total Neoadjuvant Therapy (TNT) in Patients With T3 (a/b/c) Rectal Cancer[NCT06097416] | Phase 3 | 100 participants (Anticipated) | Interventional | 2024-10-31 | Not yet recruiting | ||
| A Randomized, Phase II Study of Concurrent Radiotherapy and Oxaliplatin, Capecitabine With or Without Cetuximab in Rectal Cancer Tumor Stratified by KRAS Mutation Status.[NCT00795301] | Phase 2 | 74 participants | Interventional | 2008-07-31 | Active, not recruiting | ||
| Retrospective Study Comparing Neoadjuvent Short Course of Radiotherapy to Conventional Chemoradiation in Cancer Rectum[NCT04814784] | 48 participants (Anticipated) | Observational | 2021-03-31 | Not yet recruiting | |||
| Effects of Different Treatment for Anorectal Function of Patients With Rectal Cancer: a Study Protocol for a Prospective, Observational, Controlled, Multicentre Study[NCT05671809] | 402 participants (Anticipated) | Observational [Patient Registry] | 2023-01-01 | Not yet recruiting | |||
| Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer: A Randomized Phase II Trial of the German Rectal Cancer Study Group[NCT02363374] | Phase 2 | 311 participants (Actual) | Interventional | 2015-03-25 | Completed | ||
| Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study[NCT00842686] | Phase 2 | 60 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
| Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy[NCT00855946] | 46 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| Preoperative Short-course Radiotherapy With Local Boost Versus Conventional Preoperative Short-course Radiotherapy for Rectal Cancer[NCT02498353] | 100 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | |||
| Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer[NCT01152710] | Phase 2 | 57 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer: a Multicenter Randomised Controlled Trial[NCT03465982] | 340 participants (Anticipated) | Interventional | 2018-06-05 | Recruiting | |||
| Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer[NCT06114420] | 500 participants (Anticipated) | Observational | 2023-01-30 | Recruiting | |||
| Pre-operative Radiation Therapy (RT) and Temozolomide (TMZ) in Patients With Newly Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)[NCT03480867] | Phase 1 | 0 participants (Actual) | Interventional | 2017-03-31 | Withdrawn (stopped due to competing study was opened by the surgeon after this trial was opened) | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2011-01-12 | Completed | ||
| OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)[NCT02335957] | 489 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study[NCT00594477] | Phase 1 | 100 participants (Actual) | Interventional | 2008-01-04 | Completed | ||
| Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
| Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer[NCT00006812] | Phase 2 | 0 participants | Interventional | 2001-03-31 | Terminated | ||
| A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum[NCT00145769] | Phase 3 | 326 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver[NCT00003834] | Phase 2 | 44 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| Total Neoadjuvant Therapy in Rectal Cancer Treatment[NCT04747951] | Phase 4 | 280 participants (Anticipated) | Interventional | 2020-10-30 | Recruiting | ||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy[NCT00736944] | Phase 2 | 30 participants (Actual) | Interventional | 2008-12-19 | Completed | ||
| Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection[NCT02546895] | 2,000 participants (Anticipated) | Observational | 2015-09-30 | Recruiting | |||
| Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx[NCT00003627] | Phase 3 | 160 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer[NCT04069884] | 540 participants (Anticipated) | Interventional | 2019-08-20 | Recruiting | |||
| A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer[NCT00123851] | Phase 2 | 32 participants | Interventional | 2003-03-31 | Completed | ||
| LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer[NCT03917082] | Phase 2 | 290 participants (Anticipated) | Interventional | 2019-09-23 | Active, not recruiting | ||
| Evaluation of Three Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00006248] | Phase 2 | 78 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| A Limited Access Phase II Trial Of Capecitabine In Advanced, Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix[NCT00016926] | Phase 2 | 0 participants | Interventional | 2001-04-30 | Completed | ||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| MRI for Response Evaluation After Chemoradiation for Locally Advanced Rectal Cancer[NCT04790227] | 50 participants (Anticipated) | Observational | 2022-01-31 | Not yet recruiting | |||
| A Clinical Experience Trial to Detect the Plasma Paclitaxel Drug Concentration in Chinese Non -Small Cell Lung Cancer (NSCLC) Patients Treated With a Paclitaxel Plus Carboplatin (TC) Regimens, and Explore Individualized Treatment Using Pharmacokinetically[NCT02737709] | Phase 2 | 51 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to The study have difficulty in recruiting subjectes) | ||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer[NCT03923335] | 287 participants (Anticipated) | Observational | 2019-04-30 | Not yet recruiting | |||
| A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer[NCT00005586] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 1997-10-31 | Completed | ||
| Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era[NCT02633202] | Phase 3 | 338 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era[NCT02289807] | 0 participants (Actual) | Interventional | 2015-03-31 | Withdrawn | |||
| A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.[NCT00375999] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707] | Phase 2 | 55 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage IIIB and IV Breast Cancer Patients in Dharmais National Cancer Center Hospital, Indonesia[NCT02995772] | Phase 3 | 122 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders[NCT01525927] | Phase 2 | 2 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Principal Investigator left institution. IRB approval lapsed.) | ||
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study[NCT04776590] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| Proton Therapy for Peripheral Lymph Nodes in Breast Cancer[NCT01365845] | 18 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx[NCT00797290] | 9 participants (Actual) | Observational | 2008-06-30 | Terminated (stopped due to Slow enrollment, Feasibility issues) | |||
| 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation Versus Concurrent Chemoradiation Alone In Patients With Stage N2-3 Nasopharyngeal Carcinoma: A Phase 3 Multicenter Randomised Controlled Trial[NCT02512315] | Phase 3 | 192 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.[NCT03534713] | Phase 3 | 310 participants (Anticipated) | Interventional | 2020-07-17 | Recruiting | ||
| A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients With Stage II-B, III-B, and IV-A Carcinoma of the Cervix With Negative Paraaortic Nodes[NCT00003078] | Phase 3 | 870 participants (Anticipated) | Interventional | 1997-10-31 | Completed | ||
| A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Leas[NCT00510627] | Phase 4 | 0 participants (Actual) | Interventional | 2007-08-31 | Withdrawn (stopped due to Boston Scientific has decided to close the Study.) | ||
| A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691] | Phase 1 | 10 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851] | Phase 2 | 16 participants (Actual) | Interventional | 2015-04-30 | Active, not recruiting | ||
| A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon[NCT00425152] | Phase 3 | 2,151 participants (Actual) | Interventional | 1989-07-31 | Completed | ||
| Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial[NCT02969473] | Phase 2 | 120 participants (Anticipated) | Interventional | 2010-10-31 | Active, not recruiting | ||
| A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma[NCT04844385] | Phase 2 | 83 participants (Anticipated) | Interventional | 2021-02-20 | Recruiting | ||
| Phase Ⅲ Trial of Transcatheter Arterial Chemoembolization(TACE) Plus Recombinant Human Adenovirus Type 5 Injection for Unresectable Hepatocellular Carcinoma (HCC)[NCT01869088] | Phase 3 | 266 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy With or Without Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01872962] | Phase 3 | 480 participants (Actual) | Interventional | 2013-11-30 | Active, not recruiting | ||
| A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01540136] | Phase 3 | 402 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study[NCT03110926] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | ||
| Gene Expression Signature and Immunohistochemical Markers Associated With Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer[NCT00820690] | 80 participants (Actual) | Observational | 2008-07-31 | Active, not recruiting | |||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Outcome of Neo-adjuvant Chemotherapy Followed by Breast Conservative Surgery in Breast Cancer in Upper Egypt[NCT03696004] | Phase 2/Phase 3 | 45 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)[NCT00815308] | Phase 2 | 55 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Phase II Study of High-dose （86 Gy）Intensity Modulated Radiotherapy and Concurrent Paclitaxel and Cisplatin in Locoregionally Advanced Esophageal Cancer[NCT03535207] | 50 participants (Anticipated) | Interventional | 2018-04-01 | Recruiting | |||
| Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Cisplatin and Paclitaxel in Patients With Esophageal Cancer[NCT03082586] | 31 participants (Actual) | Interventional | 2016-11-20 | Completed | |||
| Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma[NCT04995120] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| Induction Chemotherapy With Taxotere, Cisplatin and 5-Fluorouracil Followed by Concomitant Cetuximab and Radiation for Locoregionally Advanced Squamous Cell Cancer of the Head and Neck: A Phase II Trial[NCT01467115] | Phase 2 | 1 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis[NCT03114254] | Phase 2 | 17 participants (Actual) | Interventional | 2014-12-05 | Completed | ||
| Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer[NCT00001239] | Phase 2 | 100 participants | Interventional | 1989-07-31 | Completed | ||
| Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study[NCT00888082] | Phase 3 | 102 participants (Anticipated) | Interventional | Withdrawn | |||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study[NCT01192087] | Phase 1/Phase 2 | 49 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | ||
| Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial[NCT00001250] | Phase 2 | 130 participants | Interventional | 1989-12-31 | Completed | ||
| Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis[NCT00001569] | Phase 1 | 74 participants | Interventional | 1997-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The time from the start of treatment until documentation of any clinical or radiological disease progression or death, whichever occurred first. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704156)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| SBRT Plus Gemcitabine | 5.4 |
| SBRT Plus Pembrolizumab and Trametinib | 8.2 |
The time from the start of treatment to death (NCT02704156)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| SBRT Plus Gemcitabine | 12.8 |
| SBRT Plus Pembrolizumab and Trametinib | 14.9 |
The number of patients alive at 1 year and 2 years. (NCT02704156)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 1-year OS rate | 2-year OS rate | |
| SBRT Plus Gemcitabine | 48 | 0 |
| SBRT Plus Pembrolizumab and Trametinib | 53 | 2 |
The proportion of patients without disease progressions at 1 year and 2 years. (NCT02704156)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 1-year PFS rate | 2-year PFS rate | |
| SBRT Plus Gemcitabine | 7 | 0 |
| SBRT Plus Pembrolizumab and Trametinib | 18 | 0 |
The analysis of quality of life is based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30). All scales and subscales range from 0 to 100. Regarding physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning and global health, higher scores may indicate better outcomes. In the case of fatigue, nausea and vomitting, pain, dyspnea, insomina, appetite loss, constipation, diarrhea and financial difficulties, lower scores may indicate better outcomes. Scales of all items are independent and not combined to compute a total score. (NCT02704156)
Timeframe: 3 years
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | Global health | Fatigue | Nausea and vomitting | Pain | Dyspnea | Insomina | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
| SBRT Plus Gemcitabine | 86.2 | 81.8 | 73.9 | 84.7 | 85.5 | 83.6 | 29.6 | 29.4 | 23.9 | 16.1 | 14.9 | 31.0 | 14.5 | 15.7 | 16.8 |
| SBRT Plus Pembrolizumab and Trametinib | 83.7 | 84.5 | 72.1 | 83.3 | 84.1 | 83.2 | 26.6 | 28.8 | 26.5 | 13.7 | 17.6 | 33.3 | 16.5 | 15.7 | 17.2 |
Treatment-related adverse effects are determined by National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0. (NCT02704156)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 pyrexia | Grade 3 vomitting | Grade 3 and 4 increased ALT or AST | Grade 3 stomatitis | Grade 3 rash | Grade 3 and 4 neutropenia | Grade 3 thrombocytopenia | Grade 3 increased blood bilirubin | Grade 3 hypokalemia | Grade 3 hyponatremia | Grade 3 pneumonia | Grade 3 hypertension | |
| SBRT Plus Gemcitabine | 0 | 2 | 6 | 0 | 0 | 9 | 4 | 0 | 0 | 0 | 0 | 0 |
| SBRT Plus Pembrolizumab and Trametinib | 2 | 1 | 10 | 1 | 2 | 1 | 1 | 4 | 1 | 3 | 1 | 2 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 290 |
| Pembrolizumab + Chemotherapy (Pembro Combo) | 271 |
| Cetuximab + Chemotherapy (Control) | 286 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued study drug due to an AE was reported for each treatment arm. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 36 |
| Pembrolizumab + Chemotherapy (Pembro Combo) | 90 |
| Cetuximab + Chemotherapy (Control) | 79 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 15 in the GHS/QoL combined score was compared between all participants of the pembro combo arm and the control arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 15 in the GHS/QoL combined score was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Baseline, Week 15
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 1.17 |
| Cetuximab + Chemotherapy (Control) | 0.77 |
ORR was defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro combo arm and control arm. Per protocol, ORR was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 35.6 |
| Cetuximab + Chemotherapy (Control) | 36.3 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro combo arm and control arm. Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 36.4 |
| Cetuximab + Chemotherapy (Control) | 35.7 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro combo arm and control arm. Per protocol, ORR was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 42.9 |
| Cetuximab + Chemotherapy (Control) | 38.2 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥1. Per protocol, OS was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 13.6 |
| Cetuximab + Chemotherapy (Control) | 10.4 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥20. Per protocol, OS was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 14.7 |
| Cetuximab + Chemotherapy (Control) | 11.0 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm. Per protocol, OS was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 13.0 |
| Cetuximab + Chemotherapy (Control) | 10.7 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 17.2 |
| Cetuximab + Chemotherapy (Control) | 13.6 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 19.7 |
| Cetuximab + Chemotherapy (Control) | 12.5 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 23.9 |
| Cetuximab + Chemotherapy (Control) | 14.0 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 44.7 |
| Cetuximab + Chemotherapy (Control) | 44.9 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 44.9 |
| Cetuximab + Chemotherapy (Control) | 43.3 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 49.4 |
| Cetuximab + Chemotherapy (Control) | 47.2 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as Combined Positive Score ≥20 (hereafter referred to as CPS ≥20). Per protocol, PFS was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 5.8 |
| Cetuximab + Chemotherapy (Control) | 5.3 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by immunohistochemistry (IHC) as Combined Positive Score ≥1 (hereafter referred to as CPS ≥1). Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 5.1 |
| Cetuximab + Chemotherapy (Control) | 5.0 |
"PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the Intent-To-Treat (ITT) population. PFS is reported here for all participants in the pembro combo arm and control arm. Per protocol, PFS was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 4.9 |
| Cetuximab + Chemotherapy (Control) | 5.2 |
"EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the GHS question How would you rate your overall health during the past week? (Item 29) and the QoL question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD in GHS/QoL defined as the time from baseline to the first onset of a ≥10 point decrease from baseline in GHS/QoL combined score, with confirmation. Per protocol, TTD in GHS/QoL combined score was compared between all participants of pembro combo arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in GHS/QoL combined score was compared separately between all participants of pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. Participant responses to the Swallowing scale (Items 35-38) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. TTD in EORTC QLQ-H&N35 Swallowing Score defined as the time from baseline to the first onset of a ≥10 point decrease from baseline, with confirmation. Per protocol, TTD in EORTC QLQ-H&N35 Swallowing Score was compared between all participants of pembro combo arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in EORTC QLQ-H&N35 Swallowing Score was compared separately between all participants of pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. Participant responses to the Pain scale (Items 31-34) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. TTD in EORTC QLQ-H&N35 Pain Score defined as the time from baseline to the first onset of a ≥10 point decrease from baseline, with confirmation. Per protocol, TTD in EORTC QLQ-H&N35 Pain Score was compared between all participants of pembro combo arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in EORTC QLQ-H&N35 Pain Score was compared separately between all participants of pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the GHS question How would you rate your overall health during the past week? (Item 29) and the QoL question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 15 in the GHS/QoL combined score was compared between all participants of the pembro mono arm and the control arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 15 in the GHS/QoL combined score was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Baseline, Week 15
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 0.85 |
| Cetuximab + Chemotherapy (Control) | 0.60 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro mono arm and control arm. Per protocol, ORR was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 16.9 |
| Cetuximab + Chemotherapy (Control) | 36.0 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro mono arm and control arm. Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 19.1 |
| Cetuximab + Chemotherapy (Control) | 34.9 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro mono arm and control arm. Per protocol, ORR was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 23.3 |
| Cetuximab + Chemotherapy (Control) | 36.1 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm. Per protocol, OS was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 11.5 |
| Cetuximab + Chemotherapy (Control) | 10.7 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥1. Per protocol, OS was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 12.3 |
| Cetuximab + Chemotherapy (Control) | 10.3 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥20. Per protocol, OS was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 14.8 |
| Cetuximab + Chemotherapy (Control) | 10.7 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 17.6 |
| Cetuximab + Chemotherapy (Control) | 15.0 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 20.6 |
| Cetuximab + Chemotherapy (Control) | 13.6 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 23.5 |
| Cetuximab + Chemotherapy (Control) | 15.1 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 26.2 |
| Cetuximab + Chemotherapy (Control) | 45.7 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 28.7 |
| Cetuximab + Chemotherapy (Control) | 43.9 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 33.0 |
| Cetuximab + Chemotherapy (Control) | 46.6 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm. Per protocol, PFS was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 2.3 |
| Cetuximab + Chemotherapy (Control) | 5.2 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥1. Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 3.2 |
| Cetuximab + Chemotherapy (Control) | 5.0 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥20. Per protocol, PFS was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 3.4 |
| Cetuximab + Chemotherapy (Control) | 5.3 |
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. Participant responses to the Pain scale (Items 31-34) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. TTD in EORTC QLQ-H&N35 Pain Score defined as the time from baseline to the first onset of a ≥10 point decrease from baseline, with confirmation. Per protocol, TTD in EORTC QLQ-H&N35 Pain Score was compared between all participants of pembro mono arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in EORTC QLQ-H&N35 Pain Score was compared separately between all participants of pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. Participant responses to the Swallowing scale (Items 35-38) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. TTD in EORTC QLQ-H&N35 Swallowing Score defined as the time from baseline to the first onset of a ≥10 point decrease from baseline, with confirmation. Per protocol, TTD in EORTC QLQ-H&N35 Swallowing Score was compared between all participants of pembro mono arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in EORTC QLQ-H&N35 Swallowing Score was compared separately between all participants of pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
"EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the GHS question How would you rate your overall health during the past week? (Item 29) and the QoL question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD in GHS/QoL defined as the time from baseline to the first onset of a ≥10 point decrease from baseline in GHS/QoL combined score, with confirmation. Per protocol, TTD in GHS/QoL combined score was compared between all participants of pembro mono arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in GHS/QoL combined score was compared separately between all participants of pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
The two-year event-free survival will be compared with a standard established from adult oncology data and the results of POG-9486. The two-year Kaplan-Meier estimate of event-free survival will be compared with 70% using a 1-sided test of size 0.05 using the asymptotic distribution of the complementary log-log distribution of the estimate. (NCT00274937)
Timeframe: Up to Two Year After Enrollment
| Intervention | Estimated probability (Number) |
|---|---|
| Stratum II | 0.87 |
Weight of stimulated saliva production in grams. (NCT00274937)
Timeframe: At study enrollment
| Intervention | Grams of saliva (Mean) | |
|---|---|---|
| At study Enrollment | At end of consolidation | |
| Stratum II | 4.97 | 3.39 |
Weight of unstimulated saliva production in grams. (NCT00274937)
Timeframe: At study enrollment
| Intervention | Grams of saliva (Mean) | |
|---|---|---|
| At study Enrollment | At end of consolidation | |
| Stratum II | 3.37 | 2.30 |
Disease-free survival (DFS) is defined to be time from randomization to first event, where the first event is any of ipsilateral breast tumor recurrence, local recurrence, regional recurrence, distant recurrence, contralateral second primary invasive cancer, second primary non-breast invasive cancer (excluding non-melanoma skin cancers), or death without evidence of recurrence. The distribution of DFS (eg, 5-year DFS rate) is estimated using Kaplan-Meier method, and compared between the two randomized arms (arm B vs. arm C) using stratified log rank test and stratified Cox proportional hazard model. (NCT00310180)
Timeframe: Assessed every 6 months within 5 years from registration and then annually up to 20 years, DFS rate estimated at 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A | 94.0 |
| Arm B | 92.8 |
| Arm C | 93.1 |
| Arm D | 87.6 |
Distant recurrence-free interval (DRFI) is defined as time from date of randomization or registration to the date of distant recurrence of breast cancer, or of death with distant recurrence, if death is the first manifestation of distant recurrence. The distribution of DRFI (eg, 5-year DRFI rate) is estimated using Kaplan-Meier method. (NCT00310180)
Timeframe: Assessed every 6 months within 5 years from registration and then annually up to 20 years, DRFI rate estimated at 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A | 99.3 |
| Arm B | 98.0 |
| Arm C | 98.2 |
| Arm D | 93.0 |
Overall survival (OS) is defined as time from date of randomization or registration to date of death from any cause. The distribution of OS (eg, 5-year OS rate) is estimated using Kaplan-Meier method. (NCT00310180)
Timeframe: Assessed every 6 months within 5 years from registration and then annually up to 20 years, OS rate estimated at 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A | 98.0 |
| Arm B | 98.0 |
| Arm C | 98.1 |
| Arm D | 95.9 |
Recurrence-free interval (RFS) is defined as time from date of randomization or registration to the date of first recurrence of breast cancer (ipsilateral breast tumor recurrence, local/regional recurrence, distant recurrence) or to the date of death with recurrence, if death is the first manifestation of recurrence. The distribution of RFS (eg, 5-year RFS rate) is estimated using Kaplan-Meier method. (NCT00310180)
Timeframe: Assessed every 6 months within 5 years from registration and then annually up to 20 years, RFS rate estimated at 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A | 98.8 |
| Arm B | 96.9 |
| Arm C | 97.0 |
| Arm D | 91.0 |
Disease-free survival (DFS) is defined to be time from randomization to first event, where the first event is any of ipsilateral breast tumor recurrence, local recurrence, regional recurrence, distant recurrence, contralateral second primary invasive cancer, second primary non-breast invasive cancer (excluding non-melanoma skin cancers), or death without evidence of recurrence. DFS is evaluated by recurrence score (0-10 vs. 11-15 vs. 16-20 vs. 21-25 vs. >25) and age groups (<=50 vs. 51-65 vs. 65-75). The distribution of DFS (eg, 5-year DFS rate) is estimated using Kaplan-Meier method. (NCT00310180)
Timeframe: Assessed every 6 months within 5 years from registration and then annually up to 20 years, DFS rate estimated at 5 years
| Intervention | percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RS 0-10 & Age<=50 | RS 0-10 & Age 51-65 | RS 0-10 & Age 66-75 | RS 11-15 & Age <=50 | RS 11-15 & Age 51-65 | RS 11-15 & Age 66-75 | RS 16-20 & Age <=50 | RS 16-20 & Age 51-65 | RS 16-20 & Age 66-75 | RS 21-25 & Age <=50 | RS 21-25 & Age 51-65 | RS 21-25 & Age 66-75 | RS >25 & Age <=50 | RS >25 & Age 51-65 | RS >25 & Age 66-75 | |
| Arm A | 95.1 | 94.7 | 90.5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Arm B | NA | NA | NA | 95.1 | 95.5 | 87.1 | 92.0 | 94.3 | 90.1 | 86.3 | 91.6 | 93.8 | NA | NA | NA |
| Arm C | NA | NA | NA | 94.3 | 93.9 | 91.4 | 94.7 | 92.2 | 90.2 | 92.1 | 93.4 | 90.9 | NA | NA | NA |
| Arm D | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 86.4 | 87.5 | 89.8 |
Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1. (NCT00112918)
Timeframe: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive. (NCT00112918)
Timeframe: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive. (NCT00112918)
Timeframe: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer. (NCT00112918)
Timeframe: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Patients with a DFS event | Recurrence | New Occurrence | Death | Patients without events | |
| FOLFOX4 | 237 | 219 | 3 | 17 | 718 |
| FOLFOX4 + Bv | 280 | 253 | 8 | 21 | 680 |
| XELOX+Bv | 253 | 223 | 6 | 25 | 699 |
An overall survival event was death due to any cause. (NCT00112918)
Timeframe: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | participants (Number) | |
|---|---|---|
| Patients with events | Patients without events | |
| FOLFOX4 | 115 | 840 |
| FOLFOX4 + Bv | 151 | 809 |
| XELOX+Bv | 145 | 807 |
An overall survival event was death due to any cause. (NCT00112918)
Timeframe: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).
| Intervention | participants (Number) | |
|---|---|---|
| Patients with events | Patients without events | |
| FOLFOX4 | 161 | 794 |
| FOLFOX4 + Bv | 202 | 758 |
| XELOX+Bv | 182 | 770 |
A linear regression model that controls for the stratification factors (cT-stage and cN-stage) will be used. Mean NAR scores along with standard errors and confidence intervals will be reported by treatment. The NAR score ranges from zero to 100 with lower values corresponding to better prognosis. (NCT02921256)
Timeframe: Baseline to up to 3 years
| Intervention | score on a scale (Mean) |
|---|---|
| Arm Ia (mFOLFOX6, RT, Capecitabine) | 12.6 |
| Arm II (mFOLFOX6, RT, Capecitabine, Veliparib) | 13.7 |
| Arm Ib (mFOLFOX6, RT, Capecitabine) | 14.1 |
| Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab) | 11.5 |
Pathologic Complete Response means no remaining cancer detectable in the pathology sample. Analyzed by a logistic regression model that controls for the stratification factors (cT-stage and cN-stage). Observed proportions along with confidence intervals will be presented by treatment. (NCT02921256)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Mean) |
|---|---|
| Arm Ia (mFOLFOX6, RT, Capecitabine) | 21.6 |
| Arm II (mFOLFOX6, RT, Capecitabine, Veliparib) | 33.8 |
| Arm Ib (mFOLFOX6, RT, Capecitabine) | 29.4 |
| Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab) | 31.9 |
Sphincter preservation means that the surgical procedure used to remove the tumor did not disturb the sphincter muscle. Analyzed by a logistic regression model that controls for the stratification factors (cT-stage and cN-stage). Observed proportions along with confidence intervals will be presented by treatment. (NCT02921256)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Mean) |
|---|---|
| Arm Ia (mFOLFOX6, RT, Capecitabine) | 52.5 |
| Arm II (mFOLFOX6, RT, Capecitabine, Veliparib) | 59.3 |
| Arm Ib (mFOLFOX6, RT, Capecitabine, Pembrolizumab) | 71.0 |
| Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab) | 59.4 |
The Best ORR was based on imaging and classified according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. The BOR rate was defined as the number of participants whose BOR was either complete response (CR) or partial response (PR), relative to the number of participants belonging to the trial set of interest. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 50 |
| Cisplatin/Carboplatin + 5-Flurouracil | 26.6 |
The DCR was based on imaging and classified according to RECIST Version 1.1 criteria. The DCR was defined as the number of participants whose Best Overall Response is either CR, PR or stable disease (SD), divided by the number of participants belonging to the trial set of interest multiplied by 100. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on trial. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 75.6 |
| Cisplatin/Carboplatin + 5-Flurouracil | 59.5 |
DOR was determined for participants whose BOR was either CR or PR. It was defined as the time from the first assessment of CR or PR until the event defining PFS time. PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | Weeks (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 18.1 |
| Cisplatin/Carboplatin + 5-Flurouracil | 13.9 |
The OS time was defined as the time from randomization to the date of death. If a participant was alive at the time of analysis, survival time was censored at the last date when the participant was known to be alive. If this date was after data cut-off, participants were censored at the date of data cut-off. OS was measured using Kaplan-Meier (KM) estimates. (NCT02383966)
Timeframe: Time from date of randomization up to data cutoff (assessed up to 904 days)
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 10.2 |
| Cisplatin/Carboplatin + 5-Flurouracil | 8.4 |
PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 5.5 |
| Cisplatin/Carboplatin + 5-Flurouracil | 4.2 |
PFS time was defined as the time in months from the date of randomization until first observation of PD (radiologically confirmed by Investigator), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 5.5 |
| Cisplatin/Carboplatin + 5-Flurouracil | 4.6 |
An Adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs. (NCT02383966)
Timeframe: Time from date of randomization up to data cutoff (assessed up to 904 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| TEAEs | TESAEs | TEAEs Leading to Death | AEs Leading to Discontinuation | |
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 163 | 46 | 11 | 27 |
| Cisplatin/Carboplatin + 5-Flurouracil | 75 | 21 | 8 | 8 |
Where events are defined as recurrence, second primary cancer, or death from any cause (NCT00096278)
Timeframe: 3 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil | 75.5 |
| Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | 77.4 |
Percentage of patients who did not experience an event where events are defined as death from any cause. (NCT00096278)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (mFOLFOX6) | 77.6 |
| Arm II (Bevacizumab, mFOLFOX6) | 78.7 |
"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 67.1 |
| Mutant KRAS Arm D | 65.0 |
"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 74.6 |
| Wild-type KRAS Arm D | 71.5 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 87.9 |
| Mutant KRAS Arm D | 82.7 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 87.3 |
| Wild-type KRAS Arm D | 85.6 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Mutant KRAS Arm A | 55.6 |
| Mutant KRAS Arm D | 72.3 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Wild-type KRAS Arm A | 51.1 |
| Wild-type KRAS Arm D | 73.3 |
To compare the 3-year survival achieved by docetaxel/cisplatin/5-FU based sequential therapy with platinum based chemo radiotherapy in patients with locally advanced SCCHN. Overall survival is defined as the time from date of randomisation to death from any cause. Patients alive at the time of current analysis were censored at the date last known to be alive.Kaplan-Meier method was used to estimate overall survival (NCT00095875)
Timeframe: 3-years
| Intervention | percent of patients (Number) |
|---|---|
| Arm I | 73 |
| Arm II | 78 |
Progression free survival was defined as the time from date of randomisation to disease progression or death from any cause without progression whichever occurred first; otherwise, patients were censored at the date last known to be free of progression. (NCT00095875)
Timeframe: 5 years
| Intervention | percent of patients (Number) |
|---|---|
| Arm I | 67 |
| Arm II | 69 |
Percentage of participants experiencing a complete response [CR] (complete disappearance of measurable and evaluable disease without new lesions) or partial response [PR] (greater than or equal to 50 percent decrease in the sum of the products of diameters [SOPD] of index lesions compared to the baseline SOPD, with no evidence of PD) confirmed by a subsequent assessment no less than 28 days after criteria for response were first met based on modified WHO criteria as assessed by Independent Review Committee (IRC). (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until progressive disease (PD) reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 36.4 |
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST as assessed by IRC. CR are those that persist on repeat imaging study at least 28 days after initial documentation of response. PR are those with greater than or equal to 30 percent decrease in the SOPD of index lesions compared to the baseline SOPD, with no evidence of PD. (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until PD reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 45.5 |
Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (>=50 percent decrease in sum of the products of diameters [SOPD] of index lesions compared to baseline SOPD, with no evidence of PD) confirmed by subsequent assessment no less than 28 days after criteria for response were first met) or stable disease [SD] (neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD) at least once no less than 42 days after first dose of trial treatment based on modified WHO criteria as assessed by IRC. (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until PD reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 87.9 |
Duration of response according to modified WHO criteria as assessed by IRC was defined as the time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death when death occurred within 60 days of the last tumor assessment or first administration of trial treatment (whichever was last). (NCT00971932)
Timeframe: Time from first assessment of CR or PR to PD, death or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 2.8 |
Time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00971932)
Timeframe: Time from first administration of trial treatment or last day known to be alive, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 12.8 |
The PFS time according to modified WHO criteria as assessed by IRC was defined as duration from first administration of trial treatment until PD (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT00971932)
Timeframe: Time from first administration of trial treatment to PD, death or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 4.1 |
Time to treatment failure according to modified WHO criteria as assessed by IRC was defined as the time from first administration of trial treatment until the date of the first occurrence of one of the events defining treatment failure: PD assessed by the investigator, discontinuation of treatment due to PD, discontinuation of treatment due to an adverse event (AE), start of any new anticancer therapy, or withdrawal of consent or death within 60 days of the last tumor assessment or first administration of trial treatment. (NCT00971932)
Timeframe: Time from first administration of trial treatment to treatment failure or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 4.2 |
DFS is defined as the evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason. (NCT00129389)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FAC | 98 |
| Arm B: FAC-wP | 71 |
OS event is defined as the death from any cause. (NCT00129389)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FAC | 40 |
| Arm B: FAC-wP | 31 |
Time from the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) to disease progression using a modified version of the RECIST v1.0 (see protocol Appendix H). (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 5.7 |
An objective tumor response of complete or partial response per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 that was confirmed no less than 28 days after the criteria for response were first met. Complete response = disappearance of all target lesions and partial response = ≥30% reduction in lesion size. (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | subjects (Number) |
|---|---|
| Panitumumab Plus Chemotherapy | 101 |
| Chemotherapy Alone | 73 |
Time from randomization to death (NCT00460265)
Timeframe: Upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 11.1 |
| Chemotherapy Alone | 9.0 |
Time from randomization date to date of disease progression using a modified version of the RECIST v1.0 or death. (NCT00460265)
Timeframe: Every 6 weeks until disease progression or deaths, upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 5.8 |
| Chemotherapy Alone | 4.6 |
Time from randomization date to date of disease progression using a modified version of the RECIST 1.0 (see protocol Appendix H) (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 6.8 |
| Chemotherapy Alone | 5.6 |
Time from randomization date to the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) using a modified version of the RECIST v1.0. (NCT00460265)
Timeframe: Every 6 weeks until disease progression, upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 1.4 |
| Chemotherapy Alone | 1.5 |
Time from surgery to recurrence (NCT00313560)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Erlotinib and EBRT After Pancreatectomy | 15.6 |
(NCT00313560)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| Erlotinib and EBRT After Pancreatectomy | 24.39 |
Quality of life (QOL) was assessed before CRT was started or during the first week of its administration (baseline [BL]), between completion of CRT and starting maintenance chemotherapy (time 1 [t1]), and within 3 months after completion of maintenance chemotherapy (time 2 [t2]). QLQ-PAN 26 questionnaire includes 26 questions, organized into 7 scales, with scores for each ranging from 0-100. Higher scores indicate worse health state. Therefore, decreasing (negative) scores indicate a better outcome. (NCT00313560)
Timeframe: 3 months
| Intervention | score on a scale (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pancreatic Pain (t1 vs. BL) | Pancreatic Pain (t2 vs. BL) | Pancreatic Pain (t2 vs. t1) | Digestive (t1 vs. BL) | Digestive (t2 vs. BL) | Digestive (t2 vs. t1) | Altered Bowel Habits (t1 vs. BL) | Altered Bowel Habits (t2 vs. BL) | Altered Bowel Habits (t2 vs. t1) | Jaundice (t1 vs. BL) | Jaundice (t2 vs. BL) | Jaundice (t2 vs. t1) | Body Image (t1 vs. BL) | Body Image (t2 vs. BL) | Body Image (t2 vs. t1) | Satisfaction with healthcare (t1 vs. BL) | Satisfaction with health care (t2 vs. BL) | Satisfaction with health care (t2 vs. t1) | Sexual function (t1 vs. BL) | Sexual function (t2 vs. BL) | Sexual function (t2 vs. t1) | |
| Erlotinib and EBRT After Pancreatectomy | -1.9 | -3.8 | 2.4 | -0.9 | -4.6 | -1.4 | 14.7 | 7.2 | -4.9 | -1.3 | -2 | 0 | -6.2 | -3.1 | -0.7 | 4.1 | 3.1 | 0 | -0.5 | 14.7 | 14.1 |
Quality of life (QOL) was assessed before chemoradiation therapy (CRT) was started or during the first week of its administration [baseline (BL)], between completion of CRT and starting maintenance chemotherapy [time 1 (t1)], and within 3 months after completion of maintenance chemotherapy [time 2 (t2)]. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses quality of life on three domains: symptoms (score ranges from 7-14); function (score range 21-82); and global health status (score range 2-14). Higher or increasing scores mean worse outcomes; lower or decreasing scores mean better outcomes. (NCT00313560)
Timeframe: Up to 3 months after completion of maintenance chemotherapy
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global (Time 1 vs. BL) | Global (Time 2 vs. BL) | Global (Time 2 vs. Time 1) | Functional (F) - Physical (Time 1 vs. BL) | F - Physical (Time 2 vs. BL) | F - Physical (Time 2 vs. Time 1) | F - Role (Time 1 vs. BL) | F - Role (Time 2 vs. BL) | F - Role (Time 2 vs. Time 1) | F - Cognition (Time 1 vs. BL) | F - Cognition (Time 2 vs. BL) | F - Cognition (Time 2 vs. Time 1) | F - Emotional (Time 1 vs. BL) | F - Emotional (Time 2 vs. BL) | F - Emotional (Time 2 vs. Time 1) | F - Social (Time 1 vs. BL) | F - Social (Time 2 vs. BL) | F - Social (Time 2 vs. Time 1) | Financial (Time 1 vs. BL) | Financial (Time 2 vs. BL) | Financial (Time 2 vs. Time 1) | General Symptoms (GS) - Fatigue (Time 1 vs. BL) | GS - Fatigue (Time 2 vs. BL) | GS - Fatigue (Time 2 vs. Time 1) | GS - Nausea/Vomiting (Time 1 vs. BL) | GS - Nausea/Vomiting (Time 2 vs. BL) | GS - Nausea/Vomiting (Time 2 vs. Time 1) | GS - Pain (Time 1 vs. BL) | GS - Pain (Time 2 vs. BL) | GS - Pain (Time 2 vs. Time 1) | GS - Dyspnea (Time 1 vs. BL) | GS - Dyspnea Time 2 vs. BL) | GS - Dyspnea (Time 2 vs. Time 1) | GS - Insomnia (Time 1 vs. BL) | GS - Insomnia (Time 2 vs. BL) | GS - Insomnia (Time 2 vs. Time 1) | GS - Appetite Loss (Time 1 vs. BL) | GS - Appetite Loss (Time 2 vs. BL) | GS - Appetite Loss (Time 2 vs. Time 1) | GS - Constipation (Time 1 vs. BL) | GS - Constipation (Time 2 vs. BL) | GS - Constipation (Time 2 vs. Time 1) | GS - Diarrhea (Time 1 vs. BL) | GS - Diarrhea (Time 2 vs. BL) | GS - Diarrhea (Time 2 vs. Time 1) | |
| Erlotinib and EBRT After Pancreatectomy | 1 | -1.8 | 4.6 | 0.5 | -3.2 | -6.2 | -3.1 | -0.3 | -4.4 | -2.6 | 1.2 | -1.2 | -0.4 | 2.2 | -0.6 | 3.9 | 4.4 | -3.8 | 1.7 | 2.5 | 0 | 5.7 | 5.2 | 1.7 | 2.5 | 0 | 1.9 | 2.7 | 7.2 | 5 | 1.7 | 3.8 | 1.2 | -2.5 | 0 | 2.5 | -2.5 | -15 | -5 | -4.2 | -2.5 | 0 | 14.7 | 8.8 | -6.2 |
Number of participants experiencing adverse events during chemoradiation and during adjuvant chemotherapy, Grade 2 or higher, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. This is used to determine the Toxicity profile. (NCT00313560)
Timeframe: up to 3 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | |
| Adjuvant Gemcitabine Plus Erlotinib | 15 | 14 | 3 |
| Chemoradiation Plus Erlotinib | 24 | 15 | 1 |
Time in months from the date of randomization to date of death due to any cause. OS was calculated as (date of death minus randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | months (Median) |
|---|---|
| Sunitinib | 9.4 |
| Standard of Care | 10.5 |
Probability that the participants will survive at end of 1 year from the first dose of study treatment. Calculated using data collected from baseline until death (up to 3 years after first dose of study medication). Probability calculated from Kaplan-Meier estimate. (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | ratio (Number) |
|---|---|
| Sunitinib | 0.376 |
| Standard of Care | 0.446 |
Blood samples were collected to enumerate the number of total CECs and sVEGFR1, sVEGFR2 and sVEGFR3 protein expression and/or cellular viability. (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=42, 48) | Cycle 1, Day 15 (n=28, 37) | Cycle 2, Day 1 (n=33, 35) | Cycle 2, Day 15 (n=7, 5) | Cycle 3, Day 1 (n=27, 25) | Cycle 3, Day 15 (n=4, 1) | Cycle 4, Day 1 (n=3, 5) | Cycle 5, Day 1 (n=2, 2) | EOT (n=18, 18) | |
| Standard of Care | 1176.92 | 1199.32 | 1048.31 | 852.96 | 509.75 | 231.80 | 976.79 | 2031.67 | 1087.94 |
| Sunitinib | 944.67 | 630 | 512.39 | 1310.86 | 390.09 | 923.85 | 169.24 | 145.68 | 477.83 |
Blood samples were collected to enumerate the number of total CTCs and insulin growth factor 1R positive (IGF-1R+) CTCs (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/7.5 mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=33, 28) | Cycle 1, Day 15 (n=20, 16) | Cycle 2, Day 1 (n=19, 17) | Cycle 2, Day 15 (n=3, 7) | Cycle 3, Day 1 (n=8, 15) | Cycle 3, Day 15 (n=2, 4) | Cycle 4, Day 1 (n=2, 5) | Cycle 5, Day 1 (n=2, 3) | EOT (n=17,4) | |
| Standard of Care | 17.71 | 10.69 | 3.18 | 0.86 | 10.60 | 0 | 0.60 | 0.33 | 3 |
| Sunitinib | 119.76 | 183.60 | 189 | 33.33 | 36.50 | 40.50 | 61 | 19.50 | 55 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.02 | 29.4 | 32.3 | 33.4 | 28.5 | 40.4 | 30.9 | 36.1 | 21.3 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.14 | 94.9 | 94.4 | 91.6 | 78.6 | 105 | 82.2 | 84.2 | 63.6 |
Ctrough = plasma concentration of SU012662 prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 29.9 | 37.2 | 37.3 | 39.8 | 40.1 | 38.7 | 41.9 | 28.6 |
Ctrough = plasma concentration of sunitinib prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 67.5 | 73.4 | 69.8 | 69.3 | 65.3 | 68.7 | 58.4 | 64.0 |
Ctrough = plasma concentration of total drug (Sunitinib + SU012662) prior to study drug administration dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 97.4 | 111 | 107 | 109 | 105 | 107 | 100 | 92.5 |
Time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00246571)
Timeframe: Time from first response to disease progression up to 3 years from first dose
| Intervention | months (Median) | |
|---|---|---|
| Core radiology assessment (n=3,7) | Investigator's assessment (n=10,12) | |
| Standard of Care | NA | 4.6 |
| Sunitinib | 3.0 | 3.6 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.12 | 65.53 | 62.09 | 58.20 | 50.03 | 64.61 | 51.25 | 48.07 | 42.23 |
Plasma concentrations of sKIT were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=49, 35) | Cycle 4 Day 1 (n=33, 27) | Cycle 5 Day 1 (n=28, 19) | Cycle 7 Day 1 (n=9, 8) | End Of Treatment (n=49, 11) | |
| Standard of Care | 62232.81 | 65843.75 | 63582.86 | 62885.19 | 54811.05 | 56237.50 | 72854.55 |
| Sunitinib | 61862.65 | 44987.88 | 30855.10 | 25887.88 | 21696.07 | 18166.67 | 25004.08 |
Plasma concentrations of sPlGF were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=15, 11) | Cycle 2 Day 1 (n=11, 9) | Cycle 3 Day 1 (n=5, 4) | Cycle 4 Day 1 (n=2, 3) | Cycle 5 Day 1 (n=1, 3) | Cycle 7 Day 1 (n=1, 1) | End Of Treatment (n=5, 0) | |
| Standard of Care | 37.23 | 36.24 | 40.08 | 33.23 | 51.83 | 38.50 | 0 |
| Sunitinib | 36.96 | 168.05 | 72.16 | 144.60 | 118.30 | 176.60 | 87.54 |
Plasma concentrations of sVEGF-A were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 66) | Cycle 2 Day 1 (n=67, 50) | Cycle 3 Day 1 (n=49, 37) | Cycle 4 Day 1 (n=33, 28) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 10) | End Of Treatment (n=49, 12) | |
| Standard of Care | 151.49 | 170.43 | 129.31 | 129.88 | 126.97 | 115.58 | 94.76 |
| Sunitinib | 152.28 | 455.17 | 265.56 | 274.94 | 324.09 | 241.78 | 294.66 |
Plasma concentrations of sVEGFR3 were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=48, 35) | Cycle 4 Day 1 (n=32, 27) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 9) | End Of Treatment (n=48, 10) | |
| Standard of Care | 25857.19 | 24515.83 | 29034.86 | 27929.63 | 32949 | 32004.44 | 29194 |
| Sunitinib | 24124.82 | 16299.70 | 14459.38 | 13702.81 | 16345.36 | 24795.56 | 26746.46 |
"Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause. PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death)." (NCT00246571)
Timeframe: Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)
| Intervention | Months (Median) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 2.7 | 2.5 |
| Sunitinib | 2.0 | 1.7 |
Objective response based assessment of confirmed response (CR) or confirmed partial response (PR) according to RECIST. CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with a greater than or equal to (≥) 30% decrease in the sum of the longest dimensions (SLD) of the target lesions taking as a reference the baseline SLD. (NCT00246571)
Timeframe: Baseline until response or disease progression (up to 3 years from first dose)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 6.7 | 11.5 |
| Sunitinib | 2.7 | 8.8 |
BOR: Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified WHO criteria), divided by the number of participants belonging to ITT or safety population. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 55.9 |
BOR: Percentage of participants experiencing a Complete Response (CR) (complete disappearance of measurable and evaluable disease without new lesions) or Partial Response (PR) (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified World Health Organization [WHO] criteria), divided by the number of participants belonging to intention to treat (ITT) or safety population. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 54.4 |
Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.1 |
Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 5.7 |
The OS time was defined as the time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT01177956)
Timeframe: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 12.6 |
Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.6 |
Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.2 |
Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 7.0 |
Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.8 |
The DFS was defined as the time from the first treatment intake to disease recurrence assessed (second primary cancer, local or distant recurrence, distant metastases) or death from any cause. The DFS was analyzed using Kaplan-Meier method. (NCT00865189)
Timeframe: From first time of the treatment administration to the date of second cancer, local or regional recurrence, distant metastasis or death from any cause (up to approximately 6 years)
| Intervention | months (Median) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 68.3 |
| Arm B (Bevacizumab, Chemoradiotherapy) | NA |
(NCT00865189)
Timeframe: Arm A: Week 16 to Week 23; Arm B: Week 1 to Week 7
| Intervention | cycles (Mean) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 4.4 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 4.8 |
(NCT00865189)
Timeframe: 6 cycles (12 weeks; cycle length = 14 days)
| Intervention | cycles (Mean) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 5.8 |
(NCT00865189)
Timeframe: Arm A: Week 16 to Week 23; Arm B: Week 1 to Week 7
| Intervention | cycles (Mean) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 4.5 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 5.0 |
The overall survival was defined as the time from the first treatment intake to death from any cause. (NCT00865189)
Timeframe: From the first treatment administration to the date of death (up to approximately 6 years)
| Intervention | months (Median) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | NA |
| Arm B (Bevacizumab, Chemoradiotherapy) | NA |
(NCT00865189)
Timeframe: Baseline up to approximately 6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 8.7 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 24.4 |
(NCT00865189)
Timeframe: Baseline up to approximately 6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 30.4 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 33.3 |
The surgery involving a radical rectal excision using the TME technique. (NCT00865189)
Timeframe: Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 91.3 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 97.8 |
Tumor sterilization was defined as the absence of residual tumor cells in the resected specimen including lymph nodes (ypT0-N0). The rate of sterilization of the tumoral specimen was assessed after surgery on the surgical specimen by local review. Analyses were performed for participants who have been operated as defined by the protocol (within the study and TME technique) and for all participants who have been operated. Reported is the percentage of participants with tumor sterilization. (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 23.8 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 11.4 |
The percentage of participants with a recurrence was described by type of recurrence (local and distant recurrence). (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Local recurrence | Distant recurrence | |
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 2.2 | 17.4 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 6.7 | 13.3 |
A participant with a downstaging was defined as a participant with T3 (T describes the size of the original [primary] tumor) at inclusion and T2 or T1 or T0 after surgery, or with N+ (N describes lymph nodes involvement) at inclusion and N- after surgery and if T is equal at inclusion and after surgery. The clinical tumor-node-metastasis (cTNM) classification was used at inclusion and the pathological staging tumor and nodes (ypTN) classification after surgery. Reported is the percentage of participants with tumor downstaging of the surgical specimen according to the local review and centralized review. (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Downstaging, local review (n=41, 44) | Downstaging, centralized review (n=39, 43) | |
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 65.9 | 64.1 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 54.5 | 55.8 |
"DCR - complete response, partial response, and stable disease~Complete response - disappearance of all target and non-target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter~Stable disease - neither sufficient shrinkage to qualify for partial response not sufficient increase to qualify for progressive disease" (NCT00515216)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 95.7 |
"ORR = complete response + partial response~Complete response - disappearance of all target and non-target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter" (NCT00515216)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 39.1 |
(NCT00515216)
Timeframe: 4 years
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 11.4 |
Progressive disease - at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00515216)
Timeframe: 4 years
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 6.2 |
This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 2 | 4 | 3 |
This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/C | C/C | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 3 | 1 |
This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/G | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 4 | 3 | 2 |
This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 0 | 9 | 0 |
This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | |
|---|---|---|
| +6 bp/+6 bp | +6 bp/-6 bp | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 4 |
This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| TYMS, TSER*2/*2 | TYMS, TSER*2/*3 (G) | TYMS, TSER*2/*3 (C) | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 2 | 2 |
This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | G/A | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 6 | 2 |
This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 8 | 2 |
This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/C | C/C | |
| Oxaliplatin/Leucovorin/5-FU | 3 | 6 | 2 |
This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/G | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 8 | 2 | 1 |
This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 6 | 4 |
This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | |
|---|---|---|
| +6 bp/+6 bp | +6 bp/-6 bp | |
| Oxaliplatin/Leucovorin/5-FU | 6 | 5 |
This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| TYMS, TSER*2/*2 | TYMS, TSER*2/*3 (G) | TYMS, TSER*2/*3 (C) | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 4 | 6 |
This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | G/A | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 6 | 5 | 0 |
"Percentage of partial and complete responses, according to WHO criteria:~Complete Response: Disappearance of all known disease, determined by 2 observations not less than 4 weeks apart.~Partial Response: Decrease by at least 50% of the diameters of all measurable lesions, determined by 2 observations not less than 4 weeks apart." (NCT00382720)
Timeframe: every 8 weeks up to a maximum of 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| (TE) Taxotere and Eloxatin | 23.1 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 46.6 |
| (TEX) Taxotere, Eloxatin and Xeloda | 25.6 |
The number of months measured from the date of randomization to the date of death due to any cause. (NCT00382720)
Timeframe: up to a maximum of 36 months
| Intervention | months (Median) |
|---|---|
| (TE) Taxotere and Eloxatin | 8.97 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 14.59 |
| (TEX) Taxotere, Eloxatin and Xeloda | 11.30 |
"The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause.~WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion." (NCT00382720)
Timeframe: every 8 weeks up to a maximum of 36 months
| Intervention | Months (Median) |
|---|---|
| (TE) Taxotere and Eloxatin | 4.50 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 7.66 |
| (TEX) Taxotere, Eloxatin and Xeloda | 5.55 |
Duration of response is defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of the LD of the target lesions, compared with the baseline sum LD) until the first documented sign of PD (at least a 20% increase in the sum of the LD of target lesions, compared with the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions) or death due to breast cancer. In the absence of confirmation of death, survival time was to be censored at the time of the last investigator contact. (NCT00820222)
Timeframe: From the time of the first documented confirmed complete or partial response until disease progression or death, if sooner (average of 10 months). Cut-off 11-Jun-2012
| Intervention | months (Median) |
|---|---|
| Lapatinib Plus Capecitabine | 6.2 |
| Trastuzumab Plus Capecitabine | 8.4 |
CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 millimeters (mm) on T1Weighted (T1W) Magnetic Resonance Imaging (MRI) without CNS symptoms that were considered to be unequivocal based on all relevant radiological features (e.g., associated T2W signal abnormality); the appearance of any enhancing lesion on T1W MRI with CNS symptoms; unequivocal finding of leptomeningeal disease (defined as the dissemination of cancer throughout the spinal fluid), with or without symptoms; and unequivocal finding of multifocal intraparenchymal lesions with or without symptoms. In the event of the appearance of a <6 mm lesions(s) without CNS lesions, or equivocal findings potentially suggesting leptomeningeal disease, these findings were followed with a subsequent scan within 6 weeks. If unequivocal progression was determined with the subsequent scan and/or CNS symptoms occurred, then CNS relapse crieria were met. (NCT00820222)
Timeframe: From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012
| Intervention | participants (Number) |
|---|---|
| Lapatinib Plus Capecitabine | 8 |
| Trastuzumab Plus Capecitabine | 12 |
CNS progression was documented by a brain scan and was indicated by the investigator on the follow-up electronic Case Report Form. CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 mm on T1W MRI without CNS symptoms that were considered to be unequivocal based on all relevant radiological features (e.g., associated T2W signal abnormality); the appearance of any enhancing lesion on T1W MRI with CNS symptoms; unequivocal finding of leptomeningeal disease, with or without symptoms; and unequivocal finding of multifocal intraparenchymal lesions with or without symptoms. In the event of the appearance of a <6 mm lesions(s) without CNS lesions, or equivocal findings potentially suggesting leptomeningeal disease, these findings were followed with a subsequent scan within 6 weeks. If unequivocal progression was determined with the subsequent scan and/or CNS symptoms occurred, then CNS relapse crieria were met. (NCT00820222)
Timeframe: From the time of randomization until death due to any cause (average of 10 months). Cut-off 11-Jun-2012
| Intervention | participants (Number) |
|---|---|
| Lapatinib Plus Capecitabine | 17 |
| Trastuzumab Plus Capecitabine | 15 |
Overall survival is defined as the time from randomization until death due to any cause or to the date of censor. In the absence of confirmation of death, survival time was to be censored at the time of the last investigator contact. (NCT00820222)
Timeframe: From randomization until death due to any cause (average of 10 months). Cut-off 11-Jun-2012
| Intervention | months (Median) |
|---|---|
| Lapatinib Plus Capecitabine | 22.7 |
| Trastuzumab Plus Capecitabine | 27.3 |
PFS is defined as the interval between the date of randomization and the earliest date of progressive disease (PD), or death due to any cause. PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, compared with the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions based on investigator assessment of both CNS and non-CNS for response. (NCT00820222)
Timeframe: From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012
| Intervention | months (Median) |
|---|---|
| Lapatinib Plus Capecitabine | 6.60 |
| Trastuzumab Plus Capecitabine | 8.05 |
CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 mm on T1W MRI without CNS symptoms that were considered to be unequivocal based on all relevant radiological features (e.g., associated T2W signal abnormality); the appearance of any enhancing lesion on T1W MRI with CNS symptoms; unequivocal finding of leptomeningeal disease (defined as the dissemination of cancer throughout the spinal fluid), with or without symptoms; and unequivocal finding of multifocal intraparenchymal lesions with or without symptoms. In the event of the appearance of a <6 mm lesions(s) without CNS lesions, or equivocal findings potentially suggesting leptomeningeal disease, these findings were followed with a subsequent scan within 6 weeks. If unequivocal progression was determined with the subsequent scan and/or CNS symptoms occurred, then CNS relapse crieria were met. (NCT00820222)
Timeframe: From randomization until the date of documented CNS progression (average of 10 months). Cut-off 11-Jun-2012
| Intervention | months (Mean) |
|---|---|
| Lapatinib Plus Capecitabine | 8.2 |
| Trastuzumab Plus Capecitabine | 6.7 |
CB is defined as the number of participants with evidence of confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of the LD of the target lesions, compared with the baseline sum LD) at any time or stable disease (SD, neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD [defined as at least a 20% increase in the sum of the LD of target lesions, compared with the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions] based on investigator assessment), for at least 24 weeks. (NCT00820222)
Timeframe: From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| CR | PR | SD >= 24 weeks | Clinical Benefit (CR + PR + SD >= 24 weeks) | |
| Lapatinib Plus Capecitabine | 8 | 65 | 39 | 112 |
| Trastuzumab Plus Capecitabine | 12 | 73 | 33 | 118 |
OR is defined as the number of participants with either a confirmed complete response (CR; disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of the LD of the target lesions, compared with the baseline sum LD). CR and PR were assessed per Response Evaluation Criteria in Solid Tumors (RECIST). To be assigned a status of PR or CR, a confirmatory disease assessment was to be performed 28 days (4 weeks) or greater after the criteria for response were first met. In addition, a bone scan must have been obtained to rule out the presence of new bone lesions or progression of existing bone lesions, even if the participant had no bone lesions present at Baseline. If a bone scan was performed at the time of initial response or near the time of response, the bone scan did not need to be repeated. (NCT00820222)
Timeframe: From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| CR | PR | Overall Response (CR+PR) | |
| Lapatinib Plus Capecitabine | 8 | 65 | 73 |
| Trastuzumab Plus Capecitabine | 12 | 73 | 85 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The Investigator assessed whether the AE was related to study drug. AEs were graded using the Common Toxicity Criteria from the Cancer Therapy Evaluation Program, Division of Cancer Therapy, National Cancer Institute. Grades: 0=No AE or within normal limits; 1=Mild AE; 2=Moderate AE; 3=Severe and undesirable AE; 4=Life-threatening or disabling AE; 5=Death related to AE. (NCT00820222)
Timeframe: From the first dose of study medication until 30 days after the last dose of study treatment (average of 10 months).
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndrome | Diarrhoea | Aspartate aminotransferase increased | Neutropenia | Asthenia | Fatigue | Alanine aminotransferase increased | Hypokalaemia | |
| Lapatinib Plus Capecitabine | 29 | 19 | 11 | 9 | 9 | 7 | 4 | 3 |
| Trastuzumab Plus Capecitabine | 45 | 22 | 4 | 18 | 6 | 4 | 6 | 11 |
Overall survival is defined as time from registration to death from any cause. 5-year overall survival rate is estimated using Kaplan-Meier method. (NCT00321685)
Timeframe: survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 80 |
Recurrence free survival is defined as time from surgery to disease recurrence or death without recurrence (whichever occurred first) among resected patients. 5-year recurrence-free survival rate is estimated using Kaplan-Meier method, with 90% confidence interval calculated using Greenwood's formula. (NCT00321685)
Timeframe: recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 81 |
Pathologic complete response to preoperative therapy was determined at the time of surgical resection. Pathologic complete response (pCR) is defined as no evidence of invasive cells on pathologic examination of the primary rectal cancer (or tissue from the area where the tumor had been if there is a complete clinical response). Pathologic complete response rate is calculated as number of patients achieving pathologic complete response divided by all eligible and treated patients (NCT00321685)
Timeframe: Assessed at surgery time
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 17 |
Resection rate is defined as number of patients with T3 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T3 rectal cancers (NCT00321685)
Timeframe: Assessed at surgery time
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 92 |
Resection rate is defined as number of patients with T4 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T4 rectal cancers (NCT00321685)
Timeframe: Assessed at surgery time
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 75 |
"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/FOLFIRI | 11.1 |
| Aflibercept/FOLFIRI | 19.8 |
"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 12.06 |
| Aflibercept/FOLFIRI | 13.50 |
"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 4.67 |
| Aflibercept/FOLFIRI | 6.90 |
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
| Intervention | participants (Number) | |
|---|---|---|
| At least one positive sample in the ADA assay | At least one positive sample in the NAb assay | |
| Aflibercept/FOLFIRI | 8 | 1 |
| Placebo/FOLFIRI | 18 | 2 |
"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Treatment-Emergent Adverse Event (TEAE) | Serious TEAE | TEAE leading to Death | TEAE causing permanent treatment discontinuation | |
| Aflibercept/FOLFIRI | 606 | 294 | 37 | 164 |
| Placebo/FOLFIRI | 592 | 198 | 29 | 73 |
A total of 4 samples were collected during combination therapy, from the first dose of 250 mg/m^2 cetuximab in Cycle 1 (Day 1) through the final dose in Cycle 3 (Week 3) and used to report AUC of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Weekly from Cycle 1, Day 1 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
| Intervention | micrograms*hours/milliliter (μg*h/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 21900 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 18800 |
A total of 4 samples were collected at various times during combination therapy, from the third dose of 250 mg/m^2 cetuximab in Cycle 1 (Week 3) through the final dose in Cycle 3 (Week 3) and used to report Cmax of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Weekly from Cycle 1, Week 3 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
| Intervention | micrograms per milliliter (μg/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 225 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 199 |
The Cmax of cetuximab following 400 mg/m² cetuximab dosing during Part 2 of the study is reported. As specified in the protocol, pharmacokinetics (PK) samples were not collected during Part 1 of the study, Safety Lead-In or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Cycle 1, Day 1: 0 hours [(h); immediately postdose], 1 h, 2 h, and 24 h postdose
| Intervention | micrograms per milliliter (μg/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 208 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 208 |
January 23, 2013 is the date when the first participant in the BI-manufactured cetuximab treatment arm switched to US commercial cetuximab due to changes in the manufacturing process for the BI-manufactured cetuximab necessitating the need to switch participants to US commercial cetuximab. Each participant who switched treatments received at least 2 cycles of BI-manufactured cetuximab before switching. All other components of their treatment regimen remained unchanged. The number of participants who had TEAEs during combination therapy is reported. Using January 23 cut-off, data is un-confounded by lack of BI-manufactured cetuximab. TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-in group available in Reported Adverse Event module which is summary of serious and other non-serious AEs regardless of causality. (NCT01081041)
Timeframe: Part 2: Baseline to end of combination therapy or date first participant switched to US commercial cetuximab (up to 18 weeks)
| Intervention | participants (Number) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 75 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI), | 68 |
September 27, 2013 is the date when data was last collected for the primary endpoint. Prior to this date, the manufacturing process for the BI-manufactured cetuximab was changed necessitating the need to switch participants to US commercial cetuximab. All other components of their treatment regimen remained unchanged and participants stayed in their original reporting group. Therefore, the number of participants in the BI-manufactured cetuximab treatment arm who had TEAEs includes TEAEs while participants received BI-manufactured and US-commercial cetuximab. Using September 27 cut-off, the analysis of TEAEs is confounded by the switch from BI-manufactured to US commercial cetuximab. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-In group available in Reported Adverse Events module which is summary of serious and other non-serious AEs regardless of causality. (NCT01081041)
Timeframe: Part 2: Baseline to end of combination therapy (up to 18 weeks)
| Intervention | participants (Number) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 76 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 68 |
(NCT01081041)
Timeframe: Day 1, Week 1 of Cycles 3 and 5 (postbaseline samples were collected prior to infusion).
| Intervention | participants (Number) |
|---|---|
| All Participants (Cetuximab) | 4 |
OS was defined as duration from the date of randomization to the date of death from any cause. For each participant not known to have died as of the 23 October 2014 data cutoff date for the analysis, OS was censored at the date last known to be alive. In addition, any participants on Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Date of Death from any Cause (Up to 36.3 Months)
| Intervention | Months (Median) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 9.13 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 9.23 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 9.46 |
Response was defined using RECIST, v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Stable Disease (SD) was defined as small changes that did not meet the above criteria. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
| Intervention | percentage of participants (Number) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 69.7 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 58.4 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 62.0 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version [v]1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants with a confirmed CR or PR=(number of participants whose best overall response was CR or PR)/(number of participants treated)*100. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
| Intervention | percentage of participants (Number) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 24.2 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 32.5 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 36.6 |
PFS was defined as duration from the date of randomization to the first date of objective progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had objective PD as of the 23 October 2014 data cutoff date for the analysis, PFS was censored at the date of the participant's last complete tumor assessment prior to that cutoff date. In addition, any participant in Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease or Death from any Cause (Up to 32.7 Months)
| Intervention | Months (Median) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 4.57 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 4.34 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 5.59 |
OS was defined as the time from the day of randomization (Day 0) until death by all causes. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | NA |
| Group B | NA |
Safety population was defined as all participants who received at least one dose of protocol treatment after randomization. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 100 |
| Group B | 100 |
"Peripheral neuropathy was defined as events classified with a preferred term (PT) of peripheral neuropathy according to Standardized MedDRA Queries." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 30.4 |
| Group B | 3.7 |
The PFS is the period from the date of randomization (Day 0) until the date of judgment of progression from the date of randomization, or until death by all causes, whichever comes first. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | 9.1 |
| Group B | 9.3 |
PFS rate was defined as the gross percentage of participants who survived with no evidence of progression from the day of randomization (Day 0) until 9 months after Day 0. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to 9 months after randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 46.4 |
| Group B | 47.4 |
RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria after randomization. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 80.4 |
| Group B | 87.7 |
TTF was defined as the time from the day of randomization (Day 0) until the day of protocol treatment discontinuation determination, the day of PD decision during protocol treatment, or death from any cause, whichever came the earliest. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | 8.1 |
| Group B | 6.1 |
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3, 4 and 5 | |
| Group A | 0 | 19.6 | 80.4 |
| Group B | 0 | 27.8 | 72.2 |
"Skin toxicity was defined as events classified with an system organ class of Skin and subcutaneous tissue disorders or a preferred term of paronychia." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Skin and subcutaneous tissue disorders | Paronychia | |
| Group A | 17.9 | 7.1 |
| Group B | 18.5 | 9.3 |
PCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin (H&E) evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. (NCT01818063)
Timeframe: 36 months following surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 (Paclitaxel, Carboplatin) | 3 |
| Arm 2 (Veliparib, Paclitaxel, Carboplatin) | 3 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 35.6 |
| Chemotherapy Alone | 19.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 81.1 |
| Chemotherapy Alone | 60.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00122460)
Timeframe: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 4.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00122460)
Timeframe: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 10.1 |
| Chemotherapy Alone | 7.4 |
"Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 3.3 |
Please refer to Adverse Events section for further details (NCT00122460)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 218 |
| Chemotherapy Alone | 208 |
"Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 4.8 |
| Chemotherapy Alone | 3.0 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 50.74 | 52.68 | 55.30 |
| Chemotherapy Alone | 45.15 | 45.48 | 42.49 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 62.14 | 64.64 | 61.27 |
| Chemotherapy Alone | 62.05 | 60.67 | 65.72 |
"The National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 2.0 was used to evaluate toxicity.~Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life Threatening; Grade 5: Death." (NCT00024102)
Timeframe: Reported during protocol treatment after each cycle
| Intervention | participants (Number) |
|---|---|
| Standard Chemotherapy (CMF) | 92 |
| Standard Chemotherapy (AC) | 109 |
| Capecitabine | 101 |
Percentage of patients who were alive at 2.4 years. This rate was estimated using the Kaplan Meier method. (NCT00024102)
Timeframe: Time from registration to death (up to 15 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Standard Chemotherapy | 93 |
| Capecitabine | 88 |
"Percentage of participants who were alive and relapse-free at time of analysis were counted as Alive without relapse at 2.4 years. Participants who had a first local recurrence, first distant metastasis or death from any cause were counted as relapse, first occurrence. These rates were estimated using the Kaplan Meier method" (NCT00024102)
Timeframe: randomization until date of first event, or date last known to be event free if no event was reported (up to 5 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Relapse, first occurrence | Alive without relapse | |
| Capecitabine | 20 | 80 |
| Standard Chemotherapy | 11 | 89 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
The DOR was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time of progression or death as a result of any cause. According to the Response Evaluation Criteria in Solid Tumors (RECIST V1.0) criteria, CR was the disappearance of all tumor lesions. PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions, with occurrence of no new lesions. For participants not known to have died as of the data cut-off date and who did not have progressive disease, DOR was censored at the date of last visit with adequate assessment. For participants who received subsequent anticancer therapy (after discontinuation from the study treatment) prior to disease progression or death, DOR was censored at the date of last visit with adequate assessment. (NCT00437294)
Timeframe: Randomization to last visit (up to 9.66 months)
| Intervention | months (Median) |
|---|---|
| Capecitabine + Enzastaurin | 4.27 |
| Capecitabine + Placebo | 3.47 |
OS was defined as the time in months from the date of study enrollment to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last contact date. (NCT00437294)
Timeframe: Randomization to date of death from any cause up to 20.83 months
| Intervention | months (Median) |
|---|---|
| Capecitabine + Enzastaurin | 9.86 |
| Capecitabine + Placebo | 14.88 |
Response rate was defined as percent of participants with objective response [CR or PR] over randomized and treated participants using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0) Guidelines. CR was defined as the disappearance of all tumor lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum of LDs or complete disappearance of target lesions, with persistence (but not worsening) of one or more non-target lesions. No new lesions may have appeared. (NCT00437294)
Timeframe: Randomization to last visit (up to 9.66 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Capecitabine + Enzastaurin | 11.9 |
| Capecitabine + Placebo | 11.6 |
PFS was defined as the time from randomization to the first observation of disease progression or death due to any cause. For participants not known to have died as of the data cut-off date and who did not have progressive disease, PFS was censored at the date of last visit with adequate assessment. For participants who received subsequent anticancer therapy (after discontinuation from the study treatment) prior to disease progression or death, PFS was censored at the date of last visit with adequate assessment prior to the initiation of post-discontinuation anticancer therapy. (NCT00437294)
Timeframe: Randomization to measured progressive disease or death up to 14 months
| Intervention | months (Median) |
|---|---|
| Capecitabine + Enzastaurin | 2.79 |
| Capecitabine + Placebo | 4.27 |
AUC0-tlast for Capecitabine, 5'-deoxy-5-fluorouridine (5'-DFUR) and 5-fluorouracil (5-FU) was calculated from the plasma concentration-time data for each analyte for Cycle 2, Day 1. (NCT00437294)
Timeframe: Pre-dose to 6 hours post-dose on Day 1 of Cycle 2
| Intervention | micrograms*hour/milliliter (ug*hr/mL) (Geometric Mean) | ||
|---|---|---|---|
| Capecitabine | 5'-deoxy-5-fluorouridine (5'-DFUR) | 5-fluorouracil (5-FU) | |
| Capecitabine + Enzastaurin | 6.09 | 11.6 | 0.683 |
| Capecitabine + Placebo | 4.18 | 11.0 | 0.358 |
Area Under the Concentration versus time curve during 1 dosing interval at steady state (AUCτ,ss) for Cycle 2 Day 1 for Enzastaurin, its metabolite LY326020 and total analytes (enzastaurin + LY326020). AUCτ,ss was calculated using concentration versus time data by post hoc estimation of enzastaurin, its metabolite LY326020, and total analytes (enzastaurin + LY326020). (NCT00437294)
Timeframe: From pre-dose to 24 hours post-dose on Day 1 of Cycle 2
| Intervention | nanomoles*hour per liter (nmol*hr/L) (Geometric Mean) | ||
|---|---|---|---|
| Enzastaurin | Enzastaurin Metabolite LY326020 | Total Analytes (enzastaurin + LY326020) | |
| Capecitabine + Enzastaurin | 90000 | 40700 | 137000 |
Cmax for Capecitabine, 5'-deoxy-5-fluorouridine (5'-DFUR) and its metabolites 5-fluorouracil (5-FU) was calculated from the plasma concentration-time data for each analyte for Day 1 of Cycle 2. (NCT00437294)
Timeframe: From pre-dose to 6 hours post-dose on Day 1 of Cycle 2
| Intervention | micrograms/milliliter(ug/mL) (Geometric Mean) | ||
|---|---|---|---|
| Capecitabine | 5-DFUR | 5-FU | |
| Capecitabine + Enzastaurin | 4.42 | 6.09 | 0.374 |
| Capecitabine + Placebo | 2.75 | 6.05 | 0.206 |
Data presented are the number of participants who experienced serious AEs, AEs, death due to progressive disease (PD), death due to AEs while on treatment and death during the 30-day post-treatment. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module. (NCT00437294)
Timeframe: Baseline to study completion [Cycle 19 (21 days/cycle) and 30-day safety follow-up]
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Serious AEs | Other non-serious AEs | Deaths Due to PD | Deaths Due to AEs | Deaths in 30-day follow-up | |
| Capecitabine + Enzastaurin | 12 | 38 | 13 | 4 | 6 |
| Capecitabine + Placebo | 12 | 40 | 12 | 2 | 1 |
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
One-year survival estimate is reported. Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. This analysis was planned to occur when all patients had been potentially followed for 1 year. On the basis of a 1-year survival rate of 60% from the Radiation Therapy Oncology Group (RTOG) esophageal database, 38 analyzable patients with a 1-year survival rate of 77.5% or better was needed for this trial to be deemed promising enough for development of a Phase III protocol (type I error of 0.05 and type II error of 0.20). (NCT00069953)
Timeframe: From registration to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 1 year.
| Intervention | percentage of participants (Number) |
|---|---|
| ChemoRT and Selective Surgery | 71 |
Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure
| Intervention | months (Median) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | NA |
| Arm 2: Adjuvant Chemoradiation | NA |
The number of patients who complete the recommended therapy will be counted for each arm. (NCT03515941)
Timeframe: From date of assigned therapy up to 17 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | 3 |
| Arm 2: Adjuvant Chemoradiation | 2 |
DR was defined as the time from the first recorded response (CR/PR) to the date of first documented progression or death. CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 12.7 |
Disease progression was defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 70 |
OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. (NCT00811135)
Timeframe: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 40 |
Participants who had CR or PR were considered as responders. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 66 |
TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). TTP was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 62 |
OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. OS was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 31.8 |
Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.0. BOR was defined as the best response recorded for a participant from the start of treatment until disease progression/recurrence. Percentage of participants with a BOR of confirmed CR or PR (responders) was reported. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Confirmed responses were those which were confirmed by a repeat assessment, performed 4 weeks after the criteria for response first met. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 75.0 |
PFS was defined as the time from enrollment to time of first documented disease progression or death due to any cause, whichever occurred first. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 14.2 |
TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 14.5 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS
| Intervention | participants (Number) |
|---|---|
| Celecoxib 200mg | 0 |
| Celecoxib 400mg | 1 |
| Celecoxib 600mg | 2 |
Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response(CR) | Pathologic partial response (pPR) | Progressive disease (PD) | No evidence of disease (NED) | |
| Erlotinib + Celecoxib | 6 | 1 | 5 | 2 |
At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| locoregional control | progress-free survival | overall survival rates | long term toxicity | |
| Erlotinib + Celecoxib | 60 | 37 | 55 | 0 |
Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| free of disease | isolated locoregional progression | isolated distant progression | both locoregional and distant progression | no evidence of disease, died of comorbid illness | |
| Erlotinib + Celecoxib | 4 | 4 | 2 | 1 | 3 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
"Clinical exam included laryngoscopy in office or operating room.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 16 |
"Clinical exam included laryngoscopy in office or operating room.~Partial response rate (PR) defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 |
Time from complete response to death from any cause, to disease progression or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 93.529 |
Time from diagnosis to death or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 83.960 |
Time from initiation of induction chemotherapy to death due to disease progression, to disease progression, or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 38.675 |
(NCT00736944)
Timeframe: completion of the first 10 patients induction chemotherapy
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic reaction/hypersensitivity | Other allergic reaction:cipro | Other allergic reaction:hives | Hypotension | INR | Fatigue | Alopecia | Chelitis | Dry skin | Rash | Rash:acneiform | Rash:penile (unconfirmed HSV) | Anorexia | Colitis | Constipation | Dehydration | Dental:teeth | Diarrhea | Hemorrhoids | Nausea | Taste alteration | Vomiting | Other:soft stools | Hemoglobin | Leukocytes (WBC) | Lymphopenia | Neutrophils (ANC) | Platelets | Hemmorrhage:nose | Alkaline phosphatase | SGPT (ALT) | Infection other:sinus infection | Edema:limb | Albumin, low | Calcium, low | Magnesium, low | Potassium, low | Potassium, high | Sodium, low | Phosphorus | Dizziness | Mood alteration:anger | Neuropathy:sensory (peripheral) | Vision-photophobia | Pain:thigh | Pain:tumor pain | Hiccoughs (hiccups) | Obstruction/stenosis of airway:trachea | Creatinine | GFR | Renal failure | Thrombosis/thrombus/embolism | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 1 | 1 | 1 | 1 | 1 | 10 | 5 | 1 | 1 | 1 | 7 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 8 | 8 | 8 | 8 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 4 | 3 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 |
"Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 11 | 7 |
"Clinical exam included laryngoscopy in office or operating room.~Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 13 | 17 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 14 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 17 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 61 | 39 | 0 |
| CT Scan | 30 | 48 | 22 |
| FDG-PET/CT | 36 | 56 | 8 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 43 | 57 | 0 |
| CT Scan | 14 | 50 | 36 |
| FDG-PET/CT | 24 | 66 | 10 |
"In the future, primary tumor site, nodal, and OTR by VCR (CR-x or PR-x = Y or N) will be compared with response based on CT scan (CR-x or PR-x = Y or N) using a test for difference in paired, binary values. Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests.~We are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 53 | 47 | 0 |
| CT Scan | 33 | 41 | 26 |
| FDG-PET/CT | 32 | 61 | 7 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 2 | 4 | 1 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 | 0 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 4 | 1 | 2 | 0 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 19 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 12 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 10 | 11 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 4 | 14 |
(NCT00375999)
Timeframe: One year
| Intervention | month (Median) |
|---|---|
| Treatment Group | 13.4 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
A reduction of 50% in heart volume exposed to radiation doses ≥ 5 Gy/CGE was considered preferred outcome in this study plan. (NCT01365845)
Timeframe: 2 weeks prior to starting radiation therapy.
| Intervention | % of heart receiving >= 5 Gray (Gy) (Median) |
|---|---|
| Conventional Photon Plan | 34.7 |
| 3D-Proton/Conventional Plan or 3D-proton Only | 2.7 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
DNA was extracted from tumor specimens.Screened for the presence of KRAS codon 12 and 13 mutations using a PCR clamping and melting curve technique. PCR amplification of the wild-type KRAS sequence was suppressed in this process by the incorporation in the reaction mix of a locked nucleic-acid oligomer16 spanning codons 12 and 13 of the KRAS gene. Post-PCR hybridization and melting curve analysis using fluorescently tagged oligonucleotides incorporated in the original PCR reaction permitted the identification and discrimination of distinct KRAS codon 12 and 13 missense mutations. (NCT00815308)
Timeframe: 07/29/2010-09/30/2010
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 53 |
The overall response rate was defined as the numbers of patients with a complete response (CR) or partial response (PR). CR was defined as no target lesion at follow-up computed tomography scan and barium swallow examination 3-6 weeks after completion of chemo-radiation. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT00815308)
Timeframe: 1 to 3 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 44 |
All patients were regularly monitored for possible adverse events, which were graded according to National Cancer Institute Common Toxicity Criteria version 3.0. (NCT00815308)
Timeframe: Every week during treatment and 1 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 55 |
Local failure will be assessed radiographically using endoscopy with biopsy, CT scan, and a positron emission computed tomography-CT scan. which was defined as persistence /recurrence of the tumor in the radiation therapy field. (NCT03082586)
Timeframe: 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Radiochemotherapy 1 | 0 |
| Arm 2: Radiochemotherapy 2 | 1 |
| Arm 3: Radiochemotherapy 3 | 1 |
| Arm 4: Radiochemotherapy 4 | 0 |
| Arm 5: Radiochemotherapy 5 | 0 |
| Arm 6: Radiochemotherapy 6 | 0 |
The DLTs were defined as grade >/=4 esophatitis, any other grade >/=3 nonhematological toxicity (except nausea and vomiting), or grade >/=4 hematological toxicity lasting more than 7 days, which are possibly, probably, or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. (NCT03082586)
Timeframe: 15 months
| Intervention | dose limiting toxicity (Number) |
|---|---|
| Arm 1: Radiochemotherapy 1 | 0 |
| Arm 2: Radiochemotherapy 2 | 0 |
| Arm 3：Radiochemotherapy 3 | 0 |
| Arm 4: Radiochemotherapy 4 | 1 |
| Arm 5: Radiochemotherapy 5 | 0 |
| Arm 6: Radiochemotherapy 6 | 2 |
193 reviews available for fluorouracil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; DNA Mismatch Repair; Fluorouracil; | 2022 |
MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg | 2022 |
Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Chemoradiotherapy; Chemotherapy, Adju | 2022 |
Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Lo | 2022 |
Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
The potential roles of lncRNA TINCR in triple negative breast cancer.
Topics: Fluorouracil; Humans; Neoplasm Recurrence, Local; RNA, Long Noncoding; Triple Negative Breast Neopla | 2023 |
Intralesional 5-fluorouracil as a management for cutaneous squamous cell carcinomas: A rural Australian retrospective case series.
Topics: Aged; Aged, 80 and over; Australia; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Mi | 2023 |
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).
Topics: Anus Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as | 2019 |
FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Cycle Proteins; Colorectal N | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers.
Topics: Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Recurrence, Local; R | 2020 |
Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2021 |
[Squamous cell anal carcinoma. What's next ?]
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carboplatin; Ca | 2021 |
Ocular surface squamous neoplasia: management and outcomes.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Fluorouracil; Humans; Neoplasm Recu | 2021 |
Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer: A nationwide cohort study and meta-analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Disease | 2021 |
[A Case of Liver Metastasis of Colorectal Cancer in a Hemodialysis Patient, Underwent Liver Resection and Chemotherapy after Colorectal Resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Colorectal Neoplasms; Fluorouracil; | 2021 |
[Neoadjuvant treatment for rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical | 2021 |
Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Neoplasm Recurrence, Local; Skin Neoplasm | 2021 |
Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Fl | 2017 |
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
Topics: Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deglut | 2017 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2018 |
The Selective Use of Radiation Therapy in Rectal Cancer Patients.
Topics: Chemoradiotherapy; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Neop | 2018 |
[Oxaliplatin in colorectal carcinoma: from palliation to cure].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2004 |
Interventions for cutaneous Bowen's disease.
Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Cryotherapy; Fluoroura | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; H | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; H | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; H | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; H | 2013 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis.
Topics: Administration, Topical; Aminoquinolines; Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Fl | 2015 |
Anal cancer treatment: current status and future perspectives.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; C | 2015 |
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2015 |
Before or after: is there a connection between the use of adjunctive nonmelanoma skin cancer treatments and subsequent invasive tumors?
Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Fluorouracil; Humans; Imiquimod; Neop | 2015 |
Preoperative chemotherapy for resectable thoracic esophageal cancer.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Hum | 2015 |
Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2015 |
Localized Pancreatic Cancer: Multidisciplinary Management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouraci | 2016 |
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisp | 2008 |
Colon cancer: update on adjuvant therapy.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy P | 2008 |
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
The multidisciplinary management of rectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diagnostic Imaging; Digestive System Surgic | 2009 |
[Case of indwelling catheter dislocation into the duodenum during hepatic arterial infusion chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colonic Neoplasms; Duodenum; Fluorour | 2009 |
[Neoadjuvant radiochemotherapy for rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose Fractionation, Radia | 2009 |
Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Child; Child, Preschoo | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2009 |
[Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2011 |
[A surgical (pancreatoduodenectomy) case of lymph node metastatic recurrence of colon cancer after chemotherapy].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Duoden | 2010 |
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, | 2011 |
Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2011 |
Colorectal cancer treatment.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Ob | 2010 |
[Rectal cancer: current status of multimodal therapy--when and how?].
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy, Adjuvant; Combine | 2011 |
[State of art of the radiofrequency ablation of colorectal liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Catheter Ablation; Colorec | 2011 |
[Chemotherapy and rectal cancer].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2011 |
A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neopl | 2011 |
Radiation in vulvar cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Car | 2012 |
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Circadian Clocks; Colorectal Ne | 2012 |
Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Adjuvant therapy of colorectal cancer: the next step forward.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluo | 2002 |
[Recent advance in adjuvant therapy for breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
[Weekly administration of paclitaxel with a short course of premedication for advanced or recurrent gastric cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2003 |
Adjuvant radiation therapy of patients with rectal cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colectomy; Combined Modality Therapy; Dos | 2003 |
[Adjuvant and additive therapy for cancer of the pancreas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as T | 2003 |
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Primary adenosquamous carcinoma of the liver: case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Fatal Out | 2002 |
[Adjuvant therapy of rectal cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorour | 2003 |
Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Flox | 2003 |
Management of colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Balloon Occlusion; Catheter Ablation; Colorectal Neoplasms; Combine | 2003 |
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2003 |
[Adjuvant treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2003 |
[Therapeutic strategies in colorectal cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 2003 |
Current research directions for locally advanced cervix cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2003 |
[Cutaneous neoplasms].
Topics: Adjuvants, Immunologic; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bio | 2003 |
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2003 |
[Effect of systemic chemotherapy by 5-FU with low dose CDDP (in the hospital) and UFT with low dose CDDP (in outpatient clinic) in unresectable recurrent colorectal cancer].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2003 |
[Radiotherapy for locally relapsed rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Combined Modality Thera | 2003 |
[Guidance and informed consent in colon cancer therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluor | 2003 |
[Treatment for recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2003 |
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula | 2003 |
Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carbopl | 2004 |
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2004 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
[Sequencing of adjuvant treatment after surgery for invasive breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2004 |
Adjuvant therapy for rectal cancer in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cli | 2004 |
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Ep | 2004 |
Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality | 2004 |
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2004 |
[Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2004 |
[Taxol in advanced cervical cancer].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2004 |
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2005 |
Eliminating and suppressing local-regional disease in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Lymph | 2005 |
An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Digestive System Surgical Procedur | 2005 |
[Molecular biology in clinical cancer research: the example of digestive cancers].
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2005 |
Bilateral axillary metastasis from a primary ethmoidal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Squamous Cell; Cisplatin; Ethmoid | 2006 |
A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2006 |
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli | 2006 |
Surgical adjuvant therapy for colorectal cancer: current approaches and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial | 2006 |
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2006 |
[A case of recurrent biliary cystadenocarcinoma successfully treated with 5FU/CDDP systemic chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Cystadenocarcino | 2006 |
Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Adjuvant therapy for pancreatic cancer: to treat or not to treat?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Flu | 2007 |
Salvage oesophagectomy after local failure of definitive chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagea | 2007 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2007 |
[Preoperative treatments of rectal cancers].
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2007 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2008 |
Recurrent head and neck cancer: current treatment and future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
[Adjuvant chemotherapy in breast cancer: status in 1984].
Topics: Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Drug Th | 1984 |
Adjuvant systemic therapy in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical | 1984 |
Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous C | 1984 |
Treatment of skin cancer using multiple modalities.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrosurgery; Female; F | 1982 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1995 |
[Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994].
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1995 |
[Advances in the treatment of head and neck tumors. 2. Radiochemotherapy].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Mitomycin; Neop | 1995 |
Recurrent breast cancer: presentation, diagnosis, and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast | 1993 |
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 1995 |
[Treatment of metastases of colorectal cancers].
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Recurrence, Local | 1994 |
[Bowen's disease. A report of 9 cases].
Topics: Aged; Bowen's Disease; Diagnosis, Differential; Female; Fluorouracil; Humans; Male; Middle Aged; Neo | 1994 |
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1996 |
Adjuvant drug therapy for operable breast cancer.
Topics: Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Ad | 1996 |
Anal canal cancer: current treatment and results.
Topics: Anal Canal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1996 |
Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 1996 |
Meningeal carcinomatosis as the presenting manifestation of gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 1997 |
Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1997 |
Adjuvant therapy of colorectal cancer.
Topics: Adjuvants, Immunologic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemother | 1997 |
Results of local excision followed by postoperative radiation therapy for rectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Recurrence, | 1997 |
[Clinical evaluation of chemoradiotherapy for advanced cervical cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug | 1997 |
The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1997 |
[Treatment for recurrent head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Ce | 1998 |
[Treatment strategy for recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophospha | 1998 |
[Treatment of patients with recurrent esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1999 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 1999 |
[Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1999 |
Recent meta-analyses in colorectal cancer.
Topics: Adjuvants, Immunologic; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Follow-Up Stud | 2000 |
[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Hepat | 2000 |
[Capecitabine for treatment of advanced breast cancers].
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycyti | 2000 |
Treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Colorectal Ne | 2000 |
The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topi | 2001 |
Adjuvant chemotherapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2001 |
Clinical status of capecitabine in the treatment of breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topi | 2001 |
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
[MTX/5FU sequential therapy for advanced and recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Disseminated Intravascular Co | 2001 |
[Capecitabine (Ro09-1978) for therapy of advanced and recurrent gastric cancer].
Topics: Administration, Oral; Animals; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dihydrouracil | 2001 |
[Adjuvant therapy of breast cancer].
Topics: Adult; Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, H | 2001 |
Chemoradiotherapy for rectal cancer--is there an optimal combination?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials, Phas | 2001 |
Improving chemoradiotherapy in rectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Clinica | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2001 |
Invasive bladder cancer: organ preservation by radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2002 |
Pancreatic cancer: what the oncologist can offer for palliation.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Fluoroura | 2002 |
Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2001 |
Intrahepatic arterial infusion of chemotherapy: clinical results.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor | 2002 |
Recurrent vulvar cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluor | 2002 |
Breast cancer: chest wall recurrences.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Mastectomy; Neoplasm Recurrence, Local; Practice Gui | 2002 |
[Basic trends in the combined treatment of locally spread rectal cancer].
Topics: Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperati | 1979 |
[Treatment possibilities of laryngeal cancer. Surgery--radiotherapy--chemotherapy].
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Chemotherapy, Cancer, Regional Perfusion; Co | 1975 |
Treating the relapsed patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1992 |
The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.
Topics: Animals; Cell Division; Fluorouracil; Humans; Hydroxyurea; Neoplasm Recurrence, Local; Neoplasms; Ra | 1992 |
The value of adjuvant therapy after radical surgery for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 1992 |
[Combined approach to malignant tumors of the ethmoid and other paranasal sinuses. Principles and results].
Topics: Actuarial Analysis; Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Ethmo | 1991 |
[Adjuvant therapy in colonic carcinoma].
Topics: Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Levamisole; Neoplasm | 1991 |
[Concomitant association of radiotherapy and chemotherapy in inflammatory breast cancer. Initial results of phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
Current chemotherapy of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Clinical; Colonic Neoplas | 1990 |
Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterization, Ce | 1990 |
Management of colorectal cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hu | 1990 |
Management of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Injections, Intra | 1989 |
Surgical therapy of early rectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Fluorourac | 1989 |
[5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; | 1989 |
Phase I/II study of definitive radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) for advanced or recurrent gynecologic malignancies. Preliminary report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C | 1989 |
Adjuvant cytotoxic chemotherapy for colorectal cancer: the present position.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1988 |
Chemotherapy of primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl | 1985 |
Colorectal cancer: surgical management of recurrent and metastatic disease.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Rectal Neoplas | 1988 |
Colorectal cancer. Are adjuvant therapies beneficial?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 1988 |
Adjuvant therapy of colorectal cancer. Why we still don't know.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neopla | 1988 |
The use of topical 5-fluorouracil in the treatment of genital condylomas.
Topics: Administration, Topical; Combined Modality Therapy; Condylomata Acuminata; Female; Fluorouracil; Gen | 1987 |
Adjuvant systemic therapy for resectable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1985 |
[Adjuvant chemotherapy following radical operations for cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Com | 1985 |
Patterns of metastasis and natural courses of breast carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bre | 1985 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
Controversies in the management of potentially curable breast cancer.
Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph | 1974 |
The use of cytotoxic drugs in the surgery of malignant disease.
Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma, | 1968 |
Newer concepts in chemotherapy of cancer.
Topics: Breast Neoplasms; Colonic Neoplasms; Dysgerminoma; Female; Fluorouracil; Humans; Injections, Intra-A | 1972 |
Management of cancer of the colon.
Topics: Colitis, Ulcerative; Colon; Colonic Diseases; Colonic Neoplasms; Diagnostic Errors; Fluorouracil; Hu | 1974 |
Chemotherapy of squamous cell carcinoma of the cervix, vagina, and vulva.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Female; F | 1968 |
Chemotherapy of breast cancer.
Topics: Adrenal Cortex Hormones; Alkaloids; Alkylating Agents; Androgens; Antimetabolites; Antineoplastic Ag | 1968 |
873 trials available for fluorouracil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Fe | 2021 |
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Fatigue; Fluorourac | 2022 |
Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoplasm Recu | 2022 |
Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2022 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytid | 2022 |
Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Fluorour | 2022 |
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
Topics: Adenocarcinoma; Capecitabine; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm | 2022 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adju | 2022 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adju | 2022 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adju | 2022 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adju | 2022 |
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell | 2022 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, | 2022 |
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2022 |
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms | 2022 |
Long-term results of a phase 2 study of neoadjuvant chemotherapy with molecularly targeted agents for locally advanced rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Follow-Up Studi | 2023 |
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Fluorouracil; Human | 2023 |
Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; | 2023 |
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Fluorouracil; Humans; | 2023 |
Preoperative Treatment of Locally Advanced Rectal Cancer.
Topics: Adult; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, | 2023 |
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fluorouracil; Human | 2023 |
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPL
Topics: Adenocarcinoma; Clinical Trials, Phase II as Topic; Esophagogastric Junction; Fluorouracil; Humans; | 2023 |
Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2019 |
Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant | 2019 |
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2019 |
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemot | 2020 |
Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 2020 |
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progress | 2020 |
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2020 |
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Prote | 2020 |
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neo | 2020 |
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2020 |
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2020 |
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2020 |
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neopla | 2020 |
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): Long-term results of survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2020 |
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2020 |
NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Ad | 2020 |
NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, | 2020 |
Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Flu | 2020 |
Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi | 2020 |
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free | 2020 |
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Ad | 2020 |
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2021 |
Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoad | 2021 |
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free S | 2021 |
Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Fluor | 2021 |
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free S | 2021 |
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2021 |
Tumor regression grading after preoperative hyperfractionated radiotherapy/chemoradiotherapy for locally advanced rectal cancers: interim analysis of phase III clinical study.
Topics: Chemoradiotherapy; Dose Fractionation, Radiation; Fluorouracil; Humans; Neoplasm Recurrence, Local; | 2021 |
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Topics: Aged; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Dose Fractionation, Radiation; Drug | 2021 |
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Topics: Anal Canal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2021 |
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2021 |
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free | 2017 |
Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
Topics: Adult; Age of Onset; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pro | 2017 |
Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Image Interp | 2018 |
Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colectomy | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2017 |
Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2017 |
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2019 |
Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer.
Topics: Aged; Antigens, Neoplasm; Carbonic Anhydrase IX; Chemoradiotherapy; Combined Modality Therapy; Femal | 2018 |
Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Drug Combinations; Female; Fl | 2018 |
Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Disease-Free | 2017 |
Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cetuximab; Chemoradioth | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Sur | 2018 |
Preoperative radiotherapy and local excision of rectal cancer: Long-term results of a randomised study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Mo | 2018 |
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, | 2018 |
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; CpG | 2018 |
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Doce | 2019 |
mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2019 |
Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2019 |
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chem | 2019 |
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2019 |
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bridged-Ring Compounds; C | 2019 |
Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradioth | 2019 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolid | 2019 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolid | 2019 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolid | 2019 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolid | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2019 |
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esoph | 2020 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2013 |
Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxyc | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2013 |
[Neoadjuvant chemotherapy and radiation therapy of resectable cancer recti of distal localization].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Surviv | 2013 |
Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous C | 2013 |
Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2013 |
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumo | 2013 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemot | 2013 |
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Col | 2013 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, A | 2013 |
A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2013 |
Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Anus Neoplasms; Cetuximab; Chemoradiotherapy; Cispla | 2013 |
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2013 |
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disea | 2014 |
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2013 |
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Ci | 2014 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Ci | 2014 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Ci | 2014 |
Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Ci | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2014 |
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
[ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisp | 2013 |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; | 2015 |
Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Metastatic nasopharyngeal carcinoma outcomes in patients on cisplatin with nolatrexed or 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispl | 2014 |
The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2015 |
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2015 |
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2015 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2014 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2014 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2014 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2014 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2014 |
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2015 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2015 |
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr
Topics: Adult; Aged; Capecitabine; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation | 2015 |
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2016 |
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2015 |
Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Surviva | 2015 |
p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cyclophos | 2015 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 2015 |
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; | 2015 |
Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2015 |
[Immediate results of combined therapy for local recurrences of rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2015 |
Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemor | 2015 |
Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2015 |
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female | 2015 |
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoem | 2015 |
Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2015 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combin | 2016 |
Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2015 |
Phase II study of computed tomography-guided (125)I-seed implantation plus chemotherapy for locally recurrent rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Camptoth | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2016 |
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2016 |
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ch | 2016 |
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2016 |
Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Carcinoma, Basal Cel | 2016 |
Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Topical; Adult; Antimetabolites, Antineoplastic; Carcinoma; Double-Blind Method; Eye | 2016 |
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Co | 2016 |
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2016 |
No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2016 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycyt | 2016 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
[Neoadjuvant short-term radiotherapy followed by FOLFOX chemotherapy : No standard treatment for rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil; Guide | 2016 |
Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma.
Topics: Adenoviruses, Human; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradioth | 2017 |
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2016 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fluorouracil; F | 2016 |
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2017 |
Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev | 2017 |
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; | 2017 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradi | 2017 |
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2017 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Female; Fluoro | 2008 |
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2008 |
Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colo | 2008 |
A modern regimen of pre-operative concurrent chemo-radiation therapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modalit | 2008 |
A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2008 |
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2008 |
[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diseas | 2008 |
Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe?
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Human | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
[Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytid | 2009 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
[A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2008 |
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2008 |
Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt | 2008 |
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2009 |
A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Fluorouracil; Humans; Infusion Pu | 2009 |
Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Adjuvant chemotherapy in older women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2009 |
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence In | 2009 |
Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2009 |
Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Feasibility | 2009 |
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2010 |
Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le | 2009 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2010 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2009 |
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2010 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Resp | 2010 |
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doce | 2010 |
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2011 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administrati | 2010 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administrati | 2010 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administrati | 2010 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administrati | 2010 |
Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2010 |
[Preliminary study of XELOX regimen as the first-line chemotherapy in advanced or recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2010 |
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouraci | 2010 |
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Ther | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deo | 2010 |
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; C | 2010 |
Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.
Topics: Age Factors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2011 |
Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2011 |
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; B | 2010 |
Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2011 |
Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up.
Topics: Antineoplastic Agents; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fracti | 2011 |
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Diagnostic | 2011 |
[A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2010 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2011 |
Phase II trial of capecitabine and cisplatin in advanced, persistent, or recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Hu | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitab | 2012 |
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant | 2011 |
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2011 |
Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Adenosq | 2011 |
Multimodality approach in extra cervical locally advanced cervical cancer: chemoradiation, surgery and intra-operative radiation therapy. A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-Square Dist | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistanc | 2011 |
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2012 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Duc | 2012 |
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2011 |
Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2011 |
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2011 |
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2012 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fl | 2011 |
Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2011 |
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxyc | 2011 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2011 |
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2012 |
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2012 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Feas | 2012 |
Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modal | 2012 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycyt | 2011 |
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarke | 2012 |
Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; | 2012 |
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Ant | 2013 |
Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Surv | 2012 |
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Circadian Clocks; Colorectal Ne | 2012 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2013 |
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-F | 2012 |
Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2012 |
Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2013 |
Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 2013 |
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology G
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy, Ad | 2012 |
Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Administration Schedul | 2012 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2013 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2002 |
Predictive value of (99m)Tc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 2002 |
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplasti | 2002 |
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adju | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona | 2001 |
Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2002 |
[Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breas
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotecti | 2002 |
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2003 |
Loco-regional failures in head and neck cancer: can they be effectively salvaged by nonsurgical therapeutic modalities?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 2003 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Doc | 2003 |
A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Dru | 2003 |
5-Fluorouracil and cisplatin in the treatment of advanced oral cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dru | 2003 |
Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 2003 |
PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorodeoxyglucose F18; Fluoro | 2003 |
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Deat | 2003 |
Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2004 |
A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Brachytherapy boost to the tumour bed in high risk patients after limited surgery for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast Neoplasms; Cyclop | 2003 |
Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2003 |
Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Su | 2003 |
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2003 |
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2003 |
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Chemotherapy, Adjuvant | 2003 |
First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2003 |
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2003 |
[Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2003 |
[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2003 |
Postoperative chemoradiotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Follow | 2003 |
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatogr | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2003 |
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
[Interim analysis of a prospective, randomized multi-center study by the "Liver Metastases" Study Group: adjuvant intra-arterial chemotherapy after curative liver resection of colorectal metastases].
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1998 |
[Preoperative chemoradiotherapy for locally advanced rectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; | 2003 |
[The modern organ- and function-sparing surgical treatment in oncology].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitab | 2003 |
Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2003 |
Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2004 |
Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Femal | 2004 |
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2004 |
Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 2004 |
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colorectal Neoplas | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 2004 |
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cycloph | 2004 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Mo | 2004 |
Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2004 |
[Rationale and progress of the phase III trial: intensification of the treatment of locally advanced squamous cell carcinoma of the anal canal].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2003 |
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit | 2004 |
Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas | 2004 |
Therapeutic evaluation of intralesional 5% 5-fluorouracil in condyloma acuminata.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Condylomata Acuminata; Female; Fluorouraci | 2004 |
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2004 |
Regional pelvic hyperthermia as an adjunct to chemotherapy (oxaliplatin, folinic acid, 5-fluorouracil) in pre-irradiated patients with locally recurrent rectal cancer: a pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combine | 2004 |
The toxicity rates of two different regimens of irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2003 |
Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2004 |
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of | 2004 |
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorourac | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2004 |
Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorou | 2004 |
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized c
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chi-Square Distribution; Eso | 2004 |
Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
[Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Cispla | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2004 |
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2004 |
Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Ifosfamide; | 2005 |
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2005 |
A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docet | 2004 |
Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2005 |
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; British Columbia; Chemotherapy, Ad | 2005 |
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; British Columbia; Chemotherapy, Ad | 2005 |
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; British Columbia; Chemotherapy, Ad | 2005 |
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; British Columbia; Chemotherapy, Ad | 2005 |
Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovo | 2005 |
Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Duodenal Neoplas | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2005 |
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Diseas | 2005 |
Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dose Fractionation, Radia | 2005 |
Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relatio | 2005 |
Noninvasive magnetic resonance thermography of recurrent rectal carcinoma in a 1.5 Tesla hybrid system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidi | 2005 |
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2005 |
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2005 |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survi | 2005 |
Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2005 |
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2005 |
Benefits of axillary radiotherapy unclear in women with early stage breast cancer undergoing conservative breast surgery without axillary dissection.
Topics: Antineoplastic Agents; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Female; F | 2005 |
A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2005 |
A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A | 2006 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil | 2006 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Topics: Adult; Age Distribution; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2005 |
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemot | 2005 |
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined M | 2006 |
French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Combined Modality Therapy; Dose Fractionat | 2006 |
Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bayes Theorem; Brea | 2006 |
Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy | 2006 |
A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2006 |
A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasm | 2006 |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2006 |
Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose- | 2006 |
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuv | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic | 2006 |
Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2006 |
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2006 |
Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 2006 |
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2006 |
Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 2006 |
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2006 |
Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: a case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Che | 2006 |
[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2006 |
A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2006 |
5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 2006 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Ten-year follow-up results of a randomised controlled study comparing level-I vs level-III axillary lymph node dissection for primary breast cancer.
Topics: Antineoplastic Agents; Axilla; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; F | 2006 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2007 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2007 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2007 |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; | 2007 |
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2007 |
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modal | 2007 |
Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Do | 2006 |
[Prophylactic hepatic arterial infusion chemotherapy after curative surgery of colorectal liver metastases--the viewpoint from patients' quality of life].
Topics: Angiography; Catheterization; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, | 2006 |
Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; F | 2007 |
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined | 2007 |
Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 2007 |
Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2007 |
The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Colum
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophospham | 2007 |
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2007 |
Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2007 |
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2007 |
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2007 |
Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2007 |
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2007 |
A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2007 |
Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2007 |
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2007 |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2007 |
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease P | 2007 |
Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ch | 2007 |
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxyc | 2007 |
An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Combined Modalit | 2007 |
A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cisplatin; Deo | 2007 |
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capec | 2007 |
[Impact of perioperative chemotherapy on prognosis of colorectal cancer: a report of 82 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Ther | 2008 |
Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comorbidity; Cyclopho | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2008 |
Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Dr | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 2008 |
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2008 |
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow | 2008 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Neo | 1981 |
Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Car | 1981 |
Pre- and postoperative chemoendocrine treatment with or without postoperative radiotherapy for locally advanced breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubic | 1983 |
Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Fema | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Fluorouracil; Gastrectomy | 1983 |
Combined modality approach in breast cancer with isolated or multiple metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1984 |
Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; | 1983 |
Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1983 |
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1983 |
Adjuvant therapy of colon cancer--results of a prospectively randomized trial.
Topics: BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Drug Therapy, C | 1984 |
Systemic therapy for superficial bladder cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma in Situ; Cisplatin; Clinical Trials as Topic; Cyclophospha | 1984 |
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1984 |
Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Clinical Trials as Topic; | 1984 |
Treatment of breast carcinoma recurrent after adjuvant chemoimmunotherapy.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasm | 1984 |
Adjuvant systemic therapy in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical | 1984 |
Short- or long-term chemotherapy for node-positive breast cancer: LMF 6 versus 18 cycles. SAKK study 27/76.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Clinical Trials as T | 1984 |
A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
[Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouraci | 1984 |
[Comparative study on two different types of tegafur for recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Delayed-Action Preparations; Drug Eva | 1984 |
Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastroint
Topics: Adenocarcinoma; Clinical Trials as Topic; Colectomy; Combined Modality Therapy; Fluorouracil; Follow | 1984 |
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1984 |
Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Re | 1984 |
Comparison of 5-fluorouracil and CO2 laser for treatment of vaginal condylomata.
Topics: Adolescent; Adult; Condylomata Acuminata; Female; Fluorouracil; Humans; Laser Therapy; Neoplasm Recu | 1984 |
[Prospective randomized study in advanced stomach cancer. Comparison between combinations of 5-fluorouracil and carmustine without and with adriamycin].
Topics: Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Leukocyte Cou | 1984 |
Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1982 |
Use of methotrexate and 5-FU for recurrent head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diarrhea; Drug Therapy, Combination | 1982 |
Multimodal treatment in operable breast cancer: five-year results of the CMF programme.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination | 1981 |
Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil.
Topics: Carcinoma; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; H | 1981 |
A prospective trial of 5-FU and BCNU in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; | 1981 |
A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr | 1981 |
The current status of systemic adjuvant therapy in the management of primary breast cancer.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combin | 1981 |
Adjuvant chemotherapy with chlorambucil and 5-fluorouracil in primary breast cancer (Cooperative Study Heidelberg).
Topics: Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorou | 1980 |
Divergent effect of adjuvant chemo-immunotherapy on recurrence rates in node-negative and node-positive breast cancer patients.
Topics: BCG Vaccine; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Fe | 1980 |
Follow-up adjuvant chemotherapy and chemoimmunotherapy for stage II and III carcinoma of the breast.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr | 1982 |
Favorable factors in the adjuvant therapy of breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1982 |
Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug A | 1982 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphami | 1982 |
A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clin | 1982 |
Combined adjuvant therapy of radically operated colorectal cancer patients. (chemotherapy, radiotherapy, and MER-BCG).
Topics: Adult; Aged; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Male; Midd | 1982 |
Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studi | 1981 |
Antiestrogen, cytotoxic chemotherapy, and bacillus Calmette-Guerin vaccination in stage II breast cancer: a preliminary report.
Topics: Actuarial Analysis; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema | 1980 |
Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin.
Topics: Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Erythrocyte Count; Female; Fluorouracil; | 1980 |
Phase II study of cisplatin, 5-fluorouracil and interferon-alpha in recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 1995 |
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1994 |
Intra-arterial chemotherapy using a reservoir for endocrine-refractory prostate cancer.
Topics: Abdominal Muscles; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1994 |
A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplati | 1995 |
[Postoperative adjuvant arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 1995 |
[Preventive chemotherapy for residual liver after resection of hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Hu | 1995 |
[Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1995 |
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Su | 1995 |
[Clinico-pathological studies on three preoperative combined treatments for rectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Hyper | 1995 |
p53 expression and the result of adjuvant therapy of breast cancer.
Topics: Aneuploidy; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combi | 1995 |
[High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories].
Topics: Chemotherapy, Adjuvant; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplas | 1995 |
[Clinical evaluation of sequential MTX/5-FU therapy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; Humans; | 1995 |
[Is radiotherapy necessary in the control of colorectal cancer?].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Cobalt Radioisotopes; Colectomy; Colonic | 1995 |
Alternating chemo-radiotherapy in bladder cancer: a conservative approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Adjuvant; Ci | 1995 |
Interferon as an adjuvant treatment for genital condyloma acuminatum.
Topics: Adolescent; Adult; Combined Modality Therapy; Condylomata Acuminata; Female; Fluorouracil; Genital N | 1995 |
[A pilot study of combined chemotherapy using methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) for advanced or recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Fem | 1995 |
Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1993 |
The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1995 |
Intraoperative radiotherapy for primary and recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 1995 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intestine, Small; Leucovorin; Neopl | 1995 |
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1995 |
[A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (surgery group evaluation)].
Topics: Adolescent; Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 1995 |
[A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)].
Topics: Adolescent; Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 1995 |
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 1995 |
Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case | 1995 |
Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.
Topics: Adult; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Th | 1995 |
Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigator
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1995 |
[Clinical study of ambulatory cancer chemotherapy for recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1994 |
[Effect of continuous infusion of 5-fluorouracil and daily low-dose cisplatin for inoperable recurrent cancer of the stomach and colon].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasm | 1995 |
Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer--toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Institution study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Cyclophosphamide | 1995 |
Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1995 |
Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1995 |
A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Resistance; | 1995 |
5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1995 |
[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Dizziness; Dru | 1995 |
Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil | 1994 |
A phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Fluorouracil; H | 1995 |
Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1994 |
Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Mod | 1994 |
[Efficacy of intrahepatic arterial chemotherapy to prevent recurrence of residual liver in metastatic liver cancer patients after hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Epirubicin; Female; Fluorou | 1994 |
[Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Do | 1994 |
[Hepatic arterial infusion after hepatectomy for liver metastases of colorectal carcinoma to prevent residual hepatic recurrence].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Floxuridine; Flu | 1994 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
[Intra-arterial infusion chemotherapy for recurrent breast cancer via an implantable system--the second report].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1994 |
Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1994 |
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
A clinical trial of continuous cisplatin-fluorouracil induction chemotherapy and supracricoid partial laryngectomy for glottic carcinoma classified as T2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 1994 |
A phase II trial of ifosfamide, 5-fluorouracil, and leucovorin in recurrent uterine cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Female; Fluo | 1994 |
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherap | 1994 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1994 |
[Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 1994 |
[Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1994 |
Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovor | 1994 |
Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms | 1994 |
A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 1994 |
[Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1993 |
[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy]
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Ch | 1994 |
A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middl | 1993 |
[Combination therapy with low dose adriamycin for advanced or recurrent breast cancer. Hokkaido Breast Cancer Treatment Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1993 |
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.
Topics: Aged; Brachytherapy; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; | 1993 |
Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; B | 1995 |
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 1995 |
[Simultaneous radiochemotherapy in recurrent and metastatic breast neoplasm. Clinical experience].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1995 |
Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1995 |
Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 1995 |
[Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 1995 |
Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1996 |
A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1995 |
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1996 |
Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1996 |
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Flu | 1996 |
Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 1996 |
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1996 |
Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1996 |
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1996 |
Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1996 |
A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Antidotes; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; | 1996 |
A phase I study of methotrexate administration following 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug A | 1996 |
5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Epirubicin; Female; Fluorour | 1996 |
[Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy].
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1995 |
[Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Col | 1995 |
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer--the second report].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatectomy; Hepatic Artery; Human | 1996 |
[The preventive effect of weekly high-dose 5-FU infusion (WHF) after resection of hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; H | 1996 |
[Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Ad | 1996 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent pelvic tumors with or without radiotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1996 |
[Intra-arterial infusion chemotherapy for breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fema | 1996 |
Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modalit | 1996 |
Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1996 |
Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; | 1996 |
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 1996 |
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
[Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coloni | 1997 |
Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Carcinoma; Dose-Response Relationship, Drug; Fem | 1997 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1997 |
Fluorouracil and high-dose leucovorin with radiotherapy as adjuvant therapy for rectal cancer. Results of a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 1997 |
Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bleomy | 1997 |
Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1997 |
Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1997 |
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1997 |
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergi | 1997 |
Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 1997 |
Breast conserving therapy in stage I & II breast cancer in Korea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1997 |
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1997 |
[Optimization of combined radiotherapy and chemotherapy in treatment of non-small cell lung carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Effects of intravesical instillation of 5-fluorouracil and interferon in patients with recurrent superficial urinary bladder carcinoma. A clinical and pharmacodynamic study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 1997 |
Concurrent chemoradiotherapy for salvage in relapsed squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent cervical cancer with or without radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 1997 |
[Clinical efficacy of post-TUR prophylactic chemotherapy for superficial bladder cancer--the result of co-operative prospective randomized trial].
Topics: Administration, Intravesical; Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, An | 1997 |
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 1997 |
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1997 |
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1997 |
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1997 |
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1997 |
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1997 |
Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1997 |
Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1997 |
Refractory breast cancer: a comparison of two different chemotherapy regimens.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Ant | 1997 |
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1998 |
Postoperative adjuvant radiotherapy and 5-fluorouracil chemotherapy for rectal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hu | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1998 |
Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1998 |
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neopla | 1998 |
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosph | 1998 |
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1998 |
Long-term follow-up of a randomized trial on adjuvant chemotherapy and hormonal therapy in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 1998 |
[Pelvic wall recurrence of cervix carcinomas. Combined surgical-radio-chemotherapeutic procedure (CORCT)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant; | 1998 |
Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1998 |
5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Squamous Cell | 1998 |
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fl | 1998 |
Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubici | 1998 |
[A randomized controlled trial with methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) vs 5-FU alone in advanced or recurrent gastric carcinoma. Tokai Hokuriku THP Study Group].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1998 |
Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 1998 |
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free S | 1998 |
A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; | 1999 |
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combin | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 1999 |
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1999 |
A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1999 |
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
[Adjuvant chemotherapy after curative surgery for non-metastatic colorectal carcinomas (2-year results of 52 cases)].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colo | 1999 |
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 1999 |
Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclop | 1999 |
[A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylati | 1999 |
The effects of Chinese drugs for supporting healthy energy and removing blood stasis on postoperative metastasis of gastric carcinoma and ornithine decarboxylase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubic | 1998 |
Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; | 1999 |
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administrat | 1999 |
Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cispl | 1999 |
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neo | 1999 |
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cycl | 1999 |
Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial.
Topics: Administration, Intravaginal; Adult; Antimetabolites, Antineoplastic; CD4 Lymphocyte Count; Female; | 1999 |
[Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Cyclopho | 1999 |
[Effect of combination chemotherapy with multiple drugs (FLMP therapy) based on the circadian rhythms of the human body in advanced recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Administrati | 1999 |
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1999 |
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis | 1999 |
Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl | 1999 |
Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Ant | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Diseas | 2000 |
Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Di | 2000 |
A phase III randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer.
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Floxuridin | 2000 |
A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Huma | 2000 |
Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch | 2000 |
[Consolidation radiotherapy after high-dose chemotherapy and autologous bone marrow transplantation in patients with advanced breast cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2000 |
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2000 |
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2000 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cell Division | 2000 |
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adenoviruses, Human; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2000 |
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2000 |
Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters.
Topics: Age Factors; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Follo | 2000 |
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
Topics: Adenoviruses, Human; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2000 |
A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disea | 2000 |
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2000 |
Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2000 |
Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer?
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Arteries; Bleo | 2000 |
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuv | 2000 |
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Co | 2001 |
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adj | 2001 |
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adj | 2001 |
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adj | 2001 |
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adj | 2001 |
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2001 |
Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2001 |
Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neopl | 2001 |
Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.
Topics: Abdominal Neoplasms; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined | 2001 |
A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Ne | 2001 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2001 |
Regional plus systemic chemotherapy: an effective treatment in recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 2001 |
Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
[Randomized trial of adjuvant chemotherapy with or without radiotherapy in rectal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2001 |
Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyc | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2001 |
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Ne | 2001 |
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Intraoperative electron beam radiotherapy during radical surgery for locally advanced and recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 2001 |
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada | 2001 |
Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2001 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2001 |
A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP).
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2001 |
[FLEP therapy for advanced and recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2001 |
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Fr | 2001 |
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Fr | 2001 |
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Fr | 2001 |
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Fr | 2001 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Sur | 2001 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2001 |
[Preliminary clinical evaluation of continuous infusion of 5-FU and low-dose Cisplatin (LFP) therapy alone and combined with radiation therapy for treatment of advanced or recurrent esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2002 |
Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antig | 2002 |
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2002 |
Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 2002 |
Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Moda | 2002 |
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2002 |
Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Cost-Benefit Analys | 2002 |
Continuous infusion low-dose CDDP/5-FU plus radiation in inoperable or recurrent non-small-cell lung cancer: preliminary experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2002 |
Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe?
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2002 |
Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil.
Topics: Administration, Oral; BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Fol | 1976 |
Multimodal therapy for histological stage-II breast cancer. Multicentre Breast Cancer Chemotherapy Group.
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluor | 1977 |
Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer.
Topics: Adult; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; D | 1978 |
[Chemotherapy of advanced prostate cancer].
Topics: Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Eval | 1977 |
Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Follow-Up Studies; Humans; Mouth Neoplasms; Neoplasm Metasta | 1976 |
L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU).
Topics: Adenocarcinoma, Mucinous; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials | 1977 |
Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, C | 1977 |
Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients. Intermediate report of a randomized trial in 242 patients.
Topics: Administration, Oral; Aged; BCG Vaccine; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; F | 1978 |
[Survival of 5-fluorouracil-treated stomach cancer patients in the far-advanced stages].
Topics: Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Gastrectomy; Humans; Kinetics; Neoplasm Met | 1978 |
Chemotherapy in ovarian carcinoma recurrent after radiation therapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Female; Fluorourac | 1978 |
Pancreatic cancer treated with carmustine, fluorouracil, and spironolactone: a randomized study.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neopl | 1978 |
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
Topics: Carcinoma; Cyclophosphamide; Evaluation Studies as Topic; Fluorouracil; Humans; Male; Neoplasm Recur | 1976 |
[Neoadjuvant chemotherapy in combined treatment of breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1992 |
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1992 |
Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuv | 1992 |
Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group.
Topics: Administration, Intravesical; Administration, Oral; Aged; Chemotherapy, Adjuvant; Doxorubicin; Femal | 1992 |
Results of adjuvant chemotherapy for invasive uroepithelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 1992 |
Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1992 |
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; F | 1992 |
The value of adjuvant therapy after radical surgery for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Swiss adjuvant trials in women with node-negative breast cancer. OSAKO.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chlorambuc | 1992 |
Chemotherapy versus observation in high-risk node-negative breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1992 |
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla | 1990 |
Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Ce | 1991 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1992 |
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
Systemic adjuvant therapy in women with resected node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1991 |
[Concomitant association of radiotherapy and chemotherapy in inflammatory breast cancer. Initial results of phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
Adjuvant therapy with hepatic irradiation plus fluorouracil in colon carcinoma. The Gastrointestinal Tumor Study Group.
Topics: Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Liver; Male | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Combined Modality Therapy; Deglutition Disorders; Esoph | 1991 |
[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Colorectal Neoplasms; Combined Mo | 1990 |
[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supp
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; F | 1990 |
[Early phase II study of the combined use of AO-90 methionine-free amino acid solution and anticancer agents (5-FU and MMC) in patients with advanced and recurrent gastrointestinal cancer. AO-90 Study group].
Topics: Adult; Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1990 |
Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. A prospective, randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1990 |
A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 1990 |
[Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cisplatin | 1990 |
[Adjuvant chemotherapy improves chances of survival in curative surgery of colon cancer, Dukes' stage C].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1990 |
Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1990 |
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinom | 1990 |
Treatment of extensive vulvar condylomata acuminata with topical 5-fluorouracil.
Topics: Administration, Topical; Adolescent; Adult; Combined Modality Therapy; Condylomata Acuminata; Drug A | 1990 |
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1990 |
Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1987 |
Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
[Intra-arterial chemotherapy with methotrexate and 5-fluorouracil in extensive locoregional recurrences of cervix cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouracil; Huma | 1988 |
[Can the occurrence of extrahepatic metastases in regional chemotherapy of the liver be prevented by adding systemic chemotherapy? A randomized multicenter study].
Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps | 1989 |
Conservation therapy of breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials a | 1989 |
Combination chemotherapy with etoposide and 5-fluorouracil in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combinat | 1989 |
[Studies of second-look operations (SLO) in ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphami | 1989 |
Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1989 |
Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Results of a multicentric randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1989 |
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
Topics: Aged; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Interaction | 1989 |
The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1989 |
A randomized controlled study of (2"R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1989 |
Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; C | 1989 |
Salvage treatments in relapsing resectable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
[Adjuvant 5-fluorouracil lacquer administration for reducing the rate of recurrence of condylomata acuminata following laser surgery treatment].
Topics: Adult; Combined Modality Therapy; Condylomata Acuminata; Fluorouracil; Genital Neoplasms, Male; Huma | 1989 |
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Levamisole; Lymp | 1989 |
Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; C | 1989 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1988 |
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1989 |
Continuous infusion fluoropyrimidines as salvage therapy for patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Mi | 1988 |
Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid | 1986 |
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1988 |
Adjuvant therapy of colorectal cancer. Why we still don't know.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neopla | 1988 |
Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukocyte M | 1987 |
Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1987 |
Recurrence patterns in a prospective study of patients with stage II breast cancer treated with endocrine-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as To | 1987 |
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1987 |
Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 1987 |
Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Clinical Trials as To | 1986 |
Local control and survival in early breast cancer: the Milan trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1986 |
Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Tr | 1986 |
[Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clini | 1986 |
Fluorouracil in chemoprophylaxis of colorectal cancer. Results of a controlled clinical trial.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; | 1986 |
Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1987 |
Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results.
Topics: Administration, Intravesical; Administration, Oral; Aged; Carcinoma, Transitional Cell; Combined Mod | 1987 |
[A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxoru | 1986 |
Age as a prognostic factor in recurrent breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1986 |
Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina.
Topics: Administration, Intravaginal; Administration, Topical; Carcinoma in Situ; Combined Modality Therapy; | 1986 |
The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1985 |
Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
Adjuvant systemic therapy for resectable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1985 |
A randomized trial of oral 5-fluorouracil versus placebo as adjuvant therapy in colorectal cancer Dukes' B and C: results after 5 years observation time.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Double-Blind Method; Fluorou | 1985 |
A randomized controlled trial of prophylactic cytotoxic chemotherapy in potentially curable breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clin | 1985 |
[Adjuvant chemotherapy following radical operations for cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Com | 1985 |
Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer.
Topics: Adult; Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorourac | 1985 |
Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.
Topics: Adult; Catheters, Indwelling; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colo | 1985 |
Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group study (76-16).
Topics: Abscess; Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1985 |
[Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1985 |
[A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Administrat | 1985 |
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans | 1986 |
Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study.
Topics: Chemical and Drug Induced Liver Injury; Cholestasis; Colonic Neoplasms; Combined Modality Therapy; F | 1985 |
Combination chemo-radiotherapy for residual, recurrent or inoperable carcinoma of the rectum: E.C.O.G. study (EST 3276).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality Therapy; Fem | 1985 |
Controversies in the management of potentially curable breast cancer.
Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph | 1974 |
Cancer of the gastrointestinal tract. Radiation therapy.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurr | 1974 |
A pilot study for the evaluation of a new regime of combined therapy for the radical treatment of marginally operable rectal (or colo-rectal) cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studies as Topic; Female; Fluor | 1974 |
[Therapeutic trial with 5-fluorouracil ointment].
Topics: Adult; Aged; Carcinoma, Basal Cell; Clinical Trials as Topic; Evaluation Studies as Topic; Facial Ne | 1970 |
Chemotherapy in primary therapy of cancer of the breast.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mast | 1967 |
Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.
Topics: Adult; Aged; Axilla; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouraci | 1968 |
Complications and toxic manifestations of surgical adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Blood Cell Count; Blood Platelets; Blood Transfusion; Breast Neoplasms; Clinical Trials | 1968 |
1622 other studies available for fluorouracil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemoradiotherapy; Cli | 2022 |
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2022 |
Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Humans; | 2021 |
[A Case of Advanced Gastric Cancer Successfully Treated with mFOLFOX6 Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Neopla | 2021 |
[A case of pembrolizumab responding to recurrent small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome].
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pr | 2021 |
PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Esophageal Squa | 2022 |
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Drug Combinations; Fluorouraci | 2021 |
Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals.
Topics: Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit Analysis; Fluorouracil; Hospit | 2021 |
The survival impact of preoperative FOLFOX for resectable locally advanced rectal cancer: the R-NAC-01 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male; Midd | 2022 |
[Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Female; Fluorouracil; Humans; Hypera | 2022 |
[A Case of Curative Resection after Neoadjuvant Chemotherapy for Locally-Advanced Sigmoid Colon Carcinoma with Urinary Bladder Invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Fluorouracil; Humans; Leucovorin; Ma | 2021 |
[A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fem | 2021 |
Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene | 2022 |
Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer.
Topics: B7-H1 Antigen; Biomarkers, Tumor; CD8 Antigens; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2022 |
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2022 |
Folinic Acid, Fluorouracil, and Oxaliplatin Therapy for Recurrent Esophageal Cancer with Syndrome of Inadequate Antidiuretic Hormone Secretion (SIADH) After Preoperative Cisplatin/5-Fluorouracil Therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; | 2022 |
Long-term survival in a patient with recurrent nasopharyngeal carcinoma treated with capecitabine.
Topics: Capecitabine; Fluorouracil; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Rec | 2022 |
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2022 |
Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (N | 2022 |
Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo | 2022 |
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2022 |
Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Flu | 2022 |
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cisplatin; Deoxycytidine; Drug-Related | 2022 |
Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.
Topics: Apoptosis Regulatory Proteins; beta Catenin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Colo | 2022 |
5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information.
Topics: Colorectal Neoplasms; Fluorouracil; HT29 Cells; Humans; Neoplasm Recurrence, Local; Tumor Microenvir | 2022 |
Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female | 2022 |
The association of abdominal adiposity with premature discontinuation of postoperative chemotherapy in colon cancer.
Topics: Adiposity; Cohort Studies; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Recurrence, | 2022 |
A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinot | 2022 |
New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2022 |
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2022 |
Early-stage colon cancer with high MALAT1 expression is associated with the 5-Fluorouracil resistance and future metastasis.
Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Ge | 2022 |
Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinom | 2022 |
The treatment efficacy of three-layered functional polymer materials as drug carrier for orthotopic colon cancer.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Endothelial Cells; Fluorouracil; Humans | 2022 |
Efficacy and safety of topical 5-fluorouracil in conjunctival intraepithelial neoplasia refractory to interferon alpha-2b.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Conjunctival Neoplasms; Fem | 2023 |
Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional
Topics: Catenins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2022 |
CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis.
Topics: Animals; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mice; Mice, N | 2022 |
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio | 2023 |
[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; | 2022 |
MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients.
Topics: Fluorouracil; Humans; MicroRNAs; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms | 2022 |
The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Capecitabine; Chemotherapy, Adjuvant; Coloni | 2022 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Conjunctival papilloma treatment outcomes: a 12-year-retrospective study.
Topics: Antineoplastic Agents; Conjunctival Neoplasms; Female; Fluorouracil; Humans; Interferon alpha-2; Mal | 2023 |
Conjunctival papilloma treatment outcomes: a 12-year-retrospective study.
Topics: Antineoplastic Agents; Conjunctival Neoplasms; Female; Fluorouracil; Humans; Interferon alpha-2; Mal | 2023 |
Conjunctival papilloma treatment outcomes: a 12-year-retrospective study.
Topics: Antineoplastic Agents; Conjunctival Neoplasms; Female; Fluorouracil; Humans; Interferon alpha-2; Mal | 2023 |
Conjunctival papilloma treatment outcomes: a 12-year-retrospective study.
Topics: Antineoplastic Agents; Conjunctival Neoplasms; Female; Fluorouracil; Humans; Interferon alpha-2; Mal | 2023 |
Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Female; Fluorouracil; Follow-Up Stu | 2023 |
Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Female; Fluorouracil; Follow-Up Stu | 2023 |
Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Female; Fluorouracil; Follow-Up Stu | 2023 |
Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.
Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Female; Fluorouracil; Follow-Up Stu | 2023 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Definitive chemoradiation in nonmetastatic squamous cell carcinoma anal canal: A single-institution experience.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2022 |
Primary Squamous Cell Carcinoma of the Liver with Good Response to Carboplatin and 5-Flurouracil: A Case Report.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Carboplatin; Carcinoma, Squamous Cell; Female; | 2022 |
Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluor | 2023 |
[A Case Report of Stage Ⅳb Thoracic Esophageal Cancer Responding to Multidisciplinary Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq | 2022 |
[A Case of Multiple Lung Metastases of Pancreatic Cancer with 50 Months Survival by Sequential Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands.
Topics: Female; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; NK Cell Lectin-Like Receptor S | 2023 |
Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fasting; Ferropto | 2023 |
[A Case of Recurrent Rectal Cancer with Acute Lower Extremity Arterial Occlusion during Treatment with Bevacizumab].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorourac | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; | 2023 |
Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids.
Topics: beta Catenin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Colonic Neopl | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrenc | 2023 |
Poor Prognosis in Patients With Stage III Colorectal Cancer Receiving Adjuvant FOLFOX/CAPOX Therapy Is Predicted by the Presence of Many Poorly Differentiated Clusters.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm | 2023 |
PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Chemotherapy, Adjuvan | 2023 |
FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Colorectal Neoplasms; Fluorou | 2023 |
Laparoscopic versus open two-stage hepatectomy for bilobar colorectal liver metastases: A bi-institutional, propensity score-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2019 |
Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance?
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Co | 2019 |
YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2020 |
Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy.
Topics: Adult; Aged; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mismatch Repair; | 2020 |
[Successful Multidisciplinary Treatment Accomplished by Collaboration of Multiple Clinical Departments for Synchronous Quadruple Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 2019 |
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophagea | 2019 |
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Prescho | 2019 |
Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Fluorouracil | 2020 |
Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Fema | 2019 |
[A Case of Lung Metastases from Rectal Cancer Treated for Quite Long with FOLFIRI plus Ramucirumab as a Late Line of Therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2019 |
[A Case Altered Consciousness Due to 5-Fluorouracil-Induced Hyperammonemia in a Patient with Recurrent Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consciousn | 2019 |
Modeling the stem cell hypothesis: Investigating the effects of cancer stem cells and TGF-β on tumor growth.
Topics: Animals; Antineoplastic Agents; Calibration; CD8-Positive T-Lymphocytes; Drug Administration Schedul | 2019 |
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2019 |
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2020 |
Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fem | 2020 |
Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Colonic Neoplas | 2021 |
Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2019 |
YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2020 |
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brazil; Bridged-Ring Compounds; Can | 2020 |
Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluo | 2020 |
Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2020 |
Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; Disease-Free Survival; D | 2020 |
Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas | 2020 |
[Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2019 |
[Questionnaire Survey on Adjuvant Chemotherapy for Colorectal Cancer in Yamaguchi Prefecture].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2019 |
[A Case of Lymph Node Recurrence with Invasion to the Trachea after the Resection of Esophageal Cancer Treated by Multidisciplinary Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq | 2019 |
Prodigiosin impairs autophagosome-lysosome fusion that sensitizes colorectal cancer cells to 5-fluorouracil-induced cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagosomes; Autophagy; Caco-2 Cells; Cell Death; Cell | 2020 |
Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Factor Analysis, Statistical; Febrile N | 2020 |
Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Femal | 2020 |
Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadj | 2021 |
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
[Long-Term Survival of a Patient with Advanced Recurrent Rectal Cancer Treated with a Multidisciplinary Therapy including Five Operations-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Fluorouracil; Humans; Ne | 2020 |
[Locally Advanced Rectal Cancer Curatively Resected after Modified FOLFOXIRI plus Bevacizumab Chemotherapy-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Human | 2020 |
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2020 |
Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery.
Topics: Administration, Cutaneous; Aged; Carcinoma, Basal Cell; Chemotherapy, Adjuvant; Female; Fluorouracil | 2020 |
Challenges in Reirradiation of Intrahepatic Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2020 |
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; D | 2021 |
Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2020 |
Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Li | 2020 |
Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma | 2021 |
Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemorad | 2020 |
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy.
Topics: Aged; Biopsy; CD3 Complex; CD8-Positive T-Lymphocytes; Cell Lineage; Cell Proliferation; Disease-Fre | 2020 |
Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2019 |
Adjuvant Treatment with 5-Fluorouracil and Oxaliplatin Does Not Influence Cardiac Function, Neurovascular Control, and Physical Capacity in Patients with Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2020 |
Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Mitomycin; | 2020 |
Observational study of ocular surface squamous neoplasia: Risk factors, diagnosis, management and outcomes at a tertiary eye hospital in South Africa.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Carcinoma, Squamous Cell; Eye Neoplasms; Female; Flu | 2020 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcita | 2021 |
Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Capeci | 2021 |
5-Fluorouracil Is Associated With a Decreased Recurrence Risk in Odontogenic Keratocyst Management: A Retrospective Cohort Study.
Topics: Fluorouracil; Humans; Neoplasm Recurrence, Local; Odontogenic Cysts; Odontogenic Tumors; Recurrence; | 2021 |
Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2020 |
3D printed intelligent scaffold prevents recurrence and distal metastasis of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Chemoth | 2020 |
A Prospective, Single-arm, Multicenter Trial of Diverting Stoma Followed by Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer: YCOG 1305 (PROBE Study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2022 |
FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Glucuro | 2020 |
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2020 |
Even a partial pathological response is associated with lower relapse rates in patients with operable rectal cancer undergoing neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase | 2021 |
Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreati | 2021 |
Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Extracellular Matrix; Extracel | 2020 |
The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Microsatell | 2022 |
Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadj | 2021 |
What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2021 |
Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2021 |
Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplati | 2020 |
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiothera | 2021 |
Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2021 |
[Two Cases of Resectable Liver Metastasis from Colorectal Cancer with Pathological Complete Response after Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2020 |
[A Case of Disturbance of Consciousness Due to Hyperammonemia during Chemotherapy for Metastasis of Sigmoid Colon Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Consciousness; Female; Fluorouracil; Humans; H | 2020 |
[Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2020 |
Staging Paradox and Discrepancy in Adjuvant Chemotherapy in Patients with T4N0, T1-2N1, and T3N1 Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2021 |
Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolidation Chemot | 2021 |
Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradioth | 2021 |
Initial topical monotherapy may increase the risk of recurrence in patients with extramammary Paget's disease.
Topics: Fluorouracil; Humans; Imiquimod; Neoplasm Recurrence, Local; Paget Disease, Extramammary; Retrospect | 2021 |
A Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2021 |
Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; | 2021 |
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2021 |
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer.
Topics: Adenocarcinoma; Adenosylhomocysteinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherap | 2021 |
Hyperammonemia-induced impaired consciousness following mFOLFOX6 therapy in a patient with recurrent rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consciousness; Female; Fluorouracil; Humans; Hyperam | 2021 |
Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2021 |
Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Drug | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; De | 2021 |
Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2022 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidenc | 2021 |
Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Fluo | 2022 |
Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Therapy, Combination; Fluorouracil; | 2022 |
Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: Is it Safe?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2021 |
Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Flu | 2022 |
Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2021 |
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase II as | 2021 |
High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2021 |
Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2021 |
A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; | 2017 |
Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Colectomy; Female; Fluorouracil; | 2017 |
Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2017 |
Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Hum | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitab | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurr | 2017 |
Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Capecit | 2017 |
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2017 |
Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer.
Topics: Adult; Aged; Biliary Tract Neoplasms; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Fema | 2017 |
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Topics: Adult; Aged; Cetuximab; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neoplasm Metastas | 2018 |
WNT/β-Catenin Signaling Inhibitor IC-2 Suppresses Sphere Formation and Sensitizes Colorectal Cancer Cells to 5-Fluorouracil.
Topics: beta Catenin; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Gene Expression Regulation, Ne | 2017 |
Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2018 |
Chemoresistance to 5-FU inhibited by 635 nm LED irradiation in CD133+ KB cell line.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell | 2018 |
Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.
Topics: Administration, Cutaneous; Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Ma | 2017 |
Arterioportal shunt incidental to treatment with oxaliplatin that mimics recurrent gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arteriovenous Fistula; Biopsy; Capecitabine; | 2017 |
Outcomes of patients with abdominoperineal resection (APR) and low anterior resection (LAR) who had very low rectal cancer.
Topics: Anal Canal; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Digestive System Surgi | 2017 |
Topical 5-Fluorouracil for Women With High-Grade Vaginal Intraepithelial Neoplasia.
Topics: Administration, Intravaginal; Antimetabolites, Antineoplastic; Dissection; Female; Fluorouracil; Hum | 2017 |
Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2018 |
[Gastric Cancer Recurrence in 12 Years after Surgical Resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Fluorouracil; Gastrectomy; Humans; Inte | 2017 |
[Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2018 |
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Comparing Topical Treatments for Basal Cell Carcinoma.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Fluorouracil; Humans; Imiquimod; Neopla | 2018 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetax | 2018 |
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colec | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2018 |
Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Fluorouracil; Heterografts; Humans; | 2018 |
[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Gastrointes | 2018 |
[Neoadjuvant chemotherapy with concurrent chemoradiotherapy in the treatment of nasopharyngeal cancer: Southern Tunisian experience].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2018 |
Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein.
Topics: Adenocarcinoma, Mucinous; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2019 |
Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Ci | 2018 |
Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: An Updated Analysis of Long-Term Follow-Up from Single Institution.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, | 2018 |
Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemoradiotherapy, A | 2018 |
Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fe | 2019 |
Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
Building evidence-based treatment recommendations for advanced anal cancer: the time is now.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Neop | 2018 |
Treatment Effects Can Mimic Recurrent Extramammary Paget Disease in Perianal Skin.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Anus Neoplasms; Biomarkers, Tumor; Biops | 2018 |
The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuv | 2018 |
Experience of Definitive Chemoradiation for Oesophageal Cancer Within a Large Regional Cancer Treatment Centre: Improving Outcomes and Tolerability.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Cap | 2018 |
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2018 |
Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil Dehydro | 2018 |
The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemo | 2018 |
Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2019 |
Adjuvant Chemotherapy in Rectal Cancer Patients Treated With Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study.
Topics: Aged; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluoro | 2019 |
Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
Topics: Adult; Aged; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Diseas | 2018 |
Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Combined Modality Therapy; Fluorouracil; | 2018 |
A Case Report of Recurrent Metastatic Sebaceous Carcinoma Which Showed Favorable Response Tt Non-Fluorouracil Based Chemotherapy.
Topics: Adenocarcinoma, Sebaceous; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Doxorubic | 2018 |
FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biom | 2019 |
Outcomes after up-front surgery and metronomic neoadjuvant chemotherapy with S-1 or UFT for early tongue squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 2019 |
Experience in Intra-arterial Chemotherapy using Two Protocols for the Treatment of OSCC over Two Decades at the University Hospital Vienna.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2018 |
Neoadjuvant Capecitabine Results in Similar Total Lymph Node Harvests as 5-Fluorouracil but an Increased Number of Lymph Nodes Containing Adenocarcinoma on Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal | 2018 |
Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
Topics: Administration, Ophthalmic; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 2019 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2019 |
Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Female; Fluoroura | 2019 |
Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Interaction | 2019 |
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
[Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin- based treatment due to potentially resectable liver metastases].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 2018 |
Impact of pelvic bone marrow irradiation on the hematological toxicity of subsequent chemotherapy in rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemoradiotherapy; Fluorouracil; Humans | 2019 |
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related | 2018 |
SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherap | 2019 |
Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cohort Studies; Fluorou | 2018 |
Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2019 |
Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cause of Death; | 2018 |
[A Case of Recurrent Colon Cancer with Long-Term Complete Response Treated with FOLFOX Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Flu | 2018 |
[A Super-Elderly Patient with Recurrent Colon Cancer with Metastasis Effectively Treated with Capecitabine plus Bevacizumab Chemotherapy-A Case Report].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2018 |
[A Case of Long-Term Survival in a Patient with Ascending Colon Cancer and Synchronous Multiple Liver Metastases after Multimodality Therapy Including Multiple Hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Ascending; Colonic Neoplasms; Female; F | 2018 |
Ten-year outcome of curative "exclusive" chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2019 |
[Curative Transanal Resection after Neoadjuvant Chemotherapy for Lower Rectal Cancer-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Middle Aged; Neoadjuva | 2019 |
[Two Cases of Locally Advanced Rectal Cancer and Lower Rectal Cancer Resected Successfully That Enabled Anus Preservation after Preoperative Chemotherapy].
Topics: Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Middle | 2019 |
Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Cohort Studies; D | 2019 |
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; | 2019 |
Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2019 |
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clo | 2019 |
[A Case of Colostomy-Free and Long-Term Survival with 5-FU/CDDP for Local Recurrence of Anal Cancer after Chemoradiation Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Colostomy; Female | 2019 |
Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Esophageal Neoplasms; | 2019 |
Ipsilateral neck radiotherapy in N2b well-lateralized tonsil cancer - Approach with caution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2019 |
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2019 |
[A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Hum | 2019 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cost | 2019 |
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2019 |
Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; | 2019 |
Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, | 2019 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2019 |
Long-term Esophageal Cancer Survivor Treated by Bypass for Esophagobronchial Fistula After Chemoradiotherapy: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Chemoradiotherapy; Cisplat | 2019 |
Induction chemotherapy challenges for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; | 2013 |
Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2013 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck | 2013 |
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Chemoradiotherapy; C | 2013 |
Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2013 |
Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Ex | 2013 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
Routine defunctioning stoma after chemoradiation and total mesorectal excision: a single-surgeon experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colostomy; Dose Fractiona | 2013 |
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Chemotherapy, Adjuvant; Colonic Neoplasms; Cyclin D1; Femal | 2014 |
Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine | 2013 |
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
The impact of glycemic levels in patients with colon cancer.
Topics: Antineoplastic Agents; Blood Glucose; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diet; Fluorourac | 2013 |
The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2015 |
Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Delayed-Action Pr | 2013 |
[Tolerance and efficacy of preoperative radiation therapy for elderly patients treated for rectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Dose Fractionation, Radiatio | 2013 |
REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; C | 2013 |
Clinical outcome and patterns of recurrence of head and neck squamous cell carcinoma with a limited field of postoperative radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neop | 2013 |
Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2013 |
Virchow lymph node metastatic recurrence of sigmoid colon cancer with severe lymph node metastases successfully treated using systemic chemotherapy combined with radiotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2014 |
Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2013 |
Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Colonic Neoplasms; Ethnicity; Female; Fluorouracil; Humans; | 2014 |
Evolving role of neoadjuvant therapy in rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com | 2013 |
[A case of relapsed colon cancer successfully treated by capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouraci | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2013 |
Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Lym | 2013 |
Palliative 5-fluorouracil and cisplatin chemotherapy in recurrent metastatic sebaceous carcinoma: Case report and literature review.
Topics: Adenocarcinoma, Sebaceous; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Cisplatin; Fe | 2016 |
Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Anastomosis, Surgical; Anastomotic Leak; | 2013 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
[Use of hydrogel tissues with 5-fluorouracil and sodium alginate, "COLETEX-5-FTUR," for radiomodification in cancer patients receiving radiation therapy].
Topics: Adult; Aged; Alginates; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fluorouracil; Glucuronic A | 2013 |
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryoni | 2013 |
Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.
Topics: Antimetabolites, Antineoplastic; BRCA1 Protein; Chromosome Fragile Sites; Dihydrouracil Dehydrogenas | 2013 |
Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy; Colonoscop | 2014 |
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Disease-Free | 2013 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic; Hum | 2013 |
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell L | 2014 |
Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neopl | 2014 |
Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Disease-F | 2014 |
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2013 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemothera | 2014 |
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj | 2014 |
Predicting distant metastasis and chemoresistance using plasma miRNAs.
Topics: Antineoplastic Agents; Case-Control Studies; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female | 2014 |
[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2014 |
Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Chemoradiotherapy response in recurrent rectal cancer.
Topics: Adult; Aged; Chemoradiotherapy; Fluorouracil; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imag | 2014 |
Multimodal treatment for t1-2 supraglottic cancer: the impact of tumor location.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
[Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Metformin: a potential therapeutic agent for recurrent colon cancer.
Topics: Animals; Cell Movement; Colonic Neoplasms; Female; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; M | 2014 |
A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cispl | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-R | 2014 |
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2014 |
[Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Cisplatin; Combine | 2014 |
Preoperative chemoradiotherapy in rectal cancer induces changes in the expression of nuclear β-catenin: prognostic significance.
Topics: Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Capecitabine; Chemoradiotherapy; Colorecta | 2014 |
A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2014 |
Patterns of recurrence after trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemot | 2014 |
Intradural tumor recurrence after resection of extradural metastasis: a rare but potential complication of intraoperative durotomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; C | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2014 |
Bridge-to-surgery stent placement versus emergency surgery for acute malignant colonic obstruction.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Colonic Diseases; Color | 2014 |
Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad | 2016 |
External beam radiotherapy ± chemotherapy in the treatment of anal canal cancer: a single-institute long-term experience on 100 patients.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Cisplatin; Combined Modality Therapy; Female; Fluoro | 2014 |
[Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2014 |
Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Combined Modality Therapy; Fe | 2014 |
Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecit | 2014 |
Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; C | 2014 |
A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2014 |
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2014 |
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2014 |
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2015 |
TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
HepG2 cells recovered from apoptosis show altered drug responses and invasiveness.
Topics: Ablation Techniques; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Dos | 2014 |
Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Prolife | 2014 |
Helical tomotherapy combined with capecitabine in the preoperative treatment of locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluo | 2014 |
[Adjuvant chemoradiotherapy in advanced gastric cancer: experience in 168 patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Fe | 2014 |
Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 2014 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2014 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
Post-chemoradiation intraoperative electron-beam radiation therapy boost in resected locally advanced rectal cancer: long-term results focused on topographic pattern of locoregional relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; E | 2014 |
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2014 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2015 |
The role of adjuvant chemotherapy in stage II colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2015 |
Resident rounds part III: plaque on left areola of an African-American woman.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Biopsy; Black or African American; B | 2014 |
SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Wester | 2014 |
Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2014 |
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Col | 2014 |
Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2015 |
Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer.
Topics: Animals; Anticarcinogenic Agents; beta Catenin; Biomarkers, Tumor; Cell Line, Tumor; Colon; Colonic | 2014 |
Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Topics: Aged; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Female; Fluorouracil; | 2015 |
Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Aspirin; Capecitabin | 2014 |
Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2014 |
Breast cancer: combining bevacizumab with chemotherapy--from maintenance to second-line treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2014 |
[Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv | 2014 |
Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response | 2014 |
Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplati | 2015 |
Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fema | 2015 |
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carb | 2014 |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2014 |
Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
BRCA2-associated therapy-related acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Duct | 2015 |
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemother | 2015 |
Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclo | 2015 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; | 2015 |
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2014 |
Comparative survival effectiveness between pre-operative and postoperative chemoradiotherapy for locally advanced rectal cancer: a retrospective study in Phramongkutklao Hospital.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modalit | 2014 |
[Analysis of the treatment and prognosis for gestational trophoblastic neoplasia patients with urinary system and adrenal glands metastasis].
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Combined Chemotherapy Protocols; China; Fema | 2014 |
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Proto | 2014 |
Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2015 |
Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta-Thromboglobulin; Camptothecin; Capecitabine; Co | 2015 |
Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2015 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Administration | 2015 |
Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2015 |
LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.
Topics: Adult; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; | 2015 |
Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy | 2015 |
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2015 |
The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells.
Topics: Aged; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subf | 2015 |
Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Female; Fluorouracil; F | 2015 |
Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxyc | 2014 |
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Campt | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Dormancy activation mechanism of oral cavity cancer stem cells.
Topics: Base Sequence; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell T | 2015 |
Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2015 |
Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
[Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 2015 |
Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 2015 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2015 |
Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy.
Topics: Aged; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hyperthe | 2015 |
[Outcome of hepatoblastoma: experience with 63 patients received chemotherapy with the regimen C5V].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Doxorubicin; Fem | 2015 |
Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Topics: Adult; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2016 |
LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification.
Topics: Adult; Aged; Chemoembolization, Therapeutic; Cholangiocarcinoma; Enbucrilate; Epirubicin; Female; Fl | 2015 |
Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced pancreatic cancer: a case report.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adju | 2015 |
Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy | 2015 |
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2015 |
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Dise | 2016 |
Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Role of Adjuvant Chemotherapy in ypT0-2N0 Patients Treated with Preoperative Chemoradiation Therapy and Radical Resection for Rectal Cancer.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chem | 2015 |
Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neopla | 2015 |
Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2014 |
Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; | 2015 |
[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
Evaluation of a 36 Gy elective node irradiation dose in anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2015 |
Endoscopic treatment of inverted papilloma attached in the frontal sinus/recess.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Child; Endoscopy; Female; Fluoroura | 2015 |
Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
Topics: Acyltransferases; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; California; Chemotherapy | 2016 |
The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 2016 |
Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2015 |
Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2016 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2015 |
Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2015 |
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
Topics: Adenocarcinoma; Adenosine Triphosphate; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Anti | 2016 |
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wester | 2016 |
From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capeci | 2015 |
A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Cyclophospha | 2016 |
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Topics: Adenocarcinoma; Aged; Case-Control Studies; Chemoradiotherapy, Adjuvant; Colostomy; Disease-Free Sur | 2016 |
[Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Fluorouracil; Gas | 2015 |
Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2015 |
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Decision-Making; Colonic Neoplasms; Co | 2016 |
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Databases | 2016 |
[Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 2016 |
Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Dise | 2016 |
Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2016 |
Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiothe | 2016 |
Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis.
Topics: Aged; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free S | 2016 |
Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2016 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2017 |
Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Conjuncti | 2016 |
Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Fe | 2016 |
Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; DNA Methylation; Fem | 2016 |
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Squamous Cell; Disease-Free Survival; Fluorouracil; Follow-Up Stu | 2016 |
[Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy].
Topics: Chemoradiotherapy; Digestive System Surgical Procedures; Fluorouracil; Humans; Neoadjuvant Therapy; | 2016 |
Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2016 |
RE: Effects of adjuvant chemotherapy on recurrence, survival and quality of life in stage II colon cancer patients: a 24-month follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2016 |
Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2016 |
Non-surgical management of rectal cancer. Series of 68 cases, long follow up in two leading centres in Argentina.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Argentina; Chemoradiotherapy; Disease-F | 2016 |
Response to RE: Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2016 |
A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy, Combi | 2016 |
[Research hotspot and progress of preoperative chemoradiotherapy for rectal cancer].
Topics: Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxyc | 2016 |
Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
Topics: Adult; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluor | 2016 |
Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2016 |
Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; ATP-Binding Cassette Transporters; Colorectal Neoplasms; Dise | 2016 |
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasm | 2017 |
Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
Topics: Adaptor Proteins, Signal Transducing; Aged; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; | 2016 |
Adjuvant chemoradiotherapy instead of revision radical resection after local excision for high-risk early rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2016 |
Clinical characteristics of young-age onset gastric cancer in Korea.
Topics: Adult; Age of Onset; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; | 2016 |
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dige | 2016 |
Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrectomy; Humans; La | 2016 |
Usefulness of chemoradiotherapy for inoperable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2017 |
Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level.
Topics: Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carci | 2016 |
Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Radiation field size and dose determine oncologic outcome in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma.
Topics: Adult; Aged; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Female; | 2016 |
Microsatellite instability & survival in patients with stage II/III colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; H | 2016 |
[Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cost-Benefit Analysis; Female; Fluorour | 2016 |
Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-F | 2017 |
Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer.
Topics: Animals; Biomarkers, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Fluorouracil; Gastrec | 2018 |
Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cet | 2017 |
Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; | 2017 |
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2017 |
Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemothe | 2017 |
The extracellular domain of E cadherin linked to invasiveness in colorectal cancer: a new resistance and relapses monitoring serum-bio marker?
Topics: Adult; Aged; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; C | 2017 |
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2008 |
Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survi | 2008 |
Platinum-based chemotherapy in triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 2008 |
Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, An | 2008 |
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Stud | 2008 |
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2008 |
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2008 |
Capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; C | 2008 |
Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2009 |
Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E | 2008 |
[A recurrent case of lipid-secreting carcinoma of the breast successfully treated with capecitabine].
Topics: Biopsy; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lipid Metabolis | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Bre | 2009 |
The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Combined Mod | 2008 |
Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2008 |
Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Ci | 2008 |
Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Prote | 2008 |
[Two cases of squamous cell carcinoma of upper urinary tract with hypercalcemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
[Docetaxel-Cisplatin-5-Fu Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasm | 2007 |
Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T | 2009 |
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2009 |
Treatment outcome of locally advanced nasopharyngeal cancer with concurrent chemoradiotherapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Child; Cisplatin; F | 2008 |
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, W | 2009 |
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, A | 2009 |
Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose Fractionation, Radiati | 2009 |
Arterial infusion chemotherapy in patient with repeated recurrent tumor of cecal cancer: report of a case.
Topics: Antimetabolites, Antineoplastic; Cecal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Huma | 2008 |
Recurrent disease four years after surgery and adjuvant chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2008 |
Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2009 |
[Analysis of the diagnosis and treatment of cervical minimal deviation adenocarcinoma].
Topics: Actins; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryoni | 2008 |
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combin | 2008 |
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2009 |
Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2009 |
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinati | 2009 |
Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemother | 2010 |
Benefit of radiation boost after whole-breast radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2009 |
High-dose rate brachytherapy using inverse planning simulated annealing for locoregionally advanced cervical cancer: a clinical report with 2-year follow-up.
Topics: Adenocarcinoma; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2009 |
Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous | 2009 |
Clinical outcome of oropharyngeal carcinoma treated with platinum-based chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplat | 2009 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
Preoperative radiochemotherapy in the treatment of advanced oral cancer: outcome of 276 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cohort Studie | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Female; | 2009 |
Chemosensitivity and survival in gastric cancer patients with microsatellite instability.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Female; Fluorouracil; Humans; Lymphatic | 2009 |
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2009 |
Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2009 |
[Clinical analysis of 22 cases of esophageal adenosquamous carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Adenosquamou | 2009 |
Recurrence of treated ciliary body melanoma following trabeculectomy.
Topics: Aged; Brachytherapy; Ciliary Body; Combined Modality Therapy; Conjunctival Neoplasms; Eye Enucleatio | 2009 |
Highlights from: The 45th Annual Meeting of the American Society of Clinical Oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
A case of 5-fluorouracil-induced acute psychosis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
[Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dexamethasone; Do | 2009 |
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2009 |
Rectal angiosarcoma after adjuvant chemoradiotherapy for adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fatal Outcome; Fluorouracil | 2009 |
Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Verrucous | 2009 |
Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deox | 2010 |
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplat | 2009 |
Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chi-Square Distribution; Female; Fl | 2009 |
The necessity of chemotherapy in T3N0M0 colon cancer without risk factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2009 |
Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dih | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2009 |
Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capeci | 2009 |
[Metachronous metastasis from rectal adenocarcinoma to the penis--case report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2010 |
Chemotherapy: Adding oxaliplatin to the equation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as | 2009 |
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; | 2010 |
[Clinical impact of extracapsular extension of axillary lymph node metastases in breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cisplatin; Combined Modali | 2009 |
[A case of advanced esophageal cancer that has come back eight years after combined modality therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2009 |
[Evaluation of bevacizumab for advanced colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2010 |
[Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
[Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2010 |
Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Combined Modality Therapy; | 2010 |
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che | 2010 |
Acute promyelocytic leukemia in a young patient with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubici | 2011 |
Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 2010 |
Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Prognostic value of perineural invasion in patients with stage II colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2010 |
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot | 2010 |
Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Digestiv | 2011 |
[Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adju | 2010 |
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2010 |
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2010 |
Continuous fall in hemoglobin level is a poor prognostic factor in patients with nasopharyngeal carcinoma treated with radiotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2010 |
Management of inflammatory breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2011 |
Anal function and intersphincteric resection.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; | 2010 |
Postoperative chemoradiotherapy for extrahepatic bile duct cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; CA-19-9 | 2011 |
Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2010 |
VEGF -460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Female; Fluo | 2011 |
[Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2010 |
Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer.
Topics: Aged; Aortic Aneurysm, Abdominal; Aortic Dissection; Breast Neoplasms; Capecitabine; Deoxycytidine; | 2010 |
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv | 2011 |
The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplati | 2010 |
High-grade acute organ toxicity as a positive prognostic factor in primary radiochemotherapy for anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2011 |
Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2010 |
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubici | 2011 |
[Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose Fractionation, Radia | 2010 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Conjunctival Neoplas | 2011 |
Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Ci | 2010 |
Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Feasibility | 2010 |
Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2010 |
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorodeox | 2011 |
Squamous cell carcinoma of the anal margin: the university of Florida experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Mild clinical phenotype of Kindler syndrome associated with late diagnosis and skin cancer.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Basement Membrane; Blister; Carcinoma, Basal Cell; Cry | 2010 |
5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, | 2011 |
[Surgical vs nonsurgical treatment of basal cell carcinoma].
Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Clinical Trials as Topic; Combined Mo | 2010 |
Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Combined Moda | 2011 |
A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Consolida | 2011 |
[Early stage breast cancer: is exclusive radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2011 |
Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Early Detection of Canc | 2011 |
Chemoresistant hepatoblastoma in a patient with mosaic trisomy 18 treated with orthotopic liver transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Chromosomes, H | 2011 |
Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fem | 2010 |
[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; | 2010 |
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; F | 2011 |
Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell | 2011 |
[A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
[A case of recurrent esophageal cancer successfully treated by combined therapies].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 2010 |
[A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phyto | 2010 |
[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, | 2010 |
Oral candidiasis mimicking tongue cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Candidiasis, Oral; | 2011 |
Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2011 |
Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Eye Neoplasms; Female; Fluorouracil; Humans; Ma | 2011 |
Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma | 2012 |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; | 2011 |
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2010 |
Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
Scan? Cure? Sure!
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic | 2011 |
Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2012 |
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2011 |
Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diseas | 2012 |
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit | 2011 |
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2011 |
Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma | 2011 |
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema | 2011 |
Single nucleotide polymorphisms of integrin alpha-2 and beta-3 genes are not associated with relapse-free and overall survival in colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female | 2011 |
MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Topics: Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Chemo | 2011 |
Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2012 |
Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2012 |
Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2011 |
Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq | 2011 |
Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doce | 2011 |
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Va | 2011 |
Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis.
Topics: Amputation, Surgical; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2011 |
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2011 |
Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adj | 2012 |
Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch | 2011 |
FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2011 |
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2011 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; Fl | 2011 |
Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blood | 2012 |
[Intraabdominal chemotherapy of prevailing forms of colon cancer].
Topics: Abdominal Cavity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Fluo | 2011 |
Common cancer stem cell gene variants predict colon cancer recurrence.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2011 |
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2012 |
NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, Squamou | 2011 |
Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Topics: Abdominal Neoplasms; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ch | 2012 |
Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squam | 2012 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecit | 2012 |
Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Ch | 2012 |
Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neopl | 2012 |
Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2011 |
Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2012 |
A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2012 |
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; De | 2012 |
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; C | 2012 |
Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Child | 2012 |
Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.
Topics: Administration, Intravesical; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cr | 2012 |
Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes.
Topics: Carcinoma; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluo | 2012 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2013 |
Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.
Topics: Adult; Aged; Analysis of Variance; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycyt | 2012 |
Interobserver variability in target volume delineation in postoperative radiochemotherapy for gastric cancer. A pilot prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil; Follow-Up S | 2012 |
Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2012 |
Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2012 |
Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esop | 2013 |
Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Case-Control Studies; Chemoradiotherapy, Adjuvant; Dis | 2012 |
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Chemot | 2012 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy | 2013 |
Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2012 |
Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2012 |
Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2012 |
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose F | 2012 |
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2012 |
Evaluation of the efficacy of modified De Gramont and modified FOLFOX4 regimens for adjuvant therapy of locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2011 |
Short-term results and long-term oncologic outcomes between neoadjuvant chemoradiotherapy and adjuvant postoperative chemoradiotherapy for stage III rectal cancer: a case-matched study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemoradiotherapy; Female; Flu | 2012 |
Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; D | 2012 |
Resistant gestational trophoblastic neoplasia patients treated with 5-fluorouracil plus actinomycin D.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dactinomycin; Female; Fluorou | 2012 |
Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug | 2013 |
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2013 |
Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2012 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta | 2013 |
Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherap | 2013 |
Predictors of ocular surface squamous neoplasia recurrence after excisional surgery.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctival Neoplasms; | 2012 |
The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary | 2013 |
Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free S | 2012 |
Effects of reduced dose intensity of modified FOLFOX6 in patients with metastatic or recurrent colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2011 |
Multidisciplinary therapy consisting of minimally invasive resection, irradiation, and intra-arterial infusion of 5-fluorouracil for maxillary sinus carcinomas.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Infusio | 2013 |
Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2013 |
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemoth | 2013 |
[Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2012 |
Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fem | 2013 |
Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Topics: Aged; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2013 |
New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.
Topics: Antineoplastic Agents; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorou | 2012 |
Oncologically safe distal resection margins in rectal cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Survival of patients with pathologic T0N+ oral and oropharyngeal cancer after neoadjuvant therapy and surgery: the minority report.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2013 |
Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2013 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free | 2012 |
Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy, | 2012 |
Extensive characterization of sphere models established from colorectal cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; C | 2013 |
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2013 |
[A case of cutaneous mammary re-irradiation].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Ch | 2012 |
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2013 |
Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adj | 2012 |
Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2013 |
Local recurrence of gastric cancer after total gastrectomy: an unusual presentation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2012 |
Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2012 |
Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
Topics: Adenocarcinoma; Aged; Anal Canal; Brazil; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Mic | 2013 |
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brid | 2013 |
[Esophageal cancer: outcome according to therapeutic strategy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemo | 2012 |
Impact of adjuvant chemoradiotherapy for rectal cancer on the long-term quality of life and late side effects: a multicentric clinical evaluation by the Turkish Oncology Group.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2012 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 2013 |
Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antine | 2013 |
Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Dose Fractionation | 2013 |
Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2013 |
Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherap | 2013 |
"FAR" chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouracil; Glottis; Huma | 2002 |
Chemotherapy with or without radiotherapy in patients with locoregionally recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2002 |
Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hepat | 1996 |
Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2002 |
[Salvage operation for esophageal cancer after radical chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin.
Topics: Adenocarcinoma; Afferent Loop Syndrome; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2002 |
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2002 |
Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors.
Topics: Adult; Dactinomycin; Drug Resistance, Multiple; Female; Fluorouracil; Humans; Leukopenia; Neoplasm R | 2002 |
Long-term results of reirradiation for patients with recurrent rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
[A case of recurrent gallbladder cancer responding to low-dose 5-FU and CDDP therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2002 |
Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
[A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2002 |
Gastrostomy-site tumor recurrence is not always fatal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Carcinoma, Squamous Cell; Flu | 2003 |
Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Sq | 2001 |
[Chemoradiotherapy using platinum analogs/5-FU for advanced esophageal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2002 |
[Recurrence of right breast cancer at the thoracic wall successfully treated with intra-arterial infusion of doxorubicin hydrochloride--a case report].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2002 |
[A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes].
Topics: Carcinoid Tumor; Combined Modality Therapy; Doxorubicin; Electrocoagulation; Female; Fluorouracil; H | 2002 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
A favourable pathological stage after neoadjuvant radiochemotherapy in patients with initially irresectable rectal cancer correlates with a favourable prognosis.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Recurrence, | 2003 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2003 |
[Cisplatin, 5-fluorouracil, and high-dose leucovorin for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2003 |
Chemoradiation for adenocarcinoma of the anus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Sq | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
Sebaceous carcinoma of the vulva.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Epirubicin; Fe | 2003 |
Successful treatment with 5-Fu.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma in Situ; Conjunctival Neoplasms; Cor | 2003 |
Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2003 |
Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2003 |
Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer--preliminary results.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progress | 2003 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxy | 2003 |
S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug | 2003 |
Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2003 |
[Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cisplatin; Deoxycy | 2003 |
Relapse patterns after chemo-radiation for carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2003 |
Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2003 |
Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2003 |
Conjunctival intraepithelial neoplasia.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma in | 2003 |
[Combined usage of taxotere in induction chemotherapy of head and neck neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2003 |
Concurrent chemoradiotherapy with protracted infusion of 5-FU and cisplatin for postoperative recurrent or residual esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2003 |
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2003 |
Response to preoperative chemoradiation in stage II and III rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; | 2003 |
CLOSED PELVIC PERFUSION: A NEW APPROACH TO THE PROBLEM OF ADVANCED GYNECOLOGIC MALIGNANCY.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Drug Therapy; Female; Fluorouracil; Geni | 1965 |
Total cystectomies in the surgical treatment of rectal cancer with prior chemoradiation: analysis of postoperative morbidity and survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystecto | 2004 |
[Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2003 |
[A case of Vp4 hepatocellular carcinoma treated with surgical resection and continuous intrahepatic artery infusion chemotherapy of low-dose cisplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 2003 |
Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models | 2003 |
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Sche | 2003 |
Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2003 |
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Fl | 2003 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 2003 |
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2003 |
[Principles of postoperative therapy in rectal carcinoma].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2004 |
Using loco-regional recurrence as an indicator of the quality of breast cancer treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2004 |
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy | 2004 |
Extracapsular spread of nodal metastasis as a prognostic factor in rectal cancer.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Mod | 2004 |
Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis | 2004 |
Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Fluorouraci | 2004 |
Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; M | 2004 |
[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Defici | 2004 |
[Colorectal cancer: what should be the management of primary tumour?].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon; Colonoscopy; Colorectal Neoplasms; D | 2004 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
[Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dih | 2004 |
[Radiotherapy of carcinomas of the anal canal. Tenon Hospital experience].
Topics: Aged; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Ch | 2003 |
Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2004 |
Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Carcinoma; Cell Adhesion Molecules; C | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2004 |
Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2004 |
Treatment issues in pediatric gastric adenocarcinoma.
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Sig | 2004 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm | 2003 |
[Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxyc | 2004 |
[Effecting observation of 3-dimensional conformal radiotherapy combined with chemotherapy for rectal cancer of postoperative local recurrence].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2004 |
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; E | 2004 |
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Chemotherapy for recurrent or persistent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Cisplatin; Clinical Tria | 2004 |
Chemoradiotherapy for rectal cancer--when, why, and how?
Topics: Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; | 2004 |
Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Dogs; Female; Fluorouracil; Gastrointesti | 2004 |
[Successful hepatic arterial infusion therapy of CDDP/5-FU/IFN-beta3 for recurrent hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2004 |
[A case of postoperative pelvic metastasis and multiple liver metastases of the rectal cancer successfully treated by arterial infusion therapy with 5-FU/leucovorin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans; Iliac Artery; | 2004 |
[A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
[Evaluation of intra-arterial infusion chemotherapy associated with radiotherapy for two cases of local recurrence of rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 2004 |
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati | 2004 |
[The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2004 |
Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square | 2004 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Adjuvant chemotherapy in colorectal cancer.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colectomy; Colorectal | 2004 |
Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
[Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2004 |
Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Adjuvant chemo-radiotherapy in ampullary cancers.
Topics: Adult; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct N | 2005 |
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation.
Topics: Adult; Aged; Antineoplastic Agents; Caenorhabditis elegans Proteins; Chemotherapy, Adjuvant; DNA, Ne | 2005 |
Hepatic arterial infusion after liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dex | 2005 |
[Present treatment strategies for rectal carcinoma].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Endosonography; Fluorourac | 2005 |
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2005 |
Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2005 |
[Local failure-related factors of esophageal carcinoma after concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female | 2005 |
Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 2005 |
Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma. Results of 8-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Dose Fractionat | 2005 |
Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Coh | 2005 |
Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA | 2005 |
Preoperative chemoradiation in rectal cancer: why we need a common language.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Progression; Dose F | 2005 |
[Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Recurrent squamous cell carcinoma in the neopharynx treated successfully with topical 5-fluorouracil.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Fluorourac | 2005 |
Outcome after the introduction of a multimodality treatment program for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2005 |
Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2005 |
Prophylactic hepatic irradiation following curative resection of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2005 |
Radiation therapy and simultaneous chemotherapy for recurrent cervical carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis.
Topics: Adenocarcinoma, Sebaceous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Eyelid Neopl | 2005 |
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; | 2005 |
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2005 |
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluoro | 2005 |
Response to neoadjuvant therapy for rectal cancer: influence on long-term results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
[Transcatheter hepatic arterial chemoembolization on recurrent hepatocellular carcinoma after resection].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2005 |
Accelerated radiotherapy for advanced laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
[A case of recurrent breast cancer successfully treated with capecitabine monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Deoxycyti | 2005 |
Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers | 2005 |
Predicting recurrence risk for synchronous primary colon cancers.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cecal N | 2004 |
Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Doxo | 2005 |
Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Carboplatin; Cispla | 2005 |
Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Moda | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |
Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cispl | 2005 |
Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer.
Topics: Aged; Case-Control Studies; Chemotherapy, Adjuvant; Chi-Square Distribution; Female; Fluorouracil; H | 2005 |
Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma; Case-Control Studies; Cisplat | 2005 |
Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohis | 2005 |
Induction redux: once more with taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
[Range of combined treatment of locally advanced skin cancer].
Topics: Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cel | 2005 |
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2005 |
[Radiofrequency ablation (RFA) in colorectal cancer with hepatic metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasm | 2005 |
[Five cases of locally advanced rectal cancer or local recurrence performed intra-arterial infusion chemotherapy via the internal iliac artery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Iliac Artery; Infusion | 2005 |
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined | 2005 |
[A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; An | 2005 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2006 |
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2006 |
Outcome of preoperative concurrent chemoradiotherapy and surgery for resectable lingual squamous cell carcinoma greater than 3 cm: the possibility of less extensive surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2006 |
Long-term results after neoadjuvant radiochemotherapy for locally advanced resectable extraperitoneal rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2006 |
[A case of recurrent gastric cancer with improvement of obstructive symptoms caused by carcinomatous peritonitis and prolonged survival by chemotherapy with combined use of Paclitaxel and 5-FU].
Topics: Adenocarcinoma, Scirrhous; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2006 |
Drug interaction between capecitabine and warfarin: a case report and review of the literature.
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine | 2006 |
Recurrence and 5-FU sensitivity of stage I/II node-negative breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluor | 2006 |
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2006 |
The efficacy of intratumoural 5-fluorouracil for the treatment of equine sarcoids.
Topics: Animals; Antimetabolites, Antineoplastic; Equidae; Female; Fluorouracil; Horse Diseases; Horses; Mal | 2006 |
[Neoadjuvant chemotherapy before radiotherapy in treatment of patients with cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Coronary artery spasm induced by capecitabine.
Topics: Adult; Angina Pectoris; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, | 2006 |
Management of multicentric lesions of the lower genital tract.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cryosurgery; Female; Fluorouracil; Humans; | 2007 |
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ci | 2006 |
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Disease-Free Survi | 2007 |
Pancreatoblastoma in a teenage patient.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Recurrent gestational trophoblastic tumor: management and risk factors for recurrence.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; | 2006 |
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant | 2006 |
[Factors related to recurrence of choriocarcinoma and evaluation of treatment outcomes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin; Chorionic G | 2006 |
[Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
How can we decide on orbital exenteration for second eye in a patient with basal cell carcinoma?
Topics: Aged; Antineoplastic Agents; Carcinoma, Basal Cell; Cheek; Dose Fractionation, Radiation; Fluorourac | 2006 |
Adaptive design: estimation and inference with censored data in a semiparametric model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Computer Simulation; Confidenc | 2007 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin | 2006 |
[Concurrent low-dose cisplatin/5-FU chemotherapy and radiation for the recurrent gastric carcinoma--case reports].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2006 |
Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Fluorouracil; Gene Expression | 2006 |
Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Drug Resistance, Neoplasm; Etoposide; Female; | 2006 |
Analysis of clinical outcomes and prognostic factors of neoadjuvant chemoradiotherapy combined with surgery: intraperitoneal versus extraperitoneal rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Fema | 2006 |
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Female; | 2006 |
Prognostic markers of local relapse in rectal cancer: are we any further forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-F | 2006 |
Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2006 |
Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosp | 2006 |
Neoplastic mesorectal microfoci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 2006 |
Comparison of local recurrence and distant metastases between breast cancer patients after postmastectomy radiotherapy with and without immediate TRAM flap reconstruction.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2006 |
Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2006 |
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Chemotherapy, A | 2007 |
Does clinical and radiological response predict complete tumor control in N2-N3 squamous cell head and neck cancer after non-operative management of the neck?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2006 |
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chi-Square Distributi | 2006 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Chemotherapy, A | 2007 |
Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
[Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
FDG-PET in colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinic | 2006 |
Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinom | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2007 |
Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2006 |
[Management and prognosis in stage IV gestational trophoblastic neoplasia patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Fema | 2006 |
Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[A phase I study of combination-therapy using personalized peptide vaccine and UFT/UZEL for advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; | 2006 |
[Utility of arterial infusion chemotherapy and radiation therapy for the pelvic local recurrence of rectal cancer].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2006 |
Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2007 |
HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 2007 |
Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2007 |
Neoadjuvant chemotherapy in advanced penile carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2007 |
Editorial comment on: Neoadjuvant chemotherapy in advanced penile carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2007 |
[Outcome of gestational trophoblastic neoplasia patients with residual lung tumor after completion of treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Human; | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2007 |
[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; C | 2007 |
Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease- | 2007 |
Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluoro | 2007 |
Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Fluoro | 2007 |
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distribution; Color | 2007 |
Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2007 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Appen | 2007 |
Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 2007 |
One more change of paradigm in breast cancer treatment. Postmastectomy radiotherapy for patients with one to three lymph node metastases?
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2007 |
An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compound | 2008 |
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2007 |
Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Peopl | 2007 |
[A case of local recurrence of colon cancer responding to chemotherapy with low-dose oxaliplatin, 5-FU and l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; C | 2007 |
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2007 |
Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
[Diagnosis and prognosis study of breast carcinoma with micropapillary component].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2007 |
[Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2007 |
Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Epirubicin; | 2007 |
Effect of radiation dose on local control in breast cancer.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modal | 2008 |
[Postoperative radiotherapy of the chest wall in patients with male breast cancer].
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Ch | 2007 |
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2008 |
[A case of recurrent breast cancer with multiple liver metastases responding to combination therapy of capecitabine and MPA].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2007 |
Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cispl | 2007 |
[Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
Laparoscopic total mesorectal excision after neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; Female; Fluorouracil; F | 2007 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
[A patient with recurrent sigmoid colon cancer in whom pleural effusion and ascites resolved after FOLFOX 4 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Fluorouracil; Humans; Leuco | 2007 |
A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cisplatin; Combined Modality T | 2007 |
Treatment of metastatic urachal carcinoma in an elderly woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Com | 2008 |
Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2008 |
Orbital invasion despite topical anti-metabolite therapy for conjunctival carcinoma.
Topics: Administration, Topical; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Con | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for recurrence and survival rate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hum | 2008 |
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Chemotherapy, Adjuvant; Colectomy; Color | 2008 |
[Treatment of colonic cancer and follow up].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colon; Colonic Neoplasms; Colost | 2007 |
[Treatment of rectal cancer and follow up].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonoscopy; Endoscopy; Female; Fluorouraci | 2007 |
[Chemotherapy in patients with colorectal carcinoma: applicability of data from clinical trials for the individual patient].
Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Mod | 2008 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Intraoperative radiation therapy in resected pancreatic carcinoma: long-term analysis.
Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluo | 2008 |
Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Confidence I | 2008 |
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Combi | 2009 |
Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease-Free Survival; Dr | 2008 |
Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
[Treatment of advanced maxillary sinus squamous carcinoma: an analysis of 92 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2008 |
Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
[A case of recurrent rectal cancer with lymphangiosis carcinomatosa successfully treated with modified FOLFOX6 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Lung Neopl | 2008 |
Disseminated melanoma. Biologic behavior and treatment.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Fluorouracil; Humans; Hydrazine | 1967 |
5-fluorouracil therapy for cancer of the stomach.
Topics: Animals; Fluorouracil; Hematopoietic System; Humans; Mice; Neoplasm Recurrence, Local; Radiography; | 1967 |
[Drug therapy in advanced squamous cell carcinoma of the ORL region].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1984 |
Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Cholestasis, Extrahepatic; Combined Modality Therapy; Doxorubicin; | 1984 |
High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose-Res | 1983 |
Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms.
Topics: Choriocarcinoma; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Hydatidiform Mole, Invas | 1984 |
Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Administr | 1980 |
Chemotherapy for head and neck cancer relapsing after radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Ther | 1981 |
Adjuvant and palliative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Humans; Liver | 1981 |
Colorectal cancer. Radiotherapy.
Topics: Animals; Carcinoembryonic Antigen; Colonic Neoplasms; Dose-Response Relationship, Radiation; Fluorou | 1982 |
Multidisciplinary treatment of maxillary sinus carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1983 |
Non-platinum-containing combination chemotherapy for stage III-IV head and neck squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamid | 1983 |
Ten years' experience with a multimodality treatment of advanced stages of rectal cancer.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Re | 1983 |
Sequential half-body irradiation (SHBI) and combination chemotherapy as salvage treatment for failed Ewing's sarcoma--a pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Child; Fluor | 1984 |
[Clinical evaluation of neocarzinostatin in digestive system cancer. 1. Administration of neocarzinostatin in advanced and recurrent carcinoma of the stomach].
Topics: Antibiotics, Antineoplastic; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; | 1983 |
[Clinical evaluation of neocarzinostatin in digestive system cancer. 2. Clinical studies on the administration of neocarzinostatin in advanced and recurrent carcinoma of the pancreas].
Topics: Antibiotics, Antineoplastic; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Parenteral; | 1983 |
Chemotherapy for adenocystic carcinoma.
Topics: Alkylating Agents; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Fluorouracil; Humans; Lung Neop | 1980 |
Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Doxorubicin; Drug | 1983 |
Prognostic significance of hormone receptors in early recurrence of breast cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1983 |
Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy.
Topics: Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Colonic Neoplasms; Combined Modali | 1984 |
Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1983 |
Combined modality therapy for esophageal squamous cell carcinoma.
Topics: Abdomen; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Esophageal Neoplasms; Eso | 1983 |
Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases.
Topics: Adult; Aged; Antineoplastic Agents; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Drug Th | 1983 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra | 1984 |
Prophylactic long-term treatment of bladder tumors with oral chemotherapy (tegafur).
Topics: Actuarial Analysis; Administration, Oral; Adult; Aged; Combined Modality Therapy; Female; Fluorourac | 1984 |
[Effects of long-term administration of Tegafur on patients with relapsing advanced carcinoma (stage D) of the prostate].
Topics: Aged; Estrogens; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo | 1983 |
Intra-arterial infusion chemotherapy in rectal cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluoroura | 1984 |
Chemotherapy programs of the National Prostatic Cancer Project (NPCP).
Topics: Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Evaluation; Drug Ther | 1980 |
Carcinoma of the hand: a 20-year experience.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Female; Fluorouracil; Fol | 1984 |
[Simultaneous combined radio-/chemotherapy of locally recurring breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cobalt Radioisotopes; | 1984 |
Wide local excision in the treatment of vulvar carcinoma in situ: a reappraisal.
Topics: Administration, Topical; Adult; Aged; Carcinoma in Situ; Female; Fluorouracil; Follow-Up Studies; Hu | 1984 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
Ineffectiveness of 5-fluorouracil and cis-platin as second-line chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1984 |
Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorourac | 1984 |
[Use of adriamycin in the treatment of metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Castr | 1984 |
[Effect of CAF'-endocrine therapy on advanced and recurrent breast cancer].
Topics: Adult; Aged; Androstanols; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calcito | 1984 |
Basal cell carcinoma. Treatment modalities and recommendations.
Topics: Carcinoma, Basal Cell; Cryosurgery; Electrosurgery; Facial Neoplasms; Fluorouracil; Humans; Neoplasm | 1983 |
Psychosocial implications of adjuvant chemotherapy. A two-year follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Attitude; Breast Neoplasms; Combined Modality Therap | 1983 |
[Partial laryngectomy following combined FAR therapy--evaluation of survival rate and region of recurrence studied by an antomical map].
Topics: Combined Modality Therapy; Fluorouracil; Humans; Laryngeal Neoplasms; Laryngectomy; Neoplasm Recurre | 1983 |
[Procedure and results of combined radiation and surgical treatment of laryngeal cancer patients].
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco | 1983 |
Malignant tumors of the vagina. Classification and approach to treatment.
Topics: Adenocarcinoma; Adolescent; Adult; Carcinoma in Situ; Carcinoma, Squamous Cell; Child; Diethylstilbe | 1983 |
Multimodal treatment of locoregionally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Cyclopho | 1983 |
[Survival and factors related to the survival of recurrent breast cancer patients--a study with quantification theory].
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1983 |
Condyloma acuminatum of the urethra: problems in eradication.
Topics: Adult; Combined Modality Therapy; Condylomata Acuminata; Electrocoagulation; Fluorouracil; Humans; M | 1984 |
The natural history of gastric cancer and prognostic factors influencing survival.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic M | 1984 |
Intravesical high dose 5-fluorouracil instillations combined with allopurinol--a therapeutic alternative in the treatment of multiple bladder tumors.
Topics: Allopurinol; Carcinoma, Transitional Cell; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm | 1984 |
[Radiotherapy and combined modality treatment of advanced gastrointestinal tumors. Analysis of morbidity in 101 patients].
Topics: Aged; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hyperthermia, Ind | 1984 |
Inhibition of stomal recurrence in laryngectomy with preoperative far therapy. A statistical evaluation.
Topics: Combined Modality Therapy; Diterpenes; Fluorouracil; Humans; Laryngeal Neoplasms; Laryngectomy; Neop | 1984 |
Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Combined Modality The | 1984 |
Conservative management of low grade neoplasms of the male urethra: a preliminary report.
Topics: Adult; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Middle Ag | 1980 |
[Combined chemoimmunotherapy in stomach cancer and hematosarcoma].
Topics: Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hemangiosarcoma; Humans; Immunotherapy; N | 1980 |
[Use of a combination of pyrogenal and drug preparations in the overall treatment of breast cancer].
Topics: Adult; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1980 |
[Combination chemotherapy including anablastine in disseminated breast cancer].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; | 1981 |
[ACF combination consisting of adriamycin, cyclophosphamide and oral futraful for recurrent advanced breast cancer (author's transl)].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Flu | 1981 |
Chemoradiotherapeutic prevention of local recurrence after stapled anastomoses in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Follow-Up Studies; Humans; | 1981 |
Effectiveness of postoperative adjuvant therapy with cytotoxic chemotherapy (cytosine arabinoside, mitomycin C, 5-fluorouracil) or immunotherapy (neuraminidase-modified allogeneic cells) in the prevention of recurrence of Duke's B and C colon cancer.
Topics: Aged; Colonic Neoplasms; Cytarabine; Female; Fluorouracil; Humans; Immunotherapy; Male; Middle Aged; | 1981 |
[Chemotherapy of stomach cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cisplatin; Doxorubicin; Drug Administration Sched | 1982 |
[Clinical trial of UFT in recurrent or advanced cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1982 |
Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; | 1983 |
Concurrent chemotherapy and radiotherapy for nonmetastatic, Stage IV breast cancer. A pilot study by the Southeastern Cancer Study Group.
Topics: Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, C | 1983 |
Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1981 |
Treatment of maxillary cancer with three-combined method.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Male; Maxillary Neoplasms; Middle Aged; Neoplasm Recurren | 1980 |
The medical management of breast cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castrati | 1982 |
Topical 5-FU helpful in reducing the rate of recurrence of condylomata acuminata.
Topics: Condylomata Acuminata; Female; Fluorouracil; Genital Neoplasms, Female; Genital Neoplasms, Male; Hum | 1982 |
[Non-surgically treated primary malignant lymphoma of the brain: recurrences in 2 occasions following the cessations of antineoplastic agent administration].
Topics: Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphoma; Mitomycins | 1982 |
[Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat | 1982 |
[Ancillary chemotherapy with trofosfamid, methotrexate and fluoro-uracil in cancer of the breast (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphat | 1981 |
Anaplastic malignant neoplasms: diagnosis and treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorub | 1981 |
The use of dinitrochlorobenzene in the treatment of vulvar carcinoma in situ.
Topics: Administration, Topical; Adult; Carcinoma in Situ; Dinitrochlorobenzene; Female; Fluorouracil; Human | 1981 |
[Late results of the combined treatment of stomach cancer in relation to individual tumor sensitivity to 5-fluorouracil].
Topics: Adult; Drug Resistance; Female; Fluorouracil; Gastrectomy; Humans; In Vitro Techniques; Male; Middle | 1981 |
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Dru | 1981 |
Topical 5-fluorouracil treatment of vaginal intraepithelial neoplasia.
Topics: Administration, Topical; Adult; Aged; Carcinoma in Situ; Drug Evaluation; Female; Fluorouracil; Huma | 1981 |
Concomitant hepatic radiation and intraarterial fluorinated pyrimidine therapy: correlation of liver scan, liver function tests, and plasma CEA with tumor response.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Carcinoembryonic Antigen; Fluorouracil; Humans; I | 1981 |
Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1980 |
[Adjuvant chemotherapy in breast neoplasms. Clinical and immunologic results].
Topics: Adult; Aged; Breast Neoplasms; Concanavalin A; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph | 1980 |
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medr | 1980 |
Basal cell carcinoma.
Topics: Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Cryosurgery; Female; Fluorouracil; Humans; Male; N | 1980 |
Chemotherapy of recurrent/advanced cervical cancer: results of the Yale University PBM-PFU protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Female | 1994 |
[Hepatocellular carcinoma in pregnancy].
Topics: Adult; Carcinoma, Hepatocellular; Cesarean Section; Chemotherapy, Adjuvant; Combined Modality Therap | 1994 |
Whole abdominal radiotherapy and concomitant 5-fluorouracil as adjuvant therapy in advanced colon cancer.
Topics: Abdomen; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hum | 1995 |
Cancer recurrence following laparoscopic colectomy. Report of two patients treated with heated intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Laparosco | 1995 |
Combined radiochemotherapy for postoperative recurrence of oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1995 |
Positron emission tomography in the detection of residual laryngeal carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, | 1995 |
[The experience of concurrent radiotherapy and chemotherapy for advanced or recurrent esophageal cancers--continuous infusion of 5-FU and low dose cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1995 |
[Treatment using concomitant radiochemotherapy of N+ M0 stage urothelial tumors of the bladder].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1995 |
Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1995 |
Breast cancer: are imaging studies cost effective following breast cancer and adjuvant therapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 1995 |
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 1993 |
Fine needle aspiration (FNA) in diagnosing recurrent squamous cell carcinoma of the head and neck: truth or consequences?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cobalt Rad | 1993 |
Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Che | 1995 |
Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carci | 1995 |
Multimodality therapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1995 |
Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: a Southwest Oncology Group Pilot study.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hum | 1995 |
[Home therapy approach in cancer patients-nutrition therapy (case 1-1)--a case of recurrent gastric cancer with home parenteral nutrition].
Topics: Fluorouracil; Home Infusion Therapy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Parenter | 1994 |
[The use of endolymphatic chemotherapy in patients with metastatic stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox | 1995 |
Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Fluor | 1994 |
Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Chemot | 1994 |
Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1995 |
[A case report of rectal cancer with lymph node metastasis effectively treated by neoadjuvant chemotherapy of 5-FU oral and low-dose CDDP transarterial administration].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1994 |
Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Comb | 1994 |
[Effects of combination chemotherapy using 5-FU, leucovorin, and CDDP (FLP therapy) for noncurative resected or recurrent stomach cancer in outpatients].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant | 1994 |
Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1994 |
[The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1994 |
Chemoradiotherapy of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 1994 |
[Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1994 |
Patterns of early treatment failure in non-metastatic nasopharyngeal carcinoma: a study based on CT scanning.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; C | 1994 |
Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1994 |
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer.
Topics: Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit | 1993 |
Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, | 1994 |
Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1994 |
[Radiotherapy versus radiotherapy plus 5-FU in inoperable or recurrent rectal cancer].
Topics: Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal Neoplasms | 1994 |
[Adjuvant chemotherapy in ovarian carcinoma. Preliminary results].
Topics: Adnexa Uteri; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bulgaria; Carcinoma; Chem | 1993 |
Histopathological findings after preoperative chemo-radiotherapy in oral and oropharyngeal carcinoma. A study of 28 resected specimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1993 |
Results of treatment of laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Female; Fluorouracil | 1994 |
Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin.
Topics: Anal Gland Neoplasms; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Co | 1993 |
[Reservoir system implantation technique via the inferior epigastric artery for local recurrence of rectal cancer].
Topics: Aged; Cisplatin; Embolization, Therapeutic; Evaluation Studies as Topic; Female; Fluorouracil; Human | 1993 |
Carboquone combined with methotrexate and 5-fluorouracil for recurrent and advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Female; Fluorouracil; | 1993 |
[Successful treatment of recurrent multiple lung metastasis from colon cancer with combination chemotherapy using methotrexate, 5-fluorouracil, and high-dose leucovorin: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; Hu | 1993 |
[Evaluation of neoadjuvant combination chemotherapy with pirarubicin, carmofur and tamoxifen citrate on outpatients with advanced and recurrence breast cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 1994 |
Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxoru | 1994 |
Epidermoid carcinoma of the anal canal: treatment by combined radiation and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo | 1993 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
[Intra-arterial chemotherapy with 5-FU (weekly high dose 5-FU HAI) for the prevention of tumor recurrence in residual liver after hepatic resection of metastasis from colorectal cancer].
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; | 1993 |
[Clinical effect and characteristics of low dose leucovorin and high dose 5-FU therapy in patients with recurrent gastric cancer--a new method of biochemical modulation].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1993 |
Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; | 1993 |
Dose-intensive therapy for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Bra | 1993 |
Chemoradiotherapy of anal carcinoma: tumour response and acute toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1993 |
Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administ | 1993 |
[Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy in metastatic breast cancer].
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 1993 |
Second-look laparotomy in the management of patients after radical surgery for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamid | 1993 |
[Metachronous liver metastases treated with repeated liver resections and chemotherapy].
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neop | 1993 |
Treatment of relapsing anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1993 |
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1993 |
[Quandrantectomy in the conservative treatment of breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Thera | 1993 |
Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1993 |
Postoperative radiation therapy for high-risk colon carcinoma.
Topics: Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Lymphatic Metastas | 1993 |
DNA content and tumor response to induction chemotherapy in patients with advanced laryngeal squamous cell carcinoma.
Topics: Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplati | 1993 |
Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
Topics: Adult; Antineoplastic Agents; Carcinoma; Chemotaxis, Leukocyte; Chemotherapy, Adjuvant; Colorectal N | 1995 |
Neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breas | 1996 |
Prognostic value of tumor regression during radiotherapy or chemoradiotherapy for advanced head and neck cancers: regarding Jaulerry et al. IJROBP 33(2):271-279; 1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1996 |
Synergistic inhibitory effects of interferon-alpha and 5-fluorouracil in meningioma cells in vitro.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carbon Radioisotopes; Cell Division; Drug Syn | 1996 |
Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A | 1995 |
Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1996 |
c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1995 |
Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
Curative reoperations for locally recurrent rectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Ma | 1996 |
Locally advanced rectal cancer: resection and intraoperative radiotherapy using the flab method combined with preoperative or postoperative radiochemotherapy.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Intraoperative Period | 1996 |
Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 1996 |
Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation.
Topics: Actuarial Analysis; Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineop | 1996 |
[Association of 5-FU, CDDP and hypofractionated radiotherapy in recurrences of subtentorial astrocytomas and malignant gliomas in adults].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; | 1990 |
Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 1996 |
[A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluorou | 1996 |
[Infiltrating cancer of the bladder: can radiochemotherapy be an alternative to cystectomy?].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1996 |
Comparison by carcinoembryonic antigen doubling time of hepatic injection and infusion for unresectable hepatic metastasis from colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; Female; F | 1995 |
[Usefulness of continuous arterial infusion chemotherapy for post operative multiple recurrence and residual hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 1996 |
[Indication of prophylactic hepatic arterial-infusion chemotherapy after hepatic resection for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusi | 1996 |
[Preoperative chemoradiation therapy for lower rectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1996 |
[A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 1996 |
Preoperative radiotherapy for rectal cancer: benefits and controversies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neopl | 1996 |
Postoperative radiotherapy for locally advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 1996 |
Month-long postoperative radiotherapy and 5-FU improve survival in rectal cancer.
Topics: Antimetabolites, Antineoplastic; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; | 1996 |
Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
Progress in rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1996 |
[A case of recurrent gallbladder cancer with marked response to arterial infusion chemotherapy and transarterial embolization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Drug Administration Sche | 1997 |
[A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colectomy; Colonic Neop | 1997 |
[Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chem | 1997 |
Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 1997 |
Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Fluorourac | 1997 |
[Combined breast-preserving surgery, chemotherapy and radiotherapy in the treatment of breast carcinoma. Effect of the interval between surgery and the beginning of radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
[The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy].
Topics: Antimetabolites, Antineoplastic; Celiac Artery; Combined Modality Therapy; Evaluation Studies as Top | 1996 |
Neoadjuvant treatment of local recurrence of rectal cancer: our experience.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1997 |
Carcinoma of the esophagus treated with radical chemoradiation 19 years after irradiation for recurrent breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamou | 1997 |
[A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 1997 |
Intensive chemotherapy using cisplatin and fluorouracil followed by radiotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1997 |
Locally recurrent colorectal cancer: IOERT and EBRT +/-5-FU and maximal resection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal | 1997 |
[The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Female; Fluoroura | 1997 |
Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 1997 |
Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model.
Topics: Animals; Anti-Infective Agents, Local; Antimetabolites, Antineoplastic; Chlorhexidine; Colorectal Ne | 1997 |
Effectiveness of selective neck dissection for management of the clinically negative neck.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
[High-dosage chemotherapy and autologous transplant of hematopoietic germ cells from peripheral blood in high-risk recurrence carcinoma of the breast (with >= or 10 involved axillary nodes at diagnosis) Preliminary results of the Solti 9301 cooperative st
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Combin | 1997 |
[Preoperative irradiation and interstitial radiotherapy-hyperthermia boost in breast tumors > or = 3 cm. The Düsseldorf experience].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A | 1997 |
[A case of multiple liver metastasis and local recurrence from rectal cancer effectively treated by arterial infusion chemotherapy using low-dose 5-fluorouracil, cisplatin and LV].
Topics: Adult; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sch | 1997 |
[A case of postoperative recurrence of hepatocellular carcinoma successfully treated with arterial infusion chemotherapy using cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1997 |
Four years experience of primary intra-arterial chemotherapy (PIAC) for locally advanced and recurrent breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast | 1997 |
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 1998 |
Topical treatment of vaginal recurrence of endometrial carcinoma with 5-fluorouracil: case-report.
Topics: Adenocarcinoma; Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; B | 1997 |
Conservative surgery and radiotherapy in early stage breast cancer: a comparison between tumourectomy and quadrantectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 1998 |
Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial.
Topics: Abdomen; Adenocarcinoma; Adjuvants, Immunologic; Anal Canal; Antidotes; Antimetabolites, Antineoplas | 1998 |
[Successful chemotherapy based on in vitro chemosensitivity testing in a case of recurrent thymic carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Adenosquamous; Cis | 1998 |
Diagnosis and management of metastatic gastrinoma by multimodality treatment including liver transplantation: report of a case.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fema | 1998 |
Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1997 |
[How I treat colorectal cancer. I. Prevention and adjuvant treatment].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antimeta | 1998 |
Cyclophosphamide, adriamycin, 5-fluorouracil and high-dose toremifene for patients with advanced/recurrent breast cancer. The Japan Toremifene Cooperative Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1998 |
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Female; Fluorouraci | 1998 |
p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Immuno | 1998 |
[Intra-arterial infusion chemotherapy for unresectable or recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Doxorubicin | 1998 |
Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 1998 |
Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 1998 |
The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neopl | 1998 |
[Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1998 |
High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Carcinom | 1998 |
[Combined chemotherapy with low-dose cisplatin, tegafur and uracil in a case with neck recurrence of laryngeal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
[Second recurrence of a local spinocellular cutaneous epithelioma: treatment with intra-arterial sequential chemo-infusion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1998 |
[Results of organ-preserving and reconstructive surgery of the mandible in patients with cancer of the oral cavity].
Topics: Adult; Alveolar Process; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; H | 1998 |
Adjuvant chemotherapy for patients with resected Dukes' C and high-risk B2 colon cancer with fluorouracil and levamisole.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; | 1998 |
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1999 |
The effectiveness of chemotherapy with cisplatin and 5-fluorouracil for recurrent small cell neuroendocrine carcinoma of the rectum: report of a case.
Topics: Adenoma, Villous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcino | 1999 |
[Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic N | 1999 |
[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, | 1999 |
Induction chemotherapy and radiation therapy for T4 oropharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisp | 1999 |
Complete regression of recurrent esophageal carcinoma with reduced expression of glutathione S-transferase-pi by treatment with continuous infusion of 5-fluorouracil and low-dose cisplatin infusion.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
[Total pelvic exenteration and rectal cancer. Apropos of 20 cases].
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 1999 |
[A case of liver metastases from gastric cancer responding to induced hypertensive chemotherapy with angiotensin II].
Topics: Aged; Angiotensin II; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic C | 1999 |
[A case of recurrent colon cancer with complete response to modulation chemotherapy using low-dose leucovorin and 5-fluorouracil].
Topics: Aged; Antimetabolites, Antineoplastic; Colon, Sigmoid; Combined Modality Therapy; Fluorouracil; Huma | 1999 |
Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Flu | 1999 |
Colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1999 |
Adjuvant regional chemotherapy after hepatic resection for colorectal metastases.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 1999 |
Estradiol receptor and prognostic parameters of human breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 1999 |
Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB-IVA squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; F | 1999 |
[A case of local recurrence of rectal cancer responding to local intraarterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Huma | 1999 |
High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 1999 |
Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisp | 1999 |
Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Catheterization, Central Venous; Cohort Studies; Colonic | 1999 |
Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 1999 |
The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma, | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
Pre-operative chemoradiotherapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, Antineoplast | 1999 |
Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carci | 1999 |
Improved outcome following preoperative radiochemotherapy: 40.5 Gy accelerated hyperfractionation and 5-fluorouracil suppositories for patients with carcinoma of the lower rectum.
Topics: Administration, Rectal; Aged; Antimetabolites, Antineoplastic; Carcinoma; Case-Control Studies; Comb | 1999 |
[Efficacy of adjuvant hepatic arterial infusion chemotherapy following resection of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 1999 |
[Palliative chemo-radiotherapy for abdominal recurrence of esophageal carcinoma--case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combi | 1999 |
Treatment of mammographically detected minimal breast cancer in an older woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2000 |
Primary neuroendocrine small cell carcinoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Carcinoma, | 2000 |
[Successful treatment of a patient with recurrent ovarian clear cell adenocarcinoma under combination chemotherapy of 5-FU (civ) and low-dose CDDP (i.v.)].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2000 |
Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Conjunctiv | 2000 |
Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2000 |
Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2000 |
The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bone Marrow Transplant | 1999 |
Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: value of adjuvant irradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 1999 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility Studies; Female | 2000 |
[Initial locoregional chemotherapy in recurrent and locoregional advanced or inoperable stages of pelvic uterine and anorectal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Cisplatin; D | 1995 |
Continuous intra-arterial 5-FU chemotherapy in a patient with a repeated recurrence of rectal cancer: report of a case.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Fluorouracil; Humans; Infusions, In | 2000 |
Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting | 2000 |
Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Marrow; Bon | 2000 |
Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2000 |
Wide-field radiation as adjunct to adjuvant chemotherapy in high-risk cases with early breast cancer: do it or not?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cause of Death; Chemotherapy, Adju | 2000 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Colonic Neopla | 2000 |
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
Local recurrence after mastectomy and adjuvant CMF: implications for adjuvant radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2000 |
The bulky 6-cm barrel-shaped lesion of the cervix: primary surgery and postoperative chemoradiation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 2000 |
Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2000 |
Malignant proliferating trichilemmal tumor in the skin over the breast: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Squamous | 2000 |
Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy for maxillary sinus carcinoma.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Maxi | 2000 |
[Chemotherapy for unresectable recurrent or metastatic squamous cell carcinomas of the head and neck].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2000 |
Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; | 2000 |
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2000 |
[Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine | 2000 |
Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Spontaneous apparent clinical resolution with histologic persistence of a case of extramammary Paget's disease: response to topical 5-fluorouracil.
Topics: Anus Neoplasms; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Humans; Neop | 2000 |
Efficacy of intra-hepatectomy 5-FU on recurrence and metastasis of human hepatocellular carcinoma in nude mice.
Topics: Animals; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms, Expe | 2001 |
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; D | 2001 |
Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 2001 |
[The prospects of the outpatient clinic or home anti-cancer chemotherapy for unresectable recurrence of colorectal cancer].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 2000 |
[Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrouracil Dehydr | 2000 |
Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Biomarkers, T | 2001 |
Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2001 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytid | 2001 |
Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
Fourth International Conference on Colorectal Cancer: adjuvant treatment of colon cancer--introduction.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Therap | 2001 |
Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody | 2001 |
Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluor | 2001 |
Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Car | 2001 |
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Resist | 2001 |
[Effective combination chemotherapy for a recurrent case of carcinoma of the remnant stomach].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2001 |
[Treatment of rectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Combined Modality Therapy; Drug Therapy, Combination | 2001 |
[Clinical experience of intermittent administration of 5-FU and CDDP to patients with advanced and recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2001 |
Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuva | 2001 |
[Intermittent administration of 5-FU and isovorin to patients with advanced and recurrent colon cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2001 |
T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Mo | 2001 |
[Therapy results of locoregional recurrences in rectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2001 |
Locally recurrent adenoid cystic carcinoma of the left antrum: response to epirubicin, cisplatin and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; Disease-Free S | 2001 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compou | 2001 |
Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma in Situ; Conjunctival Neopla | 2002 |
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2001 |
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2001 |
Markers of drug resistance in relapsing colon cancer.
Topics: Aneuploidy; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette | 2002 |
Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases.
Topics: Adult; Aged; Angiography; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Ducts, Extrah | 2002 |
High-dose adjuvant chemotherapy for patients with high-risk breast cancer: efficacy is still an open question.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvan | 2000 |
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clin | 2002 |
Results of an organ preservation protocol with induction chemotherapy and radiotherapy in patients with locally advanced pyriform sinus carcinoma.
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Laryngeal Neoplasms; Neoplasm Recurrence | 2002 |
[A case of recurrent rectal cancer responding to weekly low-dose CPT-11/isovorin/5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Fl | 2002 |
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine | 2002 |
Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adj | 2002 |
Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Digestive System S | 2002 |
Metastatic astrocytoma in the parotid.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biopsy, Needle; Brain Neop | 2002 |
Trimodal combination therapy for maxillary sinus carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combin | 2002 |
Management of oral and pharyngeal cancer: a multidisciplinary approach.
Topics: Bleomycin; Carcinoma, Squamous Cell; Fluorouracil; Humans; Lymphatic Metastasis; Mouth Floor; Mouth | 1975 |
The value of combined 5-fluorouracil and x-ray therapy in the palliation of locally recurrent and inoperable rectal carcinoma.
Topics: Fluorouracil; Humans; Neoplasm Recurrence, Local; Palliative Care; Radiotherapy Dosage; Rectal Neopl | 1975 |
[Radiotherapy of inoperable orofacial squamous epithelial carcinomas following pharmacologically induced partial synchronization].
Topics: Aged; Carcinoma, Squamous Cell; Cell Movement; DNA; Fluorouracil; Humans; Male; Mouth Neoplasms; Neo | 1975 |
Seven-drug polychemotherapy in the treatment of advanced and recurrent squamous carcinoma of the female genital tract.
Topics: Adult; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Dac | 1975 |
Long-term topical 5-FU therapy: report of two cases.
Topics: Administration, Topical; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Neoplas | 1978 |
[Therapeutic advances in digestive oncology. III. Chemotherapy of digestive system cancers].
Topics: Adenocarcinoma; Digestive System Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplas | 1979 |
Results of cytostatic therapy of metastasizing testicular tumors.
Topics: Fluorouracil; Humans; Neoplasm Recurrence, Local; Postoperative Period; Radiotherapy, High-Energy; R | 1978 |
Observations on the postoperative tumor growth behavior of certain islet cell tumors.
Topics: Adenoma, Islet Cell; Fasting; Fluorouracil; Gastrins; Humans; Liver Neoplasms; Neoplasm Metastasis; | 1976 |
[Status and problems of the treatment of metastatic rectal cancer].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Neoplasm Recurren | 1979 |
[Regression of a recurrent malignant glioma by combined chemoradiotherapy utilizing carboquone, FT-207 and telecobalt--report of a case (author's transl)].
Topics: Azirines; Brain Neoplasms; Carbazilquinone; Cobalt Radioisotopes; Drug Therapy, Combination; Fluorou | 1977 |
Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study.
Topics: Administration, Topical; Carcinoma, Basal Cell; Curettage; Fluorouracil; Follow-Up Studies; Humans; | 1979 |
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gas | 1979 |
Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Me | 1979 |
Topical 5-fluorouracil in the treatment of intraepithelial neoplasia of the vagina.
Topics: Administration, Topical; Carcinoma in Situ; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local | 1979 |
Some newer approaches to the treatment of the mucosa of patients with superficial bladder cancer: 1. Continuous bladder irrigation with 5-fluorouracil.
Topics: Fluorouracil; Humans; Mucous Membrane; Neoplasm Recurrence, Local; Therapeutic Irrigation; Urinary B | 1979 |
Postirradiation squamous cell carcinoma in situ of the vagina: treatment by topical 20 percent 5-fluorouracil cream.
Topics: Administration, Topical; Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; | 1979 |
[Synchronization of squamous-cell carcinoma cell populations by 5-fluorouracil in radiation therapy].
Topics: Aged; Carcinoma, Squamous Cell; Cell Cycle; Fluorouracil; Humans; In Vitro Techniques; Interphase; L | 1979 |
Bowen's disease and 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Bowen's Disease; Carcinoma, Squamous Cell; Female; Fluorouraci | 1979 |
[How could the results of surgical treatment of bronchogenic carcinoma be improved? (authors transl)].
Topics: Angiography; Carcinoma, Bronchogenic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoroura | 1978 |
Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma.
Topics: Administration, Topical; Carcinoma, Basal Cell; Face; Fluorouracil; Humans; Neoplasm Recurrence, Loc | 1978 |
[Contribution to the radiation therapy of malignant tumors in the regions of the head and neck using the synchronization effects of fluorouracil (author's transl)].
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal | 1978 |
Chemotherapy for known residual disease after resection of gastric and colorectal cancer.
Topics: Carcinoembryonic Antigen; Carmustine; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; H | 1978 |
Ongoing trials in the surgical adjuvant management of colorectal cancer.
Topics: Antineoplastic Agents; BCG Vaccine; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; F | 1978 |
Chemoimmunotherapy of syngeneic mouse mammary carcinomas employing methanol extraction residue.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; BCG Vaccine; Cyclophosphamide; Female; Fluorouracil; | 1976 |
[Chemotherapy of bronchial carcinomas (author's transl)].
Topics: Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Drug Therapy, | 1975 |
Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluo | 1977 |
Bowen's Disease of the Finger.
Topics: Adult; Aged; Bowen's Disease; Carcinoma, Squamous Cell; Female; Fingers; Fluorouracil; Humans; Male; | 1977 |
Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate.
Topics: Adenocarcinoma; Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil | 1977 |
Chemotherapy of carcinoma of the cervix.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Squamous Cel | 1977 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
[Combination chemotherapy in the treatment of polymetastic breast cancer. Comparison of therapeutic effects of 2 methods of sequential drug administration. Role of adriamycin in these combinations].
Topics: Adenocarcinoma; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drug Tol | 1976 |
Clinical chemistry and breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Melphalan; Methotrexat | 1976 |
[Late results of the prophylactic treatment with 5-fluorouracil of cancer of the large intestine and rectum].
Topics: Adult; Aged; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Large | 1976 |
Combined chemotherapy and cryosurgery for oral cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cryosurgery; Drug Therapy, Combination | 1975 |
Squamous-cell carcinoma of the anus arising in a giant condyloma acuminatum: report of a case.
Topics: Administration, Topical; Anal Canal; Anus Diseases; Anus Neoplasms; Carcinoma, Squamous Cell; Condyl | 1975 |
Chemotherapy in the treatment strategy of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1975 |
Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laparotomy, and radiation therapy.
Topics: Adenocarcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Laparotomy; Melp | 1975 |
Combination chemotherapy as an adjuvant treatment in operable breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Intradermal 5-fluorouracil in the treatment of basal cell carcinoma of the face.
Topics: Aged; Carcinoma, Basal Cell; Facial Neoplasms; Female; Fluorouracil; Humans; Injections, Intradermal | 1976 |
New attitudes in cancer treatment: breast cancer and adjuvant therapy.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotr | 1976 |
Intraarterial 5-FU-infusion and simultaneous radiotherapy as palliative treatment of recurrent rectal cancer.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Iliac Artery; Infusions, Intra | 1992 |
[The efficacy of polychemotherapy with cisplatin, methotrexate and 5-fluorouracil in inoperable forms of squamous cell cancer of the head and neck area].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Eva | 1992 |
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle | 1992 |
[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeut | 1992 |
Comparison of partial and modified radical mastectomy in the community setting--"10 years later".
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; | 1992 |
[Prophylactic chemotherapy by regional arterial infusion in resected hepatoma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 1992 |
Combination of 5-FU cisplatinum and hypofractionated irradiation followed by split-course radiotherapy in 47 patients with unresectable non small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 1992 |
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A | 1992 |
[The percutaneous-endocavitary irradiation of esophageal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Cisplatin; Combined Modali | 1992 |
[A case of complete response of locally advanced breast cancer to arterial infusion chemotherapy: cannulation through the right femoral artery and combined use of G-CSF].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, I | 1992 |
Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; | 1992 |
Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Comb | 1992 |
Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Com | 1992 |
Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 1992 |
[Transanorectal ultrasonography in the evaluation of extension and the monitoring of epidermoid cancers of the anus treated by radiation or chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1992 |
T1 squamous cell carcinoma of the arytenoid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arytenoid Cartilage; | 1992 |
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi | 1992 |
[Cancer chemotherapy for recurrence of breast cancer employing implantable system via right internal mammary vein].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Cycl | 1992 |
Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1992 |
[Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1992 |
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and | 1992 |
Intra-abdominal panniculitis can mimic recurrent stomach carcinoma.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diagnosis, Diff | 1992 |
Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance | 1992 |
Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery .
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide: feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1992 |
Intravenous or oral adjuvant CMF for node-positive breast cancer.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemot | 1992 |
Achieving local control for inflammatory carcinoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cobalt Radioisotopes; C | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
[A case of recurrent hepatocellular carcinoma after hepatic resection surviving over five years by hepatic arterial infusion of lipiodol-anticancer drug suspension].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 1991 |
Squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 1991 |
Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1991 |
[Successful treatment of recurrent kidney pelvic squamous cell cancer with chemotherapy and radiotherapy: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug | 1991 |
[Systemic therapy in recurrent and primary advanced cervix cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Response of brain metastases from breast cancer to systemic chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 1992 |
[Adjuvant treatment of resected colon cancers using a 5-fluorouracil-levamisole combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1991 |
A metastatic breast carcinoma presenting as autoimmune hemolytic anemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1991 |
Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Animals; Azoxymethane; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dise | 1991 |
Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cispl | 1991 |
[Evaluation of continuous intra-arterial infusion chemotherapy after hepatic resection of liver metastases in colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1991 |
[Interstitial hyperthermia (MINERVE) for perineal local recurrence of rectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cispl | 1991 |
Combined modality treatment of advanced cancers of the oral cavity and oropharynx.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1991 |
Intraoperative radiation therapy in the treatment of recurrent carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
The force of change in the management of squamous-cell cancer of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1991 |
Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1991 |
Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusi | 1991 |
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: results of a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1991 |
[Adjuvant chemotherapy in premenopausal women].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1991 |
[Results of treatment following breast-saving therapy: analysis of intramammary recurrence].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, | 1990 |
Combined-modality therapy for rectal carcinoma--the time has come.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal | 1991 |
Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1991 |
5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 1991 |
Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1991 |
Treatment of metastatic gastric carcinoma with a modified FAMTX chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1990 |
[Intra-arterial chemotherapy in inoperable and recurrent rectal tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Injections, Intr | 1990 |
[Evaluation of subselective intraarterial infusion chemotherapy in advanced gastric cancer and recurrence case-evaluated on factors other than direct effects].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 1990 |
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1990 |
A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fluo | 1990 |
Thermochemotherapy in inoperable head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheters, Indwellin | 1990 |
What is the optimal regimen of cisplatin plus 5-FU for head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1990 |
Combined modality therapy for locally advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
[Is levamisole combined with fluorouracil efficient in colorectal cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Levamiso | 1990 |
[A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation; Female; Fluor | 1990 |
Esthesioneuroblastoma. Complete tumor response after induction chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Female; Fluorouracil; Humans; Inf | 1990 |
Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; D | 1990 |
A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil.
Topics: Administration, Topical; Adolescent; Adult; Condylomata Acuminata; Female; Fluorouracil; Genital Neo | 1990 |
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dose-Response R | 1990 |
Advanced head and neck cancer: low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Fluoro | 1990 |
Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; F | 1990 |
Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1985 |
Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Induction therapy in head and neck cancer. A comparison of two regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Unresectable and locally recurrent rectal cancer treated with radiotherapy or bilateral internal iliac artery infusion of 5-fluorouracil.
Topics: Adult; Aged; Fluorouracil; Humans; Iliac Artery; Infusions, Intra-Arterial; Middle Aged; Neoplasm Re | 1986 |
Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1986 |
Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1986 |
Nonoperative therapy for squamous-cell cancer of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1987 |
[Combined chemotherapy and radiotherapy in recurrent tumors of the head and neck region].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1987 |
CDDP and 5-FU after prior VBM or VBM after prior CDDP and 5-FU in the management of recurrent squamous cell carcinoma of the head and neck?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
External beam radiotherapy for rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 1987 |
Hyperthermia as an adjuvant to radiation- and/or chemotherapy in far advanced recurrences of the head and neck region.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1987 |
The treatment of advanced recurrent carcinoma of the uterine cervix with platinum based cytotoxic chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Flu | 1987 |
Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carci | 1988 |
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1989 |
[Intra-arterial chemotherapy of local recurrences of gastrointestinal tumors].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neopla | 1989 |
Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, A | 1989 |
[Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Carcinoma, Squamous Cell; | 1989 |
[Factors modifying remission in cytostatic chemotherapy of squamous cell carcinoma recurrence in the area of the head and neck].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1989 |
96-hour continuous infusion of cis-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1989 |
[Buschke-Lowenstein tumor of the anal area].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Cisplatin; Condylomata Ac | 1989 |
Multimodal treatment for inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1989 |
Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
Epidermoid carcinoma of the anal canal. Results of treatment by combined chemotherapy and radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1989 |
Concurrent radiation and chemotherapy in vulvar carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1989 |
[Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Combined Moda | 1989 |
[Anal canal carcinoma: diagnosis--therapy--prognosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Female; F | 1989 |
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 1989 |
[Intra-arterial infusion chemotherapy of locally advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraducta | 1989 |
[A case of recurrent hepatocellular carcinoma successfully treated by arterial chemoembolization in combination with local hyperthermia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 1989 |
[Effect of sequential MTX/5-FU therapy for a case of disseminated intravascular coagulation syndrome associated with recurrence of gastric cancer--a case report].
Topics: Adenocarcinoma, Scirrhous; Adult; Disseminated Intravascular Coagulation; Fluorouracil; Humans; Male | 1989 |
[Synchronization therapy as a palliative measure in incurable head and neck tumors].
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and | 1985 |
Postcricoid carcinoma: a retrospective study of 13 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1985 |
Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1989 |
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck | 1989 |
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor | 1989 |
Factors associated with local recurrence as a first site of failure following the conservative treatment of early breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort S | 1989 |
[Early adjuvant intraportal chemotherapy with 5-fluorouracil after hepatic resection of colorectal metastasis: a preliminary clinical and pharmacokinetic study].
Topics: Adult; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; I | 1989 |
Ten-year results of FAC adjuvant chemotherapy trial in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche | 1989 |
Radiation therapy with/without simultaneous weekly 5 F.U. in locally recurrent carcinoma of the recto-sigmoid.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal | 1989 |
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule | 1989 |
Drug availability is an issue for cancer patients, too.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; | 1989 |
Neoadjuvant therapy of squamous cell carcinoma of the esophagus: role of resection and benefit in partial responders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1989 |
[Successful treatment of a patient with recurrent ovarian cancer by lentinan combined with intraarterial 5FU].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hum | 1989 |
A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong.
Topics: Adult; Aged; Brachytherapy; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; H | 1989 |
Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1989 |
[Clinical effectiveness of arterial infusion chemotherapy in advanced and recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1989 |
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1989 |
Clinical management of recurrent hepatocellular carcinoma after primary resection.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fluorouracil; Follow-Up S | 1988 |
Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1988 |
Nonfunctioning islet cell carcinoma of the pancreas. Complete response to continuous 5-fluorouracil infusion.
Topics: Adenoma, Islet Cell; Catheters, Indwelling; Fluorouracil; Humans; Infusions, Intravenous; Male; Midd | 1988 |
Management of human papillomavirus-associated genital lesions in men.
Topics: Adolescent; Adult; Combined Modality Therapy; Condylomata Acuminata; Cryosurgery; Fluorouracil; Geni | 1989 |
Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder.
Topics: Adenocarcinoma; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Middle Age | 1989 |
[Combination cisplatin, fluorouracil and low-dose radiotherapy in recurrent soft tissue sarcomas].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Sarcoma; Sof | 1986 |
[Experimental chemotherapy of ovarian cancers heterotransplanted in nude mice].
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1985 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1987 |
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1987 |
[RI angiography with 99mTc and 201T1-chloride scintigraphy in determining the effectiveness of intra-arterial infusion in chemotherapy of locally advanced and recurrent breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Doxorubicin; Female | 1986 |
[Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment].
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Eval | 1986 |
Intraarterial chemotherapy and hyperthermia for pain control in patients with recurrent rectal cancer.
Topics: Aged; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Male; Middle A | 1986 |
Preoperative chemotherapy and radiotherapy in the management of epidermoid carcinoma of the anal canal.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 1987 |
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Drug E | 1987 |
Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1987 |
Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery.
Topics: Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Mitomycin; Mitomyci | 1987 |
[Results of combined radiochemotherapy of intracranial ependymoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebral Ventric | 1987 |
[Clinical results of CDDP, MMC and 5-FU combination chemotherapy in advanced or recurrent gastrointestinal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1987 |
[Experience with CDDP therapy in advanced and recurrent gastric cancer cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Doxorubic | 1987 |
Concurrent combined chemotherapy and radiation therapy in gastrointestinal cancers.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Human | 1987 |
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1988 |
Radiotherapy for the prevention of local-regional recurrence in high risk patients post mastectomy receiving adjuvant chemotherapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphami | 1988 |
Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell; Cisp | 1988 |
Cisplatin and 5-fluorouracil in advanced and recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Flu | 1988 |
Adjuvant chemotherapy with and without radiotherapy in stage II breast cancer.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplat | 1988 |
A phase II study of sequential methotrexate and 5-fluorouracil in colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1988 |
[Topical chemotherapy in the surgical treatment of recurrent skin carcinoma].
Topics: Administration, Topical; Aged; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; N | 1988 |
[Intravesical ectopic recurrence of bladder tumors].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Doxorubicin; Female; Fluorouracil; Hum | 1988 |
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo | 1988 |
Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy.
Topics: Bronchial Fistula; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Etoposide; Fluorouraci | 1988 |
Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Evaluation of bolus cis-platinum and continuous 5-fluorouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Do | 1988 |
Integration of full-dose adjuvant chemotherapy with definitive radiotherapy for primary breast cancer: four-year update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1988 |
Sequential combination of 5-fluorouracil, cis-platinum and irradiation. 1. Advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 1988 |
Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Flu | 1988 |
[Intraarterial infusion of oncostasis in patients with recurrent cervical cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 1988 |
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1988 |
Experience with an annular phased array hyperthermia system in the treatment of advanced recurrences of the pelvis.
Topics: Combined Modality Therapy; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Hyperthermia, | 1988 |
[Cisplatin-5 fluorouracil in cervicofacial cancer recurrence].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Facial Neoplasms; Fluorouracil; Head and | 1988 |
Results of carbon dioxide laser therapy and topical 5-fluorouracil treatment for subclinical condyloma found by magnified penile surface scanning.
Topics: Administration, Topical; Combined Modality Therapy; Condylomata Acuminata; Fluorouracil; Humans; Las | 1988 |
[Local treatment of locally recurrent breast cancers].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Doxoru | 1988 |
[Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast C
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 1988 |
The follow up study of intra-arterial infusion chemotherapy with local vein blocking as a surgical neo-adjuvant treatment for locally advanced breast cancer.
Topics: Breast; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up St | 1988 |
Preoperative irradiation and 5-fluorouracil suppository for carcinoma of the rectum.
Topics: Aged; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neop | 1988 |
Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
[Induction chemotherapy with cisplatin-5 fluorouracil. Current results in cervicofacial carcinology].
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1987 |
Results in the management of locally unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1986 |
[Chemotherapy of advanced and recurrent colorectal cancer].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality | 1986 |
Regional adjuvant irradiation for adenocarcinoma of the cecum.
Topics: Adenocarcinoma; Cecal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrenc | 1987 |
Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1987 |
[Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Thera | 1987 |
Fatal acute tumor lysis syndrome with metastatic breast carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Breast Neoplasms; Cyclophos | 1987 |
[Effect of post operative maintenance chemotherapy against ovarian cancer].
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Mice; Mice, | 1987 |
[Treatment of locally advanced cancer of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 1987 |
Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; D | 1987 |
[A case of recurrent gastric cancer successfully treated with a combination of cisplatin and carmofur].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1987 |
Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Fe | 1987 |
Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
[Ovarian function and recurrence in adjuvant chemotherapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 1987 |
Significance of plasma retinol binding protein levels in recurrence of breast tumors in women.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta Carotene; Breast Neoplasms; Carotenoids; Cispla | 1987 |
Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
[5-Fluorouracil treatment of condylomata acuminata].
Topics: Administration, Topical; Adult; Condylomata Acuminata; Female; Fluorouracil; Genital Neoplasms, Fema | 1986 |
Treatment of recurrent carcinoma of the cervix with bromocriptine.
Topics: Adult; Aged; Bromocriptine; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; Neo | 1986 |
Allergic reaction to 5-fluorouracil infusion.
Topics: Angioedema; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dru | 1986 |
Destruction of both extensive local recurrent and primary breast cancer with topical aqueous 5-FU: a clinical observation.
Topics: Administration, Topical; Breast Neoplasms; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neopla | 1986 |
[Chemotherapy of recurrent squamous cell carcinomas in the ENT area with cisplatin/adriamycin (DDP/ADM) and methotrexate/5-fluorouracil (MTX/5-Flu): a retrospective comparison of 2 protocols].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1986 |
[Early adjuvant intraportal chemotherapy after hepatectomy for metastases of colorectal origin].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Parenter | 1986 |
Partial and total skinning vulvectomy in treatment of carcinoma in situ of the vulva.
Topics: Adolescent; Adult; Aged; Carcinoma in Situ; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recu | 1986 |
Plasma levels of a viral protein during adjuvant treatment: reflection of murine mammary tumor status and therapeutic effect.
Topics: Animals; Antigens, Neoplasm; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; | 1986 |
Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; | 1986 |
Management of locoregional recurrent breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality T | 1986 |
Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1986 |
[Oral administration of 5-fluorouracil (5-FU) with intravesical chemotherapy as prophylaxis against recurrence of superficial bladder tumors].
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Female; Fluorouracil; Humans; Male; | 1986 |
[Combination cisplatin, 5-FU and low-dose radiotherapy in recurrent carcinomas of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1986 |
Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherap | 1986 |
Alteration of chemotherapy (cisplatin and 5-FU) and radiotherapy in the management of advanced or recurrent head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
A reappraisal of oophorectomy in carcinoma of the breast.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modalit | 1987 |
Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.
Topics: Colonic Neoplasms; DNA, Neoplasm; Drug Resistance; Fluorouracil; Gene Amplification; Humans; Male; M | 1987 |
Combined cryosurgical, chemotherapeutic, and radiotherapeutic management of T1-4N0M0 oral cavity cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cobalt Radioi | 1985 |
Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neopla | 1985 |
Our experience regarding precautional chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1985 |
Management of inflammatory carcinoma of the breast. A combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined M | 1985 |
Carcinoma of the tongue and floor of the mouth. Preliminary results of a multidisciplinary approach.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1985 |
[Therapy of recurrent squamous cell cancers in the ENT area with the sequential methotrexate (MTX)/5-fluorouracil (5-Fu) protocol].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 1985 |
Maintenance chemotherapy for high-risk patients. A preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1985 |
Intraepithelial neoplasia of the neovagina.
Topics: Adult; Carcinoma in Situ; Epithelium; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; | 1985 |
The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |
Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Female; Fluorouracil | 1985 |
Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcin | 1986 |
The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasm | 1986 |
Treatment of persistent or recurrent ovarian carcinoma with sequential methotrexate and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 1986 |
Fluorouracil paste treatment of thin basal cell carcinomas.
Topics: Adult; Aged; Carcinoma, Basal Cell; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo | 1985 |
[Risk-related surgical treatment of colorectal tumors].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Post | 1985 |
Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphami | 1985 |
[Chemotherapy for recurrent breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 1985 |
Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Chromatography, | 1985 |
Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.
Topics: Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Hepatic Artery; Hum | 1985 |
Weight gain during adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Body Weight; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Melphala | 1985 |
A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Ev | 1985 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
Colorectal cancer: speculations on the role of intraperitoneal therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Coloni | 1985 |
Adjuvant therapy in rectal cancer: a protocol proposal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Inf | 1985 |
[Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1985 |
A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1985 |
[Clinical evaluation of FAR therapy (radiotherapy with 5FU and vitamin A) for laryngeal cancer. II. Rates of control and complications].
Topics: Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Laryngeal Neoplasms; Neoplasm Re | 1985 |
Early diagnosis and management of premalignant lesions and early invasive cancers of the vulva.
Topics: Adult; Aged; Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metas | 1971 |
Current concepts in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Adult; Androgens; Breast Neoplasms; Castration; Estrogens; Female; Fluorouracil; Huma | 1972 |
[Therapy of bronchial carcinoma. Intermittent high-dosage polychemotherapy of bronchial carcinoma in combination with radical surgery for the prevention of recurrences and in primarily inoperable patients].
Topics: Adult; Aged; Antineoplastic Agents; Austria; Bronchial Neoplasms; Cyclophosphamide; Female; Fluorour | 1973 |
Cancer of the tongue.
Topics: Bleomycin; Carcinoma, Squamous Cell; Dental Caries; Electrocoagulation; Fluorides, Topical; Fluorour | 1973 |
[Intra-arterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institut Gustave Roussy].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Facial Neoplasms | 1973 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Reoperation in carcinoma of the colon following resection and adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurr | 1966 |
The second look operation for carcinoma of the colon after administration of 5-fluorouracil.
Topics: Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; | 1968 |
[Treatment of terminal cancer and relapsed cancer by 5-5-FU(5-fluorouracil)].
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Lymphoma; M | 1968 |
[FSH and steroid hormone excretion in breast cancer during chemotherapy].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Breast Neoplasms; Cyclophosphamide; Estrogens; Female; F | 1972 |
Condyloma acuminatum of male urethra. Successful management with 5-fluorouracil.
Topics: Adult; Condylomata Acuminata; Diverticulum; Fistula; Fluorouracil; Humans; Male; Neoplasm Recurrence | 1974 |
Cancer chemotherapy in urology.
Topics: Adenocarcinoma; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Chlorambucil; Cobal | 1971 |
The origin and significance of vulvar Paget's disease.
Topics: Aged; Female; Fluorouracil; Humans; Microscopy, Electron; Middle Aged; Neoplasm Recurrence, Local; P | 1972 |
[Local treatment of skin neoplasms with 5 per cent fluorouracil ointment (report of 6 cases)].
Topics: Adenocarcinoma, Scirrhous; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorourac | 1972 |
Chemotherapy for adenocarcinoma and alveolar cell carcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Female; Fluorouracil; Follow-Up Studies; | 1974 |
Studies on the mechanism and prevention of local recurrence of carcinoma at the suture line after colonic resection.
Topics: Animals; Carcinoma, Hepatocellular; Colon; Colonic Neoplasms; Fluorouracil; Intestinal Mucosa; Liver | 1971 |
Prevention of recurrent cancer of the large bowel.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; Ligati | 1974 |
Arterial infusion and radiation therapy in the treatment of advanced cancer of the nasal cavity and paranasal sinuses.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Carotid Artery, External; Carotid Artery, Internal; Chemot | 1973 |
Intra-arterial infusion for head and neck cancers.
Topics: Aged; Antineoplastic Agents; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Arteries; Cath | 1973 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Chemotherapy for recurrent carcinoma of the breast.
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Hepatic Artery; Humans; Injections, | 1972 |
Hormones, chemotherapy, and the breast cancer patient.
Topics: Administration, Oral; Adrenalectomy; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Female; Fluoro | 1972 |
[Preliminary results of the use of 5-fluoruracil to prevent recurrences and metastases following radical surgery for stomach cancer].
Topics: Adenocarcinoma; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; N | 1972 |
The value of megavolt therapy in carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Cardia; Cell Division; Cobalt Isotopes; Female; Fluorouracil | 1972 |
[The reactivity of the RES in cancer of the gastrointestinal tract and during treatment with fluorofur].
Topics: Achlorhydria; Adult; Aged; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Furans; Go | 1972 |
[Oral, florid papillomatosis].
Topics: Adrenal Cortex Hormones; Aged; Female; Fluorouracil; Humans; Injections, Intramuscular; Lip Neoplasm | 1973 |
Topical use of 5-fluorouracil.
Topics: Aged; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local; Skin Neoplasm | 1973 |
Gynecologic oncology.
Topics: Alkylating Agents; Ascites; Biopsy; Dactinomycin; Endometrium; Female; Fluorouracil; Genital Neoplas | 1973 |
Hypertrophic scar after cryotherapy and topical tretinoin.
Topics: Administration, Topical; Carcinoma, Basal Cell; Carmustine; Cicatrix; Connective Tissue; Cryosurgery | 1973 |
An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast.
Topics: Administration, Oral; Adult; Aged; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Drug Therap | 1974 |
The treatment of premalignant and malignant lesions of the vulva.
Topics: Administration, Topical; Adult; Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Female; Fluoroura | 1974 |
Cyclical combination chemotherapy in advanced breast cancer.
Topics: Age Factors; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1974 |
Cyclophosphamide. Evaluation in recurrent and progressive ovarian cancer.
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ova | 1967 |
Systemic chemotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fema | 1967 |
Therapeutic implications from a mathematical model characterizing the course of breast cancer.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mastectomy; | 1969 |
Prospects for the control of metastases.
Topics: Anticoagulants; Breast Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Recur | 1969 |
Evaluation of adjunctive chemotherapy for recurrent cancer.
Topics: Animals; Breast Neoplasms; Female; Fluorouracil; Humans; Mice; Neoplasm Recurrence, Local; Neoplasms | 1970 |
Chemotherapy of colorectal cancer.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Recurrence, Local; Rectal Neoplasms | 1972 |
Treatment with 5-fluorouracil in prophylaxis of relapses and metastases of stomach cancer.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Injections, Intravenous; Mal | 1972 |
A follow-up study of treatment of basal cell carcinoma with 5-fluorouracil ointment.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Recu | 1972 |
Topical chemotherapy of advanced cutaneous malignancy with 5-Fluorouracil creme.
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Esthetics | 1971 |
A comparison of chemical peeling, dermabrasion, and 5-fluourouracil in cancer prophylaxis.
Topics: Cautery; Dermabrasion; Fluorouracil; Humans; Keratosis; Neoplasm Recurrence, Local; Phenols; Sunscre | 1971 |
[5-Fluorouracil in local therapy of precancerous conditions and carcinoma of the skin].
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis; Neoplasm Recurrenc | 1971 |
Embryonal cell carcinoma of the ovary. Report of a case.
Topics: Abdominal Neoplasms; Adolescent; Age Factors; Black People; Cyclophosphamide; Drug Therapy, Combinat | 1971 |
Intra-arterial chemotherapy for recurrent neoplasms.
Topics: Adult; Aged; Catheterization; Female; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intra | 1967 |
Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions.
Topics: Antigen-Antibody Reactions; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatitis; Dermatitis, | 1970 |
Combined surgery, radiotherapy, and regional chemotherapy in carcinoma of the paranasal sinuses.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Ethmoid Sinus; Fluoroura | 1970 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
Chemotherapy for tumors of chest wall and base of neck by arterial infusion.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head and Neck Neoplasms; He | 1968 |
Treatment of cancer with weekly intravenous 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, | 1968 |
Intermittent intra-arterial infusion for cancer: a simple, inexpensive, outpatient method for prolonged regional chemotherapy.
Topics: Ambulatory Care; Antineoplastic Agents; Catheterization; Fluorouracil; Humans; Injections, Intra-Art | 1968 |
[Perioperative antiblastic drug therapy with triethyleniminobenzoquinone and 5-fluorouracil in uterine neoplasms].
Topics: Antineoplastic Agents; Carcinoma; Female; Fluorouracil; Humans; Hysterectomy; Neoplasm Metastasis; N | 1968 |
[Cancer and appendicitis--death due to incidental appendicitis in recurrent stomach cancer with successful chemotherapy].
Topics: Antineoplastic Agents; Appendicitis; Cholestasis; Female; Fluorouracil; Humans; Middle Aged; Mitomyc | 1968 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
Treatment of carcinoma of the bladder with combined radiotherapy, chemotherapy, and surgery.
Topics: Animals; Cricetinae; Female; Fluorouracil; Humans; Hydroxyurea; Male; Mitomycins; Neoplasm Metastasi | 1969 |
Local injection of fluorouracil in skin cancer.
Topics: Adenocarcinoma; Fluorouracil; Humans; Injections; Male; Middle Aged; Neoplasm Recurrence, Local; Per | 1969 |